FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Coelho, DF
   Ferraz, MVF
   Marques, ETA
   Lins, RD
   Viana, IFT
AF Coelho, Danilo F.
   Ferraz, Matheus V. F.
   Marques, Ernesto T. A.
   Lins, Roberto D.
   Viana, Isabelle F. T.
TI The influence of biotinylation on the ability of a computer designed
   protein to detect B-cells producing anti-HIV-1 2F5 antibodies
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Top7; Antigen; Biotin; Vaccine; Molecular dynamics
ID DE-NOVO DESIGN; MOLECULAR-DYNAMICS; BIOTIN; STABILITY; AVIDIN; MODEL;
   GP41; IDENTIFICATION; COMPLEX
AB Antibodies against the HIV-1 2F5 epitope are known as one of the most powerful and broadly protective anti-HIV antibodies. Therefore, vaccine strategies that include the 2F5 epitope in their formulation require a robust method to detect specific anti-2F5 antibody production by B cells. Towards this goal, we have biotinylated a previously reported computer-designed protein carrying the HIV-1 2F5 epitope aiming the further development of a platform to detect human B-cells expressing anti-2F5 antibodies through flow cytometry. Biophysical and immunological properties of our devised protein were characterized by computer simulation and experimental methods. Biotinylation did not affect folding and improved protein stability and solubility. The biotinylated protein exhibited similar binding affinity trends compared to its unbiotinylated counterpart and was recognized by anti-HIV-1 2F5 antibodies expressed on the surface of patient-derived peripheral blood mononuclear cells. Moreover, we present a high affinity marker for the identification of epitope-specific B cells that can be used to measure the efficacy of vaccine strategies based on the HIV-1 envelope protein. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Coelho, Danilo F.; Ferraz, Matheus V. F.; Marques, Ernesto T. A.; Lins, Roberto D.; Viana, Isabelle F. T.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, 50670465 Recife, PE, Canada.
   [Coelho, Danilo F.; Ferraz, Matheus V. F.; Lins, Roberto D.] Univ Fed Pernambuco, Dept Fundamental Chem, 50740540 Recife, PE, Canada.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
RP Lins, RD; Viana, IFT (corresponding author), Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, 50670465 Recife, PE, Canada.
EM roberto.lins@cpqam.fiocruz.br; isabelle.viana@cpqam.fiocruz.br
RI Ferraz, Matheus/AAC-9213-2020; Lins, Roberto D/J-7511-2012; Coelho,
   Danilo Fernandes/AAC-9206-2020; Marques, Ernesto T. A/L-4967-2013
OI Lins, Roberto D/0000-0002-3983-8025; Coelho, Danilo
   Fernandes/0000-0002-1111-0825; Marques, Ernesto T. A/0000-0003-3826-9358
FU CAPESCAPES; Biomol; CNPqNational Council for Scientific and
   Technological Development (CNPq); INCT-FCx; FACEPE
FX This work was supported by CAPES, Biomol, CNPq, INCT-FCx and FACEPE.
   Computational resources were provided by the Brazilian National
   Supercomputing Center (LNCC).
CR Ahn M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050192
   Azim-Zadeh O, 2007, J BIOL CHEM, V282, P21609, DOI 10.1074/jbc.M610921200
   BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E
   Bayer E A, 1980, Methods Biochem Anal, V26, P1
   BAYER EA, 1990, METHOD ENZYMOL, V184, P138
   Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI DOI 10.1007/978-94-015-7658-1_21
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bogusiewicz A, 2004, ANAL BIOCHEM, V327, P156, DOI 10.1016/j.ab.2004.01.011
   Boschek CB, 2009, PROTEIN ENG DES SEL, V22, P325, DOI 10.1093/protein/gzp007
   Burton DR, 2010, P NATL ACAD SCI USA, V107, P17859, DOI 10.1073/pnas.1012923107
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chivers CE, 2011, BIOCHEM J, V435, P55, DOI 10.1042/BJ20101593
   Cunha KC, 2015, BIOPOLYMERS, V103, P351, DOI 10.1002/bip.22626
   Day R, 2002, J MOL BIOL, V322, P189, DOI 10.1016/S0022-2836(02)00672-1
   Elia G, 2008, PROTEOMICS, V8, P4012, DOI 10.1002/pmic.200800097
   Elzahhar P, 2019, METHODS MOL BIOL, V2000, P125, DOI 10.1007/978-1-4939-9516-5_11
   Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09
   Hockney R. W., 1970, Methods in computational physics. IX. Plasma physics, P135
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Kramer RM, 2012, BIOPHYS J, V102, P1907, DOI 10.1016/j.bpj.2012.01.060
   Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200
   Mock Donald M., 2008, V418, P209
   MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Pall S, 2013, COMPUT PHYS COMMUN, V184, P2641, DOI 10.1016/j.cpc.2013.06.003
   Perchiacca JM, 2014, PROTEIN ENG DES SEL, V27, P29, DOI 10.1093/protein/gzt058
   Rybak JN, 2005, NAT METHODS, V2, P291, DOI 10.1038/NMETH745
   RYLATT DB, 1977, ARCH BIOCHEM BIOPHYS, V183, P113, DOI 10.1016/0003-9861(77)90425-8
   Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2
   TAKASHIMA I, 1990, METHOD ENZYMOL, V184, P497
   TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273
   VANN WF, 1990, METHOD ENZYMOL, V184, P537
   Viana IFT, 2013, LECT NOTES COMPUT SC, V8213, P94, DOI 10.1007/978-3-319-02624-4_9
   Viana IFT, 2013, RSC ADV, V3, P11790, DOI 10.1039/c3ra41562g
   WILCHEK M, 1984, IMMUNOL TODAY, V5, P39, DOI 10.1016/0167-5699(84)90027-6
   Wilchek M, 2006, IMMUNOL LETT, V103, P27, DOI 10.1016/j.imlet.2005.10.022
   Yazawa A, 2006, BIOL PHARM BULL, V29, P1480, DOI 10.1248/bpb.29.1480
   YOLKEN RH, 1990, METHOD ENZYMOL, V184, P529
NR 45
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD DEC
PY 2019
VL 93
AR 107442
DI 10.1016/j.jmgm.2019.107442
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA JN9ZO
UT WOS:000497247700005
PM 31479948
DA 2020-12-16
ER

PT J
AU Lebov, JF
   Arias, JF
   Balmaseda, A
   Britt, W
   Cordero, JF
   Galvao, LA
   Garces, AL
   Hambidge, KM
   Harris, E
   Ko, A
   Krebs, N
   Marques, ETA
   Martinez, AM
   McClure, E
   Miranda, DB
   Moreira, MEL
   Mussi-Pinhata, MM
   Ochoa, TJ
   Osorio, JE
   Scalabrin, DMF
   Schultz-Cherry, S
   Seage, GR
   Stolka, K
   Ugarte-Gil, CA
   Vega, CMV
   Welton, M
   Ximenes, R
   Zorrilla, C
AF Lebov, Jill F.
   Arias, Juan F.
   Balmaseda, Angel
   Britt, William
   Cordero, Jose F.
   Galvao, Luiz Augusto
   Lucia Garces, Ana
   Hambidge, K. Michael
   Harris, Eva
   Ko, Albert
   Krebs, Nancy
   Marques, Ernesto T. A.
   Martinez, Alexander M.
   McClure, Elizabeth
   Miranda-Filho, Democrito B.
   Lopes Moreira, Maria Elisabeth
   Mussi-Pinhata, Marisa M.
   Ochoa, Theresa J.
   Osorio, Jorge E.
   Scalabrin, Deolinda M. F.
   Schultz-Cherry, Stacey
   Seage, George R., III
   Stolka, Kristen
   Augusto Ugarte-Gil, Cesar
   Vega, Carmen Milagros Velez
   Welton, Michael
   Ximenes, Ricardo
   Zorrilla, Carmen
TI International prospective observational cohort study of Zika in infants
   and pregnancy (ZIP study): study protocol (vol 19, 282, 2019)
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Correction
C1 [Lebov, Jill F.; McClure, Elizabeth; Stolka, Kristen] RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
   [Arias, Juan F.; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Balmaseda, Angel] Complejo Nacl Salud, Ctr Nacl Diagnost & Referencia, Managua, Nicaragua.
   [Britt, William] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
   [Cordero, Jose F.; Welton, Michael] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Galvao, Luiz Augusto] Fiocruz MS, Ctr Global Hlth CRIS, Rio De Janeiro, Brazil.
   [Lucia Garces, Ana] Ctr Amer & Panama INCAP, Fdn Alimentac & Nutr, Guatemala City, Guatemala.
   [Hambidge, K. Michael; Krebs, Nancy] Univ Colorado, Sect Nutr, Pediat, Aurora, CO USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Fundacao Oswaldo Cruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] Fiocruz MS, Dept Virol & Expt Therapeut, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Martinez, Alexander M.] Imbanaco Med Ctr, Res Inst, Cali, Colombia.
   [Miranda-Filho, Democrito B.] Univ Pernambuco, Microcephaly Epidem Res Grp, PPGCS, Recife, PE, Brazil.
   [Lopes Moreira, Maria Elisabeth] Fiocruz MS, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru.
   [Osorio, Jorge E.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Seage, George R., III] Harvard Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Vega, Carmen Milagros Velez] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Ximenes, Ricardo] Univ Fed Pernambuco, Microcephaly Epidem Res Grp, Dept Med Trop, Recife, PE, Brazil.
   [Zorrilla, Carmen] Maternal Infant Studies Ctr CEMI, San Juan, PR USA.
RP Lebov, JF (corresponding author), RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
EM jlebov@rti.org
RI Ugarte-Gil, Cesar/E-6074-2013; Marques, Ernesto T. A/L-4967-2013
OI Ugarte-Gil, Cesar/0000-0002-2833-9087; Marques, Ernesto T.
   A/0000-0003-3826-9358; Galvao, Luiz Augusto/0000-0002-3918-0286;
   McClure, Elizabeth/0000-0001-8659-5444
FU NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R25 MH083617] Funding Source: Medline; NATIONAL INSTITUTE OF
   MENTAL HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R25MH083617, R25MH083617, R25MH083617] Funding Source: NIH
   RePORTER
CR Lebov JF, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2430-4
NR 1
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD NOV 19
PY 2019
VL 19
IS 1
AR 423
DI 10.1186/s12884-019-2589-8
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA KE3OE
UT WOS:000508467800004
PM 31744466
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Duraes-Carvalho, R
   Ludwig-Begall, LF
   Salemi, M
   Lins, RD
   Marques, ETA
AF Duraes-Carvalho, Ricardo
   Ludwig-Begall, Louisa F.
   Salemi, Marco
   Lins, Roberto D.
   Marques, Ernesto T. A.
TI Influence of directional positive Darwinian selection-driven evolution
   on arboviruses Dengue and Zika virulence and pathogenesis
SO MOLECULAR PHYLOGENETICS AND EVOLUTION
LA English
DT Article
DE Arbovirus; Selection-driven evolution; Virulence; Pathogenesis
ID VIRUS; POPULATION; PROTEINS; DISEASE; PALMITOYLATION; EMERGENCE;
   DYNAMICS; GENETICS; ACCURATE
AB Dengue (DENV) and Zika (ZIKV) viruses are antigenically and evolutionarily related; immunological cross-reactions between them have been associated to both cross-protection and infection-enhanced mechanisms. Here, DENV-1-4 and ZIKV were investigated through Bayesian coalescent-based approaches and selection-driven Darwinian evolution methods using robust datasets. Our findings show that both DENV and ZIKV, driven essentially by directional positive selection, have undergone evolution and diversification and that their entire polyproteins are subject to an intense directional evolution. Interestingly, positively selected codons mapped here are directly associated to DENV-1-2 virulence as well as the ZIKV burgeoning 2015-16 outbreak in the Americas, therefore, having impact on the pathogenesis of these viruses. Biochemical prediction analysis focusing on markers involved in virulence and viral transmission dynamics identified alterations in NGlycosylation-, Phosphorylation- and Palmitoylation-sites in ZIKV sampled from different countries, hosts and isolation sources. Taking into account both DENV-ZIKV co-circulation either into and/or out of flavivirus-endemic regions, as well as recombination and quasispecies scenarios, these results indicate the action of a selection-driven evolution affecting the biology, virulence and pathogenesis of these pathogens in a non-randomized environment.
C1 [Duraes-Carvalho, Ricardo; Lins, Roberto D.; Marques, Ernesto T. A.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Dept Virol, BR-50740465 Recife, PE, Brazil.
   [Ludwig-Begall, Louisa F.] Univ Liege, Fac Vet Med, FARAH Res Ctr, Vet Virol & Anim Viral Dis,Dept Infect & Parasit, Liege, Belgium.
   [Salemi, Marco] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32608 USA.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Duraes-Carvalho, R (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Dept Virol, BR-50740465 Recife, PE, Brazil.
EM rdcarval@gmail.com
RI Marques, Ernesto T. A/L-4967-2013; Lins, Roberto D/J-7511-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Lins, Roberto
   D/0000-0002-3983-8025
FU FACEPE; MCT/CNPq DCR, Brazil [300063/2018-0, DCR-0026-2.12/16,
   APQ-1776-2.12/15]
FX Duraes-Carvalho was supported by FACEPE and MCT/CNPq DCR grants
   [300063/2018-0, DCR-0026-2.12/16 and APQ-1776-2.12/15], Brazil.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Azeredo Elzinandes Leal, 2018, PLoS Curr, V10, DOI 10.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5
   Baele G, 2013, MOL BIOL EVOL, V30, P239, DOI 10.1093/molbev/mss243
   Bagno FF, 2019, J CLIN VIROL, V113, P27, DOI 10.1016/j.jcv.2019.02.006
   Biek R, 2010, MOL ECOL, V19, P3515, DOI 10.1111/j.1365-294X.2010.04679.x
   Carbaugh DL, 2019, J VIROL, V93, DOI [10.1128/JVI.00113-19, 10.1128/jvi.00113-19]
   Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456
   Chevillon C, 2003, TRENDS MICROBIOL, V11, P415, DOI 10.1016/S0966-842X(03)00206-3
   de Borba L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001624
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Dietrich LEP, 2004, EMBO REP, V5, P1053, DOI 10.1038/sj.embor.7400277
   Domingo E, 2012, MICROBIOL MOL BIOL R, V76, P159, DOI 10.1128/MMBR.05023-11
   dos Santos CND, 2000, VIROLOGY, V274, P292, DOI 10.1006/viro.2000.0457
   Draper JM, 2007, J LIPID RES, V48, P1873, DOI 10.1194/jlr.M700179-JLR200
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Dyer MD, 2007, BIOINFORMATICS, V23, pI159, DOI 10.1093/bioinformatics/btm208
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Enkhbayar P, 2004, PROTEINS, V54, P394, DOI 10.1002/prot.10605
   Freire MCLC, 2017, ACS OMEGA, V2, P3913, DOI 10.1021/acsomega.7b00608
   Fritzell C, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006533
   GARCIABARRENO B, 1989, J VIROL, V63, P925
   Gutierrez S, 2012, CURR OPIN VIROL, V2, P546, DOI 10.1016/j.coviro.2012.08.001
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Huang YJS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00022
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Jun SR, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1894-3
   Kaverin NV, 2002, J GEN VIROL, V83, P2497, DOI 10.1099/0022-1317-83-10-2497
   Keck F, 2015, VIRUSES-BASEL, V7, P5257, DOI 10.3390/v7102872
   Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005
   Lewis-Rogers N, 2009, MOL BIOL EVOL, V26, P969, DOI 10.1093/molbev/msp009
   Lipsitch M, 2007, J R SOC INTERFACE, V4, P787, DOI 10.1098/rsif.2007.0229
   Liu ZY, 2019, NAT REV MICROBIOL, V17, P131, DOI 10.1038/s41579-018-0134-9
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Paixao ES, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000530
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Prestwood TR, 2008, J VIROL, V82, P8411, DOI 10.1128/JVI.00611-08
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   R Core Team, 2014, R LANG ENV STAT COMP
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Ribeiro GS, 2018, LANCET GLOB HEALTH, V6, pE140, DOI 10.1016/S2214-109X(17)30496-5
   Richt JA, 2003, J CLIN MICROBIOL, V41, P3198, DOI 10.1128/JCM.41.7.3198-3205.2003
   Rodriguez-Morales AJ, 2016, TRAVEL MED INFECT DI, V14, P177, DOI 10.1016/j.tmaid.2016.05.004
   Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Schneider WL, 2001, J VIROL, V75, P6566, DOI 10.1128/JVI.75.14.6566-6571.2001
   Suwanmanee S, 2017, J MICROBIOL, V55, P81, DOI 10.1007/s12275-017-6494-4
   Valiant WG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44323-y
   van Boheemen S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02652-w
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Wan J, 2007, NAT PROTOC, V2, P1573, DOI 10.1038/nprot.2007.225
   Wang WK, 2002, J VIROL, V76, P4662, DOI 10.1128/JVI.76.9.4662-4665.2002
   Wargo AR, 2012, CURR OPIN VIROL, V2, P538, DOI 10.1016/j.coviro.2012.07.007
   Weaver SC, 2017, MBIO, V8, DOI 10.1128/mBio.02063-16
   Weaver S, 2018, MOL BIOL EVOL, V35, P773, DOI 10.1093/molbev/msx335
   White MK, 2016, ANN NEUROL, V80, P479, DOI 10.1002/ana.24748
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Carrillo-Hernandez MY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2976-1
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zou CL, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007202
NR 63
TC 0
Z9 0
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1055-7903
EI 1095-9513
J9 MOL PHYLOGENET EVOL
JI Mol. Phylogenet. Evol.
PD NOV
PY 2019
VL 140
AR 106607
DI 10.1016/j.ympev.2019.106607
PG 9
WC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics &
   Heredity
GA JD0TF
UT WOS:000489688500021
PM 31473337
DA 2020-12-16
ER

PT J
AU Ximenes, RAD
   Miranda, DD
   Brickley, EB
   Montarroyos, UR
   Martelli, CMT
   de Araujo, TVB
   Rodrigues, LC
   de Albuquerque, MDPM
   de Souza, WV
   Castanha, PMD
   Franca, RFO
   Dhalia, R
   Marques, ETA
   Alves, SV
   Bezerra, LCA
   Braga, MC
   Brainer, ACM
   Carvalho, MDCG
   Cordeiro, MT
   Dimech, G
   Eickmann, SH
   Brandao, SP
   Gois, ADL
   Goncalves, AV
   Gouveia, MDL
   de Melo, APL
   Muniz, LF
   Oliveira, DMD
   Pastich, F
   Pinto, MH
   Ramos, RCF
   Rocha, MAW
   Silva, PFS
   de Vasconcelos, RAL
   Ventura, CVDC
   Ventura, LMVD
AF Ximenes, Ricardo Arraes de Alencar
   Miranda-Filho, Democrito de Barros
   Brickley, Elizabeth B.
   Montarroyos, Ulisses Ramos
   Martelli, Celina Maria Turchi
   de Araujo, Thalia Velho Barreto
   Rodrigues, Laura C.
   de Albuquerque, Maria de Fatima Pessoa Militao
   de Souza, Wayner Vieira
   Castanha, Priscila Mayrelle da Silva
   Franca, Rafael F. O.
   Dhalia, Rafael
   Marques, Ernesto T. A.
   Alves, Sandra Valongueiro
   Bezerra, Luciana Caroline Albuquerque
   Braga, Maria Cynthia
   Brainer, Alessandra Cintia Mertens
   Carvalho, Maria Durce Costa Gomes
   Cordeiro, Marli Tenorio
   Dimech, Geroge
   Eickmann, Sophie Helena
   Brandao Filho, Sinval Pinto
   Gois, Adriana de Oliveira Lima
   Goncalves, Andreia Veras
   Gouveia, Mariana de Carvalho Leal
   de Melo, Ana Paula Lopes
   Muniz, Lilian Ferreira
   Oliveira, Danielle Maria da Silva
   Pastich, Fabiana
   Pinto, Maria Helena
   Ramos, Regina Coeli Ferreira
   Rocha, Maria Angela Wanderley
   Silva, Paula Fabiana Sobral
   de Vasconcelos, Romulo Augusto Lucena
   Ventura, Camila Vieira de Oliveira Carvalho
   Ventura, Liana Maria Vieira de Oliveira
CA MERG
TI Zika virus infection in pregnancy: Establishing a case definition for
   clinical research on pregnant women with rash in an active transmission
   setting
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID US TERRITORIES; ANTIBODIES; EPIDEMIC; EXPOSURE; OUTCOMES; JANUARY;
   UPDATE; BRAZIL
AB Defining cases of Zika virus (ZIKV) infection is a critical challenge for epidemiological research. Due to ZIKV's overlapping clinical features and potential immunologic cross-reactivity with other flaviviruses and the current lack of an optimal ZIKV-specific diagnostic assay, varying approaches for identifying ZIKV infections have been employed to date. This paper presents the laboratory results and diagnostic criteria developed by the Microcephaly Epidemic Research Group for defining cases of maternal ZIKV infection in a cohort of pregnant women with rash (N = 694) recruited during the declining 2015-2017 epidemic in northeast Brazil. For this investigation, we tested maternal sera for ZIKV by quantitative reverse transcription polymerase chain reaction (qRT-PCR), Immunoglobulin (Ig) M and IgG3 enzyme-linked immunosorbent assays (ELISAs), and Plaque Reduction Neutralization Test (PRNT50). Overall, 23.8% of participants tested positive by qRT-PCR during pregnancy (range of detection: 0-72 days after rash onset). However, the inter-assay concordance was lower than expected. Among women with qRT-PCR-confirmed ZIKV and further testing, only 10.1% had positive IgM tests within 90 days of rash, and only 48.5% had ZIKV-specific PRNT50 titers >= 20 within 1 year of rash. Given the complexity of these data, we convened a panel of experts to propose an algorithm for identifying ZIKV infections in pregnancy based on all available lines of evidence. When the diagnostic algorithm was applied to the cohort, 26.9% of participants were classified as having robust evidence of a ZIKV infection during pregnancy, 4.0% as having moderate evidence, 13.3% as having limited evidence of a ZIKV infection but with uncertain timing, and 19.5% as having evidence of an unspecified flavivirus infection before or during pregnancy. Our findings suggest that integrating longitudinal data from nucleic acid and serologic testing may enhance diagnostic sensitivity and underscore the need for an on-going dialogue regarding the optimization of strategies for defining cases of ZIKV in research.
C1 [Ximenes, Ricardo Arraes de Alencar] Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.
   [Ximenes, Ricardo Arraes de Alencar; Miranda-Filho, Democrito de Barros] Univ Pernambuco, Dept Med Interna, Recife, PE, Brazil.
   [Brickley, Elizabeth B.; Rodrigues, Laura C.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Montarroyos, Ulisses Ramos] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Martelli, Celina Maria Turchi; de Albuquerque, Maria de Fatima Pessoa Militao; de Souza, Wayner Vieira; Castanha, Priscila Mayrelle da Silva; Franca, Rafael F. O.; Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [de Araujo, Thalia Velho Barreto] Univ Fed Pernambuco, Dept Med Social, Recife, PE, Brazil.
   [Castanha, Priscila Mayrelle da Silva; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Castanha, Priscila Mayrelle da Silva] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Ximenes, RAD (corresponding author), Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.; Ximenes, RAD (corresponding author), Univ Pernambuco, Dept Med Interna, Recife, PE, Brazil.
EM raaximenes@uol.com.br
RI Montarroyos, Ulisses/AAJ-7527-2020; Marques, Ernesto T. A/L-4967-2013;
   Dhalia, Rafael/AAD-5432-2020; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Brickley, Elizabeth/U-3625-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Brickley, Elizabeth/0000-0003-0280-2288;
   Turchi Martelli, Celina Maria/0000-0002-2491-0688
FU Wellcome TrustWellcome Trust [205377/Z/16/Z, MC_PC_15088]; UK's
   Department for International Development [205377/Z/16/Z]; Wellcome
   Trust's Enhancing Research Activity in Epidemic Situations programme
   [107779/Z/15/Z, ER1505, ER1601]; European Union's Horizon 2020 research
   and innovation program under ZikaPLAN grant [734584]; Medical Research
   Council on behalf of the Newton Fund [MC_PC_15088]; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq) [309722/2017-9, 308590/2013-9,
   306708/2014-0, 308491/2013-0, 306222/20132]; Secretaria de Vigilancia em
   Saude/Ministerio da Saude de Brasil Resposta a Emergencia em Saude
   Publica -Zika vi'rus e Microcefalia [837058/2016]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel SuperiorCAPES; Departamento de
   Ciencia e Tecnologia [440839/2016-5]
FX This work was supported by the: Wellcome Trust & the UK's Department for
   International Development (205377/Z/16/Z to LCR;
   https://wellcome.ac.uk/), the Wellcome Trust's Enhancing Research
   Activity in Epidemic Situations programme (107779/Z/15/Z; with ER1505 &
   ER1601 to RAAX), the European Union's Horizon 2020 research and
   innovation program (https://ec.europa.eu/programmes/horizon2020/) under
   ZikaPLAN grant agreement No. 734584 (https://zikaplan.tghn.org/), the
   Medical Research Council on behalf of the Newton Fund and the Wellcome
   Trust (MC_PC_15088 to LCR; https://mrc.ukri.org/), the Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico(309722/2017-9to RAAX,
   308590/2013-9 to DBMF, and 306708/2014-0 to CMTM, 308491/2013-0 to
   MFPMA, 306222/20132 to WVS;http://www.cnpq.br/), Secretaria de
   Vigilancia em Saude/Ministerio da Saude de Brasil Resposta a Emergencia
   em Saude Publica -Zika vi ' rus e Microcefalia (837058/2016 to RAAX),
   the Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnologico,
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (http://www.capes.gov.br/), & the Departamento de Ciencia e Tecnologia
   (http://rebrats.saude.gov.br/noticias/59DECIT)for Prevencao e Combate a
   o virus Zika I (440839/2016-5 to RAAX). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Barzon L, 2018, CLIN INFECT DIS, V66, P1173, DOI 10.1093/cid/cix967
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Castanha PMS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007246
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Centers for Disease Control and Prevention, 2018, ZIK MAC ELISA INSTR
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Cortes F, 2018, ACTA TROP, V182, P190, DOI 10.1016/j.actatropica.2018.03.006
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Fischer C, 2018, EMERG INFECT DIS, V24, P888, DOI 10.3201/eid2405.171747
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Judice CC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22159-2
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
   Lowe R, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010096
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394
   Nascimento EJM, 2018, J VIROL METHODS, V257, P62, DOI 10.1016/j.jviromet.2018.04.009
   Oduyebo T, 2017, MMWR-MORBID MORTAL W, V66, P781, DOI 10.15585/mmwr.mm6629e1
   Paixao ES, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy073
   Pomar L, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4431
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Rodriguez-Barraquer I, 2018, ZIKA EMERGENCE DENGU
   Safronetz D, 2017, EMERG INFECT DIS, V23, P1577, DOI 10.3201/eid2309.162043
   Secretaria de Vigilancia em Saude-Ministerio da Saude-Brasil. Ministerio da Saude SituacAo epidemiologica de ocorrencia de microcefalias no Brasil, 2015, B EPIDEMIOLOGICO, V46
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Teixeira MG, 2016, AM J PUBLIC HEALTH, V106, P601, DOI 10.2105/AJPH.2016.303113
   Theel ES, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01972-17, 10.1128/JCM.01972-17]
   WHO, 2016, WHOZIKVSUR161
NR 30
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2019
VL 13
IS 10
AR e0007763
DI 10.1371/journal.pntd.0007763
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA JK6WK
UT WOS:000494982700021
PM 31589611
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-16
ER

PT J
AU Davi, C
   Pastor, A
   Oliveira, T
   Neto, FBD
   Braga-Neto, U
   Bigham, AW
   Bamshad, M
   Marques, ETA
   Acioli-Santos, B
AF Davi, Caio
   Pastor, Andre
   Oliveira, Thiego
   de Lima Neto, Fernando B.
   Braga-Neto, Ulisses
   Bigham, Abigail W.
   Bamshad, Michael
   Marques, Ernesto T. A.
   Acioli-Santos, Bartolomeu
TI Severe Dengue Prognosis Using Human Genome Data and Machine Learning
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Dengue genetics; severe dengue; complex genome signatures; machine
   learning
ID T-CELL RESPONSES; HEMORRHAGIC-FEVER; CROSS-VALIDATION; IMMUNE
   ACTIVATION; VIRUS-INFECTIONS; SHOCK SYNDROME; GENE; CLASSIFICATION;
   POLYMORPHISMS; CANCER
AB Dengue has become one of the most important worldwide arthropod-borne diseases. Dengue phenotypes are based on laboratorial and clinical exams, which are known to be inaccurate. Objective: We present a machine learning approach for the prediction of dengue fever severity based solely on human genome data. Methods: One hundred and two Brazilian dengue patients and controls were genotyped for 322 innate immunity single nucleotide polymorphisms (SNPs). Our model uses a support vector machine algorithm to find the optimal loci classification subset and then an artificial neural network (ANN) is used to classify patients into dengue fever or severe dengue. Results: The ANN trained on 13 key immune SNPs selected under dominant or recessive models produced median values of accuracy greater than 86%, and sensitivity and specificity over 98% and 51%, respectively. Conclusion: The proposed classification method, using only genome markers, can be used to identify individuals at high risk for developing the severe dengue phenotype even in un-infected conditions. Significance: Our results suggest that the genetic context is a key element in phenotype definition in dengue. The methodology proposed here is extendable to other Mendelian based and genetically influenced diseases.
C1 [Davi, Caio] Texas A&M Univ, Dept Elect & Comp Engn, Pernambuco Fed Inst Educ, College Stn, TX 77843 USA.
   [Pastor, Andre] Sertao Pernambucano Fed Inst Educ Sci & Technol, Petrolina, PE, Brazil.
   [Oliveira, Thiego; de Lima Neto, Fernando B.] Univ Pernambuco, Dept Comp Engn, Recife, PE, Brazil.
   [Braga-Neto, Ulisses] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX 77843 USA.
   [Bigham, Abigail W.] Univ Michigan, Dept Anthropol, Ann Arbor, MI 48109 USA.
   [Bamshad, Michael] Univ Washington, Seattle, WA 98195 USA.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Acioli-Santos, Bartolomeu] Oswaldo Cruz Fundat, Dept Virol, Aggeu Magalhaes Inst, Recife, PE, Brazil.
RP Acioli-Santos, B (corresponding author), Oswaldo Cruz Fundat, Dept Virol, Aggeu Magalhaes Inst, Recife, PE, Brazil.
EM bartacioli@cpqam.fiocruz.br
RI Batista, Ewerthon/AAY-5409-2020; Marques, Ernesto T. A/L-4967-2013; Lima
   Neto, Fernando/G-4592-2011
OI Marques, Ernesto T. A/0000-0003-3826-9358; Santos, Bartolomeu Acioli
   dos/0000-0002-4994-0648; Davi, Caio/0000-0001-8609-5458; Lima Neto,
   Fernando/0000-0003-1200-225X; Pastor, Andre/0000-0002-5133-9616
FU PROEP-FIOCRUZ-CPqAM [APQ-1597-2-02/15CNPq]; PAPES VIINational Council
   for Scientific and Technological Development (CNPq) [401910/2015-6]
FX The work of B. AcioliSantos was supported in part by the
   PROEP-FIOCRUZ-CPqAM under Grant APQ-1597-2-02/15CNPq and in part by
   PAPES VII under Grant 401910/2015-6.
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Ali I., 2017, J APPL BIOINFORMA CO, V3
   [Anonymous], 2013, NATURE, V496, P398, DOI DOI 10.1038/496398A
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Ball TB, 2007, AIDS, V21, P1091, DOI 10.1097/QAD.0b013e3280ef6ae1
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   Braga-Neto U, 2004, PATTERN RECOGN, V37, P1267, DOI 10.1016/j.patcog.2003.08.017
   Braga-Neto UM, 2014, BIOINFORMATICS, V30, P3349, DOI 10.1093/bioinformatics/btu527
   Braga-Neto UM, 2004, BIOINFORMATICS, V20, P374, DOI 10.1093/bioinformatics/btg419
   Brasier AR, 2015, J CLIN VIROL, V64, P97, DOI 10.1016/j.jcv.2015.01.011
   Brasier AR, 2012, AM J TROP MED HYG, V86, P341, DOI 10.4269/ajtmh.2012.11-0469
   Butthep P, 2006, PEDIATR INFECT DIS J, V25, P894, DOI 10.1097/01.inf.0000237918.85330.b9
   BYRD RH, 1995, SIAM J SCI COMPUT, V16, P1190, DOI 10.1137/0916069
   Chakrabarti A, 2011, J INTERF CYTOK RES, V31, P49, DOI 10.1089/jir.2010.0120
   Chang TH, 2006, MICROBES INFECT, V8, P157, DOI 10.1016/j.micinf.2005.06.014
   Chatterjee S, 2018, MED BIOL ENG COMPUT, V56, P709, DOI 10.1007/s11517-017-1722-y
   Chen W, 2017, SCI REP-UK, V7, DOI 10.1038/srep40242
   Choi, 2015, EXP MOL MED, V47
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   Davi C., 2018, P 11 BRAZ S BIOINF, P28
   Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Fan RE, 2008, J MACH LEARN RES, V9, P1871
   Fang X, 2012, FEMS IMMUNOL MED MIC, V66, P134, DOI 10.1111/j.1574-695X.2012.00995.x
   Fathima AS, 2011, INT J COMPUTER SCI I, V8, P322
   Fernandez-Rodriguez A, 2015, INFECT GENET EVOL, V36, P339, DOI 10.1016/j.meegid.2015.10.006
   Gomes ALV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011267
   Green DS, 2017, J BIOL CHEM, V292, P13925, DOI 10.1074/jbc.R116.774745
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   He XB, 2013, ACTA BIOCH BIOPH SIN, V45, P241, DOI 10.1093/abbs/gms122
   Hsieh MF, 2006, J IMMUNOL, V177, P1855, DOI 10.4049/jimmunol.177.3.1855
   Huang SJ, 2018, CANCER GENOM PROTEOM, V15, P41, DOI 10.21873/cgp.20063
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P985, DOI 10.1073/pnas.0609954104
   Jiang XD, 2014, 2014 IEEE GLOBAL CONFERENCE ON SIGNAL AND INFORMATION PROCESSING (GLOBALSIP), P1398, DOI 10.1109/GlobalSIP.2014.7032357
   Kantarci OH, 2008, ARCH NEUROL-CHICAGO, V65, P349, DOI 10.1001/archneurol.2007.66
   Kayesh MEH, 2017, INFECT GENET EVOL, V51, P203, DOI 10.1016/j.meegid.2017.04.003
   Keogh E., 2011, ENCY MACHINE LEARNIN, P257, DOI DOI 10.1007/978-0-387-30164-8_192
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Lim SM, 2016, ONCOTARGET, V7, P24942, DOI 10.18632/oncotarget.7886
   Lin RJ, 2009, J IMMUNOL, V183, P8035, DOI 10.4049/jimmunol.0902728
   Lingappa JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028632
   Lins AJCC, 2017, COMPUT METH PROG BIO, V152, P93, DOI 10.1016/j.cmpb.2017.09.013
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mangada MM, 2002, J INFECT DIS, V185, P1697, DOI 10.1086/340822
   McLachlan G., 2005, ANAL MICROARRAY GENE, V422
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Muthusamy K, 2016, INDIAN J MED RES, V144, P587, DOI 10.4103/0971-5916.200894
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Tuan NM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003638
   Palma-Ocampo HK, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0383-4
   Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   PEREZ MLP, 1987, HAEMATOLOGIA, V20, P83
   Phakhounthong K, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1078-y
   Powers D. M. W., 2011, J MACH LEARN TECHNOL, V2, P37, DOI DOI 10.9735/2229-3981
   Radzol ARM, 2017, P ANN INT IEEE EMBS, P2875, DOI 10.1109/EMBC.2017.8037457
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Sethi L., 2013, YEAST, V1484
   Sharma D, 2015, J VIROL, V89, P1489, DOI 10.1128/JVI.02027-14
   Shathasivam P, 2015, P NATL ACAD SCI USA, V112, pE3000, DOI 10.1073/pnas.1504671112
   Shaukat, 2015, ARXIV151107353
   Siriyasatien P, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1034-5
   Soundravally R, 2007, HUM IMMUNOL, V68, P973, DOI 10.1016/j.humimm.2007.09.007
   Sreenivasan P, 2018, INDIAN J PEDIATR, V85, P433, DOI 10.1007/s12098-017-2591-y
   Tang J, 2014, I C NETWORK PROTOCOL, P374, DOI 10.1109/ICNP.2014.61
   Tanner L, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000196
   Useche YM, 2019, J INFECT PUBLIC HEAL, V12, P43, DOI 10.1016/j.jiph.2018.08.009
   Wang WK, 2003, VIROLOGY, V305, P330, DOI 10.1006/viro.2002.1704
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Xavier-Carvalho C, 2017, INFECT GENET EVOL, V56, P99, DOI 10.1016/j.meegid.2017.11.009
   Zhang JY, 2008, PROG NAT SCI-MATER, V18, P741, DOI 10.1016/j.pnsc.2007.11.022
NR 81
TC 5
Z9 5
U1 0
U2 9
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
EI 1558-2531
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD OCT
PY 2019
VL 66
IS 10
BP 2861
EP 2868
DI 10.1109/TBME.2019.2897285
PG 8
WC Engineering, Biomedical
SC Engineering
GA IZ6LA
UT WOS:000487192000017
PM 30716030
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Drexler, JF
AF Marques, Ernesto T. A.
   Drexler, Jan Felix
TI Complex Scenario of Homotypic and Heterotypic Zika Virus Immune
   Enhancement
SO MBIO
LA English
DT Letter
DE Zika virus; antibody-dependent enhancement; congenital malformation;
   outbreak
C1 [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Marques, Ernesto T. A.] Fundacao Oswaldo Cruz MS, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Drexler, Jan Felix] Charite Univ Med Berlin, Inst Virol, Berlin, Germany.
   [Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Humbold Univ Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Berlin Inst Hlth, Berlin, Germany.
   [Drexler, Jan Felix] Charite Univ Med Berlin, German Ctr Infect Res DAB, Berlin, Germany.
RP Drexler, JF (corresponding author), Charite Univ Med Berlin, Inst Virol, Berlin, Germany.; Drexler, JF (corresponding author), Free Univ Berlin, Berlin, Germany.; Drexler, JF (corresponding author), Humbold Univ Berlin, Berlin, Germany.; Drexler, JF (corresponding author), Berlin Inst Hlth, Berlin, Germany.; Drexler, JF (corresponding author), Charite Univ Med Berlin, German Ctr Infect Res DAB, Berlin, Germany.
EM felix.drexler@charite.de
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
FU European Union's Horizon 2020 research and innovation program through
   the ZIKAlliance project [734548]
FX This work was supported by the European Union's Horizon 2020 research
   and innovation program through the ZIKAlliance project (grant agreement
   734548).
CR Castanha PMS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007246
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726
   Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Lum FM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20305-4
   Maidji E, 2006, AM J PATHOL, V168, P1210, DOI 10.2353/ajpath.2006.050482
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mbio.01390-17, 10.1128/mBio.01390-17]
   Pedroso C, 2019, EMERG INFECT DIS, V25, P1485, DOI 10.3201/eid2508.190113
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Shim BS, 2019, MBIO, V10, DOI 10.1128/mBio.00758-19
   Zambrana JV, 2018, P NATL ACAD SCI USA, V115, P9294, DOI 10.1073/pnas.1804672115
NR 13
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2019
VL 10
IS 5
AR e01849-19
DI 10.1128/mBio.01849-19
PG 2
WC Microbiology
SC Microbiology
GA JJ1JB
UT WOS:000493915800002
PM 31481385
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Lima, MC
   de Mendonca, LR
   Rezende, AM
   Carrera, RM
   Anibal-Silva, CE
   Demers, M
   D'Aiuto, L
   Wood, J
   Chowdari, KV
   Griffiths, M
   Lucena-Araujo, AR
   Barral-Netto, M
   Azevedo, EAN
   Alves, RW
   Farias, PCS
   Marques, ETA
   Castanha, PMS
   Donald, CL
   Kohl, A
   Nimgaonkar, VL
   Franca, RFO
AF Lima, Morganna C.
   de Mendonca, Leila R.
   Rezende, Antonio M.
   Carrera, Raquel M.
   Anibal-Silva, Conceicao E.
   Demers, Matthew
   D'Aiuto, Leonardo
   Wood, Joel
   Chowdari, Kodavali, V
   Griffiths, Michael
   Lucena-Araujo, Antonio R.
   Barral-Netto, Manoel
   Azevedo, Elisa A. N.
   Alves, Renan W.
   Farias, Pablo C. S.
   Marques, Ernesto T. A.
   Castanha, Priscila M. S.
   Donald, Claire L.
   Kohl, Alain
   Nimgaonkar, Vishwajit L.
   Franca, Rafael F. O.
TI The Transcriptional and Protein Profile From Human Infected
   Neuroprogenitor Cells Is Strongly Correlated to Zika Virus Microcephaly
   Cytokines Phenotype Evidencing a Persistent Inflammation in the CNS
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Zika virus; central nervous system; inflammation; type-I interferon;
   interferonopathy; microcephaly; Zika congenital syndrome and cytokines
ID INTERFERON-ALPHA; NEURAL PROGENITORS; GENE-EXPRESSION; HUMAN BRAIN;
   STEM-CELLS; CXCL10; ASTROCYTES; DIFFERENTIATION; ACTIVATION; EXPOSURE
AB Zika virus (ZIKV) infection during pregnancy is associated with microcephaly, a congenital malformation resulting from neuroinflammation and direct effects of virus replication on the developing central nervous system (CNS). However, the exact changes in the affected CNS remain unknown. Here, we show by transcriptome analysis (at 48 h post-infection) and multiplex immune profiling that human induced-neuroprogenitor stem cells (hiNPCs) respond to ZIKV infection with a strong induction of type-I interferons (IFNs) and several type-I IFNs stimulated genes (ISGs), notably cytokines and the pro-apoptotic chemokines CXCL9 and CXCL10. By comparing the inflammatory profile induced by a ZIKV Brazilian strain with an ancestral strain isolated from Cambodia in 2010, we observed that the response magnitude differs among them. Compared to ZIKV/Cambodia, the experimental infection of hiNPCs with ZIKV/Brazil resulted in a diminished induction of ISGs and lower induction of several cytokines (IFN-alpha, IL-1 alpha/beta, IL-6, IL-8, and IL-15), consequently favoring virus replication. From ZIKV-confirmed infant microcephaly cases, we detected a similar profile characterized by the presence of IFN-alpha, CXCL10, and CXCL9 in cerebrospinal fluid (CSF) samples collected after birth, evidencing a sustained CNS inflammation. Altogether, our data suggest that the CNS may be directly affected due to an unbalanced and chronic local inflammatory response, elicited by ZIKV infection, which contributes to damage to the fetal brain.
C1 [Lima, Morganna C.; de Mendonca, Leila R.; Rezende, Antonio M.; Anibal-Silva, Conceicao E.; Azevedo, Elisa A. N.; Alves, Renan W.; Farias, Pablo C. S.; Marques, Ernesto T. A.; Franca, Rafael F. O.] Fiocruz MS, Oswaldo Cruz Fdn, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Carrera, Raquel M.; Griffiths, Michael] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Demers, Matthew; D'Aiuto, Leonardo; Wood, Joel; Chowdari, Kodavali, V; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
   [Lucena-Araujo, Antonio R.] Fed Univ Pemambuco UFPE, Recife, PE, Brazil.
   [Barral-Netto, Manoel] Fiocruz MS, Oswaldo Cruz Fdn, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Marques, Ernesto T. A.; Castanha, Priscila M. S.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Donald, Claire L.; Kohl, Alain] Univ Glasgow, Ctr Vitus Res, MRC, Glasgow, Lanark, Scotland.
   [Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
RP Franca, RFO (corresponding author), Fiocruz MS, Oswaldo Cruz Fdn, Inst Aggeu Magalhaes, Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br
RI Da Silva Castanha, Priscila Mayrelle/G-1785-2012; Marques, Ernesto T.
   A/L-4967-2013; Barral Netto, Manoel/B-3904-2009; Rezende, Antonio
   Mauro/S-2126-2018
OI Da Silva Castanha, Priscila Mayrelle/0000-0002-1220-5308; Marques,
   Ernesto T. A/0000-0003-3826-9358; Azevedo, Elisa/0000-0002-1774-4095;
   Donald, Claire/0000-0002-4370-0707; Demers, Matthew/0000-0002-4103-9812;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Barral Netto,
   Manoel/0000-0002-5823-7903; Rezende, Antonio Mauro/0000-0003-4775-1779
FU Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco/FACEPE
   [APQ-0055.2.11/16, APQ-0044.2.11/16]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPqNational Council for
   Scientific and Technological Development (CNPq) [439975/2016-6]; UK
   Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12014/8, MR/N017552/1]; Stanley Medical Research Institute
   [07R-1712]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [MH63480, D43 TW009114]; Cura Zika-University of Pittsburgh
FX The research leading to these results received funding from the Fundacao
   de Amparo a Ciencia e Tecnologia de Pernambuco/FACEPE, grant agreement
   nos. APQ-0055.2.11/16 and APQ-0044.2.11/16, and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPq grant agreement
   439975/2016-6 under RF coordination and responsibility. UK Medical
   Research Council Grants MC_UU_12014/8 and MR/N017552/1 under AK's
   coordination. VN received grant support from the Stanley Medical
   Research Institute (07R-1712), National Institutes of Health (MH63480
   and D43 TW009114) and Cura Zika-University of Pittsburgh. The funders
   had no role in study design, data collection, and analysis, decision to
   publish, or preparation of the manuscript.
CR Akwa Y, 1998, J IMMUNOL, V161, P5016
   Asensio VC, 2001, J VIROL, V75, P7067, DOI 10.1128/JVI.75.15.7067-7077.2001
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Blank T, 2016, IMMUNITY, V44, P901, DOI 10.1016/j.immuni.2016.04.005
   Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164
   Brahma R, 2018, VIRAL IMMUNOL, V31, P321, DOI 10.1089/vim.2017.0116
   Brito CAA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3313-4
   Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005
   Brownell J, 2014, J VIROL, V88, P1582, DOI 10.1128/JVI.02007-13
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campbell IL, 1999, BRAIN RES, V835, P46, DOI 10.1016/S0006-8993(99)01328-1
   Castro MAA, 2009, BIOINFORMATICS, V25, P1468, DOI 10.1093/bioinformatics/btp246
   Chimelli L, 2018, J NEUROPATH EXP NEUR, V77, P193, DOI 10.1093/jnen/nlx116
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125
   Crow YJ, 2011, ANN NY ACAD SCI, V1238, P91, DOI 10.1111/j.1749-6632.2011.06220.x
   Cuadrado E, 2013, BRAIN, V136, P245, DOI 10.1093/brain/aws321
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Devakumar D, 2018, LANCET INFECT DIS, V18, pE1, DOI [10.1016/s1473-3099(17)30398-5, 10.1016/S1473-3099(17)30398-5]
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Esser-Nobis K, 2019, J VIROL, V93, DOI 10.1128/JVI.00640-19
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Gabriel E, 2017, CELL STEM CELL, V20, P397, DOI 10.1016/j.stem.2016.12.005
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Goutieres F, 1998, ANN NEUROL, V44, P900, DOI 10.1002/ana.410440608
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Hanners NW, 2016, CELL REP, V15, P2315, DOI 10.1016/j.celrep.2016.05.075
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107
   Huang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34793
   Klein RS, 2005, J VIROL, V79, P11457, DOI 10.1128/JVI.79.17.11457-11466.2005
   Klok MD, 2015, ANN CLIN TRANSL NEUR, V2, P774, DOI 10.1002/acn3.213
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2016, JAMA-J AM MED ASSOC, V315, P1945, DOI 10.1001/jama.2016.2899
   Li C, 2016, CELL STEM CELL, V19, P672, DOI 10.1016/j.stem.2016.10.017
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Naveca FG, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170542
   Ornelas AMM, 2017, ANN NEUROL, V81, P152, DOI 10.1002/ana.24839
   Padovan E, 2002, J LEUKOCYTE BIOL, V71, P669
   Paz-Bailey G, 2019, NEW ENGL J MED, V380, P198, DOI 10.1056/NEJMc1814416
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Shipley Mackenzie M, 2016, J Vis Exp, P53193, DOI 10.3791/53193
   Singh PK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29329-2
   Souza BSF, 2016, SCI REP-UK, V6, DOI 10.1038/srep39775
   Sui YJ, 2006, EUR J NEUROSCI, V23, P957, DOI 10.1111/j.1460-9568.2006.04631.x
   Sui YJ, 2004, AM J PATHOL, V164, P1557, DOI 10.1016/S0002-9440(10)63714-5
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   van Heteren JT, 2008, GLIA, V56, P568, DOI 10.1002/glia.20639
   Yockey LJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao1680
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zanini F, 2018, ELIFE, V7, DOI 10.7554/eLife.32942
   Zhang F, 2017, EBIOMEDICINE, V25, P95, DOI 10.1016/j.ebiom.2017.10.019
NR 69
TC 6
Z9 6
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 16
PY 2019
VL 10
AR 1928
DI 10.3389/fimmu.2019.01928
PG 14
WC Immunology
SC Immunology
GA IR4ZR
UT WOS:000481443300001
PM 31474994
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Lebov, JF
   Arias, JF
   Balmaseda, A
   Britt, W
   Cordero, JF
   Galvao, LA
   Garces, AL
   Hambidge, KM
   Harris, E
   Ko, A
   Krebs, N
   Marques, ETA
   Martinez, AM
   McClure, E
   Miranda, DB
   Moreira, MEL
   Mussi-Pinhata, MM
   Ochoa, TJ
   Osorio, JE
   Scalabrin, DMF
   Schultz-Cherry, S
   Seage, GR
   Stolka, K
   Ugarte-Gil, CA
   Vega, CMV
   Welton, M
   Ximenes, R
   Zorrilla, C
AF Lebov, Jill F.
   Arias, Juan F.
   Balmaseda, Angel
   Britt, William
   Cordero, Jose F.
   Galvao, Luiz Augusto
   Garces, Ana Lucia
   Hambidge, K. Michael
   Harris, Eva
   Ko, Albert
   Krebs, Nancy
   Marques, Ernesto T. A.
   Martinez, Alexander M.
   McClure, Elizabeth
   Miranda-Filho, Democrito B.
   Lopes Moreira, Maria Elisabeth
   Mussi-Pinhata, Marisa M.
   Ochoa, Theresa J.
   Osorio, Jorge E.
   Scalabrin, Deolinda M. F.
   Schultz-Cherry, Stacey
   Seage, George R., III
   Stolka, Kristen
   Augusto Ugarte-Gil, Cesar
   Vega, Carmen Milagros Velez
   Welton, Michael
   Ximenes, Ricardo
   Zorrilla, Carmen
TI International prospective observational cohort study of Zika in infants
   and pregnancy (ZIP study): study protocol
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Zika virus; Pregnancy; Latin America; Microcephaly
ID VIRUS-INFECTION; BIRTH-DEFECTS; CLINICAL-MANIFESTATIONS; EMERGENCE;
   EXPOSURE; FETUSES; HISTORY; UPDATE; STATES; BRAZIL
AB Background Until recently, Zika virus (ZIKV) infections were considered mild and self-limiting. Since 2015, they have been associated with an increase in microcephaly and other birth defects in newborns. While this association has been observed in case reports and epidemiological studies, the nature and extent of the relationship between ZIKV and adverse pregnancy and pediatric health outcomes is not well understood. With the unique opportunity to prospectively explore the full spectrum of issues related to ZIKV exposure during pregnancy, we undertook a multi-country, prospective cohort study to evaluate the association between ZIKV and pregnancy, neonatal, and infant outcomes. Methods At research sites in ZIKV endemic regions of Brazil (4 sites), Colombia, Guatemala, Nicaragua, Puerto Rico (2 sites), and Peru, up to 10,000 pregnant women will be recruited and consented in the first and early second trimesters of pregnancy and then followed through delivery up to 6 weeks post-partum; their infants will be followed until at least 1 year of age. Pregnant women with symptomatic ZIKV infection confirmed by presence of ZIKV RNA and/or IgM for ZIKV will also be enrolled, regardless of gestational age. Participants will be tested monthly for ZIKV infection; additional demographic, physical, laboratory and environmental data will be collected to assess the potential interaction of these variables with ZIKV infection. Delivery outcomes and detailed infant assessments, including physical and neurological outcomes, will be obtained. Discussion With the emergence of ZIKV in the Americas and its association with adverse pregnancy outcomes in this region, a much better understanding of the spectrum of clinical outcomes associated with exposure to ZIKV during pregnancy is needed. This cohort study will provide information about maternal, fetal, and infant outcomes related to ZIKV infection, including congenital ZIKV syndrome, and manifestations that are not detectable at birth but may appear during the first year of life. In addition, the flexibility of the study design has provided an opportunity to modify study parameters in real time to provide rigorous research data to answer the most critical questions about the impact of congenital ZIKV exposure.
C1 [Lebov, Jill F.; McClure, Elizabeth; Stolka, Kristen] RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
   [Arias, Juan F.; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
   [Balmaseda, Angel] Complejo Nacl Salud, Ctr Nacl Diagnost & Referencia, Managua, Nicaragua.
   [Britt, William] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
   [Cordero, Jose F.; Welton, Michael] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Galvao, Luiz Augusto] Fiocruz MS, Ctr Global Hlth CRIS, Rio De Janeiro, Brazil.
   [Garces, Ana Lucia] Fdn Alimentac & Nutr Cent Amer & Panama INCAP, Guatemala City, Guatemala.
   [Hambidge, K. Michael; Krebs, Nancy] Univ Colorado, Sect Nutr, Pediat, Aurora, CO USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Fundacao Oswaldo Cruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] Fiocruz MS, Dept Virol & Expt Therapeut, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Martinez, Alexander M.] Imbanaco Med Ctr, Res Inst, Cali, Colombia.
   [Miranda-Filho, Democrito B.] Univ Pernambuco, Programa Posgrad Ciencias Saude PPGCS, Microcephaly Epidem Res Grp, Recife, PE, Brazil.
   [Lopes Moreira, Maria Elisabeth] Fiocruz MS, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru.
   [Osorio, Jorge E.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Seage, George R., III] Harvard Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Vega, Carmen Milagros Velez] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Ximenes, Ricardo] Univ Fed Pernambuco, Microcephaly Epidem Res Grp, Dept Med Trop, Recife, PE, Brazil.
   [Zorrilla, Carmen] Maternal Infant Studies Ctr CEMI, San Juan, PR USA.
RP Lebov, JF (corresponding author), RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
EM jlebov@rti.org
RI Ugarte-Gil, Cesar/E-6074-2013; Marques, Ernesto T. A/L-4967-2013; Ko,
   Albert Icksang/P-2343-2015; Moreira, Maria Elisabeth Lopes/AAA-3775-2020
OI Ugarte-Gil, Cesar/0000-0002-2833-9087; Marques, Ernesto T.
   A/0000-0003-3826-9358; Ko, Albert Icksang/0000-0001-9023-2339; Moreira,
   Maria Elisabeth Lopes/0000-0002-2034-0294; McClure,
   Elizabeth/0000-0001-8659-5444; Martinez-Blanco, Alexander
   Maximiliano/0000-0001-5755-1776; Galvao, Luiz
   Augusto/0000-0002-3918-0286
FU U.S. National Institute of Child Health and Human Development
   (NICHD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute of Environmental Health Sciences (NIEHS)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS);
   Fundacao Oswaldo Cruz-Fiocruz, Brazil; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [U01HD040636, U01HD040636, U01HD040636, U01HD040636]
   Funding Source: NIH RePORTER
FX This study is funded through grants from the U.S. National Institute of
   Child Health and Human Development (NICHD); National Institute of
   Allergy and Infectious Diseases (NIAID); National Institute of
   Environmental Health Sciences (NIEHS); and Fundacao Oswaldo
   Cruz-Fiocruz, Brazil. Representatives from each institution provided
   general support, scientific input, and peer review of the study design,
   protocol, consent forms, data collection forms, and analysis plan.
CR Albuquerque MDPM, 2016, EMERG INFECT DIS, V22, P1090, DOI [10.32032/eid2206.160062, 10.3201/eid2206.160062]
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Besnard M, 2016, EUROSURVEILLANCE, V21, P22, DOI 10.2807/1560-7917.ES.2016.21.13.30181
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cerbino-Neto J, 2016, EMERG INFECT DIS, V22, P1318, DOI 10.3201/eid2207.160375
   Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Guillemette-Artur P, 2016, PEDIATR RADIOL, V46, P1032, DOI 10.1007/s00247-016-3619-6
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Hurtado-Villa P, 2017, PEDIATR INFECT DIS J, V36, P1017, DOI [10.1097/INF.0000000000001670, 10.1097/inf.0000000000001670]
   Kleber de Oliveira Wanderson, 2016, MMWR Morb Mortal Wkly Rep, V65, P242, DOI 10.15585/mmwr.mm6509e2
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Cuevas EL, 2016, MMWR-MORBID MORTAL W, V65, P1409, DOI 10.15585/mmwr.mm6549e1
   Mallet H. P., 2016, Bulletin Epidemiologique Hebdomadaire, P367
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Paixao ES, 2016, AM J PUBLIC HEALTH, V106, P606, DOI 10.2105/AJPH.2016.303112
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Prazeres J, 2016, BRAZIL JAMA OPHTHALM, V134, P529, DOI [10.1001/jamaophthalmol.2016.0267, DOI 10.1001/JAMA0PHTHALM0L.2016.0267]
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zin AA, 2017, JAMA PEDIATR, V171, P847, DOI 10.1001/jamapediatrics.2017.1474
NR 33
TC 5
Z9 5
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD AUG 7
PY 2019
VL 19
IS 1
AR 282
DI 10.1186/s12884-019-2430-4
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA IO2TY
UT WOS:000479235900001
PM 31391005
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Castanha, PMS
   Souza, WV
   Braga, C
   de Araujo, TVB
   Ximenes, RAA
   Albuquerque, MDPM
   Montarroyos, UR
   Miranda, DB
   Cordeiro, MT
   Dhalia, R
   Marques, ETA
   Rodrigues, LC
   Martelli, CMT
   de Brito, CAA
   Batista, JDL
   Bezerra, LCA
   Rocha, MAW
   Carvalho, MDCG
   Silva, PFS
   Pastich, F
   Valongueiro, S
   Melo, AP
   Montarroyos, U
   Ramos, RCF
   Brandao, SP
AF Castanha, Priscila M. S.
   Souza, Wayner V.
   Braga, Cynthia
   Barreto de Araujo, Thalia Velho
   Ximenes, Ricardo A. A.
   Albuquerque, Maria de Fatima P. M.
   Montarroyos, Ulisses R.
   Miranda-Filho, Democrito B.
   Cordeiro, Marli T.
   Dhalia, Rafael
   Marques, Ernesto T. A., Jr.
   Rodrigues, Laura C.
   Martelli, Celina M. T.
   Antunes de Brito, Carlos Alexandre
   Lyra Batista, Joanna d'Arc
   Albuquerque Bezerra, Luciana Caroline
   Wanderley Rocha, Maria Angela
   Costa Gomes Carvalho, Maria Durce
   Sobral Silva, Paula Fabiana
   Pastich, Fabiana
   Valongueiro, Sandra
   Melo, Ana Paula
   Montarroyos, Ulisses
   Ferreira Ramos, Regina Coeli
   Brandao Filho, Sinval Pinto
CA Microcephaly Epidemic Res Grp
TI Perinatal analyses of Zika- and dengue virus-specific neutralizing
   antibodies: A microcephaly case-control study in an area of high dengue
   endemicity in Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID LOAD
AB Laboratory confirmation of Zika virus (ZIKV) infection during pregnancy is challenging due to cross-reactivity with dengue virus (DENV) and limited knowledge about the kinetics of anti-Zika antibody responses during pregnancy. We described ZIKV and DENV serological markers and the maternal-fetal transfer of antibodies among mothers and neonates after the ZIKV microcephaly outbreak in Northeast Brazil (2016). We included 89 microcephaly cases and 173 neonate controls at time of birth and their mothers. Microcephaly cases were defined as newborns with a particular head circumference (2 SD below the mean). Two controls without microcephaly were matched by the expected date of delivery and area of residence. We tested maternal serum for recent (ZIKV genome, IgM and IgG3 anti-NS1) and previous (ZIKV and DENV neutralizing antibodies [NAbs]) markers of infection. Multiple markers of recent or previous ZIKV and DENV infection in mothers were analyzed using principal component analysis (PCA). At delivery, 5.6% of microcephaly case mothers and 1.7% of control mothers were positive for ZIKV IgM. Positivity for ZIKV IgG3 anti-NS1 was 8.0% for case mothers and 3.5% for control mothers. ZIKV NAbs was slightly higher among mothers of cases (69.6%) than that of mothers of controls (57.2%; p = 0.054). DENV exposure was detected in 85.8% of all mothers. PCA discriminated two distinct components related to recent or previous ZIKV infection and DENV exposure. ZIKV NAbs were higher in newborns than in their corresponding mothers (p<0.001). We detected a high frequency of ZIKV exposure among mothers after the first wave of the ZIKV outbreak in Northeast Brazil. However, we found low sensitivity of the serological markers to recent infection (IgM and IgG3 anti-NS1) in perinatal samples of mothers of microcephaly cases. Since the neutralization test cannot precisely determine the time of infection, testing for ZIKV immune status should be performed as early as possible and throughout pregnancy to monitor acute Zika infection in endemic areas.
C1 [Castanha, Priscila M. S.; Souza, Wayner V.; Braga, Cynthia; Barreto de Araujo, Thalia Velho; Albuquerque, Maria de Fatima P. M.; Cordeiro, Marli T.; Dhalia, Rafael; Marques, Ernesto T. A., Jr.; Martelli, Celina M. T.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Recife, PE, Brazil.
   [Castanha, Priscila M. S.; Ximenes, Ricardo A. A.; Montarroyos, Ulisses R.; Miranda-Filho, Democrito B.] Univ Pernambuco, Sch Med Sci, Recife, PE, Brazil.
   [Barreto de Araujo, Thalia Velho; Ximenes, Ricardo A. A.] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Rodrigues, Laura C.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
RP Martelli, CMT (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Recife, PE, Brazil.
EM turchicm@gmail.com
RI Da Silva Castanha, Priscila Mayrelle/G-1785-2012; Souza, Wayner
   V/H-3798-2013; Dhalia, Rafael/AAD-5432-2020; Braga, Maria
   Cynthia/A-8204-2013; Marques, Ernesto T. A/L-4967-2013; Montarroyos,
   Ulisses/AAJ-7527-2020
OI Da Silva Castanha, Priscila Mayrelle/0000-0002-1220-5308; Braga, Maria
   Cynthia/0000-0002-7862-6455; Marques, Ernesto T. A/0000-0003-3826-9358;
   Turchi Martelli, Celina Maria/0000-0002-2491-0688
FU Brazilian Ministry of Health, Pan American Health Organization,
   Enhancing Research Activity in Epidemic Situations; National Advisory
   Board of Scientific and Technological Development (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico [CNPq])National Council for
   Scientific and Technological Development (CNPq) [306708/2014-0,
   308818/2013-0, 308590/2013-9, 308491/2013-0, 304174/2014-9,
   306222/2013-2]; European Union's Horizon 2020 research and innovation
   programme under Zika-PLAN [734584]; CuraZika
FX This study was funded by the Brazilian Ministry of Health, Pan American
   Health Organization, Enhancing Research Activity in Epidemic Situations.
   Some of the investigators received partial support from the National
   Advisory Board of Scientific and Technological Development (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico [CNPq]; scholarship
   306708/2014-0 to CMTM, 308818/2013-0 to RAAX, 308590/2013-9 to DBM-F,
   308491/2013-0 to MFPMA, 304174/2014-9 to CB, and 306222/2013-2 to WVS).
   LCR is partly funded by the European Union's Horizon 2020 research and
   innovation programme under Zika-PLAN (grant agreement no. 734584). The
   study also received parcial support from CuraZika to ETAM. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Andrade DV, 2018, VIRUS RES, V254, P27, DOI 10.1016/j.virusres.2017.06.019
   Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Barreto ML, 2016, LANCET, V387, P919, DOI 10.1016/S0140-6736(16)00545-6
   Barzon L, 2018, CLIN INFECT DIS, V66, P1173, DOI 10.1093/cid/cix967
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brazilian Minister of Health, 2017, MONITORAMENTO DOS CA
   Brazilian Minister of Health, 2017, 57 BRAZ MIN HLTH
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fritzell C, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006533
   Goncalves A, 2018, J INFECT DIS, V217, P1060, DOI 10.1093/infdis/jix678
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Keasey SL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00036-17
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Krow-Lucal ER, 2018, LANCET CHILD ADOLESC, V2, P204, DOI 10.1016/S2352-4642(18)30020-8
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lindsey NP, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01115-17
   Maeda A, 2013, VET J, V195, P33, DOI 10.1016/j.tvjl.2012.08.019
   Magalhaes T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006055
   Marinho F, 2016, EPIDEMIOL SERV SAUDE, V25, P701, DOI [10.5123/s1679-49742016000400004, 10.5123/S1679-49742016000400004]
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mbio.01390-17, 10.1128/mBio.01390-17]
   Pan American Health Organization, 2019, EP UPD YELL FEV 25 J
   Pan American Health Organization, 2018, EP REP BRAZ
   Pan American Health Organization, 2018, REG ZIK EP UPD AM
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Simmons G, 2018, CLIN INFECT DIS, V66, P1181, DOI 10.1093/cid/cix972
   SMFM Consult Series #39, 2016, J INFECT DIS, V214, pB9
   World Health Organization, 2018, ZIK VIR SIT REP
   World Health Organization, 2018, ZIK VIR FACT SHEET
   Ye Q, 2016, INFECT GENET EVOL, V43, P43, DOI 10.1016/j.meegid.2016.05.004
NR 46
TC 9
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2019
VL 13
IS 3
AR e0007246
DI 10.1371/journal.pntd.0007246
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA HS3YU
UT WOS:000463799300043
PM 30856223
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Rodriguez-Barraquer, I
   Costa, F
   Nascimento, EJM
   Nery, N
   Castanha, PMS
   Sacramento, GA
   Cruz, J
   Carvalho, M
   De Olivera, D
   Hagan, JE
   Adhikarla, H
   Wunder, EA
   Coelho, DF
   Azar, SR
   Rossi, SL
   Vasilakis, N
   Weaver, SC
   Ribeiro, GS
   Balmaseda, A
   Harris, E
   Nogueira, ML
   Reis, MG
   Marques, ETA
   Cummings, DAT
   Ko, AI
AF Rodriguez-Barraquer, Isabel
   Costa, Federico
   Nascimento, Eduardo J. M.
   Nery Junior, Nivison
   Castanha, Priscila M. S.
   Sacramento, Gielson Almeida
   Cruz, Jaqueline
   Carvalho, Mayara
   De Olivera, Daiana
   Hagan, Jose E.
   Adhikarla, Haritha
   Wunder, Elsio A., Jr.
   Coelho, Danilo F.
   Azar, Sasha R.
   Rossi, Shannan L.
   Vasilakis, Nikos
   Weaver, Scott C.
   Ribeiro, Guilherme S.
   Balmaseda, Angel
   Harris, Eva
   Nogueira, Mauricio L.
   Reis, Mitermayer G.
   Marques, Ernesto T. A.
   Cummings, Derek A. T.
   Ko, Albert I.
TI Impact of preexisting dengue immunity on Zika virus emergence in a
   dengue endemic region
SO SCIENCE
LA English
DT Article
ID INFECTION; ANTIBODY; ENHANCEMENT; OUTBREAK; SALVADOR
AB The clinical outcomes associated with Zika virus (ZIKV) in the Americas have been well documented, but other aspects of the pandemic, such as attack rates and risk factors, are poorly understood. We prospectively followed a cohort of 1453 urban residents in Salvador, Brazil, and, using an assay that measured immunoglobulin G3 (IgG3) responses against ZIKV NS1 antigen, we estimated that 73% of individuals were infected during the 2015 outbreak. Attack rates were spatially heterogeneous, varying by a factor of 3 within a community spanning 0.17 square kilometers. Preexisting high antibody titers to dengue virus were associated with reduced risk of ZIKV infection and symptoms. The landscape of ZIKV immunity that now exists may affect the risk for future transmission.
C1 [Rodriguez-Barraquer, Isabel] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Costa, Federico; Nery Junior, Nivison; Ribeiro, Guilherme S.] Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil.
   [Costa, Federico; Nery Junior, Nivison; Sacramento, Gielson Almeida; Cruz, Jaqueline; Carvalho, Mayara; De Olivera, Daiana; Hagan, Jose E.; Wunder, Elsio A., Jr.; Ribeiro, Guilherme S.; Reis, Mitermayer G.; Ko, Albert I.] Fundacao Oswaldo Cruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Costa, Federico; Hagan, Jose E.; Adhikarla, Haritha; Wunder, Elsio A., Jr.; Reis, Mitermayer G.; Ko, Albert I.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06510 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Castanha, Priscila M. S.; Coelho, Danilo F.; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz MS, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
   [Coelho, Danilo F.] Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740540 Recife, PE, Brazil.
   [Azar, Sasha R.] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.
   [Rossi, Shannan L.; Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Ribeiro, Guilherme S.; Reis, Mitermayer G.] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
   [Balmaseda, Angel] Sustainable Sci Inst, Managua, Nicaragua.
   [Balmaseda, Angel] Minist Hlth, Ctr Nacl Diagnost Referencia, Lab Nacl Virol, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Sao Paulo, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
   [Cummings, Derek A. T.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA.
   [Cummings, Derek A. T.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32611 USA.
RP Ko, AI (corresponding author), Fundacao Oswaldo Cruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.; Ko, AI (corresponding author), Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06510 USA.; Cummings, DAT (corresponding author), Univ Florida, Dept Biol, Gainesville, FL 32611 USA.; Cummings, DAT (corresponding author), Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32611 USA.
EM datc@ufl.edu; albert.ko@yale.edu
RI Marques, Ernesto T. A/L-4967-2013; Coelho, Danilo
   Fernandes/AAC-9206-2020; Ribeiro, Guilherme/B-6624-2008; Vasilakis,
   Nikos/ABE-7318-2020; Ko, Albert Icksang/P-2343-2015; Costa,
   Federico/G-1838-2015; Wunder, Elsio Augusto/C-2733-2013; Nogueira,
   Mauricio L/B-7599-2012; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Reis, Mitermayer/AAO-9742-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Coelho, Danilo
   Fernandes/0000-0002-1111-0825; Ribeiro, Guilherme/0000-0002-6798-2059;
   Ko, Albert Icksang/0000-0001-9023-2339; Costa,
   Federico/0000-0001-6951-2336; Wunder, Elsio Augusto/0000-0002-5239-8511;
   Nogueira, Mauricio L/0000-0003-1102-2419; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Reis, Mitermayer/0000-0002-3051-9060;
   Rocha Nery Junior, Nivison Ruy/0000-0002-8164-0602; Hagan,
   Jose/0000-0002-1837-6319; CRUZ, JAQUELINE/0000-0003-4128-1008
FU Yale School of Public Health; Oswaldo Cruz Foundation, Brazilian
   Ministry of Health; Brazilian National Council for Scientific and
   Technological DevelopmentNational Council for Scientific and
   Technological Development (CNPq) [400830/2013-2, 440891/2016-7];
   Brazilian National Council for Scientific and Technological Development
   (INCT-Dengue); Coordination for the Improvement of Higher Education
   Personnel, Brazilian Ministry of Education [440891/2016-7]; Research
   Support Foundation for the State of Bahia [FAPESB PET0026/2013,
   APP0044/2016, 10206/2015, PET0022/2016]; Research Support Foundation for
   the State of Sao Paulo [FAPESP 2013/21719-3, 2016/15021-1]; CuraZika
   Foundation; Wellcome TrustWellcome Trust [102330/Z/13/Z]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 AI121207, R01 TW009504, R01 AI052473, U01
   AI088752, R25 TW009338, R01 NS064905, R24 AI120942, U01 AI115577, R01
   AI099631, U54 AI065359, P01 AI106695, U19 AI118610, U54 GM088491, R01
   AI114703]; McLaughlin Fellowship Fund; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R25TW009338, R01TW009504, R25TW009338] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI118610, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   P01AI106695, R24AI120942, P01AI106695, P01AI106695, U19AI118610,
   P01AI106695, P01AI106695, U19AI118610, P01AI106695, U19AI118610,
   U19AI118610, U19AI118610, U19AI118610, P01AI106695, U19AI118610,
   R24AI120942, R01AI099631, U19AI118610, P01AI106695, U19AI118610,
   P01AI106695, R24AI120942, U01AI115577, P01AI106695, U19AI118610,
   R01AI099631, P01AI106695, R01AI121207, U19AI118610, U19AI118610,
   U19AI118610, P01AI106695, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, P01AI106695, P01AI106695, U19AI118610, U19AI118610,
   U19AI118610, R01AI099631, P01AI106695, P01AI106695, U19AI118610,
   R24AI120942, P01AI106695, P01AI106695, U01AI115577, P01AI106695,
   R01AI114703, P01AI106695, R01AI114703, P01AI106695, R01AI099631,
   P01AI106695, P01AI106695, U19AI118610, U19AI118610, U19AI118610,
   P01AI106695, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, R01AI121207, U19AI118610, P01AI106695, P01AI106695,
   P01AI106695, U19AI118610, R01AI099631, R01AI114703, P01AI106695,
   R01AI121207, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   R01AI099631, U19AI118610, P01AI106695, P01AI106695, U19AI118610,
   U19AI118610, P01AI106695, U19AI118610, U19AI118610] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491] Funding
   Source: NIH RePORTER
FX Supported by grants from the Yale School of Public Health; Oswaldo Cruz
   Foundation, Brazilian Ministry of Health; Brazilian National Council for
   Scientific and Technological Development (400830/2013-2, 440891/2016-7,
   and INCT-Dengue); Coordination for the Improvement of Higher Education
   Personnel, Brazilian Ministry of Education [440891/2016-7, National
   Postdoctoral Program (PNPD)]; Research Support Foundation for the State
   of Bahia (FAPESB PET0026/2013, APP0044/2016, 10206/2015, and
   PET0022/2016); Research Support Foundation for the State of Sao Paulo
   (FAPESP 2013/21719-3 and 2016/15021-1); CuraZika Foundation
   (curazika.pitt.edu); Wellcome Trust (102330/Z/13/Z); and NIH grants R01
   AI121207, R01 TW009504, R01 AI052473, U01 AI088752, R25 TW009338, R01
   NS064905, R24 AI120942, U01 AI115577, R01 AI099631, U54 AI065359, P01
   AI106695, U19 AI118610, R01 AI114703, and U54 GM088491. S.R.A. was
   funded in part by the McLaughlin Fellowship Fund.
CR Abbink P, 2018, NAT MED, V24, P721, DOI 10.1038/s41591-018-0056-0
   ANDERSON R M, 1991
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Brazilian Institute of Geography and Statistics, EST POP 2017 CIT BAH
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332
   Costa F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003338
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Durbin AP, 2016, TRENDS IMMUNOL, V37, P635, DOI 10.1016/j.it.2016.08.006
   Felzemburgh RDM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002927
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Ferguson NM, 1999, PHILOS T R SOC B, V354, P757, DOI 10.1098/rstb.1999.0428
   Hagan JE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004275
   Kikuti M, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1015-6
   Kikuti M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003937
   Kucharski AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004726
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lowe R, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010096
   Mammen MP, 2008, PLOS MED, V5, P1605, DOI 10.1371/journal.pmed.0050205
   McCracken MK, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006487
   Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Narvaez F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001397
   Nascimento EJM, 2018, J VIROL METHODS, V257, P62, DOI 10.1016/j.jviromet.2018.04.009
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mbio.01390-17, 10.1128/mBio.01390-17]
   Nogueira ML, 2018, CLIN MICROBIOL INFEC, V24, P646, DOI 10.1016/j.cmi.2017.11.004
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Paploski IAD, 2016, EMERG INFECT DIS, V22, P1438, DOI 10.3201/eid2208.160496
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   R Core Team, 2016, R LANG ENV STAT COMP
   Reis RB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000228
   Ribeiro GS, 2018, LANCET GLOB HEALTH, V6, pE140, DOI 10.1016/S2214-109X(17)30496-5
   Rojas DP, 2016, EUROSURVEILLANCE, V21, P26, DOI 10.2807/1560-7917.ES.2016.21.28.30283
   Salvador Secretary of Health, 2018, SIT EP DENG CHIK ZIK
   Sariol CA, 2018, TRENDS MICROBIOL, V26, P186, DOI 10.1016/j.tim.2017.10.004
   Towers S, 2016, EPIDEMICS-NETH, V17, P50, DOI 10.1016/j.epidem.2016.10.003
   Zambrana JV, 2018, P NATL ACAD SCI USA, V115, P9294, DOI 10.1073/pnas.1804672115
NR 43
TC 81
Z9 80
U1 1
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD FEB 8
PY 2019
VL 363
IS 6427
BP 607
EP +
DI 10.1126/science.aav6618
PG 36
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HK6SM
UT WOS:000458114200043
PM 30733412
OA Bronze
DA 2020-12-16
ER

PT J
AU Koopmans, M
   de Lamballerie, X
   Jaenisch, T
   Rosenberger, KD
   Morales, I
   Marques, ETA
   Viana, IFT
   Brasil, P
   Rabello, R
   Avelino-Silva, VI
   Segurado, A
   Alexander, N
   Mayaud, P
   Netto, EM
   Tami, A
   Bethencourt, S
   Miranda, MC
   Lozano, A
   Soria, C
   Cisneros, SPS
   Gotuzzo, E
   Guzman, MG
   Rodriguez, PAM
   Lopez-Gatell, H
   Hegewisch-Taylor, J
   Borja-Aburto, VH
   Bonilla, CRG
   Hoen, B
   van Roode, M
   Rockx, B
AF Koopmans, Marion
   de lamballerie, Xavier
   Jaenisch, Thomas
   Rosenberger, Kerstin D.
   Morales, Ivonne
   Marques, Ernesto T. A.
   Viana, Isabelle F. T.
   Brasil, Patricia
   Rabello, Renata
   Avelino-Silva, Vivian I.
   Segurado, Aluisio
   Alexander, Neal
   Mayaud, Philippe
   Netto, Eduardo Martins
   Tami, Adriana
   Bethencourt, Sarah
   Consuelo Miranda, Maria
   Lozano, Anyela
   Soria, Carmen
   Salgado Cisneros, Silvia P.
   Gotuzzo, Eduardo
   Guzman, Maria G.
   Rodriguez, Pedro A. M.
   Lopez-Gatell, Hugo
   Hegewisch-Taylor, Jennifer
   Hugo Borja-Aburto, Victor
   Gonzalez Bonilla, Cesar R.
   Hoen, Bruno
   van Roode, Martine
   Rockx, Barry
CA ZIKAlliance Consortium
TI Familiar barriers still unresolved-a perspective on the Zika virus
   outbreak research response
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
AB Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children. We reviewed the timeline of patient cohort initiation in relation to the Zika virus epidemic and mapped key events regarding funding, regulatory approvals, and site preparation during this timeline. We then assessed barriers and delays that the international research team experienced through a systematic telephone interview. We have identified three major bottlenecks in the implementation of a swift response: the absence of a timeline for the funding process, delays in regulatory and ethical approval, and the challenging logistics of laboratory support, including diagnostics. These bottlenecks illustrate the clear and urgent need for implementing a strong and permanent global emerging infectious diseases research capacity that has structured funding, enables long-term partnerships, and develops basic clinical and laboratorial research and a response infrastructure that is ready to deploy.
C1 [Koopmans, Marion; van Roode, Martine; Rockx, Barry] Erasmus MC, Rotterdam, Netherlands.
   [de lamballerie, Xavier] Aix Marseille Univ, Unite Virus Emergents, Marseille, France.
   [Jaenisch, Thomas] Heidelberg Univ Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [Rosenberger, Kerstin D.; Morales, Ivonne] Heidelberg Univ Hosp, Dept Infect Dis, Heidelberg, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Viana, Isabelle F. T.; Brasil, Patricia; Rabello, Renata] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Recife, PE, Brazil.
   [Avelino-Silva, Vivian I.; Segurado, Aluisio] Univ Sao Paulo, Sao Paulo, Brazil.
   [Alexander, Neal; Mayaud, Philippe] London Sch Hyg & Trop Med, London, England.
   [Netto, Eduardo Martins] Univ Fed Bahia, Salvador, BA, Brazil.
   [Tami, Adriana; Bethencourt, Sarah] Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Tami, Adriana; Bethencourt, Sarah] Univ Carabobo, Fac Ciencias Salud, Valencia, Venezuela.
   [Consuelo Miranda, Maria; Lozano, Anyela] Univ Ind Santander, Bucaramanga, Colombia.
   [Soria, Carmen] Univ Catolica, Santiago De Guayaquil, Guayaqil, Ecuador.
   [Salgado Cisneros, Silvia P.] Inst Nacl Invest Salud Publ Dr Leopoldo Izquieta, Guayaquil, Ecuador.
   [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, San Martin De Porres, Peru.
   [Guzman, Maria G.; Rodriguez, Pedro A. M.] Inst Trop Med Pedro Kouri, Havana, Cuba.
   [Lopez-Gatell, Hugo; Hegewisch-Taylor, Jennifer] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico.
   [Hugo Borja-Aburto, Victor; Gonzalez Bonilla, Cesar R.] Mexican Inst Social Secur, Mexico City, DF, Mexico.
   [Hoen, Bruno] INSERM, Paris, France.
RP Koopmans, M (corresponding author), Erasmus MC, Virosci, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.
EM m.koopmans@erasmusmc.nl
RI Netto, Eduardo/D-1432-2013; Avelino-Silva, Vivian I/L-2640-2013;
   Marques, Ernesto T. A/L-4967-2013; Segurado, Aluisio C/K-2229-2012;
   Koopmans, Marion/Y-9170-2019; Viana, Isabelle/M-4435-2017
OI Netto, Eduardo/0000-0003-1691-6761; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Marques, Ernesto T. A/0000-0003-3826-9358;
   Segurado, Aluisio C/0000-0002-6311-8036; Koopmans,
   Marion/0000-0002-5204-2312; Martinez, Pedro A./0000-0002-9886-6448;
   Hegewisch Taylor, Jennifer/0000-0002-1057-2921; Miranda Montoya, Maria
   Consuelo/0000-0001-5730-0723; Viana, Isabelle/0000-0003-4648-6635
FU EU Directorate General for Research [734548]
FX The work described in the manuscript was funded by the EU Directorate
   General for Research grant number 734548 (ZIKAlliance). The sponsor of
   the study had no role in study design, data collection, data analysis,
   data interpretation, or writing of the report. We thank Sandra Kamga for
   her support in collecting information from the questionnaires. We also
   thank Martine van Roode and Barry Rockx that assisted MK in drafting an
   interview with a list of questions for the cohort initiation part of the
   study and, with the help of Sandra Kamga, created interviews to assess
   the list of possible barriers encountered.
CR Alirol E, 2017, BMC MED ETHICS, V18, DOI 10.1186/s12910-017-0201-1
   Braga JU, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179725
   Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Granger D, 2017, J CLIN MICROBIOL, V55, P2127, DOI [10.1128/jcm.00580-17, 10.1128/JCM.00580-17]
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Lee WT, 2017, J CLIN MICROBIOL, V22, P56
   Ministerio de Saude (MS), 2015, B EPIDEMIOL, V46, P1
   Paules CI, 2017, ANN INTERN MED, V167, P805, DOI 10.7326/M17-2496
   Perkins MD, 2017, LANCET, V390, P2111, DOI 10.1016/S0140-6736(17)31224-2
   Reusken CB, 2018, CLIN MICROBIOL INFEC, V24, P221, DOI 10.1016/j.cmi.2017.12.010
   Reveiz L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180220
   Ribeiro CD, 2018, SCIENCE, V362, P404, DOI 10.1126/science.aau5229
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Van Kerkhove MD, 2016, LANCET GLOB HEALTH, V4, pE911, DOI 10.1016/S2214-109X(16)30255-8
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 18
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD FEB
PY 2019
VL 19
IS 2
BP E59
EP E62
DI 10.1016/S1473-3099(18)30497-3
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA HJ6LD
UT WOS:000457299500006
PM 30420230
DA 2020-12-16
ER

PT J
AU Oliveira, RAS
   de Oliveira, EF
   Fernandes, AIV
   Brito, CAA
   Marques, ETA
   Tenorio, MC
   Gil, LHGV
AF Oliveira, Renato A. S.
   de Oliveira-Filho, Edmilson F.
   Fernandes, Ana I., V
   Brito, Carlos A. A.
   Marques, Ernesto T. A.
   Tenorio, Marli C.
   Gil, Laura H. G., V
TI Previous dengue or Zika virus exposure can drive to infection
   enhancement or neutralisation of other flaviviruses
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE ADE; flavivirus; dengue; Zika
ID ANTIBODY-DEPENDENT ENHANCEMENT; PERNAMBUCO; FEVER; STATE
AB BACKGROUND Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person's life possible. After primary DENV infection, life-long immunity is developed for the infecting serotype. Since DENV and Zika virus (ZIKV) arc antigenically similar, the possibility of cross-reactions has attracted attention and has been demonstrated in vitro.
   OBJECTIVE The aim of this study was to investigate whether immune-sera from DENV and ZIKV infected patients would cross-react in vitro with other Flaviviridae family members.
   METHODS Cross reaction of the studied samples with yellow fever virus (YFV), West Nile virus (WNV), Rocio virus (ROCV), Saint Louis virus (SLEV) and Ilheus virus (ILHV) has been investigated by plaque reduction neutralisation test (PRNT) and the antibody-dependent enhancement (ADE) by flow-cytometry.
   FINDINGS Antibodies against ZIKV and DENV virus cross-reacted with other flaviviruses either neutralising or enhancing the infection. Thus, viral entrance into FcRFc gamma RII-expressing cells were influenced by the cross-reactive antibodies. ZIKV or DENV immune sera enhanced cellular infection by WNV, ILHV, ROCV and SLEV. Finally, DENV immune sera presented higher neutralising activity for YFV and SLEV. While ZIKV immune sera neutralised WNV, ILHV and ROCV with high frequencies of positivity.
   MAIN CONCLUSIONS The co-circulation of those viruses in the same area represents a risk for the development of severe infections if they spread throughout the country. Successive flavivirus infections may have an impact on disease pathogenesis, as well as on the development of safe vaccine strategies.
C1 [Oliveira, Renato A. S.; de Oliveira-Filho, Edmilson F.; Marques, Ernesto T. A.; Tenorio, Marli C.; Gil, Laura H. G., V] Inst Aggeu Magalhaes, Dept Virol, Fundacao Oswaldo Cruz, Recife, PE, Brazil.
   [Oliveira, Renato A. S.] Univ Fed Paraiba, Dept Fisiol & Patol, Joao Pessoa, Paraiba, Brazil.
   [de Oliveira-Filho, Edmilson F.] Charite Univ Med Berlin, Berlin, Germany.
   [Fernandes, Ana I., V] Univ Fed Paraiba, Hosp Univ Lauro Wanderley, Serv Doencas Infecciosas & Parasitarias, Joao Pessoa, Paraiba, Brazil.
   [Fernandes, Ana I., V] Univ Fed Paraiba, Escola Tecn Saude, Grp Estudos & Pesquisas Imunol Humana, Joao Pessoa, Paraiba, Brazil.
   [Brito, Carlos A. A.] Univ Fed Pernambuco, Dept Med Clin, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Oliveira, RAS (corresponding author), Inst Aggeu Magalhaes, Dept Virol, Fundacao Oswaldo Cruz, Recife, PE, Brazil.; Oliveira, RAS (corresponding author), Univ Fed Paraiba, Dept Fisiol & Patol, Joao Pessoa, Paraiba, Brazil.
EM renaoliveira1977@gmail.com
RI Oliveira, Renato/AAN-9879-2020; Marques, Ernesto T. A/L-4967-2013;
   Oliveira, Renato/AAN-9394-2020; Oliveira-Filho, Edmilson/A-6305-2012
OI Oliveira, Renato/0000-0002-4044-0794; Marques, Ernesto T.
   A/0000-0003-3826-9358; Oliveira-Filho, Edmilson/0000-0002-3771-1565
FU Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (Facepe) [BFP-0117-2.11/13, APQ 1380-5.05/15]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [DCR-0003-5.05/16]
FX To Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (Facepe) (grant BFP-0117-2.11/13), for granting RASO a visiting research
   fellowship and EFO-F (grant APQ 1380-5.05/15) and CNPq
   (DCR-0003-5.05/16), and to Louisa F. Ludwig-Begall, for the careful
   English proofreading of this manuscript.
CR Amarilla AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199071
   Andrade P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08845-3
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   de Oliveira EF, 2018, TRANSBOUND EMERG DIS, V65, P1094, DOI 10.1111/tbed.12829
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dowd KA, 2014, J VIROL, V88, P11726, DOI 10.1128/JVI.01140-14
   George J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10901-1
   Goldani LZ, 2017, BRAZ J INFECT DIS, V21, P123, DOI 10.1016/j.bjid.2017.02.004
   Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113
   Katzelnick LC, 2015, SCIENCE, V349, P1338, DOI 10.1126/science.aac5017
   Kum DB, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0092-2
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Santos JJS, 2014, AN ACAD BRAS CIENC, V86, P1749, DOI 10.1590/0001-3765201420130332
NR 23
TC 9
Z9 9
U1 1
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e190098
DI 10.1590/0074-02760190098
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA IR8UC
UT WOS:000481716000001
PM 31411310
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU D'Aiuto, L
   McNulty, J
   Hartline, C
   Demers, M
   Kalkeri, R
   Wood, J
   McClain, L
   Chattopadhyay, A
   Zhi, Y
   Naciri, J
   Smith, A
   Yolken, R
   Chowdari, K
   Zepeda-Velazquez, C
   Dokuburra, CB
   Marques, E
   Ptak, R
   Kinchington, P
   Watkins, S
   Prichard, M
   Bloom, D
   Nimgaonkar, V
AF D'Aiuto, Leonardo
   McNulty, James
   Hartline, Caroll
   Demers, Matthew
   Kalkeri, Raj
   Wood, Joel
   McClain, Lora
   Chattopadhyay, Ansuman
   Zhi, Yun
   Naciri, Jennifer
   Smith, Adam
   Yolken, Robert
   Chowdari, Kodavali
   Zepeda-Velazquez, Carlos
   Dokuburra, Chanti Babu
   Marques, Ernesto
   Ptak, Roger
   Kinchington, Paul
   Watkins, Simon
   Prichard, Mark
   Bloom, David
   Nimgaonkar, Vishwajit
TI R430: A potent inhibitor of DNA and RNA viruses
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HERPES-SIMPLEX-VIRUS; HOST SHUTOFF RNASE; GENE-EXPRESSION; NEONATAL
   HERPES; MESSENGER-RNAS; INFECTION; AMARYLLIDACEAE; NEURONS; REPLICATION;
   DEGRADATION
AB Acyclovir (ACV) is an effective antiviral agent for treating lytic Herpes Simplex virus, type 1 (HSV-1) infections, and it has dramatically reduced the mortality rate of herpes simplex encephalitis. However, HSV-1 resistance to ACV and its derivatives is being increasingly documented, particularly among immunocompromised individuals. The burgeoning drug resistance compels the search for a new generation of more efficacious anti-herpetic drugs. We have previously shown that trans-dihydrolycoricidine (R430), a lycorane-type alkaloid derivative, effectively inhibits HSV-1 infections in cultured cells. We now report that R430 also inhibits ACV-resistant HSV-1 strains, accompanied by global inhibition of viral gene transcription and enrichment of H3K27me3 methylation on viral gene promoters. Furthermore, we demonstrate that R430 prevents HSV-1 reactivation from latency in an ex vivo rodent model. Finally, among a panel of DNA viruses and RNA viruses, R430 inhibited Zika virus with high therapeutic index. Its therapeutic index is comparable to standard antiviral drugs, though it has greater toxicity in non-neuronal cells than in neuronal cells. Synthesis of additional derivatives could enable more efficacious antivirals and the identification of active pharmacophores.
C1 [D'Aiuto, Leonardo; Demers, Matthew; Wood, Joel; Naciri, Jennifer; Smith, Adam; Chowdari, Kodavali; Nimgaonkar, Vishwajit] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.
   [McNulty, James; Zepeda-Velazquez, Carlos; Dokuburra, Chanti Babu] McMaster Univ, Dept Chem & Chem Biol, 1280 Main St West, Hamilton, ON L8S 4M1, Canada.
   [Hartline, Caroll; Prichard, Mark] Univ Alabama Birmingham, UAB Sch Med, 1720 2nd Ave S, Birmingham, AL 35294 USA.
   [Kalkeri, Raj; Ptak, Roger] Southern Res Inst, Drug Dev, Dept Infect Dis Res, 431 Aviat Way, Frederick, MD 21701 USA.
   [McClain, Lora] Magee Womens Res Inst, 204 Craft Ave, Pittsburgh, PA 15213 USA.
   [Zhi, Yun] Tsinghua Univ, Sch Med, Dept Pharmacol & Pharmaceut Sci, Beijing, Peoples R China.
   [Yolken, Robert] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Neurovirol, 600 North Wolfe St,Blalock 1105, Baltimore, MD 21287 USA.
   [Marques, Ernesto] Univ Pittsburgh, Dept Infect Dis & Microbiol, 9022 BST3,3501 Fifth Ave, Pittsburgh, PA 15260 USA.
   [Kinchington, Paul] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Eye & Ear Inst 1016, Pittsburgh, PA 15213 USA.
   [Watkins, Simon] Univ Pittsburgh, Dept Cell Biol, 3500 Terrace St,S362 Biomed Sci Tower South, Pittsburgh, PA 15261 USA.
   [Bloom, David] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Box 100266 JHMHC, Gainesville, FL 32610 USA.
   [Nimgaonkar, Vishwajit] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA.
   [Chattopadhyay, Ansuman] Hlth Sci Lib Syst, Mol Biol Informat Serv, 3550 Terrace St, Pittsburgh, PA 15261 USA.
RP Nimgaonkar, V (corresponding author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.; Nimgaonkar, V (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA.
EM vishwajitNL@upmc.edu
RI McNulty, James/E-7871-2011; Marques, Ernesto T. A/L-4967-2013;
   Zepeda-Velazquez, Carlos/ABH-3524-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Zepeda-Velazquez,
   Carlos/0000-0002-8130-2232; watkins, simon/0000-0003-4092-1552; McNulty,
   James/0000-0002-7123-7588; Demers, Matthew/0000-0002-4103-9812
FU Stanley Medical Research Institute [07R-1712]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [MH63480, NS096405, AI22640, EY08098]; National Institutes of
   Allergy and Infectious Diseases, National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN272201100016I, HHSN27200013]; Research to Prevent
   Blindness IncResearch to Prevent Blindness (RPB); Eye & Ear Foundation
   of Pittsburgh; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Eye Institute (NEI) [P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098, P30EY008098,
   P30EY008098, P30EY008098, P30EY008098, P30EY008098] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [R01MH063480, R01MH063480,
   R01MH063480, R01MH063480, R01MH063480, R01MH063480, R01MH063480,
   R01MH063480, R01MH063480, R01MH063480, R01MH063480, R01MH063480,
   R01MH063480, R01MH063480] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS)
   [R21NS096405, R21NS096405] Funding Source: NIH RePORTER
FX We thank the CuraZika Pilot Grant Program. Funded in part by grants from
   the Stanley Medical Research Institute (07R-1712) and NIH (MH63480,
   NS096405). We thank the NIAID Division of Microbiology and Infectious
   Diseases for facilitating the antiviral assays. Work performed in the
   laboratory of MNP was funded in whole or in part by the National
   Institutes of Allergy and Infectious Diseases, National Institutes of
   Health, under contract HHSN272201100016I, Task Order HHSN27200013. PRK
   acknowledges NIH awards AI22640 and EY08098; and unrestricted grants
   from Research to Prevent Blindness Inc and Eye & Ear Foundation of
   Pittsburgh.
CR Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Chowdhury M. A, 2016, AM J THER, V23
   D'Aiuto L, 2017, ANTIVIR RES, V142, P136, DOI 10.1016/j.antiviral.2017.03.016
   D'Aiuto L, 2014, ORGANOGENESIS, V10, P365, DOI 10.1080/15476278.2015.1011921
   D'Aiuto L, 2015, SCHIZOPHRENIA BULL, V41, P123, DOI 10.1093/schbul/sbu032
   DEVIRAO GB, 1994, J VIROL, V68, P1271, DOI 10.1128/JVI.68.3.1271-1282.1994
   Dimitrion Peter, 2017, Mol Neuropsychiatry, V3, P28, DOI 10.1159/000476034
   Evidente A, 2009, PLANTA MED, V75, P501, DOI 10.1055/s-0029-1185340
   FARRELL MJ, 1991, P NATL ACAD SCI USA, V88, P790, DOI 10.1073/pnas.88.3.790
   GABRIELSEN B, 1992, J NAT PROD, V55, P1569, DOI 10.1021/np50089a003
   Gardella C, 2011, BJOG-INT J OBSTET GY, V118, P187, DOI 10.1111/j.1471-0528.2010.02785.x
   Grout P, 1976, J R Coll Gen Pract, V26, P428
   Hellden A, 2003, NEPHROL DIAL TRANSPL, V18, P1135, DOI 10.1093/ndt/gfg119
   HONESS RW, 1977, J VIROL, V21, P584, DOI 10.1128/JVI.21.2.584-600.1977
   Kim JJ, 2004, AM J MED GENET B, V130B, P19
   Kimberlin DW, 2004, CLIN MICROBIOL REV, V17, P1, DOI 10.1128/CMR.17.1.1-13.2004
   King CA, 2015, J VIROL, V89, P11347, DOI 10.1128/JVI.02008-15
   KORBA BE, 1991, ANTIVIR RES, V15, P217, DOI 10.1016/0166-3542(91)90068-3
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kuo T, 2014, VACCINE, V32, P6733, DOI 10.1016/j.vaccine.2014.10.002
   Lin X, 2012, PLANT METHODS, V8, DOI 10.1186/1746-4811-8-48
   Looker KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114989
   Maiti M, 2016, ORG BIOMOL CHEM, V14, P8743, DOI 10.1039/c6ob01189f
   Malvy D, 2005, CLIN INFECT DIS, V41, P320, DOI 10.1086/431585
   McClain L, 2015, ANTIVIR RES, V121, P16, DOI 10.1016/j.antiviral.2015.06.005
   McNulty J, 2016, ACS MED CHEM LETT, V7, P46, DOI 10.1021/acsmedchemlett.5b00318
   Prichard MN, 2009, ANTIMICROB AGENTS CH, V53, P5251, DOI 10.1128/AAC.00417-09
   Ramachandran S, 2008, VIROLOGY, V378, P254, DOI 10.1016/j.virol.2008.05.034
   REARDON JE, 1989, J BIOL CHEM, V264, P7405
   RENARDNOZAKI J, 1989, RES VIROLOGY, V140, P115, DOI 10.1016/S0923-2516(89)80089-5
   Revu O, 2016, CHEMISTRYSELECT, V1, P5895
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Shu MF, 2013, J VIROL, V87, P13569, DOI 10.1128/JVI.02603-13
   Shu M, 2013, P NATL ACAD SCI USA, V110, pE1669, DOI 10.1073/pnas.1305475110
   SPIVACK JG, 1987, J VIROL, V61, P3841, DOI 10.1128/JVI.61.12.3841-3847.1987
   Steiner I, 2007, LANCET NEUROL, V6, P1015, DOI 10.1016/S1474-4422(07)70267-3
   STEVENS JG, 1987, SCIENCE, V235, P1056, DOI 10.1126/science.2434993
   Stranska R, 2005, J CLIN VIROL, V32, P7, DOI 10.1016/j.jcv.2004.04.002
   Tsuruma R, 2008, ONCOGENE, V27, P3054, DOI 10.1038/sj.onc.1210952
   Wang K, 2007, J VIROL, V81, P6817, DOI 10.1128/JVI.00166-07
   Young RC, 2010, ARCH OPHTHALMOL-CHIC, V128, P1178, DOI 10.1001/archophthalmol.2010.187
NR 41
TC 2
Z9 2
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 9
PY 2018
VL 8
AR 16662
DI 10.1038/s41598-018-33904-y
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GZ7CL
UT WOS:000449632300071
PM 30413769
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Magalhaes, T
   Foy, BD
   Marques, ETA
   Ebel, GD
   Weger-Lucarelli, J
AF Magalhaes, Tereza
   Foy, Brian D.
   Marques, Ernesto T. A.
   Ebel, Gregory D.
   Weger-Lucarelli, James
TI Mosquito-borne and sexual transmission of Zika virus: Recent
   developments and future directions
SO VIRUS RESEARCH
LA English
DT Review
DE Zika; Virus; Arbovirus; Mosquito; Sex; Sexual transmission
ID AEDES-AEGYPTI MOSQUITOS; FEMALE GENITAL-TRACT; YELLOW-FEVER VIRUS; WEST
   NILE VIRUS; UNITED-STATES; DENGUE VIRUS; VERTICAL TRANSMISSION;
   SOUTHEASTERN SENEGAL; FOREST MAMMALS; CULEX-PIPIENS
AB Zika virus (ZIKV; Genus Flavivirus, Family Flaviviridae) has recently emerged in Asia and the Americas to cause large outbreaks of human disease. The outbreak has been characterized by high attack rates, birth defects in infants and severe neurological complications in adults. ZIKV is transmitted to humans by Aedes mosquitoes, but recent evidence implicates sexual transmission as playing an important role as well. This review highlights the transmission of ZIKV in humans, with a focus on both mosquito and sexually-transmitted routes and their outcomes. We also discuss critical directions for future research.
C1 [Magalhaes, Tereza; Foy, Brian D.; Ebel, Gregory D.; Weger-Lucarelli, James] Colorado State Univ, Arthropod Borne & Infect Dis Lab, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Expt Therapeut, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Foy, BD (corresponding author), Colorado State Univ, Arthropod Borne & Infect Dis Lab, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
EM brian.foy@colostate.edu
RI Marques, Ernesto T. A/L-4967-2013; Magalhaes, Tereza/V-6632-2019; Foy,
   Brian/E-6230-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Foy,
   Brian/0000-0002-9117-203X; Weger-Lucarelli, James/0000-0002-9483-1694
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI067380, R21AI125996,
   R21AI129464]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21AI125996, R01AI067380, R01AI067380,
   R01AI067380, R01AI067380, R01AI067380, R01AI067380, R21AI129464,
   R01AI067380, R01AI067380, R01AI067380, R01AI067380, R21AI125996,
   R01AI067380, R21AI129464, R01AI067380, R01AI067380, R01AI067380,
   R01AI067380] Funding Source: NIH RePORTER
FX This publication was supported by the National Institute of Allergy and
   Infectious Diseases of the National Institutes of Health under award
   numbers R01AI067380, R21AI125996 and R21AI129464. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Akoua-Koffi C, 2001, B SOC PATHOL EXOT, V94, P227
   Diaz-Quionez JA, 2016, VIRUS GENES, V52, P855, DOI 10.1007/s11262-016-1384-0
   Aliota MT, 2016, EMERG INFECT DIS, V22, P1857, DOI 10.3201/eid2210.161082
   Aliota MT, 2016, SCI REP-UK, V6, DOI 10.1038/srep28792
   Amraoui F, 2016, EURO SURVEILL, V21
   Armstrong P, 2016, MMWR-MORBID MORTAL W, V65, P286, DOI 10.15585/mmwr.mm6511e1
   Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
   Atkinson B., 2016, GENOME ANNOUNC, V4
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Bartellas E, 2000, BRIT J OBSTET GYNAEC, V107, P964, DOI 10.1111/j.1471-0528.2000.tb10397.x
   Barzon L., 2016, EURO SURVEILL, V21
   Baud D, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12614
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   Berggren EK, 2011, SEX TRANSM DIS, V38, P172, DOI 10.1097/OLQ.0b013e3181f41b96
   Berthet N, 2014, VECTOR-BORNE ZOONOT, V14, P862, DOI 10.1089/vbz.2014.1607
   Blohm G.M., 2017, GENOME ANNOUNC, V5
   Boccolini D, 2016, EURO SURVEILL, V21
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Brooks RB, 2016, MMWR-MORBID MORTAL W, V65, P915, DOI 10.15585/mmwr.mm6534e2
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Dutra HLC, 2016, CELL HOST MICROBE, V19, P771, DOI 10.1016/j.chom.2016.04.021
   Carrington LB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00290
   Chan JFW, 2016, EBIOMEDICINE, V14, P112, DOI 10.1016/j.ebiom.2016.11.017
   Chico RM, 2012, JAMA-J AM MED ASSOC, V307, P2079, DOI 10.1001/jama.2012.3428
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Ciota AT, 2017, EMERG INFECT DIS, V23, P880, DOI 10.3201/eid2305.162041
   Coelho FC, 2016, INT J INFECT DIS, V51, P128, DOI 10.1016/j.ijid.2016.08.023
   Coffey LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171148
   Cooper TG, 2010, HUM REPROD UPDATE, V16, P231, DOI 10.1093/humupd/dmp048
   CORNET M, 1979, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V17, P149
   Costa-da-Silva AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171951
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Davis NC, 1929, J EXP MED, V50, P81, DOI 10.1084/jem.50.1.81
   DAVIS NELSON C., 1930, JOUR EXP MED, V51, P703, DOI 10.1084/jem.51.5.703
   de Thoisy B, 2004, T ROY SOC TROP MED H, V98, P409, DOI 10.1016/j.trstmh.2003.12.003
   de Thoisy B, 2009, VECTOR-BORNE ZOONOT, V9, P157, DOI 10.1089/vbz.2007.0280
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Di Luca M, 2016, EURO SURVEILL, V21
   Diagne CT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1231-2
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   Diallo D, 2014, AM J TROP MED HYG, V90, P1003, DOI 10.4269/ajtmh.13-0404
   Diallo M, 2003, EMERG INFECT DIS, V9, P362, DOI 10.3201/eid0903.020219
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dodson BL, 2017, PEERJ, V5, DOI 10.7717/peerj.3096
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duggal NK, 2017, CELL REP, V18, P1751, DOI 10.1016/j.celrep.2017.01.056
   FAGBAMI A, 1977, TROP GEOGR MED, V29, P187
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Favoretto S., 2016, BIORXIV, P1
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EURO SURVEILL, V21
   Freour T., 2016, EURO SURVEILL, V21
   Froeschl G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2123-9
   Garcia-Rejon JE, 2011, AM J TROP MED HYG, V84, P489, DOI 10.4269/ajtmh.2011.10-0654
   Gaskell KM, 2017, EMERG INFECT DIS, V23, P137, DOI 10.3201/eid2301.161300
   Gendernalik A, 2017, AM J TROP MED HYG, V96, P1338, DOI 10.4269/ajtmh.16-0963
   Goertz GP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005654
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8
   Grischott F, 2016, TRAVEL MED INFECT DI, V14, P313, DOI 10.1016/j.tmaid.2016.07.002
   Gubler DJ, 1996, ACTA TROP, V61, P169, DOI 10.1016/0001-706X(95)00103-L
   Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Haddow AD, 2017, EMERG INFECT DIS, V23, P1274, DOI 10.3201/eid2308.170036
   Hall-Mendelin S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004959
   Hamer DH, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0571-z
   Hanley KA, 2013, INFECT GENET EVOL, V19, P292, DOI 10.1016/j.meegid.2013.03.008
   Harrington LC, 2005, AM J TROP MED HYG, V72, P209, DOI 10.4269/ajtmh.2005.72.209
   Harrower J, 2016, EMERG INFECT DIS, V22, P1855, DOI 10.3201/eid2210.160951
   Hart CE, 2017, EMERG INFECT DIS, V23, P559, DOI 10.3201/eid2303.161636
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Heitmann A, 2017, EURO SURVEILL, V22
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huang YJS, 2016, VECTOR-BORNE ZOONOT, V16, P673, DOI 10.1089/vbz.2016.2058
   Johnson BJ, 2017, INSECTS, V8, DOI 10.3390/insects8010005
   Kenney JL, 2017, AM J TROP MED HYG, V96, P1235, DOI 10.4269/ajtmh.16-0865
   Khan S, 2016, J EXP MED, V213, P2913, DOI 10.1084/jem.20161289
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Ladner JT, 2016, GENOME ANNOUNC, V4
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Ledermann JP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003188
   Lee V. H., 1958, B WORLD HEALTH ORGAN, V46, P669
   Li MI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001792
   Li XF, 2016, EBIOMEDICINE, V12, P170, DOI 10.1016/j.ebiom.2016.09.022
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   Lozier M, 2016, MMWR-MORBID MORTAL W, V65, P1219, DOI 10.15585/mmwr.mm6544a4
   Lustig Y, 2016, EURO SURVEILL, V21
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Mathers MJ, 2017, DTSCH ARZTEBL INT, V114, P186, DOI 10.3238/arztebl.2017.0186
   Mboera LEG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004313
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   MONLUN E, 1993, B SOC PATHOL EXOT, V86, P21
   MOORE DL, 1975, ANN TROP MED PARASIT, V69, P49, DOI 10.1080/00034983.1975.11686983
   Morales MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005351
   Moreira J, 2017, CLIN MICROBIOL INFEC, V23, P296, DOI 10.1016/j.cmi.2016.12.027
   Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17
   Moudy RM, 2007, AM J TROP MED HYG, V77, P365, DOI 10.4269/ajtmh.2007.77.365
   Moureau G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117849
   Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nicastri E., 2016, EURO SURVEILL, V21
   Nicastri E, 2016, EMERG INFECT DIS, V22, P2228, DOI 10.3201/eid2212.161280
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P739, DOI [10.15585/mmwr.mm6529e1, 10.15585/mmwr.mm6539e1]
   Souto IO, 2018, ENFERM INFEC MICR CL, V36, P21, DOI 10.1016/j.eimc.2016.10.009
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   PAHO/WHO, 2016, ZIK EP UPD
   Pauleta JR, 2010, J SEX MED, V7, P136, DOI 10.1111/j.1743-6109.2009.01538.x
   Paz-Bailey G., 2017, N ENGL J MED
   Penot P, 2017, EURO SURVEILL, V22
   Pomar L, 2017, ULTRASOUND OBSTET GY
   Prisant N, 2017, CLIN INFECT DIS, V64, P107, DOI 10.1093/cid/ciw669
   Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   ROCHE JC, 1983, ANN INST PASTEUR VIR, V134, P233, DOI 10.1016/S0769-2617(83)80062-8
   Rosilainy Surubi Fernandes S. S. C., 2017, MEMCRIAS I O CRUZ, V112, P1
   Roundy CM, 2017, EMERG INFECT DIS, V23, P625, DOI 10.3201/eid2304.161484
   Ruckert C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15412
   Russell K, 2017, CLIN INFECT DIS, V64, P211, DOI 10.1093/cid/ciw692
   SALUZZO J-F, 1979, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V17, P19
   Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263
   Septfons A, 2016, EURO SURVEILL, V21
   Shi M, 2016, J VIROL, V90, P659, DOI 10.1128/JVI.02036-15
   Siddharthan V, 2017, VIROLOGY, V507, P89, DOI 10.1016/j.virol.2017.04.013
   Smartt C. T., 2017, J MED ENTOMOL
   Smith DR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005296
   SMITHBURN KC, 1949, ANN TROP MED PARASIT, V43, P74, DOI 10.1080/00034983.1949.11685396
   Stoddard ST, 2013, P NATL ACAD SCI USA, V110, P994, DOI 10.1073/pnas.1213349110
   Styer LM, 2007, PLOS PATHOG, V3, P1262, DOI 10.1371/journal.ppat.0030132
   Swaminathan S, 2016, NEW ENGL J MED, V375, P1907, DOI 10.1056/NEJMc1610613
   Teasdale CA, 2017, ARCH SEX BEHAV, V46, P539, DOI 10.1007/s10508-016-0818-z
   Thangamani S, 2016, AM J TROP MED HYG, V95, P1169, DOI 10.4269/ajtmh.16-0448
   Torres JR, 2016, INT J INFECT DIS, V51, P127, DOI 10.1016/j.ijid.2016.08.025
   TraoreLamizana M, 1996, J MED ENTOMOL, V33, P760, DOI 10.1093/jmedent/33.5.760
   Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Visseaux B, 2016, LANCET INFECT DIS, V16, P1220, DOI 10.1016/S1473-3099(16)30387-5
   Waltz E, 2016, NAT BIOTECHNOL, V34, P221, DOI 10.1038/nbt0316-221
   Weger-Lucarelli J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005101
   WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P263, DOI 10.1016/0035-9203(58)90085-3
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   World Health Organization (WHO), 2016, GLOB HLTH SECT STRAT
   World Health Organization (WHO), 2016, PREV SEX TRANSM ZIK
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 157
TC 17
Z9 17
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD AUG 2
PY 2018
VL 254
SI SI
BP 1
EP 9
DI 10.1016/j.virusres.2017.07.011
PG 9
WC Virology
SC Virology
GA GQ9CW
UT WOS:000442064500001
PM 28705681
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Nascimento, EJM
   George, JK
   Velasco, M
   Bonaparte, MI
   Zheng, LY
   DiazGranados, CA
   Marques, ETA
   Huleatt, JW
AF Nascimento, Eduardo J. M.
   George, James K.
   Velasco, Melissa
   Bonaparte, Matthew I.
   Zheng, Lingyi
   DiazGranados, Carlos A.
   Marques, Ernesto T. A.
   Huleatt, James W.
TI Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to
   dengue virus
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Enzyme-Linked immunosorbent assay; Flavivirus; Neutralization assay;
   Non-Structural protein 1; Dengue virus; IgG; Seroprevalence
ID VACCINE; ANTIBODIES; ASSAY
AB Dengue virus infection elicits immune responses to multiple viral antigens including antibodies to dengue nonstructural protein 1 (NS1) which are rapidly induced and detected within days of infection. The recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV; Sanofi Pasteur) uses the yellow fever vaccine virus as a back-bone but expresses dengue virus pre-membrane and envelop proteins. Since CYD-TDV does not express dengue NS1, we evaluated the utility of dengue NS1-specific IgG antibodies as biomarkers of dengue exposure in CYD-TDV recipients and controls. We optimized and evaluated a quantitative anti-dengue NS1 IgG enzyme linked immunosorbent assay (ELISA). Parameters assessed included: accuracy, dilutability/linearity, precision, limit of quantitation and specificity. The assay specificity was further evaluated using Japanese Encephalitis virus, West Nile virus, Yellow Fever virus or Zika virus positive sera samples collected following confirmed infection or vaccination. Receiver-operating-characteristics (ROC) curves as well as sensitivity and specificity for discriminating previous dengue exposure were assessed using 1250 reference samples. Overall, the anti-dengue NS1 IgG ELISA was able to discriminate previous dengue exposure from non-exposure before vaccination with CYD-TDV (ROC area under the curve > 0.9). Assessment of paired samples from 2511 vaccinated participants showed high overall agreement (93%) between pre-vaccination and post-vaccination dengue serostatus classification based on the anti-dengue NS1 IgG ELISA. However, misclassification of dengue serostatus was observed after vaccination likely due to a combination of asymptomatic dengue infections, assay variability and a modest effect of CYD-TDV on the anti-dengue NS1 IgG ELISA readout.
C1 [Nascimento, Eduardo J. M.; George, James K.; Velasco, Melissa; Bonaparte, Matthew I.; Zheng, Lingyi; DiazGranados, Carlos A.; Huleatt, James W.] Sanofi Pasteur, Discovery Dr, Swiftwater, PA 18370 USA.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Grad Sch Publ Hlth, Biomed Sci Tower 3,Room 9052,3501 5th Ave, Pittsburgh, PA 15261 USA.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Biomed Sci Tower 3,Room 9052,3501 5th Ave, Pittsburgh, PA 15261 USA.
   [Marques, Ernesto T. A.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Av Prof Moraes Rego S-N,Campus UFPE, BR-50740465 Recife, PE, Brazil.
RP Huleatt, JW (corresponding author), Sanofi Pasteur, Discovery Dr, Swiftwater, PA 18370 USA.
EM Eduardo.Nascimento@sanofi.com; James.Huleatt@sanofi.com
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
FU Sanofi Pasteur
FX This study was funded by Sanofi Pasteur.
CR Arredondo-Garcia JL, 2018, CLIN MICROBIOL INFEC, V24, P755, DOI 10.1016/j.cmi.2018.01.018
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2
   Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004
   Hernandez-Avila M, 2016, SALUD PUBLICA MEXICO, V58, P71, DOI 10.21149/spm.v58i1.7670
   ICH Harmonized Tripartite Guideline, 2005, VAL AN PROC TEXT MET
   Malisheni M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00863
   Moodie Z, 2017, J INFECT DIS
   *NAT COMM CLIN LAB, 2004, EP17A NCCLS
   OCONNELL MA, 1993, CHEMOMETR INTELL LAB, V20, P97, DOI 10.1016/0169-7439(93)80008-6
   Olivera-Botello G, 2016, J INFECT DIS, V214, P994, DOI 10.1093/infdis/jiw297
   Quinn CP, 2002, EMERG INFECT DIS, V8, P1103, DOI 10.3201/eid0810.020380
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Scherwitzl I, 2017, CURR OPIN VIROL, V23, P95, DOI 10.1016/j.coviro.2017.04.002
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Timiryasova TM, 2013, AM J TROP MED HYG, V88, P962, DOI 10.4269/ajtmh.12-0461
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   World Hlth Org, 2017, VACCINE, V35, P1200, DOI 10.1016/j.vaccine.2016.10.070
NR 21
TC 20
Z9 21
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUL
PY 2018
VL 257
BP 48
EP 57
DI 10.1016/j.jviromet.2018.03.007
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA GI8BA
UT WOS:000434745600009
PM 29567514
OA Other Gold
DA 2020-12-16
ER

PT J
AU Nascimento, EJM
   Huleatt, JW
   Cordeiro, MT
   Castanha, PMS
   George, JK
   Grebe, E
   Welte, A
   Brown, M
   Burke, DS
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Huleatt, James W.
   Cordeiro, Marli T.
   Castanha, Priscila M. S.
   George, James K.
   Grebe, Eduard
   Welte, Alex
   Brown, Monique
   Burke, Donald S.
   Marques, Ernesto T. A.
TI Development of antibody biomarkers of long term and recent dengue virus
   infections
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Antibody; IgG subclasses; IgG3; Long term; Recent infection; Virus
   exposure; Biomarker
ID RESPONSES; DIAGNOSIS; RECIFE; COHORT; BRAZIL; FEVER; TESTS; PHASE;
   SERUM; IGM
AB Dengue virus (DENV) infections elicit antibody responses to the non-structural protein 1 (NS1) that are associated with protection against disease. However, the antibody isotypes and subclasses involved, and their kinetics have not been extensively studied. We characterized the antibody responses to DENV NS1 by enzyme linked immunosorbent assay (ELISA) in a longitudinal cohort of 266 confirmed dengue cases in Recife, Northeast Brazil. Samples were collected during the febrile phase and up to over 3 years after onset of symptoms. The antibodies investigated [IgA, IgM, total IgG (all subclasses measured together) and each subclass (IgG2, IgG3 and IgG4) measured separately] had distinct kinetic profiles following primary or secondary DENV infections. Of interest, most of these antibodies were consistently detected greater than 6 months after onset of symptoms, except for IgG3. Anti-dengue NS1-specific IgG was consistently detected from the acute phase to beyond 3 years after symptom onset. In contrast, anti-dengue NS1-specific IgG3 was detected within the first week, peaked at week 2-3, and disappeared within 4-6 months after onset of symptoms. The mean duration of the IgG3 positive signal was 149 days (ranging from 126 to 172 days). In conclusion, anti-dengue NS1-specific IgG and IgG3 are potential biomarkers of long-term and recent (less than 6 months) DENV infections, respectively.
C1 [Nascimento, Eduardo J. M.; Burke, Donald S.; Marques, Ernesto T. A.] Univ Pittsburgh, Grad Sch Publ Hlth, Biomed Sci Tower 3,Room 9052,3501 5th Ave, Pittsburgh, PA 15261 USA.
   [Nascimento, Eduardo J. M.; Burke, Donald S.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Biomed Sci Tower 3,Room 9052,3501 5th Ave, Pittsburgh, PA 15261 USA.
   [Nascimento, Eduardo J. M.; Huleatt, James W.; George, James K.; Brown, Monique] Sanofi Pasteur, One Discovery Dr, Swiftwater, PA 18370 USA.
   [Cordeiro, Marli T.; Castanha, Priscila M. S.; Marques, Ernesto T. A.] Fiocruz MS, Aggeu Magalhaes Inst, Oswaldo Cruz Fdn, Av Prof Moraes Rego S-N,Campus UFPE, BR-50740465 Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Sch Med Sci, Recife, PE, Brazil.
   [Grebe, Eduard; Welte, Alex] DST NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, Western Cape, South Africa.
RP Marques, ETA (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Biomed Sci Tower 3,Room 9052,3501 5th Ave, Pittsburgh, PA 15261 USA.
EM Eduardo.Nascimento@sanofi.com; marques@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Grebe, Eduard/0000-0001-7046-7245
FU Sanofi Pasteur; CuraZika Alliance
FX This study was funded by Sanofi Pasteur. The IgG3 assay development was
   also funded by CuraZika Alliance.
CR Ahmed NH, 2014, J VECTOR DIS, V51, P194
   Alagarasu K, 2016, EPIDEMIOL INFECT, V144, P876, DOI 10.1017/S0950268815001922
   Balmaseda A, 2003, CLIN DIAGN LAB IMMUN, V10, P317, DOI 10.1128/CDLI.10.2.317-322.2003
   Beatty PR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3787
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   Grange L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00280
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Kaabinejadian S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066298
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
   Koraka P, 2001, J CLIN MICROBIOL, V39, P4332, DOI 10.1128/JCM.39.12.4332-4338.2001
   Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863
   Peeling RW, 2010, NAT REV MICROBIOL, pS30, DOI 10.1038/nrmicro2459
   Plennevaux E, 2018, CLIN INFECT DIS, V66, P1164, DOI 10.1093/cid/cix966
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Sa-Ngasang A, 2006, EPIDEMIOL INFECT, V134, P820, DOI 10.1017/S0950268805005753
   Scherwitzl I, 2017, CURR OPIN VIROL, V23, P95, DOI 10.1016/j.coviro.2017.04.002
   Seaton KE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94355
   Shu PY, 2000, J MED VIROL, V62, P224, DOI 10.1002/1096-9071(200010)62:2&lt;224::AID-JMV14&gt;3.0.CO;2-C
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Yates NL, 2011, AIDS, V25, P2089, DOI 10.1097/QAD.0b013e32834b348e
NR 26
TC 16
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUL
PY 2018
VL 257
BP 62
EP 68
DI 10.1016/j.jviromet.2018.04.009
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA GI8BA
UT WOS:000434745600011
PM 29684416
OA Other Gold
DA 2020-12-16
ER

PT J
AU Viana, IFT
   Coelho, DF
   Palma, ML
   Nascimento, EJM
   Gu, G
   Lima, LFO
   Foti, L
   Krieger, MA
   Pilcher, C
   Calzavara-Silva, CE
   Mailliard, RB
   Rinaldo, CR
   Dhalia, R
   Marques, ETA
AF Viana, I. F. T.
   Coelho, D. F.
   Palma, M. L.
   Nascimento, E. J. M.
   Gu, G.
   Lima, L. F. O.
   Foti, L.
   Krieger, M. A.
   Pilcher, C.
   Calzavara-Silva, C. E.
   Mailliard, R. B.
   Rinaldo, C. R.
   Dhalia, R.
   Marques, E. T. A.
TI Detection of IgG3 antibodies specific to the human immunodeficiency
   virus type 1 (HIV-1) p24 protein as marker for recently acquired
   infection
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Early infection marker; ELISA; HIV; AIDS; recent infection
ID ASSAYS; RESPONSES; SUBCLASSES; ANTIGENS
AB Reducing the risk of human immunodeficiency virus type 1 (HIV-1) transmission is still a public health priority. The development of effective control strategies relies on the quantification of the effects of prophylactic and therapeutic measures in disease incidence. Although several assays can be used to estimate HIV incidence, these estimates are limited by the poor performance of these assays in distinguishing recent from long-standing infections. To address such limitation, we have developed an assay to titrate p24-specific IgG3 antibodies as a marker of recent infection. The assay is based on a recombinant p24 protein capable to detect total IgG antibodies in sera using a liquid micro array and enzyme-linked immunosorbent assay. Subsequently, the assay was optimised to detect and titrate anti-p24 IgG3 responses in a panel of sequential specimens from seroconverters over 24 months. The kinetics of p24-specific IgG3 titres revealed a transient peak in the 4 to 5-month period after seroconversion. It was followed by a sharp decline, allowing infections with less than 6 months to be distinguished from older ones. The developed assay exhibited a mean duration of recent infection of 144 days and a false-recent rate of ca. 14%. Our findings show that HIV-1 p24-specific IgG3 titres can be used as a tool to evaluate HIV incidence in serosurveys and to monitor the efficacy of vaccines and other transmission control strategies.
C1 [Viana, I. F. T.; Coelho, D. F.; Dhalia, R.; Marques, E. T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Inst, Rio De Janeiro, RJ, Brazil.
   [Viana, I. F. T.; Coelho, D. F.; Nascimento, E. J. M.; Gu, G.; Marques, E. T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Viana, I. F. T.; Palma, M. L.; Nascimento, E. J. M.; Mailliard, R. B.; Rinaldo, C. R.; Marques, E. T. A.] Univ Pittsburgh, Infect Dis & Microbiol Dept, Pittsburgh, PA 15260 USA.
   [Coelho, D. F.] Univ Fed Pernambuco, Fundamental Chem Dept, Recife, PE, Brazil.
   [Gu, G.] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Lima, L. F. O.; Foti, L.; Krieger, M. A.] Fiocruz MS, Carlos Chagas Inst, Rio De Janeiro, RJ, Brazil.
   [Lima, L. F. O.] Technol Inst Parana TECPAR, Curitiba, Parana, Brazil.
   [Foti, L.; Krieger, M. A.] Mol Biol Inst Parana IBMP, Curitiba, Parana, Brazil.
   [Pilcher, C.] UCSF Sch Med, San Francisco, CA USA.
   [Calzavara-Silva, C. E.] Fiocruz MS, Rene Rachou Res Ctr, Rio De Janeiro, RJ, Brazil.
RP Viana, IFT (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Inst, Rio De Janeiro, RJ, Brazil.; Viana, IFT (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.; Viana, IFT (corresponding author), Univ Pittsburgh, Infect Dis & Microbiol Dept, Pittsburgh, PA 15260 USA.
EM isabelle.viana@cpqam.fiocruz.br
RI Dhalia, Rafael/AAD-5432-2020; Mailiiard, Robbie/M-9723-2015; Coelho,
   Danilo Fernandes/AAC-9206-2020; Marques, Ernesto T. A/L-4967-2013;
   Krieger, Marco/AAE-8611-2020; Foti, Leonardo/F-1763-2014; Viana,
   Isabelle/M-4435-2017
OI Coelho, Danilo Fernandes/0000-0002-1111-0825; Marques, Ernesto T.
   A/0000-0003-3826-9358; Foti, Leonardo/0000-0003-2948-9914;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401; Viana,
   Isabelle/0000-0003-4648-6635; Mailliard, Robbie/0000-0001-5501-503X
FU Coordination for the Improvement of Higher Education Personnel, Brazil
   [9848-12-6]; National Institutes of Health - NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA;
   Brazilian National Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq) [PA-14-328]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01 AI035041];
   Molecular Biology Institute of Parana - IBMP, Brazil; Center for Vaccine
   Research at the University of Pittsburgh, USA; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI035041,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, U01AI035041] Funding Source: NIH RePORTER
FX The authors would like to thank the Multicenter AIDS Cohort Study team
   for its valuable cooperation with this project. Dr Seth Horn, Department
   of Chemistry, University of Pittsburgh, is acknowledged for providing
   access to the circular dichroism facility. This work was supported by
   the Coordination for the Improvement of Higher Education Personnel
   (I.F.T.V., Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -
   CAPES, grant number 9848-12-6), Brazil; by the National Institutes of
   Health - NIH in a partnership with the Brazilian National Council for
   Scientific and Technological Development (I.F.T.V.,E.T.A.M., Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico, grant number
   PA-14-328); by the NIH (C.R.R., R.B.M., grant number U01 AI035041,
   University of Pittsburgh Multicenter AIDS Cohort Study (MACS)); by the
   Molecular Biology Institute of Parana - IBMP, Brazil (L.F.O.L.,L.F.,
   M.A.K., no specific grant); and by the Center for Vaccine Research at
   the University of Pittsburgh, USA (M.L.P., D.F.C., E.J.M.N, G.G., no
   specific grant). The other authors received no specific grant from any
   funding agency, commercial or not-for-profit sectors to perform this
   research.
CR Administration UFaD, 2001, GUID IND BIOAN METH
   Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Atun R, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001045
   Banerjee K, 2010, AIDS RES HUM RETROV, V26, P445, DOI 10.1089/aid.2009.0223
   Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   Crestani S, 2016, J IMMUNOL METHODS, V435, P17, DOI 10.1016/j.jim.2016.05.002
   Curtis KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064201
   DeSilva B, 2003, PHARM RES-DORDR, V20, P1885, DOI 10.1023/B:PHAM.0000003390.51761.3d
   Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
   FERRANTE A, 1990, PEDIATR INFECT DIS J, V9, pS16
   GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Keating SM, 2012, J CLIN MICROBIOL, V50, P3968, DOI 10.1128/JCM.01454-12
   KHALIFE J, 1988, AIDS RES HUM RETROV, V4, P3, DOI 10.1089/aid.1988.4.3
   MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075
   Moyo S, 2015, VIRUSES-BASEL, V7, P5508, DOI 10.3390/v7102887
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   Park SY, 2014, J VIROL, V88, P2977, DOI 10.1128/JVI.03128-13
   Press W, 2011, WHO LIB CATALOGUING, P1
   SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F
   Stapleton NM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1608
   Tomaras GD, 2009, CURR OPIN HIV AIDS, V4, P373, DOI 10.1097/COH.0b013e32832f00c0
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   Wilson KM, 2004, AIDS, V18, P2253, DOI 10.1097/00002030-200411190-00005
   Yates NL, 2011, AIDS, V25, P2089, DOI 10.1097/QAD.0b013e32834b348e
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 29
TC 3
Z9 3
U1 1
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2018
VL 146
IS 10
BP 1293
EP 1300
DI 10.1017/S0950268818001218
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA GO3YN
UT WOS:000439936400014
PM 29925445
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Fischer, C
   Pedroso, C
   Mendrone, A
   de Filippis, AMB
   Vallinoto, ACR
   Ribeiro, BM
   Durigon, EL
   Marques, ETA
   Campos, GS
   Viana, IFT
   Levi, JE
   Scarpelli, LC
   Nogueira, ML
   Bastos, MD
   Souza, NCS
   Khouri, R
   Lira, SMC
   Komninakis, SV
   Baronti, C
   Charrel, RN
   Kummerer, BM
   Drosten, C
   Brites, C
   de Lamballerie, X
   Niedrig, M
   Netto, EM
   Drexler, JF
AF Fischer, Carlo
   Pedroso, Celia
   Mendrone, Alfredo, Jr.
   Bispo de Filippis, Ana Maria
   Rosario Vallinoto, Antonio Carlos
   Ribeiro, Bergmann Morais
   Durigon, Edison Luiz
   Marques, Ernesto T. A., Jr.
   Campos, Gubio S.
   Viana, Isabelle F. T.
   Levi, Jose Eduardo
   Scarpelli, Luciano Cesar
   Nogueira, Mauricio Lacerda
   Bastos, Michele de Souza
   Santiago Souza, Nathalia C.
   Khouri, Ricardo
   Costa Lira, Sanny M.
   Komninakis, Shirley Vasconcelos
   Baronti, Cecile
   Charrel, Remi N.
   Kuemmerer, Beate M.
   Drosten, Christian
   Brites, Carlos
   de lamballerie, Xavier
   Niedrig, Matthias
   Netto, Eduardo Martins
   Drexler, Jan Felix
TI External Quality Assessment for Zika Virus Molecular Diagnostic Testing,
   Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INFECTION; LOAD
AB We conducted an external quality assessment of Zika virus molecular diagnostic tests in Brazil using a new Zika virus standard. Of 15 laboratories, 73% showed limited sensitivity and specificity. Viral load estimates varied significantly. Continuous quality assurance is required for adequate estimates of Zika virus-associated disease and determination of patient care.
C1 [Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Charite, German Ctr Infect Res, Berlin, Germany.
   [Pedroso, Celia; Brites, Carlos; Netto, Eduardo Martins] Hosp Univ Prof Edgard Santos, LAPI, Salvador, BA, Brazil.
   [Mendrone, Alfredo, Jr.; Levi, Jose Eduardo] Fdn Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Bispo de Filippis, Ana Maria] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Rosario Vallinoto, Antonio Carlos] Fed Univ Para, Belem, Para, Brazil.
   [Ribeiro, Bergmann Morais] Univ Brasilia, Brasilia, DF, Brazil.
   [Durigon, Edison Luiz; Levi, Jose Eduardo; Santiago Souza, Nathalia C.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Marques, Ernesto T. A., Jr.; Viana, Isabelle F. T.] Fundacao Oswaldo Cruz, Pernambuco, Brazil.
   [Campos, Gubio S.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Levi, Jose Eduardo; Scarpelli, Luciano Cesar] Diagnost Amer DASA, Sao Paulo, Brazil.
   [Levi, Jose Eduardo; Costa Lira, Sanny M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto, Sao Jose De Rio Preto, Brazil.
   [Bastos, Michele de Souza] Fdn Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Khouri, Ricardo] Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Komninakis, Shirley Vasconcelos] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Baronti, Cecile; Charrel, Remi N.; de lamballerie, Xavier] Aix Marseille Univ, Marseille, France.
   [Baronti, Cecile; Charrel, Remi N.; de lamballerie, Xavier] Assistance Publ Hop Marseille, Marseille, France.
   [Kuemmerer, Beate M.] Univ Bonn, Med Ctr, Bonn, Germany.
   [Niedrig, Matthias] Robert Koch Inst, Berlin, Germany.
RP Drexler, JF (corresponding author), Inst Virol, Helmut Ruska Haus, Campus Charite Mitte,Charitepl 1, D-10098 Berlin, Germany.
EM felix.drexler@charite.de
RI Brites, Carlos/D-1353-2013; Vallinoto, Antonio Carlos/AAL-9501-2020;
   Marques, Ernesto T. A/L-4967-2013; Netto, Eduardo/D-1432-2013;
   Komninakis, Shirley V/B-2915-2010; Ribeiro, Bergmann Morais/C-7114-2015;
   Bastos, Michele/AAS-7386-2020; Khouri, Ricardo/M-3184-2018; Nogueira,
   Mauricio L/B-7599-2012; Viana, Isabelle/M-4435-2017
OI Brites, Carlos/0000-0002-4673-6991; Vallinoto, Antonio
   Carlos/0000-0003-1135-6507; Marques, Ernesto T. A/0000-0003-3826-9358;
   Netto, Eduardo/0000-0003-1691-6761; Komninakis, Shirley
   V/0000-0001-7784-3418; Ribeiro, Bergmann Morais/0000-0002-1061-196X;
   Bastos, Michele/0000-0003-3450-666X; Khouri,
   Ricardo/0000-0001-5664-4436; Nogueira, Mauricio L/0000-0003-1102-2419;
   Viana, Isabelle/0000-0003-4648-6635; Drexler, Jan
   Felix/0000-0002-3509-0232; Fischer, Carlo/0000-0001-9163-2406
FU German Centre for Infection Research; European Union's Horizon research
   and innovation program (ZIKAlliance) [734548]; EVAg [653316]
FX This work was supported by the German Centre for Infection Research
   through a fast-track program for Zika virus outbreak response to J.F.D.
   and is partially supported by the European Union's Horizon 2020 research
   and innovation program (ZIKAlliance, grant agreement no. 734548 to
   X.d.L. and EVAg, grant agreement no. 653316 to C.D.).
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Baylis SA, 2017, TRANSFUSION, V57, P748, DOI 10.1111/trf.14026
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Domingo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036291
   Domingo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000833
   Drexler JF, 2009, PLOS MED, V6, P210, DOI 10.1371/journal.pmed.1000031
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Niedrig M, 2006, CLIN CHEM, V52, P1851, DOI 10.1373/clinchem.2005.064451
NR 15
TC 11
Z9 11
U1 0
U2 8
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2018
VL 24
IS 5
BP 888
EP 892
DI 10.3201/eid2405.171747
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GD2TP
UT WOS:000430355500012
PM 29470164
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU de Araujo, TVB
   Ximenes, RADA
   Miranda, DD
   Souza, WV
   Montarroyos, UR
   de Melo, APL
   Valongueiro, S
   de Albuquerque, MDPM
   Braga, C
   Brandao, SP
   Cordeiro, MT
   Vazquez, E
   Cruz, DDS
   Henriques, CMP
   Bezerra, LCA
   Castanha, PMD
   Dhalia, R
   Marques, ETA
   Martelli, CMT
   Rodrigues, LC
AF Barreto de Araujo, Thalia Velho
   de Alencar Ximenes, Ricardo Arraes
   Miranda-Filho, Democrito de Barros
   Souza, Wayner Vieira
   Montarroyos, Ulisses Ramos
   Lopes de Melo, Ana Paula
   Valongueiro, Sandra
   Pessoa Militao de Albuquerque, Maria de Fatima
   Braga, Cynthia
   Brandao Filho, Sinval Pinto
   Cordeiro, Marli Tenorio
   Vazquez, Enrique
   Souza Cruz, Danielle di Cavalcanti
   Pessanha Henriques, Claudio Maierovitch
   Albuquerque Bezerra, Luciana Caroline
   da Silva Castanha, Priscila Mayrelle
   Dhalia, Rafael
   Azevedo Marques-Junior, Ernesto Torres
   Turchi Martelli, Celina Maria
   Rodrigues, Laura Cunha
CA Investigators Microcephaly Epidem
TI Association between microcephaly, Zika virus infection, and other risk
   factors in Brazil: final report of a case-control study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID BIRTH-DEFECTS; GESTATIONAL-AGE; PREGNANCY; INFANTS; FETUSES; SMOKING
AB Background A Zika virus epidemic emerged in northeast Brazil in 2015 and was followed by a striking increase in congenital microcephaly cases, triggering a declaration of an international public health emergency. This is the final report of the first case-control study evaluating the potential causes of microcephaly: congenital Zika virus infection, vaccines, and larvicides. The published preliminary report suggested a strong association between microcephaly and congenital Zika virus infection.
   Methods We did a case-control study in eight public maternity hospitals in Recife, Brazil. Cases were neonates born with microcephaly, defined as a head circumference of 2 SD below the mean. Two controls without microcephaly were matched to each case by expected date of delivery and area of residence. We tested the serum of cases and controls and the CSF of cases for detection of Zika virus genomes with quantitative RT-PCR and for detection of IgM antibodies with capture-IgM ELISA. We also tested maternal serum with plaque reduction neutralisation assays for Zika and dengue viruses. We estimated matched crude and adjusted odds ratios with exact conditional logistic regression to determine the association between microcephaly and Zika virus infection.
   Findings We screened neonates born between Jan 15 and Nov 30, 2016, and prospectively recruited 91 cases and 173 controls. In 32 (35%) cases, congenital Zika virus infection was confirmed by laboratory tests and no controls had confirmed Zika virus infections. 69 (83%) of 83 cases with known birthweight were small for gestational age, compared with eight (5%) of 173 controls. The overall matched odds ratio was 73.1 (95% CI 13.0-infinity) for microcephaly and Zika virus infection after adjustments. Neither vaccination during pregnancy or use of the larvicide pyriproxyfen was associated with microcephaly. Results of laboratory tests for Zika virus and brain imaging results were available for 79 (87%) cases; within these cases, ten were positive for Zika virus and had cerebral abnormalities, 13 were positive for Zika infection but had no cerebral abnormalities, and 11 were negative for Zika virus but had cerebral abnormalities.
   Interpretation The association between microcephaly and congenital Zika virus infection was confirmed. We provide evidence of the absence of an effect of other potential factors, such as exposure to pyriproxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles and rubella, or measles, mumps, and rubella) during pregnancy, confirming the findings of an ecological study of pyriproxyfen in Pernambuco and previous studies on the safety of Tdap vaccine administration during pregnancy.
C1 [Barreto de Araujo, Thalia Velho; Valongueiro, Sandra] Univ Fed Pernambuco, Dept Social Med, Recife, PE, Brazil.
   [de Alencar Ximenes, Ricardo Arraes] Univ Fed Pernambuco, Dept Trop Med, Recife, PE, Brazil.
   [de Alencar Ximenes, Ricardo Arraes; Miranda-Filho, Democrito de Barros; Montarroyos, Ulisses Ramos] Univ Pernambuco, Recife, PE, Brazil.
   [Souza, Wayner Vieira; Pessoa Militao de Albuquerque, Maria de Fatima; Braga, Cynthia; Brandao Filho, Sinval Pinto; Cordeiro, Marli Tenorio; da Silva Castanha, Priscila Mayrelle; Dhalia, Rafael; Azevedo Marques-Junior, Ernesto Torres; Turchi Martelli, Celina Maria] Oswaldo Cruz Fdn Fiocruz, Res Ctr Aggeu Magalhaes CPqAM, Recife, PE, Brazil.
   [Lopes de Melo, Ana Paula] Univ Fed Pernambuco, Dept Community Hlth, Vitoria De Santo Antao, Brazil.
   [Vazquez, Enrique] Pan Amer Hlth Org, Brasilia, DF, Brazil.
   [Souza Cruz, Danielle di Cavalcanti] Inst Materno Infantil Fernando Figueira, Recife, PE, Brazil.
   [Pessanha Henriques, Claudio Maierovitch] Brazilian Minist Hlth, Brasilia, DF, Brazil.
   [Albuquerque Bezerra, Luciana Caroline] State Hlth Dept Pernambuco, Recife, PE, Brazil.
   [Azevedo Marques-Junior, Ernesto Torres] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Rodrigues, Laura Cunha] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
RP de Araujo, TVB (corresponding author), Univ Fed Pernambuco, BR-50670901 Recife, PE, Brazil.
EM thalia@ufpe.br
RI Montarroyos, Ulisses/AAJ-7527-2020; Dhalia, Rafael/AAD-5432-2020; Braga,
   Maria Cynthia/A-8204-2013; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Brandao-Filho, Sinval Pinto/AAP-4792-2020; Souza,
   Wayner V/H-3798-2013; Marques, Ernesto T. A/L-4967-2013
OI Braga, Maria Cynthia/0000-0002-7862-6455; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Brandao-Filho, Sinval
   Pinto/0000-0003-3768-2810; Marques, Ernesto T. A/0000-0003-3826-9358;
   Turchi Martelli, Celina Maria/0000-0002-2491-0688; Souza,
   Wayner/0000-0002-0939-9332
FU Brazilian Ministry of Health; Pan American Health Organization;
   Enhancing Research Activity in Epidemic Situations; Medical Research
   CouncilMedical Research Council UK (MRC) [MC_PC_15088] Funding Source:
   researchfish
FX Brazilian Ministry of Health, Pan American Health Organization, and
   Enhancing Research Activity in Epidemic Situations.
CR Albuquerque MDPM, 2016, EMERG INFECT DIS, V22, P1090, DOI [10.32032/eid2206.160062, 10.3201/eid2206.160062]
   Alirol E, 2011, LANCET INFECT DIS, V11, P131, DOI 10.1016/S1473-3099(10)70223-1
   Ashwal S, 2009, NEUROLOGY, V73, P887, DOI 10.1212/WNL.0b013e3181b783f7
   Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brito C, 2015, ACTA MEDICA PORT, V28, P679
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fenton TR, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-59
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Hackshaw A, 2011, HUM REPROD UPDATE, V17, P589, DOI 10.1093/humupd/dmr022
   HIRJI KF, 1989, AM STAT, V43, P7, DOI 10.2307/2685158
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Instituto de Pesquisa Economica Aplicada, 2014, SIT SOC POP NEGR EST
   Ko TJ, 2014, PEDIATR NEONATOL, V55, P20, DOI 10.1016/j.pedneo.2013.05.005
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Marinho F, 2016, EPIDEMIOL SERV SAUDE, V25, P701, DOI [10.5123/s1679-49742016000400004, 10.5123/S1679-49742016000400004]
   de Albuquerque MDPM, 2016, MEM I OSWALDO CRUZ, V111, P774, DOI 10.1590/0074-02760160291
   Ministerio da Saude (BR), 2014, INF TECN IMPL VAC AD
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Panchaud A, 2016, CLIN MICROBIOL REV, V29, P659, DOI 10.1128/CMR.00014-16
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Schaub B, 2017, LANCET INFECT DIS, V17, P520, DOI [10.1016/S1473-3099(17)30102-0, 10.1016/s1473-3099(17)30102-0]
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   STATA, EX LOG REGR REF MAN, P507
   Vouga M, 2016, PRENATAL DIAG, V36, P799, DOI 10.1002/pd.4880
   Walls T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009536
   WHO, 2016, SCREEN ASS MAN NON I
NR 33
TC 113
Z9 115
U1 5
U2 45
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAR
PY 2018
VL 18
IS 3
BP 328
EP 336
DI 10.1016/S1473-3099(17)30727-2
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA FX2ZO
UT WOS:000425938000040
PM 29242091
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Duangkhae, P
   Erdos, G
   Ryman, KD
   Watkins, SC
   Falo, LD
   Marques, ETA
   Barratt-Boyes, SM
AF Duangkhae, Parichat
   Erdos, Geza
   Ryman, Kate D.
   Watkins, Simon C.
   Falo, Louis D., Jr.
   Marques, Ernesto T. A., Jr.
   Barratt-Boyes, Simon M.
TI Interplay between Keratinocytes and Myeloid Cells Drives Dengue Virus
   Spread in Human Skin
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID DENDRITIC CELLS; IMMUNE-RESPONSES; LANGERHANS CELLS; MAST-CELLS;
   INFECTION; IL-1-BETA; ALPHA; QUANTITATION; MOSQUITOS; DELIVERY
AB The skin is the site of dengue virus (DENV) transmission following the bite of an infected mosquito, but the contribution of individual cell types within skin to infection is unknown. We studied the dynamics of DENV infection in human skin explants using quantitative in situ imaging. DENV replicated primarily in the epidermis and induced a transient IFN-alpha response. DENV infected a wide range of cells, including Langerhans cells, macrophages, dermal dendritic cells, mast cells, fibroblasts, and lymphatic endothelium, but keratinocytes were the earliest targets of infection and made up 60% of infected cells over time. Virus inoculation led to recruitment and infection of Langerhans cells, macrophages, and dermal dendritic cells, and these cells emigrated from skin in increased numbers as a result of infection. DENV induced expression of proinflammatory cytokines and chemokines by infected keratinocytes. Blocking keratinocyte-derived IL-1 beta alone reduced infection of Langerhans cells, macrophages, and dermal dendritic cells by 75-90% and reduced the overall number of infected cells in dermis by 65%. These data show that the innate response of infected keratinocytes attracts virus-permissive myeloid cells that inadvertently spread DENV infection. Our findings highlight a role for keratinocytes and their interplay with myeloid cells in dengue.
C1 [Duangkhae, Parichat; Ryman, Kate D.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave, Pittsburgh, PA 15261 USA.
   [Duangkhae, Parichat; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Erdos, Geza] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15261 USA.
   [Ryman, Kate D.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA.
   [Watkins, Simon C.] Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA 15261 USA.
   [Watkins, Simon C.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15261 USA.
   [Watkins, Simon C.; Falo, Louis D., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
RP Barratt-Boyes, SM (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave, Pittsburgh, PA 15261 USA.
EM smbb@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Falo, Louis/ABD-1499-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; watkins,
   simon/0000-0003-4092-1552
FU Government Pharmaceutical Organization of Thailand
FX We thank Amanda Smith and Priscila Castanha for technical support;
   Jeffrey Gusenoff, J. Peter Rubin, Barbara Chakurda, Lauren Kokai, and
   Julia Moore for providing anonymized skin specimens; Sujan Shresta for
   providing DENV NS3 Ab; Jared Evans for providing DENV isolate 16681, and
   the NIH Biodefense and Emerging Infectious Research Resources
   Repository, NIAID, for providing DENV isolate K0049. Parichat Duangkhae
   was supported by a scholarship from the Government Pharmaceutical
   Organization of Thailand.
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bourke CD, 2015, INT J PARASITOL, V45, P215, DOI 10.1016/j.ijpara.2014.11.002
   Bustos-Arriaga J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001420
   Cerny D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004548
   Cologna R, 2005, J VIROL, V79, P853, DOI 10.1128/JVI.79.2.853-859.2005
   Conway MJ, 2014, J VIROL, V88, P164, DOI 10.1128/JVI.02235-13
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000
   Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705
   ENK AH, 1993, J IMMUNOL, V150, P3698
   Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Korkmaz E, 2015, ACTA BIOMATER, V24, P96, DOI 10.1016/j.actbio.2015.05.036
   Lim PY, 2011, J VIROL, V85, P5197, DOI 10.1128/JVI.02692-10
   Limon-Flores AY, 2005, INT J EXP PATHOL, V86, P323, DOI 10.1111/j.0959-9673.2005.00445.x
   McCracken MK, 2014, J VIROL, V88, P1881, DOI 10.1128/JVI.01218-13
   Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017
   Milora KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6230
   Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622
   Payne AF, 2006, J VIROL METHODS, V134, P183, DOI 10.1016/j.jviromet.2006.01.003
   Pingen M, 2016, IMMUNITY, V44, P1455, DOI 10.1016/j.immuni.2016.06.002
   Rider P, 2011, J IMMUNOL, V187, P4835, DOI 10.4049/jimmunol.1102048
   Rodriguez-Madoz JR, 2010, J VIROL, V84, P4845, DOI 10.1128/JVI.02514-09
   Schmid MA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005676
   Schmid MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004541
   St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108
   Stoitzner P, 1999, J LEUKOCYTE BIOL, V66, P462
   Styer LM, 2007, PLOS PATHOG, V3, P1262, DOI 10.1371/journal.ppat.0030132
   Surasombatpattana P, 2014, J INVEST DERMATOL, V134, P281, DOI 10.1038/jid.2013.251
   Surasombatpattana P, 2012, J INVEST DERMATOL, V132, P2103, DOI 10.1038/jid.2012.76
   Surasombatpattana P, 2011, INFECT GENET EVOL, V11, P1664, DOI 10.1016/j.meegid.2011.06.009
   Tapias V, 2013, NEUROBIOL DIS, V54, P158, DOI 10.1016/j.nbd.2012.11.018
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Troupin A, 2016, J IMMUNOL, V197, P4382, DOI 10.4049/jimmunol.1600846
   Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553
NR 35
TC 18
Z9 18
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAR
PY 2018
VL 138
IS 3
BP 618
EP 626
DI 10.1016/j.jid.2017.10.018
PG 9
WC Dermatology
SC Dermatology
GA FX0QD
UT WOS:000425749900033
PM 29106931
OA Bronze
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Burke, DS
AF Marques, Ernesto T. A.
   Burke, Donald S.
TI Tradition and innovation in development of a Zika vaccine
SO LANCET
LA English
DT Editorial Material
ID VIRUS
C1 [Marques, Ernesto T. A.; Burke, Donald S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.; Burke, Donald S.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] FIOCRUZ Pernambuco, Dept Virol & Expt Therapeut, Inst Aggeu Magalhaes, Recife, PE, Brazil.
RP Marques, ETA (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.; Marques, ETA (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.; Marques, ETA (corresponding author), FIOCRUZ Pernambuco, Dept Virol & Expt Therapeut, Inst Aggeu Magalhaes, Recife, PE, Brazil.
EM marques@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR [Anonymous], 2017, LANCET INFECT DIS, V17, P1003, DOI 10.1016/S1473-3099(17)30534-0
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Gaudinski MR, 2017, LANCET
   Maciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693
   Marston HD, 2016, NEW ENGL J MED, V375, P1209, DOI 10.1056/NEJMp1607762
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Modjarrad K, 2017, LANCET
   PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3
   Paules CI, 2017, JAMA-J AM MED ASSOC, V317, P691, DOI 10.1001/jama.2016.21079
   Salk JE, 1955, AM J PUBLIC HEALTH N, V45, P151, DOI 10.2105/AJPH.45.2.151
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
NR 12
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB 10
PY 2018
VL 391
IS 10120
BP 516
EP 517
DI 10.1016/S0140-6736(17)33107-0
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA FV5VB
UT WOS:000424649400006
PM 29217377
OA Bronze
DA 2020-12-16
ER

PT J
AU Loeffler, F
   Lins, R
   Fischer, N
   Viana, I
   Cataldi, C
   Leite, B
   Magalhaes, T
   Cordeiro, MT
   Marques, ET
   Jaenisch, T
AF Loeffler, Felix
   Lins, Roberto
   Fischer, Nico
   Viana, Isabelle
   Cataldi, Catarina
   Leite, Bruno
   Magalhaes, Tereza
   Cordeiro, Marli
   Marques, Ernesto
   Jaenisch, Thomas
TI UNEXPECTED PROPERTIES OF A ZIKA NS2B EPITOPE SUGGEST ITS POTENTIAL AS A
   BIOMARKER FOR DIAGNOSIS AND PROGNOSIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTHM)
CY OCT 28-NOV 01, 2018
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Takeda Pharmaceut Int AG, Novartis Social Business, Celgene Corp, Techlab Inc, Indiana Univ, Sch Med, B EI Resources, Sanofi Pasteur, Welcome, PLOS, Elsevier
C1 [Loeffler, Felix] Max Planck Inst Colloids & Interfaces, Potsdam, Germany.
   [Lins, Roberto; Viana, Isabelle; Cataldi, Catarina; Leite, Bruno; Cordeiro, Marli] Fundacao Oswaldo Cruz, Recife, PE, Brazil.
   [Fischer, Nico; Jaenisch, Thomas] Heidelberg Univ Hosp, Heidelberg, Germany.
   [Magalhaes, Tereza] Colorado State Univ, Ft Collins, CO 80523 USA.
   [Marques, Ernesto] Univ Pittsburgh, Pittsburgh, PA USA.
RI Marques, Ernesto T. A/L-4967-2013; Loeffler, Felix F/K-6192-2016
OI Marques, Ernesto T. A/0000-0003-3826-9358; Loeffler, Felix
   F/0000-0002-8227-2522
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2018
VL 99
IS 4
SU S
MA 943
BP 297
EP 297
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA HP0WF
UT WOS:000461386603279
DA 2020-12-16
ER

PT J
AU Pastor, AF
   Rocha, A
   Cassemiro, KD
   Tenorio, M
   Melo, P
   Grilis, MR
   Rhuama, M
   Rezende, AM
   Neto, OPD
   Marques, E
   Dhalia, R
AF Pastor, Andre Filipe
   Rocha, Abraham
   Cassemiro, Klecia de Melo
   Tenorio, Marli
   Melo, Paula
   Grilis, Maria Rosangela
   Rhuama, Maressa
   Rezende, Antonio Mauro
   de Melo Neto, Osvaldo Pompilio
   Marques, Ernesto, Jr.
   Dhalia, Rafael
TI Evaluation of the recombinant antigens Wb14 and WbT for the capture
   antibody diagnosis of lymphatic filariasis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE immunodiagnostic; Wuchereria bancrofti; ELISA; biotechnology
ID BRUGIA-MALAYI; IGG4; RESPONSES; WBSXP-1; TOOLS; SERUM
AB BACKGROUND Lymphatic filariasis (LF) is a parasitic disease caused mainly by the Wuchereria bancrofti worm and that affects up to 120 million people worldwide. LF is the second cause of chronic global deformity, responsible for 15 million people with lymphedema (elephantiasis) and 25 million men with scrotal hydrocele. Its diagnosis is still associated with numerous difficulties, such as the sample collection periods (microfilaria nocturnal periodicity) and limited diagnostic kits.
   OBJECTIVES The aim of this work was to evaluate two recombinant antigens (Wb14 and WbT) as part of an enzyme-linked immunosorbent assay (ELISA) based antibody capture tests for LF.
   METHODS The recombinant antigens rWb14 and rWbT were expressed in Escherichia coli BL21 and an antibody capture ELISA was performed. For this, sera were used from microfilaremic individuals with W. bancrofti (MF), chronic pathology (CP), individuals infected with Strongyloides (SP) and healthy controls from endemic (EN) and non-endemic (NE) areas.
   FINDINGS Both tests showed similar results, with 90% sensitivity and 96.6% specificity. In comparison with the BM14 ELISA commercial test, the Wb14 and WbT antigens performed with identical sensitivity but greater specificity. Reduced positivity with the CP suggested a potential to monitor cure. This was not confirmed, however, when sera from individuals up to seven years after treatment were assayed.
   MAIN CONCLUSIONS The Wb14 and WbT ELISAs were considered efficient and promising diagnostic tests. Due to the importance of antibody capture analysis to evaluate the Global Program to Eliminate Lymphatic Filariasis (GPELF), the tests proposed here appear as great alternatives to the available commercial system.
C1 [Pastor, Andre Filipe; Rocha, Abraham; Tenorio, Marli; Melo, Paula; Grilis, Maria Rosangela; Rhuama, Maressa; Rezende, Antonio Mauro; de Melo Neto, Osvaldo Pompilio; Marques, Ernesto, Jr.; Dhalia, Rafael] Inst Aggeu Magalhaes, Fundacao Oswaldo Cruz Fiocruz, Recife, PE, Brazil.
   [Pastor, Andre Filipe; Rhuama, Maressa; de Melo Neto, Osvaldo Pompilio; Dhalia, Rafael] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Rocha, Abraham; Melo, Paula; Grilis, Maria Rosangela] Inst Aggeu Magalhaes, Serv Referencia Nacl Filarioses, Fundacao Oswaldo Cruz Fiocruz, Recife, PE, Brazil.
   [Pastor, Andre Filipe] Inst Fed Ciencia & Tecnol Sertao Pernambucano, Campus Floresta, Floresta, PE, Brazil.
   [Rocha, Abraham] Hosp Otavio Freitas, Recife, PE, Brazil.
   [Cassemiro, Klecia de Melo] Inst Nacl Canc, Lab Patol Clin, Rio De Janeiro, RJ, Brazil.
RP Pastor, AF (corresponding author), Inst Aggeu Magalhaes, Fundacao Oswaldo Cruz Fiocruz, Recife, PE, Brazil.; Pastor, AF (corresponding author), Univ Fed Pernambuco, Recife, PE, Brazil.; Pastor, AF (corresponding author), Inst Fed Ciencia & Tecnol Sertao Pernambucano, Campus Floresta, Floresta, PE, Brazil.
EM andrefilipe.pastor@gmail.com
RI Rezende, Antonio M/S-2126-2018; Marques, Ernesto T. A/L-4967-2013;
   Dhalia, Rafael/AAD-5432-2020; de Melo Neto, Osvaldo P/B-1366-2015
OI Rezende, Antonio M/0000-0003-4775-1779; Marques, Ernesto T.
   A/0000-0003-3826-9358; de Melo Neto, Osvaldo P/0000-0001-5402-7346
FU FACEPE [APQ-0058-4.00/13]; FIOCRUZ-PE
FX FACEPE (APQ-0058-4.00/13), FIOCRUZ-PE.
CR Alcantara de Souza Paula Fernanda, 2014, Revista de Patologia Tropical, V43, P427, DOI 10.5216/rpt.v43i4.33604
   ALMOND NM, 1986, IMMUNOLOGY, V59, P633
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P441
   Baskar LKV, 2004, MICROBIOL IMMUNOL, V48, P519, DOI 10.1111/j.1348-0421.2004.tb03547.x
   CHANDRASHEKAR R, 1994, MOL BIOCHEM PARASIT, V64, P261, DOI 10.1016/0166-6851(94)00035-2
   Damgaard J, 2016, ACTA TROP, V161, P26, DOI 10.1016/j.actatropica.2016.05.003
   DISSANAYAKE S, 1993, MOL BIOCHEM PARASIT, V62, P143, DOI 10.1016/0166-6851(93)90191-Y
   Hamlin KL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001941
   Iqbal J, 2006, J MED MICROBIOL, V55, P401, DOI 10.1099/jmm.0.46376-0
   Janardhan S, 2011, J HELMINTHOL, V85, P1, DOI 10.1017/S0022149X10000118
   Joseph H, 2011, ANN TROP MED PARASIT, V105, P567, DOI 10.1179/2047773211Y.0000000008
   Krushna NSA, 2009, MICROBIOL IMMUNOL, V53, P173, DOI 10.1111/j.1348-0421.2009.00114.x
   Kubofcik J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001930
   Lammie Patrick J, 2004, Filaria J, V3, P9, DOI 10.1186/1475-2883-3-9
   MAIZELS RM, 1987, PARASITE IMMUNOL, V9, P49, DOI 10.1111/j.1365-3024.1987.tb00488.x
   MORE SJ, 1990, TROP MED PARASITOL, V41, P403
   Nunes L. V., 2016, Asian Pacific Journal of Tropical Disease, V6, P521, DOI 10.1016/S2222-1808(16)61081-2
   Ottesen EA, 2000, TROP MED INT HEALTH, V5, P591, DOI 10.1046/j.1365-3156.2000.00620.x
   Pandiaraja P, 2010, DIAGN MICR INFEC DIS, V68, P410, DOI 10.1016/j.diagmicrobio.2010.07.015
   Pandiaraja P, 2010, EXP PARASITOL, V125, P236, DOI 10.1016/j.exppara.2010.01.027
   RAMZY RMR, 2002, T R SOC MED HYG, V96, P225
   Rao KVN, 2000, MOL BIOCHEM PARASIT, V107, P71, DOI 10.1016/S0166-6851(99)00231-5
   Rocha A, 2009, MEM I OSWALDO CRUZ, V104, P621, DOI 10.1590/S0074-02762009000400015
   Steel C, 2013, CLIN VACCINE IMMUNOL, V20, P1155, DOI 10.1128/CVI.00252-13
   Terhell AJ, 2003, AM J TROP MED HYG, V68, P33, DOI 10.4269/ajtmh.2003.68.33
   Weil GJ, 2007, TRENDS PARASITOL, V23, P78, DOI 10.1016/j.pt.2006.12.001
   Weil GJ, 2011, ACTA TROP, V120, pS19, DOI 10.1016/j.actatropica.2010.04.010
   Weil GJ, 1997, PARASITOL TODAY, V13, P401, DOI 10.1016/S0169-4758(97)01130-7
   WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1
   Ximenes C, 2014, MEM I OSWALDO CRUZ, V109, P978, DOI 10.1590/0074-0276140155
NR 30
TC 2
Z9 2
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2018
VL 113
IS 5
AR e170435
DI 10.1590/0074-02760170435
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA GA9WT
UT WOS:000428693000005
PM 29590236
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Lam, PK
   Rosenberger, K
   Tam, DTH
   Chanpheaktra, N
   See, LLC
   Sandoval, EP
   Laksono, IS
   Sarker, M
   Marques, ET
   Tami, A
   Simmons, C
   Wolbers, M
   Wills, B
   Jaenisch, T
AF Phung Khanh Lam
   Rosenberger, Kerstin
   Dong Thi Hoai Tam
   Chanpheaktra, Ngoun
   See, Lucy Lum Chai
   Pleites Sandoval, Ernesto
   Laksono, Ida Safitri
   Sarker, Malabika
   Marques, Ernesto T.
   Tami, Adriana
   Cameron Simmons
   Marcel Wolbers
   Bridget Wills
   Jaenisch, Thomas
TI PREDICTORS FOR SEVERE DENGUE: RESULTS FROM A PROSPECTIVE MULTI-CENTRE
   STUDY IN EIGHT COUNTRIES ACROSS ASIA AND LATIN AMERICA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Phung Khanh Lam; Dong Thi Hoai Tam; Cameron Simmons; Marcel Wolbers; Bridget Wills] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam.
   [Rosenberger, Kerstin; Jaenisch, Thomas] Heidelberg Univ Hosp, Sect Clin Trop Med, Heidelberg, Germany.
   [Chanpheaktra, Ngoun] Angkor Hosp Children, Siem Reap, Cambodia.
   [See, Lucy Lum Chai] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia.
   [Pleites Sandoval, Ernesto] Hosp Nacl Ninos Benjamin Bloom, San Salvador, El Salvador.
   [Laksono, Ida Safitri] Gadjah Mada Univ, Yogyakarta, Indonesia.
   [Sarker, Malabika] BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh.
   [Marques, Ernesto T.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Tami, Adriana] Univ Carabobo, Fac Ciencias Salud, Dept Parasitol, Valencia, Venezuela.
RI Lum, Lucy/Q-9871-2017; Marques, Ernesto T. A/L-4967-2013
OI Lum, Lucy/0000-0002-7452-4208; Marques, Ernesto T.
   A/0000-0003-3826-9358; Tami, Adriana/0000-0002-1918-9144
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 63
BP 21
EP 21
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851501063
DA 2020-12-16
ER

PT J
AU Brasil, P
   Marques, ET
   Tami, A
   Sandoval, EP
   Caprara, A
   Magalhaes, T
   Calvet, G
   Bethencourt, S
   Guzman, MG
   Simmons, CP
   Bispo, A
   Cordeiro, MT
   Wills, B
   Rosenberger, K
   Jaenisch, T
AF Brasil, Patricia
   Marques, Ernesto T.
   Tami, Adriana
   Sandoval, Ernesto Pleitess
   Caprara, Andrea
   Magalhaes, Tereza
   Calvet, Guilherme
   Bethencourt, Sarah
   Guzman, Maria G.
   Simmons, Cameron P.
   Bispo, Ana
   Cordeiro, Marli Tenorio
   Wills, Bridget
   Rosenberger, Kerstin
   Jaenisch, Thomas
TI CLINICAL CHARACTERIZATION OF ACUTE ZIKA PATIENTS IN BRAZIL, VENEZUELA,
   AND EL SALVADOR IN 2015/16
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Brasil, Patricia; Calvet, Guilherme; Bispo, Ana] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Marques, Ernesto T.; Magalhaes, Tereza; Cordeiro, Marli Tenorio] Fundacao Oswaldo Cruz, Recife, PE, Brazil.
   [Tami, Adriana] Univ Med Ctr Groningen, Groningen, Netherlands.
   [Sandoval, Ernesto Pleitess] Hosp Natl Ninos Benjamin Bloom, San Salvador, El Salvador.
   [Caprara, Andrea] Univ Estadual Ceara, Fortaleza, Ceara, Brazil.
   [Bethencourt, Sarah] Univ Carabobo, Valencia, Venezuela.
   [Guzman, Maria G.] Pedro Kouri Inst, Havana, Cuba.
   [Simmons, Cameron P.; Wills, Bridget] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam.
   [Rosenberger, Kerstin; Jaenisch, Thomas] Heidelberg Univ Hosp, Heidelberg, Germany.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Tami,
   Adriana/0000-0002-1918-9144
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 749
BP 236
EP 236
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851502272
DA 2020-12-16
ER

PT J
AU Palma, ML
   Martins, FS
   Marques, ET
   Douradinha, B
AF Palma, Mariana L.
   Martins, Flaviano S.
   Marques, Ernesto T., Jr.
   Douradinha, Bruno
TI DEVELOPMENT OF A MUCOSAL VACCINE AGAINST HIV BASED ON
   GENETICALLY-ENGINEERED SACCHAROMYCES CEREVISIAE PROBIOTIC STRAINS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Palma, Mariana L.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Martins, Flaviano S.] Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Marques, Ernesto T., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Douradinha, Bruno] Fdn Ri MED, Palermo, Italy.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 1929
BP 606
EP 606
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851503483
DA 2020-12-16
ER

PT J
AU Magalhaes, T
   Braga, C
   Cordeiro, MT
   Oliveira, ALS
   Castanha, PMS
   Maciel, APR
   Amancio, NML
   Gouveia, PN
   Peixoto-da-Silva, VJ
   Peixoto, TFL
   Britto, H
   Lima, PV
   Lima, ARS
   Rosenberger, KD
   Jaenisch, T
   Marques, ETA
AF Magalhaes, Tereza
   Braga, Cynthia
   Cordeiro, Marli T.
   Oliveira, Andre L. S.
   Castanha, Priscila M. S.
   Maciel, Ana Paula R.
   Amancio, Nathalia M. L.
   Gouveia, Pollyanne N.
   Peixoto-da-Silva, Valter J., Jr.
   Peixoto, Thaciana F. L.
   Britto, Helena
   Lima, Priscilla V.
   Lima, Andreza R. S.
   Rosenberger, Kerstin D.
   Jaenisch, Thomas
   Marques, Ernesto T. A.
TI Zika virus displacement by a chikungunya outbreak in Recife, Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
AB Background
   Several arboviruses, including dengue virus (DENV), Zika virus (ZIKV) and chikungunya virus (CHIKV), transmitted by Aedes mosquitoes, circulate in northeast Brazil. Diseases caused by these viruses are of great public health relevance, however, their epidemiological features in areas where the three viruses co-circulate are scarce. Here, we present analyses of molecular and serological diagnostics in a prospective study of acute febrile patients recruited from May 2015 to May 2016 in Recife, Brazil.
   Methods
   Two hundred sixty-three acute febrile patients with symptoms suggestive of an arboviral disease who attended an urgent heath care clinic in the Recife Metropolitan Region in northeast Brazil were enrolled. Acute and convalescent blood samples were collected and tested using molecular and serological assays for infection with DENV, ZIKV and CHIKV.
   Results
   Quantitative real-time reverse-transcriptase polymerase chain reactions (qRTPCR) performed on acute phase sera detected no patients positive for DENV, but 26 (9.9%) positive for ZIKV and 132 (50.2%) positive for CHIKV. There were a few suspected and only one confirmed dengue case. Specific serological assays for ZIKV and CHIKV confirmed the qRTPCR data. Analyses of DENV IgM and IgG ELISAs in the context of qRTPCR results suggested high levels of cross reactive antibodies in ZIKV-positive samples. Results from neutralization assays highly corroborated those from qRTPCR and ZIKV ELISA, indicating very few positive DENV cases. ZIKV infections were temporally clustered in the first months of the study and started to decrease concomitantly with an increase in CHIKV infections in August 2015. The proportion of CHIKV infections increased significantly in September 2015 and remained high until the end of the study period, with an average of 84.7% of recruited patients being diagnosed from August 2015 to May 2016. ZIKV infections exhibited a female bias and the cases were spread over the study site, while CHIKV cases had a male bias and were spatially clustered in each month.
   Conclusions
   In 2015 +/- 2016 in the Recife Metropolitan Region, we detected the tail end of a Zika epidemic, which was displaced by a chikungunya epidemic. Few dengue cases were identified despite a high number of official dengue notifications in the area during this period. We show here important epidemiological features of these cases.
C1 [Magalhaes, Tereza; Cordeiro, Marli T.; Castanha, Priscila M. S.; Lima, Priscilla V.; Lima, Andreza R. S.; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Lab Virol & Expt Therapeut, Recife, PE, Brazil.
   [Magalhaes, Tereza] Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab AIDL, Ft Collins, CO 80523 USA.
   [Braga, Cynthia] Fiocruz MS, IAM, Dept Parasitol, Recife, PE, Brazil.
   [Braga, Cynthia; Britto, Helena] Inst Integral Med Prof Fernando Figueira, Recife, PE, Brazil.
   [Oliveira, Andre L. S.] Fiocruz MS, IAM, Stat & Geoproc Lab, Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Fac Med Sci, Recife, PE, Brazil.
   [Maciel, Ana Paula R.; Amancio, Nathalia M. L.; Gouveia, Pollyanne N.; Peixoto-da-Silva, Valter J., Jr.; Peixoto, Thaciana F. L.] IMIP, Urgent Hlth Care Unit, Paulista, Brazil.
   [Rosenberger, Kerstin D.; Jaenisch, Thomas] Heidelberg Univ Hosp, Sect Clin Trop Med, Dept Infect Dis, Heidelberg, Germany.
   [Jaenisch, Thomas] German Ctr Infect Res DZIF, Partner Site Heidelberg, Heidelberg, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Magalhaes, T; Marques, ETA (corresponding author), Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Lab Virol & Expt Therapeut, Recife, PE, Brazil.; Magalhaes, T (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab AIDL, Ft Collins, CO 80523 USA.; Marques, ETA (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
EM tereza.magalhaes@colostate.edu; emarques@cpqam.fiocruz.br
RI Da Silva Castanha, Priscila Mayrelle/G-1785-2012; Braga, Maria
   Cynthia/A-8204-2013; Marques, Ernesto T. A/L-4967-2013; Magalhaes,
   Tereza/V-6632-2019
OI Da Silva Castanha, Priscila Mayrelle/0000-0002-1220-5308; Braga, Maria
   Cynthia/0000-0002-7862-6455; Marques, Ernesto T. A/0000-0003-3826-9358; 
FU European Union's Seventh Framework Programme for research, technological
   development and demonstrationEuropean Union (EU) [FP7-281803 IDAMS,
   IDAMS 45]; State of Pernambuco funding agency (Fundacao de Amparo a
   Ciencia e Tecnologia do Estado de Pernambuco-FACEPE) [PPSUS
   APQ-0302-4.01/13]; European Union's Horizon 2020 Research and Innovation
   Programme under ZIKAlliance [734548]; National Institute of Allergy and
   Infectious Diseases of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI129464]; ZikaCura (PITT-FIOCRUZ Alliance); Brazilian national
   funding agency (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico of Brazil-CNPq) [472360/2013-2]
FX This study was funded by the European Union's Seventh Framework
   Programme for research, technological development and demonstration
   (grant FP7-281803 IDAMS; http://www.idams.eu/), where it has been
   designated with publication reference number IDAMS 45; the State of
   Pernambuco funding agency (Fundacao de Amparo a Ciencia e Tecnologia do
   Estado de Pernambuco-FACEPE; grant PPSUS APQ-0302-4.01/13); the European
   Union's Horizon 2020 Research and Innovation Programme under ZIKAlliance
   (grant 734548); the National Institute of Allergy and Infectious
   Diseases of the National Institutes of Health (grant R21AI129464); the
   ZikaCura (PITT-FIOCRUZ Alliance); and the Brazilian national funding
   agency (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico of
   Brazil-CNPq; grant 472360/2013-2). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the funding agencies. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P668, DOI 10.1590/0037-8682-0279-2016
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P553, DOI 10.1590/0037-8682-0245-2016
   Aubry M, 2017, EMERG INFECT DIS, V23
   Cabral-Castro MJ, 2016, J CLIN VIROL, V82, P108, DOI 10.1016/j.jcv.2016.07.017
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Azevedo RDD, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049006219
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dirlikov E, 2016, MMWR-MORBID MORTAL W, V65, P451, DOI 10.15585/mmwr.mm6517e2
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Goertz GP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005654
   Governo do Estado de Pernambuco, 2015, B PLUV
   Granger D, 2017, J CLIN MICROBIOL, V55, P2127, DOI [10.1128/jcm.00580-17, 10.1128/JCM.00580-17]
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Jaenisch T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002320
   Lambrechts L, 2012, J VIROL, V86, P1853, DOI 10.1128/JVI.06458-11
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Magalhaes T, 2018, VIRUS RES, V254, P1, DOI 10.1016/j.virusres.2017.07.011
   Ministerio da Saude Brasil, 2017, MON CAS DENG FEBR CH, V52
   Ministerio da Saude Brasil, 2015, PROT VIG RESP PEL VI
   Ministerio da Saude Brasil, 2015, MON CAS DENG FEBR CH, V48
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Organizaco Pan-Americana da Saude, 2016, B SEM
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Pessoa R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003201
   Rances E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002548
   Renault P, 2007, AM J TROP MED HYG, V77, P727
   Ruckert C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15412
   van Meer MPA, 2017, J CLIN VIROL, V92, P25, DOI 10.1016/j.jcv.2017.05.001
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Warrilow D, 2002, J MED VIROL, V66, P524, DOI 10.1002/jmv.2176
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zeller H, 2016, J INFECT DIS, V214, pS436, DOI 10.1093/infdis/jiw391
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
NR 42
TC 22
Z9 22
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2017
VL 11
IS 11
AR e0006055
DI 10.1371/journal.pntd.0006055
PG 25
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA VI3XC
UT WOS:000480724600001
PM 29108009
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Castanha, PMS
   Montarroyos, UR
   Silveira, SMM
   Albuquerque, GDM
   Mello, MJG
   Lopes, KGS
   Cordeiro, MT
   Marques, ETA
   Martelli, CMT
   Braga, C
AF Castanha, P. M. S.
   Montarroyos, U. R.
   Silveira, S. M. M.
   Albuquerque, G. D. M.
   Mello, M. J. G.
   Lopes, K. G. S.
   Cordeiro, M. T.
   Marques, E. T. A., Jr.
   Martelli, C. M. T.
   Braga, C.
TI Incidence and risk factors for Dengue virus (DENV) infection in the
   first 2 years of life in a Brazilian prospective birth cohort
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Children; cohort; dengue virus; incidence
ID HEMORRHAGIC-FEVER; ANTIBODIES; CHILDREN; TRANSMISSION; NORTHEAST;
   RESPONSES; SEVERITY; KINETICS; INFANTS
AB This study assessed the incidence and risk factors for dengue virus (DENV) infection among children in a prospective birth cohort conducted in the city of Recife, a hyperendemic dengue area in Northeast Brazil. Healthy pregnant women (n = 415) residing in Recife who agreed to have their children followed were enrolled. Children were followed during their first 24 months of age (May/2011-June/2014), before the 2015 Zika virus outbreak. DENV infection was detected by reverse-transcriptase polymerase chain reaction and/or serology (anti-DENV IgM/IgG). The incidence rates per 1000 person-years (py) and its association with risk factors by age bands (0-12, > 12-30 months) were estimated through Poisson regression models. Forty-nine dengue infections were detected; none progressed to severe forms. The incidence rates were 107.6/1000py (95% CI 76.8-150.6) and 93.3/1000py (95% CI 56.1-154.4) in the first and second years of age, respectively. Male children (risk ratios (RR) = 2.33; 95% CI 1.09-4.98) and those born to DENV-naive mothers (RR = 2.42; 95% CI 1.01-5.80) were at greater risk of infection in the first year of age. In the second year, children born to Caucasian/Asian descent skin colour mothers had a threefold higher risk of infection (RR = 3.34; 95% CI: 1.08-10.33). These data show the high exposure of children to DENV infection in our setting and highlight the role of biological factors in this population's susceptibility to infection.
C1 [Castanha, P. M. S.; Albuquerque, G. D. M.; Lopes, K. G. S.; Cordeiro, M. T.; Marques, E. T. A., Jr.; Martelli, C. M. T.; Braga, C.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Av Prof Moraes Rego S-N,Campus UFPE, Recife, PE, Brazil.
   [Castanha, P. M. S.; Montarroyos, U. R.] Univ Pernambuco, Fac Med Sci, Biol Sci Inst, Recife, PE, Brazil.
   [Silveira, S. M. M.; Mello, M. J. G.; Braga, C.] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [Marques, E. T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Marques, E. T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
RP Castanha, PMS (corresponding author), Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Av Prof Moraes Rego S-N,Campus UFPE, Recife, PE, Brazil.
EM castanha.priscila@gmail.com
RI Montarroyos, Ulisses/AAJ-7527-2020; Marques, Ernesto T. A/L-4967-2013;
   Braga, Maria Cynthia/A-8204-2013; amsalu, ribka/G-8780-2019; Da Silva
   Castanha, Priscila Mayrelle/G-1785-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Braga, Maria
   Cynthia/0000-0002-7862-6455; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688
FU National Council for Scientific and Technological Development of the
   Brazilian government [482915/2010-2 MCT/CNPq-14/2010]; Strategic Program
   to Support Health Research/PAPES VI [407697/2012-8]
FX We thank the mothers and their infants, for participating in the study;
   and the nurses and clinical staff from IMIP who assisted with the study.
   This work was supported by the National Council for Scientific and
   Technological Development of the Brazilian government (C.B., grant
   482915/2010-2 MCT/CNPq-14/2010); and the Strategic Program to Support
   Health Research/PAPES VI (C.B., grant 407697/2012-8).
CR Anker M, 2011, WEST PAC SURVEILL RE, V2, P17, DOI [10.5365/wpsar.2011.2.1.002, 10.5365/WPSAR.2011.2.1.002]
   Arguello DF, 2015, AM J TROP MED HYG, V92, P486, DOI 10.4269/ajtmh.14-0231
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Braga C, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00095815
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   BRAVO JR, 1987, T ROY SOC TROP MED H, V81, P816, DOI 10.1016/0035-9203(87)90041-1
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Clapham H, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004262
   Clayton D, 1993, STAT MODELS EPIDEMIO, P3421
   Corbett KS, 2015, J INFECT DIS, V211, P590, DOI 10.1093/infdis/jiu481
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Sierra BDL, 2007, ARCH VIROL, V152, P533, DOI 10.1007/s00705-006-0869-x
   Del Principe D, 2013, CURR MOL MED, V13, P499
   Endy TP, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00183
   Endy TP, 2010, CURR TOP MICROBIOL, V338, P1, DOI 10.1007/978-3-642-02215-9_1
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Gordon A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002462
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170
   Jain A, 2010, FEMS IMMUNOL MED MIC, V59, P119, DOI 10.1111/j.1574-695X.2010.00670.x
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Leite RC, 2014, J CLIN VIROL, V60, P16, DOI [10.1016/j.jcv.2014.02.009, 10.1016/J.JCV.2014.02.009]
   Libraty DH, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000171
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Muenchhoff M, 2014, J INFECT DIS, V209, pS120, DOI 10.1093/infdis/jiu232
   Pengsaa K, 2006, J INFECT DIS, V194, P1570, DOI 10.1086/508492
   Raza FA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089868
   Ribeiro CF, 2013, J PEDIATR-US, V163, P1514, DOI 10.1016/j.jpeds.2013.06.040
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Teixeira MG, 2012, TROP MED INT HEALTH, V17, P1391, DOI 10.1111/j.1365-3156.2012.03086.x
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Thai KTD, 2005, TROP MED INT HEALTH, V10, P379, DOI 10.1111/j.1365-3156.2005.01388.x
   Alera MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004337
   Tran NBC, 2009, J INFECT DIS, V200, P1893, DOI 10.1086/648407
   Verhagen LM, 2014, J INFECTION, V69, pS77, DOI 10.1016/j.jinf.2014.07.020
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
NR 38
TC 4
Z9 4
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 2017
VL 145
IS 14
BP 2971
EP 2979
DI 10.1017/S095026881700214X
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA FK0ZG
UT WOS:000413208700011
PM 28918772
OA Bronze
DA 2020-12-16
ER

PT J
AU Bosch, I
   de Puig, H
   Hiley, M
   Carre-Camps, M
   Perdomo-Celis, F
   Narvaez, CF
   Salgado, DM
   Senthoor, D
   O'Grady, M
   Phillips, E
   Durbin, A
   Fandos, D
   Miyazaki, H
   Yen, CW
   Gelvez-Ramirez, M
   Warke, RV
   Ribeiro, LS
   Teixeira, MM
   Almeida, RP
   Munoz-Medina, JE
   Ludert, JE
   Nogueira, ML
   Colombo, TE
   Terzian, ACB
   Bozza, PT
   Calheiros, AS
   Vieira, YR
   Barbosa-Lima, G
   Vizzoni, A
   Cerbino-Neto, J
   Bozza, FA
   Souza, TML
   Trugilho, MRO
   de Filippis, AMB
   de Sequeira, PC
   Marques, ETA
   Magalhaes, T
   Diaz, FJ
   Restrepo, BN
   Marin, K
   Mattar, S
   Olson, D
   Asturias, EJ
   Lucera, M
   Singla, M
   Medigeshi, GR
   de Bosch, N
   Tam, J
   Gomez-Marquez, J
   Clavet, C
   Villar, L
   Hamad-Schifferli, K
   Gehrke, L
AF Bosch, Irene
   de Puig, Helena
   Hiley, Megan
   Carre-Camps, Marc
   Perdomo-Celis, Federico
   Narvaez, Carlos F.
   Salgado, Doris M.
   Senthoor, Dewahar
   O'Grady, Madeline
   Phillips, Elizabeth
   Durbin, Ann
   Fandos, Diana
   Miyazaki, Hikaru
   Yen, Chun-Wan
   Gelvez-Ramirez, Margarita
   Warke, Rajas V.
   Ribeiro, Lucas S.
   Teixeira, Mauro M.
   Almeida, Roque P.
   Munoz-Medina, Jose E.
   Ludert, Juan E.
   Nogueira, Mauricio L.
   Colombo, Tatiana E.
   Terzian, Ana C. B.
   Bozza, Patricia T.
   Calheiros, Andrea S.
   Vieira, Yasmine R.
   Barbosa-Lima, Giselle
   Vizzoni, Alexandre
   Cerbino-Neto, Jose
   Bozza, Fernando A.
   Souza, Thiago M. L.
   Trugilho, Monique R. O.
   de Filippis, Ana M. B.
   de Sequeira, Patricia C.
   Marques, Ernesto T. A.
   Magalhaes, Tereza
   Diaz, Francisco J.
   Restrepo, Berta N.
   Marin, Katerine
   Mattar, Salim
   Olson, Daniel
   Asturias, Edwin J.
   Lucera, Mark
   Singla, Mohit
   Medigeshi, Guruprasad R.
   de Bosch, Norma
   Tam, Justina
   Gomez-Marquez, Jose
   Clavet, Charles
   Villar, Luis
   Hamad-Schifferli, Kimberly
   Gehrke, Lee
TI Rapid antigen tests for dengue virus serotypes and Zika virus in patient
   serum
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID OF-CARE TESTS; NS1 ANTIGEN; DIAGNOSIS; URINE; INFECTIONS; SAMPLES;
   SALIVA; IGM
AB The recent Zika virus (ZIKV) outbreak demonstrates that cost-effective clinical diagnostics are urgently needed to detect and distinguish viral infections to improve patient care. Unlike dengue virus (DENV), ZIKV infections during pregnancy correlate with severe birth defects, including microcephaly and neurological disorders. Because ZIKV and DENV are related flaviviruses, their homologous proteins and nucleic acids can cause cross-reactions and false-positive results in molecular, antigenic, and serologic diagnostics. We report the characterization of monoclonal antibody pairs that have been translated into rapid immunochromatography tests to specifically detect the viral nonstructural 1 (NS1) protein antigen and distinguish the four DENV serotypes (DENV1-4) and ZIKV without cross-reaction. To complement visual test analysis and remove user subjectivity in reading test results, we used image processing and data analysis for data capture and test result quantification. Using a 30-ml serum sample, the sensitivity and specificity values of the DENV1-4 tests and the pan-DENV test, which detects all four dengue serotypes, ranged from 0.76 to 1.00. Sensitivity/specificity for the ZIKV rapid test was 0.81/0.86, respectively, using a 150-mu l serum input. Serum ZIKV NS1 protein concentrations were about 10-fold lower than corresponding DENV NS1 concentrations in infected patients; moreover, ZIKV NS1 protein was not detected in polymerase chain reactionpositive patient urine samples. Our rapid immunochromatography approach and reagents have immediate application in differential clinical diagnosis of acute ZIKV and DENV cases, and the platform can be applied toward developing rapid antigen diagnostics for emerging viruses.
C1 [Bosch, Irene; de Puig, Helena; Hiley, Megan; Carre-Camps, Marc; Senthoor, Dewahar; O'Grady, Madeline; Phillips, Elizabeth; Durbin, Ann; Fandos, Diana; Miyazaki, Hikaru; Yen, Chun-Wan; Tam, Justina; Gomez-Marquez, Jose; Gehrke, Lee] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
   [Bosch, Irene] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   [de Puig, Helena; Hamad-Schifferli, Kimberly] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
   [Carre-Camps, Marc; Fandos, Diana] Univ Ramon Llull, Inst Quim Sarria, Barcelona, Spain.
   [Perdomo-Celis, Federico; Narvaez, Carlos F.; Salgado, Doris M.] Univ Surcolombiana, Fac Salud, Programa Med, Neiva, Colombia.
   [Durbin, Ann] Harvard Med Sch, Div Med Sci, Program Virol, Boston, MA 02115 USA.
   [Gelvez-Ramirez, Margarita; Villar, Luis] Univ Ind Santander, Santander, Colombia.
   [Gelvez-Ramirez, Margarita; Villar, Luis] AEDES Program, Santander, Colombia.
   [Warke, Rajas V.] HiMedia Labs Pvt Ltd, Bombay, Maharashtra, India.
   [Ribeiro, Lucas S.; Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Immunopharmacol Grp, Ave Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
   [Almeida, Roque P.] Univ Fed Sergipe, Hosp Univ, Empresa Brasileira Serv Hosp EBSERH, Dept Med Interna & Patol, Aracaju, Brazil.
   [Munoz-Medina, Jose E.] Inst Mexicano Seguro Social, Lab Cent Epidemiol, Ave Jacarandas S-N, Mexico City 02990, DF, Mexico.
   [Ludert, Juan E.] Inst Politecn Nacl CINVESTAV IPN, Ctr Invest & Estudios Avanzados, Dept Infect & Patogenesis Mol, Mexico City, DF, Mexico.
   [Nogueira, Mauricio L.; Colombo, Tatiana E.; Terzian, Ana C. B.] Fac Med Sao Jose Rio Preto FAMERP, Sao Jose Do Rio Preto, Brazil.
   [Bozza, Patricia T.; Calheiros, Andrea S.; Souza, Thiago M. L.] Fiocruz MS, Oswaldo Cruz Fdn, Immunopharmacol Lab, Rio De Janeiro, Brazil.
   [Vieira, Yasmine R.; Barbosa-Lima, Giselle; Vizzoni, Alexandre; Cerbino-Neto, Jose; Bozza, Fernando A.] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Souza, Thiago M. L.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Rio De Janeiro, Brazil.
   [Trugilho, Monique R. O.] Fiocruz MS, Toxinol Lab, Rio De Janeiro, Brazil.
   [Trugilho, Monique R. O.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, Brazil.
   [de Filippis, Ana M. B.; de Sequeira, Patricia C.] Fiocruz MS, Flavivirus Lab, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A.; Magalhaes, Tereza] Fiocruz MS, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA.
   [Magalhaes, Tereza] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Diaz, Francisco J.] Univ Antioquia, Sch Med, Immunovirol Grp, Medellin, Colombia.
   [Restrepo, Berta N.; Marin, Katerine] Univ CES, ICMT, Sabaneta, Antioquia, Colombia.
   [Mattar, Salim] Univ Cordoba, Monteria, Cordoba, Colombia.
   [Olson, Daniel; Asturias, Edwin J.] Univ Colorado, Sch Med, Dept Pediat, Div Infect Dis, Aurora, CO 80045 USA.
   [Lucera, Mark] Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO 80045 USA.
   [Singla, Mohit] All India Inst Med Sci, Dept Paediat, New Delhi, India.
   [Medigeshi, Guruprasad R.] Translat Hlth Sci & Technol Inst, Faridabad, India.
   [de Bosch, Norma] Univ Cent Venezuela, Caracas, Venezuela.
   [Tam, Justina; Clavet, Charles] WEAC, Winchester, MA 01890 USA.
   [Hamad-Schifferli, Kimberly] Univ Massachusetts, Dept Engn, Boston, MA 02125 USA.
   [Gehrke, Lee] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
RP Gehrke, L (corresponding author), MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.; Hamad-Schifferli, K (corresponding author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.; Hamad-Schifferli, K (corresponding author), Univ Massachusetts, Dept Engn, Boston, MA 02125 USA.; Gehrke, L (corresponding author), Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
EM kim.hamad@umb.edu; lgehrke@mit.edu
RI Neto, Jose Cerbino/P-3713-2018; Esteban, Munoz Medina Jose/B-6186-2015;
   Teixeira, Mauro M/A-4587-2008; Ludert, Juan E./H-5658-2019; Vizzoni,
   Alexandre/W-8718-2019; Marques, Ernesto T. A/L-4967-2013; Magalhaes,
   Tereza/V-6632-2019; Nogueira, Mauricio L/B-7599-2012; Medigeshi,
   Guruprasad/V-1566-2019; Bozza, Fernando A/A-2618-2013; Asturias,
   Edwin/D-9842-2016
OI Neto, Jose Cerbino/0000-0001-9254-917X; Esteban, Munoz Medina
   Jose/0000-0002-1289-4457; Teixeira, Mauro M/0000-0002-6944-3008;
   Vizzoni, Alexandre/0000-0003-0004-5084; Marques, Ernesto T.
   A/0000-0003-3826-9358; Nogueira, Mauricio L/0000-0003-1102-2419; Bozza,
   Fernando A/0000-0003-4878-0256; Souza, Thiago/0000-0003-2212-3899;
   /0000-0002-5368-6996; MARIN VELASQUEZ, KATERINE/0000-0003-0028-0500;
   Asturias, Edwin/0000-0002-1275-0787; Narvaez,
   Carlos/0000-0003-0129-5210; Perdomo Celis, Federico/0000-0003-0119-8306;
   Secchim Ribeiro, Lucas/0000-0001-8876-3827; Medigeshi,
   Guruprasad/0000-0001-5333-9743; Bozza, Patricia/0000-0001-8349-9529
FU National Council for Scientific and Technological Development of
   BrazilNational Council for Scientific and Technological Development
   (CNPq); Foundation for Research Support of the State of Rio de Janeiro,
   Brazil (FAPERJ); European Union's Horizon program [734857, 734584];
   Programa Pesquisa para o SUS-Fundacao de Amparo a Ciencia e Tecnologia
   (PPSUS-FACEPE) project of the Cura Zika Alliance, University of
   Pittsburgh [APQ-0302-4.01/13]; Department of Biotechnology, Government
   of IndiaDepartment of Biotechnology (DBT) India
   [BT/PR5132/MED/15/84/2012]; Wellcome Trust/DBT India AllianceWellcome
   Trust [IA/S/14/1/501291]; U.S. Public Health ServiceUnited States Public
   Health Service [AI100190]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [13/21719-3, 16/15021-1]; Science, Technology and Innovation
   Fund; Colombia-Fondo de Ciencia, Tecnologia e Innovacion of Sistema
   General de Regalias [BPIN 2013000100011]; AEDES Network; La Caixa
   FellowshipLa Caixa Foundation; Rafael del Pino Foundation; Broshy
   Fellowship; MIT-Tata Center for Technology and Design fellowship;
   MIT-Singapore University of Technology and Design International Design
   Center grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21AI100190, R33AI100190, R33AI100190,
   R21AI100190, R33AI100190, R33AI100190] Funding Source: NIH RePORTER
FX F.A.B., M.M.T., A.C.B.T., and P.C.d.-S. received funding from the
   National Council for Scientific and Technological Development of Brazil
   and from the Foundation for Research Support of the State of Rio de
   Janeiro, Brazil (FAPERJ). A.M.B.d.F. was supported by the European
   Union's Horizon 2020 program under grant agreement numbers 734857 and
   734584. E.T.A.M. was supported by Programa Pesquisa para o SUS-Fundacao
   de Amparo a Ciencia e Tecnologia (PPSUS-FACEPE) project APQ-0302-4.01/13
   of the Cura Zika Alliance, University of Pittsburgh. G.R.M. received
   research support from the Department of Biotechnology, Government of
   India (sanction no. BT/PR5132/MED/15/84/2012) and Wellcome Trust/DBT
   India Alliance (IA/S/14/1/501291). L.G. received support from the U.S.
   Public Health Service (grant AI100190). M.L.N. received support from
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (grants
   13/21719-3 and 16/15021-1). L.V. received support from the Science,
   Technology and Innovation Fund, Colombia-Fondo de Ciencia, Tecnologia e
   Innovacion of Sistema General de Regalias (BPIN 2013000100011) and the
   AEDES Network. H.d.P. received support from a La Caixa Fellowship, a
   Rafael del Pino Foundation, a Broshy Fellowship, an MIT-Tata Center for
   Technology and Design fellowship, and an MIT-Singapore University of
   Technology and Design International Design Center grant. M. Benioff and
   L. Benioffprovided support toward obtaining commercially available Zika
   samples.
CR Abramoff, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andries AC, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1551-x
   Andries AC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004100
   Andries AC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001993
   Becerra A, 2009, J MED VIROL, V81, P1403, DOI 10.1002/jmv.21538
   Becerra A, 2009, J GEN VIROL, V90, P810, DOI 10.1099/vir.0.004416-0
   Bhamla MS, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-016-0009
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bingham AM, 2016, MMWR MORB MORTAL WKL, V65
   Blacksell SD, 2011, CLIN VACCINE IMMUNOL, V18, P2095, DOI 10.1128/CVI.05285-11
   Brown WC, 2016, NAT STRUCT MOL BIOL, V23, P865, DOI 10.1038/nsmb.3268
   Chuansumrit A, 2011, DIAGN MICR INFEC DIS, V71, P467, DOI 10.1016/j.diagmicrobio.2011.08.020
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Estofolete CF, 2016, J CLIN VIROL, V81, P25, DOI 10.1016/j.jcv.2016.05.012
   FALCONAR AKI, 1991, J GEN VIROL, V72, P961, DOI 10.1099/0022-1317-72-4-961
   Forshey BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004398
   Fry SR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001199
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Kao Chuan-Liang, 2005, Journal of Microbiology Immunology and Infection, V38, P5
   Korhonen EM, 2014, J CLIN VIROL, V61, P353, DOI 10.1016/j.jcv.2014.08.021
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lee J, 2015, DIAGN MICR INFEC DIS, V82, P128, DOI 10.1016/j.diagmicrobio.2015.03.009
   Lukman N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5253842
   Miller R. K., 1989, MACHINE VISION
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191
   O'Farrell B., 2013, IMMUNOASSAY HDB, P89
   Ong A, 2007, INT J INFECT DIS, V11, P263, DOI 10.1016/j.ijid.2006.02.012
   Osorio L, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-361
   Pardee K, 2016, CELL, V165, P1255, DOI 10.1016/j.cell.2016.04.059
   Peeling RW, 2010, CLIN MICROBIOL INFEC, V16, P1062, DOI 10.1111/j.1469-0691.2010.03279.x
   Peeling RW, 2010, NAT REV MICROBIOL, pS30, DOI 10.1038/nrmicro2459
   Saito Y, 2015, JPN J INFECT DIS, V68, P455, DOI 10.7883/yoken.JJID.2014.441
   Tricou V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001309
   Tricou V, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-142
   Tyrrell C. H., 2013, LATERAL FLOW SMART P
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Vivek R, 2017, DIAGN MICR INFEC DIS, V87, P229, DOI 10.1016/j.diagmicrobio.2016.09.020
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Wang SM, 2010, AM J TROP MED HYG, V83, P690, DOI 10.4269/ajtmh.2010.10-0117
   Zhang B, 2017, NAT MED, V23, P548, DOI 10.1038/nm.4302
   ZIKV Detect IgM Capture ELISA by InBios International Inc, 2016, MEDWATCH FDA SAF INF
NR 47
TC 66
Z9 68
U1 3
U2 32
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 27
PY 2017
VL 9
IS 409
AR eaan1589
DI 10.1126/scitranslmed.aan1589
PG 13
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA FI3PX
UT WOS:000411879400005
PM 28954927
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Castanha, PMS
   Nascimento, EJM
   Braga, C
   Cordeiro, MT
   de Carvalho, OV
   de Mendonca, LR
   Azevedo, EAN
   Franca, RFO
   Dhalia, R
   Marques, ETA
AF Castanha, Priscila M. S.
   Nascimento, Eduardo J. M.
   Braga, Cynthia
   Cordeiro, Marli T.
   de Carvalho, Otavio V.
   de Mendonca, Leila R.
   Azevedo, Elisa A. N.
   Franca, Rafael F. O.
   Dhalia, Rafael
   Marques, Ernesto T. A.
TI Enhancement of Zika Infection by Dengue-Specific Antibodies Does Not
   Alter the Production of Interleukin 6 in Fc gamma RII-Expressing K562
   Cells
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID DEPENDENT ENHANCEMENT; VIRUS
C1 [Castanha, Priscila M. S.; Braga, Cynthia; Cordeiro, Marli T.; de Carvalho, Otavio V.; de Mendonca, Leila R.; Azevedo, Elisa A. N.; Franca, Rafael F. O.; Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Inst Biol Sci, Fac Med Sci, Recife, PE, Brazil.
   [Braga, Cynthia] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Marques, ETA (corresponding author), Ctr Vaccine Res, 3501 Fifth Ave,9052 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA.
EM marques@pitt.edu
RI Braga, Maria Cynthia/A-8204-2013; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Marques, Ernesto T. A/L-4967-2013; Dhalia,
   Rafael/AAD-5432-2020
OI Braga, Maria Cynthia/0000-0002-7862-6455; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Marques, Ernesto T. A/0000-0003-3826-9358;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
FU Brazilian Federal Agency for Support and Evaluation of Graduate
   Education; Center for Vaccine Research, University of Pittsburgh;
   Fogarty Training Program [D43TW006592 Pitt GIDRTP/323 NIH]; National
   Council for Scientific and Technological DevelopmentNational Council for
   Scientific and Technological Development (CNPq) [482915/2010-2
   MCT/CNPq-321 14/2010]; Strategic Program to Support Health
   Research/PAPES VI [322 407697/2012-8]; National Institute of Allergy and
   Infectious Diseases, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19 AI56541]
FX This work was supported by the Brazilian Federal Agency for Support and
   Evaluation of Graduate Education; Center for Vaccine Research,
   University of Pittsburgh; Fogarty Training Program (grant number
   D43TW006592 Pitt GIDRTP/323 NIH to P. M. S. C.); National Council for
   Scientific and Technological Development (grant number 482915/2010-2
   MCT/CNPq-321 14/2010); Strategic Program to Support Health
   Research/PAPES VI (grant number 322 407697/2012-8); and National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health (grant number U19 AI56541).
CR Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Halstead SB, 2017, EMERG INFECT DIS, V23, P569, DOI 10.3201/eid2304.161879
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Hueston L, 2017, J INFECT DIS, V216, P612, DOI 10.1093/infdis/jix344
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Mahalingam S, 2017, LANCET INFECT DIS, V17, P686, DOI 10.1016/S1473-3099(17)30340-7
   Ng JKW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004031
NR 10
TC 4
Z9 4
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2017
VL 216
IS 5
BP 614
EP 615
DI 10.1093/infdis/jix346
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FG6UY
UT WOS:000410532400015
PM 28931227
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Freire, MCLC
   Pol-Fachin, L
   Coelho, DF
   Viana, IFT
   Magalhaes, T
   Cordeiro, MT
   Fischer, N
   Loeffler, FF
   Jaenisch, T
   Franca, RF
   Marques, ETA
   Lins, RD
AF Freire, Marjorie C. L. C.
   Pol-Fachin, Laercio
   Coelho, Danilo F.
   Viana, Isabelle F. T.
   Magalhaes, Tereza
   Cordeiro, Marli T.
   Fischer, Nico
   Loeffler, Felix F.
   Jaenisch, Thomas
   Franca, Rafael F.
   Marques, Ernesto T. A.
   Lins, Roberto D.
TI Mapping Putative B-Cell Zika Virus NS1 Epitopes Provides Molecular Basis
   for Anti-NS1 Antibody Discrimination between Zika and Dengue Viruses
SO ACS OMEGA
LA English
DT Article
ID GROMOS FORCE-FIELD; PRINTED ELECTRODE; PROTEIN NS1; DYNAMICS;
   ASSOCIATION; LOOPS; ASSAY
AB B-cell epitope sequences from Zika virus (ZIKV) NS1 protein have been identified using epitope prediction tools. Mapping these sequences onto the NS1 surface reveals two major conformational epitopes and a single linear one. Despite an overall average sequence identity of ca. 55% between the NS1 from ZIKV and the four dengue virus (DENV) serotypes, epitope sequences were found to be highly conserved. Nevertheless, nonconserved epitope-flanking residues are responsible for a dramatically divergent electrostatic surface potential on the epitope regions of ZIKV and DENV2 serotypes. These findings suggest that strategies for differential diagnostics on the basis of short linear NS1 sequences are likely to fail due to immunological cross-reactions. Overall, results provide the molecular basis of differential discrimination between Zika and DENVs by NS1 monoclonal antibodies.
C1 [Freire, Marjorie C. L. C.; Pol-Fachin, Laercio; Coelho, Danilo F.; Viana, Isabelle F. T.; Magalhaes, Tereza; Cordeiro, Marli T.; Franca, Rafael F.; Marques, Ernesto T. A.; Lins, Roberto D.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, BR-50740465 Recife, PE, Brazil.
   [Pol-Fachin, Laercio; Coelho, Danilo F.; Lins, Roberto D.] Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740670 Recife, PE, Brazil.
   [Fischer, Nico; Jaenisch, Thomas] Heidelberg Univ Hosp, Dept Infect Dis, Sect Clin Trop Med, INF 324, D-69120 Heidelberg, Germany.
   [Loeffler, Felix F.] Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, Muhlenberg 1, D-14476 Potsdam, Germany.
   [Fischer, Nico; Loeffler, Felix F.; Jaenisch, Thomas] Heidelberg Univ, Karlsruhe Inst Technol KIT, HEiKA Heidelberg Karlsruhe Res Partnership, D-76131 Karlsruhe, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Marques, ETA; Lins, RD (corresponding author), Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, BR-50740465 Recife, PE, Brazil.; Lins, RD (corresponding author), Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740670 Recife, PE, Brazil.; Marques, ETA (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
EM marques@pitt.edu; roberto.lins@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Magalhaes, Tereza/V-6632-2019;
   Loeffler, Felix F/K-6192-2016; Loeffler, Felix F/C-7920-2017; Lins,
   Roberto D/J-7511-2012; Coelho, Danilo Fernandes/AAC-9206-2020; Viana,
   Isabelle/M-4435-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Loeffler, Felix
   F/0000-0002-8227-2522; Loeffler, Felix F/0000-0002-8227-2522; Lins,
   Roberto D/0000-0002-3983-8025; Coelho, Danilo
   Fernandes/0000-0002-1111-0825; Viana, Isabelle/0000-0003-4648-6635;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
FU FACEPE; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq); CuraZika Foundation
FX This work was supported by grants from FACEPE, CAPES, CNPq and CuraZika
   Foundation. Computational resources were provided by the Brazilian
   National Supercomputing Center (LNCC).
CR Abraham M. J., 2015, SOFTWAREX, V1-2, P19
   Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Borley DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061122
   Brown WC, 2016, NAT STRUCT MOL BIOL, V23, P865, DOI 10.1038/nsmb.3268
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cavalcanti IT, 2012, BIOCHEM ENG J, V67, P225, DOI 10.1016/j.bej.2012.06.016
   Cecchetto J, 2017, BIOSENS BIOELECTRON, V87, P949, DOI 10.1016/j.bios.2016.08.097
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Dawes BE, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.7
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dias ACMS, 2013, BIOSENS BIOELECTRON, V44, P216, DOI 10.1016/j.bios.2012.12.033
   Edeling MA, 2014, P NATL ACAD SCI USA, V111, P4285, DOI 10.1073/pnas.1322036111
   Figueiredo A, 2015, SCI REP-UK, V5, DOI 10.1038/srep07865
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362
   Flower DR, 2013, NAT CHEM BIOL, V9, P748, DOI 10.1038/nchembio.1383
   Gutsche I, 2011, P NATL ACAD SCI USA, V108, P8003, DOI 10.1073/pnas.1017338108
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827, DOI 10.1128/JCM.38.5.1827-1831.2000
   Johnson BW, 2009, CLIN VACCINE IMMUNOL, V16, P1052, DOI 10.1128/CVI.00095-09
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Kuno Goro, 2003, Adv Virus Res, V61, P3, DOI 10.1016/S0065-3527(03)61001-8
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lover AA, 2016, LANCET INFECT DIS, V16, P1331, DOI 10.1016/S1473-3099(16)30462-5
   Lutteke T, 2006, GLYCOBIOLOGY, V16, p71R, DOI 10.1093/glycob/cwj049
   Maeda A, 2013, VET J, V195, P33, DOI 10.1016/j.tvjl.2012.08.019
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pol-Fachin L, 2012, J CHEM THEORY COMPUT, V8, P4681, DOI 10.1021/ct300479h
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183
   Rubinstein ND, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-287
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Silva MMS, 2014, TALANTA, V128, P505, DOI 10.1016/j.talanta.2014.06.009
   Song H, 2016, NAT STRUCT MOL BIOL, V23, P456, DOI 10.1038/nsmb.3213
   Stadler V, 2008, ANGEW CHEM INT EDIT, V47, P7132, DOI 10.1002/anie.200801616
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sumita LM, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658089, 10.1590/s1678-9946201658089]
   TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273
   Viana IFT, 2013, RSC ADV, V3, P11790, DOI 10.1039/c3ra41562g
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   Wong SJ, 2017, EBIOMEDICINE, V16, P136, DOI 10.1016/j.ebiom.2017.01.008
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
NR 55
TC 15
Z9 15
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD JUL
PY 2017
VL 2
IS 7
BP 3913
EP 3920
DI 10.1021/acsomega.7b00608
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA FG2GV
UT WOS:000409909900090
PM 30023708
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Brito, CAA
   Azevedo, F
   Cordeiro, MT
   Marques, ETA
   Franca, RFO
AF Brito, Carlos A. A.
   Azevedo, Fernanda
   Cordeiro, Marli T.
   Marques, Ernesto T. A., Jr.
   Franca, Rafael F. O.
TI Central and peripheral nervous system involvement caused by Zika and
   chikungunya coinfection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID VIRUS; INFECTION; HISTORY
C1 [Brito, Carlos A. A.] Fed Univ Pernambuco UFPE, Dept Clin Med, Recife, PE, Brazil.
   [Azevedo, Fernanda] Santa Joana Hosp, Dept Neurol, Recife, PE, Brazil.
   [Cordeiro, Marli T.; Marques, Ernesto T. A., Jr.; Franca, Rafael F. O.] Fiocruz MS, Aggeu Magalhaes Inst, Oswaldo Cruz Fdn, Dept Virol & Expt Therapy, Recife, PE, Brazil.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res Pittsburgh, Pittsburgh, PA USA.
RP Franca, RFO (corresponding author), Fiocruz MS, Aggeu Magalhaes Inst, Oswaldo Cruz Fdn, Dept Virol & Expt Therapy, Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU FACEPE - Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco under
   RFOF [APQ-0055.2.11/16, APQ-0044.2.11/16]
FX The research leading to these results received funding from the FACEPE -
   Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco, grant agreement
   nos. APQ-0055.2.11/16 and APQ-0044.2.11/16 under RFOF coordination and
   responsibility. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   Brito C, 2015, ACTA MEDICA PORT, V28, P679
   Brooks JB, 2016, J INFECT PUBLIC HLTH
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Chandak NH, 2009, NEUROL INDIA, V57, P177, DOI 10.4103/0028-3886.51289
   Chusri S, 2011, AM J TROP MED HYG, V85, P386, DOI 10.4269/ajtmh.2011.10-0725
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Franca RFO, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004760
   MATHIAS CJ, 1989, J NEUROL SCI, V94, P255, DOI 10.1016/0022-510X(89)90235-9
   Mercado M, 2016, EURO SURVEILL, P21
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Omarjee R., 2014, EURO SURVEILL, V19
   Pessoa R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003201
   Roth A, 2014, EURO SURVEILL, V19
   Solet J. L., 2007, PLOS BIOL, V77, P727
   Tandale BV, 2009, J CLIN VIROL, V46, P145, DOI 10.1016/j.jcv.2009.06.027
   Taraphdar D, 2012, AM J TROP MED HYG, V86, P720, DOI 10.4269/ajtmh.2012.11-0704
   Villamil-Gomez WE, 2016, INT J INFECT DIS
   Waggoner JJ, 2016, CLIN INFECT DIS
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zambrano H, 2016, AM J TROP MED HYG
   Zinszer K, 2017, EMERG INFECT DIS, V23, P92, DOI 10.3201/eid2301.161274
NR 24
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2017
VL 11
IS 7
AR e0005583
DI 10.1371/journal.pntd.0005583
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FE2PD
UT WOS:000408057300004
PM 28704365
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Faria, NR
   Quick, J
   Claro, IM
   Theze, J
   de Jesus, JG
   Giovanetti, M
   Kraemer, MUG
   Hill, SC
   Black, A
   da Costa, AC
   Franco, LC
   Silva, SP
   Wu, CH
   Raghwani, J
   Cauchemez, S
   du Plessis, L
   Verotti, MP
   de Oliveira, WK
   Carmo, EH
   Coelho, GE
   Santelli, ACFS
   Vinhal, LC
   Henriques, CM
   Simpson, JT
   Loose, M
   Andersen, KG
   Grubaugh, ND
   Somasekar, S
   Chiu, CY
   Munoz-Medina, JE
   Gonzalez-Bonilla, CR
   Arias, CF
   Lewis-Ximenez, LL
   Baylis, SA
   Chieppe, AO
   Aguiar, SF
   Fernandes, CA
   Lemos, PS
   Nascimento, BLS
   Monteiro, HAO
   Siqueira, IC
   de Queiroz, MG
   de Souza, TR
   Bezerra, JF
   Lemos, MR
   Pereira, GF
   Loudal, D
   Moura, LC
   Dhalia, R
   Franca, RF
   Magalhaes, T
   Marques, ET
   Jaenisch, T
   Wallau, GL
   de Lima, MC
   Nascimento, V
   de Cerqueira, EM
   de Lima, MM
   Mascarenhas, DL
   Neto, JPM
   Levin, AS
   Tozetto-Mendoza, TR
   Fonseca, SN
   Mendes-Correa, MC
   Milagres, FP
   Segurado, A
   Holmes, EC
   Rambaut, A
   Bedford, T
   Nunes, MRT
   Sabino, EC
   Alcantara, LCJ
   Loman, NJ
   Pybus, OG
AF Faria, N. R.
   Quick, J.
   Claro, I. M.
   Theze, J.
   de Jesus, J. G.
   Giovanetti, M.
   Kraemer, M. U. G.
   Hill, S. C.
   Black, A.
   da Costa, A. C.
   Franco, L. C.
   Silva, S. P.
   Wu, C. -H.
   Raghwani, J.
   Cauchemez, S.
   du Plessis, L.
   Verotti, M. P.
   de Oliveira, W. K.
   Carmo, E. H.
   Coelho, G. E.
   Santelli, A. C. F. S.
   Vinhal, L. C.
   Henriques, C. M.
   Simpson, J. T.
   Loose, M.
   Andersen, K. G.
   Grubaugh, N. D.
   Somasekar, S.
   Chiu, C. Y.
   Munoz-Medina, J. E.
   Gonzalez-Bonilla, C. R.
   Arias, C. F.
   Lewis-Ximenez, L. L.
   Baylis, S. A.
   Chieppe, A. O.
   Aguiar, S. F.
   Fernandes, C. A.
   Lemos, P. S.
   Nascimento, B. L. S.
   Monteiro, H. A. O.
   Siqueira, I. C.
   de Queiroz, M. G.
   de Souza, T. R.
   Bezerra, J. F.
   Lemos, M. R.
   Pereira, G. F.
   Loudal, D.
   Moura, L. C.
   Dhalia, R.
   Franca, R. F.
   Magalhaes, T.
   Marques, E. T., Jr.
   Jaenisch, T.
   Wallau, G. L.
   de Lima, M. C.
   Nascimento, V.
   de Cerqueira, E. M.
   de Lima, M. M.
   Mascarenhas, D. L.
   Moura Neto, J. P.
   Levin, A. S.
   Tozetto-Mendoza, T. R.
   Fonseca, S. N.
   Mendes-Correa, M. C.
   Milagres, F. P.
   Segurado, A.
   Holmes, E. C.
   Rambaut, A.
   Bedford, T.
   Nunes, M. R. T.
   Sabino, E. C.
   Alcantara, L. C. J.
   Loman, N. J.
   Pybus, O. G.
TI Establishment and cryptic transmission of Zika virus in Brazil and the
   Americas
SO NATURE
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; EVOLUTION; TIME; EMERGENCE; MODELS; DENGUE;
   BAHIA; RECOMBINATION; SEQUENCES; SELECTION
AB Transmission of Zika virus (ZIKV) in the Americas was first confirmed in May 2015 in northeast Brazil(1). Brazil has had the highest number of reported ZIKV cases worldwide (more than 200,000 by 24 December 20162) and the most cases associated with microcephaly and other birth defects (2,366 confirmed by 31 December 20162). Since the initial detection of ZIKV in Brazil, more than 45 countries in the Americas have reported local ZIKV transmission, with 24 of these reporting severe ZIKV-associated disease(3). However, the origin and epidemic history of ZIKV in Brazil and the Americas remain poorly understood, despite the value of this information for interpreting observed trends in reported microcephaly. Here we address this issue by generating 54 complete or partial ZIKV genomes, mostly from Brazil, and reporting data generated by a mobile genomics laboratory that travelled across northeast Brazil in 2016. One sequence represents the earliest confirmed ZIKV infection in Brazil. Analyses of viral genomes with ecological and epidemiological data yield an estimate that ZIKV was present in northeast Brazil by February 2014 and is likely to have disseminated from there, nationally and internationally, before the first detection of ZIKV in the Americas. Estimated dates for the international spread of ZIKV from Brazil indicate the duration of pre-detection cryptic transmission in recipient regions. The role of northeast Brazil in the establishment of ZIKV in the Americas is further supported by geographic analysis of ZIKV transmission potential and by estimates of the basic reproduction number of the virus.
C1 [Faria, N. R.; Theze, J.; Kraemer, M. U. G.; Hill, S. C.; Raghwani, J.; du Plessis, L.; Pybus, O. G.] Univ Oxford, Dept Zool, Oxford OX1 3SY, England.
   [Faria, N. R.; Franco, L. C.; Silva, S. P.; Lemos, P. S.; Nascimento, B. L. S.; Monteiro, H. A. O.; Nunes, M. R. T.] Minist Hlth, Evandro Chagas Inst, Ananindeua, Brazil.
   [Quick, J.; Loman, N. J.] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.
   [Claro, I. M.; da Costa, A. C.; Levin, A. S.; Tozetto-Mendoza, T. R.; Mendes-Correa, M. C.; Segurado, A.; Sabino, E. C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Claro, I. M.; da Costa, A. C.; Levin, A. S.; Tozetto-Mendoza, T. R.; Mendes-Correa, M. C.; Segurado, A.; Sabino, E. C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [de Jesus, J. G.; Giovanetti, M.; Siqueira, I. C.; Alcantara, L. C. J.] Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Giovanetti, M.] Univ Roma Tor Vergata, Rome, Italy.
   [Kraemer, M. U. G.] Harvard Med Sch, Boston, MA USA.
   [Kraemer, M. U. G.] Boston Childrens Hosp, Boston, MA USA.
   [Black, A.; Bedford, T.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Black, A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Wu, C. -H.] Univ Oxford, Dept Stat, Oxford OX1 3LB, England.
   [Cauchemez, S.] Inst Pasteur, Math Modelling Infect Dis, Paris, France.
   [Cauchemez, S.] Inst Pasteur, Ctr Bioinformat Biostat & Integrat Biol, Paris, France.
   [Cauchemez, S.] Ctr Natl Rech Sci, URA3012, Paris, France.
   [Verotti, M. P.] Minist Hlth, Coordena Lab Saude CGLAB DEVIT SVS, Brasilia, DF, Brazil.
   [de Oliveira, W. K.] Minist Hlth, Coordena Geral Vigilincia & Resposta Emergencias, Brasilia, DF, Brazil.
   [de Oliveira, W. K.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Data & Knowledge Integrat Hlth CIDACS, Salvador, BA, Brazil.
   [Carmo, E. H.; Henriques, C. M.] Minist Hlth, Dept Vigilincia Doencas Transmissiveis, Brasilia, DF, Brazil.
   [Coelho, G. E.; Santelli, A. C. F. S.; Vinhal, L. C.] Minist Hlth, Coordena Geral Programas Controle & Preven Malari, Brasilia, DF, Brazil.
   [Coelho, G. E.] PAHO, Buenos Aires, DF, Argentina.
   [Santelli, A. C. F. S.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Simpson, J. T.] Ontario Inst Canc Res, Toronto, ON, Canada.
   [Loose, M.] Univ Nottingham, Nottingham, England.
   [Andersen, K. G.; Grubaugh, N. D.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Somasekar, S.; Chiu, C. Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Somasekar, S.; Chiu, C. Y.] Univ Calif San Francisco, Dept Med Infect & Dis, San Francisco, CA 94143 USA.
   [Munoz-Medina, J. E.; Gonzalez-Bonilla, C. R.] Inst Mexicano Seguro Social, Div Labs Vigilancia & Invest Epidemiol, Mexico City, DF, Mexico.
   [Arias, C. F.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca, Morelos, Mexico.
   [Lewis-Ximenez, L. L.] Inst Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Baylis, S. A.] Paul Ehrlich Inst, Langen, Germany.
   [Chieppe, A. O.; Aguiar, S. F.; Fernandes, C. A.] Lab Cent Saude Publ Noel Nutels, Rio De Janeiro, Brazil.
   [de Queiroz, M. G.; de Souza, T. R.; Bezerra, J. F.] Labo Cent Saude Publ Estado Rio Grande Norte, Natal, RN, Brazil.
   [de Souza, T. R.] Univ Potiguar Rio Grande Norte, Natal, RN, Brazil.
   [Bezerra, J. F.] Fundacao Natalense Ensino & Cultura, Natal, RN, Brazil.
   [Lemos, M. R.; Pereira, G. F.; Loudal, D.; Moura, L. C.] Lab Cent Saude Publ Estado Paraiba, Joao Pessoa, Paraiba, Brazil.
   [Dhalia, R.; Franca, R. F.; Magalhaes, T.; Marques, E. T., Jr.; Wallau, G. L.] Fundacao Oswaldo Cruz FIOCRUZ, Recife, PE, Brazil.
   [Magalhaes, T.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Jaenisch, T.] Univ Heidelberg Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [de Lima, M. C.; Nascimento, V.; de Cerqueira, E. M.] Lab Cent Saude Publ Estado Alagoas, Maceio, Brazil.
   [de Lima, M. M.] Univ Estadual Feira de Santana, Feira Santana, Bahia, Argentina.
   [Mascarenhas, D. L.] Secretaria Saude Feira Santana, Feira De Santana, Bahia, Brazil.
   [Moura Neto, J. P.] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Fonseca, S. N.] Hosp Sao Francisco, Ribeirao Preto, Brazil.
   [Milagres, F. P.] Univ Fed Tocantins, Palmas, Brazil.
   [Holmes, E. C.] Univ Sydney, Sydney, NSW, Australia.
   [Rambaut, A.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3FL, Midlothian, Scotland.
   [Rambaut, A.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Nunes, M. R. T.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Pybus, O. G.] Metabiota, San Francisco, CA 94104 USA.
RP Pybus, OG (corresponding author), Univ Oxford, Dept Zool, Oxford OX1 3SY, England.; Loman, NJ (corresponding author), Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.; Sabino, EC (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.; Sabino, EC (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.; Alcantara, LCJ (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.; Pybus, OG (corresponding author), Metabiota, San Francisco, CA 94104 USA.
EM sabinoec@usp.br; lalcan@bahia.fiocruz.br; n.j.loman@bham.ac.uk;
   oliver.pybus@zoo.ox.ac.uk
RI Rambaut, Andrew/B-2481-2009; Loman, Nicholas/Z-1573-2019; Magalhaes,
   Tereza/V-6632-2019; da-Costa, Antonio Charlys/G-1548-2010; Segurado,
   Aluisio C/K-2229-2012; Marques, Ernesto T. A/L-4967-2013; Giovanetti,
   Marta/AAK-7408-2020; Dhalia, Rafael/AAD-5432-2020; de Siqueira, Isadora
   Cristina/R-9953-2016; Esteban, Munoz Medina Jose/B-6186-2015; Arias,
   Carlos/O-4036-2019; Levin, Anna S/C-8831-2012; Pybus, Oliver
   G/B-2640-2012; Bezerra, Joao Felipe/AAE-2500-2020; Wallau, Gabriel
   Luz/B-5911-2008; milagres, flavio/Q-2403-2019; Sabino, Ester
   Cerdeira/F-7750-2010; Faria, Nuno R/I-2975-2012; Oliveira, Claudia
   DL/G-8618-2011; Bezerrra, Joao/C-8867-2017
OI Rambaut, Andrew/0000-0003-4337-3707; da-Costa, Antonio
   Charlys/0000-0001-5516-5177; Segurado, Aluisio C/0000-0002-6311-8036;
   Marques, Ernesto T. A/0000-0003-3826-9358; de Siqueira, Isadora
   Cristina/0000-0002-2520-4099; Esteban, Munoz Medina
   Jose/0000-0002-1289-4457; Arias, Carlos/0000-0003-3130-4501; Levin, Anna
   S/0000-0003-2427-8368; Pybus, Oliver G/0000-0002-8797-2667; Wallau,
   Gabriel Luz/0000-0002-1419-5713; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Faria, Nuno R/0000-0001-8839-2798;
   Bezerrra, Joao/0000-0002-9978-628X; Black, Allison/0000-0002-6618-4127;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Wu,
   Chieh-Hsi/0000-0001-9386-725X; Loman, Nicholas/0000-0002-9843-8988;
   Raghwani, Jayna/0000-0001-8538-4995; Theze, Julien/0000-0001-8188-9494;
   Alcantara, Luiz/0000-0002-6769-9931; Giovanetti,
   Marta/0000-0002-5849-7326; Vinhal Frutuoso, Livia
   Carla/0000-0001-7926-1075; Grubaugh, Nathan/0000-0003-2031-1933; Hill,
   Sarah/0000-0002-2995-2596; Loose, Matthew/0000-0002-5264-0929; Holmes,
   Edward/0000-0001-9596-3552
FU MRC/Wellcome Trust/Newton Fund Zika Rapid Response grant
   [MC_PC_15100/ZK/16-078]; USAID Emerging Pandemic Threats Program-2
   PREDICT-2United States Agency for International Development (USAID)
   [AID-OAA-A-14-00102]; MRC Bioinformatics Fellowship; Sir Henry Dale
   Fellowship [204311/Z/16/Z]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [457480/2014-9, 302584/2015-3,
   439975/2016-6]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2012/03417-7]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R35 GM119774,
   R01 HL105704]; NSFNational Science Foundation (NSF) [DGE-1256082];
   Abbott Laboratories, Inc.Abbott Laboratories; National Health and
   Medical Research CouncilNational Health and Medical Research Council of
   Australia [GNT1037231]; MRCMedical Research Council UK (MRC); CRUKCancer
   Research UK [ANR00310]; Wellcome TrustWellcome Trust; Royal SocietyRoyal
   Society of London [101237/Z/13/Z]; ERCEuropean Research Council (ERC)
   [614725-PATHPHYLODYN, 278433-PREDEMICS]; EUEuropean Union (EU)
   [643476-COMPARE, 734548-ZIKAlliance]; IDAMS; DENFREE; DengueTools;
   PPSUSFACEPE [APQ-0302-4.01/13]; FACEPE [APQ-0044.2.11/16,
   APQ-0055.2.11/16]; German Ministry of Health; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/L015080/1, MR/M501621/1,
   MC_PC_15100] Funding Source: researchfish; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL105704, R01HL105704, R01HL105704,
   R01HL105704, R01HL105704, R01HL105704, R01HL105704, R01HL105704,
   R01HL105704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, R33AI120977,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   R21AI120977, R33AI120977, R21AI120977] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R35GM119774,
   R35GM119774, R35GM119774, R35GM119774, R35GM119774] Funding Source: NIH
   RePORTER
FX We thank Fundacao Oswaldo Cruz in Bahia and Pernambuco states,
   University of Sao Paulo, Instituto Evandro Chagas, and the Brazilian
   Zika virus surveillance network for their essential contributions. We
   thank the following for giving us permission to use their unpublished
   genomes available on GenBank: R. Lanciotti, J. Lednicky, A. Enfissi, F.
   Baldanti, R. Shabman, B. Picket, R. Schinazi, M. Bonaldo, M. Gale, M.
   Capobianchi and C. Concetta, M. Leguia, J. Alberto Diaz, E.
   Sevilla-Reyes, A. Franz, M. GarciaBlanco and M. J. van Hemert. We thank
   P. Fernando da Costa Vasconcelos, S. Guerreiro Rodrigues, J. Cardoso, J.
   Vasconcelos, J. Vianez Jr, J. Gil Melgaco, J. Blumel, M. C. Brito
   Lobato, L. Nunes Fava, C. Ayres, L. Abade and F. Campos. L. C. J. A.
   thanks QIAGEN for reagents and equipment and M. R. T. N. thanks FERPEL
   for consumables. We thank Oxford Nanopore for technical support,
   particularly R. Dokos, Z. McDougall, S. Cowan, G. Sanghera, and O.
   Hartwell. This work was supported by an MRC/Wellcome Trust/Newton Fund
   Zika Rapid Response grant (MC_PC_15100/ZK/16-078) and by the USAID
   Emerging Pandemic Threats Program-2 PREDICT-2 (Cooperative Agreement
   AID-OAA-A-14-00102). N. J. L. is supported by an MRC Bioinformatics
   Fellowship. N. R. F. is funded by a Sir Henry Dale Fellowship (grant
   204311/Z/16/Z). CNPq contributed to trip expenses (grant 457480/2014-9).
   A.C.d.C. was supported by FAPESP # 2012/03417-7 and M. R. T. N. by CNPq
   grant no. 302584/2015-3. A. B. and T. B. were supported by NIH award R35
   GM119774. A. B. is supported by the NSF Graduate Research Fellowship
   Program (grant DGE-1256082). T. B. is a Pew Biomedical Scholar. C.Y.C.
   is partially supported by NIH grant R01 HL105704 and an award from
   Abbott Laboratories, Inc. E. C. H. is supported by a National Health and
   Medical Research Council Australia Fellowship (GNT1037231). C.- H. W. is
   supported by the MRC and CRUK (ANR00310) and by the Wellcome Trust and
   Royal Society (grant 101237/Z/13/Z). S. C. H. is supported by the
   Wellcome Trust. This research received funding from the ERC under grant
   agreements 614725-PATHPHYLODYN and 278433-PREDEMICS, and from EU Horizon
   2020 under agreements 643476-COMPARE and 734548-ZIKAlliance. T. J. and
   E. T. M. acknowledge funding from IDAMS, DENFREE, DengueTools, and
   PPSUSFACEPE (project APQ-0302-4.01/13). R. F. F. received funding from
   FACEPE (APQ-0044.2.11/16 and APQ-0055.2.11/16) and from CNPq
   (439975/2016-6). S. A. B. was supported by the Sicherheit von Blut und
   Geweben hinsichtlich der Abwesenheit von Zikaviren from the German
   Ministry of Health.
CR [Anonymous], 2014, R LANG ENV COMP
   Baele G, 2013, MOL BIOL EVOL, V30, P239, DOI 10.1093/molbev/mss243
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Bouckaert R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003537
   Bruen TC, 2006, GENETICS, V172, P2665, DOI 10.1534/genetics.105.048975
   Caminade C, 2017, P NATL ACAD SCI USA, V114, P119, DOI 10.1073/pnas.1614303114
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cori A, 2013, AM J EPIDEMIOL, V178, P1505, DOI 10.1093/aje/kwt133
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   De Maio N, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005421
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Edwards CJ, 2011, CURR BIOL, V21, P1251, DOI 10.1016/j.cub.2011.05.058
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gharbi M, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-166
   Giovanetti M, 2016, INFECT GENET EVOL, V41, P142, DOI 10.1016/j.meegid.2016.03.030
   Grubaugh N. D., 2017, NATURE
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   Cuong HQ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001322
   Holmes EC, 2003, J VIROL, V77, P11296, DOI 10.1128/JVI.77.20.11296-11298.2003
   Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Kozlov AM, 2015, BIOINFORMATICS, V31, P2577, DOI 10.1093/bioinformatics/btv184
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lessler J, 2016, B WORLD HEALTH ORGAN, V94, P841, DOI 10.2471/BLT.16.174540
   Liu H, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.109
   Liu-Helmersson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089783
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Metsky HC, 2017, NATURE
   Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176
   Ministerio da Saade, 2017, B EP SECR VIG SAUD
   Naccache SN, 2016, EMERG INFECT DIS, V22, P1788, DOI 10.3201/eid2210.160663
   O'Brien JD, 2009, MOL BIOL EVOL, V26, P801, DOI 10.1093/molbev/msp003
   Pacheco O., 2016, NEW ENGL J MED
   PAHO/WHO, 2016, PAHO WHO ZIK EP UPD
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Perkins TA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.126, 10.1038/nmicrobiol.2016.126]
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Quick J., 2017, NAT PROTOCOLS
   Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rocklov J, 2016, EBIOMEDICINE, V9, P250, DOI 10.1016/j.ebiom.2016.06.009
   Schierup MH, 2000, GENETICS, V156, P879
   Shapiro B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021
   Trosemeier J-H, 2016, GENOME ANNOUNC, V4
   Vasconcelos PFC, 2016, VECTOR-BORNE ZOONOT, V16, P295, DOI 10.1089/vbz.2016.1952
   Vogel G, 2016, SCIENCE, V354, P1088, DOI 10.1126/science.354.6316.1088
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 62
TC 226
Z9 230
U1 7
U2 81
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 15
PY 2017
VL 546
IS 7658
BP 406
EP +
DI 10.1038/nature22401
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX5BK
UT WOS:000403250900035
PM 28538727
OA Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Palma, ML
   Duangkhae, P
   Douradinha, B
   Viana, IFT
   Rigato, PO
   Dhalia, R
   Mailliard, RB
   Barratt-Boyes, SM
   Nascimento, EJM
   Oshiro, TM
   Duarte, AJD
   Marques, ETA
AF Palma, M. L.
   Duangkhae, P.
   Douradinha, B.
   Viana, I. F. T.
   Rigato, P. O.
   Dhalia, R.
   Mailliard, R. B.
   Barratt-Boyes, S. M.
   Nascimento, E. J. M.
   Oshiro, T. M.
   da Silva Duarte, A. J.
   Marques, E. T. A.
TI Development of potent class II transactivator gene delivery systems
   capable of inducing de novo MHC II expression in human cells, in vitro
   and ex vivo
SO GENE THERAPY
LA English
DT Article
ID MAMMARY ADENOCARCINOMA CELLS; SMOOTH-MUSCLE-CELLS; DNA VACCINES;
   TUMOR-CELLS; EPIGENETIC REGULATION; LENTIVIRAL VECTORS;
   IMMUNE-RESPONSES; MASTER REGULATOR; DENDRITIC CELLS; BINDING DOMAIN
AB Class II transactivator (CIITA) induces transcription of major histocompatibility complex (MHC) II genes and can potentially be used to improve genetic immunotherapies by converting non-immune cells into cells capable of presenting antigens to CD4(+) T cells. However, CIITA expression is tightly controlled and it remains unclear whether distinct non-immune cells differ in this transactivator regulation. Here we describe the development of gene delivery systems capable of promoting the efficient CIITA expression in non-immune cell lines and in primary human cells of an ex vivo skin explant model. Different human cell types undergoing CIITA overexpression presented high-level de novo expression of MHC II, validating the delivery systems as suitable tools for the CIITA evaluation as a molecular adjuvant for gene therapies.
C1 [Palma, M. L.; Duangkhae, P.; Douradinha, B.; Viana, I. F. T.; Barratt-Boyes, S. M.; Nascimento, E. J. M.; Marques, E. T. A.] Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave,9th Floor, Pittsburgh, PA USA.
   [Palma, M. L.; Rigato, P. O.; Oshiro, T. M.; da Silva Duarte, A. J.] Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, Sao Paulo, Brazil.
   [Douradinha, B.] Fdn RiMED, Palermo, Italy.
   [Rigato, P. O.] Secretary Hlth Sao Paulo, Inst Adolfo Lutz, Ctr Immunol, Sao Paulo, Brazil.
   [Dhalia, R.; Marques, E. T. A.] Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Virol Dept, Recife, PE, Brazil.
   [Mailliard, R. B.; Barratt-Boyes, S. M.; Marques, E. T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
RP Marques, ETA (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave,9th Floor, Pittsburgh, PA USA.
EM marques@pitt.edu
RI Oshiro, Telma M/C-7152-2012; Dhalia, Rafael/AAD-5432-2020; Douradinha,
   Bruno/R-5832-2017; Marques, Ernesto T. A/L-4967-2013; Viana,
   Isabelle/M-4435-2017; Mailiiard, Robbie/M-9723-2015; Duarte, Alberto J
   S/D-4382-2012; de Lucena Palma, Mariana/P-3682-2016
OI Oshiro, Telma M/0000-0002-8791-9233; Marques, Ernesto T.
   A/0000-0003-3826-9358; Viana, Isabelle/0000-0003-4648-6635; de Lucena
   Palma, Mariana/0000-0002-9194-6680; Mailliard,
   Robbie/0000-0001-5501-503X; Douradinha, Bruno/0000-0002-9980-4505
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/20649-6, 2011/12134-6,
   2012/22171-9]; Fondazione Ri.MED
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo Grants 2011/20649-6, 2011/12134-6 and 2012/22171-9 and by
   the Fondazione Ri.MED. BD is a Fondazione Ri.MED Associate Scholar. We
   thank Stefan P Lamers for manuscript editing. We also acknowledge Dr
   Patricia A Toniolo and Dr Elizabeth R Wonderlich for assistance with the
   lentivirus transduction system, and Dr Jared Evans for kindly providing
   the pcDNAl-eGFP plasmid.
CR Asirvatham AJ, 2008, MOL IMMUNOL, V45, P1995, DOI 10.1016/j.molimm.2007.10.035
   Barbaro AD, 2005, EUR J IMMUNOL, V35, P603, DOI 10.1002/eji.200425378
   Barbaro AD, 2002, EUR J IMMUNOL, V32, P1309, DOI 10.1002/1521-4141(200205)32:5<1309::AID-IMMU1309>3.0.CO;2-4
   Barbieri G, 2002, INT IMMUNOL, V14, P839, DOI 10.1093/intimm/dxf060
   Beaulieu YB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148753
   Belperron AA, 1999, INFECT IMMUN, V67, P5163, DOI 10.1128/IAI.67.10.5163-5169.1999
   Beyer WR, 2002, J VIROL, V76, P1488, DOI 10.1128/JVI.76.3.1488-1495.2002
   Bhat KP, 2010, IMMUNOL CELL BIOL, V88, P807, DOI 10.1038/icb.2010.45
   Bhat KP, 2010, J BIOL CHEM, V285, P25893, DOI 10.1074/jbc.M110.127746
   Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249
   Breckpot K, 2007, HUM GENE THER, V18, P536, DOI 10.1089/hum.2007.006
   Camacho-Carvajal MM, 2004, INT IMMUNOL, V16, P65, DOI 10.1093/intimm/dxh010
   CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367
   Chiu E, 2015, J IMMUNOL, V194, P6102, DOI 10.4049/jimmunol.1402026
   Clark KR, 2001, CURR OPIN MOL THER, V3, P375
   Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626
   Croft M, 1997, CRIT REV IMMUNOL, V17, P89, DOI 10.1615/CritRevImmunol.v17.i1.40
   Douradinha B, 2014, VIRUS RES, V179, P231, DOI 10.1016/j.virusres.2013.11.007
   Fan W, 2013, ASIAN PAC J CANCER P, V14, P987, DOI 10.7314/APJCP.2013.14.2.987
   Feltquate DM, 1997, J IMMUNOL, V158, P2278
   Frangione V, 2010, INT J CANCER, V127, P1614, DOI 10.1002/ijc.25183
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Gialitakis M, 2010, MOL CELL BIOL, V30, P2046, DOI 10.1128/MCB.00906-09
   Gourley TS, 2002, J IMMUNOL, V168, P4414, DOI 10.4049/jimmunol.168.9.4414
   Green MR, 2006, J IMMUNOL, V177, P3865, DOI 10.4049/jimmunol.177.6.3865
   Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985
   Greer SF, 2004, J IMMUNOL, V173, P376, DOI 10.4049/jimmunol.173.1.376
   Gresch O, 2012, METHODS MOL BIOL, V801, P65, DOI 10.1007/978-1-61779-352-3_5
   Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000
   He Y, 2007, CURR OPIN MOL THER, V9, P439
   Hu BL, 2011, IMMUNOL REV, V239, P45, DOI 10.1111/j.1600-065X.2010.00967.x
   Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221
   Jordan Elizabeth T, 2008, J Biomol Tech, V19, P328
   KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295
   Kim D, 2008, J IMMUNOL, V180, P7019, DOI 10.4049/jimmunol.180.10.7019
   Kong XC, 2009, J MOL CELL CARDIOL, V46, P292, DOI 10.1016/j.yjmcc.2008.10.023
   KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1
   LeibundGut-Landmann S, 2004, EUR J IMMUNOL, V34, P1513, DOI 10.1002/eji.200424964
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lohsen S, 2014, GENES IMMUN, V15, P543, DOI 10.1038/gene.2014.49
   Lu XQ, 2003, CANCER IMMUNOL IMMUN, V52, P592, DOI 10.1007/s00262-003-0404-9
   Maciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693
   Mah C, 2004, MOL THER, V9, P458, DOI 10.1016/j.ymthe.2004.01.006
   MartinezSoria E, 1996, INT IMMUNOL, V8, P543, DOI 10.1093/intimm/8.4.543
   McCluskie MJ, 1999, MOL MED, V5, P287, DOI 10.1007/BF03402065
   Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712
   Morgan JE, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150091
   Mortara L, 2006, CLIN CANCER RES, V12, P3435, DOI 10.1158/1078-0432.CCR-06-0165
   Mortara L, 2009, INT IMMUNOL, V21, P655, DOI 10.1093/intimm/dxp034
   MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851
   Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61
   Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078
   Nakamura MC, 2014, J BONE MINER RES, V29, P287, DOI 10.1002/jbmr.2161
   Oliveira SC, 1999, BRAZ J MED BIOL RES, V32, P207, DOI 10.1590/S0100-879X1999000200009
   Raval A, 2003, J IMMUNOL, V170, P922, DOI 10.4049/jimmunol.170.2.922
   Rice AD, 2014, J VIROL, V88, P7753, DOI 10.1128/JVI.00185-14
   Rousseau A, 2016, NATURE, V536, P184, DOI 10.1038/nature18943
   Sartoris S, 1998, J IMMUNOL, V161, P814
   Scharer CD, 2015, NUCLEIC ACIDS RES, V43, P3128, DOI 10.1093/nar/gkv182
   Schlahsa L, 2014, TRANSFUSION, V54, P1961, DOI 10.1111/trf.12631
   Schnappauf F, 2003, EUR J IMMUNOL, V33, P2337, DOI 10.1002/eji.200323490
   Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511
   Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116
   Smith MA, 2011, J BIOL CHEM, V286, P7893, DOI 10.1074/jbc.M110.165431
   Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000
   STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J
   Tan PH, 2005, BLOOD, V105, P3824, DOI 10.1182/blood-2004-10-3880
   Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410
   Thompson JA, 2006, CANCER RES, V66, P1147, DOI 10.1158/0008-5472.CAN-05-2289
   Toniolo PA, 2015, J IMMUNOL, V194, P3180, DOI 10.4049/jimmunol.1401635
   Ulbricht T, 2012, J CELL BIOL, V199, P49, DOI 10.1083/jcb.201112015
   Voong LN, 2008, J BIOL CHEM, V283, P9031, DOI 10.1074/jbc.M706487200
   Wang Y, 2005, HUM GENE THER, V16, P187, DOI 10.1089/hum.2005.16.187
   Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6
   Westerheide SD, 1997, J IMMUNOL, V158, P4812
   Wong AW, 2003, NAT IMMUNOL, V4, P891, DOI 10.1038/ni960
   Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007
   Wu XY, 2011, NUCLEIC ACIDS RES, V39, P9549, DOI 10.1093/nar/gkr651
   Xia J, 2015, BBA-GENE REGUL MECH, V1849, P665, DOI 10.1016/j.bbagrm.2015.03.001
   Xu Y, 2007, J BIOL CHEM, V282, P26046, DOI 10.1074/jbc.M703652200
   Yee CSK, 2005, J IMMUNOL, V174, P1222, DOI 10.4049/jimmunol.174.3.1222
   Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752
   Zhou XR, 2007, IMMUNOLOGY, V122, P476, DOI 10.1111/j.1365-2567.2007.02674.x
NR 83
TC 1
Z9 1
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD JUN
PY 2017
VL 24
IS 6
BP 342
EP 352
DI 10.1038/gt.2017.25
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA EX8AP
UT WOS:000403471200002
PM 28414303
DA 2020-12-16
ER

PT J
AU Chotiwan, N
   Brewster, CD
   Magalhaes, T
   Weger-Lucarelli, J
   Duggal, NK
   Ruckert, C
   Nguyen, C
   Luna, SMG
   Fauver, JR
   Andre, B
   Gray, M
   Black, WC
   Kading, RC
   Ebel, GD
   Kuan, G
   Balmaseda, A
   Jaenisch, T
   Marques, ETA
   Brault, AC
   Harris, E
   Foy, BD
   Quackenbush, SL
   Perera, R
   Rovnak, J
AF Chotiwan, Nunya
   Brewster, Connie D.
   Magalhaes, Tereza
   Weger-Lucarelli, James
   Duggal, Nisha K.
   Ruckert, Claudia
   Chilinh Nguyen
   Luna, Selene M. Garcia
   Fauver, Joseph R.
   Andre, Barb
   Gray, Meg
   Black, William C.
   Kading, Rebekah C.
   Ebel, Gregory D.
   Kuan, Guillermina
   Balmaseda, Angel
   Jaenisch, Thomas
   Marques, Ernesto T. A.
   Brault, Aaron C.
   Harris, Eva
   Foy, Brian D.
   Quackenbush, Sandra L.
   Perera, Rushika
   Rovnak, Joel
TI Rapid and specific detection of Asian- and African-lineage Zika viruses
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID MEDIATED ISOTHERMAL AMPLIFICATION; REAL-TIME DETECTION;
   CHIKUNGUNYA-VIRUS; DENGUE VIRUS; CLINICAL-EVALUATION; FRENCH-POLYNESIA;
   TRANSMISSION; ASSAY; IDENTIFICATION; PHYLOGENY
AB Understanding the dynamics of Zika virus transmission and formulating rational strategies for its control require precise diagnostic tools that are also appropriate for resource-poor environments. We have developed a rapid and sensitive loop-mediated isothermal amplification (LAMP) assay that distinguishes Zika viruses of Asian and African lineages. The assay does not detect chikungunya virus or flaviviruses such as dengue, yellow fever, or West Nile viruses. The assay conditions allowed direct detection of Zika virus RNA in cultured infected cells; in mosquitoes; in virus-spiked samples of human blood, plasma, saliva, urine, and semen; and in infected patient serum, plasma, and semen samples without the need for RNA isolation or reverse transcription. The assay offers rapid, specific, sensitive, and inexpensive detection of the Asian-lineage Zika virus strain that is currently circulating in the Western hemisphere, and can also detect the African-lineage Zika virus strain using separate, specific primers.
C1 [Chotiwan, Nunya; Brewster, Connie D.; Weger-Lucarelli, James; Ruckert, Claudia; Chilinh Nguyen; Luna, Selene M. Garcia; Fauver, Joseph R.; Andre, Barb; Gray, Meg; Black, William C.; Kading, Rebekah C.; Ebel, Gregory D.; Foy, Brian D.; Quackenbush, Sandra L.; Perera, Rushika; Rovnak, Joel] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Chotiwan, Nunya; Magalhaes, Tereza; Weger-Lucarelli, James; Ruckert, Claudia; Chilinh Nguyen; Luna, Selene M. Garcia; Fauver, Joseph R.; Gray, Meg; Black, William C.; Kading, Rebekah C.; Ebel, Gregory D.; Foy, Brian D.; Perera, Rushika] Colorado State Univ, Coll Vet Med & Biomed Sci, Arthropod Borne Infect Dis Labs, Ft Collins, CO 80523 USA.
   [Magalhaes, Tereza; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Expt Therapeut, Recife, PE, Brazil.
   [Duggal, Nisha K.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
   [Kuan, Guillermina] Minist Hlth, Ctr Salud Socrates Flores Vivas, Managua, Nicaragua.
   [Balmaseda, Angel] Minist Hlth, Ctr Nacl Diagnost & Referencia, Lab Nacl Virol, Managua, Nicaragua.
   [Jaenisch, Thomas] Heidelberg Univ Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [Jaenisch, Thomas] German Ctr Infect Res DZIF, Partner Site Heidelberg, Heidelberg, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Sch Publ Hlth, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
RP Rovnak, J (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
EM joel.rovnak@colostate.edu
RI Magalhaes, Tereza/V-6632-2019; Rovnak, Joel/I-7379-2017; Marques,
   Ernesto T. A/L-4967-2013; Foy, Brian/E-6230-2017
OI Rovnak, Joel/0000-0003-4518-9030; Marques, Ernesto T.
   A/0000-0003-3826-9358; Ruckert, Claudia/0000-0003-3732-6752; Graham,
   Barbara/0000-0002-4221-1979; Garcia-Luna, Selene M./0000-0001-8420-5078;
   Fauver, Joseph/0000-0001-8099-2991; Weger-Lucarelli,
   James/0000-0002-9483-1694; Chotiwan, Nunya/0000-0003-3214-6605; Foy,
   Brian/0000-0002-9117-203X
FU National Institute of Allergy and Infectious Diseases (NIAID) of the
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [RO1AI067380, R01AI0833680, R21AI129464,
   R01AI099631, R21AI129488-01]; NIH/NIAID International Collaborations in
   Infectious Disease Research Program [U01AI088647]; Fundacao de Amparo a
   Ciencia e Tecnologia do Estado de Pernambuco [APQ-0302-4.01/13];
   European UnionEuropean Union (EU) [(FP7-281803 IDAMS) (41)]; Fogarty
   Training Grant [2D43TW001130-08]; Centers for Disease Control and
   PreventionUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA; Department of Microbiology,
   Immunology, and Pathology; College of Veterinary Medicine and Biomedical
   Sciences at Colorado State University; Office of the Vice President for
   Research, Colorado State University; FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW001130,
   D43TW001130, D43TW001130, D43TW001130, D43TW001130, D43TW001130,
   D43TW001130, D43TW001130, D43TW001130, D43TW001130, D43TW001130,
   D43TW001130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01AI106695, P01AI106695,
   P01AI106695, U19AI118610, R01AI067380, P01AI106695, R01AI099631,
   U19AI118610, U19AI118610, P01AI106695, U19AI118610, U19AI118610,
   P01AI106695, R21AI129488, U19AI118610, P01AI106695, R01AI099631,
   P01AI106695, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   P01AI106695, U19AI118610, P01AI106695, P01AI106695, U01AI088647,
   U19AI118610, U19AI118610, P01AI106695, P01AI106695, U19AI118610,
   U19AI118610, U19AI118610, R01AI067380, U19AI118610, U19AI118610,
   R01AI067380, R21AI129464, U19AI118610, P01AI106695, R01AI067380,
   U19AI118610, P01AI106695, U19AI118610, U19AI118610, P01AI106695,
   P01AI106695, R01AI099631, U19AI118610, P01AI106695, P01AI106695,
   U01AI088647, U19AI118610, U19AI118610, U19AI118610, P01AI106695,
   U19AI118610, R01AI067380, R21AI129464, R01AI099631, P01AI106695,
   U19AI118610, U19AI118610, P01AI106695, U19AI118610, R01AI099631,
   P01AI106695, U19AI118610, R01AI099631, U19AI118610, P01AI106695,
   U01AI088647, R01AI067380, P01AI106695, P01AI106695, U19AI118610,
   P01AI106695, U19AI118610, P01AI106695, U19AI118610, U19AI118610,
   R01AI067380, P01AI106695, U19AI118610, U19AI118610, R01AI067380,
   U19AI118610, P01AI106695, U19AI118610, P01AI106695, P01AI106695,
   R01AI099631, U19AI118610, U19AI118610, P01AI106695, R01AI067380,
   R01AI099631, P01AI106695, U19AI118610, R21AI129488, U19AI118610,
   R01AI067380, R01AI099631, U19AI118610, R01AI067380, U19AI118610,
   U19AI118610, U19AI118610, P01AI106695, P01AI106695, U19AI118610,
   U19AI118610, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, U19AI118610, R01AI067380, U19AI118610, U19AI118610,
   P01AI106695, U19AI118610, P01AI106695, U19AI118610, U19AI118610,
   U19AI118610, U19AI118610, R01AI067380, P01AI106695, U19AI118610,
   P01AI106695, P01AI106695, R01AI067380, U19AI118610, U19AI118610,
   U01AI088647, P01AI106695, U19AI118610, U01AI088647, R01AI067380,
   P01AI106695, R01AI099631] Funding Source: NIH RePORTER
FX The research reported in this publication was supported by the National
   Institute of Allergy and Infectious Diseases (NIAID) of the NIH (award
   nos. RO1AI067380 to J.W.-L., C.R., J.R.F., and G.D.E.; R01AI0833680 to
   W.C.B.; R21AI129464 to B.D.F., C.N., M.G., T.M., and E.T.A.M.;
   R01AI099631 to A.B.; and R21AI129488-01 to R.P. and J.R.) and the
   NIH/NIAID International Collaborations in Infectious Disease Research
   Program (U01AI088647). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH. Additional support was provided by the Fundacao de Amparo a Ciencia
   e Tecnologia do Estado de Pernambuco (APQ-0302-4.01/13 to E.T.A.M.) and
   the European Union (FP7-281803 IDAMS) (41). S.M.G.L. is supported by
   Fogarty Training Grant 2D43TW001130-08 "Training in dengue prevention
   and control." N.K.D. and A.C.B. were supported by the Centers for
   Disease Control and Prevention. This submission represents the views
   solely of the authors and does not constitute those of the Centers for
   Disease Control and Prevention or the U.S. government. B.A., C.D.B.,
   R.P., R.C.K., S.L.Q., and J.R. were supported by the Department of
   Microbiology, Immunology, and Pathology and the College of Veterinary
   Medicine and Biomedical Sciences at Colorado State University, and
   B.D.F., R.P., T.M., and N.C. were supported by the Office of the Vice
   President for Research, Colorado State University.
CR Balmaseda A, 1999, AM J TROP MED HYG, V61, P893, DOI 10.4269/ajtmh.1999.61.893
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Goto M, 2009, BIOTECHNIQUES, V46, P167, DOI 10.2144/000113072
   Grubaugh ND, 2016, CELL HOST MICROBE, V19, P481, DOI 10.1016/j.chom.2016.03.002
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Kwallah AO, 2013, J VIROL METHODS, V193, P23, DOI 10.1016/j.jviromet.2013.05.004
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Le Roux CA, 2009, J CLIN MICROBIOL, V47, P645, DOI 10.1128/JCM.01412-08
   Li MI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001792
   Lu X, 2012, AM J TROP MED HYG, V87, P947, DOI 10.4269/ajtmh.2012.11-0721
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P95, DOI 10.2450/2015.0066-15
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mori Y, 2004, J BIOCHEM BIOPH METH, V59, P145, DOI 10.1016/j.jbbm.2003.12.005
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Parida M, 2005, J CLIN MICROBIOL, V43, P2895, DOI 10.1128/JCM.43.6.2895-2903.2005
   Parida M, 2004, J CLIN MICROBIOL, V42, P257, DOI 10.1128/JCM.42.1.257-263.2004
   Parida MM, 2007, J CLIN MICROBIOL, V45, P351, DOI 10.1128/JCM.01734-06
   Parida MM, 2006, J CLIN MICROBIOL, V44, P4172, DOI 10.1128/JCM.01487-06
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Peyrefitte CN, 2008, J CLIN MICROBIOL, V46, P3653, DOI 10.1128/JCM.01188-08
   Quan JY, 2011, NAT PROTOC, V6, P242, DOI 10.1038/nprot.2010.181
   Roze B, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.9.30154
   Salazar MI, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-9
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Tanner N. A., 2014, CURR PROTOC MOL BIOL, V105
   Teoh BT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-387
   Vera-Maloof FZ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004263
   Waggoner JJ, 2016, EMERG INFECT DIS, V22, P1295, DOI 10.3201/eid2207.160326
   Waggoner JJ, 2016, J CLIN VIROL, V78, P57, DOI 10.1016/j.jcv.2016.01.007
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P263, DOI 10.1016/0035-9203(58)90085-3
NR 50
TC 42
Z9 44
U1 0
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 3
PY 2017
VL 9
IS 388
AR eaag0538
DI 10.1126/scitranslmed.aag0538
PG 13
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA ET7HC
UT WOS:000400464700003
PM 28469032
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Palma, MD
   Duangkhae, P
   Douradinha, B
   Dhalia, R
   Mailliard, RB
   Barratt-Boyes, S
   Oshiro, TM
   Marques, ETD
   Duarte, AJD
AF Palma, Mariana de Lucena
   Duangkhae, Parichat
   Douradinha, Bruno
   Dhalia, Rafael
   Mailliard, Robbie B.
   Barratt-Boyes, Simon
   Oshiro, Telma Miyuki
   Marques, Ernesto Torres de Azevedo
   Duarte, Alberto Jose da Silva
TI Engineering of novel Class II Transactivator gene delivery systems as
   molecular adjuvants to improve genetic immunotherapies by inducing de
   novo MHC II expression in human cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Immunologists (AAI)
CY MAY 12-16, 2017
CL Washington, DC
SP Amer Assoc Immunologists
RI Marques, Ernesto T. A/L-4967-2013; Dhalia, Rafael/AAD-5432-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2017
VL 198
IS 1
SU S
MA 79.16
PG 4
WC Immunology
SC Immunology
GA FD8EC
UT WOS:000407757000413
DA 2020-12-16
ER

PT J
AU Palma, MD
   Duangkhae, P
   Douradinha, B
   Dhalia, R
   Mailliard, RB
   Barratt-Boyes, S
   Oshiro, TM
   Marques, ETD
   Duarte, AJD
AF Palma, Mariana de Lucena
   Duangkhae, Parichat
   Douradinha, Bruno
   Dhalia, Rafael
   Mailliard, Robbie B.
   Barratt-Boyes, Simon
   Oshiro, Telma Miyuki
   Marques, Ernesto Torres de Azevedo
   Duarte, Alberto Jose da Silva
TI Engineering of novel Class II Transactivator gene delivery systems as
   molecular adjuvants to improve genetic immunotherapies by inducing de
   novo MHC II expression in human cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Immunologists (AAI)
CY MAY 12-16, 2017
CL Washington, DC
SP Amer Assoc Immunologists
RI Dhalia, Rafael/AAD-5432-2020; Mailiiard, Robbie/M-9723-2015; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2017
VL 198
IS 1
SU S
MA 79.16
PG 4
WC Immunology
SC Immunology
GA FD8EC
UT WOS:000407757000396
DA 2020-12-16
ER

PT J
AU Possas, C
   Brasil, P
   Marzochi, MCA
   Tanuri, A
   Martins, RM
   Marques, ETA
   Bonaldo, MC
   Ferreira, AGP
   Lourenco-de-Oliveira, R
   Nogueira, RMR
   Sequeira, PC
   Marzochi, KBF
   Homma, A
AF Possas, Cristina
   Brasil, Patricia
   Marzochi, Mauro C. A.
   Tanuri, Amilcar
   Martins, Reinaldo M.
   Marques, Ernesto T. A.
   Bonaldo, Myrna C.
   Ferreira, Antonio G. P.
   Lourenco-de-Oliveira, Ricardo
   Nogueira, Rita Maria R.
   Sequeira, Patricia C.
   Marzochi, Keyla B. F.
   Homma, Akira
TI Zika puzzle in Brazil: peculiar conditions of viral introduction and
   dissemination - A Review
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Review
DE Zika; microcephaly; congenital Zika syndrome; neurological disorders;
   pathogenesis; epidemiology
ID VIRUS-INFECTION; DENGUE VIRUS; SEXUAL TRANSMISSION; AEDES-AEGYPTI;
   PREGNANCY; JANUARY; AMERICA; WOMEN; SEMEN; BIRTH
AB This article discusses the peculiar conditions that favoured the unexpected introduction of Zika virus into the poorest northeastern region of Brazil in 2015, its speed of transmission to other Brazilian states, other Latin American countries and other regions, and the severity of related neurological disorders in newborns and adults. Contrasting with evidence that Zika had so far caused only mild cases in humans in the last six decades, the epidemiological scenario of this outbreak in Brazil indicates dramatic health effects: in 2015, an increase of 20-fold in notified cases of microcephaly and/or central nervous system (CNS) alterations suggestive of Zika congenital infection, followed by an exponential increase in 2016, with 2366 cumulative cases confirmed in the country by the end of December 2016. A significant increase in Guillain-Barre syndrome in adults has also been reported. Factors involved in viral dissemination, neural pathogenesis and routes of transmission in Brazil are examined, such as the role of social and environmental factors and the controversies involved in the hypothesis of antibody-dependent enhancement, to explain the incidence of congenital Zika syndrome in Brazil. Responses to the Zika outbreak and the development of new products are also discussed.
C1 [Possas, Cristina; Martins, Reinaldo M.; Homma, Akira] Fdn Oswaldo Cruz Fiocruz, Bio Manguinhos, Rio De Janeiro, RJ, Brazil.
   [Brasil, Patricia] Fdn Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin Doencas Febris Agudas, Rio De Janeiro, Brazil.
   [Marzochi, Mauro C. A.; Marzochi, Keyla B. F.] Fdn Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin & Vigilincia Leishmaniose, Rio De Janeiro, Brazil.
   [Tanuri, Amilcar] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, RJ, Brazil.
   [Marques, Ernesto T. A.] Fdn Oswaldo Cruz Fiocruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Bonaldo, Myrna C.] Fdn Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, Rio De Janeiro, RJ, Brazil.
   [Ferreira, Antonio G. P.] Fdn Oswaldo Cruz Fiocruz, Bio Manguinhos, Dept Reativos Diagnost, Rio De Janeiro, RJ, Brazil.
   [Lourenco-de-Oliveira, Ricardo] Fdn Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, Rio De Janeiro, RJ, Brazil.
   [Nogueira, Rita Maria R.; Sequeira, Patricia C.] Fdn Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, RJ, Brazil.
RP Possas, C (corresponding author), Fdn Oswaldo Cruz Fiocruz, Bio Manguinhos, Rio De Janeiro, RJ, Brazil.
EM cristina.possas@bio.fiocruz.br
RI Martins, Reinaldo/I-3413-2015; Marques, Ernesto T. A/L-4967-2013;
   Possas, Cristina/AAJ-3840-2020
OI Martins, Reinaldo/0000-0002-0667-532X; Marques, Ernesto T.
   A/0000-0003-3826-9358; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); FIOCRUZ
FX CNPq, FAPERJ, FIOCRUZ
CR Ayres CFJ, 2016, LANCET INFECT DIS, V16, P278, DOI 10.1016/S1473-3099(16)00073-6
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Bonaldo MC, 2014, HUM VACC IMMUNOTHER, V10, P1256, DOI 10.4161/hv.28117
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Coelho FC, 2016, INT J INFECT DIS, V51, P128, DOI 10.1016/j.ijid.2016.08.023
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   De Carvalho NS, 2016, BRAZ J INFECT DIS, V20, P282, DOI 10.1016/j.bjid.2016.02.006
   de Melo Freire CCIA, 2015, BIORXIV
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Eyer L, 2016, J INFECT DIS, V214, P707, DOI 10.1093/infdis/jiw226
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Favoretto S, 2016, BIORXIV
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P894, DOI 10.1016/S1473-3099(16)30153-0
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Meaney-Delman D, 2016, OBSTET GYNECOL, V127, P642, DOI 10.1097/AOG.0000000000001378
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   MS-Ministerio da Saude/Secretaria de Vigilancia em Saude, 2016, B EPIDEMIOLOGICO
   MS-Ministerio da Saude/Secretaria de Vigilancia em Saude, 2017, B EPIDEMIOLOGICO, V48, P10
   MS-Ministerio da Saude/Secretaria de Vigilancia em Saude/Centro de Operacoes de Emergencia em Saude Publica sobre Febre Amarela, 2017, 282017 MS COES
   MS-Ministerio da Saude/Secretaria de Vigilancia em Saude/Centro de Operacoes de Emergencias em Saude Publica sobre Microce-falias, 2017, 572016 MS CTR OP EM
   MS-Ministerio da Saude/Secretaria de Vigilancia em Saude/Centro de Operacoes de Emergencias em Saude Publica sobre Microce-falias, 2016, 282016 MS CTR OP EM
   MS-Ministerio da Saude/Secretaria de Vigilancia em Saude/Centro de Operacoes de Emergencias em Saude Publica sobre Microce-falias, 2016, 562016 MS CTR OP EM
   Munoz LS, 2016, SEMIN REPROD MED
   NIAID/NIH-National Institute of Allergy and Infectious Diseases/National Institutes of Health, 2016, ZIK VIR TREATM RES
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   PAHO/WHO-Pan American Health Organization/World Healt Organization, 2016, ZIK EP REP BRAZ
   PAHO/WHO-Pan American Health Organization/World Health Organization, 2016, CAS DEF
   PAHO-Pan American Health Organization, 2017, REG ZIK EP LOG UPD A
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Possas C, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016023
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reefhuis J, 2016, EMERG INFECT DIS, V22, P828, DOI 10.3201/eid2205.160290
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   Simeone RM, 2016, MMWR-MORBID MORTAL W, V65, P514, DOI 10.15585/mmwr.mm6520e1
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Soares CN, 2016, J CLIN VIROL, V83, P63, DOI 10.1016/j.jcv.2016.08.297
   Wang L, 2016, CELL HOST MICROBE, V19, P561, DOI 10.1016/j.chom.2016.04.006
   World Health Organization, 2016, ZIK SIT REP ZIK VIR
NR 62
TC 19
Z9 20
U1 0
U2 20
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY
PY 2017
VL 112
IS 5
BP 319
EP 327
DI 10.1590/0074-02760160510
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA ET3EG
UT WOS:000400159600001
PM 28443985
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Oliveira, RAD
   Cordeiro, MT
   de Moura, PMMF
   Baptista, PNB
   Braga-Neto, UD
   Marques, ETD
   Gil, LHVG
AF dos Santos Oliveira, Renato Antonio
   Cordeiro, Marli Tenorio
   Mendes Freire de Moura, Patricia Muniz
   Bapti Baptista Filho, Paulo Neves
   Braga-Neto, Ulisses de Mendonca
   de Azevedo Marques Junior, Ernesto Torres
   Vega Gonzales Gil, Laura Helena
TI Serum cytokine/chemokine profiles in patients with dengue fever (DF) and
   dengue hemorrhagic fever (FHD) by using protein array
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Dengue fever; Dengue hemorrhagic fever; Cytokines protein array;
   Prognostic marker
ID CD40 LIGAND; GRO-ALPHA; CHEMOKINES; PATHOGENESIS; EXPRESSION; INFECTION;
   CYTOKINE; RESPONSES; COHORT
AB Background: DENV infection can induce different clinical manifestations varying from mild forms to dengue fever (DF) or the severe hemorrhagic fever (DHF). Several factors are involved in the progression from DF to DHF. No marker is available to predict this progression. Such biomarker could allow a suitable medical care at the beginning of the infection, improving patient prognosis.
   Objectives: The aim of this study was to compare the serum expression levels of acute phase proteins in a well-established cohort of dengue fever (DF) and dengue hemorrhagic fever (DHF) patients, in order to individuate a prognostic marker of diseases severity.
   Study design: The serum levels of 36 cytokines, chemokines and acute phase proteins were determined in DF and DHF patients and compared to healthy volunteers using a multiplex protein array and near infrared (NIR) fluorescence detection. Serum levels of IL-lra, IL-23, MIF, sCD40 ligand, IP-10 and GRO-alpha were also determined by ELISA.
   Results: At the early stages of infection, GRO-alpha and IP-10 expression levels were different in DF compared to DHF patients. Besides, GRO-a was positively correlated with platelet counts and IP-10 was negatively correlated with total protein levels.
   Conclusions: These findings suggest that high levels of GRO-alpha during acute DENV infection may be associated with a good prognosis, while high levels of IP-10 may be a warning sign of infection severity. (C) 2017 Elsevier B.V. All rights reserved.
C1 [dos Santos Oliveira, Renato Antonio; Cordeiro, Marli Tenorio; de Azevedo Marques Junior, Ernesto Torres; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz Fiocruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [Mendes Freire de Moura, Patricia Muniz; Braga-Neto, Ulisses de Mendonca] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX 77843 USA.
   [de Azevedo Marques Junior, Ernesto Torres] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Mendes Freire de Moura, Patricia Muniz] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Bapti Baptista Filho, Paulo Neves] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Ctr Pesquisas Aggeu Magalhaes CPqAM, Ave Prof Moraes Rego S-N Campus UFPE Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Oliveira, Renato/A-2863-2013; Marques, Ernesto T. A/L-4967-2013;
   Oliveira, Renato/AAN-9394-2020; Oliveira, Renato/AAN-9879-2020
OI Oliveira, Renato/0000-0002-4044-0794; Marques, Ernesto T.
   A/0000-0003-3826-9358; Oliveira, Renato/0000-0002-4044-0794; Moura,
   Patricia/0000-0003-4259-388X
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [CNPq404453/2012-0]
FX This work was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) [Grant number CNPq404453/2012-0].
CR Aloui C, 2014, INT J MOL SCI, V15, P22342, DOI 10.3390/ijms151222342
   Amaral DCG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-23
   Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01
   Back A.T., 2013, INFECT ECOL EPIDEMIO, V3
   Bakaysa SL, 2014, MOL HUM REPROD, V20, P701, DOI 10.1093/molehr/gau028
   Bellinato DF, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8603263
   Boehlen F, 2001, TRANSFUSION MED, V11, P403, DOI 10.1046/j.1365-3148.2001.00340.x
   Bowman LR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004551
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Chintakuntlawar AV, 2009, J INTERF CYTOK RES, V29, P657, DOI 10.1089/jir.2009.0006
   Conroy AL, 2015, INT J INFECT DIS, V40, P45, DOI 10.1016/j.ijid.2015.07.027
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Danese S, 2003, GUT, V52, P1435, DOI 10.1136/gut.52.10.1435
   Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873
   Freedman JE, 2003, CIRC RES, V92, P944, DOI 10.1161/01.RES.0000074030.98009.FF
   Gleissner CA, 2012, CURR VASC PHARMACOL, V10, P563
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Johansson S, 2015, ALIMENT PHARM THER, V42, P1111, DOI 10.1111/apt.13389
   Kumar Y, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001887
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Malavige GN, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-341
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Moreno-Altamirano MMB, 2004, SCAND J IMMUNOL, V60, P631, DOI 10.1111/j.0300-9475.2004.01519.x
   Nischalke HD, 2012, J HEPATOL, V56, P758, DOI 10.1016/j.jhep.2011.10.019
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Persson-Dajotoy T, 2003, J IMMUNOL, V170, P5309, DOI 10.4049/jimmunol.170.10.5309
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Saito M, 2004, CLIN EXP IMMUNOL, V138, P299, DOI 10.1111/j.1365-2249.2004.02626.x
   Samanta J, 2015, WORLD J CLIN CASES, V3, P125, DOI 10.12998/wjcc.v3.i2.125
   Sanz MJ, 2012, EUR J IMMUNOL, V42, P278, DOI 10.1002/eji.201142231
   Souza L.J., 2004, BRAZ J INFECT DIS, V8, P150
   Stanaway J.D., 2016, LANCET INFECT DIS
   Sun PF, 2006, J IMMUNOL, V177, P6497, DOI 10.4049/jimmunol.177.9.6497
   Tseng YL, 2010, CYTOKINE, V51, P195, DOI 10.1016/j.cyto.2010.05.002
   Whitehorn J, 2011, VACCINE, V29, P7221, DOI 10.1016/j.vaccine.2011.07.022
   Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023
   Yamashita K, 2005, INFLAMMATION, V29, P17, DOI 10.1007/s10753-006-8964-4
   Zhao LZ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1596-x
NR 41
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD APR
PY 2017
VL 89
BP 39
EP 45
DI 10.1016/j.jcv.2017.02.007
PG 7
WC Virology
SC Virology
GA EO6FW
UT WOS:000396788400009
PM 28242509
DA 2020-12-16
ER

PT J
AU Jaenisch, T
   Rosenberger, KD
   Brito, C
   Brady, O
   Brasil, P
   Marques, ETA
AF Jaenisch, Thomas
   Rosenberger, Kerstin Daniela
   Brito, Carlos
   Brady, Oliver
   Brasil, Patricia
   Marques, Ernesto T. A.
TI Risk of microcephaly after Zika virus infection in Brazil, 2015 to 2016
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
AB Objective To estimate the risk of microcephaly in babies born to women infected by the Zika virus during pregnancy in Brazil in an epidemic between 2015 and 2016.
   Methods We obtained data on the number of notified and confirmed microcephaly cases in each Brazilian state between November 2015 and October 2016 from the health ministry. For Pernambuco State, one of the hardest hit, weekly data were available from August 2015 to October 2016 for different definitions of microcephaly. The absolute risk of microcephaly was calculated using the average number of live births reported in each state in the corresponding time period between 2012 and 2014 and assuming two infection rates: 10% and 50%. The relative risk was estimated using the reported background frequency of microcephaly in Brazil of 1.98 per 10 000 live births.
   Findings The estimated absolute risk of a notified microcephaly case varied from 0.03 to 17.1% according to geographical area, the definition of microcephaly used and the infection rate. Assuming a 50% infection rate, there was an 18-127 fold higher probability of microcephaly in children born to mothers with infection during pregnancy compared with children born to mothers without infection during pregnancy in Pernambuco State. For a 10% infection rate, the probability was.88-635 folds higher.
   Conclusion A large variation in the estimated risk of microcephaly was found in Brazil. Research is needed into possible effect modifiers, reliable measures of Zika virus infection and clear endpoints for congenital malformations.
C1 [Jaenisch, Thomas; Rosenberger, Kerstin Daniela] Univ Heidelberg Hosp, Dept Infect Dis, Sect Clin Trop Med, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.
   [Brito, Carlos] Univ Fed Pernambuco, Dept Internal Med, Recife, PE, Brazil.
   [Brady, Oliver] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Brasil, Patricia] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A.] Aggeu Magalhaes Res Ctr, Virol & Expt Therapeut Lab, Recife, PE, Brazil.
RP Jaenisch, T (corresponding author), Univ Heidelberg Hosp, Dept Infect Dis, Sect Clin Trop Med, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.
EM thomas.jaenisch@urz.uni-heidelberg.de
RI Marques, Ernesto T. A/L-4967-2013; Brady, Oliver/P-9421-2019; Jaenisch,
   Thomas/H-3473-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Brady,
   Oliver/0000-0002-3235-2129; 
FU European Union's Horizon 2020 research and innovation programme
   (ZIKAlliance grant) [734548]
FX This work was supported by the European Union's Horizon 2020 research
   and innovation programme (ZIKAlliance grant agreement no. 734548) and
   Seventh Framework Programme for Research and Technological Development
   (International Research Consortium on Dengue Risk Assessment, Management
   and Surveillance, IDAMS, grant agreement no. 281803). The manuscript has
   been given the IDAMS publication reference number IDAMS 35.
CR [Anonymous], 2015, MICR BRAZ POT LINK Z
   [Anonymous], 2016, NASC VIV BRAS
   [Anonymous], 2016, HUFFINGTON POST
   [Anonymous], 2015, FREQ MICR NASC BRAS
   Barreto ML, 2016, LANCET, V387, P919, DOI 10.1016/S0140-6736(16)00545-6
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Brito C, 2015, ACTA MEDICA PORT, V28, P679
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Culjat M, 2016, CLIN INFECT DIS, V63, P805, DOI 10.1093/cid/ciw324
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dyer O, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i383
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Jouannic JM, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00625-5
   Keeling MJ, 1997, SCIENCE, V275, P65, DOI 10.1126/science.275.5296.65
   Microcefalia e outran alteracOes do sistema nervoso central, 2016, 90 SEVSSESPE MICR OU
   Microcefalia e outras afteracoes do sistema nervoso central, 2016, 70 SEVSSESPE MICR OU
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Monitoramento dos casos de microcefalia no Brasil, 2016, 48 MON CAS MICR BRAS
   Pan American Health Organization World Health Organization, 2015, EP AL NEUR SYNDR CON
   Partlow J, 2016, WASHINGTON POST
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Silviera M., 2015, NAO ENGRAVIDEM AGORA
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
NR 30
TC 41
Z9 42
U1 0
U2 8
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD MAR
PY 2017
VL 95
IS 3
BP 191
EP 198
DI 10.2471/BLT.16.178608
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EN4IX
UT WOS:000395972300008
PM 28250532
OA Green Published, Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Castanha, PMS
   Nascimento, EJM
   Braga, C
   Cordeiro, MT
   de Carvalho, OV
   de Mendonca, LR
   Azevedo, EAN
   Franca, RFO
   Dhalia, R
   Marques, ETA
AF Castanha, Priscila M. S.
   Nascimento, Eduardo J. M.
   Braga, Cynthia
   Cordeiro, Marli T.
   de Carvalho, Otavio V.
   de Mendonca, Leila R.
   Azevedo, Elisa A. N.
   Franca, Rafael F. O.
   Dhalia, Rafael
   Marques, Ernesto T. A.
TI Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; antibody dependent enhancement; dengue antibodies
AB Anti-Flavivirus antibodies are highly cross-reactive and may facilitate Zika virus (ZIKV) infection through the antibody-dependent enhancement (ADE) mechanism. We demonstrate that dengue-specific antibodies enhance the infection of a primary Brazilian ZIKV isolate in a Fc gamma RII-expressing K562 cell line. In addition, we demonstrate that serum samples from dengue-immune pregnant women enhanced ZIKV infection. These findings highlight the need for epidemiological studies and animal models to further confirm the role of ADE in the development of congenital and neurological complications associated with ZIKV infections.
C1 [Castanha, Priscila M. S.; Braga, Cynthia; Cordeiro, Marli T.; de Carvalho, Otavio V.; de Mendonca, Leila R.; Azevedo, Elisa A. N.; Franca, Rafael F. O.; Dhalia, Rafael; Marques, Ernesto T. A.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Inst Biol Sci, Fac Med Sci, Recife, PE, Brazil.
   [Braga, Cynthia] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [de Carvalho, Otavio V.] Univ Fed Vicosa, Vicosa, MG, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Marques, ETA (corresponding author), Ctr Vaccine Res, 3501 5th Ave,9052 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA.
EM marques@pitt.edu
RI amsalu, ribka/G-8780-2019; Marques, Ernesto T. A/L-4967-2013; Da Silva
   Castanha, Priscila Mayrelle/G-1785-2012; Braga, Maria
   Cynthia/A-8204-2013; Dhalia, Rafael/AAD-5432-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Braga, Maria Cynthia/0000-0002-7862-6455;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
FU Brazilian Federal Agency for Support and Evaluation of Graduate
   Education (CAPES)CAPES; Center for Vaccine Research, University of
   Pittsburgh; Fogarty Training Program [D43TW006592 Pitt GIDRTP/ 323 NIH];
   National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [482915/2010-2 MCT/CNPq-321 14/2010]; Strategic Program to
   Support Health Research/PAPES VI [322 407697/2012-8]; National Institute
   of Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19 AI56541]
FX This work was supported by the Brazilian Federal Agency for Support and
   Evaluation of Graduate Education (CAPES); Center for Vaccine Research,
   University of Pittsburgh; Fogarty Training Program (D43TW006592 Pitt
   GIDRTP/ 323 NIH to P. M. S. C.); National Council for Scientific and
   Technological Development (CNPq) (482915/2010-2 MCT/CNPq-321 14/2010);
   Strategic Program to Support Health Research/PAPES VI (322
   407697/2012-8); and the National Institute of Allergy and Infectious
   Diseases (U19 AI56541).
CR Braga C, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00095815
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Durbin AP, 2016, TRENDS IMMUNOL, V37, P635, DOI 10.1016/j.it.2016.08.006
   FAGBAMI AH, 1987, CYTOBIOS, V49, P49
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
NR 15
TC 68
Z9 70
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 1
PY 2017
VL 215
IS 5
BP 781
EP 785
DI 10.1093/infdis/jiw638
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA ER2PO
UT WOS:000398636500018
PM 28039355
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Ferreira, MLB
   de Brito, CAA
   Moreira, AJP
   Machado, MID
   Henriques-Souza, A
   Cordeiro, MT
   Marques, ETD
   Pena, LJ
AF Brito Ferreira, Maria Lucia
   Antunes de Brito, Carlos Alexandre
   Porto Moreira, Alvaro Jose
   de Morais Machado, Maria Iris
   Henriques-Souza, Adelia
   Cordeiro, Marli Tenorio
   de Azevedo Marques, Ernesto Torres, Jr.
   Pena, Lindomar Jose
TI Guillain-Barre Syndrome, Acute Disseminated Encephalomyelitis and
   Encephalitis Associated with Zika Virus Infection in Brazil: Detection
   of Viral RNA and Isolation of Virus during Late Infection
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; TRANSMISSION
AB Zika virus (ZIKV) emerged in Brazil in 2015, which was followed by an increase of Guillain-Barre Syndrome (GBS) cases. We report the epidemiological, clinical, and laboratory findings of the first six neurological cases associated with ZIKV in Brazil seen in a reference neurology hospital in Pernambuco, Brazil. In all cases, ZIKV was detected in serum and/or cerebrospinal fluid (CSF) samples. In this case series, four cases were defined as GBS, one as acute disseminated encephalomyelitis (ADEM) and the other as encephalitis. ZIKV was detected in all cases by RT-PCR and virus isolation was successful in two patients. The time between ZIKV acute symptoms and the development of neurological manifestations varied from 3 to 13 days and ZIKV was detected between 15 and 34 days after the initial symptoms. Our results highlight the need to include ZIKV as a differential diagnosis for neurological syndromes in countries with circulation of this arbovirus. Because the viremia in these patients appears to persist longer, direct diagnostic techniques such as RT-PCR and viral isolation should be considered even if it is after the acute phase of viral infection.
C1 [Brito Ferreira, Maria Lucia; Porto Moreira, Alvaro Jose; de Morais Machado, Maria Iris] Hosp Restorat, Dept Neurol, Recife, PE, Brazil.
   [Antunes de Brito, Carlos Alexandre] Fed Univ Pernambuco UFPE, Dept Med, Av Prof Moraes Rego 1235,Cidade Univ, BR-50670901 Recife, PE, Brazil.
   [Henriques-Souza, Adelia] Hosp Restauracao, Dept Pediat, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio; de Azevedo Marques, Ernesto Torres, Jr.; Pena, Lindomar Jose] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, FIOCRUZ, Recife, PE, Brazil.
RP de Brito, CAA (corresponding author), Fed Univ Pernambuco UFPE, Dept Med, Av Prof Moraes Rego 1235,Cidade Univ, BR-50670901 Recife, PE, Brazil.
EM lucabrito@uol.com.br; cbritoc@gmail.com; alvarojpm@yahoo.com.br;
   irismorais@terra.com.br; adelianeuro@gmail.com; marli.tenorio@gmail.com;
   marques@pitt.edu; lindomar.pena@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
FU FACEPE; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX LJP is supported by grants from FACEPE and CNPq.
CR [Anonymous], 2016, ZIK EP UPD, P1
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Brazilian Ministry of Health, 2015, PROT AT SAUD RESP OC
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Control ECfDPa, 2014, RAP RISK ASS ZIK VIR
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   Marli T, 2016, J INFECT DIS, V214, P1897
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Oehler E., 2014, Eurosurveillance, V19, P20720
   Pan American Health Organization, 2015, 1 DEC 2015 NEUR SYND
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Smith DW, 2016, LANCET, V387, P1486, DOI 10.1016/S0140-6736(16)00564-X
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
NR 24
TC 25
Z9 26
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
BP 1405
EP 1409
DI 10.4269/ajtmh.17-0106
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5VW
UT WOS:000423222300020
PM 29140242
OA Bronze, Green Published
DA 2020-12-16
ER

PT J
AU Cordeiro, MT
   Brito, CAA
   Pena, LJ
   Castanha, PMS
   Gil, LHVG
   Lopes, KGS
   Dhalia, R
   Meneses, JA
   Ishigami, AC
   Mello, LM
   Alencar, LXE
   Guarines, KM
   Rodrigues, LC
   Marques, ETA
AF Cordeiro, Marli T.
   Brito, Carlos A. A.
   Pena, Lindomar J.
   Castanha, Priscila M. S.
   Gil, Laura H. V. G.
   Lopes, Kennya G. S.
   Dhalia, Rafael
   Meneses, Jucille A.
   Ishigami, Ana C.
   Mello, Luisa M.
   Alencar, Liciana X. E.
   Guarines, Klarissa M.
   Rodrigues, Laura C.
   Marques, Ernesto T. A.
TI Results of a Zika Virus (ZIKV) Immunoglobulin M-Specific Diagnostic
   Assay Are Highly Correlated With Detection of Neutralizing Anti-ZIKV
   Antibodies in Neonates With Congenital Disease
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; microcephaly; congenital Zika; anti-ZIKV IgM; ZIKV
   antibodies
ID INFECTION; DENGUE; BRAZIL
AB Background. Usually, immunoglobulin M (IgM) serologic analysis is not sufficiently specific to confirm Zika virus (ZIKV) infection. However, since IgM does not cross the placenta, it may be a good marker of infection in neonates.
   Methods. We tested blood from 42 mothers and neonates with microcephaly and collected cerebrospinal fluid (CSF) specimens from 30 neonates. Molecular assays were performed for detection of ZIKV, dengue virus, and chikungunya virus; IgM enzyme-linked immunosorbent assays and plaque-reduction neutralization tests (PRNTs) were performed to detect ZIKV and dengue virus. No control neonates without microcephaly were evaluated.
   Results. Among neonates, all 42 tested positive for ZIKV IgM: 38 of 42 serum specimens (90.5%) were positive, whereas 30 of 30 CSF specimens (100%) were positive. ZIKV IgM-specific ELISA ratios, calculated as the mean optical density (OD) of the test sample when reacted on viral antigen divided by the mean OD of the negative control when reacted with viral antigen, were higher in CSF specimens (median, 14.9 [range, 9.3-16.4]) than in serum (median, 8.9 [range, 2.1-20.6]; P =.0003). All ZIKV IgM-positive results among the neonates were confirmed by the detection of neutralizing antibodies. Mother/neonate pairs with primary ZIKV infection had neutralizing antibodies to ZIKV only, and mother/neonate pairs with ZIKV virus infection secondary to infection with another flavivirus had high titers of neutralizing antibodies to ZIKV. Among secondary infections, median titers in serum were 2072 (range, 232-12 980) for mothers and 2730 (range, 398-12 980) for neonates (P < .0001), and the median titer in CSF was 93 (range, 40-578) among neonates (P < .0001).
   Conclusions. Among neonates, detection of ZIKV IgM in serum is confirmatory of congenital ZIKV infection, and detection of ZIKV IgM in CSF is confirmatory of neurologic infection. Therefore, we recommend testing for ZIKV IgM in neonates suspected of having congenital ZIKV infection and performance of PRNTs in equivocal cases.
C1 [Cordeiro, Marli T.; Pena, Lindomar J.; Castanha, Priscila M. S.; Gil, Laura H. V. G.; Lopes, Kennya G. S.; Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Dept Virol, Recife, PE, Brazil.
   [Brito, Carlos A. A.] Univ Fed Pernambuco, Dept Clin Med, Recife, PE, Brazil.
   [Meneses, Jucille A.; Ishigami, Ana C.; Mello, Luisa M.] Inst Med Integral Prof Fernando Figueira, Dept Pediat, Recife, PE, Brazil.
   [Alencar, Liciana X. E.; Guarines, Klarissa M.] Secretaria Saude Estado Pernambuco, Cent Publ Hlth Lab, Recife, PE, Brazil.
   [Rodrigues, Laura C.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Marques, ETA (corresponding author), FIOCRUZ PE, Dept Virol, Ctr Pesquisas Aggeu Magalhaes CPqAM, Av Prof Moraes Rego SN,Campus UFPE,Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM marques@pitt.edu
RI Dhalia, Rafael/AAD-5432-2020; Marques, Ernesto T. A/L-4967-2013; Da
   Silva Castanha, Priscila Mayrelle/G-1785-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308
FU Brazilian government "Programa de pesquisas para o SUS / Fundacao de
   amparo a ciencia e tecnologia de PE" (PPSUS/FACEPE) [APQ: 0302-4.01/13];
   Medical Research CouncilMedical Research Council UK (MRC) [MC_PC_15088]
   Funding Source: researchfish
FX This study was supported by the Brazilian government "Programa de
   pesquisas para o SUS / Fundacao de amparo a ciencia e tecnologia de PE"
   (PPSUS/FACEPE - grant APQ: 0302-4.01/13).
CR Brasil P, 2016, NEW ENGL J MED, DOI [10.1056/NEJMoa160241412, DOI 10.1056/NEJMOA160241412]
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Chen LH, 2016, ANN INTERN MED, V164, P613, DOI 10.7326/M16-0150
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Paula Freitas B, 2016, JAMA OPHTHALMOL, DOI [10.1001/jamaophthlmol.2016.0267, DOI 10.1001/JAMAOPHTHLMOL.2016.0267]
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Fenton TR, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-59
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   World Health Organization, INT HLTH REG EM COMM
NR 23
TC 29
Z9 29
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 15
PY 2016
VL 214
IS 12
BP 1897
EP 1904
DI 10.1093/infdis/jiw477
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EJ3RT
UT WOS:000393130000018
PM 27923950
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Eder, M
   Bezerra, LC
   Outtes, FS
   Dimech, GS
   Ximenes, RA
   Dhalia, R
   Cordeiro, DM
   Marques, ET
   Martelli, CMT
AF Eder, M.
   Bezerra, L. C.
   Outtes, F. S.
   Dimech, G. S.
   Ximenes, R. A.
   Dhalia, R.
   Cordeiro, D. M.
   Marques, E. T.
   Martelli, C. M. T.
TI Arbovirus epidemiology in pregnant women in Pernambuco state, Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Eder, M.] London Sch Hyg & Trop Med, London, England.
   [Eder, M.] Fac Epidemiol & Populat Hlth, London, England.
   [Bezerra, L. C.; Outtes, F. S.; Dimech, G. S.] Pernambuco State Hlth Dept SES PE, Recife, PE, Brazil.
   [Ximenes, R. A.] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Dhalia, R.; Cordeiro, D. M.] Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Marques, E. T.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Martelli, C. M. T.] Ctr Pesquisa Aggeu Magalhaes Fiocruz, Saude Colet, Recife, PE, Brazil.
RI Dhalia, Rafael/AAD-5432-2020; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2016
VL 53
SU S
MA 08.003
BP 14
EP 14
DI 10.1016/j.ijid.2016.11.041
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA VE8AG
UT WOS:000440378400030
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Martelli, CMT
   Castanha, P
   Cortes, F
   Rodrigues, L
   Marques, ET
   Eder, M
AF Martelli, C. M. T.
   Castanha, P.
   Cortes, F.
   Rodrigues, L.
   Marques, E. T.
   Eder, M.
TI High levels of exposure of Zika and Dengue infections detected using
   plaque reduction neutralization assay in Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Martelli, C. M. T.] Ctr Pesquisa Aggeu Magalhaes Fiocruz, Saude Colet, Recife, PE, Brazil.
   [Castanha, P.] Fiocruz Pernambuco, Recife, PE, Brazil.
   [Cortes, F.] LSHTM, London, England.
   [Rodrigues, L.; Marques, E. T.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Eder, M.] North West London Hosp NHS Trust, Infect & Trop Med, Harrow, Middx, England.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
FU PAHO; Brazilian MoH; ERAES
FX PAHO, Brazilian MoH and ERAES.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2016
VL 53
SU S
MA 08.005
BP 15
EP 15
DI 10.1016/j.ijid.2016.11.043
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA VE8AG
UT WOS:000440378400032
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Argolo, AFLDE
   Feres, VCD
   Cordeiro, MT
   da Silveira, LA
   Guilarde, AO
   Marques, ETD
   de Souza, WV
   Martelli, CMT
AF Lopes de Teive e Argolo, Angela Ferreira
   de Rezende Feres, Valeria Christina
   Cordeiro, Marli Tenorio
   da Silveira, Lucimeire Antonelli
   Guilarde, Adriana Oliveira
   de Azevedo Marques, Ernesto Torres, Jr.
   de Souza, Wayner Vieira
   Turchi Martelli, Celina Maria
TI High frequency of pre-existing neutralizing antibody responses in
   patients with dengue during an outbreak in Central Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Dengue virus; Neutralizing antibody; Dengue fever; Brazil
ID PLAQUE-REDUCTION NEUTRALIZATION; ORIGINAL ANTIGENIC SIN;
   VIRUS-INFECTIONS; SEROTYPES; ASSAY
AB Background: This study aims to identify dengue neutralizing antibody response in patients with dengue from a well-characterized cohort during an outbreak in central Brazil, 2012-2013.
   Methods: We analyzed paired samples from 40 patients with severe dengue and 20 patients with dengue. Eligibility criteria were: IgM, NS1Ag and/or RT-PCR positivity and positive IgG result. Plaque reduction neutralization test (PRNT50) from DENV-1 to DENV-4 was performed to identify serotype-specific NAbs response. An infecting serotype was defined as >= 4-fold increase in DENV NAbs in paired samples. Monotypic response was classified as PRNT50 >= 1/20 to only one DENV serotype, and multitypic response was considered to be PRNT50 >= 1/20 to two or more serotypes simultaneously.
   Results: Patients were mainly adults. Virological dengue infection was confirmed by RT-PCR: DENV-4 (n = 14) and DENV-1 (n = 10). Forty-four out of 60 (73.3 %) patients had NAbs to DENV-4, DENV-1(68.3 %), DENV-2 (68.3 %) and DENV-3 (61.6 %) respectively. Fifteen percent of the cases presented monotypic response, whereas 85 % had multitypic response. DENV-4 infected-patients presented the greatest difference in PRNT50 titers compared with other serotypes. Pre-existing DENV NAbs was not correlated with disease severity. This was the first time that DENV-4 was implicated in an epidemic in the region.
   Conclusion: Our data indicates high exposure of multiple DENV serotypes in all age groups in the pre-dengue vaccine era and also previous to Zika virus introduction in Brazil.
C1 [Lopes de Teive e Argolo, Angela Ferreira; da Silveira, Lucimeire Antonelli; Guilarde, Adriana Oliveira; Turchi Martelli, Celina Maria] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Rua 235,St Univ, BR-74605050 Goiania, Go, Brazil.
   [Lopes de Teive e Argolo, Angela Ferreira] Secretaria Estadual Saude Goias LACEN GO, Publ Hlth Lab, Av Contorno 3-556, BR-74853120 Goiania, Go, Brazil.
   [de Rezende Feres, Valeria Christina] Univ Fed Goias, Coll Pharm, Av Univ, BR-74605220 Goiania, Go, Brazil.
   [Cordeiro, Marli Tenorio; de Azevedo Marques, Ernesto Torres, Jr.; de Souza, Wayner Vieira; Turchi Martelli, Celina Maria] Fundacao Oswaldo, Ctr Pesquisas Aggeu Magalhaes, Av Prof Moraes Rego 1235, BR-50670901 Recife, PE, Brazil.
   [de Azevedo Marques, Ernesto Torres, Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Argolo, AFLDE (corresponding author), Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Rua 235,St Univ, BR-74605050 Goiania, Go, Brazil.; Argolo, AFLDE (corresponding author), Secretaria Estadual Saude Goias LACEN GO, Publ Hlth Lab, Av Contorno 3-556, BR-74853120 Goiania, Go, Brazil.
EM angelafarmaceutica@hotmail.com
RI Souza, Wayner V/H-3798-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Lopes,
   Angela/0000-0002-7261-2079; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688; Souza, Wayner/0000-0002-0939-9332
FU Fundacao de Amparo a Pesquisa em Goias [FAPEG]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico [CNPq]National Council for
   Scientific and Technological Development (CNPq) [PRONEX-REDE DENGUE
   73/2009, 201210267000729]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [306489/2010-4, 305281/2010-0]
FX This work was supported by the Fundacao de Amparo a Pesquisa em Goias
   [FAPEG] and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico [CNPq] [PRONEX-REDE DENGUE 73/2009 # 201210267000729].
   C.M.T.M. and W.V.S. received research scholarships [CNPq numbers
   306489/2010-4, 305281/2010-0].
CR Barreto Maurício L., 2008, Estud. av., V22, P53, DOI 10.1590/S0103-40142008000300005
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brazilian Institute of Geography and Statistics (IBGE), IBGE STAT SER
   Brazilian Ministry of Health, 2014, DENG CAS BRAZ MAJ RE
   Brazilian Ministry of Health, 2011, HLTH BRAZ 2010 HLTH, P157
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Corbett KS, 2015, J INFECT DIS, V211, P590, DOI 10.1093/infdis/jiu481
   Araujo FMD, 2006, MEM I OSWALDO CRUZ, V101, P925, DOI 10.1590/S0074-02762006000800017
   de Figueiredo RMP, 2011, REV INST MED TROP SP, V53, P321, DOI 10.1590/S0036-46652011000600004
   Santos Cecília Luiza Simões dos, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P11, DOI 10.1590/S0036-46652003000100003
   GUBLER DJ, 1985, AM J TROP MED HYG, V34, P170, DOI 10.4269/ajtmh.1985.34.170
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   LAILLE M, 1991, J MED VIROL, V34, P51, DOI 10.1002/jmv.1890340109
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lorono-Pino MA, 1999, AM J TROP MED HYG, V61, P725, DOI 10.4269/ajtmh.1999.61.725
   MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985
   Pan American Health Organization/World Health Organization, 2014, COMM DIS HLTH AN HLT
   Rainwater-Lovett K, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-233
   Feres VCR, 2006, J CLIN VIROL, V37, P179, DOI 10.1016/j.jcv.2006.07.004
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Salje H, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002952
   Secretariat of Health of Goias, 2013, DENG B GOIAS 2013
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Thomas SJ, 2009, AM J TROP MED HYG, V81, P825, DOI 10.4269/ajtmh.2009.08-0625
   van Panhuis WG, 2010, J INFECT DIS, V202, P1002, DOI 10.1086/656141
   VinodKumar CS, 2013, J INFECT PUBLIC HEAL, V6, P302, DOI 10.1016/j.jiph.2013.01.004
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   WHO, 2007, GUID PLAQ RED NEUTR
   WHO, 1997, DENG HAEM FEV DIAGN, P1
   World Health Organization, 2009, DENG GUID DIAGN TREA
NR 35
TC 2
Z9 2
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 7
PY 2016
VL 16
AR 546
DI 10.1186/s12879-016-1867-6
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA DY9HM
UT WOS:000385444500003
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Williamson, H
   Hamlet, C
   White, P
   Harcourt, D
   Cadogan, J
   Paling, T
   Marques, E
AF Williamson, H.
   Hamlet, C.
   White, P.
   Harcourt, D.
   Cadogan, J.
   Paling, T.
   Marques, E.
TI The acceptability and feasibility of using an online psychosocial
   intervention (YP Face IT) to support adolescents struggling with
   appearance-altering conditions
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Meeting Abstract
CT 20th Anniversary Conference of the British-Skin-Foundation on Skin Deep
   - 20 Years of Research
CY OCT 13, 2016
CL Roayl Coll Phys, London, ENGLAND
SP British Skin Fdn
HO Roayl Coll Phys
C1 [Williamson, H.; Hamlet, C.; White, P.; Harcourt, D.] Univ West England, Ctr Appearance Res, Bristol, Avon, England.
   [Cadogan, J.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Paling, T.; Marques, E.] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
EI 1365-2133
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD OCT
PY 2016
VL 175
SU 2
SI SI
MA EP-77
BP 67
EP 68
PG 2
WC Dermatology
SC Dermatology
GA DW8IC
UT WOS:000383897500085
DA 2020-12-16
ER

PT J
AU Lucas, CGDO
   Matassoli, FL
   Pecanha, LMT
   Santillo, BT
   Oliveira, LMD
   Oshiro, TM
   Marques, ETDA
   Oxenius, A
   de Arruda, LB
AF Lucas, Carolina G. D. O.
   Matassoli, Flavio L.
   Pecanha, Ligia M. T.
   Santillo, Bruna Tereso
   da Silva Oliveira, Luanda Mara
   Oshiro, Telma Miyuki
   Marques, Ernesto T. D. A., Jr.
   Oxenius, Annette
   de Arruda, Luciana B.
TI Dendritic cells primed with a chimeric plasmid containing HIV-1-gag
   associated with lysosomal-associated protein-1 (LAMP/gag) is a potential
   therapeutic vaccine against HIV
SO FASEB JOURNAL
LA English
DT Article
DE HIV immunotherapy; T-cell activation; dendritic cell vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REGULATORY T-CELLS; 1-INFECTED
   INDIVIDUALS; VIROLOGICAL RESPONSES; MEMBRANE PROTEIN-1; II COMPARTMENT;
   GAG; INFECTION; ELICITS; CD4(+)
AB The decline in number and function of T cells is a hallmark of HIV infection, and preservation or restoration of HIV-specific cellular immune response is a major goal of AIDS treatment. Dendritic cells (DCs) play a key role in the initiation and maintenance of the immune response, and their use as a vaccine vehicle is a promising strategy for enhancing vaccine efficacy. We evaluated the potential of DC-mediated immunization with a DNA vaccine consisting of HIV-1-p55gag (gag, group-specific antigen) associated to lysosomal associated protein (LAMP) sequence (LAMP/gag vaccine). Immunization of mice with mouse DCs transfected with LAMP/gag (Lg-mDCs) stimulated more potent B-and T-cell responses than naked DNA or DCs pulsed with inactivated HIV. Anti-Gag antibody levels were sustained for at least 3 mo after immunization, and recall T-cell responses were also strongly detected at this time point. Human DCs transfected with LAMP/gag (Lg-hDCs) were also activated and able to stimulate greater T-cell response than native gag-transfected DCs. Coculture between Lg-hDCs and T lymphocytes obtained from patients with HIV resulted in upregulation of CD38, CD69, HLA-DR, and granzyme B by CD4(+) and CD8(+) T cells, and increased IFN-gamma and TNF-alpha production. These results indicate that the use of LAMP/gag-DC may be an efficient strategy for enhancing immune function in patients with HIV.
C1 [Lucas, Carolina G. D. O.; Matassoli, Flavio L.; de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Virol, Rio De Janeiro, Brazil.
   [Pecanha, Ligia M. T.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunol, Rio De Janeiro, Brazil.
   [Santillo, Bruna Tereso; da Silva Oliveira, Luanda Mara; Oshiro, Telma Miyuki] Univ Sao Paulo, Escola Med, Dept Dermatol, Lab Dermatol & Imunodeficiencias LIM 56, Sao Paulo, Brazil.
   [Santillo, Bruna Tereso; Oxenius, Annette] Swiss Fed Inst Technol, Inst Microbiol, Zurich, Switzerland.
   [Marques, Ernesto T. D. A., Jr.] Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Marques, Ernesto T. D. A., Jr.] Fundacao Oswaldo Cruz Fiocruz Pernambuco, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol, Recife, PE, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, CCS, Lab I SS 048, Bloco 1,Av Carlos Chagas Filho,377 Cidade Univ, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM arruda@micro.ufrj.br
RI Marques, Ernesto T. A/L-4967-2013; Oshiro, Telma M/C-7152-2012; Arruda,
   Luciana B/N-9086-2013; Tereso Santillo, Bruna/P-6047-2016; da Silva
   Oliveira, Luanda Mara/E-7273-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Oshiro, Telma
   M/0000-0002-8791-9233; Tereso Santillo, Bruna/0000-0003-2851-1657; da
   Silva Oliveira, Luanda Mara/0000-0003-0903-8219; Lucas,
   Carolina/0000-0003-4590-2756
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES;
   Coordination for the Improvement of Higher Education Personnel)CAPES;
   CAPES/Programa Professor Visitante do Exterior-Ciencias sem Fronteiras
   (CAPES-Special Visiting Researcher, Science Without Borders program);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   National Council for Scientific and Technological Development)National
   Council for Scientific and Technological Development (CNPq); Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ; Research Support Foundation of the State of Rio de Janeiro);
   Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [310030-113947]
FX The authors thank Dr. James K. Hildreth (University of California-Davis,
   Davis, CA, USA) and Dr. J. Thomas August (The Johns Hopkins School of
   Medicine, Baltimore, MD, USA) for kindly providing the anti-Gag M1 and
   anti-LAMP-2 antibodies, respectively; Dr. Helio Dutra [Instituto de
   Ciencias Biomedicas, Universidade Federal do Rio de Janeiro (UFRJ)] for
   helpful assistance with flow cytometry; and Joao Baltazar (Instituto de
   Microbiologia Paulo de Goes, UFRJ) for technical support. This work was
   supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES; Coordination for the Improvement of Higher Education Personnel),
   CAPES/Programa Professor Visitante do Exterior-Ciencias sem Fronteiras
   (CAPES-Special Visiting Researcher, Science Without Borders program),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   National Council for Scientific and Technological Development), Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ; Research Support Foundation of the State of Rio de Janeiro),
   and the Swiss National Science Foundation Grant 310030-113947 (to A.O.).
   C.G.D.O.L. and F.L.M. were the recipients of FAPERJ and CAPES
   fellowships. The authors declare no conflicts of interest.
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Andres C, 2015, J VIROL, V89, P9189, DOI 10.1128/JVI.01062-15
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Ayinde D, 2015, J VIROL, V89, P6994, DOI 10.1128/JVI.00069-15
   Brandt L, 2011, JAIDS-J ACQ IMM DEF, V57, P101, DOI 10.1097/QAI.0b013e318215a991
   Breton G, 2013, J IMMUNOL, V191, P2194, DOI 10.4049/jimmunol.1200646
   Buisson S, 2009, J INFECT DIS, V199, P1862, DOI 10.1086/599122
   Chen Wei-Ti, 2013, J AIDS Clin Res, V4, P218
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Chun TW, 2010, AIDS, V24, P2803, DOI 10.1097/QAD.0b013e328340a239
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Costiniuk CT, 2013, AIDS RES HUM RETROV, V29, P266, DOI [10.1089/aid.2011.0343, 10.1089/AID.2011.0343]
   Godinho RMD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099887
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   DCV2/MANON07-ORVACS Study Group, 2013, SCI TRANSL MED, V5
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574
   Erikstrup C, 2010, JAIDS-J ACQ IMM DEF, V53, P303, DOI 10.1097/QAI.0b013e3181ca3f7c
   Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632
   Ferrando-Martinez S, 2012, J VIROL, V86, P3667, DOI 10.1128/JVI.07034-11
   Frank I, 2002, J VIROL, V76, P2936, DOI 10.1128/JVI.76.6.2936-2951.2002
   French MA, 2013, AIDS, V27, P519, DOI 10.1097/QAD.0b013e32835cb720
   Gandhi RT, 2002, ANNU REV MED, V53, P149, DOI 10.1146/annurev.med.53.082901.104011
   Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002
   Hel Z, 2002, J IMMUNOL, V169, P4778, DOI 10.4049/jimmunol.169.9.4778
   Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999
   Kalams SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029231
   Kaushik S, 2013, AIDS RES HUM RETROV, V29, P501, DOI [10.1089/aid.2012.0200, 10.1089/AID.2012.0200]
   Kim CJ, 2013, J IMMUNOL, V191, P2164, DOI 10.4049/jimmunol.1300829
   KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992
   Klatt NR, 2012, MUCOSAL IMMUNOL, V5, P646, DOI 10.1038/mi.2012.38
   Kovari H, 2013, CLIN INFECT DIS, V56, P870, DOI 10.1093/cid/cis919
   Krathwohl MD, 2006, J INFECT DIS, V193, P494, DOI 10.1086/499597
   Kulkarni V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111085
   Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117
   Levy Y, 2006, AIDS, V20, P405, DOI 10.1097/01.aids.0000206504.09159.d3
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
   Mishra S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097881
   Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861
   Presicce P, 2012, AIDS, V26, P263, DOI 10.1097/QAD.0b013e32834ed8df
   Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998
   Schenal M, 2005, AIDS, V19, P653, DOI 10.1097/01.aids.0000166088.85951.25
   Sciaranghella G, 2013, AIDS, V27, P175, DOI 10.1097/QAD.0b013e32835bd1f0
   Selvaraj A, 2013, PATHOG DIS, V69, P184, DOI 10.1111/2049-632X.12067
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Simon GG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008574
   Smed-Sorensen A, 2011, CURR OPIN HIV AIDS, V6, P405, DOI 10.1097/COH.0b013e328349b06b
   Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5
   Turk G, 2013, J VIROL, V87, P7445, DOI 10.1128/JVI.00865-13
   Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8
   Wilgenhof S, 2011, J IMMUNOTHER, V34, P448, DOI 10.1097/CJI.0b013e31821dcb31
   Yonkers NL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023884
NR 55
TC 1
Z9 1
U1 0
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2016
VL 30
IS 8
BP 2970
EP 2984
DI 10.1096/fj.201500059
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA DS7WP
UT WOS:000380994000029
PM 27199296
DA 2020-12-16
ER

PT J
AU Gearhart, TL
   Montelaro, RC
   Schurdak, ME
   Pilcher, CD
   Rinaldo, CR
   Kodadek, T
   Park, Y
   Islam, K
   Yurko, R
   Marques, ETA
   Burke, DS
AF Gearhart, Tricia L.
   Montelaro, Ronald C.
   Schurdak, Mark E.
   Pilcher, Chris D.
   Rinaldo, Charles R.
   Kodadek, Thomas
   Park, Yongseok
   Islam, Kazi
   Yurko, Raymond
   Marques, Ernesto T. A., Jr.
   Burke, Donald S.
TI Selection of a potential diagnostic biomarker for HIV infection from a
   random library of non-biological synthetic peptoid oligomers
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE HIV; Diagnostic; Biomarker; Peptoid; Infectious disease; ELISA
AB Non-biological synthetic oligomers can serve as ligands for antibodies. We hypothesized that a random combinatorial library of synthetic poly-N-substituted glycine oligomers, or peptoids, could represent a random "shape library" in antigen space, and that some of these peptoids would be recognized by the antigen-binding pocket of disease-specific antibodies. We synthesized and screened a one bead one compound combinatorial library of peptoids, in which each bead displayed an 8-mer peptoid with ten possible different amines at each position (10(8) theoretical variants). By screening one million peptoid/beads we found 112 (approximately 1 in 10,000) that preferentially bound immunoglobulins from human sera known to be positive for anti-HIV antibodies. Reactive peptoids were then re-synthesized and rigorously evaluated in plate-based ELISAs. Four peptoids showed very good, and one showed excellent, properties for establishing a sero-diagnosis of HIV. These results-demonstrate the feasibility of constructing sero-diagnostic assays for infectious diseases from libraries of random molecular shapes. In this study we sought a proof-of-principle that we could identify a potential diagnostic antibody ligand biomarker for an infectious disease in a random combinatorial library of 100 million peptoids. We believe that this is the first evidence that it is possible to develop sero-diagnostic assays - for any infectious disease - based on screening random libraries of non-biological molecular shapes. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Gearhart, Tricia L.; Montelaro, Ronald C.; Marques, Ernesto T. A., Jr.; Burke, Donald S.] Univ Pittsburgh, Ctr Vaccine Res, 9014 Biomed Sci Tower 3,3501 Fifth Ave, Pittsburgh, PA 15261 USA.
   [Schurdak, Mark E.] Univ Pittsburgh, Drug Discovery Inst, 3501 Fifth Ave, Pittsburgh, PA 15261 USA.
   [Pilcher, Chris D.] Univ Calif San Francisco, Ctr AIDS Res, SFGH 80, 1001 Potrero Ave, San Francisco, CA 94110 USA.
   [Rinaldo, Charles R.; Park, Yongseok; Marques, Ernesto T. A., Jr.; Burke, Donald S.] Univ Pittsburgh, Grad Sch Publ Hlth, 130 DeSoto St, Pittsburgh, PA USA.
   [Kodadek, Thomas] Scripps Res Inst, 130 Scripps Way, Jupiter, FL 33458 USA.
   [Islam, Kazi; Yurko, Raymond] Univ Pittsburgh, Peptide Synth Facil, 300 Technol Dr, Pittsburgh, PA 15219 USA.
RP Burke, DS (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 9014 Biomed Sci Tower 3,3501 Fifth Ave, Pittsburgh, PA 15261 USA.
EM donburke@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Park, Yongseok/J-8901-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Park,
   Yongseok/0000-0003-3891-3991; Schurdak, Mark/0000-0002-1146-3268
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1068374]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI035043, UM1AI035043, UM1AI035043,
   UM1AI035043, UM1AI035043, UM1AI035043, UM1AI035043, UM1AI035043,
   UM1AI035043] Funding Source: NIH RePORTER
FX This work was supported by the Bill and Melinda Gates Foundation grant
   #OPP1068374. We thank the Consortium for the Evaluation and Performance
   of HIV Incidence Assays (CEPHIA) and the Multicenter AIDS Cohort Study
   (MACS) for providing serum samples. We also thank Michael Castigliano
   for help during the initial library screening process.
CR Alluri PG, 2003, J AM CHEM SOC, V125, P13995, DOI 10.1021/ja036417x
   BALL JM, 1994, J IMMUNOL METHODS, V171, P37, DOI 10.1016/0022-1759(94)90226-7
   Doran TM, 2015, ACS CHEM BIOL, V10, P401, DOI 10.1021/cb5007618
   Figliozzi GM, 1996, METHOD ENZYMOL, V267, P437
   KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310
   LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0
   Raveendra B., 2013, DISCOVERY PEPTOID LI
   Reddy MM, 2011, CELL, V144, P132, DOI 10.1016/j.cell.2010.11.054
NR 8
TC 3
Z9 3
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD AUG
PY 2016
VL 435
BP 85
EP 89
DI 10.1016/j.jim.2016.05.001
PG 5
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA DS2OS
UT WOS:000380624000011
PM 27182050
OA Green Published, Other Gold
DA 2020-12-16
ER

PT J
AU El-Bacha, T
   Struchiner, CJ
   Cordeiro, MT
   Almeida, FCL
   Marques, ET
   Da Poian, AT
AF El-Bacha, Tatiana
   Struchiner, Claudio J.
   Cordeiro, Marli Tenorio
   Almeida, Fabio C. L.
   Marques, Ernesto Torres, Jr.
   Da Poian, Andrea T.
TI H-1 Nuclear Magnetic Resonance Metabolomics of Plasma Unveils Liver
   Dysfunction in Dengue Patients
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NMR-SPECTROSCOPY; HUMAN-BLOOD; AMINO-ACID; SERUM; INFECTION; GLUTAMINE;
   URINE
AB Dengue, due to its global burden, is the most important arthropod-borne flavivirus disease, and early detection lowers fatality rates to below 1%. Since the metabolic resources crucial for viral replication are provided by host cells, detection of changes in the metabolic profile associated with disease pathogenesis could help with the identification of markers of prognostic and diagnostic importance. We applied H-1 nuclear magnetic resonance exploratory metabolomics to study longitudinal changes in plasma metabolites in a cohort in Recife, Brazil. To gain statistical power, we used innovative paired multivariate analyses to discriminate individuals with primary and secondary infection presenting as dengue fever (DF; mild) and dengue hemorrhagic fever (DHF; severe) and subjects with a nonspecific nondengue (ND) illness (ND subjects). Our results showed that a decrease in plasma low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) discriminated dengue virus (DENV)-infected subjects from ND subjects, and also, subjects with severe infection even presented a decrease in lipoprotein concentrations compared to the concentrations in subjects with mild infection. These results add to the ongoing discussion that the manipulation of lipid metabolism is crucial for DENV replication and infection. In addition, a decrease in plasma glutamine content was characteristic of DENV infection and disease severity, and an increase in plasma acetate levels discriminated subjects with DF and DHF from ND subjects. Several other metabolites shown to be altered in DENV infection and the implications of these alterations are discussed. We hypothesize that these changes in the plasma metabolome are suggestive of liver dysfunction, could provide insights into the underlying molecular mechanisms of dengue virus pathogenesis, and could help to discriminate individuals at risk of the development of severe infection and predict disease outcome.
   IMPORTANCE
   Dengue, due to its global burden, is the most important mosquito-borne viral disease. There is no specific treatment for dengue disease, and early detection lowers fatality rates to below 1%. In this study, we observed the effects of dengue virus infection on the profile of small molecules in the blood of patients with mild and severe infection. Variations in the profiles of these small molecules reflected the replication of dengue virus in different tissues and the extent of tissue damage during infection. The results of this study showed that the molecules that changed the most were VLDL, LDL, and amino acids. We propose that these changes reflect liver dysfunction and also that they can be used to discriminate subjects with mild dengue from those with severe dengue.
C1 [El-Bacha, Tatiana; Almeida, Fabio C. L.; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, RJ, Brazil.
   [Struchiner, Claudio J.] Fundacao Oswaldo Cruz, Dept Doencas Endem Samuel Pessoa, Rio De Janeiro, RJ, Brazil.
   [Cordeiro, Marli Tenorio; Marques, Ernesto Torres, Jr.] Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Almeida, Fabio C. L.] Univ Fed Rio de Janeiro, Ctr Nacl Biol Estrutural & Bioimagem, Rio De Janeiro, RJ, Brazil.
   [Marques, Ernesto Torres, Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [El-Bacha, Tatiana] Univ Fed Rio de Janeiro, Inst Nutr Josue de Castro, Rio De Janeiro, RJ, Brazil.
RP El-Bacha, T; Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, RJ, Brazil.
EM tatiana@nutricao.ufrj.br; dapoian@bioqmed.ufrj.br
RI Da Poian, Andrea T./V-1699-2019; Marques, Ernesto T. A/L-4967-2013;
   Struchiner, Claudio J/M-9360-2013; El-Bacha, Tatiana/ABH-1287-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Struchiner, Claudio
   J/0000-0003-2114-847X; Da Poian, Andrea/0000-0002-3969-704X; El-Bacha,
   Tatiana/0000-0003-0809-0218
FU MCTI \ Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [306669/2013-7, 483229/2010-5]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [E-26/201.571/2014, E-26/201.167/2014, E-26/110.092/2013];
   Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS)
   [AMS-NAF2-ElBacha] Funding Source: researchfish
FX This work, including the efforts of Andrea T. Da Poian, was funded by
   MCTI vertical bar Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) (306669/2013-7). This work, including the efforts of
   Tatiana El-Bacha, was funded by MCTI vertical bar Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) (483229/2010-5). This
   work, including the efforts of Claudio J. Struchiner, was funded by MCTI
   vertical bar Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq). This work, including the efforts of Tatiana
   El-Bacha, was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES). This work, including the efforts of Tatiana
   El-Bacha, was funded by Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) (E-26/201.571/2014). This
   work, including the efforts of Andrea T. Da Poian, was funded by
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ) (E-26/201.167/2014 and E-26/110.092/2013). This work,
   including the efforts of Claudio J. Struchiner, was funded by Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ).
CR Albuquerque LM, 2009, J PROTEOME RES, V8, P5431, DOI 10.1021/pr900236f
   Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376
   BELL JD, 1987, FEBS LETT, V215, P311, DOI 10.1016/0014-5793(87)80168-0
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Birungi G, 2010, J PROTEOME RES, V9, P6523, DOI 10.1021/pr100727m
   Biswas HH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003904
   Brasier AR, 2015, J CLIN VIROL, V64, P97, DOI 10.1016/j.jcv.2015.01.011
   Brazil Ministry of Health, 2015, B EPIDEMIOLOGICO, V48
   Cassol E, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-203
   Chambers JW, 2010, J VIROL, V84, P1867, DOI 10.1128/JVI.02123-09
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cui L, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002373
   Dieterle F, 2006, ANAL CHEM, V78, P4281, DOI 10.1021/ac051632c
   Dona AC, 2014, ANAL CHEM, V86, P9887, DOI 10.1021/ac5025039
   DUNHAM CM, 1991, CIRC SHOCK, V35, P78
   El-Bacha T, 2007, BBA-MOL BASIS DIS, V1772, P1158, DOI 10.1016/j.bbadis.2007.08.003
   Fontaine KA, 2015, J VIROL, V89, P2358, DOI 10.1128/JVI.02309-14
   Fontaine KA, 2014, J VIROL, V88, P4366, DOI 10.1128/JVI.03134-13
   Gonzalez I., 2011, MIXOMICS OMICS DATA
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Heaton NS, 2010, CELL HOST MICROBE, V8, P422, DOI 10.1016/j.chom.2010.10.006
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   Ishida H, 2013, BIOCHEM BIOPH RES CO, V437, P127, DOI 10.1016/j.bbrc.2013.06.051
   Le Cao KA, 2009, BIOINFORMATICS, V25, P2855, DOI 10.1093/bioinformatics/btp515
   Lu CJ, 2012, TALANTA, V100, P51, DOI 10.1016/j.talanta.2012.07.076
   Ludwig C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-366
   Munshi SU, 2011, J VIRAL HEPATITIS, V18, pE591, DOI 10.1111/j.1365-2893.2011.01488.x
   Nascimento EJM, 2014, CRIT REV IMMUNOL, V34, P227, DOI 10.1615/CritRevImmunol.2014010212
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Nchoutmboube JA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003401
   Newsholme F, 1999, J NUTR BIOCHEM, V10, P316
   Nie CY, 2014, J VIRAL HEPATITIS, V21, P53, DOI 10.1111/jvh.12122
   Pando-Robles V, 2014, J PROTEOMICS, V111, P16, DOI 10.1016/j.jprot.2014.06.029
   Parsons HM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-234
   Pinto J, 2015, J PROTEOME RES, V14, P1263, DOI 10.1021/pr5011982
   R Core Team, 2015, R LANG ENV STAT COMP
   Saito T, 2013, METABOLISM, V62, P1577, DOI 10.1016/j.metabol.2013.07.002
   Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632
   Shahfiza N, 2015, ASIAN PAC J TROP MED, V8, P452, DOI [10.1016/S1995-7645(14)60359-X, 10.1016/j.apjtm.2015.05.012]
   Soto-Acosta R, 2013, VIROLOGY, V442, P132, DOI 10.1016/j.virol.2013.04.003
   Tiziani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004251
   TOLLINGER CD, 1979, CLIN CHEM, V25, P1787
   van Gorp ECM, 2002, CLIN INFECT DIS, V34, P1150, DOI 10.1086/339539
   Vastag L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002124
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Voge NV, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004449
   Westerhuis JA, 2010, METABOLOMICS, V6, P119, DOI 10.1007/s11306-009-0185-z
   Wijeyesekera A, 2012, J PROTEOME RES, V11, P2224, DOI 10.1021/pr2010154
   World Health Organization, 2009, DENG GUID DIAGN TREA
   World Health Organization, 2011, COMPR GUID PREV CONT
NR 50
TC 16
Z9 16
U1 2
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2016
VL 90
IS 16
BP 7429
EP 7443
DI 10.1128/JVI.00187-16
PG 15
WC Virology
SC Virology
GA DU6EJ
UT WOS:000382306500032
PM 27279613
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Castanha, PMS
   Braga, C
   Cordeiro, MT
   Souza, AI
   Silva, CD
   Martelli, CMT
   van Panhuis, WG
   Nascimento, EJM
   Marques, ETA
AF Castanha, Priscila M. S.
   Braga, Cynthia
   Cordeiro, Marli T.
   Souza, Ariani I.
   Silva, Claudeir D., Jr.
   Martelli, Celina M. T.
   van Panhuis, Willem G.
   Nascimento, Eduardo J. M.
   Marques, Ernesto T. A.
TI Placental Transfer of Dengue Virus (DENV)-Specific Antibodies and
   Kinetics of DENV Infection-Enhancing Activity in Brazilian Infants
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE dengue; placental transfer; IgG; newborn; antibody dependent enhancement
ID TRANSPLACENTAL TRANSFER; HEMORRHAGIC-FEVER; IGG SUBCLASSES; LIFE;
   PATHOGENESIS; PREGNANCY; MEASLES; DECAY; FCRN
AB Background. Maternal-fetal transferred dengue virus ( DENV)-specific antibodies have been implicated in the immunopathogenesis of dengue during infancy. Methods. A prospective birth cohort was established in a dengue-endemic area in the Northeast Region of Brazil. DENV-specific immunoglobulin G ( IgG) and DENV-1-4 serotype-specific neutralizing antibody ( NAb) levels were assessed in 376 paired maternal and umbilical cord blood samples. The kinetics of enhancing activity by maternally acquired DENV antibodies was determined in serum samples from children enrolled in the cohort. Results. Mothers were mostly immune to DENV-3 alone ( 53.7%) or combined with DENV-4 ( 30.6%). Levels of DENV-specific IgG, DENV-3 NAbs, and DENV-4 NAbs were significantly higher in newborns than in their respective mothers. Mothers immune to a single serotype transferred greater levels of DENV-specific IgG ( P =.02) and DENV-3 NAbs ( P =.04) than mothers immune to multiple DENV serotypes. Maternally acquired DENV-3 NAbs disappeared in > 90% of the children by the age of 4 months. The peak enhancing activity was detected by the age of 2 months ( P <.0001) and rapidly declined by the age of 4 months ( P =.0035). Conclusions. Unlike Asian infants, the enhancing activity of DENV infection by maternally transferred DENV antibodies occurs at earlier ages in Brazilian children. These findings might explain the low occurrence of severe dengue among infants in our setting.
C1 [Castanha, Priscila M. S.; Braga, Cynthia; Cordeiro, Marli T.; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Braga, Cynthia; Souza, Ariani I.; Silva, Claudeir D., Jr.] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [Martelli, Celina M. T.] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
   [van Panhuis, Willem G.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Nascimento, EJM (corresponding author), Ctr Vaccine Res, 3501 5th Ave,9052 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA.
EM ejmn@pitt.edu
RI Souza, Ariani I/C-1568-2015; Braga, Maria Cynthia/A-8204-2013; Marques,
   Ernesto T. A/L-4967-2013; Van Panhuis, Willem/S-5495-2019; Da Silva
   Castanha, Priscila Mayrelle/G-1785-2012; de Souza, Ariani
   Impieri/AAR-6884-2020
OI Souza, Ariani I/0000-0002-7917-5983; Braga, Maria
   Cynthia/0000-0002-7862-6455; Marques, Ernesto T. A/0000-0003-3826-9358;
   Van Panhuis, Willem/0000-0002-7278-9982; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; de Souza, Ariani
   Impieri/0000-0002-7917-5983; Dias da Silva Junior,
   Claudeir/0000-0002-5216-5697; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688
FU National Council for Scientific and Technological Development of the
   Brazilian government [482915/2010-2 MCT/CNPq-14/2010]; Strategic Program
   to Support Health Research/PAPES VI [407697/2012-8]; Fogarty Training
   Program [D43TW006592 Pitt GIDRTP/NIH]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW006592, D43TW006592, D43TW006592, D43TW006592, D43TW006592,
   D43TW006592, D43TW006592, D43TW006592, D43TW006592, D43TW006592] Funding
   Source: NIH RePORTER
FX This work was supported by the National Council for Scientific and
   Technological Development of the Brazilian government (grant
   482915/2010-2 MCT/CNPq-14/2010), the Strategic Program to Support Health
   Research/PAPES VI (grant 407697/2012-8), and the Fogarty Training
   Program (grant D43TW006592 Pitt GIDRTP/NIH to P. M. S. C.).
CR Argolo AFLT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-254
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Braga C, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00095815
   Brazilian Ministry of Health. Sistema de Informacao sobre Agravos de Notificacao (SINAN), 2012, SIST INF AGR NOT SIN
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cumberland P, 2007, J INFECT DIS, V196, P550, DOI 10.1086/519845
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077, DOI 10.1093/infdis/173.5.1077
   Goncalves G, 1999, EPIDEMIOL INFECT, V122, P273, DOI 10.1017/S0950268899002046
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170
   Hartter HK, 2000, PEDIATR INFECT DIS J, V19, P635, DOI 10.1097/00006454-200007000-00010
   Khamim K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003396
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Koraka P, 2001, J CLIN MICROBIOL, V39, P4332, DOI 10.1128/JCM.39.12.4332-4338.2001
   Leite RC, 2014, J CLIN VIROL, V60, P16, DOI [10.1016/j.jcv.2014.02.009, 10.1016/J.JCV.2014.02.009]
   Okoko BJ, 2001, J INFECT DIS, V184, P627, DOI 10.1086/322808
   Okoko JB, 2001, TROP MED INT HEALTH, V6, P529, DOI 10.1046/j.1365-3156.2001.00741.x
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   Pengsaa K, 2006, J INFECT DIS, V194, P1570, DOI 10.1086/508492
   Rodenhuis-Zybert IA, 2010, CELL MOL LIFE SCI, V67, P2773, DOI 10.1007/s00018-010-0357-z
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Scott S, 2007, CLIN INFECT DIS, V45, P1417, DOI 10.1086/522989
   Simmons CP, 2007, J INFECT DIS, V196, P416, DOI 10.1086/519170
   Stapleton NM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1608
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   THEIN S, 1993, J MED VIROL, V40, P102, DOI 10.1002/jmv.1890400205
   Tran NBC, 2009, J INFECT DIS, V200, P1893, DOI 10.1086/648407
   van Panhuis WG, 2011, AM J TROP MED HYG, V85, P355, DOI 10.4269/ajtmh.2011.11-0125
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   Watanaveeradej V, 2003, AM J TROP MED HYG, V69, P123, DOI 10.4269/ajtmh.2003.69.123
   Whitehorn J, 2011, VACCINE, V29, P7221, DOI 10.1016/j.vaccine.2011.07.022
NR 33
TC 19
Z9 19
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 15
PY 2016
VL 214
IS 2
BP 265
EP 272
DI 10.1093/infdis/jiw143
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DR3SM
UT WOS:000379822900014
PM 27056951
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Albuquerque, MDPM
   Araujo, TVB
   Barkokebas, A
   Bezerra, LCA
   Braga, C
   Brandao, SP
   Brito, CAA
   Cabral, RG
   Carneiro, AR
   Carvalho, MDCG
   Cordeiro, MT
   Costa, I
   Cunha, ASC
   Cruz, DDCS
   Dhalia, R
   Hazin, AN
   Katz, L
   Marques, ETA
   Martelli, CMT
   Miranda, DB
   Moraes, MMC
   Mota, C
   Van der Linden, V
   Ramos, RCF
   Rocha, MAW
   Silva, PFS
   Souza, WV
   Van der Linden, A
   Ximenes, RAA
   Batista, JDL
   Vazquez, E
   Coelho, GE
   Cortez-Escalante, JJ
   Duarte, E
   Henriques, CMP
   Melo, CFCA
   Oliveira, WK
   Schuler-Faccini, L
   Aldighieri, S
   Almiron, M
   Mendez-Rico, J
   Ramon-Pardo, P
   Rodrigues, LC
AF Albuquerque, Maria de Fatima P. M.
   Araujo, Thalia V. B.
   Barkokebas, Andreza
   Bezerra, Luciana Caroline A.
   Braga, Cynthia
   Brandao-Filho, Sinval P.
   Brito, Carlos Alexandre A.
   Cabral, Renata G.
   Carneiro, Adriana R.
   Carvalho, Maria Durce C. G.
   Cordeiro, Marli T.
   Costa-, Iran, Jr.
   Cunha, Adriana S. C.
   Cruz, Danielle D. C. S.
   Dhalia, Rafael
   Hazin, Adriano N.
   Katz, Leticia
   Marques, Ernesto T. A.
   Martelli, Celina Maria T.
   Miranda-Filho, Democrito B.
   Moraes, Monica Maria C.
   Mota, Cristina
   Van der Linden, Vanessa
   Ramos, Regina C. F.
   Rocha, Maria Angela W.
   Silva, Paula Fabiana S.
   Souza, Wayner V.
   Van der Linden, Ana
   Ximenes, Ricardo A. A.
   Batista, Joanna d'Arc L.
   Vazquez, Enrique
   Coelho, Giovanini E.
   Cortez-Escalante, Juan J.
   Duarte, Elisete
   Henriques, Claudio M. P.
   Melo, Carlos Frederico C. A.
   Oliveira, Wanderson K.
   Schuler-Faccini, Lavinia
   Aldighieri, Sylvain
   Almiron, Maria
   Mendez-Rico, Jairo
   Ramon-Pardo, Pilar
   Rodrigues, Laura C.
CA Microcephaly Epidemic Res Grp
TI Microcephaly in Infants, Pernambuco State, Brazil, 2015
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
AB We studied the clinical characteristics for 104 infants born with microcephaly in the delivery hospitals of Pernambuco State, Brazil, during 2015. Testing is ongoing to exclude known infectious causes. However, microcephaly peaked in October and demonstrated central nervous system abnormalities with brain dysgenesis and intracranial calcifications consistent with an intrauterine infection.
C1 [Martelli, Celina Maria T.] Oswaldo Cruz Fdn Fiocruz, Res Ctr Aggeu Magalhaes, NESC, Ave Prof Moraes Rego S-N,Campus UFPE,Cidade Univ, BR-50740465 Recife, PE, Brazil.
RP Martelli, CMT (corresponding author), Oswaldo Cruz Fdn Fiocruz, Res Ctr Aggeu Magalhaes, NESC, Ave Prof Moraes Rego S-N,Campus UFPE,Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM turchicm@gmail.com
RI Braga, Maria Cynthia/A-8204-2013; Dhalia, Rafael/AAD-5432-2020; Folador,
   Adriana R.C./H-6410-2016; Marques, Ernesto T. A/L-4967-2013; Batista,
   Joanna d'Arc L/O-9933-2014; Oliveira, Wanderson/AAF-5182-2019; Souza,
   Wayner V/H-3798-2013; SCHULER-FACCINI, LAVINIA/C-8309-2013
OI Braga, Maria Cynthia/0000-0002-7862-6455; Marques, Ernesto T.
   A/0000-0003-3826-9358; Batista, Joanna d'Arc L/0000-0002-3703-2845;
   Oliveira, Wanderson/0000-0002-9662-1930; SCHULER-FACCINI,
   LAVINIA/0000-0002-2428-0460; Brandao Filho, Sinval/0000-0003-3768-2810;
   Souza, Wayner/0000-0002-0939-9332; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688
FU Brazilian Ministry of Health; Pernambuco State Health Department; Pan
   American Health Organization; Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq) [306489/2010-4, 308311/2009-4,
   308590/2013-9, 301779/2009-0, 304174/2014-9, 306222/2013-2]; Medical
   Research CouncilMedical Research Council UK (MRC) [MC_PC_15088] Funding
   Source: researchfish
FX We are thankful for the support of the Brazilian Ministry of Health,
   Pernambuco State Health Department and Pan American Health Organization
   for their support.r The authors received partial support from the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (scholarship 306489/2010-4 to C.M.T.M., 308311/2009-4 to RAAX,
   308590/2013-9 to D.B.M.F., 301779/2009-0 to M.F.P.M.A., 304174/2014-9 to
   C.B., and 306222/2013-2 to W.V.S.).
CR Brazilian Ministry of Health, 2015, EP B ZIK VIR DAT
   Brazilian Ministry of Health, 2015, EPIDEMIOLOGICAL B
   Brazilian Ministry of Health, 2015, MIN HLTH CONF REL ZI
   Brazilian Ministry of Health, 2015, PROT MON RESP MICR O
   Pereira APE, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00160313
   Fenton TR, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-59
   Kleber de Oliveira Wanderson, 2016, MMWR Morb Mortal Wkly Rep, V65, P242, DOI 10.15585/mmwr.mm6509e2
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001
   Pan American Health Organization, 2015, NEUR SYNDR CONG MALF
   Trimm F, 2004, PEDIAT MOD, V2, P1
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 13
TC 52
Z9 53
U1 0
U2 9
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2016
VL 22
IS 6
BP 1090
EP 1093
DI 10.32032/eid2206.160062
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DN0YY
UT WOS:000376794200022
PM 27071041
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Oliveira, RAD
   da Silva, MMC
   Calzavara-Silva, CE
   Silva, AM
   Cordeiro, MT
   de Moura, PMMF
   Baptista, PN
   Marques, ETD
   Gil, LHVG
AF dos Santos Oliveira, Renato Antonio
   Carneiro da Silva, Mayara Marques
   Calzavara-Silva, Carlos Eduardo
   Silva, Ana Maria
   Cordeiro, Marli Tenorio
   Mendes Freire de Moura, Patricia Muniz
   Baptista Filho, Paulo Neves
   de Azevedo Marques Junior, Ernesto Torres
   Vega Gonzales Gil, Laura Helena
TI Primary dengue haemorrhagic fever in patients from northeast of Brazil
   is associated with high levels of interferon-beta during acute phase
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue fever; dengue haemorrhagic fever; type I interferon; innate
   immunity
ID VIRUS-INFECTION; DISEASE SEVERITY; ANTIBODY-RESPONSE; ALPHA PRODUCTION;
   CELL-LINES; IN-VITRO; EXPRESSION; CYTOKINES; VIREMIA; GAMMA
AB Dengue is an acute febrile disease caused by the mosquito-borne dengue virus (DENV) that according to clinical manifestations can be classified as asymptomatic, mild or severe dengue. Severe dengue cases have been associated with an unbalanced immune response characterised by an over secretion of inflammatory cytokines. In the present study we measured type I interferon (IFN-I) transcript and circulating levels in primary and secondary DENV infected patients. We observed that dengue fever (DF) and dengue haemorrhagic fever (DHF) patients express IFN-I differently. While DF and DHF patients express interferon-a similarly (52,71 +/- 7,40 and 49,05 +/- 7,70, respectively), high levels of circulating IFN-beta were associated with primary DHF patients. On the other hand, secondary DHF patients were not able to secrete large amounts of IFN-beta which in turn may have influenced the high-level of viraemia. Our results suggest that, in patients from our cohort, infection by DENV serotype 3 elicits an innate response characterised by higher levels of IFN-beta in the DHF patients with primary infection, which could contribute to control infection evidenced by the low-level of viraemia in these patients. The present findings may contribute to shed light in the role of innate immune response in dengue pathogenesis.
C1 [dos Santos Oliveira, Renato Antonio; Carneiro da Silva, Mayara Marques; Silva, Ana Maria; Cordeiro, Marli Tenorio; de Azevedo Marques Junior, Ernesto Torres; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [Calzavara-Silva, Carlos Eduardo] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Dept Imunol, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
   [de Azevedo Marques Junior, Ernesto Torres] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Mendes Freire de Moura, Patricia Muniz] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Baptista Filho, Paulo Neves] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Oliveira, Renato/AAN-9879-2020; Oliveira, Renato/A-2863-2013; Oliveira,
   Renato/AAN-9394-2020; Marques, Ernesto T. A/L-4967-2013
OI Oliveira, Renato/0000-0002-4044-0794; Oliveira,
   Renato/0000-0002-4044-0794; Marques, Ernesto T. A/0000-0003-3826-9358;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU NIAID/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI56541, N01 AI 40085]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [CNPq-550140/2010-7, CNPq-404453/2012-0]; FACEPE [APQ-1516-4.01/10];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, U19AI056541, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, U19AI056541, R21AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   R01AI040085] Funding Source: NIH RePORTER
FX NIAID/NIH (grants U19 AI56541 and N01 AI 40085), CNPq (grants
   CNPq-550140/2010-7 and CNPq-404453/2012-0 (RASO's visiting research
   fellowship)), FACEPE (grant APQ-1516-4.01/10 (MTC's research
   fellowship)). RASO and MMCS contributed equally to this work.
CR Aguirre S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002934
   Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Applied Biosystems, 2010, APPL BIOS US B
   Applied Biosystems, 2012, AMPL EFF TAQMANR GEN
   Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Back Anne Tuiskunen, 2013, Infect Ecol Epidemiol, V3, DOI 10.3402/iee.v3i0.19839
   Becquart P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-356
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Chen HW, 2013, J IMMUNOL, V191, P4194, DOI 10.4049/jimmunol.1300799
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Hernandez SID, 2014, J CLIN VIROL, V60, P196, DOI 10.1016/j.jcv.2014.04.002
   Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000
   Dong T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001192
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Halstead SB, 1988, J CHALL MOL BIO, V239, P476, DOI DOI 10.1126/SCIENCE.3277268
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Jones M, 2005, J VIROL, V79, P5414, DOI 10.1128/JVI.79.9.5414-5420.2005
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Li YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055108
   Liang ZD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023346
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Messina JP, 2015, NAT REV MICROBIOL, V13, P230, DOI 10.1038/nrmicro3430
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   Reis SRNI, 2007, MEM I OSWALDO CRUZ, V102, P983, DOI 10.1590/S0074-02762007000800014
   Torres REP, 2016, J MED VIROL, V88, P395, DOI 10.1002/jmv.24343
   Pozner FG, 2010, PLOS PATHOG, V6, P1
   Pozo-Aguilar JO, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0590-7
   Priyadarshini D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008709
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Ross TM, 2010, CLIN LAB MED, V30, P149, DOI 10.1016/j.cll.2009.10.007
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835
   Tang YQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012644
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   World Health Organization, 2009, DENG GUID DIAGN TREA
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Wu SY, 2013, J INFECTION, V67, P329, DOI 10.1016/j.jinf.2013.05.003
   Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023
NR 51
TC 11
Z9 10
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUN
PY 2016
VL 111
IS 6
BP 378
EP 384
DI 10.1590/0074-02760150453
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DQ0LC
UT WOS:000378889800004
PM 27223651
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Bayer, A
   Lennemann, NJ
   Ouyang, YS
   Bramley, JC
   Morosky, S
   Marques, ETD
   Cherry, S
   Sadovsky, Y
   Coyne, CB
AF Bayer, Avraham
   Lennemann, Nicholas J.
   Ouyang, Yingshi
   Bramley, John C.
   Morosky, Stefanie
   De Azeved Marques, Ernesto Torres, Jr.
   Cherry, Sara
   Sadovsky, Yoel
   Coyne, Carolyn B.
TI Type III Interferons Produced by Human Placental Trophoblasts Confer
   Protection against Zika Virus Infection
SO CELL HOST & MICROBE
LA English
DT Article
ID IN-VITRO; LAMBDA; BRAIN; DIFFERENTIATION; BRAZIL; CELLS
AB During mammalian pregnancy, the placenta acts as a barrier between the maternal and fetal compartments. The recently observed association between Zika virus (ZIKV) infection during human pregnancy and fetal microcephaly and other anomalies suggests that ZIKV may bypass the placenta to reach the fetus. This led us to investigate ZIKV infection of primary human trophoblasts (PHTs), which are the barrier cells of the placenta. We discovered that PHT cells from full-term placentas are refractory to ZIKV infection. In addition, medium from uninfected PHT cells protects non-placental cells from ZIKV infection. PHT cells constitutively release the type III interferon (IFN) IFN lambda 1, which functions in both a paracrine and autocrine manner to protect trophoblast and non-trophoblast cells from ZIKV infection. Our data suggest that for ZIKV to access the fetal compartment, it must evade restriction by trophoblast- derived IFNl1 and other trophoblast-specific antiviral factors and/or use alternative strategies to cross the placental barrier.
C1 [Bayer, Avraham; Ouyang, Yingshi; Sadovsky, Yoel; Coyne, Carolyn B.] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
   [Bayer, Avraham; Ouyang, Yingshi; Sadovsky, Yoel; Coyne, Carolyn B.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.
   [Lennemann, Nicholas J.; Bramley, John C.; Morosky, Stefanie; Sadovsky, Yoel; Coyne, Carolyn B.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA 15219 USA.
   [De Azeved Marques, Ernesto Torres, Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [De Azeved Marques, Ernesto Torres, Jr.] Fundacao Osvaldo Cruz FIOCRUZ, BR-50670420 Recife, PE, Brazil.
   [Cherry, Sara] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.
RP Sadovsky, Y; Coyne, CB (corresponding author), Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15213 USA.; Sadovsky, Y; Coyne, CB (corresponding author), Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.; Sadovsky, Y; Coyne, CB (corresponding author), Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA 15219 USA.
EM ysadovsky@mwri.magee.edu; coynec2@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Bramley,
   John/0000-0003-4312-5279
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-AI081759, R01-HD075665,
   T32-AI049820]; Burroughs Wellcome Investigators in the Pathogenesis of
   Infectious Disease Awards; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF
   CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [R01HD075665, R01HD075665, R01HD075665, R01HD075665,
   R01HD075665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI095500, R01AI074951,
   R01AI074951, T32AI049820, T32AI049820, R01AI074951, T32AI049820,
   R01AI074951, R01AI081759, R01AI074951, R01AI081759, R01AI081759,
   R01AI074951, T32AI049820, T32AI049820, R01AI095500, R01AI081759,
   T32AI049820, T32AI049820, T32AI049820, R01AI095500, T32AI049820,
   T32AI049820, R01AI081759, T32AI049820, T32AI049820, R01AI074951,
   R01AI074951, R01AI095500, R01AI081759, R01AI081759, R01AI074951,
   R01AI074951, T32AI049820, T32AI049820, T32AI049820, R01AI081759,
   R01AI074951, R01AI081759, T32AI049820] Funding Source: NIH RePORTER
FX We thank Saumendra Sarkar and Donald Burke (University of Pittsburgh)
   for reagents and/or advice, Ted Pierson (NIH/NIAID) and Margaret Kielian
   (Albert Einstein College of Medicine) for DENV reagents, and Kwang Sik
   Kim (Johns Hopkins University) for the HBMECs used in the study. This
   project was supported by NIH R01-AI081759 (C.B.C.), NIH R01-HD075665
   (C.B.C. and Y.S.), and T32-AI049820 (N.J.L.). In addition, C.B.C. and
   S.C. are supported by Burroughs Wellcome Investigators in the
   Pathogenesis of Infectious Disease Awards.
CR Ansarah-Sobrinho C, 2008, VIROLOGY, V381, P67, DOI 10.1016/j.virol.2008.08.021
   Bazer FW, 1996, AM J REPROD IMMUNOL, V35, P297
   Bierne H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039080
   Brasil P, 2016, N ENGL J MED
   Calvet G, 2016, LANCET INFECT DIS
   Cauchemez S, 2016, LANCET
   Delorme-Axford E, 2013, P NATL ACAD SCI USA, V110, P12048, DOI 10.1073/pnas.1304718110
   Gad HH, 2009, J BIOL CHEM, V284, P20869, DOI 10.1074/jbc.M109.002923
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lazear HM, 2015, IMMUNITY, V43, P15, DOI 10.1016/j.immuni.2015.07.001
   Lazear HM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4304
   LEFEVRE F, 1993, J BIOL CHEM, V268, P19760
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Maltepe E, 2010, J CLIN INVEST, V120, P1016, DOI 10.1172/JCI41211
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   McConkey CA, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501462
   MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   MORRISH DW, 1987, J CLIN ENDOCR METAB, V65, P1282, DOI 10.1210/jcem-65-6-1282
   Payne AF, 2006, J VIROL METHODS, V134, P183, DOI 10.1016/j.jviromet.2006.01.003
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Shu Q, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005150
   Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017
   Stins MF, 2001, MICROB PATHOGENESIS, V30, P19, DOI 10.1006/mpat.2000.0406
   Thirkill TL, 1997, J CELL BIOCHEM, V65, P460, DOI 10.1002/(SICI)1097-4644(19970615)65:4<460::AID-JCB2>3.0.CO;2-M
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7
NR 34
TC 263
Z9 268
U1 0
U2 66
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD MAY 11
PY 2016
VL 19
IS 5
BP 705
EP 712
DI 10.1016/j.chom.2016.03.008
PG 8
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA DL4HR
UT WOS:000375595500020
PM 27066743
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Cordeiro, MT
   Pena, LJ
   Brito, CA
   Gil, LH
   Marques, ET
AF Cordeiro, Marli Tenorio
   Pena, Lindomar J.
   Brito, Carlos A.
   Gil, Laura H.
   Marques, Ernesto T.
TI Positive IgM for Zika virus in the cerebrospinal fluid of 30 neonates
   with microcephaly in Brazil
SO LANCET
LA English
DT Letter
C1 [Cordeiro, Marli Tenorio; Pena, Lindomar J.; Gil, Laura H.; Marques, Ernesto T.] Fiocruz MS, Dept Virol, Ctr Pesquisas Aggeu Magalhaes CPqAM, BR-50670420 Recife, PE, Brazil.
   [Brito, Carlos A.] Univ Fed Pernambuco, Dept Clin Med, Recife, PE, Brazil.
   [Marques, Ernesto T.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Cordeiro, MT (corresponding author), Fiocruz MS, Dept Virol, Ctr Pesquisas Aggeu Magalhaes CPqAM, BR-50670420 Recife, PE, Brazil.
EM marli@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR Carrolla ID, 2007, TRAVEL MED INFECT DI, V5, P3183
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747
   World Health Organisation, 2016, WHO DIR GEN SUMM OUT
NR 4
TC 83
Z9 83
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD APR 30
PY 2016
VL 387
IS 10030
BP 1811
EP 1812
DI 10.1016/S0140-6736(16)30253-7
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DK6SS
UT WOS:000375056100017
PM 27103126
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Adibi, JJ
   Marques, ETA
   Cartus, A
   Beigi, RH
AF Adibi, Jennifer J.
   Marques, Ernesto T. A., Jr.
   Cartus, Abigail
   Beigi, Richard H.
TI Teratogenic effects of the Zika virus and the role of the placenta
SO LANCET
LA English
DT Article
ID CEREBRAL-CORTEX; HUMAN FETUS; INFECTION; CELLS; PATHOGENESIS;
   ABNORMALITIES; EXOSOMES; STEM
AB The mechanism by which the Zika virus can cause fetal microcephaly is not known. Reports indicate that Zika is able to evade the normal immunoprotective responses of the placenta. Microcephaly has genetic causes, some associated with maternal exposures including radiation, tobacco smoke, alcohol, and viruses. Two hypotheses regarding the role of the placenta are possible: one is that the placenta directly conveys the Zika virus to the early embryo or fetus. Alternatively, the placenta itself might be mounting a response to the exposure; this response might be contributing to or causing the brain defect. This distinction is crucial to the diagnosis of fetuses at risk and the design of therapeutic strategies to prevent Zika-induced teratogenesis.
C1 [Adibi, Jennifer J.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
   [Adibi, Jennifer J.; Beigi, Richard H.] Univ Pittsburgh, Dept Obstet & Gynecol & Reprod Sci, Pittsburgh, PA USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Marques, Ernesto T. A., Jr.] Oswaldo Cruz Fdn Fiocruz, Res Ctr Aggeu Magalhaes CPqAM, Recife, PE, Brazil.
   [Cartus, Abigail] Univ Texas Hlth Sci Ctr Houston, Epidemiol Human Genet & Environm Sci, Sch Publ Hlth, Houston, TX 77030 USA.
RP Adibi, JJ (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA.
EM adibij@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Adibi, Jennifer/I-8077-2016
OI Marques, Ernesto T. A/0000-0003-3826-9358; Adibi,
   Jennifer/0000-0001-6562-8315
CR Adibi JJ, 2015, J CLIN ENDOCR METAB, V100, pE1216, DOI 10.1210/jc.2015-2370
   Blazquez AB, 2014, FRONT MICROBIOL, V5, DOI [10.3389/fmicb.2014.00797, 10.3389/fmicb.2014.00266]
   Burton GJ, 2001, PLACENTA, V22, pS70, DOI 10.1053/plac.2001.0639
   Calvet G, 2016, LANCET INFECT DIS
   Cardenas I, 2010, J IMMUNOL, V185, P1248, DOI 10.4049/jimmunol.1000289
   Chahar HS, 2015, VIRUSES-BASEL, V7, P3204, DOI 10.3390/v7062770
   DEKABAN AS, 1968, J NUCL MED, V9, P471
   Delorme-Axford E, 2013, P NATL ACAD SCI USA, V110, P12048, DOI 10.1073/pnas.1304718110
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Fuchs R, 2004, TRAFFIC, V5, P725, DOI 10.1111/j.1600-0854.2004.00221.x
   Gabrielli L, 2009, J CLIN VIROL, V46, pS16, DOI 10.1016/j.jcv.2009.09.026
   Garcez PP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7474
   Gilmore EC, 2013, WIRES DEV BIOL, V2, P461, DOI 10.1002/wdev.89
   HADEED AJ, 1989, PEDIATRICS, V84, P205
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Homem CCF, 2015, NAT REV NEUROSCI, V16, P647, DOI 10.1038/nrn4021
   KENNEDY LA, 1984, TERATOLOGY, V29, P363, DOI 10.1002/tera.1420290306
   Leviton A, 2010, EARLY HUM DEV, V86, P515, DOI 10.1016/j.earlhumdev.2010.07.001
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Montiel JF, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00022
   MOSTOUFIZADEH M, 1984, ARCH PATHOL LAB MED, V108, P403
   Nascimento EJM, 2014, CRIT REV IMMUNOL, V34, P227, DOI 10.1615/CritRevImmunol.2014010212
   Pulyers JN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00092
   Sabapatha A, 2006, AM J REPROD IMMUNOL, V56, P345, DOI 10.1111/j.1600-0897.2006.00435.x
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   Sun T, 2014, NAT REV NEUROSCI, V15, P217, DOI 10.1038/nrn3707
   TOTH FD, 1994, CLIN EXP IMMUNOL, V96, P389, DOI 10.1111/j.1365-2249.1994.tb06040.x
   Zhang Q, 2012, J BIOL CHEM, V287, P40525, DOI 10.1074/jbc.M112.384446
NR 29
TC 97
Z9 103
U1 0
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD APR 9
PY 2016
VL 387
IS 10027
BP 1587
EP 1590
DI 10.1016/S0140-6736(16)00650-4
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DI8HH
UT WOS:000373741600034
PM 26952548
OA Bronze, Green Published
DA 2020-12-16
ER

PT J
AU Miranda, DD
   Martelli, CMT
   Ximenes, RAD
   Araujo, TVB
   Rocha, MAW
   Ramos, RCF
   Dhalia, R
   Franca, RFD
   Marques, ETD
   Rodrigues, LC
AF Miranda-Filho, Democrito de Barros
   Turchi Martelli, Celina Maria
   de Alencar Ximenes, Ricardo Arraes
   Barreto Araujo, Thalia Velho
   Wanderley Rocha, Maria Angela
   Ferreira Ramos, Regina Coeli
   Dhalia, Rafael
   de Oliveira Franca, Rafael Freitas
   de Azevedo Marques Junior, Ernesto Torres
   Rodrigues, Laura Cunha
TI Initial Description of the Presumed Congenital Zika Syndrome
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID VIRUS; INFECTIONS; BRAZIL
AB Objectives. To provide an initial description of the congenital syndrome presumably associated with infection by Zika virus compared with other syndromes including congenital infections of established etiologies.
   Methods. We provide an overview of a published case series of 35 cases, a clinical series of 104 cases, and published and unpublished reports of clinical and laboratory findings describing cases diagnosed since the beginning of the epidemic of microcephaly in Brazil.
   Results. About 60% to 70% of mothers report rash during pregnancy; mainly in the first trimester. Principal features are microcephaly, facial disproportionality, cutis girata, hypertonia/spasticity, hyperreflexia, and irritability; abnormal neuroimages include calcifications, ventriculomegaly, and lissencephaly. Hearing and visual abnormalities may be present.
   Conclusions. Preliminary data suggest that severe congenital abnormalities are linked to Zika virus infection. Cases have severe abnormalities, and although sharing many characteristics with congenital abnormalities associated with other viral infections, abnormalities presumably linked to the Zika virus may have distinguishing characteristics. These severe neurologic abnormalities may result in marked mental retardation and motor disabilities for many surviving offspring.
   Policy Implications. Affected nations need to prepare to provide complex and costly multidisciplinary care that children diagnosed with this new congenital syndrome will require.
C1 [Miranda-Filho, Democrito de Barros; de Alencar Ximenes, Ricardo Arraes; Wanderley Rocha, Maria Angela; Ferreira Ramos, Regina Coeli] Univ Pernambuco, Recife, PE, Brazil.
   [Turchi Martelli, Celina Maria; Dhalia, Rafael; de Oliveira Franca, Rafael Freitas; de Azevedo Marques Junior, Ernesto Torres] Fiocruz MS, Oswaldo Cruz Fdn, Res Ctr Aggeu Magalhaes CPqAM, Recife, PE, Brazil.
   [de Alencar Ximenes, Ricardo Arraes; Barreto Araujo, Thalia Velho] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Rodrigues, Laura Cunha] London Sch Hyg & Trop Med, London WC1, England.
RP Miranda, DD (corresponding author), Rua Arnobio Marques 310, BR-50100130 Recife, PE, Brazil.
EM demofilho@gmail.com
RI Marques, Ernesto T. A/L-4967-2013; Dhalia, Rafael/AAD-5432-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688
FU Brazilian Ministry of Health, Pernambuco State Health Department
   (SES-PE); Pan American Health Organization; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPqNational Council for
   Scientific and Technological Development (CNPq) [306489/2010-4,
   308311/2009-4, 308590/2013-9]; Medical Research CouncilMedical Research
   Council UK (MRC) [MC_PC_15088] Funding Source: researchfish
FX We thank the support of the Brazilian Ministry of Health, Pernambuco
   State Health Department (SES-PE) and Pan American Health Organization.
   The authors received partial support from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq (scholarship
   306489/2010-4 to C. M. T. M., 308311/2009-4 to R. A. A. X.,
   308590/2013-9 to D. B. M. F.).
CR Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Brazilian Ministry of Health, 10 BRAZ MIN HLTH
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   John CC, 2015, NATURE, V527, pS178, DOI 10.1038/nature16033
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
NR 8
TC 147
Z9 153
U1 1
U2 25
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2016
VL 106
IS 4
BP 598
EP 600
DI 10.2105/AJPH.2016.303115
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DL8SY
UT WOS:000375913000013
PM 26959258
OA Green Published
DA 2020-12-16
ER

PT J
AU Jaenisch, T
   Tam, DTH
   Kieu, NTT
   Ngoc, TV
   Nam, NT
   Kinh, NV
   Yacoub, S
   Chanpheaktra, N
   Kumar, V
   See, LLC
   Sathar, J
   Sandoval, EP
   Alfaro, GMM
   Laksono, IS
   Mahendradhata, Y
   Sarker, M
   Ahmed, F
   Caprara, A
   Benevides, BS
   Marques, ETA
   Magalhaes, T
   Brasil, P
   Netto, M
   Tami, A
   Bethencourt, SE
   Guzman, M
   Simmons, C
   Quyen, NTH
   Merson, L
   Dung, NTP
   Beck, D
   Wirths, M
   Wolbers, M
   Lam, PK
   Rosenberger, K
   Wills, B
AF Jaenisch, Thomas
   Dong Thi Hoai Tam
   Nguyen Tan Thanh Kieu
   Tran Van Ngoc
   Nguyen Tran Nam
   Nguyen Van Kinh
   Yacoub, Sophie
   Chanpheaktra, Ngoun
   Kumar, Varun
   See, Lucy Lum Chai
   Sathar, Jameela
   Sandoval, Ernesto Pleites
   Maron Alfaro, Gabriela Maria
   Laksono, Ida Safitri
   Mahendradhata, Yodi
   Sarker, Malabika
   Ahmed, Firoz
   Caprara, Andrea
   Benevides, Bruno Souza
   Marques, Ernesto T. A.
   Magalhaes, Tereza
   Brasil, Patricia
   Netto, Marco
   Tami, Adriana
   Bethencourt, Sarah E.
   Guzman, Maria
   Simmons, Cameron
   Nguyen Thanh Ha Quyen
   Merson, Laura
   Nguyen Thi Phuong Dung
   Beck, Dorothea
   Wirths, Marius
   Wolbers, Marcel
   Phung Khanh Lam
   Rosenberger, Kerstin
   Wills, Bridget
TI Clinical evaluation of dengue and identification of risk factors for
   severe disease: protocol for a multicentre study in 8 countries
SO BMC INFECTIOUS DISEASES
LA English
DT Review
DE Dengue; Asia; Latin America; Diagnosis; Risk prediction; Pathogenesis
ID HEMORRHAGIC-FEVER; PROTEIN NS1; ANTIBODY-RESPONSE; SHOCK SYNDROME;
   VIRUS; CLASSIFICATION; INFECTIONS; VIREMIA; CORRELATE; CHILDREN
AB Background: The burden of dengue continues to increase globally, with an estimated 100 million clinically apparent infections occurring each year. Although most dengue infections are asymptomatic, patients can present with a wide spectrum of clinical symptoms ranging from mild febrile illness through to severe manifestations of bleeding, organ impairment, and hypovolaemic shock due to a systemic vascular leak syndrome. Clinical diagnosis of dengue and identification of which patients are likely to develop severe disease remain challenging. This study aims to improve diagnosis and clinical management through approaches designed a) to differentiate between dengue and other common febrile illness within 72 h of fever onset, and b) among patients with dengue to identify markers that are predictive of the likelihood of evolving to a more severe disease course.
   Method/Design: This is a prospective multi-centre observational study aiming to enrol 7-8000 participants aged >= 5 years presenting with a febrile illness consistent with dengue to outpatient health facilities in 8 countries across Asia and Latin America. Patients presenting within 72 h of fever onset who do not exhibit signs of severe disease are eligible for the study. A broad range of clinical and laboratory parameters are assessed daily for up to 6 days during the acute illness, and also at a follow up visit 1 week later.
   Discussion: Data from this large cohort of patients, enrolled early with undifferentiated fever, will be used to develop a practical diagnostic algorithm and a robust clinical case definition for dengue. Additionally, among patients with confirmed dengue we aim to identify simple clinical and laboratory parameters associated with progression to a more severe disease course. We will also investigate early virological and serological correlates of severe disease, and examine genetic associations in this large heterogeneous cohort. In addition the results will be used to assess the new World Health Organization classification scheme for dengue in practice, and to update the guidelines for "Integrated Management of Childhood Illness" used in dengue-endemic countries.
C1 [Jaenisch, Thomas; Beck, Dorothea; Wirths, Marius; Rosenberger, Kerstin] Univ Heidelberg Hosp, Sect Clin Trop Med, Heidelberg, Germany.
   [Dong Thi Hoai Tam; Nguyen Tan Thanh Kieu; Yacoub, Sophie; Simmons, Cameron; Nguyen Thanh Ha Quyen; Merson, Laura; Nguyen Thi Phuong Dung; Wolbers, Marcel; Phung Khanh Lam; Wills, Bridget] Univ Oxford, Clin Res Unit, 764 Vo Kiet St,Dist 5, Ho Chi Minh City, Vietnam.
   [Dong Thi Hoai Tam] Univ Med & Pharm Ho Chi Minh City, Ho Chi Minh City, Vietnam.
   [Tran Van Ngoc] Hosp Trop Dis, Ho Chi Minh City, Vietnam.
   [Nguyen Tran Nam] Childrens Hosp 2, Ho Chi Minh City, Vietnam.
   [Nguyen Van Kinh] Natl Hosp Trop Dis, Hanoi, Vietnam.
   [Yacoub, Sophie] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England.
   [Chanpheaktra, Ngoun; Kumar, Varun] Angkor Hosp Children, Siem Reap, Cambodia.
   [See, Lucy Lum Chai] Univ Malaya Med Ctr, Kuala Lumpur, Malaysia.
   [Sathar, Jameela] Ampang Hosp, Kuala Lumpur, Malaysia.
   [Sandoval, Ernesto Pleites; Maron Alfaro, Gabriela Maria] Hosp Nacl Ninos Benjamin Bloom, San Salvador, El Salvador.
   [Laksono, Ida Safitri; Mahendradhata, Yodi] Gadjah Mada Univ, Yogyakarta, Indonesia.
   [Sarker, Malabika] BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh.
   [Ahmed, Firoz] Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.
   [Caprara, Andrea; Benevides, Bruno Souza] Univ Estadual Ceara, Fortaleza, Ceara, Brazil.
   [Marques, Ernesto T. A.; Magalhaes, Tereza] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Brasil, Patricia] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Netto, Marco] Secretaria Municipal Saude Resende, Rio De Janeiro, Brazil.
   [Tami, Adriana] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Tami, Adriana; Bethencourt, Sarah E.] Univ Carabobo, Fac Ciencias Salud, Valencia, Venezuela.
   [Guzman, Maria] Inst Pedro Kouri, Havana, Cuba.
   [Simmons, Cameron] Univ Melbourne, Peter Doherty Inst, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
   [Merson, Laura; Wolbers, Marcel; Wills, Bridget] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
   [Kumar, Varun] Rwanda Mil Hosp, Kigali, Rwanda.
   [Kumar, Varun] Univ Rwanda Kigali, Kigali, Rwanda.
   [Maron Alfaro, Gabriela Maria] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
RP Wills, B (corresponding author), Univ Oxford, Clin Res Unit, 764 Vo Kiet St,Dist 5, Ho Chi Minh City, Vietnam.; Wills, B (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.
EM bwills@oucru.org
RI Caprara, Andrea/F-8399-2012; Caprara, Andrea/I-4011-2013; Marques,
   Ernesto T. A/L-4967-2013; Jaenisch, Thomas/H-3473-2017; Mahendradhata,
   Yodi/AAQ-9044-2020; Magalhaes, Tereza/V-6632-2019; Lam,
   Phung/AAW-4108-2020; Maron, Gabriela M./N-8091-2018; Caprara,
   Andrea/O-9522-2019; Lum, Lucy/Q-9871-2017
OI Caprara, Andrea/0000-0003-1972-8205; Caprara,
   Andrea/0000-0003-1972-8205; Marques, Ernesto T. A/0000-0003-3826-9358;
   Mahendradhata, Yodi/0000-0002-4522-1785; Lam, Phung/0000-0001-7968-473X;
   Maron, Gabriela M./0000-0001-5247-5399; Caprara,
   Andrea/0000-0003-1972-8205; Lum, Lucy/0000-0002-7452-4208; Yacoub,
   Sophie/0000-0002-2910-7819; Merson, Laura/0000-0002-4168-1960; Simmons,
   Cameron P./0000-0002-9039-7392; Tami, Adriana/0000-0002-1918-9144; ,
   Varun/0000-0003-4976-6229
FU EUEuropean Union (EU) [FP7-281803 IDAMS]
FX We are grateful to all the medical, nursing and laboratory staff
   involved in supporting the study across the various sites, as well as to
   the patients and their families for their willingness to participate. We
   also want to thank all those involved in the administration of the
   project - in particular Jaswinder Kaur and Thomas Wetter at Heidelberg
   University Hospital, and Sarah Barton at OUCRU. Furthermore, we are
   thankful to all the many institutions and health ministries in the
   participating countries who helped to make this study possible. This
   study is funded by EU grant FP7-281803 IDAMS (http://www.idams.eu/) and
   is designated with IDAMS publication reference number IDAMS 31.
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Alexander N, 2011, TROP MED INT HEALTH, V16, P936, DOI 10.1111/j.1365-3156.2011.02793.x
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Guzman MG, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000811
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Hastie T., 2009, ELEMENTS STAT LEARNI
   Khor CC, 2011, NAT GENET, V43, P1139, DOI 10.1038/ng.960
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   Murgue B, 2000, J MED VIROL, V60, P432, DOI 10.1002/(SICI)1096-9071(200004)60:4&lt;432::AID-JMV11&gt;3.0.CO;2-7
   Pepe MS, 1997, J AM STAT ASSOC, V92, P991, DOI 10.2307/2965563
   Phuong CXT, 2004, AM J TROP MED HYG, V70, P172, DOI 10.4269/ajtmh.2004.70.172
   Rigau-Perez J G, 1999, P R Health Sci J, V18, P347
   Rizopoulos D, 2011, BIOMETRICS, V67, P819, DOI 10.1111/j.1541-0420.2010.01546.x
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742
   Tricou V, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-142
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Whitehorn J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059067
   WHO, 1986, DENG HAEM FEV DIAGN
   Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057
   World Health Organization, 2009, DENG GUID DIAGN TREA
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   World Health Organization, 1975, TECHN GUID DIAGN TRE
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
NR 33
TC 29
Z9 29
U1 1
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAR 11
PY 2016
VL 16
AR 120
DI 10.1186/s12879-016-1440-3
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA DG0UA
UT WOS:000371780000002
PM 26968374
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Zamith-Miranda, D
   Palma, ML
   Matos, GS
   Schiebel, JG
   Maya-Monteiro, CM
   Aronovich, M
   Bozza, PT
   Bozza, FA
   Nimrichter, L
   Montero-Lomeli, M
   Marques, ETA
   Martins, FS
   Douradinha, B
AF Zamith-Miranda, Daniel
   Palma, Mariana L.
   Matos, Gabriel S.
   Schiebel, Johnathon G.
   Maya-Monteiro, Clarissa M.
   Aronovich, Marcos
   Bozza, Patricia T.
   Bozza, Fernando A.
   Nimrichter, Leonardo
   Montero-Lomeli, Monica
   Marques, Ernesto T. A., Jr.
   Martins, Flaviano S.
   Douradinha, Bruno
TI Lipid droplet levels vary heterogeneously in response to simulated
   gastrointestinal stresses in different probiotic Saccharomyces
   cerevisiae strains
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Saccharomyces cerevisiae var boulardii; Saccharomyces cerevisiae;
   Probiotics; Lipid droplets; Gastrointestinal tract stresses; Stress
   resistance
ID YEAST STRAINS; CELL-DEATH; BOULARDII; VIABILITY; LIPOLYSIS; PRODUCTS;
   IMMUNITY; SYSTEM; TRACT; S288C
AB To exert their therapeutic action, probiotic Saccharomyces cerevisiae strains must survive harsh digestive environments. Lipid droplets accumulate in cells which undergo stress-inducing situations, supposedly having a protective role. We assessed lipid droplet levels, either naturally accumulated or induced in response to digestive challenges, of probiotic strains S. boulardii, S. cerevisiae A-905, S. cerevisiae Sc47 and S. cerevisiae L11, and of non-probiotic strains S. cerevisiae BY4741 and S. cerevisiae BY4743. Strains 905 and Sc47 had lower and higher lipid droplet levels, respectively, when compared to the remaining strains, showing that higher accumulation of these neutral lipids is not a feature shared by all probiotic Saccharomyces strains. When submitted to simulated gastric or bile salts environments, lipid droplet levels increase in all tested probiotic strains, at least for one to the induced stresses, suggesting that lipid droplets participate in the protective mechanisms against gastrointestinal stresses in probiotic Saccharomyces yeasts. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Zamith-Miranda, Daniel; Nimrichter, Leonardo] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Lab Glicobiol Eucariotos, BR-21941590 Rio De Janeiro, RJ, Brazil.
   [Palma, Mariana L.] Univ Sao Paulo, Fac Med, Lab Dermatol & Imunodeficiencias, BR-05508070 Sao Paulo, SP, Brazil.
   [Palma, Mariana L.; Schiebel, Johnathon G.; Marques, Ernesto T. A., Jr.; Douradinha, Bruno] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Matos, Gabriel S.; Montero-Lomeli, Monica] Univ Fed Rio de Janeiro, Inst Bioquirn Med Leopoldo de Meis, BR-21941590 Rio De Janeiro, RJ, Brazil.
   [Maya-Monteiro, Clarissa M.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040360 Manguinho, RJ, Brazil.
   [Aronovich, Marcos] Pesagro Rio, BR-24120191 Niteroi, RJ, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Manguinho, RJ, Brazil.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz Pernambuco, Ctr Pesquisa Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50740465 Recife, PE, Brazil.
   [Martins, Flaviano S.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Douradinha, Bruno] Fdn RiMED, I-90133 Palermo, Italy.
RP Douradinha, B (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Room 9052, Pittsburgh, PA 15213 USA.
EM douradinha@pitt.edu
RI Douradinha, Bruno/R-5832-2017; Nimrichter, Leonardo/L-3545-2014;
   Marques, Ernesto T. A/L-4967-2013; Bozza, Fernando A/A-2618-2013;
   Zamith-Miranda, Daniel/E-8877-2013
OI Nimrichter, Leonardo/0000-0001-9281-6856; Marques, Ernesto T.
   A/0000-0003-3826-9358; Bozza, Fernando A/0000-0003-4878-0256;
   Zamith-Miranda, Daniel/0000-0001-7532-2432; Soares Matos,
   Gabriel/0000-0001-8806-6212; Douradinha, Bruno/0000-0002-9980-4505;
   Martins, Flaviano/0000-0003-0741-3062; Bozza,
   Patricia/0000-0001-8349-9529
FU Conselho Nacional de Ciencia e Tecnologia (CNPq; Brasilia, DF, Brazil);
   Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Rio de Janeiro,
   RJ, Brazil); Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG,
   Belo Horizonte, MG, Brazil); Fondazione RiMED (Palermo, PA, Italy);
   FAPERJ Cientistas do Nosso Estado grant; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX We thank Professor Claudio A. Masuda from Universidade Federal do Rio de
   Janeiro, Brazil, for critically reviewing this manuscript and helpful
   scientific discussions, Stefan Lamers for manuscript editing and Jens
   Rietdorf (CAPES/CTDS) for technical assistance. This work was supported
   by grants from Conselho Nacional de Ciencia e Tecnologia (CNPq;
   Brasilia, DF, Brazil), Fundacao de Amparo a Pesquisa do Rio de Janeiro
   (FAPERJ, Rio de Janeiro, RJ, Brazil), Fundacao de Amparo a Pesquisa de
   Minas Gerais (FAPEMIG, Belo Horizonte, MG, Brazil) and Fondazione RiMED
   (Palermo, PA, Italy). MM-L is the recipient of a FAPERJ Cientistas do
   Nosso Estado grant. GSM is the recipient of a CNPq Iniciacao Cientifica
   fellowship. FSM is the recipient of a CNPq research fellowship. BD is a
   Fondazione RIMED Associate Scholar. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BLEHAUT H, 1989, BIOPHARM DRUG DISPOS, V10, P353, DOI 10.1002/bdd.2510100403
   Bourque Simon D, 2009, J Vis Exp, DOI 10.3791/1513
   Bozaquel-Morais BL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013692
   Brachmann CB, 1998, YEAST, V14, P115
   Cascio V, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-35
   Czabany T, 2008, J BIOL CHEM, V283, P17065, DOI 10.1074/jbc.M800401200
   Czerucka D, 2007, ALIMENT PHARM THER, V26, P767, DOI 10.1111/j.1365-2036.2007.03442.x
   Diosma G, 2014, WORLD J MICROB BIOT, V30, P43, DOI 10.1007/s11274-013-1419-9
   Douradinha B, 2014, BIOENGINEERED, V5, P21, DOI 10.4161/bioe.26271
   Edwards-Ingram L, 2007, APPL ENVIRON MICROB, V73, P2458, DOI 10.1128/AEM.02201-06
   EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012, EFSA J, V10, P2531, DOI [10.2903/j.efsa.2012.2531, DOI 10.2903/J.EFSA.2012.2531]
   Fei WH, 2009, BIOCHEM J, V424, P61, DOI 10.1042/BJ20090785
   FERNANDES PB, 1992, NEW APPROACHES ANTIF
   Ferraretto LF, 2012, J DAIRY SCI, V95, P4017, DOI 10.3168/jds.2011-5190
   Fietto JLR, 2004, CAN J MICROBIOL, V50, P615, DOI 10.1139/W04-050
   Garaiova M, 2014, FEMS YEAST RES, V14, P310, DOI 10.1111/1567-1364.12107
   Gaspar ML, 2008, J BIOL CHEM, V283, P25735, DOI 10.1074/jbc.M802685200
   Graff S, 2008, J GEN APPL MICROBIOL, V54, P221, DOI 10.2323/jgam.54.221
   Hapala I, 2011, BIOL CELL, V103, P271, DOI 10.1042/BC20100144
   Khor VK, 2013, CURR OPIN CLIN NUTR, V16, P632, DOI 10.1097/MCO.0b013e3283651106
   Kourelis A, 2010, J APPL MICROBIOL, V109, P260, DOI 10.1111/j.1365-2672.2009.04651.x
   Kuhle AVDA, 2005, INT J FOOD MICROBIOL, V101, P29, DOI 10.1016/j.ijfoodmicro.2004.10.039
   Kurat CF, 2006, J BIOL CHEM, V281, P491, DOI 10.1074/jbc.M508414200
   Madeira JB, 2015, MOL CELL BIOL, V35, P737, DOI 10.1128/MCB.01314-14
   Martinez M, 2002, ADV DRUG DELIVER REV, V54, P825, DOI 10.1016/S0169-409X(02)00071-6
   Montanes FM, 2011, MOL MICROBIOL, V79, P1008, DOI 10.1111/j.1365-2958.2010.07502.x
   Martins FS, 2009, LETT APPL MICROBIOL, V49, P738, DOI 10.1111/j.1472-765X.2009.02732.x
   Martins FS, 2005, J GEN APPL MICROBIOL, V51, P83, DOI 10.2323/jgam.51.83
   Palma ML, 2015, APPL MICROBIOL BIOT, V99, P6563, DOI 10.1007/s00253-015-6776-x
   Perez-Sotelo Luis Salvador, 2005, Rev Latinoam Microbiol, V47, P70
   Perricone M, 2014, FOOD MICROBIOL, V38, P26, DOI 10.1016/j.fm.2013.08.006
   Saka HA, 2012, ANNU REV CELL DEV BI, V28, P411, DOI 10.1146/annurev-cellbio-092910-153958
   Sant'Ana GD, 2009, FEMS YEAST RES, V9, P701, DOI 10.1111/j.1567-1364.2009.00523.x
   Schmidt C, 2013, METHOD CELL BIOL, V116, P15, DOI 10.1016/B978-0-12-408051-5.00002-4
   Stovicek Vratislav, 2015, Metabolic Engineering Communications, V2, P13, DOI 10.1016/j.meteno.2015.03.001
   Vieira AT, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00445
   WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107
   Zanello G, 2013, VET IMMUNOL IMMUNOP, V152, P20, DOI 10.1016/j.vetimm.2012.09.023
   Zanghellini J, 2008, FEBS J, V275, P5552, DOI 10.1111/j.1742-4658.2008.06681.x
NR 39
TC 4
Z9 4
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD MAR
PY 2016
VL 21
BP 193
EP 200
DI 10.1016/j.jff.2015.12.013
PG 8
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA DF3XO
UT WOS:000371281900019
OA Bronze
DA 2020-12-16
ER

PT J
AU Viana, IFT
   Nascimento, E
   Craigo, J
   Krieger, M
   Mailliard, R
   Dhalia, R
   Lins, R
   Marques, ETA
AF Viana, Isabelle Freire Tabosa
   Nascimento, Eduardo
   Craigo, Jodi
   Krieger, Marco
   Mailliard, Robbie
   Dhalia, Rafael
   Lins, Roberto
   Marques, Ernesto T. A.
TI De Novo Design and Biophysical Characterization of an Affinity-Enhanced
   Protein Displaying the Structure of the Broadly Neutralizing HIV-1 2F5
   Antibody Epitope
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the Biophysical-Society
CY FEB 27-MAR 02, 2016
CL Los Angeles, CA
SP Biophys Soc
C1 [Viana, Isabelle Freire Tabosa] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Viana, Isabelle Freire Tabosa; Mailliard, Robbie] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Nascimento, Eduardo; Craigo, Jodi; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
   [Krieger, Marco] Fiocruz MS, Carlos Chagas Inst, Curitiba, Parana, Brazil.
   [Dhalia, Rafael; Lins, Roberto] Fiocruz MS, Aggeu Magalhaes Inst, Recife, PE, Brazil.
RI Krieger, Marco/AAE-8611-2020; Marques, Ernesto T. A/L-4967-2013; Lins,
   Roberto D/J-7511-2012; Dhalia, Rafael/AAD-5432-2020; Mailiiard,
   Robbie/M-9723-2015
OI Marques, Ernesto T. A/0000-0003-3826-9358; Lins, Roberto
   D/0000-0002-3983-8025; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD FEB 16
PY 2016
VL 110
IS 3
SU 1
MA 1705-Plat
BP 346A
EP 346A
PG 1
WC Biophysics
SC Biophysics
GA DK7YE
UT WOS:000375142200175
DA 2020-12-16
ER

PT J
AU Braga, C
   de Albuquerque, MFPM
   Cordeiro, MT
   Castanha, PMS
   Ramesh, A
   Alexander, N
   de Mello, MJG
   Marques, ETA
   Martelli, CMT
AF Braga, Cynthia
   Pessoa Militao de Albuquerque, Maria de Fatima
   Cordeiro, Marli Tenorio
   Castanha, Priscila M. S.
   Ramesh, Anita
   Alexander, Neal
   de Mello, Maria Julia G.
   Marques, Ernesto T. A., Jr.
   Turchi Martelli, Celina M.
TI Prospective birth cohort in a hyperendemic dengue area in Northeast
   Brazil: methods and preliminary results
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE Passive Immunization; Dengue; Cohort Studies
ID VIRUS-INFECTIONS; HEMORRHAGIC-FEVER; FOLLOW-UP; ANTIBODIES; INFANTS;
   SEROTYPES; RESPONSES
AB Dengue cases have increased in younger age groups in Brazil. Maternal anti-dengue antibodies can have a protective effect in the first months of life, but their decline can increase the risk of severe dengue. A prospective birth cohort was established in 2011-2012 in the city of Recife, Pernambuco State, Brazil, to determine the incidence of serotype-specific dengue infection and the kinetics of transferred maternal anti-dengue antibodies in the first years of life. This article describes the design, methods and preliminary results of this cohort study. 354 children underwent clinical and laboratory monitoring for two years, with 15% losses to follow-up. The overall rate of new infections was approximately 10% in the first year of follow-up. Information on the force of serotype-specific dengue infection and the evaluation of transferred maternal antibodies can contribute to understanding dengue etiopathogenesis.
C1 [Braga, Cynthia; Pessoa Militao de Albuquerque, Maria de Fatima; Cordeiro, Marli Tenorio; Castanha, Priscila M. S.; Marques, Ernesto T. A., Jr.; Turchi Martelli, Celina M.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Av Moraes Rego S-N, Recife, PE, Brazil.
   [Braga, Cynthia; de Mello, Maria Julia G.] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [Ramesh, Anita; Alexander, Neal] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Turchi Martelli, Celina M.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
RP Braga, C (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Av Moraes Rego S-N, Recife, PE, Brazil.
EM braga@cpqam.fiocruz.br
RI Braga, Maria Cynthia/A-8204-2013; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Marques, Ernesto T. A/L-4967-2013
OI Braga, Maria Cynthia/0000-0002-7862-6455; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Marques, Ernesto T. A/0000-0003-3826-9358;
   Turchi Martelli, Celina Maria/0000-0002-2491-0688
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [304174/2014-9,
   308491/2013-0, 306489/2010-4]; United Kingdom Medical Research Council
   (MRC)Medical Research Council UK (MRC); Department for International
   Development (DFID) [MR/K012126/1]; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/K012126/1] Funding Source: researchfish
FX The authors of this study would like to thank Dr. Clarence Tam and Dr.
   Lyda Osorio for their methodological input during the inception of this
   cohort. We would also like to thank the Brazilian National Research
   Council (CNPq), which provided financial support to C. Braga
   (304174/2014-9), M. F. P. M. Albuquerque (308491/2013-0), and C. M. T.
   Martelli (306489/2010-4). N. Alexander receives salary support from the
   United Kingdom Medical Research Council (MRC) and the Department for
   International Development (DFID) (MR/K012126/1).
CR [Anonymous], 2013, DENG DIAGN MAN CLIN
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Endy TP, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00183
   Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316
   Gordon A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002462
   Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Kassanjee R, 2014, AIDS RES HUM RETROV, V30, P45, DOI [10.1089/aid.2013.0113, 10.1089/AID.2013.0113]
   Kirkwood BR, 2003, ESSENTIAL MED STAT
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Kristman V, 2004, EUR J EPIDEMIOL, V19, P751, DOI 10.1023/B:EJEP.0000036568.02655.f8
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Leite RC, 2014, J CLIN VIROL, V60, P16, DOI [10.1016/j.jcv.2014.02.009, 10.1016/J.JCV.2014.02.009]
   Libraty DH, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000171
   Messina JP, 2014, TRENDS MICROBIOL, V22, P138, DOI 10.1016/j.tim.2013.12.011
   MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985
   Morrison AC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000670
   Peeling RW, 2010, NAT REV MICROBIOL, pS30, DOI 10.1038/nrmicro2459
   Pengsaa K, 2006, J INFECT DIS, V194, P1570, DOI 10.1086/508492
   Prince HE, 2011, CLIN VACCINE IMMUNOL, V18, P2183, DOI 10.1128/CVI.05425-11
   Rodriguez-Barraquer I, 2011, PLOS NEGLECT TROP D, V7, pe2126
   Simmons CP, 2007, J INFECT DIS, V196, P416, DOI 10.1086/519170
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Tran NBC, 2009, J INFECT DIS, V200, P1893, DOI 10.1086/648407
   UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 2009, DIAGN EV SER, V3
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Villabona-Arenas CJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002620
   WHO, 2012, GLOB STRAT DENG PREV
   Woods CR, 2013, J PEDIATR INFECT DIS, V2, P87, DOI 10.1093/jpids/pis133
   Yoon IK, 2012, J INFECT DIS, V206, P389, DOI 10.1093/infdis/jis357
NR 31
TC 5
Z9 5
U1 0
U2 1
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PD JAN
PY 2016
VL 32
IS 1
AR e00095815
DI 10.1590/0102-311X00095815
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DF7WY
UT WOS:000371569700005
PM 26886185
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Castanha, PMD
   Nascimento, EJ
   Cordeiro, MT
   Souza, AI
   Silva, CD
   Panhuis, WG
   Martelli, CT
   Marques, ET
   Braga, C
AF Da Silva Castanha, Priscila M.
   Nascimento, Eduardo J.
   Cordeiro, Marli T.
   Souza, Ariani I.
   Silva, Claudeir D., Jr.
   Panhuis, Willem G.
   Martelli, Celina T.
   Marques, Ernesto T., Jr.
   Braga, Cynthia
TI INFLUENCE OF MATERNAL IGG PROFILE ON PLACENTAL TRANSFER OF DENGUE
   VIRUS-SPECIFIC ANTIBODIES TO NEONATES
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Da Silva Castanha, Priscila M.; Cordeiro, Marli T.; Braga, Cynthia] Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Nascimento, Eduardo J.; Marques, Ernesto T., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Souza, Ariani I.; Silva, Claudeir D., Jr.] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [Panhuis, Willem G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
   [Martelli, Celina T.] Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
RI Braga, Maria Cynthia/A-8204-2013; de Souza, Ariani
   Impieri/AAR-6884-2020; Marques, Ernesto T. A/L-4967-2013
OI Braga, Maria Cynthia/0000-0002-7862-6455; de Souza, Ariani
   Impieri/0000-0002-7917-5983; Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2015
VL 93
IS 4
SU S
MA 150
BP 45
EP 46
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VB0ZJ
UT WOS:000412844101150
DA 2020-12-16
ER

PT J
AU Palma, ML
   Zamith-Miranda, D
   Martins, FS
   Bozza, FA
   Nimrichter, L
   Montero-Lomeli, M
   Marques, ETA
   Douradinha, B
AF Palma, Mariana L.
   Zamith-Miranda, Daniel
   Martins, Flaviano S.
   Bozza, Fernando A.
   Nimrichter, Leonardo
   Montero-Lomeli, Monica
   Marques, Ernesto T. A., Jr.
   Douradinha, Bruno
TI Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is
   there room for improvement?
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review
DE Probiotics; Saccharomyces cerevisiae; Saccharomyces cerevisiae var
   boulardii; Mechanisms of action; Expression of heterologous proteins
ID ESCHERICHIA-COLI; BACTERIAL TRANSLOCATION; ANTIBIOTIC-RESISTANCE;
   IMMUNE-SYSTEM; YEAST STRAINS; BOULARDII; GENE; GUT; TYPHIMURIUM;
   EXPRESSION
AB The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application.
C1 [Palma, Mariana L.] Univ Sao Paulo, Fac Med, Lab Dermatol & Imunodeficiencias, Sao Paulo, Brazil.
   [Palma, Mariana L.; Marques, Ernesto T. A., Jr.; Douradinha, Bruno] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15213 USA.
   [Zamith-Miranda, Daniel; Nimrichter, Leonardo] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil.
   [Martins, Flaviano S.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Montero-Lomeli, Monica] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz Pernambuco, Ctr Pesquisa Aggeu Magalhaes, Lab Virol & Terapia Expt, Recife, PE, Brazil.
   [Douradinha, Bruno] Fdn RiMED, Palermo, Italy.
RP Douradinha, B (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Room 9052, Pittsburgh, PA 15213 USA.
EM brd49@pitt.edu
RI Bozza, Fernando A/A-2618-2013; Douradinha, Bruno/R-5832-2017;
   Zamith-Miranda, Daniel/E-8877-2013; Marques, Ernesto T. A/L-4967-2013;
   Nimrichter, Leonardo/L-3545-2014
OI Bozza, Fernando A/0000-0003-4878-0256; Zamith-Miranda,
   Daniel/0000-0001-7532-2432; Marques, Ernesto T. A/0000-0003-3826-9358;
   Nimrichter, Leonardo/0000-0001-9281-6856; Martins,
   Flaviano/0000-0003-0741-3062; Douradinha, Bruno/0000-0002-9980-4505
FU Fondazione RiMED (Palermo, Italy); Fundacao para o Amparo da Pesquisa do
   Estado do Rio de Janeiro (FAPERJ, Rio de Janeiro, Brazil)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ)
FX We thank the reviewers for their helpful comments and suggestions. We
   are grateful to Professor Claudio A. Masuda, from Universidade Federal
   do Rio de Janeiro, Brazil, for critically reviewing this manuscript and
   helpful scientific discussions, and to Stefan Lamers, for English
   language editing of the manuscript. We thank the funding organisms
   Fondazione RiMED (Palermo, Italy) and Fundacao para o Amparo da Pesquisa
   do Estado do Rio de Janeiro (FAPERJ, Rio de Janeiro, Brazil).
CR Ardiani A, 2010, FEMS YEAST RES, V10, P1060, DOI 10.1111/j.1567-1364.2010.00665.x
   Batista TM, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.01345-14
   Reis VCB, 2012, J IND MICROBIOL BIOT, V39, P1673, DOI 10.1007/s10295-012-1170-5
   Brandao RL, 1998, APPL ENVIRON MICROB, V64, P564
   Buts JP, 2006, DIGEST DIS SCI, V51, P1485, DOI 10.1007/s10620-005-9016-x
   Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599
   Cummins Joe, 2005, Microbial Ecology in Health and Disease, V17, P66, DOI 10.1080/08910600510044480
   Czerucka D, 2007, ALIMENT PHARM THER, V26, P767, DOI 10.1111/j.1365-2036.2007.03442.x
   Da Silva NA, 2012, FEMS YEAST RES, V12, P197, DOI 10.1111/j.1567-1364.2011.00769.x
   Dalmasso G, 2006, RES MICROBIOL, V157, P456, DOI 10.1016/j.resmic.2005.11.007
   Diosma G, 2014, WORLD J MICROB BIOT, V30, P43, DOI 10.1007/s11274-013-1419-9
   Douradinha B, 2014, BIOENGINEERED, V5, P21, DOI 10.4161/bioe.26271
   Edwards-Ingram L, 2007, APPL ENVIRON MICROB, V73, P2458, DOI 10.1128/AEM.02201-06
   Edwards-Ingram LC, 2004, GENOME RES, V14, P1043, DOI 10.1101/gr.2114704
   Feizizadeh S, 2014, PEDIATRICS, V134, pE176, DOI 10.1542/peds.2013-3950
   Ferraretto LF, 2012, J DAIRY SCI, V95, P4017, DOI 10.3168/jds.2011-5190
   Fietto JLR, 2004, CAN J MICROBIOL, V50, P615, DOI 10.1139/W04-050
   Foligne B, 2010, WORLD J GASTROENTERO, V16, P2134, DOI 10.3748/wjg.v16.i17.2134
   Gedek BR, 1999, MYCOSES, V42, P261, DOI 10.1046/j.1439-0507.1999.00449.x
   Generoso SV, 2010, ARCH MICROBIOL, V192, P477, DOI 10.1007/s00203-010-0574-8
   Girardin M, 2011, DIGEST DIS, V29, P574, DOI 10.1159/000332980
   Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.0.CO;2-K
   Gottardi R, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-30
   GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8
   Hamedi Hassan, 2013, Avicenna Journal of Medical Biotechnology, V5, P29
   Hudson LE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112660
   Kawai Shigeyuki, 2010, Bioeng Bugs, V1, P395, DOI 10.4161/bbug.1.6.13257
   Khatri I, 2013, GUT PATHOG, V5, DOI 10.1186/1757-4749-5-30
   Kourelis A, 2010, J APPL MICROBIOL, V109, P260, DOI 10.1111/j.1365-2672.2009.04651.x
   Kuhle AVDA, 2005, INT J FOOD MICROBIOL, V101, P29, DOI 10.1016/j.ijfoodmicro.2004.10.039
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   Latorre-Garcia L, 2008, WORLD J MICROB BIOT, V24, P2957, DOI 10.1007/s11274-008-9837-9
   Martins FS, 2007, J MED MICROBIOL, V56, P352, DOI 10.1099/jmm.0.46525-0
   Martins FS, 2013, MICROBES INFECT, V15, P270, DOI 10.1016/j.micinf.2012.12.007
   Martins FS, 2011, INT J MED MICROBIOL, V301, P359, DOI 10.1016/j.ijmm.2010.11.002
   Martins FS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008925
   Martins FS, 2005, J GEN APPL MICROBIOL, V51, P83, DOI 10.2323/jgam.51.83
   Mathur S, 2005, INT J FOOD MICROBIOL, V105, P281, DOI 10.1016/j.ijfoodmicro.2005.03.008
   McFarland LV, 2010, WORLD J GASTROENTERO, V16, P2202, DOI 10.3748/wjg.v16.i18.2202
   Michael S, 2013, INFLAMM BOWEL DIS, V19, P185, DOI 10.1002/ibd.23006
   Mumy KL, 2008, AM J PHYSIOL-GASTR L, V294, pG599, DOI 10.1152/ajpgi.00391.2007
   O'Horo JC, 2014, INFECTION, V42, P43, DOI 10.1007/s15010-013-0496-x
   Oliveira AF, 2012, MICROBIOL IMMUNOL, V56, P513, DOI 10.1111/j.1348-0421.2012.00477.x
   Owen JL, 2013, CURR OPIN CHEM BIOL, V17, P918, DOI 10.1016/j.cbpa.2013.06.013
   Perez-Sotelo Luis Salvador, 2005, Rev Latinoam Microbiol, V47, P70
   Perricone M, 2014, FOOD MICROBIOL, V38, P26, DOI 10.1016/j.fm.2013.08.006
   Plaza-Diaz J, 2014, WORLD J GASTROENTERO, V20, P15632, DOI 10.3748/wjg.v20.i42.15632
   Pohlmann C, 2013, BIOENGINEERED, V4, P172, DOI 10.4161/bioe.22646
   Pothoulakis C, 2009, ALIMENT PHARM THER, V30, P826, DOI 10.1111/j.1365-2036.2009.04102.x
   Rodrigues ACP, 2000, J APPL MICROBIOL, V89, P404, DOI 10.1046/j.1365-2672.2000.01128.x
   Romanin D, 2010, INT J FOOD MICROBIOL, V140, P102, DOI 10.1016/j.ijfoodmicro.2010.04.014
   Salyers AA, 2004, TRENDS MICROBIOL, V12, P412, DOI 10.1016/j.tim.2004.07.004
   Sazawal S, 2006, LANCET INFECT DIS, V6, P374, DOI 10.1016/S1473-3099(06)70495-9
   Schneiter R, 2004, GENETICS MOL CELL BI
   Sivignon A, 2015, INFLAMM BOWEL DIS, V21, P276, DOI 10.1097/MIB.0000000000000280
   Smith IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096595
   Soares RLS, 2014, WORLD J GASTROENTERO, V20, P12144, DOI 10.3748/wjg.v20.i34.12144
   Sougioultzis S, 2006, BIOCHEM BIOPH RES CO, V343, P69, DOI 10.1016/j.bbrc.2006.02.080
   Temmerman R, 2003, INT J FOOD MICROBIOL, V81, P1, DOI 10.1016/S0168-1605(02)00162-9
   Tiago FCP, 2012, J MED MICROBIOL, V61, P1194, DOI 10.1099/jmm.0.042283-0
   Vieira AT, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00445
   Wang TT, 2014, FUNGAL GENET BIOL, V64, P1, DOI 10.1016/j.fgb.2013.11.006
   Whelan K, 2007, P NUTR SOC, V66, P299, DOI 10.1017/S0029665107005551
   Wu X, 2008, AM J PHYSIOL-GASTR L, V294, pG295, DOI 10.1152/ajpgi.00173.2007
   Zanello G, 2013, VET IMMUNOL IMMUNOP, V152, P20, DOI 10.1016/j.vetimm.2012.09.023
   Zanello G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018573
NR 66
TC 39
Z9 41
U1 2
U2 43
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD AUG
PY 2015
VL 99
IS 16
BP 6563
EP 6570
DI 10.1007/s00253-015-6776-x
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA CN4DO
UT WOS:000358380300001
PM 26142388
DA 2020-12-16
ER

PT J
AU Cunha, KC
   Rusu, VH
   Viana, IFT
   Marques, ETA
   Dhalia, R
   Lins, RD
AF Cunha, Keila C.
   Rusu, Victor H.
   Viana, Isabelle F. T.
   Marques, Ernesto T. A.
   Dhalia, Rafael
   Lins, Roberto D.
TI Assessing Protein Conformational Sampling and Structural Stability via
   De Novo Design and Molecular Dynamics Simulations
SO BIOPOLYMERS
LA English
DT Article
DE protein stability; structure prediction; protein engineering
ID FORCE-FIELD; STRUCTURE PREDICTION; PARAMETER SET; HIV-1; SCAFFOLD;
   VALIDATION
AB Molecular dynamics and de novo techniques, associated to quality parameter sets, have excelled at determining the structure of small proteins with high accuracy. To achieve a detailed description of protein conformations, these methods must critically assess the thermodynamic features of the molecular ensembles. Here, a comparison of the conformational ensemble generated by molecular dynamics and de novo techniques were carried out for six Top7-based proteins carrying gp41 HIV-1 epitopes. The native Top7, a highly stable computationally designed protein, was used as benchmark. Structural stability, flexibility, and secondary structure content were assessed. The consistency of the latter was compared to experimental circular dichroism spectra for all proteins. While both methods are capable to identify the stable from unstable chimeric proteins, the sampled conformational space and flexibility differ significantly in both methods. Molecular dynamics simulations seem to better describe secondary structure content and identify regions responsible for conformational instability. The de novo method, as implemented in Rosettaa prime tool for protein design, overestimates secondary structure content. On the other hand, its empirical energy function is capable to predict the threshold for protein stability. (c) 2015 Wiley Periodicals, Inc. Biopolymers 103: 351-361, 2015.
C1 [Cunha, Keila C.; Lins, Roberto D.] Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740560 Recife, PE, Brazil.
   [Rusu, Victor H.] ETH Honggerberg, Dept Phys Chem, CH-8093 Zurich, Switzerland.
   [Viana, Isabelle F. T.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Marques, Ernesto T. A.; Dhalia, Rafael; Lins, Roberto D.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
RP Lins, RD (corresponding author), Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740560 Recife, PE, Brazil.
EM roberto.lins@cpqam.fiocruz.br
RI Dhalia, Rafael/AAD-5432-2020; Viana, Isabelle/M-4435-2017; Marques,
   Ernesto T. A/L-4967-2013; Lins, Roberto D/J-7511-2012
OI Viana, Isabelle/0000-0003-4648-6635; Marques, Ernesto T.
   A/0000-0003-3826-9358; Lins, Roberto D/0000-0002-3983-8025
FU FACEPE; CAPESCAPES [BioComputacional 051/2013]; CNPqNational Council for
   Scientific and Technological Development (CNPq); INCT-INAMI; nBioNet
FX Contract grant sponsor: FACEPE, CAPES (BioComputacional 051/2013), CNPq,
   INCT-INAMI, nBioNet
CR Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Best RB, 2013, P NATL ACAD SCI USA, V110, P17874, DOI 10.1073/pnas.1311599110
   Bolon DN, 2002, CURR OPIN CHEM BIOL, V6, P125, DOI 10.1016/S1367-5931(02)00303-4
   Bonneau R, 2002, J MOL BIOL, V322, P65, DOI 10.1016/S0022-2836(02)00698-8
   Boschek CB, 2009, PROTEIN ENG DES SEL, V22, P325, DOI 10.1093/protein/gzp007
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Dahiyat BI, 1997, J MOL BIOL, V273, P789, DOI 10.1006/jmbi.1997.1341
   Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82
   Dill KA, 2008, ANNU REV BIOPHYS, V37, P289, DOI 10.1146/annurev.biophys.37.092707.153558
   Dror RO, 2012, ANNU REV BIOPHYS, V41, P429, DOI 10.1146/annurev-biophys-042910-155245
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hockney R. W., 1970, METHODS COMPUTATIONA
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Huang PS, 2007, PROTEIN SCI, V16, P2770, DOI 10.1110/ps.073125207
   Indu S, 2011, PROTEINS, V79, P244, DOI 10.1002/prot.22878
   Kaufmann KW, 2010, BIOCHEMISTRY-US, V49, P2987, DOI 10.1021/bi902153g
   Kellogg EH, 2011, PROTEINS, V79, P830, DOI 10.1002/prot.22921
   Kim DE, 2009, J MOL BIOL, V393, P249, DOI 10.1016/j.jmb.2009.07.063
   Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468
   Koellhoffer JF, 2014, FEBS LETT, V588, P298, DOI 10.1016/j.febslet.2013.10.014
   Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427
   Lindert S, 2013, J CHEM THEORY COMPUT, V9, P3843, DOI 10.1021/ct400260c
   Lins RD, 1999, BIOPHYS J, V76, P2999, DOI 10.1016/S0006-3495(99)77453-9
   Lins RD, 2000, BIOPOLYMERS, V53, P308, DOI 10.1002/(SICI)1097-0282(20000405)53:4<308::AID-BIP3>3.0.CO;2-H
   MacKerell AD, 2001, BIOPOLYMERS, V56, P257
   Oostenbrink C, 2005, EUR BIOPHYS J BIOPHY, V34, P273, DOI 10.1007/s00249-004-0448-6
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Piana S, 2014, CURR OPIN STRUC BIOL, V24, P98, DOI 10.1016/j.sbi.2013.12.006
   Rothlisberger D, 2008, NATURE, V453, P190, DOI 10.1038/nature06879
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Shi WX, 2010, J BIOL CHEM, V285, P24290, DOI 10.1074/jbc.M110.111351
   Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959
   Simons KT, 1999, PROTEINS, V34, P82, DOI 10.1002/(SICI)1097-0134(19990101)34:1<82::AID-PROT7>3.0.CO;2-A
   Soares TA, 2005, J COMPUT CHEM, V26, P725, DOI 10.1002/jcc.20193
   Soares TA, 2004, J BIOMOL NMR, V30, P407, DOI 10.1007/s10858-004-5430-1
   Soares TA, 2010, J MOL GRAPH MODEL, V28, P755, DOI 10.1016/j.jmgm.2010.01.013
   Tagliamonte M, 2013, AIDS RES HUM RETROV, V29, pA138
   TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273
   Tyka MD, 2011, J MOL BIOL, V405, P607, DOI 10.1016/j.jmb.2010.11.008
   van Gunsteren W, 2001, CHIMIA, V55, P856
   Viana IFT, 2013, LECT NOTES COMPUT SC, V8213, P94, DOI 10.1007/978-3-319-02624-4_9
   Viana IFT, 2013, RSC ADV, V3, P11790, DOI 10.1039/c3ra41562g
   Wang CK, 2014, ACS CHEM BIOL, V9, P156, DOI 10.1021/cb400548s
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
NR 48
TC 6
Z9 6
U1 0
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3525
EI 1097-0282
J9 BIOPOLYMERS
JI Biopolymers
PD JUN
PY 2015
VL 103
IS 6
BP 351
EP 361
DI 10.1002/bip.22626
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CE2WB
UT WOS:000351680300005
PM 25677872
DA 2020-12-16
ER

PT J
AU Maciel, M
   Cruz, FDP
   Cordeiro, MT
   da Motta, MA
   Cassemiro, KMSD
   Maia, RDC
   de Figueiredo, RCBQ
   Galler, R
   Freire, MD
   August, JT
   Marques, ETA
   Dhalia, R
AF Maciel, Milton, Jr.
   Pereira Cruz, Fabia da Silva
   Cordeiro, Marli Tenorio
   da Motta, Marcia Archer
   Soares de Melo Cassemiro, Klecia Marilia
   Carvalho Maia, Rita de Cassia
   Bressan Queiroz de Figueiredo, Regina Celia
   Galler, Ricardo
   Freire, Marcos da Silva
   August, Joseph Thomas
   Marques, Ernesto T. A.
   Dhalia, Rafael
TI A DNA Vaccine against Yellow Fever Virus: Development and Evaluation
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID NEUTRALIZING ANTIBODY-RESPONSE; CLASS-II COMPARTMENT; MEMBRANE-PROTEIN;
   T-CELL; JAPANESE ENCEPHALITIS; MONOCLONAL-ANTIBODIES; PROTECTIVE
   IMMUNITY; ENVELOPE GENES; B-CELLS; MICE
AB Attenuated yellow fever (YF) virus 17D/17DD vaccines are the only available protection from YF infection, which remains a significant source of morbidity and mortality in the tropical areas of the world. The attenuated YF virus vaccine, which is used worldwide, generates both long-lasting neutralizing antibodies and strong T-cell responses. However, on rare occasions, this vaccine has toxic side effects that can be fatal. This study presents the design of two non-viral DNA-based antigen formulations and the characterization of their expression and immunological properties. The two antigen formulations consist of DNA encoding the full-length envelope protein (p/YFE) or the full-length envelope protein fused to the lysosomal-associated membrane protein signal, LAMP-1 (pL/YFE), aimed at diverting antigen processing/presentation through the major histocompatibility complex II precursor compartments. The immune responses triggered by these formulations were evaluated in H2b and H2d backgrounds, corresponding to the C57Bl/6 and BALB/c mice strains, respectively. Both DNA constructs were able to induce very strong T-cell responses of similar magnitude against almost all epitopes that are also generated by the YF 17DD vaccine. The pL/YFE formulation performed best overall. In addition to the T-cell response, it was also able to stimulate high titers of anti-YF neutralizing antibodies comparable to the levels elicited by the 17DD vaccine. More importantly, the pL/YFE vaccine conferred 100% protection against the YF virus in intracerebrally challenged mice. These results indicate that pL/YFE DNA is an excellent vaccine candidate and should be considered for further developmental studies.
C1 [Maciel, Milton, Jr.; August, Joseph Thomas; Marques, Ernesto T. A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Pereira Cruz, Fabia da Silva; Cordeiro, Marli Tenorio; Soares de Melo Cassemiro, Klecia Marilia; Bressan Queiroz de Figueiredo, Regina Celia; Marques, Ernesto T. A.; Dhalia, Rafael] Univ Fed Pernambuco UFPE, Oswaldo Cruz Fdn FIOCRUZ, Lab Virol & Terapia Expt LAVITE, Aggeu Magalhaes Res Ctr,Dept Virol, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Hlth Secretariat State Pernambuco, Cent Publ Hlth Lab LACEN, Recife, PE, Brazil.
   [da Motta, Marcia Archer; Galler, Ricardo; Freire, Marcos da Silva] Oswaldo Cruz Fdn FIOCRUZ, Inst Oswaldo Cruz, Biomanguinhos, Lab Tecnol Virol LATEV, Rio De Janeiro, Brazil.
   [Carvalho Maia, Rita de Cassia] Univ Fed Rural Pernambuco, Dept Vet Med, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Maciel, M (corresponding author), Naval Med Res Ctr, ETEC Vaccine Program, Silver Spring, MD 20910 USA.
EM emarques@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; FIGUEIREDO, REGINA CBQ/N-2800-2013;
   Dhalia, Rafael/AAD-5432-2020; FIGUEIREDO, REGINA/T-7230-2019; de Cassia
   Carvalho Maia, Rita/AAH-8741-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; de Cassia Carvalho Maia,
   Rita/0000-0001-6765-6686; FIGUEIREDO, REGINA/0000-0001-5806-0944
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services, USAUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19 AI56541, HHSN2662-00400085C, PDTIS RVR09-FIOCRUZ];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   U19AI056541, R01AI040085, U19AI056541, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R21AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   U19AI056541] Funding Source: NIH RePORTER
FX This work was supported in part with Federal Funds from the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human Services, USA under Grant No. U19
   AI56541, Contract No. HHSN2662-00400085C and PDTIS RVR09-FIOCRUZ. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   BARRETT ADT, 1986, J GEN VIROL, V67, P631, DOI 10.1099/0022-1317-67-4-631
   BRANDRISS MW, 1986, J GEN VIROL, V67, P229, DOI 10.1099/0022-1317-67-2-229
   Breugelmans JG, 2013, VACCINE, V31, P1819, DOI 10.1016/j.vaccine.2013.01.054
   Cetron Martin S, 2002, MMWR Recomm Rep, V51, P1
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   DESPRES P, 1991, J GEN VIROL, V72, P2811, DOI 10.1099/0022-1317-72-11-2811
   Disis ML, 1996, J IMMUNOL, V156, P3151
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Julander JG, 2013, ANTIVIR RES, V97, P169, DOI 10.1016/j.antiviral.2012.12.002
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Konishi E, 2003, VACCINE, V21, P3713, DOI 10.1016/S0264-410X(03)00376-1
   Konishi E, 1998, J VIROL, V72, P4925, DOI 10.1128/JVI.72.6.4925-4930.1998
   Konishi E, 2000, VACCINE, V18, P1133, DOI 10.1016/S0264-410X(99)00376-X
   Lefeuvre Anabelle, 2004, Curr Infect Dis Rep, V6, P96, DOI 10.1007/s11908-996-0005-9
   Lewis PJ, 1999, ADV VIRUS RES, V54, P129, DOI 10.1016/S0065-3527(08)60367-X
   Li L, 2012, J BIOTECHNOL, V162, P171, DOI 10.1016/j.jbiotec.2012.08.012
   LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maciel M, 2008, VIROLOGY, V378, P105, DOI 10.1016/j.virol.2008.04.043
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Miyaji KT, 2013, HUM VACCIN IMMUNOTHE, V9
   Monath TP, 2005, HUM VACCINES, V1, P207, DOI 10.4161/hv.1.5.2221
   Monath TP, 2002, AM J TROP MED HYG, V66, P533, DOI 10.4269/ajtmh.2002.66.533
   PINCUS S, 1992, VIROLOGY, V187, P290, DOI 10.1016/0042-6822(92)90317-I
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   PUTNAK JR, 1990, J GEN VIROL, V71, P1697, DOI 10.1099/0022-1317-71-8-1697
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Robinson HL, 1999, INT J MOL MED, V4, P549
   SCHLESINGER JJ, 1985, J IMMUNOL, V135, P2805
   Schultz J, 2000, INTERVIROLOGY, V43, P197, DOI 10.1159/000053988
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   Sidibe M, 2012, T ROY SOC TROP MED H, V106, P437, DOI 10.1016/j.trstmh.2012.04.002
   Stefano I, 1999, VACCINE, V17, P1042, DOI 10.1016/S0264-410X(98)00320-X
   Thomas RE, 2011, CURR DRUG SAF, V6, P145, DOI 10.2174/157488611797579258
   Van Der Most RG, 2000, J VIROL, V74, P8094, DOI 10.1128/JVI.74.17.8094-8101.2000
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
   *WHO, 1992, GLOB HLTH SIT PROJ E
   *WHO, 1998, WHO TECHN REP SER, V872
   Wu CJ, 2006, MICROBES INFECT, V8, P2578, DOI 10.1016/j.micinf.2006.06.010
NR 44
TC 20
Z9 20
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD APR
PY 2015
VL 9
IS 4
AR e0003693
DI 10.1371/journal.pntd.0003693
PG 19
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CI7VF
UT WOS:000354972200043
PM 25875109
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Ruberto, I
   Marques, E
   Burke, DS
   Van Panhuis, WG
AF Ruberto, Irene
   Marques, Ernesto
   Burke, Donald S.
   Van Panhuis, Willem G.
TI The Availability and Consistency of Dengue Surveillance Data Provided
   Online by the World Health Organization
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
AB Background
   The use of high quality disease surveillance data has become increasingly important for public health action against new threats. In response, countries have developed a wide range of disease surveillance systems enabled by technological advancements. The heterogeneity and complexity of country data systems have caused a growing need for international organizations such as the World Health Organization (WHO) to coordinate the standardization, integration, and dissemination of country disease data at the global level for research and policy. The availability and consistency of currently available disease surveillance data at the global level are unclear. We investigated this for dengue surveillance data provided online by the WHO.
   Methods and Findings
   We extracted all dengue surveillance data provided online by WHO Headquarters and Regional Offices (RO's). We assessed the availability and consistency of these data by comparing indicators within and between sources. We also assessed the consistency of dengue data provided online by two example countries (Brazil and Indonesia). Data were available from WHO for 100 countries since 1955 representing a total of 23 million dengue cases and 82 thousand deaths ever reported to WHO. The availability of data on Dengue-Net and some RO's declined dramatically after 2005. Consistency was lacking between sources (84% across all indicators representing a discrepancy of almost half a million cases). Within sources, data at high spatial resolution were often incomplete.
   Conclusions
   The decline of publicly available, integrated dengue surveillance data at the global level will limit opportunities for research, policy, and advocacy. A new financial and operational framework will be necessary for innovation and for the continued availability of integrated country disease data at the global level.
C1 [Ruberto, Irene; Burke, Donald S.; Van Panhuis, Willem G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Ruberto, I (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
EM wav10@pitt.edu
RI Van Panhuis, Willem/S-5495-2019; Marques, Ernesto T. A/L-4967-2013
OI Van Panhuis, Willem/0000-0002-7278-9982; Marques, Ernesto T.
   A/0000-0003-3826-9358; /0000-0002-5704-8094
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [49276]; US National Institute of General Medical SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [5U54GM088491]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491] Funding Source: NIH
   RePORTER
FX The contributions of IR, WGVP, and DSB to this study were supported by
   the Bill and Melinda Gates Foundation (Grant 49276, Evaluation of
   Candidate Vaccine Technologies Using Computational Models) and the US
   National Institute of General Medical Sciences (Grant 5U54GM088491,
   Computational Models of Infectious Disease Threats). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], 2002, DENGUENET WHOS INTER, V77, P300
   Bill & Melinda Gates Foundation, 2011, GLOB HLTH DAT ACC PR
   Boston Children's Hospital, GLOB HLTH LOC KNOWL
   Farrar J, 2007, TROP MED INT HEALTH, V12, P695, DOI [10.1111/j.1365-3156.2007.01838, 10.1111/j.1365-3156.2007.01838.x]
   GOOGLE, GOOGL FLU TRENDS
   GOOGLE, GOOGL DENG TRENDS
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7
   Kroeger A, 2006, LANCET, V368, P2193, DOI 10.1016/S0140-6736(06)69873-5
   McNabb SJN, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-S1-S3
   Ooi EE, 2009, CAD SAUDE PUBLICA, V25, pS115, DOI 10.1590/S0102-311X2009001300011
   Tapia-Conyer R, 2009, J CLIN VIROL, V46, pS3, DOI 10.1016/S1386-6532(09)70286-0
   UN Geographic Information Working Group (UNGIWG), 2 ADM LEV BOUND
   Walport M, 2011, LANCET, V377, P537, DOI 10.1016/S0140-6736(10)62234-9
   WHO, 2003, WHO PAHO CDC M SAN J
   WHO-PAHO, DENG REG INF NUMB CA
   WHO-WPRO, ANN DENG DAT W PAC R
   Word Health Organization, 2010, 63 WORLD HLTH ASS
   World Health Assembly, WHA41281988
NR 19
TC 11
Z9 11
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD APR
PY 2015
VL 9
IS 4
AR e0003511
DI 10.1371/journal.pntd.0003511
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CI7VF
UT WOS:000354972200004
PM 25874804
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-16
ER

PT J
AU Brasier, AR
   Zhao, YX
   Wiktorowicz, JE
   Spratt, HM
   Nascimento, EJM
   Cordeiro, MT
   Soman, KV
   Ju, H
   Recinos, A
   Stafford, S
   Wu, Z
   Marques, ETA
   Vasilakis, N
AF Brasier, Allan R.
   Zhao, Yingxin
   Wiktorowicz, John E.
   Spratt, Heidi M.
   Nascimento, Eduardo J. M.
   Cordeiro, Marli T.
   Soman, Kizhake V.
   Ju, Hyunsu
   Recinos, Adrian, III
   Stafford, Susan
   Wu, Zheng
   Marques, Ernesto T. A., Jr.
   Vasilakis, Nikos
TI Molecular classification of outcomes from dengue virus-3 infections
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Dengue; Biomarker pipeline; Selected reaction monitoring; Acute phase
   reaction
ID HEMORRHAGIC-FEVER; DISEASE SEVERITY; BIOMARKER PANEL; PATHOGENESIS;
   PREDICTION; ASSOCIATIONS; COMPLEMENT; CORRELATE; PROTEINS; PROTEOME
AB Objectives: Dengue virus (DENV) infection is a significant risk to over a third of the human population that causes a wide spectrum of illness, ranging from sub-clinical disease to intermediate syndrome of vascular complications called dengue fever complicated (DFC) and severe, dengue hemorrhagic fever (DHF). Methods for discriminating outcomes will impact clinical trials and understanding disease pathophysiology.
   Study design: We integrated a proteomics discovery pipeline with a heuristics approach to develop a molecular classifier to identify an intermediate phenotype of DENV-3 infectious outcome.
   Results: 121 differentially expressed proteins were identified in plasma from DHF vs dengue fever (DF), and informative candidates were selected using nonparametric statistics. These were combined with markers that measure complement activation, acute phase response, cellular leak, granulocyte differentiation and viral load. From this, we applied quantitative proteomics to select a 15 member panel of proteins that accurately predicted DF, DHF, and DFC using a random forest classifier. The classifier primarily relied on acute phase (A2M), complement (CFD), platelet counts and cellular leak (TPM4) to produce an 86% accuracy of prediction with an area under the receiver operating curve of >0.9 for DHF and DFC vs DF.
   Conclusions: Integrating discovery and heuristic approaches to sample distinct pathophysiological processes is a powerful approach in infectious disease. Early detection of intermediate outcomes of DENV-3 will speed clinical trials evaluating vaccines or drug interventions. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Brasier, Allan R.; Zhao, Yingxin; Wiktorowicz, John E.; Recinos, Adrian, III] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.
   [Brasier, Allan R.; Zhao, Yingxin; Wiktorowicz, John E.; Spratt, Heidi M.; Soman, Kizhake V.] UTMB, Sealy Ctr Mol Med, Galveston, TX 77555 USA.
   [Brasier, Allan R.; Zhao, Yingxin; Wiktorowicz, John E.; Spratt, Heidi M.] UTMB, Inst Translat Sci, Galveston, TX 77555 USA.
   [Wiktorowicz, John E.; Soman, Kizhake V.] UTMB, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Cordeiro, Marli T.; Marques, Ernesto T. A., Jr.] Fiocruz MS, Lab Virol & Terapie Expt, Ctr Pesquisas Aggeu Magalhaes CPqAM, Recife, PE, Brazil.
   [Stafford, Susan; Wu, Zheng] UTMB, Biomol Resource Facil, Galveston, TX 77555 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol & Immunol, Pittsburgh, PA 15260 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Biodefense & Emerging Infect Dis, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Trop Dis, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
RP Brasier, AR (corresponding author), Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.
EM arbrasie@utmb.edu
RI Vasilakis, Nikos/ABE-7318-2020; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Brasier,
   Allan/0000-0002-5012-4090
FU NIAID Clinical Proteomics Center [HHSN272200800048C]; National Center
   for Advancing Translational Science [UL1TR000071 UTMB CTSA, NIEHSP30
   ES006676]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
   [HHSN272201000040I/HHSN27200004/D04]; CNPqPRONEXNational Council for
   Scientific and Technological Development (CNPq) [DENGUE550140/2010-7];
   FACEPE project [APQ-1516-4.01/10];  [NIAIDAI56541AI049820]; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000071, UL1TR000071, UL1TR000071, UL1TR000071, UL1TR000071,
   UL1TR000071, UL1TR000071, UL1TR000071, UL1TR000071, UL1TR000071] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS)
   [P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676, P30ES006676, P30ES006676,
   P30ES006676, P30ES006676, P30ES006676] Funding Source: NIH RePORTER
FX Research support was provided by the NIAID Clinical Proteomics Center,
   HHSN272200800048C (ARB), National Center for Advancing Translational
   Science UL1TR000071 UTMB CTSA (ARB), NIEHSP30 ES006676 (ARB) and NIH
   contract HHSN272201000040I/HHSN27200004/D04 (NV). NIAIDAI56541AI049820,
   CNPqPRONEX-DENGUE550140/2010-7 - FACEPE project APQ-1516-4.01/10.
CR Addona TA, 2009, NAT BIOTECHNOL, V27, P633, DOI 10.1038/nbt.1546
   Albuquerque LM, 2009, J PROTEOME RES, V8, P5431, DOI 10.1021/pr900236f
   Anantapreecha S, 2005, EPIDEMIOL INFECT, V133, P503, DOI 10.1017/S0950268804003541
   Anders KL, 2011, AM J TROP MED HYG, V84, P127, DOI 10.4269/ajtmh.2011.10-0476
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Appanna R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013029
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boonnak K, 2011, J VIROL, V85, P1671, DOI 10.1128/JVI.00220-10
   Brasier AR, 2012, CTS-CLIN TRANSL SCI, V5, P8, DOI 10.1111/j.1752-8062.2011.00377.x
   Brasier AR, 2012, AM J TROP MED HYG, V86, P341, DOI 10.4269/ajtmh.2012.11-0469
   Brasier AR, 2010, CTS-CLIN TRANSL SCI, V3, P147, DOI 10.1111/j.1752-8062.2010.00204.x
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Chaturvedi UC, 2006, FEMS IMMUNOL MED MIC, V47, P155, DOI 10.1111/j.1574-695X.2006.00058.x
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Dinh TT, 2010, AM J TROP MED HYG, V83, P774, DOI 10.4269/ajtmh.2010.10-0090
   Fragnoud R, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-60
   Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350
   Gundry RL, 2007, PROTEOM CLIN APPL, V1, P73, DOI 10.1002/prca.200600276
   Guzman M G, 1984, Bull Pan Am Health Organ, V18, P213
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24
   Halstead SB, 2001, AM J TROP MED HYG, V65, P180, DOI 10.4269/ajtmh.2001.65.180
   Jamaluddin M, 2010, J VIROL, V84, P9533, DOI 10.1128/JVI.01005-10
   Ju Hyunsu, 2013, BMC Res Notes, V6, P365, DOI 10.1186/1756-0500-6-365
   Kumar Y, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001887
   KUSHNER I, 1988, METHOD ENZYMOL, V163, P373
   Lan NTP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000304
   Macedo GA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096314
   Malheiros S M, 1993, Arq Neuropsiquiatr, V51, P159
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Murray Natasha Evelyn Anne, 2013, Clin Epidemiol, V5, P299, DOI 10.2147/CLEP.S34440
   Nascimento EJM, 2014, CRIT REV IMMUNOL, V34, P227, DOI 10.1615/CritRevImmunol.2014010212
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Potts JA, 2008, TROP MED INT HEALTH, V13, P1328, DOI 10.1111/j.1365-3156.2008.02151.x
   Potts JA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000769
   Pretzer E, 2008, ANAL BIOCHEM, V374, P250, DOI 10.1016/j.ab.2007.12.014
   Spratt H, 2013, METHODS IN PRESS
   Stephens HAF, 2010, CURR TOP MICROBIOL, V338, P99, DOI 10.1007/978-3-642-02215-9_8
   Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x
   Thayan R, 2009, T ROY SOC TROP MED H, V103, P413, DOI 10.1016/j.trstmh.2008.12.018
   Villar-Centeno LA, 2008, AM J TROP MED HYG, V78, P370, DOI 10.4269/ajtmh.2008.78.370
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Yacoub S, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0147-9
   Zhao Y., 2013, METHODS
   Zivna I, 2002, J IMMUNOL, V168, P5959, DOI 10.4049/jimmunol.168.11.5959
NR 47
TC 7
Z9 7
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD MAR
PY 2015
VL 64
BP 97
EP 106
DI 10.1016/j.jcv.2015.01.011
PG 10
WC Virology
SC Virology
GA CF0ZP
UT WOS:000352273600018
PM 25728087
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Comber, JD
   Karabudak, A
   Huang, XF
   Piazza, PA
   Marques, ETA
   Philip, R
AF Comber, Joseph D.
   Karabudak, Aykan
   Huang, Xiaofang
   Piazza, Paolo A.
   Marques, Ernesto T. A.
   Philip, Ramila
TI Dengue virus specific dual HLA binding T cell epitopes induce CD8(+) T
   cell responses in seropositive individuals
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE CTLs; dengue virus; immunoproteomics; MHC class I; peptide vaccine
ID YELLOW-FEVER VACCINE; IMMUNOPROTEOMICS ANALYSIS; IMMUNE-RESPONSE;
   INFECTION; IMMUNOGENICITY; IDENTIFICATION; CONSERVATION; PATHOGENESIS;
   PEPTIDES; MULTIPLE
AB Dengue virus infects an estimated 300 million people each year and even more are at risk of becoming infected as the virus continues to spread into new areas. Despite the increase in viral prevalence, no anti-viral medications or vaccines are approved for treating or preventing infection. CD8(+) T cell responses play a major role in viral clearance. Therefore, effective vaccines that induce a broad, multi-functional T cell response with substantial cross-reactivity between all virus serotypes can have major impacts on reducing infection rates and infection related complications. Here, we took an immunoproteomic approach to identify novel MHC class I restricted T cell epitopes presented by dengue virus infected cells, representing the natural and authentic targets of the T cell response. Using this approach we identified 4 novel MHC-I restricted epitopes: 2 with the binding motif for HLA-A24 molecules and 2 with both HLA-A2 and HLA-A24 binding motifs. These peptides were able to activate CD8(+) T cell responses in both healthy, seronegative individuals and in seropositive individuals who have previously been infected with dengue virus. Importantly, the dual binding epitopes activated pre-existing T cell precursors in PBMCs obtained from both HLA-A2(+) and HLA-A24(+) seropositive individuals. Together, the data indicate that these epitopes are immunologically relevant T cell activating peptides presented on infected cells during a natural infection and therefore may serve as candidate antigens for the development of effective multi-serotype specific dengue virus vaccines.
C1 [Comber, Joseph D.; Karabudak, Aykan; Huang, Xiaofang; Philip, Ramila] Immunotope Inc, Doylestown, PA 18902 USA.
   [Piazza, Paolo A.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Philip, R (corresponding author), Immunotope Inc, Doylestown, PA 18902 USA.
EM RPhilip@immunotope.com
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Piazza,
   Paolo/0000-0002-2173-1342
FU National Institutes of Health Small Business Innovation ResearchUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [2 R44 A1062177-03]; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI040085, U19AI082632,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, R21AI040085, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, U19AI056541, R01AI040085, U19AI082632, R01AI040085,
   R01AI040085, U19AI056541, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health Small
   Business Innovation Research (2 R44 A1062177-03).
CR Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   BUKOWSKI JF, 1989, J VIROL, V63, P5086, DOI 10.1128/JVI.63.12.5086-5091.1989
   Comber Joseph D, 2014, Ther Adv Vaccines, V2, P77, DOI 10.1177/2051013614525375
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   Dayan GH, 2013, AM J TROP MED HYG, V89, P1058, DOI 10.4269/ajtmh.13-0304
   de Melo AB, PLOS NEGL TROP DIS, V7, pe1938
   de Melo AB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001938
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   de Alencar LXE, 2013, J TROP MED-US, V2013, DOI 10.1155/2013/648475
   Gil L, 2009, VIRAL IMMUNOL, V22, P23, DOI 10.1089/vim.2008.0063
   Guabiraba R, 2014, IMMUNOLOGY, V141, P143, DOI 10.1111/imm.12188
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guirakhoo F, 2002, VIROLOGY, V298, P146, DOI 10.1006/viro.2002.1462
   Gulukota K, 1996, GENET ANAL-BIOMOL E, V13, P81, DOI 10.1016/1050-3862(95)00156-5
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Johnson BW, 2002, AM J TROP MED HYG, V67, P260, DOI 10.4269/ajtmh.2002.67.260
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   Lindow JC, 2013, VACCINE, V31, P3347, DOI 10.1016/j.vaccine.2013.05.075
   Lund O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026494
   Malavige GN, 2013, J CLIN VIROL, V58, P605, DOI 10.1016/j.jcv.2013.10.023
   Mathew A, 1996, J CLIN INVEST, V98, P1684, DOI 10.1172/JCI118964
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Mittendorf EA, 2005, BREAST CANCER RES TR, V92, P85, DOI 10.1007/s10549-005-0988-1
   Morse MA, 2011, CLIN CANCER RES, V17, P3408, DOI 10.1158/1078-0432.CCR-10-2614
   Nascimento EJM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002497
   Nieminen JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070738
   Olsen LR, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00069
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Piazza P, 2014, CLIN EXP IMMUNOL
   Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI21512
   Shetty V, 2012, J PROTEOMICS, V75, P3270, DOI 10.1016/j.jprot.2012.03.044
   Shetty V, 2011, J PROTEOMICS, V74, P728, DOI 10.1016/j.jprot.2011.02.020
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   Slingluff CL, 2007, CLIN CANCER RES, V13, P6386, DOI 10.1158/1078-0432.CCR-07-0486
   Slingluff CL, 2011, CANCER J, V17, P343, DOI 10.1097/PPO.0b013e318233e5b2
   Testa JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048484
   Testa JS, 2012, FUTURE VIROL, V7, P1077, DOI 10.2217/FVL.12.108
   Testa JS, 2012, J INFECT DIS, V205, P647, DOI 10.1093/infdis/jir814
   Vazquez S, 2002, VACCINE, V20, P1823, DOI 10.1016/S0264-410X(01)00515-1
   Wan SW, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-37
   Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003
   Weiskopf D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00093
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Whitehorn J, 2011, VACCINE, V29, P7221, DOI 10.1016/j.vaccine.2011.07.022
   Yacoub S, 2013, CURR OPIN INFECT DIS, V26, P284, DOI 10.1097/QCO.0b013e32835fb938
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
NR 51
TC 8
Z9 8
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD DEC 2
PY 2014
VL 10
IS 12
BP 3531
EP 3543
DI 10.4161/21645515.2014.980210
PG 13
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA CG6HA
UT WOS:000353398100023
PM 25668665
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Santos, JJS
   Cordeiro, MT
   Bertani, GR
   Marques, ETA
   Gil, LHVG
AF Santos, Jefferson J. S.
   Cordeiro, Marli T.
   Bertani, Giovani R.
   Marques, Ernesto T. A.
   Gil, Laura H. V. G.
TI A two-plasmid strategy for engineering a dengue virus type 3 infectious
   clone from primary Brazilian isolate
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE reverse genetics; dengue virus; molecular cloning; infectious clone
ID REVERSE GENETICS SYSTEM; CDNA-CLONES; SUBGENOMIC REPLICONS;
   CONSTRUCTION; RNA; PROTEIN; STRAIN; EXPRESSION; YEAST
AB Dengue infections represent one of the most prevalent arthropod-borne diseases worldwide, causing a wide spectrum of clinical outcomes. Engineered infectious clone is an important tool to study Dengue virus (DENV) biology. Functional full-length cDNA clones have been constructed for many positive-strand RNA viruses and have provided valuable tools for studying the molecular mechanisms involved in viral genome replication, virion assembly, virus pathogenesis and vaccine development. We report herein the successful development of an infectious clone from a primary Brazilian isolate of dengue virus 3 (DENV3) of the genotype III. Using a two-plasmid strategy, DENV3 genome was divided in two parts and cloned separately into a yeast-bacteria shuttle vector. All plasmids were assembled in yeast by homologous recombination technique and a full-length template for transcription was obtained by in vitro ligation of the two parts of the genome. Transcript-derived DENV3 is infectious upon transfection into BHK-21 cells and in vitro characterization confirmed its identity. Growth kinetics of transcript-derived DENV3 was indistinguishable from wild type DENV3. This system is a powerful tool that will help shed light on molecular features of DENV biology, as the relationship of specific mutations and DENV pathogenesis.
C1 [Santos, Jefferson J. S.; Cordeiro, Marli T.; Marques, Ernesto T. A.; Gil, Laura H. V. G.] Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Cordeiro, Marli T.] Secretaria Saude Estado Pernambuco, Lab Cent Saude Publ, BR-50050210 Recife, PE, Brazil.
   [Bertani, Giovani R.] Univ Fed Pernambuco, Dept Bioquim, BR-50760420 Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Gil, LHVG (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Av Prof Moraes Rego S-N,Campus UFPE, BR-50670420 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Santos, Jefferson/W-9610-2019
OI Marques, Ernesto T. A/0000-0003-3826-9358; Santos,
   Jefferson/0000-0001-5895-4163
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao Oswaldo Cruz - FIOCRUZ (Papes V); Fundacao de Amparo a
   Ciencia e Tecnologia do Estado de Pernambuco (FACEPE)
   [APQ-0519-2.12/06]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [470892/2007-2]; National Institute of
   Allergy and Infectious Diseases (NIAID/NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI56541]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R21AI040085, U19AI082632, U19AI056541,
   R01AI040085, R01AI040085, U19AI056541, R01AI040085, U19AI056541,
   U19AI082632, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, U19AI056541, U19AI056541,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085] Funding Source: NIH
   RePORTER
FX The authors thank the Program for Technological Development in Tools for
   Health-PDTISFIOCRUZ for the use of its facilities, Dr. Pedro Vasconcelos
   at the Evandro Chagas Institute (Belem, Para, Brazil) for kindly
   supplying the polyclonal hyperimmune ascitic fluid used in this paper
   and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) for supporting J.J.S.S. through a graduate scholarship. This work
   is supported by research grants from Fundacao Oswaldo Cruz - FIOCRUZ
   (Papes V), Fundacao de Amparo a Ciencia e Tecnologia do Estado de
   Pernambuco (FACEPE) (APQ-0519-2.12/06), the CNPq (470892/2007-2), and
   the National Institute of Allergy and Infectious Diseases (NIAID/NIH) -
   Grant U19 AI56541.
CR Alvarez DE, 2008, VIROLOGY, V375, P223, DOI 10.1016/j.virol.2008.01.014
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Santos JJD, 2013, MEM I OSWALDO CRUZ, V108, P983, DOI 10.1590/0074-0276130298
   Das Suchismita, 2007, J Vis Exp, P220, DOI 10.3791/220
   FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980
   Galler R, 2011, MEM I OSWALDO CRUZ, V106, P905, DOI 10.1590/S0074-02762011000800001
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gil LHVG, 2006, VIRUS RES, V116, P69, DOI 10.1016/j.virusres.2005.08.011
   Gil LHVG, 2006, J VIROL, V80, P900, DOI 10.1128/JVI.80.2.900-911.2006
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Hershkovitz O, 2008, J VIROL, V82, P7666, DOI 10.1128/JVI.02274-07
   Jetten TH, 1997, AM J TROP MED HYG, V57, P285, DOI 10.4269/ajtmh.1997.57.285
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   KAPOOR M, 1995, GENE, V162, P175, DOI 10.1016/0378-1119(95)00332-Z
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   LAI CJ, 1991, P NATL ACAD SCI USA, V88, P5139, DOI 10.1073/pnas.88.12.5139
   Laurent-Rolle M, 2010, J VIROL, V84, P3503, DOI 10.1128/JVI.01161-09
   Leung JY, 2008, J VIROL, V82, P4731, DOI 10.1128/JVI.00002-08
   Lindenbach BD, 2007, FIELDS VIROLOGY, V1, P1102
   McElroy KL, 2006, J GEN VIROL, V87, P2993, DOI 10.1099/vir.0.82023-0
   Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Noble CG, 2010, ANTIVIR RES, V85, P450, DOI 10.1016/j.antiviral.2009.12.011
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Pu SY, 2011, J VIROL, V85, P2927, DOI 10.1128/JVI.01986-10
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Queiroz SRA, 2013, AN ACAD BRAS CIENC, V85, P159, DOI 10.1590/S0001-37652013005000008
   RICE C M, 1989, New Biologist, V1, P285
   Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6
   Sambrook J., 2001, MOL CLONING LAB MANU
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   Sriburi R, 2001, J VIROL METHODS, V92, P71, DOI 10.1016/S0166-0934(00)00277-9
   SUMIYOSHI H, 1992, J VIROL, V66, P5425, DOI 10.1128/JVI.66.9.5425-5431.1992
   Sutherst RW, 2004, CLIN MICROBIOL REV, V17, P136, DOI 10.1128/CMR.17.1.136-173.2004
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Yamshchikov VF, 2001, VIROLOGY, V281, P294, DOI 10.1006/viro.2000.0795
   Yun SI, 2003, J VIROL, V77, P6450, DOI 10.1128/JVI.77.11.6450-6465.2003
NR 42
TC 6
Z9 8
U1 0
U2 12
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD DEC
PY 2014
VL 86
IS 4
BP 1749
EP 1759
DI 10.1590/0001-3765201420130332
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AY4CQ
UT WOS:000347526200017
PM 25590713
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Palma, MD
   do Nascimento, EJM
   Mailliard, R
   Oshiro, TM
   Duarte, AJD
   Marques, ETD
AF Palma, Mariana de Lucena
   Moura do Nascimento, Eduardo Jose
   Mailliard, Robbie
   Oshiro, Telma Miyuki
   da Silva Duarte, Alberto Jose
   de Azevedo Marques, Ernesto Torres
TI Type-1 and type-2 polarized dendritic cells differ on complement protein
   expression
SO MOLECULAR IMMUNOLOGY
LA English
DT Meeting Abstract
CT 25th International Complement Workshop
CY SEP 14-18, 2014
CL Rio de Janeiro, BRAZIL
C1 [Palma, Mariana de Lucena; Moura do Nascimento, Eduardo Jose; Mailliard, Robbie] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
   [Palma, Mariana de Lucena; Oshiro, Telma Miyuki; da Silva Duarte, Alberto Jose; de Azevedo Marques, Ernesto Torres] Univ Sao Paulo, Fac Med, BR-05508 Sao Paulo, Brazil.
RI Marques, Ernesto T. A/L-4967-2013; Mailiiard, Robbie/M-9723-2015
OI Marques, Ernesto T. A/0000-0003-3826-9358; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD OCT
PY 2014
VL 61
IS 2
SI SI
MA 197
BP 285
EP 285
PG 1
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA AP7NZ
UT WOS:000342265300215
DA 2020-12-16
ER

PT J
AU Silva, MMS
   Dias, ACMS
   Cordeiro, MT
   Marques, E
   Goulart, MOF
   Dutra, RF
AF Silva, M. M. S.
   Dias, A. C. M. S.
   Cordeiro, M. T.
   Marques, E., Jr.
   Goulart, M. O. F.
   Dutra, R. F.
TI A thiophene-modified screen printed electrode for detection of dengue
   virus NS1 protein
SO TALANTA
LA English
DT Article
DE Screen printed electrode; Thiophene; Dengue virus; Immunosensor
ID RAPID DETECTION; ANTIGEN; TOOL; IMMUNOSENSOR; SENSITIVITY; DIAGNOSIS;
   ASSAYS; TESTS; ELISA
AB A thiophene-modified screen printed electrode (SPE) for detection of the Dengue virus non-structural protein 1 (NS1), an important marker for acute phase diagnosis, is described. A sulfur-containing heterocyclic compound, the thiophene was incorporated to a carbon ink to prepare reproducible screen printed electrodes. After cured, the thiophene SPE was coated by gold nanoparticles conjugated to Protein A to form a nanostrutured surface. The Anti-NS1 antibodies immobilized via their Fc portions via Protein A, leaving their antigen specific sites free circumventing the problem of a random antibodies immobilization. Amperometric responses to the NS1 protein of dengue virus were obtained by cyclic voltammetries performed in presence of ferrocyanide/ferricyanide as redox probe. The calibration curve of immunosensor showed a linear response from 0.04 mu g mL(-1) to 0.6 mu g mL(-1) of NS1 with a good linear correlation (r=0.991, p<0.05). The detection limit (0.015 mu g mL(-1) NS1) was lower than conventional analytical methods. In this work, thiophene monomers incorporated in the carbon ink enhanced the electroanalytical properties of the SPEs, increasing their reproducibility and sensitivity. This point-of-care testing represents a great potential for use in epidemic situations, facilitating the early diagnosis in acute phase of dengue virus. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Silva, M. M. S.; Dias, A. C. M. S.; Dutra, R. F.] Univ Fed Pernambuco, Biomed Engn Lab, BR-50670901 Recife, PE, Brazil.
   [Cordeiro, M. T.; Marques, E., Jr.] FIOCRUZ PE, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Marques, E., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Goulart, M. O. F.] Univ Fed Alagoas, Inst Chem & Biotechnol, Maceio, Brazil.
RP Dutra, RF (corresponding author), Univ Fed Pernambuco, Biomed Engn Lab, Av Prof Moraes Rego 1235,Cidade Univ, BR-50670901 Recife, PE, Brazil.
EM rosa.dutra@ufpe.br
RI Goulart, Marilia/A-1199-2013; Marques, Ernesto T. A/L-4967-2013; Dutra,
   Rosa F/O-5550-2018; Dutra, Rosa Fireman/Q-1380-2019
OI Goulart, Marilia/0000-0001-9860-3667; Marques, Ernesto T.
   A/0000-0003-3826-9358; Dutra, Rosa F/0000-0001-8314-4218; Dutra, Rosa
   Fireman/0000-0001-8314-4218
FU National Council of Scientific and Technological Development (CNPq,
   Brazil)National Council for Scientific and Technological Development
   (CNPq); Pernambuco Research Foundation (FACEPE, PE, Brazil)
FX The authors thank the National Council of Scientific and Technological
   Development (CNPq, Brazil) and the Pernambuco Research Foundation
   (FACEPE, PE, Brazil) for financial support.
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Alonso-Lomillo MA, 2010, BIOSENS BIOELECTRON, V25, P1333, DOI 10.1016/j.bios.2009.10.024
   Babacan S, 2000, BIOSENS BIOELECTRON, V15, P615, DOI 10.1016/S0956-5663(00)00115-9
   Blacksell SD, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/151967
   Blacksell SD, 2012, CLIN VACCINE IMMUNOL, V19, P804, DOI 10.1128/CVI.05717-11
   Blacksell SD, 2011, CLIN VACCINE IMMUNOL, V18, P2095, DOI 10.1128/CVI.05285-11
   Cavalcanti IT, 2012, BIOCHEM ENG J, V67, P225, DOI 10.1016/j.bej.2012.06.016
   Datta S, 2010, INDIAN J MED MICROBI, V28, P107, DOI 10.4103/0255-0857.62484
   Dias ACMS, 2013, BIOSENS BIOELECTRON, V44, P216, DOI 10.1016/j.bios.2012.12.033
   Dolatabadi JEN, 2014, ANAL METHODS-UK, V6, P3891, DOI 10.1039/c3ay41749b
   Renedo OD, 2007, TALANTA, V73, P202, DOI 10.1016/j.talanta.2007.03.050
   Fry SR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001199
   Gomes SLR, 2013, MICROCHEM J, V109, P10, DOI 10.1016/j.microc.2012.05.033
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   Koncki R, 1997, ANAL CHIM ACTA, V351, P143, DOI 10.1016/S0003-2670(97)00367-X
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   Mairuhu ATA, 2004, EUR J CLIN MICROBIOL, V23, P425, DOI 10.1007/s10096-004-1145-1
   Metters JP, 2011, ANALYST, V136, P1067, DOI 10.1039/c0an00894j
   Moi ML, 2013, J TRAVEL MED, V20, P185, DOI 10.1111/jtm.12018
   O'Reilly J. M., 1981, CARBON N Y, V21, P47
   Pei ZC, 2010, ANAL BIOCHEM, V398, P161, DOI 10.1016/j.ab.2009.11.038
   Ricci F, 2012, ELECTROCHIM ACTA, V84, P74, DOI 10.1016/j.electacta.2012.06.033
   SISSON TH, 1990, J IMMUNOL METHODS, V127, P215, DOI 10.1016/0022-1759(90)90071-3
   Somerset V, 2010, ELECTROCHIM ACTA, V55, P4240, DOI 10.1016/j.electacta.2009.01.029
   Stradiotto NR, 2003, J BRAZIL CHEM SOC, V14, P159, DOI 10.1590/S0103-50532003000200003
   Huy TQ, 2011, TALANTA, V86, P271, DOI 10.1016/j.talanta.2011.09.012
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wu ZL, 2002, J PHYS CHEM B, V106, P979, DOI 10.1021/jp011577l
   Yoshioka Y, 2006, SYNTHETIC MET, V156, P779, DOI 10.1016/j.synthmet.2006.03.013
   Zhang GJ, 2010, SENSOR ACTUAT B-CHEM, V146, P138, DOI 10.1016/j.snb.2010.02.021
NR 33
TC 30
Z9 30
U1 0
U2 45
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD OCT 1
PY 2014
VL 128
BP 505
EP 510
DI 10.1016/j.talanta.2014.06.009
PG 6
WC Chemistry, Analytical
SC Chemistry
GA AN6FE
UT WOS:000340689500072
PM 25059193
DA 2020-12-16
ER

PT J
AU Piazza, P
   Campbell, D
   Marques, E
   Hildebrand, WH
   Buchli, R
   Mailliard, R
   Rinaldo, CR
AF Piazza, P.
   Campbell, D.
   Marques, E.
   Hildebrand, W. H.
   Buchli, R.
   Mailliard, R.
   Rinaldo, C. R.
TI Dengue virus-infected human dendritic cells reveal hierarchies of
   naturally expressed novel NS3 CD8 T cell epitopes
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE CTL; dengue virus; epitope
ID HEMORRHAGIC-FEVER; PROTECTIVE ROLE; RESPONSES; VACCINE; IMMUNOPATHOLOGY;
   IMMUNODOMINANT; LYMPHOCYTES; PREDICTION; SEROTYPES; CD4(+)
AB Detailed knowledge of dengue virus (DENV) cell-mediated immunity is limited. In this study we characterize CD8(+) T lymphocytes recognizing three novel and two known non-structural protein 3 peptide epitopes in DENV-infected dendritic cells. Three epitopes displayed high conservation (75-100%), compared to the others (0-50%). A hierarchy ranking based on magnitude and polyfunctionality of the antigen-specific response showed that dominant epitopes were both highly conserved and cross-reactive against multiple DENV serotypes. These results are relevant to DENV pathogenesis and vaccine design.
C1 [Piazza, P.; Campbell, D.; Marques, E.; Mailliard, R.; Rinaldo, C. R.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Rinaldo, C. R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.
   [Marques, E.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Hildebrand, W. H.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.
   [Buchli, R.] Pure Prot LLC, Oklahoma City, OK USA.
RP Piazza, P (corresponding author), Univ Pittsburgh, Dept Infect Dis & Microbiol, Grad Sch Publ Hlth, 130 Desoto St, Pittsburgh, PA 15261 USA.
EM paolo@pitt.edu
RI Mailiiard, Robbie/M-9723-2015; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Piazza,
   Paolo/0000-0002-2173-1342; Mailliard, Robbie/0000-0001-5501-503X;
   Delucia, Diana Campbell/0000-0002-1165-6799
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U19-AI082632];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI082632, U19AI082632] Funding Source: NIH RePORTER
FX We wish to thank Dwayne Zern of the Presbyterian University Hospital,
   Pittsburgh, USA for HLA tissue typing and Dr Kimberly-Anne Mattia of
   Integral Molecular, Philadelphia, USA, for reagents and assistance
   regarding DENV neutralizing antibody assays. This work was supported in
   part by National Institutes of Health grant U19-AI082632.
CR An J, 2004, IMMUNOL LETT, V95, P167, DOI 10.1016/j.imlet.2004.07.006
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Beaumier CM, 2010, VIRAL IMMUNOL, V23, P477, DOI 10.1089/vim.2010.0034
   Buchli R, 2005, BIOCHEMISTRY-US, V44, P12491, DOI 10.1021/bi050255v
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Frahm N, 2006, NAT IMMUNOL, V7, P173, DOI 10.1038/ni1281
   Friberg H, 2011, SCI REP-UK, V1, DOI 10.1038/srep00051
   Friberg H, 2011, IMMUNOL CELL BIOL, V89, P122, DOI 10.1038/icb.2010.61
   Fried JR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000617
   Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094
   Guzman MG, 2008, T ROY SOC TROP MED H, V102, P522, DOI 10.1016/j.trstmh.2008.03.001
   Guzman MG, 2000, LANCET, V355, P1902, DOI 10.1016/S0140-6736(00)02303-5
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Im EJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002041
   Kaabinejadian S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066298
   Khan AM, 2006, CELL IMMUNOL, V244, P141, DOI 10.1016/j.cellimm.2007.02.005
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Mailliard RB, 2013, J IMMUNOL, V191, P2570, DOI 10.4049/jimmunol.1300373
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Maves RC, 2011, VACCINE, V29, P2691, DOI 10.1016/j.vaccine.2011.01.077
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Nielsen M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000107
   Olsen L. R., 2011, IMMUNOME RES, V7, P1
   Precopio ML, 2008, CYTOM PART A, V73A, P1071, DOI 10.1002/cyto.a.20646
   Remakus S, 2012, J VIROL, V86, P9748, DOI 10.1128/JVI.00981-12
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Ruckwardt TJ, 2010, J IMMUNOL, V185, P4673, DOI 10.4049/jimmunol.1001606
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   SCREATON G, 2006, NOVART FDN SYMP, V277, P251
   Screaton G, 2006, NOVART FDN SYMP, V277, P71
   Screaton Gavin, 2006, Novartis Found Symp, V277, P164, DOI 10.1002/0470058005.ch12
   Vaughan K, 2010, VIRAL IMMUNOL, V23, P259, DOI 10.1089/vim.2010.0006
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Whitehorn J, 2010, BRIT MED BULL, V95, P161, DOI 10.1093/bmb/ldq019
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zaritskaya L, 2010, EXPERT REV VACCINES, V9, P601, DOI [10.1586/erv.10.49, 10.1586/ERV.10.49]
NR 42
TC 8
Z9 8
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD SEP
PY 2014
VL 177
IS 3
BP 696
EP 702
DI 10.1111/cei.12373
PG 7
WC Immunology
SC Immunology
GA AM7JW
UT WOS:000340044000015
PM 24816171
OA Green Published
DA 2020-12-16
ER

PT J
AU van Panhuis, WG
   Hyun, S
   Blaney, K
   Marques, ETA
   Coelho, GE
   Siqueira, JB
   Tibshirani, R
   da Silva, JB
   Rosenfeld, R
AF van Panhuis, Willem G.
   Hyun, Sangwon
   Blaney, Kayleigh
   Marques, Ernesto T. A., Jr.
   Coelho, Giovanini E.
   Siqueira, Joao Bosco, Jr.
   Tibshirani, Ryan
   da Silva, Jarbas B., Jr.
   Rosenfeld, Roni
TI Risk of Dengue for Tourists and Teams during the World Cup 2014 in
   Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INFECTIOUS-DISEASES; TRAVELERS; OLYMPICS; VISITORS
AB Background: This year, Brazil will host about 600,000 foreign visitors during the 2014 FIFA World Cup. The concern of possible dengue transmission during this event has been raised given the high transmission rates reported in the past by this country.
   Methodology/Principal Findings: We used dengue incidence rates reported by each host city during previous years (2001-2013) to estimate the risk of dengue during the World Cup for tourists and teams. Two statistical models were used: a percentile rank (PR) and an Empirical Bayes (EB) model. Expected IR's during the games were generally low (<10/100,000) but predictions varied across locations and between models. Based on current ticket allocations, the mean number of expected symptomatic dengue cases ranged from 26 (PR, 10th-100th percentile: 5-334 cases) to 59 (EB, 95% credible interval: 30-77 cases) among foreign tourists but none are expected among teams. These numbers will highly depend on actual travel schedules and dengue immunity among visitors. Sensitivity analysis for both models indicated that the expected number of cases could be as low as 4 or 5 with 100,000 visitors and as high as 38 or 70 with 800,000 visitors (PR and EB, respectively).
   Conclusion/Significance: The risk of dengue among tourists during the World Cup is expected to be small due to immunity among the Brazil host population provided by last year's epidemic with the same DENV serotypes. Quantitative risk estimates by different groups and methodologies should be made routinely for mass gathering events.
C1 [van Panhuis, Willem G.; Blaney, Kayleigh] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Hyun, Sangwon; Tibshirani, Ryan; Rosenfeld, Roni] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Coelho, Giovanini E.; da Silva, Jarbas B., Jr.] Brazil Ministerio Saude, Brasilia, DF, Brazil.
   [Siqueira, Joao Bosco, Jr.] Univ Fed Goias, Goiania, Go, Brazil.
RP van Panhuis, WG (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
EM wav10@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Van Panhuis, Willem/S-5495-2019
OI Marques, Ernesto T. A/0000-0003-3826-9358; Van Panhuis,
   Willem/0000-0002-7278-9982; Hyun, Sangwon/0000-0003-0377-897X
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [49276]; US National Institute of General Medical SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [5U54GM088491]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491] Funding Source: NIH
   RePORTER
FX This work has been supported by research awards from the Bill and
   Melinda Gates Foundation (Grant 49276, Evaluation of Candidate Vaccine
   Technologies Using Computational Models) and from the US National
   Institute of General Medical Sciences (Grant 5U54GM088491, Computational
   Models of Infectious Disease Threats). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abubakar I, 2012, LANCET INFECT DIS, V12, P66, DOI 10.1016/S1473-3099(11)70246-8
   [Anonymous], 2014, FOX NEWS
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Cummings DAT, 2004, NATURE, V427, P344, DOI 10.1038/nature02225
   Duizer E, 2004, INT ALERT, V8, P2532
   EHRESMANN KR, 1995, J INFECT DIS, V171, P679, DOI 10.1093/infdis/171.3.679
   Gallego V, 2014, TRAVEL MED INFECT DI, V12, P208, DOI 10.1016/j.tmaid.2014.04.004
   Harley D, 2014, LANCET INFECT DIS, V14, P543, DOI 10.1016/S1473-3099(14)70797-2
   Hay S, 2013, NATURE, V503, P439, DOI 10.1038/503439a
   Igreja RP, 2010, CLIN INFECT DIS, V50, P616, DOI 10.1086/650177
   Iliaki E, 2014, J TRAVEL MED, V21, P214, DOI 10.1111/jtm.12117
   International Federation of Association Football, 2014, 2 3 MILL TICK 2014 F
   Johansson MA, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000168
   Lowe R, 2014, LANCET INFECT DIS, V14, P619, DOI 10.1016/S1473-3099(14)70781-9
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Panja T, 2014, 500000 FOREIGN TOURI
   Reich NG, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0414
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Wilson ME, 2014, CLIN INFECT DIS, V58, P1347, DOI 10.1093/cid/ciu122
   Wilson ME, 2014, TRAVEL MED INFECT DI, V12, P205, DOI 10.1016/j.tmaid.2014.04.001
   World Health Organization, 2008, COMM DIS AL RESP MAS
NR 22
TC 18
Z9 18
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2014
VL 8
IS 7
AR e3063
DI 10.1371/journal.pntd.0003063
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AN4IQ
UT WOS:000340551500077
PM 25079960
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Godinho, RMD
   Matassoli, FL
   Lucas, CGD
   Rigato, PO
   Goncalves, JLS
   Sato, MN
   Maciel, M
   Pecanha, LMT
   August, JT
   Marques, ETA
   de Arruda, LB
AF da Costa Godinho, Rodrigo Maciel
   Matassoli, Flavio Lemos
   de Oliveira Lucas, Carolina Goncalves
   Rigato, Paula Ordonhez
   Santos Goncalves, Jorge Luiz
   Sato, Maria Notomi
   Maciel, Milton, Jr.
   Torres Pecanha, Ligia Maria
   Thomas August, J.
   de Azevedo Marques, Ernesto Torres, Jr.
   de Arruda, Luciana Barros
TI Regulation of HIV-Gag Expression and Targeting to the
   Endolysosomal/Secretory Pathway by the Luminal Domain of
   Lysosomal-Associated Membrane Protein (LAMP-1) Enhance Gag-Specific
   Immune Response
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; VIRUS TYPE-1 GAG; CLASS-II COMPARTMENT; MHC CLASS-I;
   DNA VACCINATION; LYMPHOCYTE RESPONSES; ANTIGEN PRESENTATION; CODON
   USAGE; LONGITUDINAL ANALYSIS; ELITE CONTROLLERS
AB We have previously demonstrated that a DNA vaccine encoding HIV-p55gag in association with the lysosomal associated membrane protein-1 (LAMP-1) elicited a greater Gag-specific immune response, in comparison to a DNA encoding the native gag. In vitro studies have also demonstrated that LAMP/Gag was highly expressed and was present in MHCII containing compartments in transfected cells. In this study, the mechanisms involved in these processes and the relative contributions of the increased expression and altered traffic for the enhanced immune response were addressed. Cells transfected with plasmid DNA constructs containing p55gag attached to truncated sequences of LAMP-1 showed that the increased expression of gag mRNA required p55gag in frame with at least 741 bp of the LAMP-1 luminal domain. LAMP luminal domain also showed to be essential for Gag traffic through lysosomes and, in this case, the whole sequence was required. Further analysis of the trafficking pathway of the intact LAMP/Gag chimera demonstrated that it was secreted, at least in part, associated with exosome-like vesicles. Immunization of mice with LAMP/gag chimeric plasmids demonstrated that high expression level alone can induce a substantial transient antibody response, but targeting of the antigen to the endolysosomal/secretory pathways was required for establishment of cellular and memory response. The intact LAMP/gag construct induced polyfunctional CD4(+) T cell response, which presence at the time of immunization was required for CD8(+) T cell priming. LAMP-mediated targeting to endolysosomal/secretory pathway is an important new mechanistic element in LAMP-mediated enhanced immunity with applications to the development of novel anti-HIV vaccines and to general vaccinology field.
C1 [da Costa Godinho, Rodrigo Maciel; Matassoli, Flavio Lemos; de Oliveira Lucas, Carolina Goncalves; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
   [Rigato, Paula Ordonhez; Sato, Maria Notomi] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Dermatol Imunodeficiencias,LIM 56, Sao Paulo, Brazil.
   [Santos Goncalves, Jorge Luiz; Torres Pecanha, Ligia Maria] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunol, Rio De Janeiro, Brazil.
   [Maciel, Milton, Jr.] Naval Med Res Ctr, Infect Dis Directorate, Enter Dis Dept, Silver Spring, MD USA.
   [Maciel, Milton, Jr.; Thomas August, J.; de Azevedo Marques, Ernesto Torres, Jr.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [de Azevedo Marques, Ernesto Torres, Jr.] Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [de Azevedo Marques, Ernesto Torres, Jr.] Fiocruz Pernambuco, Dept Virol, Recife, PE, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana B/N-9086-2013; Ordonhez Rigato, Paula/J-3618-2012;
   iMed.ULisboa, M2B/B-5277-2014; Sato, Maria N/C-2853-2012; Marques,
   Ernesto T. A/L-4967-2013; Godinho, Rodrigo/G-5135-2015; Sato, Maria
   N/C-1196-2012
OI iMed.ULisboa, M2B/0000-0002-1245-3715; Marques, Ernesto T.
   A/0000-0003-3826-9358; Sato, Maria N/0000-0002-7911-1824; Lucas,
   Carolina/0000-0003-4590-2756
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37-AI41908, R21-AI44317];
   Brazilian Ministry of Health; CAPESCAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq); FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); FINEPCiencia Tecnologia e Inovacao (FINEP); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R21AI044317,
   R21AI044317] Funding Source: NIH RePORTER
FX This work was supported by Grants R37-AI41908 and R21-AI44317 from the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health; and by Brazilian Ministry of Health, CAPES, CNPq,
   FAPERJ, and FINEP. R. M. C. Godinho and F. L. Matassoli were the
   recipients of a CNPq fellowship; C.G.O. Lucas was the recipient of a
   FAPERJ fellowship. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], MOL IMMUNOL, V47, P1507
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Bazhan SI, 2010, MOL IMMUNOL, V47, P1507, DOI 10.1016/j.molimm.2010.01.020
   Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998
   Bivas-Benita M, 2013, MUCOSAL IMMUNOL, V6, P156, DOI 10.1038/mi.2012.59
   Bockl K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034723
   Bojak A, 2002, INTERVIROLOGY, V45, P275, DOI 10.1159/000067919
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494
   COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Delcayre A, 2005, BLOOD CELL MOL DIS, V35, P158, DOI 10.1016/j.bcmd.2005.07.003
   Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001
   Denzer K, 2000, J CELL SCI, V113, P3365
   DUBEY C, 1995, J IMMUNOL, V155, P45
   Durali D, 1998, J VIROL, V72, P3547, DOI 10.1128/JVI.72.5.3547-3553.1998
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10
   Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10
   Ferre AL, 2009, BLOOD, V113, P3978, DOI 10.1182/blood-2008-10-182709
   Fu TM, 1997, MOL MED, V3, P362, DOI 10.1007/BF03401683
   Fuller DH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033715
   Graf M, 2000, J VIROL, V74, P10822, DOI 10.1128/JVI.74.22.10822-10826.2000
   Hartman ZC, 2011, VACCINE, V29, P9361, DOI 10.1016/j.vaccine.2011.09.133
   Kaur M, 2009, VACCINE, V27, P2128, DOI 10.1016/j.vaccine.2009.01.128
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Langlade-Demoyen P, 2003, EUR J IMMUNOL, V33, P720, DOI 10.1002/eji.200323287
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   Midha S, 2009, EUR J IMMUNOL, V39, P159, DOI 10.1002/eji.200838058
   Nanjundappa RH, 2012, VACCINE, V30, P3519, DOI 10.1016/j.vaccine.2012.03.075
   Nanjundappa RH, 2011, VACCINE, V29, P3538, DOI 10.1016/j.vaccine.2011.02.095
   Ngumbela KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002356
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Pissani F, 2012, VACCINE, V30, P5519, DOI 10.1016/j.vaccine.2012.06.042
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491
   Pontesilli O, 1998, J INFECT DIS, V178, P1008, DOI 10.1086/515659
   Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075
   Qiu JT, 2000, J VIROL, V74, P5997, DOI 10.1128/JVI.74.13.5997-6005.2000
   Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Schliehe C, 2012, J VIROL, V86, P9782, DOI 10.1128/JVI.00694-12
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   Stober D, 2002, EUR J IMMUNOL, V32, P1099, DOI 10.1002/1521-4141(200204)32:4<1099::AID-IMMU1099>3.3.CO;2-#
   Sui YJ, 2010, P NATL ACAD SCI USA, V107, P9843, DOI 10.1073/pnas.0911932107
   Thakur A, 2012, VACCINE, V30, P4907, DOI 10.1016/j.vaccine.2012.05.049
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Vaccari M, 2005, J IMMUNOL, V175, P3502, DOI 10.4049/jimmunol.175.6.3502
   Vargas-Inchaustegui DA, 2012, J IMMUNOL, V189, P1878, DOI 10.4049/jimmunol.1201026
   Wang QM, 2012, DNA CELL BIOL, V31, P489, DOI 10.1089/dna.2011.1309
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438
   Zhang HF, 2011, CELL MOL IMMUNOL, V8, P23, DOI 10.1038/cmi.2010.59
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
NR 67
TC 9
Z9 9
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2014
VL 9
IS 6
AR e99887
DI 10.1371/journal.pone.0099887
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AJ5PV
UT WOS:000337738600077
PM 24932692
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Dobbs, A
   Nascimento, E
   Garcia-Bates, T
   Smith, A
   Marques, E
   Barratt-Boyes, S
AF Dobbs, Andrea
   Nascimento, Eduardo
   Garcia-Bates, Tatiana
   Smith, Amanda
   Marques, Ernesto
   Barratt-Boyes, Simon
TI Towards understanding the expansion of plasmablasts in dengue virus
   infections
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Dobbs, Andrea; Smith, Amanda; Marques, Ernesto; Barratt-Boyes, Simon] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Dobbs, Andrea; Nascimento, Eduardo; Smith, Amanda; Marques, Ernesto; Barratt-Boyes, Simon] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Garcia-Bates, Tatiana] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
   [Barratt-Boyes, Simon] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA HEM4P.254
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765003020
DA 2020-12-16
ER

PT J
AU Duangkhae, P
   Smith, A
   Marques, E
   Ryman, K
   Barratt-Boyes, S
AF Duangkhae, Parichat
   Smith, Amanda
   Marques, Ernesto
   Ryman, Kate
   Barratt-Boyes, Simon
TI Defining the targets of Dengue virus infection in human skin
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Duangkhae, Parichat; Smith, Amanda; Marques, Ernesto; Barratt-Boyes, Simon] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Ryman, Kate] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
   [Barratt-Boyes, Simon] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA.
   [Duangkhae, Parichat; Smith, Amanda; Marques, Ernesto; Ryman, Kate; Barratt-Boyes, Simon] Ctr Vaccine Res, Pittsburgh, PA USA.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA VIR8P.1069
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765003092
DA 2020-12-16
ER

PT J
AU Douradinha, B
   McBurney, SP
   de Melo, KMS
   Smith, AP
   Krishna, NK
   Barratt-Boyes, SM
   Evans, JD
   Nascimento, EJM
   Marques, ETA
AF Douradinha, Bruno
   McBurney, Sean P.
   Soares de Melo, Klecia M.
   Smith, Amanda P.
   Krishna, Neel K.
   Barratt-Boyes, Simon M.
   Evans, Jared D.
   Nascimento, Eduardo J. M.
   Marques, Ernesto T. A., Jr.
TI C1q binding to dengue virus decreases levels of infection and
   inflammatory molecules transcription in THP-1 cells
SO VIRUS RESEARCH
LA English
DT Article
DE Dengue; Dengue hemorrhagic fever; Dengue fever; C1q; Classical
   complement pathway; Viral persistence
ID DC-SIGN; GENE-EXPRESSION; COMPLEMENT; RECEPTOR; PROTEIN; FEVER; ENTRY
AB Dengue virus infection elicits a spectrum of clinical presentations ranging from asymptomatic to severe disease. The mechanisms leading to severe dengue are not known, however it has been reported that the complement system is hyper-activated in severe dengue. Screening of complement proteins demonstrated that C1q, a pattern recognition molecule, can bind directly to dengue virus envelope protein and to whole dengue virus serotype 2. Incubation of dengue virus serotype 2 with C1q prior to infection of THP-1 cells led to decreased virus infectivity and modulation of mRNA expression of immunoregulatory molecules suggesting reduced inflammatory responses. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Douradinha, Bruno] Fdn Ri MED, I-90133 Palermo, Italy.
   [Douradinha, Bruno; McBurney, Sean P.; Soares de Melo, Klecia M.; Smith, Amanda P.; Barratt-Boyes, Simon M.; Evans, Jared D.; Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Soares de Melo, Klecia M.; Marques, Ernesto T. A., Jr.] Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
   [Krishna, Neel K.] Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23507 USA.
   [Barratt-Boyes, Simon M.; Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
   [Evans, Jared D.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15219 USA.
RP Douradinha, B (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave,9th Floor, Pittsburgh, PA 15261 USA.
EM brd49@cvr.pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Douradinha, Bruno/R-5832-2017;
   Nascimento, Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Nascimento,
   Eduardo/0000-0002-9851-2332; Krishna, Neel/0000-0002-4615-4035; Barratt
   Boyes, Simon/0000-0002-8869-4945; Douradinha, Bruno/0000-0002-9980-4505
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R21 AI095750]; Fine
   Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R21AI095750, R21AI095750] Funding Source: NIH RePORTER
FX We thank the reviewers for their helpful comments and suggestions. B.D.
   is a Fondazione Ri.MED (Palermo, Italy) postdoctoral fellow. This work
   was partially supported by a National Institutes of Health grant R21
   AI095750 to N.K.K. J.D.E. is supported by a grant from the Fine
   Foundation.
CR Alhoot MA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001410
   Amet T, 2012, HEPATOLOGY, V55, P354, DOI 10.1002/hep.24686
   Anderluh M, 2012, CURR MED CHEM, V19, P992, DOI 10.2174/092986712799320664
   Avirutnan P, 2011, MBIO, V2, DOI 10.1128/mBio.00276-11
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902
   Bonaparte RS, 2008, J VIROL, V82, P817, DOI 10.1128/JVI.01847-07
   Chen YC, 1999, J VIROL, V73, P2650, DOI 10.1128/JVI.73.4.2650-2657.1999
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   Dong T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001192
   Fuchs A, 2010, CELL HOST MICROBE, V8, P186, DOI 10.1016/j.chom.2010.07.007
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5
   Hair PS, 2010, MOL IMMUNOL, V47, P792, DOI 10.1016/j.molimm.2009.10.006
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Hilleman MR, 2004, P NATL ACAD SCI USA, V101, P14560, DOI 10.1073/pnas.0404758101
   Hosszu KK, 2012, BLOOD, V120, P1228, DOI 10.1182/blood-2011-07-369728
   Hosszu KK, 2010, INNATE IMMUN-LONDON, V16, P115, DOI 10.1177/1753425909339815
   Mehlhop E, 2007, CELL HOST MICROBE, V2, P417, DOI 10.1016/j.chom.2007.09.015
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Silva EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057514
   Soares de Melo K.M., 2012, PRODUCTION VALIDATIO
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
NR 30
TC 11
Z9 11
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD JAN 22
PY 2014
VL 179
BP 231
EP 234
DI 10.1016/j.virusres.2013.11.007
PG 4
WC Virology
SC Virology
GA AB3FT
UT WOS:000331677400027
PM 24246304
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Nascimento, EJM
   Hottz, ED
   Garcia-Bates, TM
   Bozza, F
   Marques, ETA
   Barratt-Boyes, SM
AF Nascimento, Eduardo J. M.
   Hottz, Eugenio D.
   Garcia-Bates, Tatiana M.
   Bozza, Fernando
   Marques, Ernesto T. A., Jr.
   Barratt-Boyes, Simon M.
TI Emerging Concepts in Dengue Pathogenesis: Interplay between
   Plasmablasts, Platelets, and Complement in Triggering Vasculopathy
SO CRITICAL REVIEWS IN IMMUNOLOGY
LA English
DT Article
DE Cell activation; immune dysregulation; immune complexes; inflammation
ID VIRUS NONSTRUCTURAL PROTEIN-1; HUMAN MONOCLONAL-ANTIBODIES; ORIGINAL
   ANTIGENIC SIN; HUMAN-BONE-MARROW; MESSENGER-RNA; ACTIVATED PLATELETS;
   IMMUNE-RESPONSES; FEVER PATIENTS; CELL-DEATH; DC-SIGN
AB Dengue is a mosquito-borne disease caused by infection with dengue virus (DENV) that represents a serious and expanding global health threat. Most DENY infections are inapparent or produce mild and self-limiting illness; however a significant proportion results in severe disease characterized by vasculopathy and plasma leakage that may culminate in shock and death. The cause of dengue-associated vasculopathy is likely to be multifactorial but remains essentially unknown. Severe disease is manifest during a critical phase from 4 to 7 days after onset of symptoms, once the virus has disappeared from the circulation but before the peak of T-cell activation, suggesting that other factors mediate vasculopathy. Here, we present evidence for a combined role of plasmablasts, complement, and platelets in driving severe disease in DENY infection. Massive expansion of virus-specific plasmablasts peaks during the critical phase of infection, coincident with activation of complement and activation and depletion of platelets. We propose a step-wise model in which virus-specific antibodies produced by plasmablasts form immune complexes, leading to activation of complement and release of vasoactive anaphylatoxins. Platelets become activated through binding of complement- and antibody-coated virus, as well as direct binding of virus to DC-SIGN, leading to the release of inflammatory microparticles and cytokines and sequestration of platelets in the microvasculature. We suggest that the combined effects of anaphylatoxins, inflammatory microparticles, and platelet sequestration serve as triggers of vasculopathy in severe dengue.
C1 [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Garcia-Bates, Tatiana M.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
   [Barratt-Boyes, Simon M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA.
   [Hottz, Eugenio D.; Bozza, Fernando] Inst Oswaldo Cruz, Lab Immunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
RP Barratt-Boyes, SM (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave, Pittsburgh, PA 15260 USA.
EM smbb@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Hottz, Eugenio D/I-9850-2014; Bozza,
   Fernando A/A-2618-2013; Nascimento, Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Bozza, Fernando
   A/0000-0003-4878-0256; Nascimento, Eduardo/0000-0002-9851-2332;
   Garcia-Bates, Tatiana/0000-0001-7579-5272; Barratt Boyes,
   Simon/0000-0002-8869-4945
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI049820];
   "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" - CNPq
   project [550140/2010-7]; "Fundacao de Amparo a Ciencia e Tecnologia de
   Pernambuco" - FACEPE project [APQ-1516-4.01/10]; Fundacao de Amparo a
   Ciencia e Tecnologia do Rio de Janeiro - FAPERJ; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820] Funding Source: NIH
   RePORTER
FX This work was supported by U.S. National Institutes of Health research
   grant AI049820 (to E.T.A.M. and S.M.B.-B.) and training grant AI049820
   (to T.M.G.-B.); "Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico" - CNPq project 550140/2010-7 (to E.T.A.M.); "Fundacao de
   Amparo a Ciencia e Tecnologia de Pernambuco" - FACEPE project
   APQ-1516-4.01/10 (to E.T.A.M.); and Fundacao de Amparo a Ciencia e
   Tecnologia do Rio de Janeiro - FAPERJ (to F.B.)
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Aggrey AA, 2013, J IMMUNOL, V190, P4685, DOI 10.4049/jimmunol.1202672
   Aird WC, 2003, MAYO CLIN PROC, V78, P869, DOI 10.4065/78.7.869
   Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Antczak AJ, 2010, CELL IMMUNOL, V263, P129, DOI 10.1016/j.cellimm.2010.03.009
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Balakrishnan T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029430
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P46, DOI 10.1111/j.1574-695X.2008.00399.x
   Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Berlacher MD, 2013, AM J PATHOL, V182, P244, DOI 10.1016/j.ajpath.2012.09.005
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bhoopat L, 1996, ASIAN PAC J ALLERGY, V14, P107
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BOONPUCKNAVIG S, 1979, ARCH PATHOL LAB MED, V103, P463
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Buckner CM, 2013, J VIROL, V87, P5800, DOI 10.1128/JVI.00094-13
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   Clark KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052902
   COWAN DH, 1976, JAMA-J AM MED ASSOC, V235, P1230, DOI 10.1001/jama.235.12.1230
   Crill WD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004991
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Dixon DA, 2006, J CLIN INVEST, V116, P2727, DOI 10.1172/JC127209
   Duran A, 2013, J CLIN VIROL, V56, P199, DOI 10.1016/j.jcv.2012.11.007
   Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005
   EVANS G, 1969, BRIT J SURG, V56, P624
   Falconar AKI, 2007, CLIN VACCINE IMMUNOL, V14, P493, DOI 10.1128/CVI.00371-06
   Fitzgerald JR, 2006, MOL MICROBIOL, V59, P212, DOI 10.1111/j.1365-2958.2005.04922.x
   Fuchs A, 2010, CELL HOST MICROBE, V8, P186, DOI 10.1016/j.chom.2010.07.007
   FUNAHARA Y, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P351
   de Araujo JMG, 2009, J VIROL METHODS, V155, P34, DOI 10.1016/j.jviromet.2008.09.023
   Garcia G, 2011, INT J INFECT DIS, V15, pE38, DOI 10.1016/j.ijid.2010.09.008
   Trinidad AG, 2006, J LEUKOCYTE BIOL, V79, P1073, DOI 10.1189/jlb.1205701
   Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350
   GAWAZ M, 1995, EUR J CLIN INVEST, V25, P843, DOI 10.1111/j.1365-2362.1995.tb01694.x
   Ghosh K, 2008, J ELECTRON MICROSC, V57, P113, DOI 10.1093/jmicro/dfn007
   Guabiraba R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015680
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hamad OA, 2010, J IMMUNOL, V184, P2686, DOI 10.4049/jimmunol.0902810
   Honda S, 2009, AM J TROP MED HYG, V80, P841, DOI 10.4269/ajtmh.2009.80.841
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2013, BLOOD
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Jacobs MG, 2000, FASEB J, V14, P1603, DOI 10.1096/fj.14.11.1603
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Koraka P, 2003, J CLIN MICROBIOL, V41, P4154, DOI 10.1128/JCM.41.9.4154-4159.2003
   Koraka P, 2001, J CLIN MICROBIOL, V39, P4332, DOI 10.1128/JCM.39.12.4332-4338.2001
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kumar Y, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001887
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Lin CF, 2008, LAB INVEST, V88, P1079, DOI 10.1038/labinvest.2008.70
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Loughman A, 2005, MOL MICROBIOL, V57, P804, DOI 10.1111/j.1365-2958.2005.04731.x
   Lutz HU, 2007, MOL IMMUNOL, V44, P3862, DOI 10.1016/j.molimm.2007.06.146
   Mei HE, 2009, BLOOD, V113, P2461, DOI 10.1182/blood-2008-04-153544
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   MOUTHON L, 1995, P NATL ACAD SCI USA, V92, P3839, DOI 10.1073/pnas.92.9.3839
   Murgue B, 1997, J INFECT DIS, V175, P1497, DOI 10.1086/516486
   NAKAO S, 1989, BLOOD, V74, P1235
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   Nishioka K, 1974, Allerg Immunol (Leipz), V20-21, P385
   Noisakran S, 2012, INT J HEMATOL, V96, P600, DOI 10.1007/s12185-012-1175-x
   Noisakran S, 2012, EXP HEMATOL, V40, P250, DOI 10.1016/j.exphem.2011.11.011
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   OhAinle M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003084
   Onlamoon N, 2010, BLOOD, V115, P1823, DOI 10.1182/blood-2009-09-242990
   Pastor AF, 2013, HUM IMMUNOL, V74, P1225, DOI 10.1016/j.humimm.2013.05.005
   Peerschke EIB, 1997, J IMMUNOL, V159, P5594
   PHAN DT, 1991, HAEMATOLOGIA, V24, P13
   Priyadarshini D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008709
   Qian Y, 2010, CYTOM PART B-CLIN CY, V78B, pS69, DOI 10.1002/cyto.b.20554
   Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Rondina MT, 2011, J THROMB HAEMOST, V9, P748, DOI 10.1111/j.1538-7836.2011.04208.x
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Rothwell SW, 1996, AM J TROP MED HYG, V54, P503, DOI 10.4269/ajtmh.1996.54.503
   Schieffelin JS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-28
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Smith SA, 2013, J INFECT DIS, V207, P1898, DOI 10.1093/infdis/jit119
   Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106
   Srichaikul T, 2000, BEST PRACT RES CL HA, V13, P261, DOI 10.1053/beha.2000.0073
   Sridharan A, 2013, J VIROL, V87, P11648, DOI 10.1128/JVI.01156-13
   Steinberg BE, 2012, ANTIVIR RES, V93, P2, DOI 10.1016/j.antiviral.2011.10.019
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Sun DS, 2007, J THROMB HAEMOST, V5, P2291, DOI 10.1111/j.1538-7836.2007.02754.x
   Tam DTH, 2012, CLIN INFECT DIS, V55, P1216, DOI 10.1093/cid/cis655
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   THEIN S, 1993, J MED VIROL, V40, P102, DOI 10.1002/jmv.1890400205
   Nguyen THT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002592
   Tsai JJ, 2011, J INNATE IMMUN, V3, P530, DOI 10.1159/000322904
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Wahala WMPB, 2009, VIROLOGY, V392, P103, DOI 10.1016/j.virol.2009.06.037
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   WANG SG, 1995, VIROLOGY, V213, P254, DOI 10.1006/viro.1995.1567
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   Warkentin Theodore E, 2003, Hematology Am Soc Hematol Educ Program, P497
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Weyrich AS, 2005, CIRCULATION, V111, P633, DOI 10.1161/01.CIR.0000154607.90506.45
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Wrammert J, 2009, J CLIN IMMUNOL, V29, P151, DOI 10.1007/s10875-008-9267-3
   Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688
   Yang Kuender D., 1995, Acta Microbiologica et Immunologica Hungarica, V42, P403
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
   Zompi S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001568
NR 129
TC 18
Z9 21
U1 0
U2 5
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1040-8401
EI 2162-6472
J9 CRIT REV IMMUNOL
JI Crit. Rev. Immunol.
PY 2014
VL 34
IS 3
BP 227
EP 240
DI 10.1615/CritRevImmunol.2014010212
PG 14
WC Immunology
SC Immunology
GA AI0QI
UT WOS:000336553300004
PM 24941075
DA 2020-12-16
ER

PT J
AU Douradinha, B
   Reis, VCB
   Rogers, MB
   Torres, FAG
   Evans, JD
   Marques, ETA
AF Douradinha, Bruno
   Reis, Viviane C. B.
   Rogers, Matthew B.
   Torres, Fernando A. G.
   Evans, Jared D.
   Marques, Ernesto T. A., Jr.
TI Novel insights in genetic transformation of the probiotic yeast
   Saccharomyces boulardii
SO BIOENGINEERED
LA English
DT Article
DE Saccharomyces boulardii; promoter; expression of foreign sequences;
   screening; resistance markers
ID CLOSTRIDIUM-DIFFICILE DIARRHEA; BACTERIAL TRANSLOCATION;
   ESCHERICHIA-COLI; BREWERS-YEAST; IMMUNE-SYSTEM; CELL-SURFACE;
   CEREVISIAE; EXPRESSION; STRAIN; MICE
AB Saccharomyces boulardii (S. boulardii) is a probiotic yeast related to Saccharomyces cerevisiae (S. cerevisiae) but with distinct genetic, taxonomic, and metabolic properties. S. cerevisiae has been used extensively in biotechnological applications. Currently, many strains are available, and multiple genetic tools have been developed, which allow the expression of several exogenous proteins of interest with applications in the fields of medicine, biofuels, the food industry, and scientific research, among others. Although S. boulardii has been widely studied due to its probiotic properties against several gastrointestinal tract disorders, very few studies addressed the use of this yeast as a vector for expression of foreign genes of interest with biotechnological applications. Here we show that, despite the similarity of the two yeasts, not all genetic tools used in S. cerevisiae can be applied in S. boulardii. While transformation of the latter could be obtained using a commercial kit developed for the former, consequent screening of successful transformants had to be optimized. We also show that several genes frequently used in genetic manipulation of S. cerevisiae (e.g., promoters and resistance markers) are present in S. boulardii. Sequencing revealed a high rate of homology (>96%) between the orthologs of the two yeasts. However, we also observed some of them are not eligible to be targeted for transformation of S. boulardii. This work has important applications toward the potential of this probiotic yeast as an expression system for genes of interest.
C1 [Douradinha, Bruno] Fdn Ri MED, Palermo, Italy.
   [Douradinha, Bruno; Rogers, Matthew B.; Evans, Jared D.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Reis, Viviane C. B.; Torres, Fernando A. G.] Univ Brasilia, Inst Ciencias Biol, Ctr Biotecnol Mol, Brasilia, DF, Brazil.
   [Evans, Jared D.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Sch Med, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
RP Douradinha, B (corresponding author), Fdn Ri MED, Palermo, Italy.
EM brd49@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Torres, Fernando A.G./D-5651-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Torres, Fernando
   A.G./0000-0002-3650-7271; Douradinha, Bruno/0000-0002-9980-4505
FU Fine Foundation
FX BD is a Fondazione Ri.MED (Palermo, Italy) postdoctoral fellow. JDE is
   supported by a grant from the Fine Foundation. We thank Prof Michael
   Keogh (Albert Einstein College of Medicine, Bronx, NY) for sharing
   online useful protocols and suggestions about Saccharomyces
   manipulations (https://sites.google.com/site/mckeogh2/protocols).
CR Abosereh N. A., 2011, Australian Journal of Basic and Applied Sciences, V5, P114
   Ardiani A, 2010, FEMS YEAST RES, V10, P1060, DOI 10.1111/j.1567-1364.2010.00665.x
   Reis VCB, 2012, J IND MICROBIOL BIOT, V39, P1673, DOI 10.1007/s10295-012-1170-5
   Chee MK, 2012, G3-GENES GENOM GENET, V2, P515, DOI 10.1534/g3.111.001917
   CHIA JKS, 1995, CLIN INFECT DIS, V20, P1581, DOI 10.1093/clinids/20.6.1581
   Czerucka D, 2007, ALIMENT PHARM THER, V26, P767, DOI 10.1111/j.1365-2036.2007.03442.x
   Da Silva NA, 2012, FEMS YEAST RES, V12, P197, DOI 10.1111/j.1567-1364.2011.00769.x
   De Maeseneire S, 2012, APPL SYNTHETIC BIOL, P62
   Edwards-Ingram L, 2007, APPL ENVIRON MICROB, V73, P2458, DOI 10.1128/AEM.02201-06
   Edwards-Ingram LC, 2004, GENOME RES, V14, P1043, DOI 10.1101/gr.2114704
   ELBLE R, 1992, BIOTECHNIQUES, V13, P18
   Fietto JLR, 2004, CAN J MICROBIOL, V50, P615, DOI 10.1139/W04-050
   Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500
   Gedek BR, 1999, MYCOSES, V42, P261, DOI 10.1046/j.1439-0507.1999.00449.x
   Generoso SV, 2010, ARCH MICROBIOL, V192, P477, DOI 10.1007/s00203-010-0574-8
   Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.0.CO;2-K
   GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4
   GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8
   Hamedi Hassan, 2013, Avicenna Journal of Medical Biotechnology, V5, P29
   Izadnia F, 1998, DIGEST DIS SCI, V43, P2055, DOI 10.1023/A:1018811331596
   Kawai Shigeyuki, 2010, Bioeng Bugs, V1, P395, DOI 10.4161/bbug.1.6.13257
   Kovacs D J, 2000, J Am Board Fam Pract, V13, P138
   Latorre-Garcia L, 2008, WORLD J MICROB BIOT, V24, P2957, DOI 10.1007/s11274-008-9837-9
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martins FS, 2007, J MED MICROBIOL, V56, P352, DOI 10.1099/jmm.0.46525-0
   Martins FS, 2013, MICROBES INFECT, V15, P270, DOI 10.1016/j.micinf.2012.12.007
   Martins FS, 2011, INT J MED MICROBIOL, V301, P359, DOI 10.1016/j.ijmm.2010.11.002
   Martins FS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008925
   Martins FS, 2005, J GEN APPL MICROBIOL, V51, P83, DOI 10.2323/jgam.51.83
   McCullough MJ, 1998, J CLIN MICROBIOL, V36, P2613, DOI 10.1128/JCM.36.9.2613-2617.1998
   Michael S, 2013, INFLAMM BOWEL DIS, V19, P185, DOI 10.1002/ibd.23006
   MORTIMER RK, 1986, GENETICS, V113, P35
   Murai T, 1997, APPL ENVIRON MICROB, V63, P1362, DOI 10.1128/AEM.63.4.1362-1366.1997
   Pannunzio VG, 2004, YEAST PLASMIDS LEAST, P27
   PERLIN DS, 1989, J BIOL CHEM, V264, P21857
   PETES TD, 1980, ANNU REV BIOCHEM, V49, P845, DOI 10.1146/annurev.bi.49.070180.004213
   Pohlmann C, 2013, BIOENGINEERED, V4, P172, DOI 10.4161/bioe.22646
   SCHELLENBERG D, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90960-1
   Schneiter R, 2004, GENETICS MOL CELL BI
   Sherman F., 1997, ENCY MOL BIOL MOL ME, V6, P302
   Teste MA, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-99
   Tiago FCP, 2012, J MED MICROBIOL, V61, P1194, DOI 10.1099/jmm.0.042283-0
   Treco Douglas A, 2008, Curr Protoc Mol Biol, VChapter 13, DOI 10.1002/0471142727.mb1302s82
   WHELAN WL, 1979, GENETICS, V91, P35
NR 44
TC 11
Z9 11
U1 1
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165-5979
EI 2165-5987
J9 BIOENGINEERED
JI Bioengineered
PD JAN-FEB
PY 2014
VL 5
IS 1
BP 21
EP 29
DI 10.4161/bioe.26271
PG 9
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA AI5KQ
UT WOS:000336905700011
PM 24013355
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Santos, JJD
   Cordeiro, MT
   Bertani, GR
   Marques, ETD
   Gil, LHVG
AF da Silva Santos, Jefferson Jose
   Cordeiro, Marli Tenorio
   Bertani, Giovani Rota
   de Azevedo Marques, Ernesto Torres
   Vega Gonzales Gil, Laura Helena
TI Construction and characterisation of a complete reverse genetics system
   of dengue virus type 3
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE reverse genetics; dengue virus; molecular cloning
ID CDNA-CLONES; HEMORRHAGIC-FEVER; INFECTIOUS CLONE; VACCINE; YEAST;
   PATHOGENESIS; REPLICON; PROTEIN; STRAIN; DNA
AB Dengue virulence and fitness are important factors that determine disease outcome. However, dengue virus (DENV) molecular biology and pathogenesis are not completely elucidated. New insights on those mechanisms have been facilitated by the development of reverse genetic systems in the past decades. Unfortunately, instability of flavivirus genomes cloned in Escherichia coli has been a major problem in these systems. Here, we describe the development of a complete reverse genetics system, based on the construction of an infectious clone and replicon for a low passage DENV-3 genotype III of a clinical isolate. Both constructs were assembled into a newly designed yeast-E. coli shuttle vector by homologous recombination technique and propagated in yeast to prevent any possible genome instability in E. coli. RNA transcripts derived from the infectious clone are infectious upon transfection into BHK-21 cells even after repeated passages of the plasmid in yeast. Transcript-derived DENV-3 exhibited growth kinetics, focus formation size comparable to original DENV-3 in mosquito C6/36 cell culture. In vitro characterisation of DENV-3 replicon confirmed its identity and ability to replicate transiently in BHK-21 cells. The reverse genetics system reported here is a valuable tool that will facilitate further molecular studies in DENV replication, virus attenuation and pathogenesis.
C1 [da Silva Santos, Jefferson Jose; Cordeiro, Marli Tenorio; de Azevedo Marques, Ernesto Torres; Vega Gonzales Gil, Laura Helena] Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Dept Saude Estado Pernambuco, Lab Cent Saude Publ, Recife, PE, Brazil.
   [Bertani, Giovani Rota] Univ Fed Pernambuco, Dept Bioquim, Recife, PE, Brazil.
   [de Azevedo Marques, Ernesto Torres] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
RP Gil, LHVG (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Santos, Jefferson/W-9610-2019
OI Marques, Ernesto T. A/0000-0003-3826-9358; Santos,
   Jefferson/0000-0001-5895-4163
FU FIOCRUZ (Papes V); FACEPE [APQ-0519-2.12/06]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [470892/2007-2];
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX Financial support: FIOCRUZ (Papes V), FACEPE (APQ-0519-2.12/06), CNPq
   (470892/2007-2); JJSS receives a graduate scholarship from the CNPq.
CR Alcaraz-Estrada SL, 2010, J GEN VIROL, V91, P2713, DOI 10.1099/vir.0.024083-0
   Alvarez DE, 2005, J VIROL, V79, P6631, DOI 10.1128/JVI.79.11.6631-6643.2005
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Bouloy M, 2009, ANTIVIR RES, V84, P101, DOI 10.1016/j.antiviral.2009.08.002
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   Das S, 2007, J VIS EXP, V2007, P220
   Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001
   FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gil LHVG, 2006, J VIROL, V80, P900, DOI 10.1128/JVI.80.2.900-911.2006
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Hurrelbrink RJ, 1999, J GEN VIROL, V80, P3115, DOI 10.1099/0022-1317-80-12-3115
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   KAPOOR M, 1995, GENE, V162, P175, DOI 10.1016/0378-1119(95)00332-Z
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   Kurosu T, 2010, BIOCHEM BIOPH RES CO, V394, P398, DOI 10.1016/j.bbrc.2010.02.181
   LAI CJ, 1991, P NATL ACAD SCI USA, V88, P5139, DOI 10.1073/pnas.88.12.5139
   Lindenbach BD, 2007, FIELDS VIROLOGY, V1, P1102
   Liu WJ, 2006, J VIROL, V80, P2396, DOI 10.1128/JVI.80.5.2396-2404.2006
   MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223
   Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Pang X, 2001, BMC Microbiol, V1, P18, DOI 10.1186/1471-2180-1-18
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Pu SY, 2011, J VIROL, V85, P2927, DOI 10.1128/JVI.01986-10
   Puig-Basagoiti F, 2005, ANTIMICROB AGENTS CH, V49, P4980, DOI 10.1128/AAC.49.12.4980-4988.2005
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   RICE C M, 1989, New Biologist, V1, P285
   Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6
   Sambrook J., 2001, MOL CLONING LAB MANU
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   SIKORSKI RS, 1989, GENETICS, V122, P19
   Sriburi R, 2001, J VIROL METHODS, V92, P71, DOI 10.1016/S0166-0934(00)00277-9
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Tuiskunen A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-398
   Ubol S, 2008, VIROLOGY, V376, P290, DOI 10.1016/j.virol.2008.03.030
   Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009
   Yamshchikov VF, 2001, VIROLOGY, V281, P294, DOI 10.1006/viro.2000.0795
NR 43
TC 9
Z9 11
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD DEC
PY 2013
VL 108
IS 8
BP 983
EP 991
DI 10.1590/0074-0276130298
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 294HY
UT WOS:000330037300005
PM 24402142
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Nascimento, EJM
   Mailliard, RB
   Khan, AM
   Sidney, J
   Sette, A
   Guzman, N
   Paulaitis, M
   de Melo, AB
   Cordeiro, MT
   Gil, LVG
   Lemonnier, F
   Rinaldo, C
   August, JT
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Mailliard, Robbie B.
   Khan, Asif M.
   Sidney, John
   Sette, Alessandro
   Guzman, Nicole
   Paulaitis, Michael
   de Melo, Andrea Barbosa
   Cordeiro, Marli T.
   Gil, Laura V. G.
   Lemonnier, Francoir
   Rinaldo, Charles
   August, J. Thomas
   Marques, Ernesto T. A., Jr.
TI Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DENGUE HEMORRHAGIC-FEVER; ORIGINAL ANTIGENIC SIN; LYMPHOCYTE CLONES;
   VARIANT PEPTIDES; SUBTYPE-III; VIRUS; RESPONSES; VACCINE; BINDING; MICE
AB Anti-dengue T-cell responses have been implicated in both protection and immunopathology. However, most of the T-cell studies for dengue include few epitopes, with limited knowledge of their inter-serotype variation and the breadth of their human leukocyte antigen (HLA) affinity. In order to expand our knowledge of HLA-restricted dengue epitopes, we screened T-cell responses against 477 overlapping peptides derived from structural and non-structural proteins of the dengue virus serotype 3 (DENV3) by use of HLA class I and II transgenic mice (TgM): A2, A24, B7, DR2, DR3 and DR4. TgM were inoculated with peptides pools and the T-cell immunogenic peptides were identified by ELISPOT. Nine HLA class I and 97 HLA class II novel DENV3 epitopes were identified based on immunogenicity in TgM and their HLA affinity was further confirmed by binding assays analysis. A subset of these epitopes activated memory T-cells from DENV3 immune volunteers and was also capable of priming naive T-cells, ex vivo, from dengue IgG negative individuals. Analysis of inter-and intra-serotype variation of such an epitope (A02-restricted) allowed us to identify altered peptide ligands not only in DENV3 but also in other DENV serotypes. These studies also characterized the HLA promiscuity of 23 HLA class II epitopes bearing highly conserved sequences, six of which could bind to more than 10 different HLA molecules representing a large percentage of the global population. These epitope data are invaluable to investigate the role of T-cells in dengue immunity/pathogenesis and vaccine design.
C1 [Nascimento, Eduardo J. M.; Mailliard, Robbie B.; Rinaldo, Charles; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Khan, Asif M.; August, J. Thomas] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Khan, Asif M.] Perdana Univ, Grad Sch Med, Serdang, Selangor Darul, Malaysia.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Guzman, Nicole; Paulaitis, Michael] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
   [de Melo, Andrea Barbosa; Cordeiro, Marli T.; Gil, Laura V. G.; Marques, Ernesto T. A., Jr.] Fiocruz MS, Dept Virol & Expt Therapy, CPqAM, Recife, PE, Brazil.
   [Lemonnier, Francoir] Inst Pasteur, Unite Immunite Cellulaire Antivirale, Paris, France.
RP Nascimento, EJM (corresponding author), Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA.
EM ejmn@pitt.edu; marques@pitt.edu
RI Nascimento, Eduardo/J-4590-2014; Khan, Mohammad Asif/F-4663-2010;
   Marques, Ernesto T. A/L-4967-2013; Mailiiard, Robbie/M-9723-2015
OI Nascimento, Eduardo/0000-0002-9851-2332; Khan, Mohammad
   Asif/0000-0001-9202-279X; Marques, Ernesto T. A/0000-0003-3826-9358;
   Mailliard, Robbie/0000-0001-5501-503X
FU NIH/NAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HHSN272200900042C, U19 AI56541]
FX This work was supported by NIH/NAID contracts HHSN272200900042C (AS) and
   U19 AI56541. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Buchli R, 2004, BIOCHEMISTRY-US, V43, P14852, DOI 10.1021/bi048580q
   Capeding RZ, 2010, AM J TROP MED HYG, V82, P330, DOI 10.4269/ajtmh.2010.09-0542
   Chaturvedi UC, 2005, INDIAN J MED RES, V121, P639
   Chotiyarnwong P, 2007, ACTA CRYSTALLOGR F, V63, P386, DOI 10.1107/S1744309107013693
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Melo AB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001938
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   de Alencar LXE, 2013, J TROP MED-US, V2013, DOI 10.1155/2013/648475
   Fruci D, 2003, J IMMUNOL, V170, P2977, DOI 10.4049/jimmunol.170.6.2977
   Green S, 1997, VIROLOGY, V234, P383, DOI 10.1006/viro.1997.8648
   Green SL, 1997, VET CLIN N AM-EQUINE, V13, P1
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Gwinn W, 2003, AM J TROP MED HYG, V69, P39, DOI 10.4269/ajtmh.2003.69.39
   Harenberg A, 2013, HUM VACC IMMUNOTHER, V9, P2317, DOI 10.4161/hv.25562
   Hertz T, 2011, J VIROL, V85, P1310, DOI 10.1128/JVI.01966-10
   Imrie A, 2007, J VIROL, V81, P10081, DOI 10.1128/JVI.00330-07
   Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635
   Jung KO, 2012, J VIROL, V86, P7616, DOI 10.1128/JVI.00166-12
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Khan AM, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S4
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   KURANE I, 1993, J VIROL, V67, P6285, DOI 10.1128/JVI.67.10.6285-6288.1993
   Kurane I, 1998, VIROLOGY, V240, P169, DOI 10.1006/viro.1997.8925
   Lee KS, 2010, EMERG INFECT DIS, V16, P847, DOI 10.3201/eid1605.091006
   Li SF, 2011, VACCINE, V29, P3695, DOI 10.1016/j.vaccine.2011.03.002
   Lund O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026494
   Maciel M, 2008, VIROLOGY, V378, P105, DOI 10.1016/j.virol.2008.04.043
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261
   Mailliard RB, 2013, J IMMUNOL, V191, P2570, DOI 10.4049/jimmunol.1300373
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mathew A, 1998, J VIROL, V72, P3999, DOI 10.1128/JVI.72.5.3999-4004.1998
   Mazzon M, 2009, J INFECT DIS, V200, P1261, DOI 10.1086/605847
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Morrison AC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000670
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Okamoto Y, 1998, J GEN VIROL, V79, P697, DOI 10.1099/0022-1317-79-4-697
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Paramasivan R, 2010, INDIAN J MED RES, V132, P339
   Pascolo S, 2005, EXPERT OPIN BIOL TH, V5, P919, DOI 10.1517/14712598.5.7.919
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Rodriguez-Madoz JR, 2010, J VIROL, V84, P4845, DOI 10.1128/JVI.02514-09
   Roederer M, 2003, J IMMUNOL METHODS, V274, P221, DOI 10.1016/S0022-1759(02)00423-4
   Rohrlich PS, 2003, INT IMMUNOL, V15, P765, DOI 10.1093/intimm/dxg073
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sanchez V, 2006, VACCINE, V24, P4914, DOI 10.1016/j.vaccine.2006.03.066
   Scharnagl NC, 2007, EXPERT REV VACCINES, V6, P605, DOI 10.1586/14760584.6.4.605
   Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017
   Sidney J, 2001, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1803s31
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Sidney J, 2010, J IMMUNOL, V184, P2492, DOI 10.4049/jimmunol.0903655
   Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   Simon GG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008574
   STRAUSS G, 1994, IMMUNOGENETICS, V40, P104
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Sun JM, 2011, EMERG INFECT DIS, V17, P321, DOI 10.3201/eid1702.100396
   Tan PT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008754
   Thomas SJ, 2013, AM J TROP MED HYG, V88, P73, DOI 10.4269/ajtmh.2012.12-0361
   Toma A, 2009, DIABETES, V58, P394, DOI 10.2337/db08-0599
   Vandenbark AA, 2003, J IMMUNOL, V171, P127, DOI 10.4049/jimmunol.171.1.127
   Vaughan K, 2010, VIRAL IMMUNOL, V23, P259, DOI 10.1089/vim.2010.0006
   Weiskopf D, 2011, J IMMUNOL, V187, P4268, DOI 10.4049/jimmunol.1101970
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zeng LL, 1996, J VIROL, V70, P3108, DOI 10.1128/JVI.70.5.3108-3117.1996
   Zivna I, 2002, J IMMUNOL, V168, P5959, DOI 10.4049/jimmunol.168.11.5959
   ZIVNY J, 1995, J EXP MED, V182, P853, DOI 10.1084/jem.182.3.853
NR 77
TC 23
Z9 23
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2013
VL 7
IS 10
AR e2497
DI 10.1371/journal.pntd.0002497
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 299DW
UT WOS:000330376500034
PM 24130917
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU da Silva, MMC
   Gil, LHVG
   Marques, ETD
   Calzavara-Silva, CE
AF Carneiro da Silva, Mayara Marques
   Vega Gonzales Gil, Laura Helena
   de Azevedo Marques Junior, Ernesto Torres
   Calzavara-Silva, Carlos Eduardo
TI Potential biomarkers for the clinical prognosis of severe dengue
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue; biomarkers; apoptosis; innate immunity; quantitative real-time
   PCR
ID BLOOD MONONUCLEAR-CELLS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B;
   GENE-EXPRESSION; VIRUS-INFECTION; HEMORRHAGIC-FEVER; DENDRITIC CELLS;
   GAMMA RIII; DISEASE; RECEPTOR
AB Currently, several assays can confirm acute dengue infection at the point-of-care. However, none of these assays can predict the severity of the disease symptoms. A prognosis test that predicts the likelihood of a dengue patient to develop a severe form of the disease could permit more efficient patient triage and treatment. We hypothesise that mRNA expression of apoptosis and innate immune response-related genes will be differentially regulated during the early stages of dengue and might predict the clinical outcome. Aiming to identify biomarkers for dengue prognosis, we extracted mRNA from the peripheral blood mononuclear cells of mild and severe dengue patients during the febrile stage of the disease to measure the expression levels of selected genes by quantitative polymerase chain reaction. The selected candidate biomarkers were previously identified by our group as differentially expressed in microarray studies. We verified that the mRNA coding for CFD, MAGED1, PSMB9, PRDX4 and FCGR3B were differentially expressed between patients who developed clinical symptoms associated with the mild type of dengue and patients who showed clinical symptoms associated with severe dengue. We suggest that this gene expression panel could putatively serve as biomarkers for the clinical prognosis of dengue haemorrhagic fever.
C1 [Carneiro da Silva, Mayara Marques; Vega Gonzales Gil, Laura Helena; de Azevedo Marques Junior, Ernesto Torres] Fiocruz MS, Centro Pesquisas Aggeu Magalhaes, Dept Virol, Lab Virol & Terapia Expt, Recife, PE, Brazil.
   [de Azevedo Marques Junior, Ernesto Torres] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Calzavara-Silva, Carlos Eduardo] Fiocruz MS, Ctr Pesquisas Rene Rachou, Dept Imunol, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
RP Calzavara-Silva, CE (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Dept Imunol, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
EM calzavara@cpqrr.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-00741-11]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [550140/2010-7, 477569/2011-0]
FX FAPEMIG (CBB-APQ-00741-11), CNPq (550140/2010-7, 477569/2011-0)
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Aleyas AG, 2009, J IMMUNOL, V183, P2462, DOI 10.4049/jimmunol.0801952
   Applied Biosystems, 2012, AMPL EFF TAQMANR GEN
   Applied Biosystems, 2012, APPL BIOS US B
   Avirutnan P, 2008, VACCINE, V26, pI100, DOI 10.1016/j.vaccine.2008.11.061
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x
   Brown MG, 2009, J LEUKOCYTE BIOL, V85, P71, DOI 10.1189/jlb.0308167
   Calzavara-Silva CE, 2009, AN ACAD BRAS CIENC, V81, P671, DOI 10.1590/S0001-37652009000400006
   Chang K, 2009, J FORMOS MED ASSOC, V108, P879, DOI 10.1016/S0929-6646(09)60420-4
   Chaturvedi UC, 2006, FEMS IMMUNOL MED MIC, V47, P155, DOI 10.1111/j.1574-695X.2006.00058.x
   Cheng HJ, 2009, EXP BIOL MED, V234, P63, DOI 10.3181/0805-RM-147
   Coffey LL, 2009, MICROBES INFECT, V11, P143, DOI 10.1016/j.micinf.2008.12.006
   Conceicao TM, 2010, J INFECTION, V60, P65, DOI 10.1016/j.jinf.2009.10.003
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   delaSalle H, 1997, ADV EXP MED BIOL, V417, P345
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   Espina LM, 2003, AM J TROP MED HYG, V68, P48, DOI 10.4269/ajtmh.2003.68.48
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   Galon J, 1996, J IMMUNOL, V157, P1184
   Gibbons RV, 2009, BMJ-BRIT MED J, V324, P1563
   Gil L, 2009, VIRAL IMMUNOL, V22, P23, DOI 10.1089/vim.2008.0063
   Gilfoy F, 2009, VIROLOGY, V385, P74, DOI 10.1016/j.virol.2008.11.034
   Gomes ALV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011267
   Gray KA, 2013, NUCLEIC ACIDS RES, V41, pD545, DOI 10.1093/nar/gks1066
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   Huerta-Zepeda A, 2008, THROMB HAEMOSTASIS, V99, P936, DOI [10.1160/TH07-08-0483, 10.1160/TH07-08-0438]
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952
   Kindzelskii AL, 2000, J IMMUNOL, V164, P953, DOI 10.4049/jimmunol.164.2.953
   Kwan WH, 2005, J VIROL, V79, P7291, DOI 10.1128/JVI.79.12.7291-7299.2005
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Levy A, 2010, T ROY SOC TROP MED H, V104, P16, DOI 10.1016/j.trstmh.2009.06.013
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102
   Long HT, 2009, J INFECT DIS, V199, P537, DOI 10.1086/596507
   Long TH, 2010, J VIROL, V84, P12982, DOI 10.1128/JVI.01224-10
   Mairuhu ATA, 2004, EUR J CLIN MICROBIOL, V23, P425, DOI 10.1007/s10096-004-1145-1
   Mandelboim O, 1999, P NATL ACAD SCI USA, V96, P5640, DOI 10.1073/pnas.96.10.5640
   Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Nasirudeen AMA, 2009, J MED VIROL, V81, P1069, DOI 10.1002/jmv.21486
   Nsakran S, 2008, EXP BIOL MED, V233, P401, DOI 10.3181/0707-MR-198
   Okado-Matsumoto A, 2000, J BIOCHEM, V127, P493, DOI 10.1093/oxfordjournals.jbchem.a022632
   Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Screaton Gavin, 2006, Novartis Found Symp, V277, P164, DOI 10.1002/0470058005.ch12
   Senanayake Sanjaya, 2006, Aust Fam Physician, V35, P609
   Tsai TF, 1998, CURR OPIN INFECT DIS, V11, P547, DOI 10.1097/00001432-199810000-00006
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   WHO - World Health Organization, 2012, DENG DENG HAEM FEV
   Yen YT, 2008, J VIROL, V82, P12312, DOI 10.1128/JVI.00968-08
NR 55
TC 9
Z9 10
U1 0
U2 12
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP
PY 2013
VL 108
IS 6
BP 755
EP 762
DI 10.1590/0074-0276108062013012
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 219HX
UT WOS:000324498000012
PM 24037198
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Mailliard, RB
   Smith, KN
   Fecek, RJ
   Rappocciolo, G
   Nascimento, EJM
   Marques, ET
   Watkins, SC
   Mullins, JI
   Rinaldo, CR
AF Mailliard, Robbie B.
   Smith, Kellie N.
   Fecek, Ronald J.
   Rappocciolo, Giovanna
   Nascimento, Eduardo J. M.
   Marques, Ernesto T.
   Watkins, Simon C.
   Mullins, James I.
   Rinaldo, Charles R.
TI Selective Induction of CTL Helper Rather Than Killer Activity by Natural
   Epitope Variants Promotes Dendritic Cell-Mediated HIV-1 Dissemination
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CD8(+) T-CELLS; ORIGINAL ANTIGENIC SIN; VIRUS TYPE-I; TYPE-1; MEMORY;
   INFECTION; IMMUNITY; IMMUNODOMINANT; ACTIVATION; RESPONSES
AB The ability of HIV-1 to rapidly accumulate mutations provides the virus with an effective means of escaping CD8(+) CTL responses. In this study, we describe how subtle alterations in CTL epitopes expressed by naturally occurring HIV-1 variants can result in an incomplete escape from CTL recognition, providing the virus with a selective advantage. Rather than paralyzing the CTL response, these epitope modifications selectively induce the CTL to produce proinflammatory cytokines in the absence of target killing. Importantly, instead of dampening the immune response through CTL elimination of variant Ag-expressing immature dendritic cells (DC), a positive CTL-to-DC immune feedback loop dominates whereby the immature DC differentiate into mature proinflammatory DC. Moreover, these CTL-programmed DC exhibit a superior capacity to mediate HIV-1 trans-infection of T cells. This discordant induction of CTL helper activity in the absence of killing most likely contributes to the chronic immune activation associated with HIV-1 infection, and can be used by HIV-1 to promote viral dissemination and persistence. Our findings highlight the need to address the detrimental potential of eliciting dysfunctional cross-reactive memory CTL responses when designing and implementing anti-HIV-1 immunotherapies.
C1 [Mailliard, Robbie B.; Fecek, Ronald J.; Rappocciolo, Giovanna; Nascimento, Eduardo J. M.; Marques, Ernesto T.; Rinaldo, Charles R.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Smith, Kellie N.] Univ Pittsburgh, Dept Mol Microbiol & Genet, Pittsburgh, PA 15261 USA.
   [Watkins, Simon C.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA.
   [Mullins, James I.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   [Rinaldo, Charles R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.
RP Mailliard, RB (corresponding author), Univ Pittsburgh, 130 Desoto St, Pittsburgh, PA 15261 USA.
EM rbm19@pitt.edu
RI Marques, Ernesto/L-4514-2013; Nascimento, Eduardo/J-4590-2014;
   Mailiiard, Robbie/M-9723-2015; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Nascimento,
   Eduardo/0000-0002-9851-2332; Marques, Ernesto T. A/0000-0003-3826-9358;
   watkins, simon/0000-0003-4092-1552; Mailliard,
   Robbie/0000-0001-5501-503X; Rappocciolo, Giovanna/0000-0002-6415-0847
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01 AI-35041, R37 AI-41870, T32 AI-065380]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P01AI057005,
   P01AI057005, P01AI057005, P01AI057005, U01AI035041, T32AI065380,
   P01AI057005, P01AI057005, R37AI041870, T32AI007487, U01AI035041,
   P01AI057005, P01AI057005, U01AI035041, U01AI035041, R37AI041870,
   P01AI057005, P01AI057005, T32AI065380, T32AI065380, U01AI035041,
   U01AI035041, T32AI065380, P01AI057005, U01AI035041, P01AI057005,
   P01AI057005, U01AI035041, P01AI057005, P01AI057005, T32AI065380,
   P01AI057005, P01AI057005, P01AI057005, R37AI041870, U01AI035041,
   T32AI065380, R37AI041870, P01AI057005, P01AI057005, R37AI041870,
   U01AI035041, U01AI035041, U01AI035041, U01AI035041, R37AI041870,
   U01AI035041, P01AI057005, P01AI057005, R37AI041870, P01AI057005,
   P01AI057005, T32AI065380, U01AI035041, P01AI057005, P01AI057005,
   P01AI057005, P01AI057005, U01AI035041, T32AI007487, U01AI035041,
   U01AI035041, U01AI035041, P01AI057005, U01AI035041, P01AI057005,
   U01AI035041, P01AI057005, P01AI057005, U01AI035041, P01AI057005,
   T32AI065380, U01AI035041, T32AI065380, U01AI035041, P01AI057005,
   T32AI007487, R37AI041870, P01AI057005, P01AI057005, U01AI035041,
   P01AI057005, P01AI057005, T32AI065380, U01AI035041, U01AI035041,
   U01AI035041, U01AI035041, R37AI041870, U01AI035041, P01AI057005,
   P01AI057005, T32AI007487, P01AI057005, T32AI065380, T32AI065380,
   P01AI057005, T32AI065380, P01AI057005, T32AI007487, R37AI041870,
   U01AI035041, U01AI035041, P01AI057005, P01AI057005, P01AI057005,
   U01AI035041, U01AI035041] Funding Source: NIH RePORTER
FX This work was supported by National Institute of Allergy and Infectious
   Diseases Grants U01 AI-35041, R37 AI-41870, and T32 AI-065380.
CR BALACHANDRAN R, 1991, VIROLOGY, V180, P229, DOI 10.1016/0042-6822(91)90027-9
   Betts MR, 2004, J IMMUNOL, V172, P6407, DOI 10.4049/jimmunol.172.10.6407
   Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405
   Brander C, 1999, J IMMUNOL, V162, P4796
   Brockman MA, 2010, J VIROL, V84, P11937, DOI 10.1128/JVI.01086-10
   Buchli R, 2005, BIOCHEMISTRY-US, V44, P12491, DOI 10.1021/bi050255v
   Cale EM, 2011, J VIROL, V85, P3746, DOI 10.1128/JVI.02420-10
   Christie NM, 2009, VIROLOGY, V388, P137, DOI 10.1016/j.virol.2009.03.003
   Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Detels R, 2012, PUBLIC HEALTH, V126, P196, DOI 10.1016/j.puhe.2011.11.013
   Draenert R, 2004, J VIROL, V78, P630, DOI 10.1128/JVI.78.2.630-641.2004
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417
   Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181
   Gurunathan S, 2000, J IMMUNOL, V165, P915, DOI 10.4049/jimmunol.165.2.915
   Hay CM, 1999, J VIROL, V73, P5509, DOI 10.1128/JVI.73.7.5509-5519.1999
   Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095
   Iversen AKN, 2006, NAT IMMUNOL, V7, P179, DOI 10.1038/ni1298
   Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9
   Kalinski P, 2005, NAT REV IMMUNOL, V5, P251, DOI 10.1038/nri1569
   Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675
   Klenerman P, 1998, NATURE, V394, P482
   Klenerman P, 2002, CURR OPIN MICROBIOL, V5, P408, DOI 10.1016/S1369-5274(02)00339-9
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758
   Liu Y, 2007, J VIROL, V81, P12179, DOI 10.1128/JVI.01277-07
   Loffredo JT, 2007, J VIROL, V81, P2624, DOI 10.1128/JVI.01912-06
   Lore K, 2005, J EXP MED, V201, P2023, DOI 10.1084/jem.20042413
   Maile R, 2005, J IMMUNOL, V174, P619, DOI 10.4049/jimmunol.174.2.619
   Mailliard RB, 2002, J EXP MED, V195, P473, DOI 10.1084/jem.20011662
   Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   Nakamura Y, 2007, CANCER RES, V67, P10012, DOI 10.1158/0008-5472.CAN-07-1735
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Rappocciolo G, 2006, PLOS PATHOG, V2, P691, DOI 10.1371/journal.ppat.0020070
   Rinaldo CR, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/164203
   Rolland M, 2011, NAT MED, V17, P366, DOI 10.1038/nm.2316
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Ruedl C, 1999, J EXP MED, V189, P1875, DOI 10.1084/jem.189.12.1875
   Sanders RW, 2002, J VIROL, V76, P7812, DOI 10.1128/JVI.76.15.7812-7821.2002
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216
   Valentine LE, 2008, J VIROL, V82, P575, DOI 10.1128/JVI.00275-07
   Watchmaker PB, 2008, J IMMUNOL, V180, P3857, DOI 10.4049/jimmunol.180.6.3857
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Wolint P, 2004, J EXP MED, V199, P925, DOI 10.1084/jem.20031799
   Wooldridge L, 2010, J IMMUNOL, V185, P4625, DOI 10.4049/jimmunol.1001480
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Xiao ZG, 2007, J EXP MED, V204, P2667, DOI 10.1084/jem.20062376
   Yachi PP, 2006, IMMUNITY, V25, P203, DOI 10.1016/j.immuni.2006.05.015
NR 59
TC 24
Z9 24
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD SEP 1
PY 2013
VL 191
IS 5
BP 2570
EP 2580
DI 10.4049/jimmunol.1300373
PG 11
WC Immunology
SC Immunology
GA 204TU
UT WOS:000323393300058
PM 23913962
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Pastor, AF
   Moura, LR
   Neto, JWD
   Nascimento, EJM
   Calzavara-Silva, CE
   Gomes, ALV
   da Silva, AM
   Cordeiro, MT
   Braga-Neto, U
   Crovella, S
   Gil, LHVG
   Marques, ETA
   Acioli-Santos, B
AF Pastor, Andre F.
   Moura, Lais Rodrigues
   Neto, Jose W. D.
   Nascimento, Eduardo J. M.
   Calzavara-Silva, Carlos E.
   Gomes, Ana Lisa V.
   da Silva, Ana Maria
   Cordeiro, Marli T.
   Braga-Neto, Ulisses
   Crovella, Sergio
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
   Acioli-Santos, Bartolomeu
TI Complement factor H gene (CFH) polymorphisms C-257T, G257A and
   haplotypes are associated with protection against severe dengue
   phenotype, possible related with high CFH expression
SO HUMAN IMMUNOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; HEMORRHAGIC-FEVER; VIRUS-INFECTIONS;
   INTERFERON-GAMMA; DISEASE SEVERITY; PROTEIN NS1; RISK-FACTOR; VIRAL
   LOAD; ACTIVATION; SURVEILLANCE
AB Four genetic polymorphisms located at the promoter (C-257T) and coding regions of CFH gene (exon 2 G257A, exon 14 A2089G and exon 19 G2881T) were investigated in 121 dengue patients (DENV-3) in order to assess the relationship between allele/haplotypes variants and clinical outcomes. A statistical value was found between the CFH-257T allele (TT/TC genotypes) and reduced susceptibility to severe dengue (SD). Statistical associations indicate that individuals bearing a T allele presented significantly higher protein levels in plasma. The -257T variant is located within a NF-kappa B binding site, suggesting that this variant might have effect on the ability of the CFH gene to respond to signals via the NF-kappa B pathway. The G257A allelic variant showed significant protection against severe dengue. When CFH haplotypes effect was considered, the ancestral CG/CG promoter-exon 2 SNP genotype showed significant risk to SD either in a general comparison (ancestral x all variant genotypes), as well as in individual genotypes comparison (ancestral x each variant genotype), where the most prevalent effect was observed in the CG/CG x CA/TG comparison. These findings support the involvement of -257T, 257A allele variants and haplotypes on severe dengue phenotype protection, related with high basal CFH expression. (C) 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Pastor, Andre F.; Moura, Lais Rodrigues; Neto, Jose W. D.; Calzavara-Silva, Carlos E.; Gomes, Ana Lisa V.; da Silva, Ana Maria; Cordeiro, Marli T.; Gil, Laura H. V. G.; Marques, Ernesto T. A., Jr.; Acioli-Santos, Bartolomeu] FIOCRUZ PE, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Braga-Neto, Ulisses] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA.
   [Pastor, Andre F.; Crovella, Sergio] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Acioli-Santos, B (corresponding author), FIOCRUZ PE, Virol & Expt Therapy Lab, Av Prof Moraes Rego S-N Campus UFPE Cidade Univ, Recife, PE, Brazil.
EM bartacioli@yahoo.com
RI Nascimento, Eduardo/J-4590-2014; Neto, Jose Manoel Duarte/AAH-6963-2020;
   Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013;
   Crovella, Sergio/K-5050-2016
OI Nascimento, Eduardo/0000-0002-9851-2332; Neto, Jose Manoel
   Duarte/0000-0002-3588-2934; Marques, Ernesto T. A/0000-0003-3826-9358;
   Marques, Ernesto/0000-0003-3826-9358; Crovella,
   Sergio/0000-0001-8493-1168; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU National Institute of Allergy and Infectious Diseases (NIAID/NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19 AI56541, N01 AI 40085]; Brazilian National
   Research Council (CNPq)National Council for Scientific and Technological
   Development (CNPq) [DCR 35.0382/2004.2]; FACEPE (Fundacao de Amparo
   Ciencia e Tecnologia do Estado de Pernambuco, Brazil); NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; Division of Computing and Communication
   FoundationsNational Science Foundation (NSF)NSF - Directorate for
   Computer & Information Science & Engineering (CISE) [0845407] Funding
   Source: National Science Foundation
FX The author also acknowledge the support of the National Institute of
   Allergy and Infectious Diseases (NIAID/NIH), under Grants U19 AI56541
   and N01 AI 40085, the Brazilian National Research Council (CNPq), under
   Grant DCR 35.0382/2004.2 (to Dr. Braga-Neto), and the FACEPE (Fundacao
   de Amparo Ciencia e Tecnologia do Estado de Pernambuco, Brazil) for A.
   Pastor's fellowship.
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Alencar LXE, 2013, J TROPICAL MED, V2013, DOI DOI 10.1155/2013/648475
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Avirutnan P, 2007, PLOS PATHOG, V3, P1798, DOI 10.1371/journal.ppat.0030183
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   CHIEWSILP P, 1981, AM J TROP MED HYG, V30, P1100, DOI 10.4269/ajtmh.1981.30.1100
   Chung KM, 2006, P NATL ACAD SCI USA, V103, P19111, DOI 10.1073/pnas.0605668103
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Sierra BDL, 2007, ARCH VIROL, V152, P533, DOI 10.1007/s00705-006-0869-x
   Fang X, 2012, FEMS IMMUNOL MED MIC, P1
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Furlan M, 2000, NEPHROL DIAL TRANSPL, V15, P1112, DOI 10.1093/ndt/15.8.1112
   Gubler D, 1997, DENGUE DENGUE HEMORR
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Halme J, 2009, MOL IMMUNOL, V46, P2284, DOI 10.1016/j.molimm.2009.04.005
   Krishna VD, 2009, J VIROL, V83, P4766, DOI 10.1128/JVI.01850-08
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Luo W, 1999, SCAND J IMMUNOL, V49, P487
   Marques ETA, 2008, CAD SAUDE PUBLICA, V24, P547, DOI 10.1590/S0102-311X2008000300008
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Nishioka K, 1974, Allerg Immunol (Leipz), V20-21, P385
   Organization WH, 2004, DENGUE GUIDELINES DI
   PEREZ MLP, 1987, HAEMATOLOGIA, V20, P83
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Shresta S, 2012, MBIO, V3, DOI 10.1128/mBio.00003-12
   Soundravally R, 2007, HUM IMMUNOL, V68, P973, DOI 10.1016/j.humimm.2007.09.007
   Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x
   Tan GK, 2009, CURR OPIN INFECT DIS, V22, P302, DOI 10.1097/QCO.0b013e328329ae32
   Timar KK, 2006, MOL IMMUNOL, V43, P317, DOI 10.1016/j.molimm.2005.02.009
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   Wang WK, 2003, VIROLOGY, V305, P330, DOI 10.1006/viro.2002.1704
   Warwicker P, 1997, IMMUNOGENETICS, V46, P437, DOI 10.1007/s002510050300
   Williams SA, 1997, SCAND J IMMUNOL, V45, P7, DOI 10.1046/j.1365-3083.1997.d01-364.x
NR 43
TC 12
Z9 12
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD SEP
PY 2013
VL 74
IS 9
BP 1225
EP 1230
DI 10.1016/j.humimm.2013.05.005
PG 6
WC Immunology
SC Immunology
GA 198RG
UT WOS:000322939400026
PM 23747994
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Castanha, PMS
   Cordeiro, MT
   Martelli, CMT
   Souza, WV
   Marques, ETA
   Braga, C
AF Castanha, P. M. S.
   Cordeiro, M. T.
   Martelli, C. M. T.
   Souza, W. V.
   Marques, E. T. A., Jr.
   Braga, C.
TI Force of infection of dengue serotypes in a population-based study in
   the northeast of Brazil
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Dengue; neutralizing antibody; prevalence
ID PLAQUE-REDUCTION NEUTRALIZATION; VIRUS SEROTYPES; HEMORRHAGIC-FEVER;
   CHILDREN; TRANSMISSION; EPIDEMIOLOGY; DETERMINANTS; ADOLESCENTS;
   REEMERGENCE; PREVALENCE
AB This study investigated anti-dengue serotype-specific neutralizing antibodies in a random sample of dengue IgG-positive individuals identified in a survey performed in a hyperendemic setting in northeastern Brazil in 2005. Of 323 individuals, 174 (53.8%) had antibodies to dengue virus serotype 1 (DENV-1), 104 (32.2%) to DENV-2 and 301 (93.2%) to DENV-3. Monotypic infections by DENV-3 were the most frequent infection (35.6%). Of 109 individuals aged < 15 years, 61.5% presented multitypic infections. The force of infection estimated by a catalytic model was 0.9%, 0.4% and 2.5% person-years for DENV-1, DENV-2 and DENV-3, respectively. By the age of 5 years, about 70%, 30% and 40% of participants were immune to DENV-3, DENV-2 and DENV-1, respectively. The data suggest that infection with DENV-1, -2 and -3 is intense at early ages, demonstrating the need for research efforts to investigate dengue infection in representative population samples of Brazilian children during early infancy.
C1 [Castanha, P. M. S.; Braga, C.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Doencas Transmissiveis, Dept Parasitol, BR-50670420 Recife, PE, Brazil.
   [Cordeiro, M. T.; Marques, E. T. A., Jr.] Fundacao Oswaldo Cruz, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil.
   [Cordeiro, M. T.] Secretaria Saude Pernambuco, Lab Cent Saude Publ, Recife, PE, Brazil.
   [Martelli, C. M. T.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Martelli, C. M. T.] Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.
   [Souza, W. V.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Saude Colet, BR-50670420 Recife, PE, Brazil.
   [Marques, E. T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Castanha, PMS (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Ave Prof Moraes Rego S-N,Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM castanha.priscila@gmail.com
RI Souza, Wayner V/H-3798-2013; Publica, Inct Saude/J-9544-2013; Iats,
   Inct/K-2300-2013; Da Silva Castanha, Priscila Mayrelle/G-1785-2012;
   Marques, Ernesto T. A/L-4967-2013; Braga, Maria Cynthia/A-8204-2013;
   Marques, Ernesto/L-4514-2013
OI Da Silva Castanha, Priscila Mayrelle/0000-0002-1220-5308; Marques,
   Ernesto T. A/0000-0003-3826-9358; Braga, Maria
   Cynthia/0000-0002-7862-6455; Marques, Ernesto/0000-0003-3826-9358;
   Turchi Martelli, Celina Maria/0000-0002-2491-0688; Souza,
   Wayner/0000-0002-0939-9332
FU Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   [BFT-0190-4.06/10]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [306489/2010-4, 305281/2010-0];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI082632, U19AI056541, U19AI082632, U19AI056541,
   U19AI056541, U19AI056541] Funding Source: NIH RePORTER
FX The authors acknowledge the partial support of the P. M. S. Castanha by
   Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco (Grant
   BFT-0190-4.06/10). C. M. T. Martelli and W. V. Souza received research
   scholarships (CNPq numbers 306489/2010-4, 305281/2010-0) and are
   research members from the National Institute of Science and Technology
   for Health Technology Assessment.
CR Anderson R, 1991, INFECT DIS HUMANS DY, P63
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Capeding RZ, 2011, VACCINE, V29, P3863, DOI 10.1016/j.vaccine.2011.03.057
   Cavalcanti LP, 2011, EMERG INFECT DIS, V17, P132, DOI 10.3201/eid1701.100321
   Chang SF, 2008, J MICROBIOL IMMUNOL, V41, P377
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Ximenes RAD, 2008, INT J EPIDEMIOL, V37, P852, DOI 10.1093/ije/dyn114
   Egger JR, 2008, B WORLD HEALTH ORGAN, V86, P187, DOI 10.2471/BLT.07.040170
   Endy TP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000975
   Ferguson NM, 1999, PHILOS T R SOC B, V354, P757, DOI 10.1098/rstb.1999.0428
   Sanchez-Burgos GG, 2008, SALUD PUBLICA MEXICO, V50, P362, DOI 10.1590/s0036-36342008000500008
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Guzman MG, 2000, AM J EPIDEMIOL, V152, P793, DOI 10.1093/aje/152.9.793
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Kuno G, 1995, EPIDEMIOL REV, V17, P321, DOI 10.1093/oxfordjournals.epirev.a036196
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Pessanha JEM, 2010, REV PANAM SALUD PUBL, V27, P252, DOI 10.1590/S1020-49892010000400003
   Montenegro D, 2006, REV SOC BRAS MED TRO, V39, P9, DOI 10.1590/S0037-86822006000100002
   MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985
   Reiskind MH, 2001, TROP MED INT HEALTH, V6, P212, DOI 10.1046/j.1365-3156.2001.00703.x
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   Rico-Hesse R, 2010, CURR TOP MICROBIOL, V338, P45, DOI 10.1007/978-3-642-02215-9_4
   Rodriguez-Barraquer I, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000935
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932
   Scheaffer RL, 1979, ELEMENTARY SURVEY SA, P48
   Simasathien S, 2008, AM J TROP MED HYG, V78, P426, DOI 10.4269/ajtmh.2008.78.426
   Siqueira JC, 2002, FLORA FANEROGAMICA E, P11
   Swaminathan S, 2010, EXPERT OPIN THER PAT, V20, P819, DOI 10.1517/13543771003767476
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Wilder-Smith A, 2005, EPIDEMIOL INFECT, V133, P667, DOI 10.1017/S0950268805003821
NR 33
TC 25
Z9 26
U1 0
U2 17
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD MAY
PY 2013
VL 141
IS 5
BP 1080
EP 1088
DI 10.1017/S0950268812001367
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 118YZ
UT WOS:000317064800023
PM 22800513
DA 2020-12-16
ER

PT J
AU Homma, A
   Tanuri, A
   Duarte, AJS
   Marques, E
   de Almeida, A
   Martins, R
   Silva, JB
   Possas, C
AF Homma, Akira
   Tanuri, Amilcar
   Duarte, Alberto J. S.
   Marques, Ernesto
   de Almeida, Alexandre
   Martins, Reinaldo
   Silva-Junior, Jarbas B.
   Possas, Cristina
TI Vaccine research, development, and innovation in Brazil: A translational
   science perspective
SO VACCINE
LA English
DT Review
DE Vaccines; Innovation; Translational sciences; Brazilian immunization
   program
ID CAPACITY
AB This article examines the Brazilian innovation policy for vaccines and its impact on infectious diseases, with emphasis on advances in translational science. The results indicate significant progress, with a rapid increase over the past two decades in the number of vaccine research groups, indicating scientific excellence. Advances and gaps in technological development and in public-private partnership initiatives were also identified. We stress the crucial role of partnerships, technology transfer, and targeted policies that could accelerate Brazil's participation in global vaccine research and development. We propose that new strategies should be urgently conceived to strengthen the links between the scientific and technological policies, the National Health System, and the National Immunizations Program in Brazil to provide access to low-cost vaccines to address major public health challenges. We also discuss the lessons learned from the Brazilian experience in the implementation of governmental policies on vaccine innovation that could be applicable to other developing countries. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Homma, Akira; Martins, Reinaldo; Possas, Cristina] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Tanuri, Amilcar] Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil.
   [Duarte, Alberto J. S.; de Almeida, Alexandre] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
   [Marques, Ernesto] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Silva-Junior, Jarbas B.] Natl Secretariat Hlth Surveillance, Minist Hlth, Brasilia, DF, Brazil.
   [Marques, Ernesto] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Homma, A (corresponding author), Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
EM akira@bio.fiocruz.br
RI Martins, Reinaldo/I-3413-2015; de Almeida, Alexandre/L-5895-2019;
   Duarte, Alberto J S/D-4382-2012; Marques, Ernesto/L-4514-2013; Possas,
   Cristina/AAJ-3840-2020; Marques, Ernesto T. A/L-4967-2013; Almeida,
   Alexandre/H-3645-2012
OI Martins, Reinaldo/0000-0002-0667-532X; de Almeida,
   Alexandre/0000-0002-1694-5450; Marques, Ernesto/0000-0003-3826-9358;
   Marques, Ernesto T. A/0000-0003-3826-9358; 
CR ABRACRO Brazilian Association Representatives of Clinical Research, 2012, REPR CLIN RES REP
   Adams J, 2009, GLOBAL RES REPORT BR
   Bertrand J J, 2007, Med Trop (Mars), V67, P347
   Branston RH, 2009, MUCOSAL IMMUNOL, V2, P280, DOI 10.1038/mi.2009.19
   Chan M, 2013, VACCINE, V31, pB5, DOI 10.1016/j.vaccine.2013.02.015
   Cortes MD, 2012, BIOLOGICALS, V40, P3, DOI 10.1016/j.biologicals.2011.09.013
   Dhalia R, 2009, AN ACAD BRAS CIENC, V81, P663, DOI 10.1590/S0001-37652009000400005
   Dias F, 2012, Recent Pat DNA Gene Seq, V6, P145
   Ersching J, 2009, REV MED VIROL, V19, P301, DOI 10.1002/rmv.625
   Fontana JM, 2012, TRANSL RES, V159, P430, DOI 10.1016/j.trsl.2011.12.009
   Hochman G, 2011, CIENC SAUDE COLETIVA, V16, P375, DOI 10.1590/S1413-81232011000200002
   Homma A, 2011, CIENC SAUDE COLETIVA, V16, P445, DOI 10.1590/S1413-81232011000200008
   Homma Akira, 2003, Hist. cienc. saude-Manguinhos, V10, P671, DOI 10.1590/S0104-59702003000500011
   Homma A, 2009, BIOLOGICALS, V37, P173, DOI 10.1016/j.biologicals.2009.02.011
   Huzair F, 2011, OMICS, V15, P539, DOI 10.1089/omi.2011.0036
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Milstien JB, 2010, VACCINE, V28, P2115, DOI 10.1016/j.vaccine.2009.12.036
   Ministry of Health National HIV Vaccine Committee, 2008, BRAZ NAT HIV VACC PL
   Mudd PA, 2012, NATURE, V491, P129, DOI 10.1038/nature11443
   Possas C, 2011, J ACQUIR IMMUNE D S3, V5721, pS125
   Rathore AS, 2012, BIOPHARM INT, pS28
   Santini-Oliveira M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039310
   Tendler M, 2008, ACTA TROP, V108, P263, DOI 10.1016/j.actatropica.2008.09.002
   World Health Organisation (WHO), 2009, STAT WORLDS VACC IMM
NR 24
TC 11
Z9 11
U1 0
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 18
PY 2013
VL 31
SU 2
BP B54
EP B60
DI 10.1016/j.vaccine.2012.11.084
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 137TV
UT WOS:000318462000006
PM 23598493
DA 2020-12-16
ER

PT J
AU Queiroz, SRA
   Silva, ANMR
   Santos, JJS
   Marques, ETA
   Bertani, GR
   Gil, LHVG
AF Queiroz, Sabrina R. A.
   Silva, Andrea N. M. R.
   Santos, Jefferson J. S.
   Marques, Ernesto T. A., Jr.
   Bertani, Giovani R.
   Gil, Laura H. V. G.
TI Construction of yellow fever virus subgenomic replicons by yeast-based
   homologous recombination cloning technique
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE cloning technique; homologous recombination; replicon; reporter gene;
   yellow fever virus
ID IN-VITRO; DNA FRAGMENTS; RNA; VACCINE; IMMUNIZATION; VECTORS; SYSTEM;
   TRANSCOMPLEMENTATION; REPLICATION; EXPRESSION
AB RNA replicon derived from Flavivirus genome is a valuable tool for studying viral replication independent of virion assembly and maturation, besides being a great potencial for heterologous gene expression. In this study we described the construction of subgenomic replicons of yellow fever virus by yeast-based homologous recombination technique. The plasmid containing the yellow fever 17D strain replicon (pBSC-repYFV-17D), previously characterized, was handled to heterologous expression of the green fluorescent protein (repYFV-17D-GFP) and firefly luciferase (repYFV-17D-Luc) reporter genes. Both replicons were constructed by homologous recombination between the linearized vector pBSC-repYFV-17D and the PCR product containing homologous 25 nucleotides ends incorporated into PCR primers. The genomic organization of these constructs is similar to repYFV-17D, but with insertion of the reporter gene between the remaining 63 N-terminal nucleotides of the capsid protein and 72 C-terminal nucleotides of the E protein. The replicons repYFV-17D-GFP and repYFV-17D-Luc showed efficient replication and expression of the reporter genes. The yeast-based homologous recombination technique used in this study proved to be applicable for manipulation of the yellow fever virus genome in order to construct subgenomic replicons.
C1 [Queiroz, Sabrina R. A.; Silva, Andrea N. M. R.; Santos, Jefferson J. S.; Marques, Ernesto T. A., Jr.; Gil, Laura H. V. G.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50760420 Recife, PE, Brazil.
   [Bertani, Giovani R.] Univ Fed Pernambuco, Dept Bioquim, BR-50760420 Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Av Prof Moraes Rego,S-N,Cidade Univ,Campus Univ F, BR-50760420 Recife, PE, Brazil.
EM lgilfiocruz@gmail.com
RI Marques, Ernesto/L-4514-2013; Santos, Jefferson/W-9610-2019;
   ALMEIDA-QUEIROZ, SABRINA/I-5361-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Santos,
   Jefferson/0000-0001-5895-4163; Marques, Ernesto T. A/0000-0003-3826-9358
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R21AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085] Funding Source: NIH RePORTER
CR Aberle JH, 2005, J VIROL, V79, P15107, DOI 10.1128/JVI.79.24.15107-15113.2005
   Anraku I, 2002, J VIROL, V76, P3791, DOI 10.1128/JVI.76.8.3791-3799.2002
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   Fayzulin R, 2006, VIROLOGY, V351, P196, DOI 10.1016/j.virol.2006.02.036
   Gehrke R, 2003, J VIROL, V77, P8924, DOI 10.1128/JVI.77.16.8924-8933.2003
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gibson DG, 2008, P NATL ACAD SCI USA, V105, P20404, DOI 10.1073/pnas.0811011106
   Gubler DJ, 2007, FIELDS VIROLOGY, P1153
   Imoto J, 2007, VACCINE, V25, P1076, DOI 10.1016/j.vaccine.2006.09.059
   Ishikawa T, 2008, VACCINE, V26, P2772, DOI 10.1016/j.vaccine.2008.03.010
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   KAPOOR M, 1995, GENE, V162, P175, DOI 10.1016/0378-1119(95)00332-Z
   Khromykh AA, 2000, CURR OPIN MOL THER, V2, P555
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   KHROMYKH AA, 1994, J VIROL, V68, P4580, DOI 10.1128/JVI.68.7.4580-4588.1994
   Khromykh AA, 1998, J VIROL, V72, P7270, DOI 10.1128/JVI.72.9.7270-7279.1998
   Kofler RM, 2004, P NATL ACAD SCI USA, V101, P1951, DOI 10.1073/pnas.0307145101
   Kummerer BM., 2006, MOL BIOL FLAVIVIRUS, P1
   Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698
   Lai Ching-Juh, 2003, Adv Virus Res, V61, P469, DOI 10.1016/S0065-3527(03)61013-4
   Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997
   LINDENBACH BD, 2007, FIELDS VIROLOGY PHIL, P1100
   MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799
   Ng CY, 2007, ANTIVIR RES, V76, P222, DOI 10.1016/j.antiviral.2007.06.007
   Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451
   ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354
   Mosimann ALP, 2010, J VIROL METHODS, V163, P147, DOI 10.1016/j.jviromet.2009.09.004
   Pang X, 2001, BMC Microbiol, V1, P28, DOI 10.1186/1471-2180-1-28
   PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Rossi SL, 2007, VIROLOGY, V364, P184, DOI 10.1016/j.virol.2007.02.009
   Rossi SL, 2005, VIROLOGY, V331, P457, DOI 10.1016/j.virol.2004.10.046
   Sambrook J., 2001, MOL CLONING LAB MANU
   Scholle F, 2004, J VIROL, V78, P11605, DOI 10.1128/JVI.78.21.11605-11614.2004
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   Shi PY, 2002, VIROLOGY, V296, P219, DOI 10.1006/viro.2002.1453
   Shustov AV, 2007, J VIROL, V81, P11737, DOI 10.1128/JVI.01112-07
   SUMIYOSHI H, 1992, J VIROL, V66, P5425, DOI 10.1128/JVI.66.9.5425-5431.1992
   Suzuki R, 2009, J VIROL, V83, P1870, DOI 10.1128/JVI.01891-08
   Varnavski AN, 2000, J VIROL, V74, P4394, DOI 10.1128/JVI.74.9.4394-4403.2000
   Varnavski AN, 1999, VIROLOGY, V255, P366, DOI 10.1006/viro.1998.9564
   Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009
   Yamshchikov G, 2005, VACCINE, V23, P4785, DOI 10.1016/j.vaccine.2005.04.036
NR 46
TC 6
Z9 6
U1 1
U2 10
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD MAR
PY 2013
VL 85
IS 1
BP 159
EP 168
DI 10.1590/S0001-37652013005000008
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 177RQ
UT WOS:000321393500012
PM 23460439
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Carter, DM
   Bloom, CE
   Nascimento, EJM
   Marques, ETA
   Craigo, JK
   Cherry, JL
   Lipman, DJ
   Ross, TM
AF Carter, Donald M.
   Bloom, Chalise E.
   Nascimento, Eduardo J. M.
   Marques, Ernesto T. A.
   Craigo, Jodi K.
   Cherry, Joshua L.
   Lipman, David J.
   Ross, Ted M.
TI Sequential Seasonal H1N1 Influenza Virus Infections Protect Ferrets
   against Novel 2009 H1N1 Influenza Virus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; ADAMANTANE RESISTANCE; REACTIVE ANTIBODIES;
   IMMUNE-RESPONSES; PLAQUE ASSAY; B VIRUSES; HEMAGGLUTININ; CHALLENGE;
   VACCINE; BINDING
AB Individuals <60 years of age had the lowest incidence of infection, with similar to 25% of these people having preexisting, cross-reactive antibodies to novel 2009 H1N1 influenza. Many people >60 years old also had preexisting antibodies to novel H1N1. These observations are puzzling because the seasonal H1N1 viruses circulating during the last 60 years were not antigenically similar to novel H1N1. We therefore hypothesized that a sequence of exposures to antigenically different seasonal H1N1 viruses can elicit an antibody response that protects against novel 2009 H1N1. Ferrets were preinfected with seasonal H1N1 viruses and assessed for cross-reactive antibodies to novel H1N1. Serum from infected ferrets was assayed for cross-reactivity to both seasonal and novel 2009 H1N1 strains. These results were compared to those of ferrets that were sequentially infected with H1N1 viruses isolated prior to 1957 or more-recently isolated viruses. Following seroconversion, ferrets were challenged with novel H1N1 influenza virus and assessed for viral titers in the nasal wash, morbidity, and mortality. There was no hemagglutination inhibition (HAI) cross-reactivity in ferrets infected with any single seasonal H1N1 influenza viruses, with limited protection to challenge. However, sequential H1N1 influenza infections reduced the incidence of disease and elicited cross-reactive antibodies to novel H1N1 isolates. The amount and duration of virus shedding and the frequency of transmission following novel H1N1 challenge were reduced. Exposure to multiple seasonal H1N1 influenza viruses, and not to any single H1N1 influenza virus, elicits a breadth of antibodies that neutralize novel H1N1 even though the host was never exposed to the novel H1N1 influenza viruses.
C1 [Carter, Donald M.; Bloom, Chalise E.; Nascimento, Eduardo J. M.; Marques, Ernesto T. A.; Craigo, Jodi K.; Ross, Ted M.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.; Craigo, Jodi K.; Ross, Ted M.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
   [Marques, Ernesto T. A.; Ross, Ted M.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Cherry, Joshua L.; Lipman, David J.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA.
RP Ross, TM (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
EM tmr15@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Publica, Inct Saude/J-9544-2013;
   Marques, Ernesto/L-4514-2013; Nascimento, Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Nascimento, Eduardo/0000-0002-9851-2332
FU National Institutes of Health/National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI077771, GM083602 01]; Oak
   Ridge Visiting Scientist training program award; NIH, National Library
   of MedicineUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Library of Medicine (NLM);
   Pennsylvania Department of Health; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI077771, U01AI077771,
   U01AI077771, U01AI077771, U01AI077771] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM083602,
   R01GM083602, R01GM083602, R01GM083602] Funding Source: NIH RePORTER;
   NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Library of
   Medicine (NLM) [ZIALM000077, ZIALM000077, ZIALM000077, ZIALM000077,
   ZIALM000077, ZIALM000077, ZIALM000077, ZIALM000077, ZIALM000077] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Health/National
   Institute of Allergy and Infectious Diseases awards U01AI077771 and
   GM083602 01 to T. M. R., by an Oak Ridge Visiting Scientist training
   program award to D. M. C., and by the Intramural Research Program of the
   NIH, National Library of Medicine. This project was also funded, in
   part, by a grant from the Pennsylvania Department of Health.
CR Askonas B.A., 1982, BASIC APPL INFLUENZA, P159
   Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07
   BEARE AS, 1968, LANCET, V2, P418
   Bjorkman C, 1999, J VET DIAGN INVEST, V11, P41
   Bright RA, 2006, JAMA-J AM MED ASSOC, V295, P891, DOI 10.1001/jama.295.8.joc60020
   Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2
   Bright RA, 2003, VIROLOGY, V308, P270, DOI 10.1016/S0042-6822(03)00008-4
   Bright RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001501
   Bright RA, 2007, VACCINE, V25, P3871, DOI 10.1016/j.vaccine.2007.01.106
   BROWN LE, 1990, ARCH VIROL, V114, P1, DOI 10.1007/BF01311008
   Carter DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039435
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Giles BM, 2012, J VIROL, V86, P1500, DOI 10.1128/JVI.06034-11
   Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Itoh Y, 2009, NATURE, V460, P1021, DOI 10.1038/nature08260
   Kendal A, 1982, CONCEPTS PROCEDURES
   Krammer F, 2012, J VIROL, V86, P10302, DOI 10.1128/JVI.01336-12
   Krause JC, 2010, J VIROL, V84, P3127, DOI 10.1128/JVI.02184-09
   LUBECK M, 1982, VIROLOGY, V118, P1, DOI 10.1016/0042-6822(82)90313-0
   Maines TR, 2006, P NATL ACAD SCI USA, V103, P12121, DOI 10.1073/pnas.0605134103
   Manicassamy B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000745
   MCVERNON J, 2010, EURO SURVEILL, V15
   McVernon J, 2011, INFLUENZA OTHER RESP, V5, P7, DOI 10.1111/j.1750-2659.2010.00172.x
   Mitchell JA, 2003, VACCINE, V21, P902, DOI 10.1016/S0264-410X(02)00539-X
   O'Donnell CD, 2012, J VIROL, V86, P8625, DOI 10.1128/JVI.00147-12
   Olaleye OD, 1996, REV SCI TECH OIE, V15, P937, DOI 10.20506/rst.15.3.966
   Pappas C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011158
   Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Rowe T, 2010, VIROLOGY, V401, P257, DOI 10.1016/j.virol.2010.02.020
   Skountzou I, 2010, J IMMUNOL, V185, P1642, DOI 10.4049/jimmunol.1000091
   Steckbeck JD, 2006, J MED PRIMATOL, V35, P248, DOI 10.1111/j.1600-0684.2006.00173.x
   Steckbeck JD, 2005, J VIROL, V79, P12311, DOI 10.1128/JVI.79.19.12311-12320.2005
   Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10
   TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P9, DOI 10.1007/BF02123572
   TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P23, DOI 10.1007/BF02123574
   Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430
   Zimmer SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011601
NR 41
TC 38
Z9 38
U1 0
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2013
VL 87
IS 3
BP 1400
EP 1410
DI 10.1128/JVI.02257-12
PG 11
WC Virology
SC Virology
GA 071AR
UT WOS:000313558100010
PM 23115287
OA Green Published, Bronze
DA 2020-12-16
ER

PT S
AU Viana, IFT
   Dhalia, R
   Krieger, MA
   Marques, ETA
   Lins, RD
AF Viana, Isabelle F. T.
   Dhalia, Rafael
   Krieger, Marco A.
   Marques, Ernesto T. A.
   Lins, Roberto D.
BE Setubal, JC
   Almeida, NF
TI Influence of Scaffold Stability and Electrostatics on Top7-Based
   Engineered Helical HIV-1 Epitopes
SO ADVANCES IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
SE Lecture Notes in Computer Science
LA English
DT Proceedings Paper
CT 8th Brazilian Symposium on Bioinformatics (BSB)
CY NOV 03-07, 2013
CL Recife, BRAZIL
SP Soc Brasileira Computacao, Assoc Brasileira Bioinformatica Biologia Computac, Conselho Nacl Desenvolvimento Cientifico Tecnologico, Coordenacao Aperfeicoamento Pessoal Nivel Super, Fundacao Amparo Ciencia Tecnologia Pernambuco
ID PROTEIN; BINDING; COMPLEMENTARITY; INTERFACES; SITES; TOP7; PH
AB We have recently engineered HIV-1 epitopes into the Top7 protein as scaffold using molecular dynamics simulations. The immunogenicity of the computer-engineered chimeric proteins was verified using human patient sera. The level and quality of the immune response was correlated to the structural stability of the chimeras as determined by molecular dynamics simulations. This work offers support for this correlation by a comparison between the calculated and experimental circular dichroism spectra for a selection of the Top7-HIV-1 chimeric proteins. In addition, analyzes of surface charge distribution suggest that the maintenance of an electrostatic surface potential signature is crucial for the immunogenicity of the de novo designed proteins.
C1 [Viana, Isabelle F. T.; Lins, Roberto D.] Univ Fed Pernambuco, Dept Fundamental Chem, BR-50670560 Recife, PE, Brazil.
   [Viana, Isabelle F. T.; Lins, Roberto D.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Viana, Isabelle F. T.; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Carlos Chagas Inst, BR-81350010 Curitiba, Parana, Brazil.
   [Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
RP Viana, IFT (corresponding author), Univ Fed Pernambuco, Dept Fundamental Chem, BR-50670560 Recife, PE, Brazil.
EM roberto.lins@ufpe.br
RI Marques, Ernesto T. A/L-4967-2013; Lins, Roberto D/J-7511-2012; Dhalia,
   Rafael/AAD-5432-2020; Krieger, Marco/AAE-8611-2020; Viana,
   Isabelle/M-4435-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Lins, Roberto
   D/0000-0002-3983-8025; Viana, Isabelle/0000-0003-4648-6635
FU FACEPE; NanoBiotec-BR/CAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq); INCT-INAMI; nBioNet; Oswaldo Cruz
   Foundation
FX This work was supported by FACEPE, NanoBiotec-BR/CAPES, CNPq,
   INCT-INAMI, nBioNet and the Oswaldo Cruz Foundation.
CR ANTOSIEWICZ J, 1994, ISR J CHEM, V34, P151
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Boschek CB, 2009, PROTEIN ENG DES SEL, V22, P325, DOI 10.1093/protein/gzp007
   Bulheller BM, 2009, BIOINFORMATICS, V25, P539, DOI 10.1093/bioinformatics/btp016
   CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532
   Correa DHA, 2009, J BIOCH, V3, P164, DOI DOI 10.1038/NPR0T.2006.204
   DAVIS ME, 1990, J COMPUT CHEM, V11, P401, DOI 10.1002/jcc.540110315
   Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276
   Fiorucci S, 2010, BIOPHYS J, V98, P1921, DOI 10.1016/j.bpj.2009.12.4332
   Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Janeway CA, 2001, IMMUNOBIOLOGY IMMUNE
   JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105
   Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Leckband DE, 2000, METHODS, V20, P329, DOI 10.1006/meth.1999.0926
   McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987
   NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405
   Rostkowski M, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-6
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2
   Sinha N, 2002, CURR PROTEIN PEPT SC, V3, P601, DOI 10.2174/1389203023380431
   Soares TA, 2010, J MOL GRAPH MODEL, V28, P755, DOI 10.1016/j.jmgm.2010.01.013
   Tsai CJ, 1997, PROTEIN SCI, V6, P53
   Viana IFT, 2013, RSC ADV, V3, P11790, DOI 10.1039/c3ra41562g
   Woody RW, 2002, BIOPHYS CHEM, V101, P535, DOI 10.1016/S0301-4622(02)00187-4
NR 26
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
EI 1611-3349
BN 978-3-319-02623-7; 978-3-319-02624-4
J9 LECT NOTES COMPUT SC
PY 2013
VL 8213
BP 94
EP 103
PG 10
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods; Mathematical & Computational Biology
SC Computer Science; Mathematical & Computational Biology
GA BB3HH
UT WOS:000342778000009
DA 2020-12-16
ER

PT J
AU Viana, IFT
   Soares, TA
   Lima, LFO
   Marques, ETA
   Krieger, MA
   Dhalia, R
   Lins, RD
AF Viana, Isabelle F. T.
   Soares, Thereza A.
   Lima, Lucianna F. O.
   Marques, Ernesto T. A.
   Krieger, Marco A.
   Dhalia, Rafael
   Lins, Roberto D.
TI De novo design of immunoreactive conformation-specific HIV-1 epitopes
   based on Top7 scaffold
SO RSC ADVANCES
LA English
DT Article
ID COMPUTATIONAL DESIGN; PROTEIN FOLD; GP41; ECTODOMAIN; ANTIBODIES;
   IMMUNOGENS; MODEL; MOTIF
AB Epitope exposure strategies often fail due to high conformational instability, resulting in loss of native conformation and fast degradation. Protein scaffolding, where a structural element of an antigen protein is transplanted into a scaffold acceptor protein, has been employed as an alternative solution. However, while this approach aims to preserve the epitope structure, it frequently results in unstable chimeric scaffolds. To overcome this issue, we employed a novel computational approach to rationally engineer conformational antigens into a highly stable scaffold protein. This strategy is showcased to display conformational HIV-1 gp41-based epitopes in their native structure. From HIV-1 antigen sequence databases, we have identified short sequences with the most probable antibody-recognizable regions. These sequences were inserted into or replaced regions of the original Top7 protein with analogous secondary structure assignment. Molecular dynamics simulations were used to characterize the protein stability and structural dynamic of the chimeric proteins, leading to a selection of promising candidates whose immunogenic epitopes are suitably exposed for antibody recognition. These computer-designed recombinant proteins were produced in bacteria using codon optimized DNA sequences and their diagnostic performance was assessed by liquid microarray against a human cohort of 47 sera samples. Our results show that the Top7 protein is a suitable scaffold to provide the required structural stability to predetermined target shapes and sequences, allowing the potential use of the chimeric proteins as antigens for specific antibody recognition and/or stimulation of immune response.
C1 [Viana, Isabelle F. T.; Soares, Thereza A.; Lins, Roberto D.] Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740560 Recife, PE, Brazil.
   [Viana, Isabelle F. T.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Viana, Isabelle F. T.; Lima, Lucianna F. O.; Krieger, Marco A.] Fiocruz MS, Carlos Chagas Inst, BR-81350010 Curitiba, Parana, Brazil.
   [Dhalia, Rafael] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
RP Viana, IFT (corresponding author), Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740560 Recife, PE, Brazil.
EM rdhalia@cpqam.fiocruz.br; roberto.lins@ufpe.br
RI Viana, Isabelle/M-4435-2017; Marques, Ernesto/L-4514-2013; Krieger,
   Marco/AAE-8611-2020; Soares, Thereza A./G-1065-2010; Dhalia,
   Rafael/AAD-5432-2020; Lins, Roberto D/J-7511-2012; Marques, Ernesto T.
   A/L-4967-2013; Soares, Thereza A./M-9962-2019
OI Viana, Isabelle/0000-0003-4648-6635; Marques,
   Ernesto/0000-0003-3826-9358; Soares, Thereza A./0000-0002-5891-6906;
   Lins, Roberto D/0000-0002-3983-8025; Marques, Ernesto T.
   A/0000-0003-3826-9358; Soares, Thereza A./0000-0002-5891-6906
FU FACEPE; NanoBiotec-BR/CAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq); INCT-INAMI; nBioNet; Oswaldo Cruz
   Foundation; U.S. Department of EnergyUnited States Department of Energy
   (DOE)
FX This work was developed with financial support from FACEPE,
   NanoBiotec-BR/CAPES, CNPq, INCT-INAMI, nBioNet and the Oswaldo Cruz
   Foundation. We thank Gabriel Queiroz for valuable assistance in
   performing sequence cloning. The Environmental Molecular Sciences
   Laboratory (EMSL), a U.S. national scientific user facility sponsored by
   the U.S. Department of Energy located at the Pacific Northwest National
   Laboratory, is acknowledged for computer time allocation.
CR Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Azoitei ML, 2011, SCIENCE, V334, P373, DOI 10.1126/science.1209368
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Boschek CB, 2009, PROTEIN ENG DES SEL, V22, P325, DOI 10.1093/protein/gzp007
   Caffrey M, 2001, BBA-MOL BASIS DIS, V1536, P116, DOI 10.1016/S0925-4439(01)00042-4
   Cao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018477
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Changela A, 2011, J VIROL, V85, P2524, DOI 10.1128/JVI.02335-10
   Correia BE, 2011, J MOL BIOL, V405, P284, DOI 10.1016/j.jmb.2010.09.061
   Correia BE, 2010, STRUCTURE, V18, P1116, DOI 10.1016/j.str.2010.06.010
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fleishman SJ, 2011, SCIENCE, V332, P816, DOI 10.1126/science.1202617
   Gollub RL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002120
   Guenaga J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002806
   Guenaga J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016074
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hockney R. W., 1970, METHODS COMPUTATIONA
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Kobold S, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/721531
   Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lapelosa M, 2009, J MOL BIOL, V385, P675, DOI 10.1016/j.jmb.2008.10.089
   Lelli D, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-81
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   McLellan JS, 2011, J MOL BIOL, V409, P853, DOI 10.1016/j.jmb.2011.04.044
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Samish I, 2011, ANNU REV PHYS CHEM, V62, P129, DOI 10.1146/annurev-physchem-032210-103509
   Sharma D, 2007, P NATL ACAD SCI USA, V104, P9278, DOI 10.1073/pnas.0700351104
   Shi WX, 2010, J BIOL CHEM, V285, P24290, DOI 10.1074/jbc.M110.111351
   Soares TA, 2010, J MOL GRAPH MODEL, V28, P755, DOI 10.1016/j.jmgm.2010.01.013
   Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949
   Totrov M, 2010, VIROLOGY, V405, P513, DOI 10.1016/j.virol.2010.06.027
   Toukam DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038068
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Yanamandra K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018513
NR 45
TC 6
Z9 6
U1 0
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2013
VL 3
IS 29
BP 11790
EP 11800
DI 10.1039/c3ra41562g
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 175BI
UT WOS:000321203900062
OA Green Published
DA 2020-12-16
ER

PT J
AU de Melo, AB
   Nascimento, EJM
   Braga-Neto, U
   Dhalia, R
   Silva, AM
   Oelke, M
   Schneck, JP
   Sidney, J
   Sette, A
   Montenegro, SML
   Marques, ETA
AF de Melo, Andrea Barbosa
   Nascimento, Eduardo J. M.
   Braga-Neto, Ulisses
   Dhalia, Rafael
   Silva, Ana Maria
   Oelke, Mathias
   Schneck, Jonathan P.
   Sidney, John
   Sette, Alessandro
   Montenegro, Silvia M. L.
   Marques, Ernesto T. A.
TI T-Cell Memory Responses Elicited by Yellow Fever Vaccine are Targeted to
   Overlapping Epitopes Containing Multiple HLA-I and -II Binding Motifs
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ANTIGEN-PRESENTING CELLS; WORLDWIDE HUMAN-POPULATION; IDENTIFICATION;
   IMMUNITY; 17D; MOLECULES; PEPTIDES; PROTEINS; IMMUNIZATION; SPECIFICITY
AB The yellow fever vaccines (YF-17D-204 and 17DD) are considered to be among the safest vaccines and the presence of neutralizing antibodies is correlated with protection, although other immune effector mechanisms are known to be involved. T-cell responses are known to play an important role modulating antibody production and the killing of infected cells. However, little is known about the repertoire of T-cell responses elicited by the YF-17DD vaccine in humans. In this report, a library of 653 partially overlapping 15-mer peptides covering the envelope (Env) and nonstructural (NS) proteins 1 to 5 of the vaccine was utilized to perform a comprehensive analysis of the virus-specific CD4+ and CD8+ T-cell responses. The T-cell responses were screened ex-vivo by IFN-gamma ELISPOT assays using blood samples from 220 YF-17DD vaccinees collected two months to four years after immunization. Each peptide was tested in 75 to 208 separate individuals of the cohort. The screening identified sixteen immunodominant antigens that elicited activation of circulating memory T-cells in 10% to 33% of the individuals. Biochemical in-vitro binding assays and immunogenetic and immunogenicity studies indicated that each of the sixteen immunogenic 15-mer peptides contained two or more partially overlapping epitopes that could bind with high affinity to molecules of different HLAs. The prevalence of the immunogenicity of a peptide in the cohort was correlated with the diversity of HLA-II alleles that they could bind. These findings suggest that overlapping of HLA binding motifs within a peptide enhances its T-cell immunogenicity and the prevalence of the response in the population. In summary, the results suggests that in addition to factors of the innate immunity, "promiscuous" T-cell antigens might contribute to the high efficacy of the yellow fever vaccines.
C1 [de Melo, Andrea Barbosa; Dhalia, Rafael; Silva, Ana Maria; Marques, Ernesto T. A.] Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapeut Lab, Recife, PE, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Braga-Neto, Ulisses] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA.
   [Oelke, Mathias; Schneck, Jonathan P.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Montenegro, Silvia M. L.] Fiocruz MS, Aggeu Magalhaes Res Ctr, Dept Immunol, Recife, PE, Brazil.
RP de Melo, AB (corresponding author), Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapeut Lab, Recife, PE, Brazil.
EM marques@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; montenegro, silvia/AAD-9090-2020;
   Marques, Ernesto/L-4514-2013; Dhalia, Rafael/AAD-5432-2020; Nascimento,
   Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Nascimento, Eduardo/0000-0002-9851-2332;
   Oelke, Mathias/0000-0003-2253-6167
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI-40085]; Oswaldo
   Cruz Foundation [PDTIS-RVR9]; National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); National Science FoundationNational
   Science Foundation (NSF) [CCF-0845407]; Brazilian Council for Higher
   Education (CAPES); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R21AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grant AI-40085;
   the Oswaldo Cruz Foundation, PDTIS-RVR9; the National Council for
   Scientific and Technological Development (CNPq); the National Science
   Foundation, CCF-0845407; and the Brazilian Council for Higher Education
   (CAPES), AB's doctoral scholarship). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27
   Co MDT, 2009, IMMUNOLOGY, V128, pe718, DOI 10.1111/j.1365-2567.2009.03070.x
   Co MDT, 2002, VIROLOGY, V293, P151, DOI 10.1006/viro.2001.1255
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
   Gerloni M, 2000, P NATL ACAD SCI USA, V97, P13269, DOI 10.1073/pnas.230429197
   Gerloni M, 2005, J IMMUNOL, V175, P6551, DOI 10.4049/jimmunol.175.10.6551
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B
   KILGUS J, 1991, J IMMUNOL, V146, P307
   Kobayashi H, 2001, CANCER RES, V61, P7577
   Lund O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026494
   Maciel M, 2008, VIROLOGY, V378, P105, DOI 10.1016/j.virol.2008.04.043
   MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994
   Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
   Oelke M, 2005, TRENDS MOL MED, V11, P412, DOI 10.1016/j.molmed.2005.07.005
   Oelke M, 2004, CLIN IMMUNOL, V110, P243, DOI 10.1016/j.clim.2003.11.014
   Oelke M, 2003, NAT MED, V9, P619, DOI 10.1038/nm869
   OSULLIVAN D, 1991, J IMMUNOL, V147, P2663
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Pulendran B, 2009, NAT REV IMMUNOL, V9, P741, DOI 10.1038/nri2629
   Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Roederer M, 2003, J IMMUNOL METHODS, V274, P221, DOI 10.1016/S0022-1759(02)00423-4
   Sidney J, 2001, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1803s31
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Sidney J, 2010, J IMMUNOL, V184, P2492, DOI 10.4049/jimmunol.0903655
   Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Wang B, 2001, J IMMUNOL, V167, P1283, DOI 10.4049/jimmunol.167.3.1283
   Wilson DB, 2004, MOL IMMUNOL, V40, P1047, DOI 10.1016/j.molimm.2003.11.022
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
NR 43
TC 24
Z9 24
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2013
VL 7
IS 1
AR e1938
DI 10.1371/journal.pntd.0001938
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 081ZB
UT WOS:000314360200004
PM 23383350
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-16
ER

PT J
AU Garcia-Bates, TM
   Cordeiro, MT
   Nascimento, EJM
   Smith, AP
   de Melo, KMS
   McBurney, SP
   Evans, JD
   Marques, ETA
   Barratt-Boyes, SM
AF Garcia-Bates, Tatiana M.
   Cordeiro, Marli T.
   Nascimento, Eduardo J. M.
   Smith, Amanda P.
   de Melo, Klecia M. Soares
   McBurney, Sean P.
   Evans, Jared D.
   Marques, Ernesto T. A., Jr.
   Barratt-Boyes, Simon M.
TI Association between Magnitude of the Virus-Specific Plasmablast Response
   and Disease Severity in Dengue Patients
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ORIGINAL ANTIGENIC SIN; ANTIBODY-DEPENDENT ENHANCEMENT; CROSS-REACTIVE
   B; HEMORRHAGIC-FEVER; PERIPHERAL-BLOOD; IMMUNE ACTIVATION; CELL
   RESPONSES; INFECTION; CHILDREN; HUMANS
AB Dengue is a globally expanding disease caused by infection with dengue virus (DENV) that ranges from febrile illness to acute disease with serious complications. Secondary infection predisposes individuals to more severe disease, and B lymphocytes may play a role in this phenomenon through production of Ab that enhance infection. To better define the acute B cell response during dengue, we analyzed peripheral B cells from an adult Brazilian hospital cohort with primary and secondary DENV infections of varying clinical severity. Circulating B cells in dengue patients were proliferating, activated, and apoptotic relative to individuals with other febrile illnesses. Severe secondary DENV infection was associated with extraordinary peak plasmablast frequencies between 4 and 7 d of illness, averaging 46% and reaching 87% of B cells, significantly greater than those seen in mild illness or primary infections. On average >70% of IgG-secreting cells in individuals with severe secondary DENV infection were DENV specific. Plasmablasts produced Ab that cross-reacted with heterotypic DENV serotypes, but with a 3-fold greater reactivity to DENV-3, the infecting serotype. Plasmablast frequency did not correlate with acute serum-neutralizing Ab titers to any DENV serotype regardless of severity of disease. These findings indicate that massive expansion of DENV-specific and serotype cross-reactive plasmablasts occurs in acute secondary DENV infection of adults in Brazil, which is associated with increasing disease severity. The Journal of Immunology, 2013, 190: 80-87.
C1 [Garcia-Bates, Tatiana M.; Nascimento, Eduardo J. M.; Smith, Amanda P.; de Melo, Klecia M. Soares; McBurney, Sean P.; Evans, Jared D.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Garcia-Bates, Tatiana M.; Nascimento, Eduardo J. M.; Smith, Amanda P.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Cordeiro, Marli T.; de Melo, Klecia M. Soares; Marques, Ernesto T. A., Jr.] Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
   [McBurney, Sean P.; Evans, Jared D.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA.
   [Barratt-Boyes, Simon M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15261 USA.
RP Barratt-Boyes, SM (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 9046 Biomed Sci Tower 3,3501 5th Ave, Pittsburgh, PA 15261 USA.
EM smbb@pitt.edu
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto T. A/L-4967-2013;
   Marques, Ernesto/L-4514-2013; Nascimento, Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Nascimento, Eduardo/0000-0002-9851-2332;
   Barratt Boyes, Simon/0000-0002-8869-4945; Garcia-Bates,
   Tatiana/0000-0001-7579-5272
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI049820, AI118297];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, U19AI082632, T32AI049820,
   U19AI082632, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Training Grant
   AI049820 (to T.M.G.-B.) and National Institutes of Health Research Grant
   AI118297.
CR Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Balakrishnan T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029430
   Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Balmaseda A, 2010, J INFECT DIS, V201, P5, DOI 10.1086/648592
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Brazil Ministry of Health, 2005, DENG DIAGN MAN CLIN
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   Crill WD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004991
   Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   Devignot S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011671
   Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005
   Gawoski JM, 2003, ARCH PATHOL LAB MED, V127, P1026
   Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Guzman MG, 2000, AM J EPIDEMIOL, V152, P804, DOI 10.1093/aje/152.9.804
   Guzman MG, 2000, AM J EPIDEMIOL, V152, P793, DOI 10.1093/aje/152.9.793
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P350
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Hammond SN, 2005, AM J TROP MED HYG, V73, P1063
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   Kyu SY, 2009, J IMMUNOL METHODS, V340, P42, DOI 10.1016/j.jim.2008.09.025
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   LITTAUA R, 1990, J IMMUNOL, V144, P3183
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Mathew A, 2011, J INFECT DIS, V204, P1514, DOI 10.1093/infdis/jir607
   Midgley CM, 2011, J VIROL, V85, P410, DOI 10.1128/JVI.01826-10
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Qian Y, 2010, CYTOM PART B-CLIN CY, V78B, pS69, DOI 10.1002/cyto.b.20554
   Rodriguez-Barraquer I, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000935
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932
   Schieffelin JS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-28
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Siqueira JB, 2011, SAUDE BRASIL 2010 AN, P157
   Thai KTD, 2011, CLIN MICROBIOL INFEC, V17, P1823, DOI 10.1111/j.1469-0691.2010.03434.x
   Wahala WMPB, 2009, VIROLOGY, V392, P103, DOI 10.1016/j.virol.2009.06.037
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Zivna I, 2002, J IMMUNOL, V168, P5959, DOI 10.4049/jimmunol.168.11.5959
   Zompi S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001568
   Zompi S, 2012, J IMMUNOL, V188, P404, DOI 10.4049/jimmunol.1102124
NR 58
TC 43
Z9 45
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JAN 1
PY 2013
VL 190
IS 1
BP 80
EP 87
DI 10.4049/jimmunol.1103350
PG 8
WC Immunology
SC Immunology
GA 061FB
UT WOS:000312832500010
PM 23203929
OA Green Accepted, Bronze
DA 2020-12-16
ER

PT J
AU Carvalho-Leandro, D
   Ayres, CFJ
   Guedes, DRD
   Suesdek, L
   Melo-Santos, MAV
   Oliveira, CF
   Cordeiro, MT
   Regis, LN
   Marques, ET
   Gil, LH
   Magalhaes, T
AF Carvalho-Leandro, D.
   Ayres, C. F. J.
   Guedes, D. R. D.
   Suesdek, L.
   Melo-Santos, M. A. V.
   Oliveira, C. F.
   Cordeiro, M. T.
   Regis, L. N.
   Marques, E. T.
   Gil, L. H.
   Magalhaes, T.
TI Immune transcript variations among Aedes aegypti populations with
   distinct susceptibility to dengue virus serotype 2
SO ACTA TROPICA
LA English
DT Article
DE Mosquito; Dengue virus; Immune response; Toll; JAK-STAT; RNAi
ID ORAL INFECTION; VECTOR COMPETENCE; SINDBIS VIRUS; PATHWAY; EXPRESSION;
   MIDGUT; RNAI; QUANTITATION; SUPPRESSORS; STRAINS
AB The innate immune response of insects is one of the factors that may dictate their susceptibility to viral infection. Two immune signaling pathways, Toll and JAK-STAT, and the RNA interference (RNAi) pathway are involved in Aedes aegypti responses against dengue virus (DENV), however natural differences in these antiviral defenses among mosquito populations have not been studied. Here, two field Ae. aegypti populations from distinct ecological environments, one from Recife and the other from Petrolina (Brazil), and a laboratory strain were studied for their ability to replicate a primary isolate of dengue virus serotype 2 (DENV-2). Virus infectivity and replication were determined in insect tissues collected after viral exposure through reverse-transcription real time PCR (RT-PCR). The expression of a transcript representing these defense mechanisms (Toll, JAK-STAT and RNAi) in the midgut and fat body was studied with RTPCR to evaluate variations in innate immune mechanisms possibly employed against DENV. Analyses of infection rates indicated that the field populations were more susceptible to DENV-2 infection than the lab strain. There were distinct expression patterns among mosquito populations, in both control and infected insects. Moreover, lower expression of immune molecules in DENV-2-infected insects compared to controls was observed in the two field populations. These results suggest that natural variations in vector competence against DENV may be partly due to differences in mosquito defense mechanisms, and that the down-regulation of immune transcripts after viral infection depends on the insect strain. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Carvalho-Leandro, D.; Ayres, C. F. J.; Guedes, D. R. D.; Melo-Santos, M. A. V.; Oliveira, C. F.; Regis, L. N.; Magalhaes, T.] Fiocruz Pernambuco, Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Entomol, Recife, PE, Brazil.
   [Ayres, C. F. J.; Guedes, D. R. D.; Melo-Santos, M. A. V.; Oliveira, C. F.; Regis, L. N.; Marques, E. T.; Gil, L. H.] Fiocruz Pernambuco, CPqAM, Programa Posgrad Saude Publ, Recife, PE, Brazil.
   [Carvalho-Leandro, D.; Ayres, C. F. J.] Univ Fed Pernambuco UFPE, Ctr Ciencias Biol, Dept Zool, Programa Posgrad Biol Anim, Recife, PE, Brazil.
   [Suesdek, L.] Inst Butantan Sao Paulo, Parasitol Lab, Sao Paulo, Brazil.
   [Suesdek, L.] Univ Sao Paulo, Inst Ciencias Biomed, Programa Posgrad Biol Relacao Patogeno Hospedeiro, BR-09500900 Sao Paulo, Brazil.
   [Cordeiro, M. T.; Marques, E. T.; Gil, L. H.] Fiocruz Pernambuco, CPqAM, Lab Virol & Terapia Expt LaViTE, Recife, PE, Brazil.
   [Cordeiro, M. T.] Secretaria Saude Pernambuco, Recife, PE, Brazil.
   [Marques, E. T.] Univ Pittsburg, Ctr Vaccine Res, Pittsburg, KS USA.
RP Magalhaes, T (corresponding author), Fiocruz Pernambuco, CPqAM, LaViTE, Recife, PE, Brazil.
EM danilo@cpqam.fiocruz.br; tans@cpqam.fiocruz.br;
   dguedes@cpqam.fiocruz.br; linrocha@butantan.gov.br;
   mavarjal@cpqam.fiocruz.br; claudia@cpqam.fiocruz.br;
   marli@cpqam.fiocruz.br; leda@cpqam.fiocruz.br; marques@pitt.edu;
   laura@cpqam.fiocruz.br; tecamagalhaes@hotmail.com
RI Publica, Inct Saude/J-9544-2013; Ayres, Constancia/AAQ-3448-2020;
   Magalhaes, Tereza/V-6632-2019; Suesdek, Lincoln/C-7943-2013; Marques,
   Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Suesdek, Lincoln/0000-0001-6829-738X; Marques, Ernesto T.
   A/0000-0003-3826-9358; Marques, Ernesto/0000-0003-3826-9358
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [Universal 479029/2010-5, Pronex Rede Dengue 550140/2010-7]; FACEPE
   [PPSUS/APQ-1361-4.00/08]; FIOCRUZ; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI056541, U19AI056541,
   U19AI056541, U19AI056541, U19AI056541] Funding Source: NIH RePORTER
FX We thank Dr. Brian D. Foy (CSU, USA) for providing the opportunity for
   the one-month training in the techniques used in this study, and Dr.
   Marcos H. F. Sorgine (UFRJ, Brazil) for his helpful comments on an early
   version of the manuscript. We also thank the staff of Recife and
   Petrolina City Halls for collaborating with mosquito egg collection, and
   the PDTIS program at FIOCRUZ for supplying reagents for real-time PCRs
   and for technical support with these assays. Financial support for this
   work was obtained from CNPq (Grants Universal 479029/2010-5 and Pronex
   Rede Dengue 550140/2010-7), FACEPE (Grant PPSUS/APQ-1361-4.00/08) and
   FIOCRUZ.
CR Bartholomay LC, 2010, SCIENCE, V330, P88, DOI 10.1126/science.1193162
   Behura SK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001385
   Bennett KE, 2002, AM J TROP MED HYG, V67, P85, DOI 10.4269/ajtmh.2002.67.85
   Bivalkar-Mehla S, 2011, VIRUS RES, V155, P1, DOI 10.1016/j.virusres.2010.10.003
   Black WC, 2002, ARCH MED RES, V33, P379, DOI 10.1016/S0188-4409(02)00373-9
   Blair CD, 2011, FUTURE MICROBIOL, V6, P265, DOI [10.2217/FMB.11.11, 10.2217/fmb.11.11]
   Boissiere Anne, 2012, PLoS Pathog, V8, pe1002742, DOI 10.1371/journal.ppat.1002742
   Bonizzoni M, 2012, G3-GENES GENOM GENET, V2, P103, DOI 10.1534/g3.111.001107
   Colpitts TM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002189
   Diallo M, 2008, T ROY SOC TROP MED H, V102, P493, DOI 10.1016/j.trstmh.2008.02.010
   Dong YM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000423
   Fragkoudis R, 2008, INSECT MOL BIOL, V17, P647, DOI 10.1111/j.1365-2583.2008.00834.x
   GUBLER DJ, 1979, AM J TROP MED HYG, V28, P1045, DOI 10.4269/ajtmh.1979.28.1045
   Hess AM, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-45
   IBGE, 2010, CENS DEM 2010
   Keene KM, 2004, P NATL ACAD SCI USA, V101, P17240, DOI 10.1073/pnas.0406983101
   Ketting RF, 2011, DEV CELL, V20, P148, DOI 10.1016/j.devcel.2011.01.012
   Khoo CCH, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-130
   Kong YY, 2006, J VIROL METHODS, V138, P123, DOI 10.1016/j.jviromet.2006.08.003
   Lambrechts L, 2011, TRENDS PARASITOL, V27, P111, DOI 10.1016/j.pt.2010.12.001
   Lambrechts L, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-160
   Lan Q., 1992, Insect Molecular Biology, V1, P71, DOI 10.1111/j.1365-2583.1993.tb00107.x
   Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948
   Lin CC, 2004, J BIOL CHEM, V279, P3308, DOI 10.1074/jbc.M309749200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lourenco-De-Oliveira R, 2004, T ROY SOC TROP MED H, V98, P43, DOI 10.1016/S0035-9203(03)00006-3
   Magalhaes T, 2008, ARCH INSECT BIOCHEM, V68, P134, DOI 10.1002/arch.20238
   Magalhaes T, 2008, EXP PARASITOL, V120, P364, DOI 10.1016/j.exppara.2008.09.003
   [Ministerio da Sande Secretaria de Vigilancia em Sande], 2008, RED NAC MON RES AED
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   Payne AF, 2006, J VIROL METHODS, V134, P183, DOI 10.1016/j.jviromet.2006.01.003
   Ramirez JL, 2010, DEV COMP IMMUNOL, V34, P625, DOI 10.1016/j.dci.2010.01.006
   Ramirez JL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001561
   Salazar MI, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-9
   Sanchez-Vargas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000299
   Sanders HR, 2005, INSECT BIOCHEM MOLEC, V35, P1293, DOI 10.1016/j.ibmb.2005.07.006
   Schneider JR, 2011, INFECT GENET EVOL, V11, P11, DOI 10.1016/j.meegid.2010.10.019
   Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200
   Sim S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010678
   Souza-Neto JA, 2009, P NATL ACAD SCI USA, V106, P17841, DOI 10.1073/pnas.0905006106
   TABACHNICK WJ, 1985, AM J TROP MED HYG, V34, P1219, DOI 10.4269/ajtmh.1985.34.1219
   TARDIEUX I, 1990, AM J TROP MED HYG, V43, P308, DOI 10.4269/ajtmh.1990.43.308
   van Cleef KWR, 2011, METHODS MOL BIOL, V721, P201, DOI 10.1007/978-1-61779-037-9_12
   Vargas REM, 2010, INFECT GENET EVOL, V10, P580, DOI 10.1016/j.meegid.2010.01.004
   de Melo-Santos MAV, 2009, BIOL CONTROL, V49, P186, DOI 10.1016/j.biocontrol.2009.01.011
   Vazeille-Falcoz M, 1999, AM J TROP MED HYG, V60, P292, DOI 10.4269/ajtmh.1999.60.292
   Vidal P.O., 2011, INFECT GENETICS EVOL
   Xi ZY, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000098
   Zou Z, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002394
NR 49
TC 17
Z9 17
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD NOV
PY 2012
VL 124
IS 2
BP 113
EP 119
DI 10.1016/j.actatropica.2012.07.006
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 014JT
UT WOS:000309372600002
PM 22877626
DA 2020-12-16
ER

PT J
AU Jung, KO
   Khan, AM
   Tan, BYL
   Hu, YL
   Simon, GG
   Nascimento, EJM
   Lemonnier, F
   Brusic, V
   Miotto, O
   Tan, TW
   Marques, ETA
   Dhalia, R
   Salmon, J
   August, JT
AF Jung, Keun-Ok
   Khan, Asif M.
   Tan, Benjamin Yong Liang
   Hu, Yongli
   Simon, Gregory G.
   Nascimento, Eduardo J. M.
   Lemonnier, Francois
   Brusic, Vladimir
   Miotto, Olivo
   Tan, Tin Wee
   Marques, Ernesto T. A.
   Dhalia, Rafael
   Salmon, Jerome
   August, J. Thomas
TI West Nile Virus T-Cell Ligand Sequences Shared with Other Flaviviruses:
   a Multitude of Variant Sequences as Potential Altered Peptide Ligands
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MHC CLASS-I; TRANSGENIC MICE; IMMUNE-RESPONSE; INFLUENZA-A; DENGUE;
   IDENTIFICATION; EPITOPE; CD4(+); RECOGNITION; EXPRESSION
AB Phylogenetic relatedness and cocirculation of several major human pathogen flaviviruses are recognized as a possible cause of deleterious immune responses to mixed infection or immunization and call for a greater understanding of the inter-Flavivirus protein homologies. This study focused on the identification of human leukocyte antigen (HLA)-restricted West Nile virus (WNV) T-cell ligands and characterization of their distribution in reported sequence data of WNV and other flaviviruses. H-2-deficient mice transgenic for either A2, A24, B7, DR2, DR3, or DR4 HLA alleles were immunized with overlapping peptides of the WNV proteome, and peptide-specific T-cell activation was measured by gamma interferon (IFN-gamma) enzyme-linked immunosorbent spot (ELISpot) assays. Approximately 30% (137) of the WNV proteome peptides were identified as HLA-restricted T-cell ligands. The majority of these ligands were conserved in similar to >= 88% of analyzed WNV sequences. Notably, only 51 were WNV specific, and the remaining 86, chiefly of E, NS3, and NS5, shared an identity of nine or more consecutive amino acids with sequences of 64 other flaviviruses, including several major human pathogens. Many of the shared ligands had an incidence of >50% in the analyzed sequences of one or more of six major flaviviruses. The multitude of WNV sequences shared with other flaviviruses as interspecies variants highlights the possible hazard of defective T-cell activation by altered peptide ligands in the event of dual exposure to WNV and other flaviviruses, by either infection or immunization. The data suggest the possible preferred use of sequences that are pathogen specific with minimum interspecies sequence homology for the design of Flavivirus vaccines.
C1 [Jung, Keun-Ok; Khan, Asif M.; Simon, Gregory G.; Salmon, Jerome; August, J. Thomas] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Khan, Asif M.; Hu, Yongli; August, J. Thomas] Perdana Univ, Grad Sch Med, Serdang, Selangor Darul, Malaysia.
   [Khan, Asif M.; Tan, Benjamin Yong Liang; Hu, Yongli; Tan, Tin Wee] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Lemonnier, Francois] Inst Pasteur, Unite Immunite Cellulaire Antivirale, Paris, France.
   [Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
   [Miotto, Olivo] Mahidol Univ, Fac Trop Med, Mahidol Oxford Res Unit, Bangkok, Thailand.
   [Marques, Ernesto T. A.; Dhalia, Rafael] Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Salmon, Jerome] Inst Gustave Roussy, Unite Retrovirus Endorgenes & Elements Retroides, Villejuif, France.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
EM taugust@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Publica, Inct Saude/J-9544-2013;
   Marques, Ernesto/L-4514-2013; Khan, Mohammad Asif/F-4663-2010; Tan, Tin
   Wee/B-8963-2009; Dhalia, Rafael/AAD-5432-2020; Miotto,
   Olivo/AAE-7124-2019; Brusic, Vladimir/B-1478-2008; Nascimento,
   Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Khan, Mohammad Asif/0000-0001-9202-279X;
   Tan, Tin Wee/0000-0002-4062-2854; Brusic, Vladimir/0000-0003-0523-5266;
   Nascimento, Eduardo/0000-0002-9851-2332; Miotto,
   Olivo/0000-0001-8060-6771; Francois, Lemonnier/0000-0002-6741-2742
CR Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Brien JD, 2007, EUR J IMMUNOL, V37, P1855, DOI 10.1002/eji.200737196
   Cheuk E, 2002, J IMMUNOL, V169, P5571, DOI 10.4049/jimmunol.169.10.5571
   Cook S, 2006, ARCH VIROL, V151, P309, DOI 10.1007/s00705-005-0626-6
   Cope AP, 1999, ARTHRITIS RHEUM, V42, P1497, DOI 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-#
   de la Rosa G, 2005, J LEUKOCYTE BIOL, V77, P699, DOI 10.1189/jlb.0904529
   Diamond MS, 2009, FRONT BIOSCI-LANDMRK, V14, P3024, DOI 10.2741/3432
   Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0
   FUGGER L, 1994, P NATL ACAD SCI USA, V91, P6151, DOI 10.1073/pnas.91.13.6151
   Goodridge HS, 2007, J IMMUNOL, V178, P3107, DOI 10.4049/jimmunol.178.5.3107
   Hu NJ, 2005, VACCINE, V23, P5231, DOI 10.1016/j.vaccine.2005.07.032
   Kalergis AM, 2000, J IMMUNOL, V165, P280, DOI 10.4049/jimmunol.165.1.280
   Katsara M, 2008, EXPERT OPIN BIOL TH, V8, P1873, DOI [10.1517/14712590802494501, 10.1517/14712590802494501 ]
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   Koo QY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005352
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   KURANE I, 1995, J GEN VIROL, V76, P2243, DOI 10.1099/0022-1317-76-9-2243
   Lanteri MC, 2008, J INFECT DIS, V197, P1296, DOI 10.1086/586898
   Larsen MV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012697
   Lin HH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-8
   Lin HH, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S12-S22
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   Loirat D, 2000, J IMMUNOL, V165, P4748, DOI 10.4049/jimmunol.165.8.4748
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Lundegaard C, 2010, IMMUNOLOGY, V130, P309, DOI 10.1111/j.1365-2567.2010.03300.x
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   McGinnis S, 2004, NUCLEIC ACIDS RES, V32, pW20, DOI 10.1093/nar/gkh435
   McMurtrey CP, 2008, P NATL ACAD SCI USA, V105, P2981, DOI 10.1073/pnas.0711874105
   Miotto O, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S1-S18
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Murray KO, 2011, EPIDEMIOL INFECT, V139, P807, DOI 10.1017/S0950268811000185
   Nielsen M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000107
   Pajot A, 2004, EUR J IMMUNOL, V34, P3060, DOI 10.1002/eji.200425463
   Pajot A, 2006, MICROBES INFECT, V8, P2783, DOI 10.1016/j.micinf.2006.08.009
   Parsons R, 2008, J IMMUNOL, V181, P1563, DOI 10.4049/jimmunol.181.2.1563
   Pascolo S, 2005, EXPERT OPIN BIOL TH, V5, P919, DOI 10.1517/14712598.5.7.919
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Petersen LR, 2001, EMERG INFECT DIS, V7, P611
   Purtha WE, 2007, EUR J IMMUNOL, V37, P1845, DOI 10.1002/eji.200737192
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   Regner M, 2001, J IMMUNOL, V166, P3820, DOI 10.4049/jimmunol.166.6.3820
   Richards KA, 2007, J VIROL, V81, P7608, DOI 10.1128/JVI.02834-06
   Roederer M, 2003, J IMMUNOL METHODS, V274, P221, DOI 10.1016/S0022-1759(02)00423-4
   Rohrlich PS, 2003, INT IMMUNOL, V15, P765, DOI 10.1093/intimm/dxg073
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI21512
   Rothman AL, 2010, CURR TOP MICROBIOL, V338, P83, DOI 10.1007/978-3-642-02215-9_7
   Screaton G, 2006, NOVART FDN SYMP, P251
   Screaton G, 2006, NOVART FDN SYMP, P171
   Screaton Gavin, 2006, Novartis Found Symp, V277, P164, DOI 10.1002/0470058005.ch12
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x
   Sharpe AH, 2009, IMMUNOL REV, V229, P5, DOI 10.1111/j.1600-065X.2009.00784.x
   SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2
   SLOANLANCASTER J, 1994, J EXP MED, V180, P1195, DOI 10.1084/jem.180.4.1195
   SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1
   Smith HL, 2011, J INFECT DIS, V203, P513, DOI 10.1093/infdis/jiq074
   Smithburn K.C., 1940, AM J TROP MED HYG, V20, P471, DOI [10.4269/ajtmh.1940.s1-20.471, DOI 10.4269/AJTMH.1940.S1-20.471]
   Sonderstrup G, 1999, IMMUNOL REV, V172, P335, DOI 10.1111/j.1600-065X.1999.tb01377.x
   STRAUSS G, 1994, IMMUNOGENETICS, V40, P104
   Taneja V, 1999, IMMUNOL REV, V169, P67, DOI 10.1111/j.1600-065X.1999.tb01307.x
   Theodossis A, 2010, P NATL ACAD SCI USA, V107, P5534, DOI 10.1073/pnas.1000032107
   Tung CW, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-446
   Vandenbark AA, 2003, J IMMUNOL, V171, P127, DOI 10.4049/jimmunol.171.1.127
   Welsh RM, 2003, NAT MED, V9, P820, DOI 10.1038/nm0703-820
   Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Zeng LL, 1996, J VIROL, V70, P3108, DOI 10.1128/JVI.70.5.3108-3117.1996
NR 73
TC 13
Z9 13
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2012
VL 86
IS 14
BP 7616
EP 7624
DI 10.1128/JVI.00166-12
PG 9
WC Virology
SC Virology
GA 969ZO
UT WOS:000306098100015
PM 22573867
OA Bronze, Green Published
DA 2020-12-16
ER

PT J
AU McCormick, KD
   Liu, SF
   Jacobs, JL
   Marques, ETA
   Sluis-Cremer, N
   Wang, TY
AF McCormick, Kevin D.
   Liu, Shufeng
   Jacobs, Jana L.
   Marques, Ernesto T. A., Jr.
   Sluis-Cremer, Nicolas
   Wang, Tianyi
TI Development of a Robust Cytopathic Effect-Based High-Throughput
   Screening Assay To Identify Novel Inhibitors of Dengue Virus
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PROTEIN-SYNTHESIS; STREPTOVITACIN; REPLICATION; TUMOR
AB We have developed a robust cytopathic effect-based high-throughput screening assay to identify inhibitors of dengue virus (DENY) infection. Screening of a small natural product library yielded 11 hits. Four of these were found to be potent inhibitors of DENY, although serotype differences were noted. Taken together, these data suggest that screening of larger and more complex molecule libraries may result in the identification of more potent and specific DENV inhibitors.
C1 [McCormick, Kevin D.; Liu, Shufeng; Jacobs, Jana L.; Marques, Ernesto T. A., Jr.; Wang, Tianyi] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
   [McCormick, Kevin D.; Wang, Tianyi] Univ Pittsburgh, Sch Med, Grad Program Mol Virol & Microbiol, Pittsburgh, PA USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Sluis-Cremer, Nicolas] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
RP Wang, TY (corresponding author), Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
EM tywang@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013;
   Publica, Inct Saude/J-9544-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU University of PittsburghUniversity of Pittsburgh
FX This work is supported by the central development research fund (CRDF)
   from the University of Pittsburgh.
CR Chan J, 2004, RNA, V10, P528, DOI 10.1261/rna.5200204
   DALES S, 1965, P NATL ACAD SCI USA, V54, P462, DOI 10.1073/pnas.54.2.462
   Diamond MS, 2002, VIROLOGY, V304, P211, DOI 10.1006/viro.2002.1685
   Durbin AP, 2011, VIRUSES-BASEL, V3, P1800, DOI 10.3390/v3101800
   Gubler Duane J, 2006, Novartis Found Symp, V277, P3, DOI 10.1002/0470058005.ch2
   KONDO S, 1979, J ANTIBIOT, V32, P1069, DOI 10.7164/antibiotics.32.1069
   KUBO I, 1993, J NAT PROD, V56, P220, DOI 10.1021/np50092a006
   LEVITT NEIL H., 1967, J VIROL, V1, P693
   Rodenhuis-Zybert IA, 2010, CELL MOL LIFE SCI, V67, P2773, DOI 10.1007/s00018-010-0357-z
   SABIN AB, 1966, P NATL ACAD SCI USA, V55, P1141, DOI 10.1073/pnas.55.5.1141
   STAFFORD ME, 1973, J CELL PHYSIOL, V82, P121, DOI 10.1002/jcp.1040820114
NR 11
TC 10
Z9 10
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2012
VL 56
IS 6
BP 3399
EP 3401
DI 10.1128/AAC.06425-11
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 947LZ
UT WOS:000304432800083
PM 22391547
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Rigato, PO
   Maciel, M
   Goldoni, AL
   Piubelli, OG
   Orii, NM
   Marques, ET
   August, JT
   Duarte, AJD
   Sato, MN
AF Rigato, Paula Ordonhez
   Maciel, Milton, Jr.
   Goldoni, Adriana Leticia
   Piubelli, Orlando Guerra
   Orii, Noemia Mie
   Marques, Ernesto Torres
   August, Joseph Thomas
   da Silva Duarte, Alberto Jose
   Sato, Maria Notomi
TI Maternal LAMP/p55gagHIV-1 DNA Immunization Induces In Utero Priming and
   a Long-Lasting Immune Response in Vaccinated Neonates
SO PLOS ONE
LA English
DT Article
ID EARLY-LIFE; T-CELL; HYPERSENSITIVITY RESPONSE; ALLERGEN EXPOSURE;
   MEMBRANE-PROTEIN; II COMPARTMENT; TRANSMISSION; MICE; GAG; SENSITIZATION
AB Infants born to HIV-infected mothers are at high risk of becoming infected during gestation or the breastfeeding period. A search is thus warranted for vaccine formulations that will prevent mother-to-child HIV transmission. The LAMP/gag DNA chimeric vaccine encodes the HIV-1 p55gag fused to the lysosome-associated membrane protein-1 (LAMP-1) and has been shown to enhance anti-Gag antibody (Ab) and cellular immune responses in adult and neonatal mice; such a vaccine represents a new concept in antigen presentation. In this study, we evaluated the effect of LAMP/gag DNA immunization on neonates either before conception or during pregnancy. LAMP/gag immunization of BALB/c mice before conception by the intradermal route led to the transfer of anti-Gag IgG1 Ab through the placenta and via breastfeeding. Furthermore, there were an increased percentage of CD4+ CD25+ Foxp3+ T cells in the spleens of neonates. When offspring were immunized with LAMP/gag DNA, the anti-Gag Ab response and the Gag-specific IFN-gamma-secreting cells were decreased. Inhibition of anti-Gag Ab production and cellular responses were not observed six months after immunization, indicating that maternal immunization did not interfere with the long-lasting memory response in offspring. Injection of purified IgG in conjunction with LAMP/gag DNA immunization decreased humoral and cytotoxic T-cell responses. LAMP/gag DNA immunization by intradermal injection prior to conception promoted the transfer of Ab, leading to a diminished response to Gag without interfering with the development of anti-Gag T- and B-cell memory. Finally, we assessed responses after one intravenous injection of LAMP/gag DNA during the last five days of pregnancy. The intravenous injection led to in utero immunization. In conclusion, DNA vaccine enconding LAMP-1 with Gag and other HIV-1 antigens should be considered in the development of a protective vaccine for the maternal/fetal and newborn periods.
C1 [Rigato, Paula Ordonhez; Goldoni, Adriana Leticia; Piubelli, Orlando Guerra; Orii, Noemia Mie; da Silva Duarte, Alberto Jose; Sato, Maria Notomi] Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, Dept Dermatol,LIM 56, Sao Paulo, Brazil.
   [Maciel, Milton, Jr.] USN, Enter Dis Dept, Infect Dis Directorate, Med Res Ctr, Silver Spring, MD USA.
   [Marques, Ernesto Torres] Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [August, Joseph Thomas] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RP Rigato, PO (corresponding author), Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, Dept Dermatol,LIM 56, Sao Paulo, Brazil.
EM marisato@usp.br
RI Marques, Ernesto/L-4514-2013; Sato, Maria N/C-1196-2012; Publica, Inct
   Saude/J-9544-2013; Ordonhez Rigato, Paula/J-3618-2012; Goldoni, Adriana
   Leticia/I-1912-2012; Marques, Ernesto T. A/L-4967-2013; Sato, Maria
   N/C-2853-2012
OI Marques, Ernesto/0000-0003-3826-9358; Sato, Maria N/0000-0002-7911-1824;
   Goldoni, Adriana Leticia/0000-0002-4298-8526; Marques, Ernesto T.
   A/0000-0003-3826-9358; 
FU Ministerio da Saude do Brasil [914BRA1101]; Fundacao de Amparo a
   Pesquisa de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2004/14443-2]; Laboratorio de Investigacao Medica,
   Unidade 56 do Hospital das Clinicas da Faculdade de Medicina de Sao
   Paulo
FX This work was supported by Ministerio da Saude do Brasil - Programa
   Nacional de HIV/AIDS/DST (914BRA1101), Fundacao de Amparo a Pesquisa de
   Sao Paulo (FAPESP n<SUP>o</SUP> 2004/14443-2) and Laboratorio de
   Investigacao Medica, Unidade 56 do Hospital das Clinicas da Faculdade de
   Medicina de Sao Paulo. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Becquet R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007397
   BOGEN B, 1993, EMBO J, V12, P357, DOI 10.1002/j.1460-2075.1993.tb05664.x
   Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486
   de Alencar BCG, 2009, INFECT IMMUN, V77, P4383, DOI 10.1128/IAI.01459-08
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   de Brito CA, 2009, IMMUNOTHERAPY-UK, V1, P883, DOI 10.2217/IMT.09.38
   Fusaro AE, 2002, INT ARCH ALLERGY IMM, V127, P208, DOI 10.1159/000053865
   Fusaro AE, 2007, IMMUNOLOGY, V122, P107, DOI 10.1111/j.1365-2567.2007.02618.x
   Fusaro AE, 2009, IMMUNOLOGY, V128, pe541, DOI 10.1111/j.1365-2567.2008.03028.x
   Gerdts V, 2000, NAT MED, V6, P929, DOI 10.1038/78699
   Goldoni AL, 2011, IMMUNOBIOLOGY, V216, P505, DOI 10.1016/j.imbio.2010.08.007
   Hassett DE, 1997, J VIROL, V71, P7881, DOI 10.1128/JVI.71.10.7881-7888.1997
   Horwitz DA, 2008, EUR J IMMUNOL, V38, P912, DOI 10.1002/eji.200738109
   John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918
   JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116
   Kanwar B, 2010, CURR OPIN HIV AIDS, V5, P151, DOI 10.1097/COH.0b013e328335c0c1
   Kim J, 2009, J IMMUNOL, V182, P2583, DOI 10.4049/jimmunol.0803247
   Lohman-Payne B, 2010, CLIN PERINATOL, V37, P787, DOI 10.1016/j.clp.2010.08.005
   Manickan E, 1997, J CLIN INVEST, V100, P2371, DOI 10.1172/JCI119777
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Okuda K, 2001, J IMMUNOL, V167, P5478, DOI 10.4049/jimmunol.167.9.5478
   Rigato PO, 2010, VIROLOGY, V406, P37, DOI 10.1016/j.virol.2010.06.050
   Rigato PO, 2009, IMMUNOTHERAPY-UK, V1, P141, DOI 10.2217/1750743X.1.1.141
   Rinaldi M, 2006, VACCINE, V24, P4586, DOI 10.1016/j.vaccine.2005.08.030
   Sedegah M, 2003, J IMMUNOL, V171, P3148, DOI 10.4049/jimmunol.171.6.3148
   Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004
   Siegrist CA, 1998, EUR J IMMUNOL, V28, P4138, DOI 10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.0.CO;2-L
   UNAIDS, 2010, AIDS EP UPD
   Victor JR, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-11
   Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39
   Xin Ke-Qin, 2002, Biological Procedures Online, V3, P91, DOI 10.1251/bpo27
   Xin KQ, 2003, J GENE MED, V5, P438, DOI 10.1002/jgm.356
NR 33
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2012
VL 7
IS 2
AR e31608
DI 10.1371/journal.pone.0031608
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 925DP
UT WOS:000302741300081
PM 22355381
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Rust, NM
   Papa, MP
   Scovino, AM
   da Silva, MMC
   Calzavara-Silva, CE
   Marques, ETD
   Pecanha, LMT
   Scharfstein, J
   Arruda, LB
AF Rust, Naiara Miranda
   Papa, Michelle Premazzi
   Scovino, Aline Miranda
   Carneiro da Silva, Mayara Marques
   Calzavara-Silva, Carlos Eduardo
   de Azevedo Marques, Ernesto Torres, Jr.
   Torres Pecanha, Ligia Maria
   Scharfstein, Julio
   Arruda, Luciana B.
TI Bradykinin enhances Sindbis virus infection in human brain microvascular
   endothelial cells
SO VIROLOGY
LA English
DT Article
DE Sindbis; Bradykinin; Endothelial cells; Apoptosis
ID RESPIRATORY SYNCYTIAL VIRUS; GLYCOGEN-SYNTHASE KINASE-3; AGE-DEPENDENT
   RESISTANCE; HUMAN IMMUNE CELLS; SUBSTANCE-P; KALLIKREIN/KININ PROTECTS;
   INHIBITING APOPTOSIS; VIRAL ENCEPHALITIS; SIGNALING PATHWAY; RHINOVIRUS
   COLDS
AB Sindbis virus (SINV) induces inflammatory and vasoactive responses that are associated with rash and arthritis in human infections. The mechanisms underlying infection-associated microvasculopathy are still unknown. We investigated whether endothelial cells infected by SINV are differentially responsive to bradykinin (BK), a potent inducer of inflammatory edema in a broad range of infectious diseases. Human endothelial cells (HBMECs) infected with SINV presented an upregulation of bradykinin B2 receptors (BK2R) expression. Also, BK reduced SINV-induced apoptosis and enhanced virus replication in HBMECs in a way dependent on BK2R, PI3 kinase and ERK signaling. Strikingly, intracerebral infection of mice in the presence of a BK2R antagonist reduced the local viral load. Our data suggest that SINV infection renders human endothelial cells hypersensitive to BK, which increases host cell survival and viral replication. Ongoing studies may clarify if the deregulation of the kinin pathway contributes to infection-associated vasculopathies in life-threatening arbovirus infections. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Arruda, Luciana B.] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, CCS, BR-21941902 Rio De Janeiro, Brazil.
   [Scovino, Aline Miranda; Scharfstein, Julio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941902 Rio De Janeiro, Brazil.
   [Carneiro da Silva, Mayara Marques; de Azevedo Marques, Ernesto Torres, Jr.] Fiocruz MS, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Torres Pecanha, Ligia Maria] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio De Janeiro, Brazil.
RP Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, CCS, Bloco 1,Av Carlos Chagas Filho,373 Cidade Univ, BR-21941902 Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana/B-5806-2014; Arruda, Luciana B/N-9086-2013; Marques,
   Ernesto T. A/L-4967-2013; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; CALZAVARA-SILVA,
   CARLOS/0000-0002-1406-6401; Miranda Rust, Naiara/0000-0002-5107-5745
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX This work was supported by CNPq and FAPERJ. N.M.Rust was the recipient
   of a CNPq fellowship; M.P.Papa was the recipient of a FAPERJ fellowship.
CR Aksamitiene E, 2011, CELL SIGNAL, V23, P1794, DOI 10.1016/j.cellsig.2011.06.014
   Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349
   Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649
   Austin CE, 1997, J BIOL CHEM, V272, P11420
   BARNETT JKC, 1990, AM REV RESPIR DIS, V142, P162, DOI 10.1164/ajrccm/142.1.162
   Bengtson SH, 2007, INT IMMUNOPHARMACOL, V7, P1880, DOI 10.1016/j.intimp.2007.07.002
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Bledsoe G, 2006, NEPHROL DIAL TRANSPL, V21, P624, DOI 10.1093/ndt/gfi225
   Bovenzi V, 2010, J CELL PHYSIOL, V222, P168, DOI 10.1002/jcp.21933
   Calabrese LH, 2005, INFECT DIS CLIN N AM, V19, P963, DOI 10.1016/j.idc.2005.09.002
   CHAI KX, 1993, J BIOL CHEM, V268, P24498
   CHATURVEDI UC, 1991, J GEN VIROL, V72, P859, DOI 10.1099/0022-1317-72-4-859
   Christiansen SC, 2008, INT ARCH ALLERGY IMM, V147, P299, DOI 10.1159/000144037
   Dhanushkodi NR, 2011, VIRAL IMMUNOL, V24, P237, DOI 10.1089/vim.2010.0120
   Folkerts G, 2000, AM J RESP CRIT CARE, V161, P1666, DOI 10.1164/ajrccm.161.5.9710002
   FRASER JRE, 1986, CLIN RHEUM DIS, V12, P369
   Greco S, 2006, J ENDOCRINOL, V188, P79, DOI 10.1677/joe.1.06433
   Griffin DE, 2005, CURR TOP MICROBIOL, V289, P57
   GRIFFIN DE, 1994, ARCH VIROL, P31
   Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200
   Heitsch H, 2000, DRUG NEWS PERSPECT, V13, P213
   Ho WZ, 2002, FASEB J, V16, P616, DOI 10.1096/fj.01-0655fje
   Irani DN, 1996, J IMMUNOL, V156, P3850
   Irusta PM, 2004, PROG MOL SUBCELL BIO, V36, P71
   Jaffar-Bandjee MC, 2009, MICROBES INFECT, V11, P1206, DOI 10.1016/j.micinf.2009.10.001
   JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257
   Kaman WE, 2009, MED MICROBIOL IMMUN, V198, P39, DOI 10.1007/s00430-008-0103-4
   Kerr DA, 2002, J VIROL, V76, P10393, DOI 10.1128/JVI.76.20.10393-10400.2002
   Kim JV, 2009, NATURE, V457, P191, DOI 10.1038/nature07591
   Krieg T, 2004, AM J PHYSIOL-HEART C, V287, pH2606, DOI 10.1152/ajpheart.00600.2004
   Labrada L, 2002, J VIROL, V76, P11688, DOI 10.1128/JVI.76.22.11688-11703.2002
   Laine M, 2004, J INTERN MED, V256, P457, DOI 10.1111/j.1365-2796.2004.01413.x
   Lee CJ, 2005, J VIROL, V79, P8388, DOI 10.1128/JVI.79.13.8388-8399.2005
   Levine B, 2002, CURR TOP MICROBIOL, V265, P95
   Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556
   Li Y, 2001, J NEUROIMMUNOL, V121, P67, DOI 10.1016/S0165-5728(01)00439-8
   LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988
   MENKE JG, 1994, J BIOL CHEM, V269, P21583
   Monteiro AC, 2009, J IMMUNOL, V183, P3700, DOI 10.4049/jimmunol.0900895
   Monteiro AC, 2007, PLOS PATHOG, V3, P1730, DOI 10.1371/journal.ppat.0030185
   NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133
   Nikolskaia OV, 2006, J CLIN INVEST, V116, P2739, DOI [10.1172/JC127798, 10.1172/JCI27798.]
   Penna C, 2008, J CELL MOL MED, V12, P435, DOI 10.1111/j.1582-4934.2007.00210.x
   Prado GN, 2002, J CELL PHYSIOL, V193, P275, DOI 10.1002/jcp.10175
   PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120
   REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I
   Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004
   Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577
   Ryman KD, 2007, J GEN VIROL, V88, P518, DOI 10.1099/vir.0.82359-0
   Sammels LM, 1999, J GEN VIROL, V80, P739, DOI 10.1099/0022-1317-80-3-739
   Sarid R, 2001, CELL DEATH DIFFER, V8, P1224, DOI 10.1038/sj.cdd.4400926
   Stins MF, 1997, IN VITRO CELL DEV-AN, V33, P243
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997
   Trgovcich J, 1999, VIROLOGY, V263, P339, DOI 10.1006/viro.1999.9913
   Tripp RA, 2000, J VIROL, V74, P1614, DOI 10.1128/JVI.74.4.1614-1622.2000
   Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917
   Valarcher JF, 2006, J GEN VIROL, V87, P1659, DOI 10.1099/vir.0.81755-0
   Valenti C, 2010, BRIT J PHARMACOL, V161, P1616, DOI 10.1111/j.1476-5381.2010.00995.x
   VANDERMEIJDEN PE, 2010, CELL, V139, P1143
   Wang CR, 2005, ARTHRITIS RHEUM-US, V52, P1319, DOI 10.1002/art.20991
   Wang H, 2008, J GEN VIROL, V89, P2651, DOI 10.1099/vir.0.2008/005314-0
   Wang S, 2008, BRAIN, V131, P1241, DOI 10.1093/brain/awn060
   Wollmann G, 2005, J VIROL, V79, P6005, DOI 10.1128/JVI.79.10.6005-6022.2005
   Xia CF, 2004, HYPERTENSION, V43, P452, DOI 10.1161/01.HYP.0000110905.29389.e5
   Yao YY, 2008, CARDIOVASC RES, V80, P354, DOI 10.1093/cvr/cvn223
   Yin H, 2005, J BIOL CHEM, V280, P8022, DOI 10.1074/jbc.M407179200
   Zhang WJ, 2011, J IMMUNOL, V187, P1764, DOI 10.4049/jimmunol.1002315
   Zimmer G, 2003, J BIOL CHEM, V278, P46854, DOI 10.1074/jbc.M306949200
NR 69
TC 10
Z9 11
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 5
PY 2012
VL 422
IS 1
BP 81
EP 91
DI 10.1016/j.virol.2011.10.003
PG 11
WC Virology
SC Virology
GA 859UW
UT WOS:000297902300009
PM 22047990
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Lund, O
   Nascimento, EJM
   Maciel, M
   Nielsen, M
   Larsen, MV
   Lundegaard, C
   Harndahl, M
   Lamberth, K
   Buus, S
   Salmon, J
   August, TJ
   Marques, ETA
AF Lund, Ole
   Nascimento, Eduardo J. M.
   Maciel, Milton, Jr.
   Nielsen, Morten
   Larsen, Mette Voldby
   Lundegaard, Claus
   Harndahl, Mikkel
   Lamberth, Kasper
   Buus, Soren
   Salmon, Jerome
   August, Thomas J.
   Marques, Ernesto T. A., Jr.
TI Human Leukocyte Antigen (HLA) Class I Restricted Epitope Discovery in
   Yellow Fewer and Dengue Viruses: Importance of HLA Binding Strength
SO PLOS ONE
LA English
DT Article
ID JAPANESE ENCEPHALITIS VACCINES; T-LYMPHOCYTE RESPONSES; DOUBLE-KNOCKOUT
   MICE; CELL RESPONSES; FEVER VACCINE; CTL EPITOPES; PROTEINS; TARGETS;
   CONSULTATION; SAFETY
AB Epitopes from all available full-length sequences of yellow fever virus (YFV) and dengue fever virus (DENV) restricted by Human Leukocyte Antigen class I (HLA-I) alleles covering 12 HLA-I supertypes were predicted using the NetCTL algorithm. A subset of 179 predicted YFV and 158 predicted DENV epitopes were selected using the EpiSelect algorithm to allow for optimal coverage of viral strains. The selected predicted epitopes were synthesized and approximately 75% were found to bind the predicted restricting HLA molecule with an affinity, K-D, stronger than 500 nM. The immunogenicity of 25 HLA-A*02:01, 28 HLA-A*24:02 and 28 HLA-B*07:02 binding peptides was tested in three HLA-transgenic mice models and led to the identification of 17 HLA-A*02: 01, 4 HLA-A*2402 and 4 HLA-B*07: 02 immunogenic peptides. The immunogenic peptides bound HLA significantly stronger than the non-immunogenic peptides. All except one of the immunogenic peptides had K-D below 100 nM and the peptides with K-D below 5 nM were more likely to be immunogenic. In addition, all the immunogenic peptides that were identified as having a high functional avidity had K-D below 20 nM. A*02:01 transgenic mice were also inoculated twice with the 17DD YFV vaccine strain. Three of the YFV A*02:01 restricted peptides activated T-cells from the infected mice in vitro. All three peptides that elicited responses had an HLA binding affinity of 2 nM or less. The results indicate the importance of the strength of HLA binding in shaping the immune response.
C1 [Lund, Ole; Nielsen, Morten; Larsen, Mette Voldby; Lundegaard, Claus] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark.
   [Harndahl, Mikkel; Lamberth, Kasper; Buus, Soren] Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Div Expt Immunol, DK-2200 Copenhagen, Denmark.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Maciel, Milton, Jr.; Salmon, Jerome; August, Thomas J.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Marques, Ernesto T. A., Jr.] Oswaldo Cruz Fdn FIOCRUZ, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
RP Lund, O (corresponding author), Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark.
EM lund@cbs.dtu.dk
RI Nascimento, Eduardo/J-4590-2014; Buus, Soren/F-5446-2010; Nielsen,
   Morten/E-7754-2011; Publica, Inct Saude/J-9544-2013; Nielsen,
   Morten/AAL-8700-2020; Lund, Ole/F-4437-2014; Marques,
   Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013; Lundegaard,
   Claus/B-3938-2012
OI Nascimento, Eduardo/0000-0002-9851-2332; Nielsen,
   Morten/0000-0001-7885-4311; Nielsen, Morten/0000-0001-7885-4311; Lund,
   Ole/0000-0003-1108-0491; Marques, Ernesto/0000-0003-3826-9358; Marques,
   Ernesto T. A/0000-0003-3826-9358; Buus, Soren/0000-0001-8363-1999
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [HHSN266200400083C, HHSN266200400025C]
FX This work was supported by NIAID contracts HHSN266200400083C,
   HHSN266200400025C (http://www.niaid.nih.gov/). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Braga-Neto UM, 2006, PLOS COMPUT BIOL, V2, P651, DOI 10.1371/journal.pcbi.0020081
   Brusic V, 2005, EXPERT REV VACCINES, V4, P407, DOI 10.1586/14760584.4.3.407
   Co MDT, 2002, VIROLOGY, V293, P151, DOI 10.1006/viro.2001.1255
   De Groot AS, 2006, DRUG DISCOV TODAY, V11, P203, DOI 10.1016/S1359-6446(05)03720-7
   Domingo C, 2009, EXPERT OPIN DRUG SAF, V8, P211, DOI [10.1517/14740330902808086 , 10.1517/14740330902808086]
   Duggan ST, 2009, DRUGS, V69, P115, DOI 10.2165/00003495-200969010-00008
   Ferguson M, 2007, VACCINE, V25, P5233, DOI 10.1016/j.vaccine.2007.05.034
   Khan AM, 2006, CELL IMMUNOL, V244, P141, DOI 10.1016/j.cellimm.2007.02.005
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Pedersen LO, 2001, EUR J IMMUNOL, V31, P2986, DOI 10.1002/1521-4141(2001010)31:10<2986::AID-IMMU2986>3.0.CO;2-R
   Pengsaa K, 2009, PEDIATR INFECT DIS J, V28, P335, DOI 10.1097/INF.0b013e3181906351
   Perez CL, 2008, J IMMUNOL, V180, P5092, DOI 10.4049/jimmunol.180.7.5092
   Rao XY, 2009, J IMMUNOL, V182, P1526, DOI 10.4049/jimmunol.182.3.1526
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rohrlich PS, 2003, INT IMMUNOL, V15, P765, DOI 10.1093/intimm/dxg073
   Roukens AH, 2008, EXPERT OPIN BIOL TH, V8, P1787, DOI [10.1517/14712598.8.11.1787, 10.1517/14712598.8.11.1787 ]
   Screaton Gavin, 2006, Novartis Found Symp, V277, P164, DOI 10.1002/0470058005.ch12
   Sette Alessandro, 2005, Immunity, V22, P155, DOI 10.1016/j.immuni.2005.01.009
   Sylvester-Hvid C, 2004, TISSUE ANTIGENS, V63, P395, DOI 10.1111/j.0001-2815.2004.00221.x
   Sylvester-Hvid C, 2002, TISSUE ANTIGENS, V59, P251, DOI 10.1034/j.1399-0039.2002.590402.x
   Tauber E, 2008, BIOL CHEM, V389, P547, DOI 10.1515/BC.2008.062
   Thomas SJ, 2009, VACCINE, V27, P355, DOI 10.1016/j.vaccine.2008.10.086
   van der Most RG, 2002, VIROLOGY, V296, P117, DOI 10.1006/viro.2002.1432
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51
NR 29
TC 19
Z9 20
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 19
PY 2011
VL 6
IS 10
AR e26494
DI 10.1371/journal.pone.0026494
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 841JB
UT WOS:000296507500078
PM 22039500
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-16
ER

PT J
AU de Melo, AB
   da Silva, MDC
   Magalhaes, MCF
   Gil, LHVG
   de Carvalho, EMF
   Braga-Neto, UM
   Bertani, GR
   Marques, ETA
   Cordeiro, MT
AF de Melo, Andrea Barbosa
   da Silva, Maria da Paz C.
   Magalhaes, Maria Cecilia F.
   Vega Gonzales Gil, Laura Helena
   Freese de Carvalho, Eduardo M.
   Braga-Neto, Ulisses M.
   Bertani, Giovani Rota
   Marques, Ernesto T. A., Jr.
   Cordeiro, Marli Tenorio
TI Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife,
   Brazil
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID SERIOUS ADVERSE EVENTS; HEMAGGLUTINATION-INHIBITION; IMMUNOFLUORESCENCE
   ASSAY; IGG ANTIBODIES; CLINICAL-TRIAL; UNITED-STATES; MAC-ELISA; VIRUS;
   DENGUE; NEUTRALIZATION
AB From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years).
C1 [de Melo, Andrea Barbosa; Magalhaes, Maria Cecilia F.; Vega Gonzales Gil, Laura Helena; Marques, Ernesto T. A., Jr.; Cordeiro, Marli Tenorio] Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
   [da Silva, Maria da Paz C.; Bertani, Giovani Rota] Univ Fed Pernambuco, Dept Bioquim, Recife, PE, Brazil.
   [Braga-Neto, Ulisses M.] Texas A&M Univ, Dept Elect Engn, College Stn, TX 77843 USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   Secretaria Saude Estado Pernambuco, Cent Publ Hlth Lab, Recife, PE, Brazil.
   [Freese de Carvalho, Eduardo M.] Aggeu Magalhaes Res Ctr, Dept Saude Colet, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Secretaria Saude Estado Pernambuco, Telephone & Cent Lab Publ Hlth, Recife, PE, Brazil.
RP Marques, ETA (corresponding author), Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, Av Moraes Rego S-N,Campus Univ Fed Pernambuco,Cid, BR-50670420 Recife, PE, Brazil.
EM abm@cpqam.fiocruz.br; mariadapazc@gmail.com; cecimag@cpqam.fiocruz.br;
   laura@cpqam.fiocruz.br; freese@cpqam.fiocruz.br; ulisses@ece.tamu.edu;
   gbertani@gmail.com; marques@pitt.edu; marli@cpqam.fiocruz.br
RI Marques, Ernesto/L-4514-2013; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU National Institute of Allergy and Infectious Diseases (NIAID/NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [N01-AI-40085]; Oswald Cruz Foundation [PDTIS-RVR9];
   National Science FoundationNational Science Foundation (NSF)
   [CCF-0845407]; Brazilian National Research Council (CAPES)National
   Council for Scientific and Technological Development (CNPq)CAPES;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R21AI040085, R01AI040085,
   R01AI040085] Funding Source: NIH RePORTER
FX The authors would like to acknowledge the support of National Institute
   of Allergy and Infectious Diseases (NIAID/NIH) Grant N01-AI-40085,
   Oswald Cruz Foundation Grant PDTIS-RVR9, National Science Foundation
   Award CCF-0845407, and the Brazilian National Research Council (CAPES;
   doctoral scholarship for Andrea Melo).
CR Arya SC, 1999, EMERG INFECT DIS, V5, P487, DOI 10.3201/eid0503.990333
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2009, GUIA VIG EP
   CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561
   Codeco CT, 2004, T ROY SOC TROP MED H, V98, P702, DOI 10.1016/j.trstmh.2003.12.019
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Oliveira RL, 2003, AM J TROP MED HYG, V69, P105, DOI 10.4269/ajtmh.2003.69.105
   DOSSANTOS CND, 1995, VIRUS RES, V35, P35
   Galler R, 1998, VACCINE, V16, P1024, DOI 10.1016/S0264-410X(97)00278-8
   Galler R, 2001, VIROLOGY, V290, P309, DOI 10.1006/viro.2001.1168
   Gómez Sergio Y, 2008, Rev. salud pública, V10, P796
   Guimard T, 2009, AM J TROP MED HYG, V81, P1141, DOI 10.4269/ajtmh.2009.09-0295
   Houghton-Triviño Natalia, 2008, Rev. salud pública, V10, P299
   Izurieta RO, 2009, J GLOB INFECT DIS, V1, P111, DOI 10.4103/0974-777X.56257
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153
   Kuno Goro, 2003, Adv Virus Res, V61, P3, DOI 10.1016/S0065-3527(03)61001-8
   LHUILLIER M, 1986, B WORLD HEALTH ORGAN, V64, P415
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   Lourenco-De-Oliveira R, 2004, T ROY SOC TROP MED H, V98, P43, DOI 10.1016/S0035-9203(03)00006-3
   Makela A, 2002, PEDIATRICS, V110, P957, DOI 10.1542/peds.110.5.957
   Marchevsky RS, 2006, BIOLOGICALS, V34, P191, DOI 10.1016/j.biologicals.2005.09.005
   Marques ETA, 2008, CAD SAUDE PUBLICA, V24, P547, DOI 10.1590/S0102-311X2008000300008
   Martin M, 2001, EMERG INFECT DIS, V7, P945, DOI 10.3201/eid0706.010605
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2002, AM J TROP MED HYG, V66, P533, DOI 10.4269/ajtmh.2002.66.533
   MONATH TPC, 1971, AM J EPIDEMIOL, V93, P122, DOI 10.1093/oxfordjournals.aje.a121232
   Figueiredo LTM, 2007, REV SOC BRAS MED TRO, V40, P224, DOI 10.1590/S0037-86822007000200016
   MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985
   Niedrig M, 2007, J VIROL METHODS, V139, P103, DOI 10.1016/j.jviromet.2006.09.009
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Niedrig M, 2008, CLIN VACCINE IMMUNOL, V15, P177, DOI 10.1128/CVI.00078-07
   NOGUEIRA RMR, 1992, REV I MED TROP, V34, P447, DOI 10.1590/S0036-46651992000500012
   Pfister M, 2005, AM J TROP MED HYG, V72, P339, DOI 10.4269/ajtmh.2005.72.339
   Pugachev KV, 2005, CURR OPIN INFECT DIS, V18, P387, DOI 10.1097/01.qco.0000178823.28585.ad
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Silva ML, 2010, CLIN VACCINE IMMUNOL, V17, P118, DOI 10.1128/CVI.00369-09
   STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568
   Suzano CES, 2006, VACCINE, V24, P1421, DOI 10.1016/j.vaccine.2005.09.033
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
   Vazquez S, 2003, J VIROL METHODS, V110, P179, DOI 10.1016/S0166-0934(03)00128-9
NR 45
TC 26
Z9 26
U1 0
U2 6
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2011
VL 85
IS 4
BP 739
EP 747
DI 10.4269/ajtmh.2011.10-0496
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 833QB
UT WOS:000295898900029
PM 21976581
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU Goldoni, AL
   Maciel, M
   Rigato, PO
   Piubelli, O
   de Brito, CA
   Melo, A
   Marques, ET
   August, JT
   Duarte, AJD
   Sato, MN
AF Goldoni, Adriana Leticia
   Maciel, Milton, Jr.
   Rigato, Paula Ordonhez
   Piubelli, Orlando
   de Brito, Cyro Alves
   Melo, Andrea
   Marques, Ernesto Torres
   August, Joseph Thomas
   da Silva Duarte, Alberto Jose
   Sato, Maria Notomi
TI Mucosal and systemic anti-GAG immunity induced by neonatal immunization
   with HIV LAMP/gag DNA vaccine in mice
SO IMMUNOBIOLOGY
LA English
DT Article
DE DNA vaccines; HIV; Mice; Mucosal; Neonates
ID T-CELL; MEMBRANE-PROTEIN; CPG MOTIFS; IN-VIVO; INTRANASAL IMMUNIZATION;
   ENVELOPE PROTEIN; DENDRITIC CELLS; II COMPARTMENT; RESPONSES; RECEPTOR
AB Vaccines capable of inducing mucosal immunity in early postnatal life until adulthood, protecting early sexual initiation, should be considered as strategies to vaccination against HIV. The HIV-1 GAG protein as a chimera with the lysosome-associated membrane protein (LAMP/gag), encoded by a DNA vaccine, is targeted to the endosomal/lysosomal compartment that contains class II MHC molecules and has been shown to be immunogenic in adult mice. Assuming that one such strategy could help to overcome the immunological immaturity in the early postnatal period, we have evaluated the systemic and mucosal immunogenicity of LAMP/gag immunization in neonatal mice. Intranasal immunization with LAMP/gag vaccine induced higher levels of sIgA and IgG anti-GAG antibodies in intestinal washes than did the gag vaccine. The combination of ID injections and the IN protocol with the chimeric vaccine promoted the increase of Ab levels in sera. Both vaccines induced splenic IFN-gamma- secreting cells against GAG peptide pools, as well as in vivo cytotoxic T lymphocyte (CTL) function, and increased the percentage of CD8+ T cells to the immunodominant class I peptide in gut and spleen. However, only the chimeric vaccine was able to enhance Th1/Th2 cytokine secretion in response to class II GAG peptide and to enhance IL-4-secreting cells against GAG peptides and p24 protein stimuli. Long-lasting humoral and cellular responses were detected until adult age, following neonatal immunization with the chimeric vaccine. The LAMP/gag vaccination was able to induce potent GAG-specific T and B cell immune responses in early life which are essential to elicit sustained and long-lasting mucosal and systemic humoral response. (C) 2010 Elsevier GmbH. All rights reserved.
C1 [Goldoni, Adriana Leticia; Rigato, Paula Ordonhez; Piubelli, Orlando; de Brito, Cyro Alves; da Silva Duarte, Alberto Jose; Sato, Maria Notomi] Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiency LIM56, BR-05403000 Sao Paulo, Brazil.
   [August, Joseph Thomas] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Melo, Andrea; Marques, Ernesto Torres] Fiocruz MS, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes CPqAM, Rio De Janeiro, Brazil.
   [Maciel, Milton, Jr.] Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
RP Sato, MN (corresponding author), Univ Sao Paulo, Inst Trop Med, Fac Med, Lab Dermatol & Imunodeficiencia, Predio 2,Av Dr Eneas de Carvalho Aguiar 500,3 And, BR-05403000 Sao Paulo, Brazil.
EM marisato@usp.br
RI Brito, Cyro/C-1910-2012; Goldoni, Adriana Leticia/I-1912-2012; Sato,
   Maria N/C-2853-2012; Marques, Ernesto/L-4514-2013; Publica, Inct
   Saude/J-9544-2013; Ordonhez Rigato, Paula/J-3618-2012; Marques, Ernesto
   T. A/L-4967-2013; Sato, Maria N/C-1196-2012
OI Brito, Cyro/0000-0002-9934-6102; Goldoni, Adriana
   Leticia/0000-0002-4298-8526; Marques, Ernesto/0000-0003-3826-9358;
   Marques, Ernesto T. A/0000-0003-3826-9358; Sato, Maria
   N/0000-0002-7911-1824
FU Ministerio da Saude do Brasil - Programa Nacional de HIV/AIDS/DST
   [914BRA1101]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); LIM-56/HCFMUSP
FX We thank Vilma dos Anjos Mesquita for the dedicated animal care, Noemia
   Orii for valuable technical assistance and Dr. Gabriela
   Ribeiro-dos-Santos for reviewing the manuscript. We thank Prof. Luis
   Carlos Ferreira for providing p24 Gag from HIV-1. This work was
   supported by Ministerio da Saude do Brasil - Programa Nacional de
   HIV/AIDS/DST (914BRA1101), FAPESP and LIM-56/HCFMUSP.
CR Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
   Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
   Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
   Brave A, 2008, VACCINE, V26, P5075, DOI 10.1016/j.vaccine.2008.03.066
   Cazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Dadaglio G, 2002, J IMMUNOL, V168, P2219, DOI 10.4049/jimmunol.168.5.2219
   Dale CJ, 2004, VACCINE, V23, P188, DOI 10.1016/j.vaccine.2004.05.024
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   de Brito CA, 2009, IMMUNOTHERAPY-UK, V1, P883, DOI 10.2217/IMT.09.38
   de Witte L, 2007, P NATL ACAD SCI USA, V104, P19464, DOI 10.1073/pnas.0703747104
   Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037
   Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
   Geijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31
   Gerdts V, 2000, NAT MED, V6, P929, DOI 10.1038/78699
   Gouws E, 2008, AIDS, V22, pS5, DOI 10.1097/01.aids.0000341773.86500.9d
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526
   Jiang JQ, 2005, J VIROL, V79, P393, DOI 10.1128/JVI.79.1.393-400.2005
   Kojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4
   Kraynyak KA, 2010, VACCINE, V28, P1942, DOI 10.1016/j.vaccine.2009.10.095
   Lambert AA, 2008, BLOOD, V112, P1299, DOI 10.1182/blood-2008-01-136473
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
   Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567
   Rollman E, 2004, GENE THER, V11, P1146, DOI 10.1038/sj.gt.3302275
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   *UNAIDS, 2008, REP GLOB AIDS EP, P1
   Valentin A, 2009, VACCINE, V27, P4840, DOI 10.1016/j.vaccine.2009.05.093
   Xiang ZQ, 2003, J IMMUNOL, V171, P4287, DOI 10.4049/jimmunol.171.8.4287
NR 34
TC 12
Z9 13
U1 0
U2 7
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD APR
PY 2011
VL 216
IS 4
BP 505
EP 512
DI 10.1016/j.imbio.2010.08.007
PG 8
WC Immunology
SC Immunology
GA 755UH
UT WOS:000289963300009
PM 20870310
DA 2020-12-16
ER

PT J
AU Rodriguez-Barraquer, I
   Cordeiro, MT
   Braga, C
   de Souza, WV
   Marques, ET
   Cummings, DAT
AF Rodriguez-Barraquer, Isabel
   Cordeiro, Marli T.
   Braga, Cynthia
   de Souza, Wayner V.
   Marques, Ernesto T.
   Cummings, Derek A. T.
TI From Re-Emergence to Hyperendemicity: The Natural History of the Dengue
   Epidemic in Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID HEMORRHAGIC-FEVER; INFECTION; VIRUS; TRANSMISSION; NICARAGUA; THAILAND;
   DYNAMICS; AMERICA; BANGKOK; DISEASE
AB Background: Dengue virus (DENV) was reintroduced into Brazil in 1986 and by 1995 it had spread throughout the country. In 2007 the number of dengue hemorrhagic fever (DHF) cases more than doubled and a shift in the age distribution was reported. While previously the majority of DHF cases occurred among adults, in 2007 53% of cases occurred in children under 15 years old. The reasons for this shift have not been determined.
   Methods and Findings: Age stratified cross-sectional seroepidemiologic survey conducted in Recife, Brazil in 2006. Serostatus was determined by ELISA based detection of Dengue IgG. We estimated time-constant and time-varying forces of infection of DENV between 1986 and 2006. We used discrete-time simulation to estimate the accumulation of monotypic and multitypic immunity over time in a population previously completely susceptible to DENV. We projected the age distribution of population immunity to dengue assuming similar hazards of infection in future years. The overall prevalence of DENV IgG was 0.80 (n = 1427). The time-constant force of infection for the period was estimated to be 0.052 (95% CI 0.041, 0.063), corresponding to 5.2% of susceptible individuals becoming infected each year by each serotype. Simulations show that as time since re-emergence of dengue goes by, multitypic immunity accumulates in adults while an increasing proportion of susceptible individuals and those with monotypic immunity are among young age groups. The median age of those monotypically immune can be expected to shift from 24 years, 10 years after introduction, to 13 years, 50 years after introduction. Of those monotypically immune, the proportion under 15 years old shifts from 27% to 58%. These results are consistent with the dengue notification records from the same region since 1995.
   Interpretation: Assuming that persons who have been monotypically exposed are at highest risk for severe dengue, the shift towards younger patient ages observed in Brazil can be partially explained by the accumulation of multitypic immunity against DENV-1, 2, and 3 in older age groups, 22 years after the re-introduction of these viruses. Serotype specific seroepidemiologic studies are necessary to accurately estimate the serotype specific forces of infection.
C1 [Rodriguez-Barraquer, Isabel; Cummings, Derek A. T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA.
   [Cordeiro, Marli T.; Braga, Cynthia; de Souza, Wayner V.; Marques, Ernesto T.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Cordeiro, Marli T.] Cent Publ Hlth Lab, Secretaria Saude Estado Pernambuco, Recife, PE, Brazil.
   [Marques, Ernesto T.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Rodriguez-Barraquer, I (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA.
EM irodrigu@jhsph.edu
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013; Braga,
   Maria Cynthia/A-8204-2013; Iats, Inct/K-2300-2013; Publica, Inct
   Saude/J-9544-2013; Souza, Wayner V/H-3798-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Braga, Maria Cynthia/0000-0002-7862-6455;
   Souza, Wayner/0000-0002-0939-9332; Rodriguez-Barraquer,
   Isabel/0000-0001-6784-1021
FU Gates FoundationBill & Melinda Gates Foundation; National Institute of
   General Medical SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [1U54GM088491-01]; National
   Institute of Allergy and Infectious Diseases (NIAID/NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19 AI56541]; PDTIS [RVR09-FIOCRUZ]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico -CNPqNational Council for
   Scientific and Technological Development (CNPq) [305947/2006-0];
   Burroughs Wellcome FundBurroughs Wellcome Fund; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI056541,
   U19AI056541, U19AI056541, U19AI056541, U19AI056541] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491, U54GM088491, U54GM088491,
   U54GM088491, U54GM088491, U54GM088491] Funding Source: NIH RePORTER
FX The authors acknowledge the support of the Gates Foundation through the
   Vaccine Modeling Initiative (I. R. B., D. A. T. C.), the National
   Institute of General Medical Sciences MIDAS grant 1U54GM088491-01 (I. R.
   B., D. A. T. C.), the National Institute of Allergy and Infectious
   Diseases (NIAID/NIH), Grant U19 AI56541 and PDTIS RVR09-FIOCRUZ (E. M.).
   W. V. de Souza was partially supported by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico -CNPq (305947/2006-0). Derek
   Cummings holds a Career Award at the Scientific Interface from the
   Burroughs Wellcome Fund. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Balmaseda A, 2006, AM J TROP MED HYG, V74, P449, DOI 10.4269/ajtmh.2006.74.449
   Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cummings DAT, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000139
   Egger JR, 2008, B WORLD HEALTH ORGAN, V86, P187, DOI 10.2471/BLT.07.040170
   Ferguson NM, 1999, PHILOS T R SOC B, V354, P757, DOI 10.1098/rstb.1999.0428
   FISCHER DB, 1970, YALE J BIOL MED, V42, P329
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859
   Gubler DJ, 2004, NAT MED, V10, P129, DOI 10.1038/nm0204-129
   Guzman Maria G., 2002, International Journal of Infectious Diseases, V6, P118, DOI 10.1016/S1201-9712(02)90072-X
   GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179
   HALSTEAD SB, 1969, AM J TROP MED HYG, V18, P997, DOI 10.4269/ajtmh.1969.18.997
   Halstead SB, 2001, AM J TROP MED HYG, V65, P180, DOI 10.4269/ajtmh.2001.65.180
   Halstead SB, 2006, REV PANAM SALUD PUBL, V20, P407, DOI 10.1590/S1020-49892006001100007
   Hammond SN, 2005, AM J TROP MED HYG, V73, P1063
   *IBGE, 2000, DEM CENS 2000 CHAR P
   KOURI GP, 1989, B WORLD HEALTH ORGAN, V67, P375
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Mendez Angela, 2003, Biomedica, V23, P180
   *MIN SAUD, 2010, SIST INF HOSP SIH SU
   Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   Teixeira MG, 2008, EMERG INFECT DIS, V14, P1663, DOI 10.3201/eid1410.071164
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS4, DOI 10.1590/S0102-311X2009001300001
   WHO/TDR, 2009, DENG GUID DIAGN TREA
NR 28
TC 89
Z9 91
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2011
VL 5
IS 1
AR e935
DI 10.1371/journal.pntd.0000935
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 711MP
UT WOS:000286596000013
PM 21245922
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Rigato, PO
   Maciel, M
   Goldoni, AL
   Piubelli, O
   de Brito, A
   Fusaro, AE
   de Alencar, LXE
   August, T
   Marques, ETA
   Duarte, AJD
   Sato, MN
AF Rigato, Paula Ordonhez
   Maciel, Milton, Jr.
   Goldoni, Adriana Leticia
   Piubelli, Orlando
   de Brito, Cyro Alves
   Fusaro, Ana Elisa
   Eurico de Alencar, Liciana Xavier
   August, Thomas
   Azevedo Marques, Ernesto Torres, Jr.
   da Silva Duarte, Alberto Jose
   Sato, Maria Notomi
TI Immunization of neonatal mice with LAMP/p55 HIV gag DNA elicits robust
   immune responses that last to adulthood
SO VIROLOGY
LA English
DT Article
DE Neonatal; Mice; DNA vaccine; HIV-1; Immunological memory
ID T-CELL; EARLY-LIFE; CLASS-II; MEMBRANE PROTEIN-1; DENDRITIC CELLS;
   VACCINE CHIMERA; PLASMID DNA; INDUCTION; MEMORY; LYMPHOCYTES
AB Successful T cell priming in early postnatal life that can generate effective long-lasting responses until adulthood is critical in HIV vaccination strategies because it prevents early sexual initiation and breastfeeding transmission of HIV. A chimeric DNA vaccine encoding p55 HIV gag associated with lysosome-associated membrane protein 1 (LAMP-1; which drives the antigen to the MIIC compartment), has been used to enhance cellular and humoral antigen-specific responses in adult mice and macaques. Herein, we investigated LAMP-1/gag vaccine immunogenicity in the neonatal period in mice and its ability to generate long-lasting effects. Neonatal vaccination with chimeric LAMP/gag generated stronger Gag-specific immune responses, as measured by the breadth of the Gag peptide-specific IFN-gamma, proliferative responsiveness, cytokine production and antibody production, all of which revealed activation of CD4+ T cells as well as the generation of a more robust CTL response compared to gag vaccine alone. To induce long-lived T and B cell memory responses, it was necessary to immunize neonates with the chimeric IAMP/gag DNA vaccine. The LAMP/gag DNA vaccine strategy could be particularly useful for generating an anti-HIV immune response in the early postnatal period capable of inducing long-term immunological memory. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Sato, Maria Notomi] Univ Sao Paulo, Lab Dermatol & Imunodeficiencia, Fac Med, Inst Trop Med,Sch Med,LIM 56, BR-05403000 Sao Paulo, Brazil.
   [Maciel, Milton, Jr.] Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [August, Thomas] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Eurico de Alencar, Liciana Xavier; Azevedo Marques, Ernesto Torres, Jr.] Fiocruz MS, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes CPqAM, Rio De Janeiro, Brazil.
   [Azevedo Marques, Ernesto Torres, Jr.] Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburg, KS USA.
RP Sato, MN (corresponding author), Univ Sao Paulo, Lab Dermatol & Imunodeficiencia, Fac Med, Inst Trop Med,Sch Med,LIM 56, Predio 2,Av Dr Eneas de Carvalho Aguiar 500,3 And, BR-05403000 Sao Paulo, Brazil.
EM marisato@usp.br
RI Goldoni, Adriana Leticia/I-1912-2012; Sato, Maria N/C-1196-2012;
   Marques, Ernesto T. A/L-4967-2013; Sato, Maria N/C-2853-2012; Ordonhez
   Rigato, Paula/J-3618-2012; Brito, Cyro/C-1910-2012; Publica, Inct
   Saude/J-9544-2013; Marques, Ernesto/L-4514-2013
OI Goldoni, Adriana Leticia/0000-0002-4298-8526; Sato, Maria
   N/0000-0002-7911-1824; Marques, Ernesto T. A/0000-0003-3826-9358; Brito,
   Cyro/0000-0002-9934-6102; Marques, Ernesto/0000-0003-3826-9358
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [141487/2005]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2004/14443-2]; Ministerio da Saude do Brasil
   [914BRA1101]; LIM-56/HCFMUSP
FX We thank Vilma dos Anjos Mesquita for the dedicated animal care, and
   Noemia Orii and Soraya Ogusuko for valuable technical assistance. We
   thank Luis Carlos Ferreira for providing p24 Gag from HIV-1. This work
   was supported by CNPq (141487/2005), FAPESP (2004/14443-2), Ministerio
   da Saude do Brasil - Programa Nacional de HIV/AIDS/DST (914BRA1101) and
   LIM-56/HCFMUSP.
CR Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
   Adkins B, 2003, J IMMUNOL, V171, P5157, DOI 10.4049/jimmunol.171.10.5157
   Amanna IJ, 2006, IMMUNOL REV, V211, P320, DOI 10.1111/j.0105-2896.2006.00392.x
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65
   Blanche S, 1997, J ACQ IMMUN DEF SYND, V14, P442, DOI 10.1097/00042560-199704150-00008
   BRITO CA, 2009, IMMUNOTHERAPY, V1, P883
   Buseyne F, 2002, J INFECT DIS, V186, P1589, DOI 10.1086/345482
   Calarota Sandra A, 2004, Expert Rev Vaccines, V3, pS135, DOI 10.1586/14760584.3.4.S135
   Capozzo AVE, 2006, J IMMUNOL, V176, P5671, DOI 10.4049/jimmunol.176.9.5671
   Cassese G, 2003, J IMMUNOL, V171, P1684, DOI 10.4049/jimmunol.171.4.1684
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   Cheng WF, 2001, J CLIN INVEST, V108, P669, DOI 10.1172/JCI12346
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Coelho-Castelo A A M, 2006, Genet Vaccines Ther, V4, P1, DOI 10.1186/1479-0556-4-1
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002
   Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728
   Gold MC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000957
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341
   Lu S, 2008, EXPERT REV VACCINES, V7, P175, DOI 10.1586/14760584.7.2.175
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726
   Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606
   Min B, 2001, J IMMUNOL, V166, P5594, DOI 10.4049/jimmunol.166.9.5594
   Muthukkumar S, 2000, J IMMUNOL, V165, P4803, DOI 10.4049/jimmunol.165.9.4803
   Pihlgren M, 2001, EUR J IMMUNOL, V31, P939, DOI 10.1002/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I
   Rigato PO, 2009, IMMUNOTHERAPY-UK, V1, P141, DOI 10.2217/1750743X.1.1.141
   Rose S, 2007, J IMMUNOL, V178, P2667, DOI 10.4049/jimmunol.178.5.2667
   Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746
   Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726
   Sedegah M, 2003, J IMMUNOL, V171, P3148, DOI 10.4049/jimmunol.171.6.3148
   Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Simon GG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008574
   Simpson CC, 2003, CLIN EXP IMMUNOL, V132, P201, DOI 10.1046/j.1365-2249.2003.02154.x
   Stevenson FK, 2004, IMMUNOL REV, V199, P5, DOI 10.1111/j.0105-2896.2004.00146.x
   *UNAIDS, 2008, AIDS EP UPD
   Valentin A, 2009, VACCINE, V27, P4840, DOI 10.1016/j.vaccine.2009.05.093
   Xin Ke-Qin, 2002, Biological Procedures Online, V3, P91, DOI 10.1251/bpo27
   Xin KQ, 2003, J GENE MED, V5, P438, DOI 10.1002/jgm.356
   Zhang J, 2002, J VIROL, V76, P11911, DOI 10.1128/JVI.76.23.11911-11919.2002
NR 45
TC 10
Z9 10
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD OCT 10
PY 2010
VL 406
IS 1
BP 37
EP 47
DI 10.1016/j.virol.2010.06.050
PG 11
WC Virology
SC Virology
GA 647BA
UT WOS:000281589400005
PM 20667577
DA 2020-12-16
ER

PT J
AU Gomes, ALV
   Wee, LJK
   Khan, AM
   Gil, LHVG
   Marques, ETA
   Calzavara-Silva, CE
   Tan, TW
AF Gomes, Ana Lisa V.
   Wee, Lawrence J. K.
   Khan, Asif M.
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
   Calzavara-Silva, Carlos E.
   Tan, Tin Wee
TI Classification of Dengue Fever Patients Based on Gene Expression Data
   Using Support Vector Machines
SO PLOS ONE
LA English
DT Article
ID PLASMACYTOID DENDRITIC CELLS; INTERFERON; INFECTION; ALGORITHMS;
   PREDICT; INNATE
AB Background: Symptomatic infection by dengue virus (DENV) can range from dengue fever (DF) to dengue haemorrhagic fever (DHF), however, the determinants of DF or DHF progression are not completely understood. It is hypothesised that host innate immune response factors are involved in modulating the disease outcome and the expression levels of genes involved in this response could be used as early prognostic markers for disease severity.
   Methodology/Principal Findings: mRNA expression levels of genes involved in DENV innate immune responses were measured using quantitative real time PCR (qPCR). Here, we present a novel application of the support vector machines (SVM) algorithm to analyze the expression pattern of 12 genes in peripheral blood mononuclear cells (PBMCs) of 28 dengue patients (13 DHF and 15 DF) during acute viral infection. The SVM model was trained using gene expression data of these genes and achieved the highest accuracy of similar to 85% with leave-one-out cross-validation. Through selective removal of gene expression data from the SVM model, we have identified seven genes (MYD88, TLR7, TLR3, MDA5, IRF3, IFN-alpha and CLEC5A) that may be central in differentiating DF patients from DHF, with MYD88 and TLR7 observed to be the most important. Though the individual removal of expression data of five other genes had no impact on the overall accuracy, a significant combined role was observed when the SVM model of the two main genes (MYD88 and TLR7) was re-trained to include the five genes, increasing the overall accuracy to similar to 96%.
   Conclusions/Significance: Here, we present a novel use of the SVM algorithm to classify DF and DHF patients, as well as to elucidate the significance of the various genes involved. It was observed that seven genes are critical in classifying DF and DHF patients: TLR3, MDA5, IRF3, IFN-alpha, CLEC5A, and the two most important MYD88 and TLR7. While these preliminary results are promising, further experimental investigation is necessary to validate their specific roles in dengue disease.
C1 [Gomes, Ana Lisa V.; Gil, Laura H. V. G.; Marques, Ernesto T. A., Jr.] Fiocruz MS, Aggeu Magalhaes Res Ctr, CPqAM, Dept Virol & Expt Therapy, Recife, PE, Brazil.
   [Wee, Lawrence J. K.; Khan, Asif M.; Tan, Tin Wee] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Calzavara-Silva, Carlos E.] Fiocruz MS, Dept Cellular & Mol Immunol, Rene Rachou Res Ctr, CPqRR, Belo Horizonte, MG, Brazil.
RP Gomes, ALV (corresponding author), Fiocruz MS, Aggeu Magalhaes Res Ctr, CPqAM, Dept Virol & Expt Therapy, Recife, PE, Brazil.
EM tinwee@bic.nus.edu.sg
RI Marques, Ernesto/L-4514-2013; Tan, Tin Wee/B-8963-2009; Marques, Ernesto
   T. A/L-4967-2013; Khan, Mohammad Asif/F-4663-2010; Publica, Inct
   Saude/J-9544-2013
OI Marques, Ernesto/0000-0003-3826-9358; Tan, Tin Wee/0000-0002-4062-2854;
   Marques, Ernesto T. A/0000-0003-3826-9358; Khan, Mohammad
   Asif/0000-0001-9202-279X; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Ciencia e Tecnologia do Estado de
   (FACEPE), Brazil; National Institutes of Health (NIH), USAUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA
FX This work was supported by the Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES), Fundacao de Amparo a Ciencia e Tecnologia do
   Estado de (FACEPE), Brazil, the National Institutes of Health (NIH),
   USA. The first author ALVG was a visiting scientist with the Department
   of Biochemistry, National University of Singapore (NUS). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555
   Chang C, 2009, LIBSVM LIB SUPPORT V
   Chen PC, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-44
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   Coffey LL, 2009, MICROBES INFECT, V11, P143, DOI 10.1016/j.micinf.2008.12.006
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Diamond MS, 2009, FRONT BIOSCI-LANDMRK, V14, P3024, DOI 10.2741/3432
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Holmes EC, 2000, TRENDS MICROBIOL, V8, P74, DOI 10.1016/S0966-842X(99)01669-8
   Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464
   Jones M, 2005, J VIROL, V79, P5414, DOI 10.1128/JVI.79.9.5414-5420.2005
   Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020
   KNIPE DP, 2007, FIELDS VIROLOGY, P250
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McKenna K, 2005, J VIROL, V79, P17, DOI 10.1128/JVI.79.1.17-27.2005
   Munoz-Jordan JL, 2010, CURR TOP MICROBIOL, V338, P35, DOI 10.1007/978-3-642-02215-9_3
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Sun PF, 2009, VIROLOGY, V383, P207, DOI 10.1016/j.virol.2008.10.022
   Tang EK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-95
   Tang YC, 2007, IEEE ACM T COMPUT BI, V4, P365, DOI 10.1109/TCBB.2007.1028
   Tanner L, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000196
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   Wee LJK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S14
   *WHO, 1997, HAEM FEV DIAGN TREAT
   Yoneyama M, 2009, IMMUNOL REV, V227, P54, DOI 10.1111/j.1600-065X.2008.00727.x
NR 29
TC 16
Z9 16
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2010
VL 5
IS 6
AR e11267
DI 10.1371/journal.pone.0011267
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 615KY
UT WOS:000279135400013
PM 20585645
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Guedes, DRD
   Cordeiro, MT
   Melo-Santos, MAV
   Magalhaes, T
   Marques, E
   Regis, L
   Furtado, AF
   Ayres, CFJ
AF Guedes, D. R. D.
   Cordeiro, M. T.
   Melo-Santos, M. A. V.
   Magalhaes, T.
   Marques, E.
   Regis, L.
   Furtado, A. F.
   Ayres, C. F. J.
TI Patient-based dengue virus surveillance in Aedes aegypti from Recife,
   Brazil
SO JOURNAL OF VECTOR BORNE DISEASES
LA English
DT Article
DE Arbovirus; entomological surveillance; mosquito; RT-PCR; vertical
   transmission
ID NATURAL VERTICAL TRANSMISSION; POLYMERASE-CHAIN-REACTION; STATE;
   CULICIDAE; DIPTERA; VECTOR
AB Background & objectives: Dengue is currently one of the most important arthropod-borne diseases and may be caused by four different dengue virus serotypes (DENV-1 to DENV-4), transmitted mainly by Aedes aegypti (Diptera: Culicidae) mosquitoes. With the lack of a dengue vaccine, vector control strategies constitute a crucial mode to prevent or reduce disease transmission. In this context, DENV detection in natural Ae. aegypti populations may serve as a potential additional tool for early prediction systems of dengue outbreaks, leading to an intensification of vector control measures, aimed at reducing disease transmission. In Brazil, this type of surveillance has been performed sporadically by a few groups and has not been incorporated as a routine activity in control programs. This study aimed at detecting DENV in natural Ae. aegypti from Recife, Pernambuco, to check the circulating serotypes and the occurrence of transovarial transmission in local mosquito populations.
   Methods: From January 2005 to June 2006, mosquitoes (adults and eggs) were collected in houses where people with clinical suspicion of dengue infection lived at. RNA was extracted from pooled mosquitoes and RT-PCR was performed in these samples for detection of the four DENV serotypes.
   Results & conclusion: Out of 83 pools of adult mosquitoes collected in the field, nine were positive for DENV: five for DENV-1, two for DENV-2 and two for DENV-3. From 139 pools of adult mosquitoes reared from collected eggs, there were 17 positive pools: three for DENV-1, 10 for DENV-2, and four for DENV-3. These results are discussed in the paper in regard to the local dengue epidemiological data. The conclusions clearly point to the informative power and sensitivity of DENV entomological surveillance and to the importance of including mosquito immature forms in this strategy.
C1 [Guedes, D. R. D.; Melo-Santos, M. A. V.; Magalhaes, T.; Regis, L.; Ayres, C. F. J.] Fiocruz MS, CPqAM, Dept Entomol, Fundacao Oswaldo Cruz, Recife, PE, Brazil.
   [Cordeiro, M. T.; Marques, E.; Furtado, A. F.] Fiocruz MS, CPqAM, Lab Virol & Terapia Expt, Recife, PE, Brazil.
   [Cordeiro, M. T.] Secretaria Saude Estado Pernambuco, Cent Lab, Recife, PE, Brazil.
RP Ayres, CFJ (corresponding author), Fiocruz MS, CPqAM, Dept Entomol, Fundacao Oswaldo Cruz, Av Moraes Rego S-N, Recife, PE, Brazil.
EM tans@cpqam.fiocruz.br
RI Magalhaes, Tereza/V-6632-2019; Ayres, Constancia/AAQ-3448-2020; Marques,
   Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU FIOCRUZ [Papes 0250.250. 110/2003, PDTSP-Rede Dengue RDVE-03]
FX The authors are thankful to the insectary and field teams from the
   Department of Entomology at CPqAM/FIOCRUZ. This work received financial
   support from FIOCRUZ (grants Papes 0250.250. 110/2003 and PDTSP-Rede
   Dengue RDVE-03).
CR Angel Bennet, 2008, Journal of Vector Borne Diseases, V45, P56
   Arunachalam N, 2008, INDIAN J MED RES, V127, P395
   Barbosa da Silva Jarbas Jr, 2002, Epidemiol Bull, V23, P3
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Cecilio AB, 2009, BRAZ J BIOL, V69, P123, DOI 10.1590/S1519-69842009000100015
   Chow VTK, 1998, AM J TROP MED HYG, V58, P578, DOI 10.4269/ajtmh.1998.58.578
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   CORDEIRO MT, 2008, VINTE ANOS EVOLUCAO, P225
   FAY R. W., 1965, MOSQUITO NEWS, V25, P276
   Fouque F, 2004, TROP MED INT HEALTH, V9, P41, DOI 10.1046/j.1365-3156.2003.01166.x
   Garcia-Rejon J, 2008, AM J TROP MED HYG, V79, P940, DOI 10.4269/ajtmh.2008.79.940
   Gu W, 2004, MED VET ENTOMOL, V18, P200, DOI 10.1111/j.0269-283X.2004.00482.x
   GUBLER DJ, 1994, AM J TROP MED HYG, V50, P50, DOI 10.4269/ajtmh.1994.50.50
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Gunther J, 2007, INTERVIROLOGY, V50, P347, DOI 10.1159/000107272
   KHIN MM, 1983, AM J TROP MED HYG, V32, P590, DOI 10.4269/ajtmh.1983.32.590
   Kow CY, 2001, J MED ENTOMOL, V38, P475, DOI 10.1603/0022-2585-38.4.475
   Lam S K, 1993, Malays J Pathol, V15, P9
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lourenco-de-Oliveira R, 2002, MEM I OSWALDO CRUZ, V97, P799, DOI 10.1590/S0074-02762002000600009
   *MIN SAUD BRAS SEC, 2008, INF EP DENG, V1
   Pinheiro VCS, 2005, MEM I OSWALDO CRUZ, V100, P833, DOI 10.1590/S0074-02762005000800003
   *PREF REC, 2009, INF EP SEM DENG
   Regis L, 2008, MEM I OSWALDO CRUZ, V103, P50, DOI 10.1590/S0074-02762008000100008
   Regis L, 2009, AN ACAD BRAS CIENC, V81, P655, DOI 10.1590/S0001-37652009000400004
   ROSEN L, 1987, AM J TROP MED HYG, V37, P398
   Urdaneta Ludmel, 2005, Infection Genetics and Evolution, V5, P177, DOI 10.1016/j.meegid.2004.09.004
   WHO, 2000, STRENGTH IMPL GLOB S
   Zeidler Julianna Dias, 2008, Rev. Saúde Pública, V42, P986, DOI 10.1590/s0034-89102008000600002
NR 30
TC 33
Z9 35
U1 0
U2 10
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0972-9062
J9 J VECTOR DIS
JI J. Vector Borne Dis.
PD JUN
PY 2010
VL 47
IS 2
BP 67
EP 75
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 606CI
UT WOS:000278398100001
PM 20539043
DA 2020-12-16
ER

PT J
AU Braga, C
   Luna, CF
   Martelli, CM
   de Souza, WV
   Cordeiro, MT
   Alexander, N
   de Albuquerque, MDPM
   Silveira, JC
   Marques, ET
AF Braga, Cynthia
   Luna, Carlos Feitosa
   Martelli, Celina MariaTurchi
   de Souza, Wayner Vieira
   Cordeiro, Marli Tenorio
   Alexander, Neal
   Pessoa Militao de Albuquerque, Maria de Fatima
   Silveira Junior, Jose Constantino
   Marques, Ernesto T.
TI Seroprevalence and risk factors for dengue infection in
   socio-economically distinct areas of Recife, Brazil
SO ACTA TROPICA
LA English
DT Article
DE Dengue; Seroprevalence; Risk factors; Spatial analysis
ID VIRUS-INFECTION; TRANSMISSION; EPIDEMIC; SURVEILLANCE; CIRCULATION;
   PREVENTION; SINGAPORE; DYNAMICS; CHILDREN; FEVER
AB Brazil currently accounts for the majority of dengue cases reported in the Americas, with co-circulation of DENV 1-3. Striking variation in the epidemiological pattern of infection within cities has been observed. Therefore, investigation of dengue transmission in small areas is important to formulate control strategies. A population-based household survey was performed in three diverse socio-economic and environmental areas of Recife, a large urban center of Brazil, between 2005 and 2006. Dengue serostatus and individual- and household-level risk factors for infection were collected in residents aged between 5 and 64 years. A total of 2833 individuals were examined, and their residences were geo-referenced. Anti-dengue IgG antibodies were measured using commercial ELISA. The dengue seroprevalence and the force of infection were estimated in each area. Individual and household variables associated with seropositivity were assessed by multilevel models for each area. A spatial analysis was conducted to identify risk gradients of dengue seropositivity using Generalized Additive Models (GAM). The dengue seroprevalence was 91.1%,87.4% 74.3%, respectively, in the deprived, intermediate and high socio-economic areas, inversely related to their socio-economic status. In the deprived area, 59% of children had already been exposed to dengue virus by the age of 5 years and the estimated force of infection was three times higher than that in the privileged area. The risk of infection increased with age in the three areas. Not commuting away from the area was a risk factor for seropositivity in the deprived area (OR = 2.26; 95% CI: 1.18-4.30). Number of persons per room was a risk factor for seropositivity in the intermediate (OR = 3.00; 95% CI: 3.21-7.37) and privileged areas (OR = 1.81; 95% Cl: 1.07-3.04). Living in a house, as opposed to an apartment, was a risk factor for seropositivity in the privileged area (OR = 3.62; 95% Cl: 2.43-5.41). The main difference between the privileged and other areas could be attributed to the much larger proportion of apartment dwellers. Intensive vector control, surveillance and community education should be considered in deprived urban areas where a high proportion of children are infected by an early age. (C) 2009 Published by Elsevier B.V.
C1 [Braga, Cynthia; Luna, Carlos Feitosa; de Souza, Wayner Vieira; Cordeiro, Marli Tenorio; Pessoa Militao de Albuquerque, Maria de Fatima; Silveira Junior, Jose Constantino; Marques, Ernesto T.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil.
   [Braga, Cynthia] Inst Med Integral Prof Fernando Figueira, BR-50070550 Recife, PE, Brazil.
   [Martelli, Celina MariaTurchi] Univ Fed Goias, Inst Patol Trop & Saude Publ, Dept Saude Colet, Setor Univ, BR-74605050 Goiania, Go, Brazil.
   [Cordeiro, Marli Tenorio] Secretaria Saude Estado Pernambuco, Lab Cent Saude Publ, BR-50050210 Recife, PE, Brazil.
   [Alexander, Neal] Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   [Pessoa Militao de Albuquerque, Maria de Fatima] Univ Fed Pernambuco, Dept Trop Med, Hosp Clin, BR-50670420 Recife, PE, Brazil.
   [Marques, Ernesto T.] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.
RP Braga, C (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Av Prof Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.
EM braga@cpqam.fiocruz.br
RI Souza, Wayner V/H-3798-2013; Marques, Ernesto/L-4514-2013; Braga, Maria
   Cynthia/A-8204-2013; Publica, Inct Saude/J-9544-2013; Marques, Ernesto
   T. A/L-4967-2013; Iats, Inct/K-2300-2013
OI Marques, Ernesto/0000-0003-3826-9358; Braga, Maria
   Cynthia/0000-0002-7862-6455; Marques, Ernesto T. A/0000-0003-3826-9358;
   Souza, Wayner/0000-0002-0939-9332; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688
FU National Institute of Allergy and Infectious Diseases (NIAID/NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19 AI56541, PDTIS RVR09-FIOCRUZ]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico -CNPqNational Council for
   Scientific and Technological Development (CNPq) [307963/2004-7,
   305947/2006-0]; Medical Research CouncilMedical Research Council UK
   (MRC) [G0700837] Funding Source: researchfish; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI056541,
   U19AI056541, U19AI056541, U19AI056541, U19AI056541] Funding Source: NIH
   RePORTER
FX The authors acknowledge the support of the National Institute of Allergy
   and Infectious Diseases (NIAID/NIH), Grant U19 AI56541 and PDTIS
   RVR09-FIOCRUZ. Martelli CMT, Albuquerque MFP and Souza WV were partially
   supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico -CNPq (scholarships 307963/2004-7, 305947/2006-0,
   respectively)
CR Barrera R, 2000, Rev Panam Salud Publica, V8, P225, DOI 10.1590/S1020-49892000000900001
   Collett D., 2002, MODELLING BINARY DAT
   da Silva-Nunes M, 2008, AM J TROP MED HYG, V79, P485, DOI 10.4269/ajtmh.2008.79.485
   Almeida MCD, 2007, J URBAN HEALTH, V84, P334, DOI 10.1007/s11524-006-9154-2
   Egger JR, 2008, B WORLD HEALTH ORGAN, V86, P187, DOI 10.2471/BLT.07.040170
   Endy TP, 2010, CURR TOP MICROBIOL, V338, P1, DOI 10.1007/978-3-642-02215-9_1
   Endy TP, 2002, AM J EPIDEMIOL, V156, P52, DOI 10.1093/aje/kwf006
   Gomez-Dantes H, 2009, CAD SAUDE PUBLICA, V25, pS19, DOI 10.1590/S0102-311X2009001300003
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   *IBGE, 2000, DEM CENS 2000 CHAR P
   *IBGE, 2009, IBGE CIT
   *ITEP, 2009, CLIM
   Kelsall JE, 1998, J ROY STAT SOC C-APP, V47, P559, DOI 10.1111/1467-9876.00128
   KO YC, 1992, AM J EPIDEMIOL, V136, P214, DOI 10.1093/oxfordjournals.aje.a116487
   Koh BKW, 2008, ANN ACAD MED SINGAP, V37, P538
   Kuno G, 1995, EPIDEMIOL REV, V17, P321, DOI 10.1093/oxfordjournals.epirev.a036196
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   Lian CW, 2006, TROP BIOMED, V23, P85
   Almeida MCD, 2008, CAD SAUDE PUBLICA, V24, P2385, DOI 10.1590/S0102-311X2008001000019
   *PAHO, 2008, EID UPD EM REEM INF
   Regis L, 2008, MEM I OSWALDO CRUZ, V103, P50, DOI 10.1590/S0074-02762008000100008
   Reiter P, 2003, EMERG INFECT DIS, V9, P86
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Siqueira JB, 2004, AM J TROP MED HYG, V71, P646, DOI 10.4269/ajtmh.2004.71.646
   Siqueira JB, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-361
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Teixeira MD, 2002, TROP MED INT HEALTH, V7, P757, DOI 10.1046/j.1365-3156.2002.00930.x
   Thai KTD, 2005, TROP MED INT HEALTH, V10, P379, DOI 10.1111/j.1365-3156.2005.01388.x
   Torralba JM, 2007, ADV MATER RES-SWITZ, V23, P1, DOI 10.4028/www.scientific.net/AMR.23.1
   Vallee J, 2009, TROP MED INT HEALTH, V14, P1134, DOI 10.1111/j.1365-3156.2009.02319.x
   Van Benthem BHB, 2005, AM J TROP MED HYG, V72, P201, DOI 10.4269/ajtmh.2005.72.201
   Vanwambeke Sophie O, 2006, Int J Health Geogr, V5, P5, DOI 10.1186/1476-072X-5-5
   Vasconcelos PFC, 1998, REV SAUDE PUBL, V32, P447, DOI 10.1590/S0034-89101998000500007
   WHO, 2007, GUID PLAQ RED NEUTR
   *WHO, 2009, 117 WHO
   Wood S., 2006, GEN ADDITIVE MODELS, P391
   Wood SN, 2003, J ROY STAT SOC B, V65, P95, DOI 10.1111/1467-9868.00374
   Yew YW, 2009, ANN ACAD MED SINGAP, V38, P667
NR 38
TC 112
Z9 115
U1 0
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD MAR
PY 2010
VL 113
IS 3
BP 234
EP 240
DI 10.1016/j.actatropica.2009.10.021
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 570KZ
UT WOS:000275677700005
PM 19896921
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Tan, PT
   Heiny, AT
   Miotto, O
   Salmon, J
   Marques, ETA
   Lemonnier, F
   August, JT
AF Tan, Paul ThiamJoo
   Heiny, A. T.
   Miotto, Olivo
   Salmon, Jerome
   Marques, Ernesto T. A., Jr.
   Lemonnier, Francois
   August, J. Thomas
TI Conservation and Diversity of Influenza A H1N1 HLA-Restricted T Cell
   Epitope Candidates for Epitope-Based Vaccines
SO PLOS ONE
LA English
DT Article
ID DOUBLE-KNOCKOUT MICE; CLASS-I SUPERTYPES; TRANSGENIC MICE; MEDIATED
   PROTECTION; LETHAL INFLUENZA; VIRUS INFECTION; CTL EPITOPES;
   HIGH-AVIDITY; LYMPHOCYTE; PEPTIDE
AB Background: The immune-related evolution of influenza viruses is exceedingly complex and current vaccines against influenza must be reformulated for each influenza season because of the high degree of antigenic drift among circulating influenza strains. Delay in vaccine production is a serious problem in responding to a pandemic situation, such as that of the current H1N1 strain. Immune escape is generally attributed to reduced antibody recognition of the viral hemagglutinin and neuraminidase proteins whose rate of mutation is much greater than that of the internal non-structural proteins. As a possible alternative, vaccines directed at T cell epitope domains of internal influenza proteins, that are less susceptible to antigenic variation, have been investigated.
   Methodology/Principal Findings: HLA transgenic mouse strains expressing HLA class I A*0201, A*2402, and B*0702, and class II DRB1*1501, DRB1*0301 and DRB1*0401 were immunized with 196 influenza H1N1 peptides that contained residues of highly conserved proteome sequences of the human H1N1, H3N2, H1N2, H5N1, and avian influenza A strains. Fifty-four (54) peptides that elicited 63 HLA-restricted peptide-specific T cell epitope responses were identified by IFN-gamma ELISpot assay. The 54 peptides were compared to the 2007-2009 human H1N1 sequences for selection of sequences in the design of a new candidate H1N1 vaccine, specifically targeted to highly-conserved HLA-restricted T cell epitopes.
   Conclusions/Significance: Seventeen (17) T cell epitopes in PB1, PB2, and M1 were selected as vaccine targets based on sequence conservation over the past 30 years, high functional avidity, non-identity to human peptides, clustered localization, and promiscuity to multiple HLA alleles. These candidate vaccine antigen sequences may be applicable to any avian or human influenza A virus.
C1 [Tan, Paul ThiamJoo; Salmon, Jerome; August, J. Thomas] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Heiny, A. T.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Miotto, Olivo] Univ Oxford, Ctr Genom & Global Hlth, Oxford, England.
   [Miotto, Olivo] Mahidol Univ, Fac Trop Med, Mahidol Oxford Res Unit, Bangkok, Thailand.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Marques, Ernesto T. A., Jr.] LaVITE, FIOCRUZ Dept Virol, Ctr Pesquisa Aggeu Magalhaes, Recife, PE, Brazil.
   [Lemonnier, Francois] Inst Pasteur, Unite Immunite Cellulaire Antivirale, Paris, France.
RP Tan, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
EM ptan4@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Miotto, Olivo/AAE-7124-2019; Publica,
   Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Miotto, Olivo/0000-0001-8060-6771;
   Francois, Lemonnier/0000-0002-6741-2742
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services, USAUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [5 U19 AI56541, HHSN2662-00400085C]; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI056541,
   U19AI056541, U19AI056541, U19AI056541, U19AI056541] Funding Source: NIH
   RePORTER
FX This work was supported in part with Federal Funds from the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human Services, USA under Grant No. 5
   U19 AI56541 and Contract No. HHSN2662-00400085C. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102
   Assarsson E, 2008, J VIROL, V82, P12241, DOI 10.1128/JVI.01563-08
   Berkhoff EGM, 2006, VACCINE, V24, P6594, DOI 10.1016/j.vaccine.2006.05.051
   Berkhoff EGM, 2004, J VIROL, V78, P5216, DOI 10.1128/JVI.78.10.5216-5222.2004
   BIDDISON WE, 2001, CURR PROTOC IMMUNOL
   Brown DM, 2006, J IMMUNOL, V177, P2888, DOI 10.4049/jimmunol.177.5.2888
   Carson RT, 1999, J IMMUNOL, V162, P1
   Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690
   Doytchinova IA, 2005, J IMMUNOL, V174, P7085, DOI 10.4049/jimmunol.174.11.7085
   Epstein SL, 2005, VACCINE, V23, P5404, DOI 10.1016/j.vaccine.2005.04.047
   Epstein SL, 1998, J IMMUNOL, V160, P322
   Epstein SL, 2002, EMERG INFECT DIS, V8, P796
   Fernandez-Sesma A, 2006, J VIROL, V80, P6295, DOI 10.1128/JVI.02381-05
   Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365
   FUGGER L, 1994, P NATL ACAD SCI USA, V91, P6151, DOI 10.1073/pnas.91.13.6151
   Gianfrani C, 2000, HUM IMMUNOL, V61, P438, DOI 10.1016/S0198-8859(00)00105-1
   Gonzalez S, 1996, NUCLEIC ACIDS RES, V24, P4456, DOI 10.1093/nar/24.22.4456
   Hamada H, 2009, J IMMUNOL, V182, P3469, DOI 10.4049/jimmunol.0801814
   Heiny AT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001190
   Jimenez GS, 2007, HUM VACCINES, V3, P157, DOI 10.4161/hv.3.5.4175
   Klenerman P, 1998, NATURE, V394, P482
   Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07
   Lalvani A, 1997, J IMMUNOL METHODS, V210, P65, DOI 10.1016/S0022-1759(97)00177-4
   Le Gall S, 2007, J CLIN INVEST, V117, P3563, DOI 10.1172/JCI32047
   Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460
   Li X, 2006, CLIN EXP RHEUMATOL, V24, P148
   Lo CY, 2008, VACCINE, V26, P2062, DOI 10.1016/j.vaccine.2008.02.047
   Maciel M, 2008, VIROLOGY, V378, P105, DOI 10.1016/j.virol.2008.04.043
   Miotto O, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S1-S18
   Mirshahidi S, 2004, J IMMUNOL, V172, P5346, DOI 10.4049/jimmunol.172.9.5346
   Mozdzanowska K, 2005, J VIROL, V79, P5943, DOI 10.1128/JVI.79.10.5943-5951.2005
   Niedermann G, 2002, CURR TOP MICROBIOL, V268, P91
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Poole E, 2004, VIROLOGY, V321, P120, DOI 10.1016/j.virol.2003.12.022
   Powell TJ, 2007, J IMMUNOL, V178, P1030, DOI 10.4049/jimmunol.178.2.1030
   Richards KA, 2009, J VIROL, V83, P6566, DOI 10.1128/JVI.00302-09
   Rimmelzwaan GF, 2009, VACCINE, V27, P6363, DOI 10.1016/j.vaccine.2009.01.016
   Rohrlich PS, 2003, INT IMMUNOL, V15, P765, DOI 10.1093/intimm/dxg073
   Sedlik C, 2000, J VIROL, V74, P5769, DOI 10.1128/JVI.74.13.5769-5775.2000
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1
   STRAUSS G, 1994, IMMUNOGENETICS, V40, P104
   Strutt TM, 2009, J CLIN IMMUNOL, V29, P145, DOI 10.1007/s10875-008-9266-4
   Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237
   Tobery TW, 2001, J IMMUNOL METHODS, V254, P59, DOI 10.1016/S0022-1759(01)00397-0
   Tompkins SM, 2007, EMERG INFECT DIS, V13, P426, DOI 10.3201/eid1303.061125
   Tsitoura DC, 1996, J IMMUNOL, V156, P2801
   Vandenbark AA, 2003, J IMMUNOL, V171, P127, DOI 10.4049/jimmunol.171.1.127
NR 50
TC 32
Z9 36
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 18
PY 2010
VL 5
IS 1
AR e8754
DI 10.1371/journal.pone.0008754
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 545EJ
UT WOS:000273715000012
PM 20090904
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Simon, GG
   Hu, YL
   Khan, AM
   Zhou, JS
   Salmon, J
   Chikhlikar, PR
   Jung, KO
   Marques, ETA
   August, JT
AF Simon, Gregory G.
   Hu, Yongli
   Khan, Asif M.
   Zhou, Jingshi
   Salmon, Jerome
   Chikhlikar, Priya R.
   Jung, Keun-Ok
   Marques, Ernesto T. A.
   August, J. Thomas
TI Dendritic Cell Mediated Delivery of Plasmid DNA Encoding LAMP/HIV-1 Gag
   Fusion Immunogen Enhances T Cell Epitope Responses in HLA DR4 Transgenic
   Mice
SO PLOS ONE
LA English
DT Article
ID MEMBRANE-PROTEIN; RHESUS MACAQUES; VACCINE CHIMERA; II COMPARTMENT;
   GENE-TRANSFER; IN-VITRO; RNA; ANTIGEN; EXPRESSION; TRANSFECTION
AB This report describes the identification and bioinformatics analysis of HLA-DR4-restricted HIV-1 Gag epitope peptides, and the application of dendritic cell mediated immunization of DNA plasmid constructs. BALB/c (H-2d) and HLA-DR4 (DRA1*0101, DRB1*0401) transgenic mice were immunized with immature dendritic cells transfected by a recombinant DNA plasmid encoding the lysosome-associated membrane protein-1/HIV-1 Gag (pLAMP/gag) chimera antigen. Three immunization protocols were compared: 1) primary subcutaneous immunization with 1x10(5) immature dendritic cells transfected by electroporation with the pLAMP/gag DNA plasmid, and a second subcutaneous immunization with the naked pLAMP/gag DNA plasmid; 2) primary immunization as above, and a second subcutaneous immunization with a pool of overlapping peptides spanning the HIV-1 Gag sequence; and 3) immunization twice by subcutaneous injection of the pLAMP/gag DNA plasmid. Primary immunization with pLAMP/gag-transfected dendritic cells elicited the greatest number of peptide specific T-cell responses, as measured by ex vivo IFN-gamma ELISpot assay, both in BALB/c and HLA-DR4 transgenic mice. The pLAMP/gag-transfected dendritic cells prime and naked DNA boost immunization protocol also resulted in an increased apparent avidity of peptide in the ELISpot assay. Strikingly, 20 of 25 peptide-specific T-cell responses in the HLA-DR4 transgenic mice contained sequences that corresponded, entirely or partially to 18 of the 19 human HLA-DR4 epitopes listed in the HIV molecular immunology database. Selection of the most conserved epitope peptides as vaccine targets was facilitated by analysis of their representation and variability in all reported sequences. These data provide a model system that demonstrates a) the superiority of immunization with dendritic cells transfected with LAMP/gag plasmid DNA, as compared to naked DNA, b) the value of HLA transgenic mice as a model system for the identification and evaluation of epitope-based vaccine strategies, and c) the application of variability analysis across reported sequences in public databases for selection of historically conserved HIV epitopes as vaccine targets.
C1 [Simon, Gregory G.; Zhou, Jingshi; Salmon, Jerome; Chikhlikar, Priya R.; Jung, Keun-Ok; Marques, Ernesto T. A.; August, J. Thomas] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Hu, Yongli; Khan, Asif M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Marques, Ernesto T. A.; August, J. Thomas] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
RP Simon, GG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
EM gsimon2@jhmi.edu
RI Marques, Ernesto/L-4514-2013; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto T. A/L-4967-2013; Khan, Mohammad Asif/F-4663-2010
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; Khan, Mohammad Asif/0000-0001-9202-279X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37-AI41908]; National Cancer InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [T32 CA9009243]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R37AI041908] Funding Source: NIH
   RePORTER
FX This work is supported by Grants R37-AI41908 from the National Institute
   of Allergy and Infectious Diseases, and the National Cancer Institute
   training grant T32 CA9009243. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Artusio E, 2006, CANCER BIOL THER, V5, P1624, DOI 10.4161/cbt.5.12.3353
   Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592
   Bedoui S, 2009, IMMUNOL CELL BIOL, V87, P255, DOI 10.1038/icb.2008.105
   Belz GT, 2002, J EXP MED, V196, P1099, DOI 10.1084/jem.20020861
   Bonehill A, 2004, J IMMUNOL, V172, P6649, DOI 10.4049/jimmunol.172.11.6649
   Bontkes HJ, 2007, GENE THER, V14, P366, DOI 10.1038/sj.gt.3302874
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014
   Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Cope AP, 1999, ARTHRITIS RHEUM, V42, P1497, DOI 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-#
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Dell K, 2008, ANTIVIR THER, V13, P495
   EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5
   FUGGER L, 1994, P NATL ACAD SCI USA, V91, P6151, DOI 10.1073/pnas.91.13.6151
   GIESE NA, 1994, J VIROL, V68, P5819, DOI 10.1128/JVI.68.9.5819-5824.1994
   Gross DA, 2004, J CLIN INVEST, V113, P425, DOI 10.1172/JCI200419418
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5
   Kalergis AM, 2000, J IMMUNOL, V165, P280, DOI 10.4049/jimmunol.165.1.280
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kurts C, 2001, J IMMUNOL, V166, P1439, DOI 10.4049/jimmunol.166.3.1439
   Landi A, 2007, J LEUKOCYTE BIOL, V82, P849, DOI 10.1189/jlb.0906561
   Lenz P, 2003, FEBS LETT, V538, P149, DOI 10.1016/S0014-5793(03)00169-8
   Liao XS, 2004, MOL THER, V9, P757, DOI 10.1016/j.ymthe.2004.02.011
   Madrenas J, 1996, Semin Immunol, V8, P83, DOI 10.1006/smim.1996.0011
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Melhem NM, 2007, EUR J IMMUNOL, V37, P2164, DOI 10.1002/eji.200636782
   Mitchell DA, 2000, J CLIN INVEST, V106, P1065, DOI 10.1172/JCI11405
   Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Nishimura Y, 2004, MOL IMMUNOL, V40, P1089, DOI 10.1016/j.molimm.2003.11.009
   Patel SD, 1997, P NATL ACAD SCI USA, V94, P8082, DOI 10.1073/pnas.94.15.8082
   Pei JM, 2007, BIOINFORMATICS, V23, P802, DOI 10.1093/bioinformatics/btm017
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rosati M, 2008, VACCINE, V26, P5223, DOI 10.1016/j.vaccine.2008.03.090
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI21512
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   Xu R, 2008, VACCINE, V26, P4819, DOI 10.1016/j.vaccine.2008.06.103
NR 43
TC 13
Z9 14
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 5
PY 2010
VL 5
IS 1
AR e8574
DI 10.1371/journal.pone.0008574
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 540NE
UT WOS:000273338500017
PM 20052293
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Dhalia, R
   Maciel, M
   Cruz, FSP
   Viana, IFT
   Palma, ML
   August, T
   Marques, ETA
AF Dhalia, Rafael
   Maciel, Milton, Jr.
   Cruz, Fabia S. P.
   Viana, Isabelle F. T.
   Palma, Mariana L.
   August, Thomas
   Marques, Ernesto T. A., Jr.
TI Membrane and envelope virus proteins co-expressed as lysosome associated
   membrane protein (LAMP) fused antigens: a potential tool to develop DNA
   vaccines against flaviviruses
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE dengue; West Nile; yellow fever; Lysosome-Associated Membrane Protein -
   LAMP; DNA vaccines
ID CLASS-II COMPARTMENT; T-CELL; RESPONSES; ANTIBODY; CHIMERA; VACCINATION;
   SEQUENCES; 17D
AB Vaccination is the most practical and cost-effective strategy to prevent the majority of the flavivirus infection to which there is an available vaccine. However, vaccines based on attenuated virus can potentially promote collateral side effects and even rare fatal reactions. Given this scenario, the development of alternative vaccination strategies such as DNA-based vaccines encoding specific flavivirus sequences are being considered. Endogenous cytoplasmic antigens, characteristically plasmid DNA-vaccine encoded, are mainly presented to the immune system through Major Histocompatibility Complex class I - MHC I molecules. The MHC I presentation via is mostly associated with a cellular cytotoxic response and often do not elicit a satisfactory humoral response. One of the main strategies to target DNA-encoded antigens to the MHC II compartment is expressing the antigen within the Lysosome-Associated Membrane Protein (LAMP). The flavivirus envelope protein is recognized as the major virus surface protein and the main target for neutralizing antibodies. Different groups have demonstrated that co-expression of flavivirus membrane and envelope proteins in mammalian cells, fused with the carboxyl-terminal of LAMP, is able to induce satisfactory levels of neutralizing antibodies. Here we reviewed the use of the envelope flavivirus protein co-expression strategy as LAMP chimeras with the aim of developing DNA vaccines for dengue, West Nile and yellow fever viruses.
C1 [Dhalia, Rafael; Cruz, Fabia S. P.; Viana, Isabelle F. T.; Palma, Mariana L.; Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Lab Virol & Terapia Expt LaViTE, BR-50670420 Recife, PE, Brazil.
   [Maciel, Milton, Jr.; August, Thomas; Marques, Ernesto T. A., Jr.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Marques, Ernesto T. A., Jr.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
RP Dhalia, R (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Lab Virol & Terapia Expt LaViTE, Av Prof Moraes Rego S-N,Caixa Postal 7472, BR-50670420 Recife, PE, Brazil.
EM rdhalia@cpqam.fiocruz.br
RI Dhalia, Rafael/AAD-5432-2020; Marques, Ernesto/L-4514-2013; Marques,
   Ernesto T. A/L-4967-2013; Viana, Isabelle/M-4435-2017
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; Viana, Isabelle/0000-0003-4648-6635
CR Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Barrett ADT, 2001, ANN NY ACAD SCI, V951, P262
   Barrett Alan D T, 2002, Curr Opin Investig Drugs, V3, P992
   Cetron Martin S, 2002, MMWR Recomm Rep, V51, P1
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Donnelly J, 2003, INT J PARASITOL, V33, P457, DOI 10.1016/S0020-7519(03)00056-0
   Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Lefeuvre Anabelle, 2004, Curr Infect Dis Rep, V6, P96, DOI 10.1007/s11908-996-0005-9
   Lewis PJ, 1999, ADV VIRUS RES, V54, P129, DOI 10.1016/S0065-3527(08)60367-X
   LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593
   Liu MA, 2003, J INTERN MED, V253, P402, DOI 10.1046/j.1365-2796.2003.01140.x
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Monath TP, 2002, J VIROL, V76, P1932, DOI 10.1128/JVI.76.4.1932-1943.2002
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Putnak Robert, 2003, Adv Virus Res, V61, P445, DOI 10.1016/S0065-3527(03)61012-2
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Robinson HL, 1999, INT J MOL MED, V4, P549
   Rocha B, 2004, CURR OPIN IMMUNOL, V16, P259, DOI 10.1016/j.coi.2004.03.004
   Schultz J, 2000, Dev Biol (Basel), V104, P109
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
   Wu CJ, 2006, MICROBES INFECT, V8, P2578, DOI 10.1016/j.micinf.2006.06.010
NR 30
TC 7
Z9 8
U1 0
U2 4
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD DEC
PY 2009
VL 81
IS 4
BP 663
EP 669
DI 10.1590/S0001-37652009000400005
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 516VD
UT WOS:000271570500005
PM 19893892
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Calzavara-Silva, CE
   Gomes, ALV
   Maia, RCC
   Acioli-Santos, B
   Gil, LHVG
   Marques, ETA
AF Calzavara-Silva, Carlos E.
   Gomes, Ana L. V.
   Maia, Rita C. C.
   Acioli-Santos, Bartolomeu
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
TI Early molecular markers predictive of dengue hemorrhagic fever
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE real-time PCR; dengue hemorrhagic fever; molecular markers
ID ORIGINAL ANTIGENIC SIN; GENE-EXPRESSION; PERIPHERAL-BLOOD;
   VIRUS-INFECTION; APOPTOSIS
AB The management of acute dengue patients during outbreaks is a challenging problem. Most of the dengue fever cases are benign, but some cases develop into a severe and possibly lethal vasculopathy, known as dengue hemorrhagic fever. Early symptoms of dengue and hemorrhagic fever are very similar. An early differential diagnosis is needed to predict which of these two clinical presentations is crucial to proper patient care and public health management. This study evaluates the predictive potential of specific mRNA expression markers of dengue hemorrhagic fever using quantitative real-time PCR assays. Six candidate "dengue hemorrhagic fever specific signature genes" were evaluated and all showed good correlation among their transcription levels at early days of infection and the later development of severe vasculopathy. The markers selected were able to indicate, at early stages of infection, the evolution of a dengue-infected patient to the severe form of the illness. Despite the fact that these results grant further validation studies, the panel of candidate prognostic markers obtained demonstrated the potential to be useful for clinical use in the form of a fast assay based in blood samples.
C1 [Calzavara-Silva, Carlos E.; Gomes, Ana L. V.; Acioli-Santos, Bartolomeu; Gil, Laura H. V. G.] Fiocruz MS, Ctr Pesquisa Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Marques, Ernesto T. A., Jr.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Div Infect Dis, Dept Med, Baltimore, MD 21205 USA.
   [Maia, Rita C. C.] Univ Fed Rural Pernambuco, Dept Vet Med, BR-50741150 Recife, PE, Brazil.
RP Calzavara-Silva, CE (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunol Celular & Mol, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM calzavara@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI56541] Funding Source: Medline
CR *APPL BIOS, 2006, 127AP0502 APPL BIOS
   *APPL BIOS, 2008, 75007500 APPL BIOS
   Bente Dennis A, 2006, Drug Discov Today Dis Models, V3, P97, DOI 10.1016/j.ddmod.2006.03.014
   Brown MG, 2009, J LEUKOCYTE BIOL, V85, P71, DOI 10.1189/jlb.0308167
   Chaturvedi UC, 2006, FEMS IMMUNOL MED MIC, V47, P155, DOI 10.1111/j.1574-695X.2006.00058.x
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Espina LM, 2003, AM J TROP MED HYG, V68, P48, DOI 10.4269/ajtmh.2003.68.48
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mosquera JA, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-26
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Shu PY, 2004, CLIN DIAGN LAB IMMUN, V11, P642, DOI 10.1128/CDLI.11.4.642-650.2004
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
NR 20
TC 4
Z9 5
U1 0
U2 2
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD DEC
PY 2009
VL 81
IS 4
BP 671
EP 677
DI 10.1590/S0001-37652009000400006
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 516VD
UT WOS:000271570500006
PM 19893893
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Nascimento, EJM
   Braga-Neto, U
   Calzavara-Silva, CE
   Gomes, ALV
   Abath, FGC
   Brito, CAA
   Cordeiro, MT
   Silva, AM
   Magalhaes, C
   Andrade, R
   Gil, LHVG
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Braga-Neto, Ulisses
   Calzavara-Silva, Carlos E.
   Gomes, Ana L. V.
   Abath, Frederico G. C.
   Brito, Carlos A. A.
   Cordeiro, Marli T.
   Silva, Ana M.
   Magalhaes, Cecilia
   Andrade, Raoni
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
TI Gene Expression Profiling during Early Acute Febrile Stage of Dengue
   Infection Can Predict the Disease Outcome
SO PLOS ONE
LA English
DT Article
ID BOLSTERED ERROR ESTIMATION; T-CELL RESPONSES; HEMORRHAGIC-FEVER;
   PERIPHERAL-BLOOD; VIRUS-INFECTIONS; SHOCK-SYNDROME; ELEVATED LEVELS;
   SEVERITY; ACTIVATION; APOPTOSIS
AB Background: We report the detailed development of biomarkers to predict the clinical outcome under dengue infection. Transcriptional signatures from purified peripheral blood mononuclear cells were derived from whole-genome gene-expression microarray data, validated by quantitative PCR and tested in independent samples.
   Methodology/Principal Findings: The study was performed on patients of a well-characterized dengue cohort from Recife, Brazil. The samples analyzed were collected prospectively from acute febrile dengue patients who evolved with different degrees of disease severity: classic dengue fever or dengue hemorrhagic fever (DHF) samples were compared with similar samples from other non-dengue febrile illnesses. The DHF samples were collected 2-3 days before the presentation of the plasma leakage symptoms. Differentially-expressed genes were selected by univariate statistical tests as well as multivariate classification techniques. The results showed that at early stages of dengue infection, the genes involved in effector mechanisms of innate immune response presented a weaker activation on patients who later developed hemorrhagic fever, whereas the genes involved in apoptosis were expressed in higher levels.
   Conclusions/Significance: Some of the gene expression signatures displayed estimated accuracy rates of more than 95%, indicating that expression profiling with these signatures may provide a useful means of DHF prognosis at early stages of infection.
RP Nascimento, EJM (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Recife, PE, Brazil.
EM marques@pitt.edu
RI Nascimento, Eduardo/J-4590-2014; Publica, Inct Saude/J-9544-2013;
   Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Nascimento, Eduardo/0000-0002-9851-2332; Marques,
   Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; Direct For Computer & Info Scie &
   EnginrNational Science Foundation (NSF)NSF - Directorate for Computer &
   Information Science & Engineering (CISE) [0845407] Funding Source:
   National Science Foundation; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI056541, U19 AI56541] Funding Source: Medline
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   BRAGA UMD, 2005, EURASIP BOOK SERIES
   Braga-Neto U, 2004, PATTERN RECOGN, V37, P1267, DOI 10.1016/j.patcog.2003.08.017
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096
   Clementi M, 2006, REPROD TOXICOL, V21, P345, DOI 10.1016/j.reprotox.2005.08.006
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713
   Juffrie M, 2000, INFECT IMMUN, V68, P702, DOI 10.1128/IAI.68.2.702-707.2000
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mangada MM, 2002, J INFECT DIS, V185, P1697, DOI 10.1086/340822
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Mustafa AS, 2001, FEMS IMMUNOL MED MIC, V30, P229, DOI 10.1111/j.1574-695X.2001.tb01575.x
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   *OPAS, 1995, DENG DENG HEM AM GUI
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Pettiford JN, 2002, CLIN EXP IMMUNOL, V128, P110, DOI 10.1046/j.1365-2249.2002.01813.x
   Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   SCHERER CA, 2007, VACCINE
   Sierra B, 2007, HUM IMMUNOL, V68, P531, DOI 10.1016/j.humimm.2007.03.001
   Sima C, 2005, PATTERN RECOGN, V38, P2472, DOI 10.1016/j.patcog.2005.03.026
   Sima C, 2005, BIOINFORMATICS, V21, P1046, DOI 10.1093/bioinformatics/bti081
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Soundravally R, 2007, HUM IMMUNOL, V68, P973, DOI 10.1016/j.humimm.2007.09.007
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Tan GK, 2009, CURR OPIN INFECT DIS, V22, P302, DOI 10.1097/QCO.0b013e328329ae32
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   *WHO, 1999, TREATM DENG FEV DENG
   Yunta M, 2003, ONCOGENE, V22, P1219, DOI 10.1038/sj.onc.1206183
NR 49
TC 48
Z9 48
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 19
PY 2009
VL 4
IS 11
AR e7892
DI 10.1371/journal.pone.0007892
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 522NJ
UT WOS:000272004600001
PM 19936257
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-16
ER

PT J
AU Rodriguez-Barraquer, I
   Marques, E
   Cummings, DA
AF Rodriguez-Barraquer, Isabel
   Marques, Ernesto
   Cummings, Derek A.
TI AGE SHIFTS OF DHF IN BRAZIL: INSIGHT FROM A SEROLOGICAL SURVEY IN RECIFE
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 18-22, 2009
CL Washington, DC
SP Amer Soc Trop Med & Hyg
C1 [Rodriguez-Barraquer, Isabel; Cummings, Derek A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Marques, Ernesto] Johns Hopkins Sch Med, Baltimore, MD USA.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2009
VL 81
IS 5
SU S
MA 353
BP 101
EP 101
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 521WK
UT WOS:000271956700353
DA 2020-12-16
ER

PT J
AU Yang, K
   Sun, K
   Srinivasan, KN
   Salmon, J
   Marques, ET
   Xu, J
   August, JT
AF Yang, K.
   Sun, K.
   Srinivasan, K. N.
   Salmon, J.
   Marques, E. T.
   Xu, J.
   August, J. T.
TI Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced
   by N immunization with a chimera of lysosome-associated membrane protein
SO GENE THERAPY
LA English
DT Article
DE SARS CoV; N; LAMP; cluster of dominant T-cell epitopes; DNA vaccine;
   ELISpot
ID MHC CLASS-I; TARGETING ANTIGEN; DNA VACCINE; COMPARTMENT; MEMORY;
   COMPLEX; CD4(+); TRAFFICKING; INDUCTION; ANTIBODY
AB In our previous study by Gupta et al, dominant T-cell epitopes of SARS CoV-N(N) protein were predicted by software. The spectrum of interferon (IFN)-gamma responses of Balb/c mice immunized against two different forms of SARS CoV-N plasmid was then analyzed. A cluster of dominant T-cell epitopes of SARS CoV-N protein was found in the N-terminus (amino acids 76-114). On the basis of this study, four different plasmids were constructed: (i) DNA encoding the unmodified N (p-N) or N70-122 (p-N70-122) as an endogenous cytoplasmic protein or (ii) DNA encoding a lysosome-associated membrane protein (LAMP) chimera with N (p-LAMP/N) or N70-122 (p-LAMP/N70-122). The immune responses of mice to these four constructs were evaluated. The results showed marked differences in the responses of the immunized mice. A single priming immunization with the p-LAMP/N construct was sufficient to elicit an antibody response. Enzyme-linked immunospot (ELISpot) assay indicated that p-LAMP/N70-122 and p-LAMP/N plasmids both elicited a greater IFN-gamma response than p-N. p-N and p-N70-122 constructs induced low or undetectable levels of cytokine secretion. We also found that the p-LAMP/N70-122 construct promoted a long-lasting T-cell memory response without an additional boost 6 months after three immunizations. These findings show that DNA vaccines, even epitope-based DNA vaccines using LAMP as chimera, can elicit both humoral and cellular immune responses. Gene Therapy (2009) 16, 1353-1362; doi:10.1038/gt.2009.92; published online 3 September 2009
C1 [Yang, K.] Fourth Mil Med Univ, Dept Immunol, Xian 710032, Shaanxi Prov, Peoples R China.
   [Yang, K.; Srinivasan, K. N.; Salmon, J.; Marques, E. T.; August, J. T.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Sun, K.] Div Biomed Sci, Singapore, Singapore.
   [Srinivasan, K. N.] Hlth Sci Author, Ctr Drug Adm, Prod Evaluat & Registrat Div, Singapore, Singapore.
   [Marques, E. T.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   [Xu, J.] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710032, Shaanxi Prov, Peoples R China.
RP Yang, K (corresponding author), Fourth Mil Med Univ, Dept Immunol, 17 Changle W Rd, Xian 710032, Shaanxi Prov, Peoples R China.
EM yangkunkun@fmmu.edu.cn; taugust@jhmi.edu
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Department of Health
   and Human Services of USA [HHSN266200400085C]; National High-tech R&D
   Program of ChinaNational High Technology Research and Development
   Program of China [2006AA02A237]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R21AI040085, R01AI040085, R01AI040085] Funding Source: NIH
   RePORTER
FX This study was supported by grants from the National Institute of
   Allergy and Infectious Diseases, the National Institutes of Health,
   Department of Health and Human Services, contract no. HHSN266200400085C
   of USA, and the National High-tech R&D Program (863 Program) of China
   (No. 2006AA02A237). We thank Chikhlikar PR, Paul Tan, Vladimir Perovic,
   Keun OK Jung, Garg S, Milton Maciel Jr, Betty Hart and Delores Henson
   for their excellent technical assistance. The support of the NIH AIDS
   Research and Reference Reagent Program in providing the SARS-N peptides
   and purified SARS-N protein is gratefully acknowledged.
CR Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Cheng WF, 2001, HUM GENE THER, V12, P235, DOI 10.1089/10430340150218387
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Dobano C, 2007, IMMUNOL LETT, V111, P92, DOI 10.1016/j.imlet.2007.05.007
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9
   Fassnacht M, 2005, CLIN CANCER RES, V11, P5566, DOI 10.1158/1078-0432.CCR-05-0699
   FUKUDA M, 1991, J BIOL CHEM, V266, P21327
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Gupta V, 2006, VIROLOGY, V347, P127, DOI 10.1016/j.virol.2005.11.042
   Hunziker W, 1996, NEPHROLOGIE, V17, P347
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Ji HX, 1999, HUM GENE THER, V10, P2727, DOI 10.1089/10430349950016474
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kang TH, 2006, IMMUNOL LETT, V106, P126, DOI 10.1016/j.imlet.2006.05.004
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Khanolkar A, 2007, IMMUNOL RES, V39, P94, DOI 10.1007/s12026-007-0081-4
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Kwon YJ, 2005, MOL PHARMACEUT, V2, P83, DOI 10.1021/mp0498953
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Peng SW, 2005, J BIOMED SCI, V12, P689, DOI 10.1007/s11373-005-9012-3
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rocha B, 2004, CURR OPIN IMMUNOL, V16, P259, DOI 10.1016/j.coi.2004.03.004
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Su Z, 2002, CANCER RES, V62, P5041
   Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   Zhao JC, 2007, J VIROL, V81, P6079, DOI 10.1128/JVI.02568-06
NR 41
TC 11
Z9 13
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD NOV
PY 2009
VL 16
IS 11
BP 1353
EP 1362
DI 10.1038/gt.2009.92
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 518CB
UT WOS:000271666600009
PM 19727132
OA Green Published, Bronze
DA 2020-12-16
ER

PT J
AU da Silva, ANMR
   Nascimento, EJM
   Cordeiro, MT
   Gil, LHVG
   Abath, FGC
   Montenegro, SML
   Marques, ETA
AF Rangel da Silva, Andrea N. M.
   Nascimento, Eduardo J. M.
   Cordeiro, Marli Tenorio
   Gil, Laura H. V. G.
   Abath, Frederico G. C.
   Montenegro, Silvia M. L.
   Marques, Ernesto T. A., Jr.
TI Identification of Continuous Human B-Cell Epitopes in the Envelope
   Glycoprotein of Dengue Virus Type 3 (DENV-3)
SO PLOS ONE
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDE; NEUTRALIZING ANTIBODY;
   REACTIVE EPITOPES; SWISS-MODEL; DOMAIN-III; PROTEIN; DETERMINANTS;
   RECOGNITION; PREDICTION
AB Background: Dengue virus infection is a growing global public health concern in tropical and subtropical regions of the world. Dengue vaccine development has been hampered by concerns that cross-reactive immunological memory elicited by a candidate vaccine could increase the risk of development of more severe clinical forms. One possible strategy to reduce risks associated with a dengue vaccine is the development of a vaccine composed of selected critical epitopes of each of the serotypes.
   Methodology/Principal Findings: Synthetic peptides were used to identify B-cell epitopes in the envelope (E) glycoprotein of dengue virus type 3 (DENV-3). Eleven linear, immunodominant epitopes distributed in five regions at amino acid (aa) positions: 51-65, 71-90, 131-170, 196-210 and 246-260 were identified by employing an enzyme-linked immunosorbent assay (ELISA), using a pool of human sera from dengue type 3 infected individuals. Peptides 11 (aa51-65), 27 and 28 (aa131-150) also reacted with dengue 1 (DENV-1) and dengue 2 (DENV-2) patient sera as analyzed through the ROC curves generated for each peptide by ELISA and might have serotype specific diagnostic potential. Mice immunized against each one of the five immunogenic regions showed epitopes 51-65, 131-170, 196-210 and 246-260 elicited the highest antibody response and epitopes 131-170, 196-210 and 246-260, elicited IFN-gamma production and T CD4+ cell response, as evaluated by ELISA and ELISPOT assays respectively.
   Conclusions/Significance: Our study identified several useful immunodominant IgG-specific epitopes on the envelope of DENV-3. They are important tools for understanding the mechanisms involved in antibody dependent enhancement and immunity. If proven protective and safe, in conjunction with others well-documented epitopes, they might be included into a candidate epitope-based vaccine.
RP da Silva, ANMR (corresponding author), Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
EM marques@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; montenegro, silvia/AAD-9090-2020;
   Publica, Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013;
   Nascimento, Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Nascimento, Eduardo/0000-0002-9851-2332
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI05641] Funding Source: Medline
CR AnandaRao R, 2005, VIRUS RES, V112, P60, DOI 10.1016/j.virusres.2005.03.022
   Apt D, 2006, VACCINE, V24, P335, DOI 10.1016/j.vaccine.2005.07.100
   Beasley DWC, 2001, VIROLOGY, V279, P447, DOI 10.1006/viro.2000.0721
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Crill WD, 2004, J VIROL, V78, P13975, DOI 10.1128/JVI.78.24.13975-13986.2004
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   HECHAVARRIA A, 2002, MANUAL PROCEDIMIENTO
   Hombach J, 2005, VACCINE, V23, P5205, DOI [10.1016/j.vaccine.2005.07.002, 10.1016/j.vaccine.2004.11.040]
   Huang JH, 1999, J MED VIROL, V57, P1, DOI 10.1002/(SICI)1096-9071(199901)57:1&lt;1::AID-JMV1&gt;3.0.CO;2-T
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   MATHEWS JH, 1991, J VIROL, V65, P5141, DOI 10.1128/JVI.65.10.5141-5148.1991
   Matsui K, 2009, VIROLOGY, V384, P16, DOI 10.1016/j.virol.2008.11.013
   Miagostovich MP, 2002, BRAZ J MED BIOL RES, V35, P869, DOI 10.1590/S0100-879X2002000800002
   Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Oliphant T, 2006, J VIROL, V80, P12149, DOI 10.1128/JVI.01732-06
   Reynolds J, 2009, CLIN EXP IMMUNOL, V155, P311, DOI 10.1111/j.1365-2249.2008.03833.x
   Roehrig JT, 1998, VIROLOGY, V246, P317, DOI 10.1006/viro.1998.9200
   ROEHRIG JT, 1992, J VIROL, V66, P3385, DOI 10.1128/JVI.66.6.3385-3390.1992
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Serafin IL, 2001, ARCH VIROL, V146, P2469, DOI 10.1007/s007050170017
   SINGH B, 1980, J IMMUNOL, V124, P1336
   Thullier P, 2001, J GEN VIROL, V82, P1885, DOI 10.1099/0022-1317-82-8-1885
   Wu HC, 2003, J GEN VIROL, V84, P2771, DOI 10.1099/vir.0.19228-0
   Wu HC, 2001, J CLIN MICROBIOL, V39, P977, DOI 10.1128/JCM.39.3.977-982.2001
   Yamada KI, 2002, J CLIN VIROL, V24, P203, DOI 10.1016/S1386-6532(01)00250-5
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW172, DOI 10.1093/nar/gki452
   Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990
   Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019
NR 37
TC 20
Z9 21
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 13
PY 2009
VL 4
IS 10
AR e7425
DI 10.1371/journal.pone.0007425
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 506WQ
UT WOS:000270808300008
PM 19826631
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Lemos, RR
   Castelletti, CH
   Lima, JL
   Marques, ET
   Oliveira, JRM
AF Lemos, R. R.
   Castelletti, C. H.
   Lima Filho, J. L.
   Marques, E. T.
   Oliveira, J. R. M.
TI In Silico Identification of New Genetic Variations as Potential Risk
   Factors for Alzheimer's Disease in a Microarray-oriented Simulation
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE In silico; Alzheimer's disease; Bioinformatics; ESTs; Microarrays
ID SINGLE NUCLEOTIDE POLYMORPHISMS; EXPRESSION; INFLAMMATION; MUTATIONS;
   DATABASE
AB Genomic and proteomic studies of neurodegenerative disorders require complementary approaches to integrate the massive amount of data generated in high throughput experimental procedures. We propose a Bioinformatics pipeline in which expression studies guide the selection of candidate genes that should be screened for potential new genetic variations from a public expressed site tags (ESTs) database. Motivated by the former interest of our group in genetic polymorphisms involved with the immune system, we selected five genes from a previous expression microarrays study of hippocampal cornu ammonis (CA1) area of Alzheimer's Disease subjects (AD). The CLCbio Workbench CombinedA (R) version 3.6.2. was initially used to build ESTs and mRNA files retrieved respectively from the Goldenpath of University of California Santa Cruz (UCSC) and National Center for Biotechnology Information (NCBI) databases and latter to perform multiple batches of Smith-Waterman alignments. A total of 116 ESTs sequences were selected after proper stringent parameters were applied to the first set of mismatches. The annotation revealed various classes of variations, most of them deletions (176). Amongst this specific group, some were frameshift deletions (35) and the virtual translation of a few others (5) were predicted to induce no change other than a single aminoacid removal, with no subsequent repercussions at the protein sequence. In addition, the analysis identified transitions (three), transversions (52), synonymous (41), non-synonymous (12), and deletions in 36 ESTs located in Untranslated Regions -UTRs (Supplementary data). Deletions are often associated to major genetics syndromes with dysmorphic features. However, various recent studies show that common microdeletions might be highly associated with common neuropsychiatric disorders such as schizophrenia, autism, mental retardation, or even in various ethnicities, detected in whole genome sequencing experiments. A virtual validation confirmed that some of the variations identified were previously reported and confirmed in DNA samples, showing that this method is a feasible way to detect genetic variations that merit further exploration in AD genetic risk factor association studies.
C1 [Lemos, R. R.; Castelletti, C. H.; Lima Filho, J. L.; Oliveira, J. R. M.] Univ Fed Pernambuco, Keizo Asami Lab LIKA, BR-50670901 Recife, PE, Brazil.
   [Marques, E. T.] Fiocruz MS, CPqAM, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Marques, E. T.] Johns Hopkins Sch Med, Div Infect Dis, Dept Med, Baltimore, MD USA.
   [Marques, E. T.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Oliveira, J. R. M.] Univ Fed Pernambuco, Dept Neuropsychiat, BR-50670901 Recife, PE, Brazil.
RP Oliveira, JRM (corresponding author), Univ Fed Pernambuco, Dept Neuropsychiat, BR-50670901 Recife, PE, Brazil.
EM joao.ricardo@ufpe.br
RI Filho, Jose Luiz Lima/M-8076-2019; Marques, Ernesto/L-4514-2013;
   Publica, Inct Saude/J-9544-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU PROPESQ-UFPE; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq); FACEPE
FX We are greatly indebted with Aaron Rowe for reviewing this manuscript.
   This study was support by the following Brazilian funding agencies and
   academic bureaus: PROPESQ-UFPE, CAPES, CNPq, and FACEPE.
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Barker G, 2003, BIOINFORMATICS, V19, P421, DOI 10.1093/bioinformatics/btf881
   Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100
   Bond J, 2003, AM J HUM GENET, V73, P1170, DOI 10.1086/379085
   Breloer M, 2008, TRENDS IMMUNOL, V29, P186, DOI 10.1016/j.it.2008.01.009
   Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351
   Coppola G, 2008, ANN NEUROL, V64, P92, DOI 10.1002/ana.21397
   Fertuzinhos SMM, 2004, J MOL NEUROSCI, V22, P251, DOI 10.1385/JMN:22:3:251
   Forment J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-5
   Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.3.CO;2-E
   Gul A, 2006, J HUM GENET, V51, P760, DOI 10.1007/s10038-006-0017-1
   Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017
   Kidd JM, 2008, NATURE, V453, P56, DOI 10.1038/nature06862
   Leal GF, 2003, J MED GENET, V40, P540, DOI 10.1136/jmg.40.7.540
   Mao GG, 2007, NUCLEIC ACIDS RES, V35, P2759, DOI 10.1093/nar/gkm189
   Miller JA, 2008, J NEUROSCI, V28, P1410, DOI 10.1523/JNEUROSCI.4098-07.2008
   Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901
   Navratil V, 2008, BIOCHIMIE, V90, P563, DOI 10.1016/j.biochi.2007.09.017
   Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7
   Oliveira JRM, 2009, J MOL NEUROSCI, V37, P74, DOI 10.1007/s12031-008-9124-0
   Picoult-Newberg L, 1999, GENOME RES, V9, P167
   Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653
   Sasaki A, 2008, MOL GENET METAB, V95, P182, DOI 10.1016/j.ymgme.2008.07.009
   Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229
   Stein LD, 2008, NAT REV GENET, V9, P678, DOI 10.1038/nrg2414
   Stephenson DT, 1996, NEUROBIOL DIS, V3, P51, DOI 10.1006/nbdi.1996.0005
   Tang JF, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-23
   Tang JF, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-438
   Tuppo EE, 2005, INT J BIOCHEM CELL B, V37, P289, DOI 10.1016/j.biocel.2004.07.009
   Useche F J, 2001, Genome Inform, V12, P194
   Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174
   Wisniewski T, 2008, LANCET NEUROL, V7, P805, DOI 10.1016/S1474-4422(08)70170-4
   Yu CE, 2002, AM J HUM GENET, V71, P100, DOI 10.1086/341291
NR 33
TC 5
Z9 5
U1 0
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD SEP
PY 2009
VL 39
IS 1-2
BP 242
EP 247
DI 10.1007/s12031-009-9191-x
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 495OT
UT WOS:000269903800026
PM 19290494
DA 2020-12-16
ER

PT J
AU Nascimento, EJM
   Silva, AM
   Cordeiro, MT
   Brito, CA
   Gil, LHVG
   Braga-Neto, U
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Silva, Ana M.
   Cordeiro, Marli T.
   Brito, Carlos A.
   Gil, Laura H. V. G.
   Braga-Neto, Ulisses
   Marques, Ernesto T. A.
TI Alternative Complement Pathway Deregulation Is Correlated with Dengue
   Severity
SO PLOS ONE
LA English
DT Article
AB Background: The complement system, a key component that links the innate and adaptive immune responses, has three pathways: the classical, lectin, and alternative pathways. In the present study, we have analyzed the levels of various complement components in blood samples from dengue fever (DF) and dengue hemorrhagic fever (DHF) patients and found that the level of complement activation is associated with disease severity.
   Methods and Results: Patients with DHF had lower levels of complement factor 3 (C3; p = 0.002) and increased levels of C3a, C4a and C5a (p<0.0001) when compared to those with the less severe form, DF. There were no significant differences between DF and DHF patients in the levels of C1q, immunocomplexes (CIC-CIq) and CRP. However, small but statistically significant differences were detected in the levels of MBL. In contrast, the levels of two regulatory proteins of the alternative pathway varied widely between DF and DHF patients: DHF patients had higher levels of factor D (p = 0.01), which cleaves factor B to yield the active (C3bBb) C3 convertase, and lower levels of factor H (p = 0.03), which inactivates the (C3bBb) C3 convertase, than did DF patients. When we considered the levels of factors D and H together as an indicator of (C3bBb) C3 convertase regulation, we found that the plasma levels of these regulatory proteins in DHF patients favored the formation of the (C3bBb) C3 convertase, whereas its formation was inhibited in DF patients (p<0.0001).
   Conclusion: The data suggest that an imbalance in the levels of regulatory factors D and H is associated with an abnormal regulation of complement activity in DHF patients.
RP Nascimento, EJM (corresponding author), Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21218 USA.
EM emarques@jhmi.edu
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013;
   Nascimento, Eduardo/J-4590-2014; Publica, Inct Saude/J-9544-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; Nascimento, Eduardo/0000-0002-9851-2332; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; Division of Computing and Communication
   FoundationsNational Science Foundation (NSF)NSF - Directorate for
   Computer & Information Science & Engineering (CISE) [0845407] Funding
   Source: National Science Foundation; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19 AI56541, U19 AI056541] Funding Source: Medline
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   ACIOLISANTOS B, PNAS UNPUB
   Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BOONPUCKNAVIG S, 1979, AM J TROP MED HYG, V28, P881, DOI 10.4269/ajtmh.1979.28.881
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chung KM, 2006, P NATL ACAD SCI USA, V103, P19111, DOI 10.1073/pnas.0605668103
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Coppo Paul, 2009, Cardiovascular & Hematological Disorders - Drug Targets, V9, P36
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   Cummings DAT, 2005, P NATL ACAD SCI USA, V102, P15259, DOI 10.1073/pnas.0507320102
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Fakhouri F, 2008, BLOOD, V112, P4542, DOI 10.1182/blood-2008-03-144691
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   HARBOE M, 2008, J CELL MOL MED
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   Karpman D, 2006, SEMIN THROMB HEMOST, V32, P128, DOI 10.1055/s-2006-939769
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Kittigul L, 2007, J CLIN VIROL, V39, P76, DOI 10.1016/j.jcv.2007.04.006
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Lutz HU, 2007, MOL IMMUNOL, V44, P3862, DOI 10.1016/j.molimm.2007.06.146
   Mehlhop E, 2007, CELL HOST MICROBE, V2, P417, DOI 10.1016/j.chom.2007.09.015
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   MITRAKUL C, 1977, AM J TROP MED HYG, V26, P975, DOI 10.4269/ajtmh.1977.26.975
   Morrison TE, 2008, CURR DRUG TARGETS, V9, P165
   NASCIMENTO EJM, J CLIN INVESTI UNPUB
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nishioka K, 1974, Allerg Immunol (Leipz), V20-21, P385
   Pierson Theodore C., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000665
   Saito M, 2004, CLIN EXP IMMUNOL, V138, P299, DOI 10.1111/j.1365-2249.2004.02626.x
   SOBEL AT, 1975, J EXP MED, V142, P139, DOI 10.1084/jem.142.1.139
   Srichaikul T, 2000, BEST PRACT RES CL HA, V13, P261, DOI 10.1053/beha.2000.0073
   Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153
   Su DHW, 2007, OPHTHALMOLOGY, V114, P1743, DOI 10.1016/j.ophtha.2007.03.054
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   Villar-Centeno LA, 2008, AM J TROP MED HYG, V78, P370, DOI 10.4269/ajtmh.2008.78.370
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   Wiersinga WJ, 2006, CLIN INFECT DIS, V43, P800, DOI 10.1086/507111
   Yamanaka A, 2008, J VIROL, V82, P927, DOI 10.1128/JVI.00992-07
NR 51
TC 80
Z9 80
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2009
VL 4
IS 8
AR e6782
DI 10.1371/journal.pone.0006782
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 488FQ
UT WOS:000269335000025
PM 19707565
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Valentin, A
   Chikhlikar, P
   Patel, V
   Rosati, M
   Maciel, M
   Chang, KH
   Silvera, P
   Felber, BK
   Pavlakis, GN
   August, JT
   Marques, ETA
AF Valentin, Antonio
   Chikhlikar, Priya
   Patel, Vainav
   Rosati, Margherita
   Maciel, Milton
   Chang, Kern-Hee
   Silvera, Peter
   Felber, Barbara K.
   Pavlakis, George N.
   August, J. Thomas
   Marques, Ernesto T. A.
TI Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in
   rhesus macaques reveals antigen-specific T-cell responses with distinct
   phenotypes
SO VACCINE
LA English
DT Article
DE Central memory; Effector memory; CD4; CD8; T cells; IFN-gamma;
   TNF-alpha; IL-2
ID IMMUNODEFICIENCY VIRUS CHALLENGE; NEUTRALIZING ANTIBODY-RESPONSE;
   CLASS-II COMPARTMENT; MEMBRANE-PROTEIN; IMMUNE-RESPONSES; VACCINATION;
   EXPRESSION; ELECTROPORATION; SEQUENCES; MONKEYS
AB Optimized DNA expression vectors encoding the native HIV-1 Gag ora fusion of Gag with the lysosomal membrane associated protein 1 (LAMP) were compared for immunogenicity upon intramuscular DNA delivery in rhesus macaques. Both vaccines elicited CD4(+) T-cell responses, but with significant differences in the phenotype of the Gag-specific cells: the native Gag induced CD4(+) responses with a phenotype of central memory-like T cells (CD28(+) CD45RA(-)), whereas the LAMP/Gag chimera induced CD4(+) responses with effector memory phenotype (CD28(-) CD45RA(-)). Antigen-specific T cells producing both IFN-gamma and TNF alpha were found in the animals receiving the native Gag, whereas the LAMP/Gag chimera induced humoral responses faster. These results demonstrate that modification of intracellular Gag trafficking results in the induction of distinct immune responses. Combinations of DNA vectors encoding both forms of antigen may be more potent in eliciting anti-HIV-1 immunity. Published by Elsevier Ltd.
C1 [Felber, Barbara K.] NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.
   [Valentin, Antonio; Patel, Vainav; Rosati, Margherita; Pavlakis, George N.] NCI, Human Retrovirus Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.
   [Chikhlikar, Priya; Maciel, Milton; Chang, Kern-Hee; August, J. Thomas; Marques, Ernesto T. A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21210 USA.
   [Marques, Ernesto T. A.] Johns Hopkins Univ, Sch Med, Dept Infect Dis, Baltimore, MD 21210 USA.
   [Silvera, Peter] So Res Inst, Frederick, MD 21701 USA.
   [Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil.
RP Felber, BK (corresponding author), NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res, POB B,Bldg 535,Room 209, Frederick, MD 21702 USA.
EM felber@ncifcrf.gov; pavlakig@mail.nih.gov
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto T. A/L-4967-2013;
   Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
FU Intramural Research Program of the NIHUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA; National
   Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); Center for Cancer ResearchUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI); NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [ZIABC010749, ZIABC010350,
   ZIABC010749, ZIABC010749, ZIABC010350, ZIABC010350, ZIABC010350,
   ZIABC010749, ZIABC010350, ZIABC010749, ZIABC010749, ZIABC010350,
   ZIABC010350, ZIABC010749, ZIABC010350, ZIABC010350, ZIABC010350,
   ZIABC010749, ZIABC010749, ZIABC010749] Funding Source: NIH RePORTER
FX We thank C. Bergamaschi and V. Kulkarni for discussions, K Nagashima for
   electron microscopy, J. Bear and P. Roth for technical assistance, and
   T. Jones for editorial assistance. We thank Jon Warren, VRP, DAIDS for
   materials and support. This research was supported by the Intramural
   Research Program of the NIH, National Cancer Institute, Center for
   Cancer Research.
CR Acierno PM, 2006, J IMMUNOL, V176, P5338, DOI 10.4049/jimmunol.176.9.5338
   Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Chen CH, 2000, VACCINE, V18, P2015, DOI 10.1016/S0264-410X(99)00528-9
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Gupta V, 2006, VIROLOGY, V347, P127, DOI 10.1016/j.virol.2005.11.042
   Halwani R, 2008, J IMMUNOL, V180, P7969, DOI 10.4049/jimmunol.180.12.7969
   Hirao LA, 2008, VACCINE, V26, P3112, DOI 10.1016/j.vaccine.2008.02.036
   KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Luckay A, 2007, J VIROL, V81, P5257, DOI 10.1128/JVI.00055-07
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   Nascimento E, 2002, MEM I OSWALDO CRUZ, V97, P105, DOI 10.1590/S0074-02762002000900021
   Obermuller S, 2002, J CELL SCI, V115, P185
   PATEL V, INDUCTION MUCO UNPUB
   Pichurin PN, 2004, ENDOCRINOLOGY, V145, P5504, DOI 10.1210/en.2004-0530
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rosati M, 2005, J VIROL, V79, P8480, DOI 10.1128/JVI.79.13.8480-8492.2005
   ROSATI M, DNA VACCINATIO UNPUB
   Rosati M, 2008, VACCINE, V26, P5223, DOI 10.1016/j.vaccine.2008.03.090
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992
   SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992
   Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731
   Sun Y, 2005, J IMMUNOL, V174, P4753, DOI 10.4049/jimmunol.174.8.4753
   Sun Y, 2006, J VIROL, V80, P10950, DOI 10.1128/JVI.01458-06
   VALENTIN A, 2009, HUM GENE TH IN PRESS
   WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955
NR 35
TC 16
Z9 16
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 30
PY 2009
VL 27
IS 35
BP 4840
EP 4849
DI 10.1016/j.vaccine.2009.05.093
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 481QV
UT WOS:000268827500017
PM 19539586
OA Green Accepted, Green Published
DA 2020-12-16
ER

PT J
AU Cordeiro, MT
   Braga-Neto, U
   Nogueira, RMR
   Marques, ETA
AF Cordeiro, Marli Tenorio
   Braga-Neto, Ulisses
   Ribeiro Nogueira, Rita Maria
   Marques, Ernesto T. A., Jr.
TI Reliable Classifier to Differentiate Primary and Secondary Acute Dengue
   Infection Based on IgG ELISA
SO PLOS ONE
LA English
DT Article
AB Background: Dengue virus infection causes a wide spectrum of illness, ranging from sub-clinical to severe disease. Severe dengue is associated with sequential viral infections. A strict definition of primary versus secondary dengue infections requires a combination of several tests performed at different stages of the disease, which is not practical.
   Methods and Findings: We developed a simple method to classify dengue infections as primary or secondary based on the levels of dengue-specific IgG. A group of 109 dengue infection patients were classified as having primary or secondary dengue infection on the basis of a strict combination of results from assays of antigen-specific IgM and IgG, isolation of virus and detection of the viral genome by PCR tests performed on multiple samples, collected from each patient over a period of 30 days. The dengue-specific IgG levels of all samples from 59 of the patients were analyzed by linear discriminant analysis (LDA), and one-and two-dimensional classifiers were designed. The one-dimensional classifier was estimated by bolstered resubstitution error estimation to have 75.1% sensitivity and 92.5% specificity. The two-dimensional classifier was designed by taking also into consideration the number of days after the onset of symptoms, with an estimated sensitivity and specificity of 91.64% and 92.46%. The performance of the two-dimensional classifier was validated using an independent test set of standard samples from the remaining 50 patients. The classifications of the independent set of samples determined by the two-dimensional classifiers were further validated by comparing with two other dengue classification methods: hemagglutination inhibition (HI) assay and an in-house anti-dengue IgG-capture ELISA method. The decisions made with the two-dimensional classifier were in 100% accordance with the HI assay and 96% with the in-house ELISA.
   Conclusions: Once acute dengue infection has been determined, a 2-D classifier based on common dengue virus IgG kits can reliably distinguish primary and secondary dengue infections. Software for calculation and validation of the 2-D classifier is made available for download.
C1 [Cordeiro, Marli Tenorio; Braga-Neto, Ulisses; Marques, Ernesto T. A., Jr.] Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Cent Lab Publ Hlth, Secretar Saude Estado Pernambuco, Recife, PE, Brazil.
   [Ribeiro Nogueira, Rita Maria] Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
   [Braga-Neto, Ulisses] Texas A&M Univ, Dept Electr & Comp Engn, College Stn, TX USA.
   [Marques, Ernesto T. A., Jr.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA.
   [Marques, Ernesto T. A., Jr.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
RP Cordeiro, MT (corresponding author), Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
EM emarques@jhmi.edu
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU National Institute of Allergy and Infectious Diseases (NIAID/NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19 AI56541, N01 AI 40085]; Brazilian National
   Research Council (CNPq)National Council for Scientific and Technological
   Development (CNPq) [DCR 35.0382/2004.2]; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, U19AI056541, R01AI040085,
   U19AI056541, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   R01AI040085, R01AI040085, R21AI040085, U19AI056541, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085] Funding Source: NIH
   RePORTER; Division of Computing and Communication FoundationsNational
   Science Foundation (NSF)NSF - Directorate for Computer & Information
   Science & Engineering (CISE) [0845407] Funding Source: National Science
   Foundation
FX The authors would like to acknowledge the support of the National
   Institute of Allergy and Infectious Diseases (NIAID/NIH), under Grants
   U19 AI56541 and N01 AI 40085. Dr. Braga-Neto would like to acknowledge
   the support of the Brazilian National Research Council (CNPq), under
   Grant DCR 35.0382/2004.2. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BRAGA UM, 2005, GENOMIC SIGNAL PROCE
   Braga-Neto U, 2004, PATTERN RECOGN, V37, P1267, DOI 10.1016/j.patcog.2003.08.017
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   CHUNGUE E, 1989, T ROY SOC TROP MED H, V83, P708, DOI 10.1016/0035-9203(89)90404-5
   CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead Scott B., 1997, P23
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Matheus S, 2005, J CLIN MICROBIOL, V43, P2793, DOI 10.1128/JCM.43.6.2793-2797.2005
   Miagostovich MP, 1999, J CLIN VIROL, V14, P183, DOI 10.1016/S1386-6532(99)00059-1
   MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985
   RDevelopmentCoreTeam, 2005, R LANG ENV STAT COMP
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Schilling S, 2004, J CLIN VIROL, V31, P179, DOI 10.1016/j.jcv.2004.03.020
   Vaughn DW, 1999, AM J TROP MED HYG, V60, P693, DOI 10.4269/ajtmh.1999.60.693
   Vorndam AV, 1997, DENGUE DENGUE HEMORR
   *WORLD ORG VOLC OB, 1997, DIR VOLC OBS 1996 19, P1
NR 23
TC 29
Z9 29
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2009
VL 4
IS 4
AR e4945
DI 10.1371/journal.pone.0004945
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 437PZ
UT WOS:000265500700003
PM 19340301
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Goldoni, A
   Maciel, M
   Rigato, P
   Piubelli, O
   Brito, C
   Fusaro, A
   Orii, N
   August, JT
   Marques, E
   Duarte, AJ
   Sato, M
AF Goldoni, Adriana
   Maciel, Milton
   Rigato, Paula
   Piubelli, Orlando
   Brito, Cyro
   Fusaro, Ana
   Orii, Noemia
   August, J. Thomas
   Marques, Ernesto
   Duarte, Alberto J.
   Sato, Maria
TI Enhanced CD4+and CD8+T Cell Responses Followed HIV DNA Lamp/gag
   Vaccination in Mice During Early Phase of Life
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 11-14, 2009
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 [Goldoni, Adriana; Rigato, Paula; Piubelli, Orlando; Brito, Cyro; Fusaro, Ana; Orii, Noemia; Duarte, Alberto J.; Sato, Maria] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [August, J. Thomas; Marques, Ernesto] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Maciel, Milton] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RI Marques, Ernesto T. A/L-4967-2013; Brito, Cyro/C-1910-2012; Sato, Maria
   N/C-1196-2012; Goldoni, Adriana Leticia/I-1912-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Brito,
   Cyro/0000-0002-9934-6102; Sato, Maria N/0000-0002-7911-1824; Goldoni,
   Adriana Leticia/0000-0002-4298-8526
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2009
VL 131
BP S83
EP S83
DI 10.1016/j.clim.2009.03.244
PG 1
WC Immunology
SC Immunology
GA 449PK
UT WOS:000266342300237
DA 2020-12-16
ER

PT J
AU Goldoni, AL
   Maciel, M
   Rigato, PO
   Piubelli, OG
   Fusaro, AE
   Brito, CA
   Orii, NM
   August, T
   Marques, E
   Duarte, AJ
   Sato, MN
AF Goldoni, A. L.
   Maciel, M.
   Rigato, P. O.
   Piubelli, O. G.
   Fusaro, A. E.
   Brito, C. A.
   Orii, N. M.
   August, T.
   Marques, E.
   Duarte, A. J.
   Sato, M. N.
TI HIV Chimeric Lamp/Gag Vaccine Induces Mucosal and Systemic Immunity in
   Neonatal Mice
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Goldoni, A. L.; Maciel, M.; Rigato, P. O.; Piubelli, O. G.; Fusaro, A. E.; Brito, C. A.; Orii, N. M.; Duarte, A. J.; Sato, M. N.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [August, T.; Marques, E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RI Marques, Ernesto T. A/L-4967-2013; Goldoni, Adriana Leticia/I-1912-2012;
   Sato, Maria N/C-1196-2012; Marques, Ernesto/L-4514-2013; Brito,
   Cyro/C-1910-2012; Ordonhez Rigato, Paula/J-3618-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Goldoni, Adriana
   Leticia/0000-0002-4298-8526; Sato, Maria N/0000-0002-7911-1824; Marques,
   Ernesto/0000-0003-3826-9358; Brito, Cyro/0000-0002-9934-6102; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 85
EP 85
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800212
DA 2020-12-16
ER

PT J
AU Rigato, PO
   Maciel, M
   Goldoni, AL
   Piubelli, OG
   Brito, CA
   August, J
   Marques, ET
   Duarte, AJ
   Sato, MN
AF Rigato, P. Ordonhez
   Maciel, M.
   Goldoni, A. L.
   Piubelli, O. G.
   Brito, C. A.
   August, J.
   Marques, E. T., Jr.
   Duarte, A. J.
   Sato, M. N.
TI Effect of Maternal Immunization with the DNA Chimeric Vaccine Lamp/Gag
   of HIV-1 in the Neonatal Immune DNA Vaccine Response
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Rigato, P. Ordonhez; Goldoni, A. L.; Piubelli, O. G.; Brito, C. A.; Duarte, A. J.; Sato, M. N.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Maciel, M.; August, J.; Marques, E. T., Jr.] Johns Hopkins Sch Med, Baltimore, MD USA.
RI Brito, Cyro/C-1910-2012; Sato, Maria N/C-1196-2012; Ordonhez Rigato,
   Paula/J-3618-2012; Goldoni, Adriana Leticia/I-1912-2012; Marques,
   Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Brito, Cyro/0000-0002-9934-6102; Sato, Maria N/0000-0002-7911-1824;
   Goldoni, Adriana Leticia/0000-0002-4298-8526; Marques,
   Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
SU 1
BP 143
EP 144
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800370
DA 2020-12-16
ER

PT J
AU Rigato, P
   Maciel, M
   Goldoni, AL
   Piubelli, OG
   Brito, CA
   Fusaro, A
   August, J
   Marques, ET
   Duarte, AJ
   Sato, MN
AF Rigato, Po
   Maciel Junior, M.
   Goldoni, A. L.
   Piubelli, O. G.
   Brito, C. A.
   Fusaro, A.
   August, J.
   Marques, E. T., Jr.
   Duarte, A. J.
   Sato, M. N.
TI CD8-and CD4-T Cell Long Lasting Cellular and Humoral Immune Response in
   Neonatal Mice Vaccination with DNA Chimeric Vaccine LAMP/Gag of HIV-1
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Rigato, Po; Goldoni, A. L.; Piubelli, O. G.; Brito, C. A.; Fusaro, A.; Duarte, A. J.; Sato, M. N.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Maciel Junior, M.; August, J.; Marques, E. T., Jr.] Johns Hopkins Sch Med, Baltimore, MD USA.
RI Sato, Maria N/C-1196-2012; Marques, Ernesto T. A/L-4967-2013; Goldoni,
   Adriana Leticia/I-1912-2012; Brito, Cyro/C-1910-2012; Ordonhez Rigato,
   Paula/J-3618-2012; Marques, Ernesto/L-4514-2013
OI Sato, Maria N/0000-0002-7911-1824; Marques, Ernesto T.
   A/0000-0003-3826-9358; Goldoni, Adriana Leticia/0000-0002-4298-8526;
   Brito, Cyro/0000-0002-9934-6102; Marques, Ernesto/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
SU 1
BP 143
EP 143
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800369
DA 2020-12-16
ER

PT J
AU Rosati, M
   Valentin, A
   Jalah, R
   Patel, V
   von Gegerfelt, A
   Bergamaschi, C
   Alicea, C
   Weiss, D
   Treece, J
   Pal, R
   Markham, PD
   Marques, ETA
   August, JT
   Khan, A
   Draghia-Akli, R
   Felber, BK
   Pavlakis, GN
AF Rosati, Margherita
   Valentin, Antonio
   Jalah, Rashmi
   Patel, Vainav
   von Gegerfelt, Agneta
   Bergamaschi, Cristina
   Alicea, Candido
   Weiss, Deborah
   Treece, Jim
   Pal, Ranajit
   Markham, Phillip D.
   Marques, Ernesto T. A.
   August, J. Thomas
   Khan, Amir
   Draghia-Akli, Ruxandra
   Felber, Barbara K.
   Pavlakis, George N.
TI Increased immune responses in rhesus macaques by DNA vaccination
   combined with electroporation
SO VACCINE
LA English
DT Article
DE HIV; SIV; DNA vaccine; electroporation; intramuscular injection; rhesus
   macaque; immune response; central memory; effector memory; T cell subset
ID IMMUNODEFICIENCY VIRUS SIVMAC251; IN-VIVO; GENE-TRANSFER; HIV VACCINES;
   II COMPARTMENT; PLASMID DNA; EXPRESSION; DELIVERY; GAG; DECREASE
AB We used optimized DNA expression vectors to compare two gene delivery methodologies in rhesus macaques, namely direct DNA injection and in vivo adaptive constant-current electroporation via the intramuscular route. The use of in vivo electroporation increased levels of gene expression and immune responses. We used an optimized HIV gag expression plasmid to show the development of new cellular immune responses in SIV-infected animals controlling viremia. Furthermore, after vaccination with SIV expression plasmids the recall responses to the SIV antigens were very high, indicating that DNA is a strong boost in the presence of antiretroviral treatment in SIV-infected animals. There was substantial animal-to-animal variability in DNA expression, revealed by plasma measurements of IL-15 produced by co-injected IL-15 DNA. IL-15 expression levels correlated with peak immune responses. Electroporation led to an expansion of antigen-specific CD4+ and CD8+ T cells of both central and effector memory phenotype. These results indicate that improved gene delivery and expression by electroporation dramatically increases immunogenicity of DNA vaccines. Electroporation is thus an important method to improve the effectiveness of DNA vaccination. Published by Elsevier Ltd.
C1 [Rosati, Margherita; Valentin, Antonio; Patel, Vainav; von Gegerfelt, Agneta; Bergamaschi, Cristina; Pavlakis, George N.] NCI, Human Retrovirus Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.
   [Jalah, Rashmi; Alicea, Candido; Felber, Barbara K.] NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.
   [Weiss, Deborah; Treece, Jim; Pal, Ranajit; Markham, Phillip D.] Adv BioSci Labs Inc, Kensington, MD 20895 USA.
   [Marques, Ernesto T. A.; August, J. Thomas] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Khan, Amir; Draghia-Akli, Ruxandra] Immune Therapeut Div Inc, VGX Pharmaceut, The Woodlands, TX 77381 USA.
RP Pavlakis, GN (corresponding author), NCI, Human Retrovirus Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA.
EM pavlakis@ncifcrf.gov
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; Draghia-Akli, Ruxandra/0000-0001-6372-4039
FU NAID/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; DIVISION OF BASIC SCIENCES - NCIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [Z01BC010350,
   Z01BC010350, Z01BC010350, Z01BC010350, Z01BC010750, Z01BC010350,
   Z01BC010350, Z01BC010350, Z01BC010749] Funding Source: NIH RePORTER;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZIABC010750, ZIABC010749, ZIABC010749, ZIABC010749,
   ZIABC010749, ZIABC010749, Z01BC010750, ZIABC010350, Z01BC010749,
   ZIABC010350, ZIABC010749, ZIABC010350, ZIABC010350, ZIABC010749,
   ZIABC010350, ZIABC010750, ZIABC010750, ZIABC010749, ZIABC010350,
   ZIABC010750, ZIABC010750, ZIABC010350, ZIABC010350, ZIABC010350,
   ZIABC010749, ZIABC010750, ZIABC010750, Z01BC010350, ZIABC010750,
   ZIABC010749, ZIABC010750, Z01BC010750, Z01BC010350, Z01BC010749,
   ZIABC010350, ZIABC010750] Funding Source: NIH RePORTER
FX We thank P. Roth for technical support, N. Miller, NAID/NIH for Support
   with macaques, S. Orndorff and the staff at Advanced BioScience
   Laboratories, Kensington, for their expert help. We thank T. Jones for
   editorial assistance.
CR Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867
   Bergamaschi C, 2008, J BIOL CHEM, V283, P4189, DOI 10.1074/jbc.M705725200
   Biragyn A, 1999, NAT BIOTECHNOL, V17, P253, DOI 10.1038/6995
   Brave A, 2007, MOL PHARMACEUT, V4, P18, DOI 10.1021/mp060098+
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Dale C. Jane, 2006, V127, P171
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Duerr A, 2006, CLIN INFECT DIS, V43, P500, DOI 10.1086/505979
   Girard MP, 2006, VACCINE, V24, P4062, DOI 10.1016/j.vaccine.2006.02.031
   Graham BS, 2006, J INFECT DIS, V194, P1650, DOI 10.1086/509259
   Hokey DA, 2006, SPRINGER SEMIN IMMUN, V28, P267, DOI 10.1007/s00281-006-0046-z
   Jalah R, 2007, DNA CELL BIOL, V26, P827, DOI 10.1089/dna.2007.0645
   Liu MA, 2006, HUM GENE THER, V17, P1051, DOI 10.1089/hum.2006.17.1051
   Lori F, 2006, SPRINGER SEMIN IMMUN, V28, P231, DOI 10.1007/s00281-006-0047-y
   Lu S, 2006, SPRINGER SEMIN IMMUN, V28, P255, DOI 10.1007/s00281-006-0028-1
   Luckay A, 2007, J VIROL, V81, P5257, DOI 10.1128/JVI.00055-07
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mathiesen I, 1999, GENE THER, V6, P508, DOI 10.1038/sj.gt.3300847
   McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605
   NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994
   Pachuk CJ, 2000, BBA-BIOMEMBRANES, V1468, P20, DOI 10.1016/S0005-2736(00)00242-X
   Patterson LJ, 2004, J VIROL, V78, P2212, DOI 10.1128/JVI.78.5.2212-2221.2004
   Prud'homme GJ, 2006, CURR GENE THER, V6, P243, DOI 10.2174/156652306776359504
   Rizzuto G, 1999, P NATL ACAD SCI USA, V96, P6417, DOI 10.1073/pnas.96.11.6417
   Rodriguez-Chavez Isaac R, 2006, Curr HIV/AIDS Rep, V3, P39, DOI 10.1007/s11904-006-0007-0
   Romano JW, 2000, J VIROL METHODS, V86, P61, DOI 10.1016/S0166-0934(99)00184-6
   Rosati M, 2005, J VIROL, V79, P8480, DOI 10.1128/JVI.79.13.8480-8492.2005
   Santra S, 2007, J VIROL, V81, P8563, DOI 10.1128/JVI.00744-07
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992
   SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992
   Sheets RL, 2006, TOXICOL SCI, V91, P610, DOI 10.1093/toxsci/kfj169
   Thorner Anna R, 2007, Curr Infect Dis Rep, V9, P71, DOI 10.1007/s11908-007-0025-0
   von Gegerfelt AS, 2007, J VIROL, V81, P1972, DOI 10.1128/JVI.01990-06
   Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213
   Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635
NR 36
TC 78
Z9 84
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD SEP 19
PY 2008
VL 26
IS 40
SI SI
BP 5223
EP 5229
DI 10.1016/j.vaccine.2008.03.090
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 356TE
UT WOS:000259799700024
PM 18468743
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Maciel, M
   Kellathur, SN
   Chikhlikar, P
   Dhalia, R
   Sidney, J
   Sette, A
   August, TJ
   Marques, ETA
AF Maciel, Milton, Jr.
   Kellathur, Srinivasan N.
   Chikhlikar, Pryia
   Dhalia, Rafael
   Sidney, John
   Sette, Alessandro
   August, Thomas J.
   Marques, Ernesto T. A., Jr.
TI Comprehensive analysis of T cell epitope discovery strategies using 17DD
   yellow fever virus structural proteins and BALB/c (H2(d)) mice model
SO VIROLOGY
LA English
DT Article
DE epitope; yellow fever virus; immunome; ELISPOT; binding assay;
   prediction software
ID VACCINE DESIGN; PEPTIDE; IDENTIFICATION; RESPONSES; SPECIFICITIES;
   NUCLEOTIDE; PREDICTION; MOLECULE; ENVELOPE; SEQUENCE
AB Immunomics research uses in silico epitope prediction, its well as in vivo and in vitro approaches. We inoculated BALB/c(H2(d)) mice with 17DD yellow fever vaccine to investigate the correlations between approaches used for epitope discovery: ELISPOT assays, binding assays, and prediction software. Our results showed a good agreement between ELISPOT and binding assays, which seemed to correlate with the protein immunogenicity. PREDBALB/c prediction software partially agreed with the ELISPOT and binding assay results, but presented low specificity. The use of prediction software to exclude peptides containing no epitopes, followed by high throughput screening of the remaining peptides by ELISPOT, and the use of MHC-biding assays to characterize the MHC restrictions demonstrated to be an efficient strategy. The results allowed the characterization of 2 MHC class I and 17 class II epitopes in the envelope protein of the YF virus in BALB/c (H2(d)) mice. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Maciel, Milton, Jr.; Kellathur, Srinivasan N.; Chikhlikar, Pryia; August, Thomas J.; Marques, Ernesto T. A., Jr.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Immunol, La Jolla, CA USA.
   [Kellathur, Srinivasan N.] Johns Hopkins Singapore, Singapore, Singapore.
   [Marques, Ernesto T. A., Jr.] Sch Med, Dept Infect Dis, Baltimore, MD USA.
   [Dhalia, Rafael; Marques, Ernesto T. A., Jr.] Oswaldo Cruz Fdn FIOCRUZ, Inst Aggeu Magalhaes, Recife, PE, Brazil.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA.
EM emarques@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Dhalia, Rafael/AAD-5432-2020;
   Publica, Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, R01AI040085, R21AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01 AI040085] Funding Source: Medline
CR Anthony DD, 2003, METHODS, V29, P260, DOI 10.1016/S1046-2023(02)00348-1
   Assarsson E, 2007, J IMMUNOL, V178, P7890, DOI 10.4049/jimmunol.178.12.7890
   Barba-Spaeth G, 2005, J EXP MED, V202, P1179, DOI 10.1084/jem.20051352
   Braga-Neto UM, 2006, PLOS COMPUT BIOL, V2, P651, DOI 10.1371/journal.pcbi.0020081
   Brien JD, 2007, EUR J IMMUNOL, V37, P1855, DOI 10.1002/eji.200737196
   Co MDT, 2002, VIROLOGY, V293, P151, DOI 10.1006/viro.2001.1255
   Disis ML, 1996, J IMMUNOL, V156, P3151
   DOSSANTOS CND, 1995, VIRUS RES, V35, P35
   Galler R, 1997, BRAZ J MED BIOL RES, V30, P157, DOI 10.1590/S0100-879X1997000200002
   Hesse MD, 2001, J IMMUNOL, V167, P1353, DOI 10.4049/jimmunol.167.3.1353
   Hoffmeister B, 2003, METHODS, V29, P270, DOI 10.1016/S1046-2023(02)00349-3
   JENNINGS AD, 1993, VACCINE, V11, P679, DOI 10.1016/0264-410X(93)90317-Q
   Johansen P, 2004, EUR J IMMUNOL, V34, P91, DOI 10.1002/eji.200324231
   Kiecker F, 2004, HUM IMMUNOL, V65, P523, DOI 10.1016/j.humimm.2004.02.017
   KURATA A, 1990, J IMMUNOL, V144, P4526
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
   MONATH TP, 1986, PATHOBIOLOGY FLAVIVI, P375
   Figueiredo LTM, 2007, REV SOC BRAS MED TRO, V40, P224, DOI 10.1590/S0037-86822007000200016
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   OchoaGaray J, 1997, MOL IMMUNOL, V34, P273, DOI 10.1016/S0161-5890(97)00019-9
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   POST PR, 1992, VIROLOGY, V188, P160, DOI 10.1016/0042-6822(92)90745-B
   Purtha WE, 2007, EUR J IMMUNOL, V37, P1845, DOI 10.1002/eji.200737192
   Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720
   Regner M, 2001, J IMMUNOL, V166, P3820, DOI 10.4049/jimmunol.166.6.3820
   Rothman AL, 1996, J VIROL, V70, P6540, DOI 10.1128/JVI.70.10.6540-6546.1996
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9
   Sette Alessandro, 2005, Immunity, V22, P155, DOI 10.1016/j.immuni.2005.01.009
   SIDNEY J, 1998, CURR PROTOCOLS IMMUN, V18, P11
   Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105
   van der Most RG, 2002, VIROLOGY, V296, P117, DOI 10.1006/viro.2002.1432
   Wilson DB, 2004, MOL IMMUNOL, V40, P1047, DOI 10.1016/j.molimm.2003.11.022
   World Health Organization, 2003, Wkly Epidemiol Rec, V78, P349
   Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zhao JC, 2007, J VIROL, V81, P6079, DOI 10.1128/JVI.02568-06
NR 39
TC 19
Z9 19
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD AUG 15
PY 2008
VL 378
IS 1
BP 105
EP 117
DI 10.1016/j.virol.2008.04.043
PG 13
WC Virology
SC Virology
GA 335UI
UT WOS:000258316100012
PM 18579176
OA Green Accepted, Green Published
DA 2020-12-16
ER

PT J
AU Khan, AM
   Miotto, O
   Nascimento, EJM
   Srinivasan, KN
   Heiny, AT
   Zhang, GL
   Marques, ET
   Tan, TW
   Brusic, V
   Salmon, J
   August, JT
AF Khan, Asif M.
   Miotto, Olivo
   Nascimento, Eduardo J. M.
   Srinivasan, K. N.
   Heiny, A. T.
   Zhang, Guang Lan
   Marques, E. T.
   Tan, Tin Wee
   Brusic, Vladimir
   Salmon, Jerome
   August, J. Thomas
TI Conservation and Variability of Dengue Virus Proteins: Implications for
   Vaccine Design
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID T-CELL RESPONSES; CRYSTAL-STRUCTURE; HEMORRHAGIC-FEVER; ENVELOPE
   PROTEIN; HIV ENVELOPE; RNA VIRUSES; INFLUENZA-A; EPITOPE; PEPTIDE; MICE
AB Background: Genetic variation and rapid evolution are hallmarks of RNA viruses, the result of high mutation rates in RNA replication and selection of mutants that enhance viral adaptation, including the escape from host immune responses. Variability is uneven across the genome because mutations resulting in a deleterious effect on viral fitness are restricted. RNA viruses are thus marked by protein sites permissive to multiple mutations and sites critical to viral structure-function that are evolutionarily robust and highly conserved. Identification and characterization of the historical dynamics of the conserved sites have relevance to multiple applications, including potential targets for diagnosis, and prophylactic and therapeutic purposes.
   Methodology/Principal Findings: We describe a large-scale identification and analysis of evolutionarily highly conserved amino acid sequences of the entire dengue virus (DENV) proteome, with a focus on sequences of 9 amino acids or more, and thus immune-relevant as potential T-cell determinants. DENV protein sequence data were collected from the NCBI Entrez protein database in 2005 (9,512 sequences) and again in 2007 (12,404 sequences). Forty-four (44) sequences (pan-DENV sequences), mainly those of nonstructural proteins and representing similar to 15% of the DENV polyprotein length, were identical in 80% or more of all recorded DENV sequences. Of these 44 sequences, 34 (similar to 77%) were present in >= 95% of sequences of each DENV type, and 27 (similar to 61%) were conserved in other Flaviviruses. The frequencies of variants of the pan-DENV sequences were low (0 to similar to 5%), as compared to variant frequencies of similar to 60 to similar to 85% in the non pan-DENV sequence regions. We further showed that the majority of the conserved sequences were immunologically relevant: 34 contained numerous predicted human leukocyte antigen (HLA) supertype-restricted peptide sequences, and 26 contained T-cell determinants identified by studies with HLA-transgenic mice and/or reported to be immunogenic in humans.
   Conclusions/Significance: Forty-four (44) pan-DENV sequences of at least 9 amino acids were highly conserved and identical in 80% or more of all recorded DENV sequences, and the majority were found to be immune-relevant by their correspondence to known or putative HLA-restricted T-cell determinants. The conservation of these sequences through the entire recorded DENV genetic history supports their possible value for diagnosis, prophylactic and/or therapeutic applications. The combination of bioinformatics and experimental approaches applied herein provides a framework for large-scale and systematic analysis of conserved and variable sequences of other pathogens, in particular, for rapidly mutating viruses, such as influenza A virus and HIV.
C1 [Khan, Asif M.; Miotto, Olivo; Heiny, A. T.; Tan, Tin Wee] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Miotto, Olivo] Natl Univ Singapore, Inst Syst Sci, Singapore 117595, Singapore.
   [Nascimento, Eduardo J. M.; Marques, E. T.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   [Srinivasan, K. N.; Marques, E. T.; Salmon, Jerome; August, J. Thomas] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Srinivasan, K. N.] Hlth Sci Author, Ctr Drug Adm, Product Evaluat & Registrat Div, Singapore, Singapore.
   [Zhang, Guang Lan; Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
RP Khan, AM (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
EM taugust@jhmi.edu
RI Brusic, Vladimir/B-1478-2008; Marques, Ernesto/L-4514-2013; Marques,
   Ernesto T. A/L-4967-2013; Khan, Mohammad Asif/F-4663-2010; Publica, Inct
   Saude/J-9544-2013; Nascimento, Eduardo/J-4590-2014; Tan, Tin
   Wee/B-8963-2009; Miotto, Olivo/AAE-7124-2019
OI Brusic, Vladimir/0000-0003-0523-5266; Marques,
   Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358;
   Khan, Mohammad Asif/0000-0001-9202-279X; Nascimento,
   Eduardo/0000-0002-9851-2332; Tan, Tin Wee/0000-0002-4062-2854; Miotto,
   Olivo/0000-0001-8060-6771
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Department of Health
   and Human Services, USA [U19 AI56541]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI056541, U19AI056541,
   U19AI056541, U19AI056541, U19AI056541] Funding Source: NIH RePORTER
FX This project has been funded in part with the Federal funds from the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services, USA,
   under Grant No. 5 U19 AI56541. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001
   Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI 10.1093/nar/gkh121
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BERZOFSKY JA, 1991, J CLIN INVEST, V88, P876, DOI 10.1172/JCI115389
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   Billoir F, 2000, J GEN VIROL, V81, P781, DOI 10.1099/0022-1317-81-3-781
   Brown SA, 2003, J IMMUNOL, V171, P4140, DOI 10.4049/jimmunol.171.8.4140
   Bui HH, 2005, IMMUNOGENETICS, V57, P304, DOI 10.1007/s00251-005-0798-y
   Chinnaiyan AM, 2002, ADV ANAT PATHOL, V9, P4
   Cope AP, 1999, ARTHRITIS RHEUM, V42, P1497, DOI 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-#
   Crochu S, 2004, J GEN VIROL, V85, P1971, DOI 10.1099/vir.0.79850-0
   de Castro E, 2006, NUCLEIC ACIDS RES, V34, pW362, DOI 10.1093/nar/gkl124
   Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757
   Esser MT, 2003, VACCINE, V21, P419, DOI 10.1016/S0264-410X(02)00407-3
   EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5
   FUGGER L, 1994, P NATL ACAD SCI USA, V91, P6151, DOI 10.1073/pnas.91.13.6151
   Gagnon SJ, 1996, J VIROL, V70, P141, DOI 10.1128/JVI.70.1.141-147.1996
   Gupta V, 2006, VIROLOGY, V347, P127, DOI 10.1016/j.virol.2005.11.042
   Haydon DT, 1998, J THEOR BIOL, V193, P601, DOI 10.1006/jtbi.1998.0726
   Heiny AT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001190
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   Holmes E. C., 2006, NOVART FDN SYMP, V277, P251
   Holmes E.C., 2006, NOVART FDN SYMP, V277, P187
   Holmes EC, 2000, TRENDS MICROBIOL, V8, P74, DOI 10.1016/S0966-842X(99)01669-8
   Holmes Edward C, 2006, Novartis Found Symp, V277, P177, DOI 10.1002/0470058005.ch13
   Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063
   Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635
   Kalergis AM, 2000, J IMMUNOL, V165, P280, DOI 10.4049/jimmunol.165.1.280
   Khan AM, 2006, CELL IMMUNOL, V244, P141, DOI 10.1016/j.cellimm.2007.02.005
   Khan AM, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S4
   Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   KURANE I, 1993, J VIROL, V67, P6285, DOI 10.1128/JVI.67.10.6285-6288.1993
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   LIVINGSTON PG, 1995, J IMMUNOL, V154, P1287
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Madrenas J, 1996, Semin Immunol, V8, P83, DOI 10.1006/smim.1996.0011
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   McGinnis S, 2004, NUCLEIC ACIDS RES, V32, pW20, DOI 10.1093/nar/gkh435
   Miotto O, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S1-S18
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Moran E, 2008, EUR J IMMUNOL, V38, P1050, DOI 10.1002/eji.200737699
   Mota J, 2005, VACCINE, V23, P3469, DOI 10.1016/j.vaccine.2004.12.028
   Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573
   Nishimura Y, 2004, MOL IMMUNOL, V40, P1089, DOI 10.1016/j.molimm.2003.11.009
   Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002
   Okamoto Y, 1998, J GEN VIROL, V79, P697, DOI 10.1099/0022-1317-79-4-697
   OSATOMI K, 1990, VIROLOGY, V176, P643, DOI 10.1016/0042-6822(90)90037-R
   Paninski L, 2003, NEURAL COMPUT, V15, P1191, DOI 10.1162/089976603321780272
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   Rico-Hesse R, 2003, ADV VIRUS RES, V59, P315, DOI 10.1016/S0065-3527(03)59009-1
   Roederer M, 2003, J IMMUNOL METHODS, V274, P221, DOI 10.1016/S0022-1759(02)00423-4
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI21512
   Sette A, 2003, IMMUNOGENETICS, V54, P830, DOI 10.1007/s00251-002-0530-0
   Sette A, 2001, BIOLOGICALS, V29, P271, DOI 10.1006/biol.2001.0297
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Shankar P, 1996, IMMUNOL LETT, V52, P23, DOI 10.1016/0165-2478(96)02574-6
   SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1
   STRAUSS G, 1994, IMMUNOGENETICS, V40, P104
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146
   Vandenbark AA, 2003, J IMMUNOL, V171, P127, DOI 10.4049/jimmunol.171.1.127
   Welsh RM, 2003, NAT MED, V9, P820, DOI 10.1038/nm0703-820
   Wheeler DL, 2005, NUCLEIC ACIDS RES, V33, pD39, DOI 10.1093/nar/gki062
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Wilson CC, 2003, J IMMUNOL, V171, P5611, DOI 10.4049/jimmunol.171.10.5611
   Xu T, 2005, J VIROL, V79, P10278, DOI 10.1128/JVI.79.16.10278-10288.2005
   Yap TL, 2007, J VIROL, V81, P4753, DOI 10.1128/JVI.02283-06
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW172, DOI 10.1093/nar/gki452
   Zinkernagel RM, 2004, SCAND J IMMUNOL, V60, P9, DOI 10.1111/j.0300-9475.2004.01460.x
NR 81
TC 61
Z9 62
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2008
VL 2
IS 8
AR e272
DI 10.1371/journal.pntd.0000272
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 385IG
UT WOS:000261807300009
PM 18698358
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Maciel, R
   August, PN
AF Marques, Ernesto T. A., Jr.
   Maciel Filho, Romulo
   August, Paul Nordstrom
TI Overcoming health inequity: potential benefits of a patient-centered
   open-source public health infostructure
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE information systems; equity in access; primary health care
ID CARE
AB The past 20 years have witnessed an astonishing increase in computational power and an incredible reduction in the cost of contemporary computer systems, but the public health infostructure in most countries has not changed significantly. This article discusses the potential benefits of applying patient-centered infostructure at the primary medical "points-of-care" services, based on networked integrated open-source technology and programming standards to develop tools to detect and reduce health inequalities. Such systems, which could be implemented from the local to the national level, would enable the expansion of evidence-based medicine, clearer identification of health inequalities, and more accurate cost-benefit analyses. In addition, the public health sector could link such databases to traditional Electronic Patient Record (EPR) systems at a greatly reduced cost by promoting the use of standards-based formats for data transfer and storage. Ultimately, the new health infostructure would help decrease health inequity. In fact, developing countries like Brazil, India, and South Africa are well-positioned to take advantage of the open-source movement and "leapfrog" countries burdened by legacy systems.
C1 [Marques, Ernesto T. A., Jr.; Maciel Filho, Romulo; August, Paul Nordstrom] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Marques, Ernesto T. A., Jr.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA.
   [August, Paul Nordstrom] Kenzen Syst Pte Ltd, Singapore, Singapore.
RP Marques, ETA (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Terapia Expt, Av Moraes Rego S-N,Campus Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM emarques@cpqam.fiocruz.br
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto T. A/L-4967-2013;
   Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
CR Baron JA, 2000, ANN EPIDEMIOL, V10, P200, DOI 10.1016/S1047-2797(00)00039-9
   Berwick DM, 2003, HEALTH AFFAIR, V22, P8, DOI 10.1377/hlthaff.22.6.8
   Eddy D, 2006, VALUE HEALTH, V9, P168, DOI 10.1111/j.1524-4733.2006.00097.x
   Eddy DM, 2007, HEALTH AFFAIR, V26, pW125, DOI 10.1377/hlthaff.26.2.w125
   Eddy DM, 2005, HEALTH AFFAIR, V24, P9, DOI 10.1377/hlthaff.24.1.9
   Peterson Margaret G E, 2005, J Med Syst, V29, P81, DOI 10.1007/s10916-005-1106-y
   Schlessinger L, 2002, J BIOMED INFORM, V35, P37, DOI 10.1016/S1532-0464(02)00006-0
   Thiru K, 2003, BMJ-BRIT MED J, V326, P1070, DOI 10.1136/bmj.326.7398.1070
NR 8
TC 8
Z9 8
U1 0
U2 5
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PD MAR
PY 2008
VL 24
IS 3
BP 547
EP 557
DI 10.1590/S0102-311X2008000300008
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 275UE
UT WOS:000254096400008
PM 18327442
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Acioli-Santos, B
   Segat, L
   Dhalia, R
   Brito, CAA
   Braga-Neto, UM
   Marques, ETA
   Crovella, S
AF Acioli-Santos, Bartolomeu
   Segat, Ludovica
   Dhalia, Rafael
   Brito, Carlos A. A.
   Braga-Neto, Ulisses M.
   Marques, Ernesto T. A.
   Crovella, Sergio
TI MBL2 Gene polymorphisms protect against development of thrombocytopenia
   associated with severe dengue phenotype
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE MBL2; polymorphisms; dengue; innate immunity; thrombocytopenia
ID MANNOSE-BINDING LECTIN; HEMORRHAGIC-FEVER; INNATE IMMUNITY; INFECTIONS;
   DISEASE; SUSCEPTIBILITY; MANIFESTATION; DEFICIENCY; ALLELE; RISK
AB Dengue disease can clinically evolve from an asymptomatic and mild disease, known as dengue fever IN), to a severe disease known as dengue hemorrhagic fever (DHF). Recent evidence has shown how host genetic factors can be correlated with severe dengue susceptibility or protection. Many of these genes, such as CD209, TNF-a, vitamin D receptor, and FC gamma receptor IIA, are components of the innate immune system, suggesting that innate responses might have a rote in dengue pathogenesis. MBL2 gene polymorphisms have been shown to modulate susceptibility or protection in many viral diseases. We investigated the involvement of MBL2 gene in the dengue clinical outcome through the analysis of MBL2 exon 1 polymorphisms (at codons 52, 54, and 57) known to be associated with reduced serum levels of the MBL protein. The genotypes of 110 well-characterized dengue-positive patients were statistically analyzed to establish possible correlations between MBL2 polymorphisms and parameters such as sex, type of infection (primary or secondary response), race/ethnicity, course of infection, and age. We found significant correlations between wild-type AA MBL2 genotype and age as associated risk factors for development of dengue-related thrombocytopenia. (C) 2008 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Segat, Ludovica; Crovella, Sergio] Univ Trieste, Genet Serv IRCCS Burlo Garofolo, Trieste, Italy.
   [Segat, Ludovica; Crovella, Sergio] Univ Trieste, Dept Dev & Reprod Sci, Trieste, Italy.
   [Acioli-Santos, Bartolomeu; Dhalia, Rafael; Brito, Carlos A. A.; Braga-Neto, Ulisses M.; Marques, Ernesto T. A.] Aggeu Magalhaes Res Ctr CPqAM FIOCRUZ, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Braga-Neto, Ulisses M.] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA.
   [Marques, Ernesto T. A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Div Infect Dis, Dept Med, Baltimore, MD USA.
   [Crovella, Sergio] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
RP Segat, L (corresponding author), Univ Trieste, Genet Serv IRCCS Burlo Garofolo, Trieste, Italy.
EM segat@burio.trieste.it
RI Dhalia, Rafael/AAD-5432-2020; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Segat, Ludovica/0000-0002-6024-1485
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI56541, N01 AI 40085] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19AI056541, R01AI040085, U19AI056541, R01AI040085,
   U19AI056541, R01AI040085, R01AI040085, R21AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   R01AI040085, U19AI056541] Funding Source: NIH RePORTER
CR Alonso DP, 2007, J INFECT DIS, V195, P1212, DOI 10.1086/512683
   Brown KS, 2007, IMMUNOL LETT, V108, P34, DOI 10.1016/j.imlet.2006.10.006
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   CHIEWSILP P, 1981, AM J TROP MED HYG, V30, P1100, DOI 10.4269/ajtmh.1981.30.1100
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x
   Dornelles LN, 2006, CLIN EXP IMMUNOL, V145, P463, DOI 10.1111/j.1365-2249.2006.03161.x
   Egger JR, 2007, EMERG INFECT DIS, V13, P924, DOI 10.3201/eid1306.070008
   Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283
   Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4
   GARRED P, 1994, EUR J IMMUNOGENET, V21, P125, DOI 10.1111/j.1744-313X.1994.tb00183.x
   GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x
   Gubler D, 1997, DENGUE DENGUE HEMORR
   Huang KJ, 2000, J GEN VIROL, V81, P2177, DOI 10.1099/0022-1317-81-9-2177
   Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713
   Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x
   Kalayanarooj S, 2007, J INFECT DIS, V195, P1014, DOI 10.1086/512244
   Larsen F, 2004, J BIOL CHEM, V279, P21302, DOI 10.1074/jbc.M400520200
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   MARQUES ETA, 2008, CAD SAUDE PUBLICA, V24, P105
   Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506
   Milanese M, 2008, AM J REPROD IMMUNOL, V59, P146, DOI 10.1111/j.1600-0897.2007.00549.x
   PEREZ MLP, 1987, HAEMATOLOGIA, V20, P83
   RABELLINO EM, 1979, J EXP MED, V149, P1273, DOI 10.1084/jem.149.6.1273
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Segal JB, 2006, ANN EPIDEMIOL, V16, P123, DOI 10.1016/j.annepidem.2005.06.052
   Seyfarth J, 2005, HUM MOL GENET, V14, P2859, DOI 10.1093/hmg/ddi318
   Soborg C, 2003, J INFECT DIS, V188, P777, DOI 10.1086/377183
   Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x
   de Souza VAUF, 2007, J CLIN VIROL, V39, P230, DOI 10.1016/j.jcv.2007.04.005
   World Health Organization, WORLD HLTH REP 2004
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Ytting H, 2006, CLIN EXP IMMUNOL, V144, P239, DOI 10.1111/j.1365-2249.2006.03068.x
NR 37
TC 42
Z9 42
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD FEB
PY 2008
VL 69
IS 2
BP 122
EP 128
DI 10.1016/j.humimm.2008.01.005
PG 7
WC Immunology
SC Immunology
GA 285PZ
UT WOS:000254790000009
PM 18361938
DA 2020-12-16
ER

PT J
AU Cordeiro, MT
   Silva, AM
   Brito, CAA
   Nascimento, EJM
   Magalhaes, MCF
   Guimaraes, GF
   Lucena-Silva, N
   de Carvalho, EMF
   Marques, ETA
AF Cordeiro, Marli Tenorio
   Silva, Ana Maria
   Brito, Carlos A. A.
   Nascimento, Eduardo J. M.
   Magalhaes, Maria Cecilia F.
   Guimaraes, Georgia F.
   Lucena-Silva, Norma
   Freese de Carvalho, Eduardo M.
   Marques, Ernesto T. A., Jr.
TI Characterization of a dengiie patient cohort in Recife, Brazil
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DENGUE HEMORRHAGIC-FEVER; RIO-DE-JANEIRO; PRIMARY-SCHOOL CHILDREN; VIRUS
   TYPE-3; VIROLOGICAL FEATURES; KAMPHAENG PHET; CO-CIRCULATION;
   EPIDEMIOLOGY; SURVEILLANCE; STATE
AB From 2004 to 2006, 658 patients with suspected dengue virus infections were enrolled in a clinical dengue cohort established in Recife, Pernambuco, located at the northeastern region of Brazil. A total of 2,364 blood samples were collected, and serum, plasma, and cells were cryopreserved. Among the suspected cases, 354 (54%) were confirmed as acute DENV-3 infection based on reverse transcription-polymerase chain reaction, virus isolation, and ELISA-IgM. According to WHO criteria, 29.4% of the positive acute cases were classified as dengue fever (DF) and 8.2% of the cases as dengue hemorrhagic fever (DHF), grade 1 or 2. The DHF cases represent 100% of those confirmed in Recife during the period of the study. The dengue cases that did not fulfill the definition of either DHF or DF were classified as DF complicated and accounted for 44.0% of the cases. All the acute cases were classified as either primary or secondary acute dengue virus infections. Secondary infection was predominant in patients with DF; however, there was no predominance of either primary or secondary infections in patients with DHF.
C1 [Cordeiro, Marli Tenorio; Silva, Ana Maria; Brito, Carlos A. A.; Nascimento, Eduardo J. M.; Magalhaes, Maria Cecilia F.; Guimaraes, Georgia F.] CPqAM, Lab Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Estado Pernambuco, Secretaria Saude, Lab Cent Saude Publ, BR-50050210 Recife, PE, Brazil.
   [Nascimento, Eduardo J. M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Brito, Carlos A. A.] Univ Fed Pernambuco, Hosp Esperanca, Dept Clin Med, Recife, PE, Brazil.
   [Lucena-Silva, Norma] Ctr Pesquisas Aggeu Magalhaes, Dept Imunol, BR-50670420 Recife, PE, Brazil.
   [Freese de Carvalho, Eduardo M.] Ctr Pesquisas Aggeu Magalhaes, Dept Saude Coletiva, BR-50670420 Recife, PE, Brazil.
RP Marques, ETA (corresponding author), 725 Wolf St,Biophys Build Room 307A, Baltimore, MD 21205 USA.
EM marli@cpqam.fiocruz.br; anasilva@cpqam.fiocruz.br;
   cbrito@cpqam.fiocruz.br; enacimento@cpqam.fiocruz.br;
   cecimag@cpqam.fiocruz.br; georgia@cpqam.fiocruz.br;
   nlucena@cpqam.fiocruz.br; freese@cpqam.fiocruz.br; emarques@jhmi.edu
RI Lucena-Silva, Norma/AAH-9437-2019; Marques, Ernesto T. A/L-4967-2013;
   Nascimento, Eduardo/J-4590-2014; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Nascimento,
   Eduardo/0000-0002-9851-2332; Marques, Ernesto/0000-0003-3826-9358
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI56541] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER
CR Anantapreecha S, 2005, EPIDEMIOL INFECT, V133, P503, DOI 10.1017/S0950268804003541
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   Campagna Delmina de S., 2006, J. Pediatr. (Rio J.), V82, P354, DOI [10.1590/S0021-75572006000600008, 10.2223/JPED.1522]
   Chadee DD, 2007, ANN TROP MED PARASIT, V101, P69, DOI 10.1179/136485907X157059
   Chaturvedi UC, 2006, FEMS IMMUNOL MED MIC, V47, P155, DOI 10.1111/j.1574-695X.2006.00058.x
   CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561
   da Costa AIP, 1998, REV SAUDE PUBL, V32, P232, DOI 10.1590/S0034-89101998000300005
   Araujo FMD, 2006, MEM I OSWALDO CRUZ, V101, P925, DOI 10.1590/S0074-02762006000800017
   de Castro JAF, 2003, MEM I OSWALDO CRUZ, V98, P1021, DOI 10.1590/S0074-02762003000800007
   Sierra BDL, 2007, ARCH VIROL, V152, P533, DOI 10.1007/s00705-006-0869-x
   Almeida MCD, 2007, J URBAN HEALTH, V84, P334, DOI 10.1007/s11524-006-9154-2
   De Simone TS, 2004, T ROY SOC TROP MED H, V98, P553, DOI 10.1016/j.trstmh.2003.09.003
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Duarte HHP, 2006, REV SAUDE PUBL, V40, P134, DOI 10.1590/S0034-89102006000100021
   Endy TP, 2002, AM J EPIDEMIOL, V156, P52, DOI 10.1093/aje/kwf006
   Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005
   Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2001, AM J TROP MED HYG, V65, P180, DOI 10.4269/ajtmh.2001.65.180
   Halstead SB, 2006, REV PANAM SALUD PUBL, V20, P407, DOI 10.1590/S1020-49892006001100007
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   Kochel TJ, 2005, J INFECT DIS, V191, P1000, DOI 10.1086/427511
   LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   MARQUES ETA, IN PRESS CAD SAUDE P
   Messer WB, 2003, EMERG INFECT DIS, V9, P800
   Miagostovich MP, 2002, BRAZ J MED BIOL RES, V35, P869, DOI 10.1590/S0100-879X2002000800002
   *MIN SAUD BRAZ SEC, 2005, DENG DIAGN MAN CLIN
   Montenegro D, 2006, REV SOC BRAS MED TRO, V39, P9, DOI 10.1590/S0037-86822006000100002
   MYINT KS, 2006, CELLULAR IMMUNE ACTI, V194, P600
   Neto RJP, 2005, BRAZ J MED BIOL RES, V38, P843, DOI 10.1590/S0100-879X2005000600005
   NOGUEIRA RMR, 1990, MEM I OSWALDO CRUZ, V85, P253, DOI 10.1590/S0074-02761990000200022
   Nogueira RMR, 2005, EMERG INFECT DIS, V11, P1376
   NOGUEIRA RMR, 1993, EPIDEMIOL INFECT, V111, P163, DOI 10.1017/S0950268800056788
   Nogueira RMR, 2001, MEM I OSWALDO CRUZ, V96, P925, DOI 10.1590/S0074-02762001000700007
   Nunes-Araujo FRF, 2003, ANN TROP MED PARASIT, V97, P415, DOI 10.1179/000349803235002263
   RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Rodriguez-Roche R, 2005, EMERG INFECT DIS, V11, P773
   Santos S. R. A., 2003, Dengue Bulletin, V27, P156
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x
   Tauil Pedro Luiz, 2002, Cad. Saúde Pública, V18, P867, DOI 10.1590/S0102-311X2002000300030
   Teixeira MD, 2002, TROP MED INT HEALTH, V7, P757, DOI 10.1046/j.1365-3156.2002.00930.x
   Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566
   Uzcategui NY, 2003, J GEN VIROL, V84, P1569, DOI 10.1099/vir.0.18807-0
   World Health Organization, 1997, DENG HAEM FEV DIAGN
NR 54
TC 56
Z9 57
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2007
VL 77
IS 6
BP 1128
EP 1134
DI 10.4269/ajtmh.2007.77.1128
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 248AH
UT WOS:000252123200026
PM 18165535
OA Bronze, Green Published
DA 2020-12-16
ER

PT J
AU Gomes, ALV
   Silva, AM
   Cordeiro, MT
   Guimaraes, GF
   Marques, ETA
   Abath, FGC
AF Gomes, A. L. V.
   Silva, A. M.
   Cordeiro, M. T.
   Guimaraes, G. F.
   Marques, E. T. A., Jr.
   Abath, F. G. C.
TI Single-tube nested PCR using immobilized internal primers for the
   identification of dengue virus serotypes
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE nested PCR; diagnosis; dengue; single-tube
ID RAPID DETECTION; REVERSE
AB Molecular techniques based on the detection of genomic sequences by reverse transcription (RT)-PCR, nested PCR, or real-time PCR have made possible the rapid diagnosis of dengue virus (DENV) infections, and these approaches have been accepted by clinical laboratories as the new standard method for the detection of dengue virus in acute-phase serum samples. One of these PCR-based assays, the two-step RT nested PCR (RT-NPCR) technique is used routinely in laboratories worldwide. In the present study, the two-step RT-NPCR as described by Lanciotti et al. [Lanciotti, R.S., Calisher, C.H., Gabler, D.J., Chang, G.J., Vorndam, AX, 1992. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J. Clin. Microbiol. 30, 545-55 1] was adapted to a novel single-tube nested PCR (STNPCR) format, which is less prone to cross-contamination and reduces reaction cost and time. When standards for each dengue serotype were tested, the detection limit of the STNPCR was at least 10 copies for DENV-1 and 100 copies for DENV-2 and DENV-3, whereas the detection limit for the two-step RT-NPCR was 100 copies for each serotype. Sera from 22 patients with confirmed DENV-3 infections and from 14 healthy individuals were then tested in the STNPCR format using the system described by Lanciotti et al. as the reference standard. The results indicated a sensitivity of 75.9% (CI 95%, 60.3-91.4) and a specificity of 100% for the RT-STNPCR. Although RT-STNPCR was less sensitive than the conventional two-step RT-NPCR for the detection of virus in serum samples, it was still adequately sensitive, and the advantages associated with a single-tube format may outweigh the somewhat lower assay sensitivity, making it useful for diagnosis in the field. (c) 2007 Elsevier B.V. All rights reserved.
C1 Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Immunol, BR-50670420 Recife, PE, Brazil.
   Johns Hopkins Univ, Div Infect Dis, Dept Med, Baltimore, MD 21205 USA.
RP Marques, ETA (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Terapia Expt, Av Moraes Rego S-N,Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM emarques@cpqam.fiocruz.br
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI056541, U19 AI056541-01, U19
   AI056541-04, U19 AI056541-02, U19 AI56541, U19 AI056541-05, U19
   AI056541-03, U19 AI056541-010004] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER
CR Abath FGC, 2002, BIOTECHNIQUES, V33, P1210, DOI 10.2144/02336bm05
   Anwar A, 2006, ANAL BIOCHEM, V352, P120, DOI 10.1016/j.ab.2006.01.046
   Chien LJ, 2006, J CLIN MICROBIOL, V44, P1295, DOI 10.1128/JCM.44.4.1295-1304.2006
   Guha P, 2005, INT J GEOM METHODS M, V2, P1, DOI 10.1142/S0219887805000429
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Kong YY, 2006, J VIROL METHODS, V138, P123, DOI 10.1016/j.jviromet.2006.08.003
   Kumaria R, 2005, DIAGN MICR INFEC DIS, V52, P311, DOI 10.1016/j.diagmicrobio.2005.04.013
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Melo FL, 2006, T ROY SOC TROP MED H, V100, P1049, DOI 10.1016/j.trstmh.2005.12.008
   Montenegro LML, 2004, T ROY SOC TROP MED H, V98, P619, DOI 10.1016/j.trstmh.2003.11.011
   Picken MM, 1996, EUR J CLIN MICROBIOL, V15, P489, DOI 10.1007/BF01691317
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI21512
NR 14
TC 17
Z9 17
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD OCT
PY 2007
VL 145
IS 1
BP 76
EP 79
DI 10.1016/j.jviromet.2007.05.003
PG 4
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 211FG
UT WOS:000249509100011
PM 17573132
OA Green Accepted
DA 2020-12-16
ER

PT J
AU Chikhlikar, P
   de Arruda, LB
   Maciel, M
   Silvera, P
   Lewis, MG
   August, JT
   Marques, ETA
AF Chikhlikar, Priya
   de Arruda, Luciana Barros
   Maciel, Milton
   Silvera, Peter
   Lewis, Mark G.
   August, J. Thomas
   Marques, Ernesto T. A.
TI DNA Encoding an HIV-1 Gag/Human Lysosome-Associated Membrane Protein-1
   Chimera Elicits a Broad Cellular and Humoral Immune Response in Rhesus
   Macaques
SO PLOS ONE
LA English
DT Article
AB Previous studies of HIV-1 p55Gag immunization of mice have demonstrated the usefulness of targeting antigens to the cellular compartment containing the major histocompatibility complex type II (MHC II) complex molecules by use of a DNA antigen formulation encoding Gag as a chimera with the mouse lysosome-associated membrane protein (mLAMP/gag). In the present study, we have analyzed the magnitude and breadth of Gag-specific T-lymphocyte and antibody responses elicited in Rhesus macaques after immunization with DNA encoding a human LAMP/gag(hLAMP/gag) chimera. ELISPOT analyses indicated that the average Gag-specific IFN-gamma response elicited by the hLAMP/gag chimera was detectable after only two or three naked DNA immunizations in all five immunized macaques and reached an average of 1000 spot-forming cells (SFC)/10(6) PBMCs. High IFN-gamma ELISPOT responses were detected in CD8(+)-depleted cells, indicating that CD4(+) T-cells play a major role in these responses. The T-cell responses of four of the macaques were also tested by use of ELISPOT to 12 overlapping 15-amino acids (aa) peptide pools containing ten peptides each, encompassing the complete Gag protein sequence. The two Mamu 08 immunized macaques responded to eight and twelve of the pools, the Mamu B01 to six, and the other macaque to five pools indicating that the hLAMP/gag DNA antigen formulation elicits a broad T-cell response against Gag. Additionally, there was a strong HIV-1-specific IgG response. The IgG antibody titers increased after each DNA injection, indicating a strong amnestic B-cell response, and were highly elevated in all the macaques after three immunizations. Moreover, the serum of each macaque recognized 13 of the 49 peptides of a 20-aa peptide library covering the complete Gag amino acid sequence. In addition, HIV-1-specific IgA antibodies were present in the plasma and external secretions, including nasal washes. These data support the findings of increased immunogenicity of genetic vaccines encoded as LAMP chimeras, including the response to DNA vaccines by non-human primates.
C1 [Chikhlikar, Priya; Maciel, Milton; August, J. Thomas; Marques, Ernesto T. A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
   [de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Silvera, Peter; Lewis, Mark G.] So Res Inst, Frederick, MD USA.
   [Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Johns Hopkins Sch Med, Div Infect Dis, Dept Med, Baltimore, MD USA.
RP Marques, ETA (corresponding author), Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
EM emarques@jhmi.edu
RI Arruda, Luciana/B-5806-2014; Marques, Ernesto T. A/L-4967-2013; Arruda,
   Luciana B/N-9086-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
FU National Institute of Allergy and Infectious Disease, National
   Institutes of Health, USAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37-AI41908, R21-AI44317,
   N01-AI-15429]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37AI041908, R01AI015429, R01AI015429,
   R01AI015429, R01AI015429, R01AI015429, R37AI041908, R01AI015429,
   R37AI041908, R37AI041908, R01AI015429, R01AI015429, R01AI015429,
   R01AI015429, R01AI015429, R01AI015429, R01AI015429, R01AI015429,
   R37AI041908, R01AI015429, R37AI041908, R01AI015429, R37AI041908,
   R01AI015429, R01AI015429, R01AI015429, R01AI015429, R01AI015429,
   R01AI015429, R01AI015429, R37AI041908, R01AI015429, R37AI041908,
   R37AI041908, R21AI044317, R21AI044317, R01AI015429] Funding Source: NIH
   RePORTER
FX Supported by Grants R37-AI41908, R21-AI44317 and N01-AI-15429 "Simian
   Vaccine Evaluation Unit'' contract from the National Institute of
   Allergy and Infectious Disease, National Institutes of Health, USA
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   BEAGLEY KW, 1989, J EXP MED, V169, P2133, DOI 10.1084/jem.169.6.2133
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   CARPIO E, 1991, AIDS RES HUM RETROV, V7, P97, DOI 10.1089/aid.1991.7.97
   Casimiro DR, 2003, J VIROL, V77, P7663, DOI 10.1128/JVI.77.13.7663-7668.2003
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005
   Drake JR, 1999, J IMMUNOL, V162, P1150
   DUBEY C, 1995, J IMMUNOL, V155, P45
   FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   GUPTA V, 2005, VIROLOGY
   Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999
   Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   MATHIESEN T, 1989, IMMUNOLOGY, V67, P453
   MATSUO K, 1992, J GEN VIROL, V73, P2445, DOI 10.1099/0022-1317-73-9-2445
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   MAZANEC MB, 1992, VIRUS RES, V23, P1, DOI 10.1016/0168-1702(92)90063-F
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   NIEDRIG M, 1991, J VIROL, V65, P4529, DOI 10.1128/JVI.65.8.4529-4533.1991
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Robinson HL, 1995, ANN NY ACAD SCI, V772, P209, DOI 10.1111/j.1749-6632.1995.tb44746.x
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648
   Su Z, 2002, CANCER RES, V62, P5041
   Su Z, 2005, J IMMUNOL, V174, P3798, DOI 10.4049/jimmunol.174.6.3798
   SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   Wu L, 2005, J VIROL, V79, P8024, DOI 10.1128/JVI.79.13.8024-8031.2005
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
NR 44
TC 24
Z9 25
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2006
VL 1
IS 2
AR e135
DI 10.1371/journal.pone.0000135
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DC
UT WOS:000207443700029
PM 17205139
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Khan, AM
   Miotto, O
   Heiny, AT
   Salmon, J
   Srinivasan, KN
   Nascimento, EJM
   Marques, ETA
   Brusic, V
   Tan, TW
   August, JT
AF Khan, Asif M.
   Miotto, Olivo
   Heiny, A. T.
   Salmon, Jerome
   Srinivasan, K. N.
   Nascimento, Eduardo J. M.
   Marques, Ernesto T. A., Jr.
   Brusic, Vladimir
   Tan, Tin Wee
   August, J. Thomas
TI A systematic bioinformatics approach for selection of epitope-based
   vaccine targets
SO CELLULAR IMMUNOLOGY
LA English
DT Article; Proceedings Paper
CT International Conference of Immunogenomics and Immunomics
CY OCT 08-12, 2006
CL Budapest, HUNGARY
DE T-cell epitopes; epitope-based vaccines; bioinformatics; pathogens;
   immune systems; information entropy; conserved sequences; immunological
   hotspots; altered-ligand effect; supertypes
ID T-CELL EPITOPES; MHC CLASS-I; HIV ENVELOPE; DENGUE; RESPONSES;
   IDENTIFICATION; PREDICTION; PROTEIN; CLUSTERS; BINDING
AB Epitope-based vaccines provide a new strategy for prophylactic and therapeutic application of pathogen-specific immunity. A critical requirement of this strategy is the identification and selection of T-cell epitopes that act as vaccine targets. This study describes current methodologies for the selection process, with dengue virus as a model system. A combination of publicly available bioinformatics algorithms and computational tools are used to screen and select antigen sequences as potential T-cell epitopes of supertype human leukocyte antigen (HLA) alleles. The selected sequences are tested for biological function by their activation of T-cells of HLA transgenic mice and of pathogen infected subjects. This approach provides an experimental basis for the design of pathogen specific, T-cell epitope-based vaccines that are targeted to majority of the genetic variants of the pathogen, and are effective for a broad range of differences in human leukocyte antigens among the global human population. (c) 2007 Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Natl Univ Singapore, Dept Microbiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
   Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
   Natl Univ Singapore, Inst Syst Sci, Singapore 119615, Singapore.
   Ctr Drug Adm, Prod Evaluat & Registrat Div, Hlth Sci Author, Singapore 138667, Singapore.
   Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   Univ Queensland, Sch Land & Food Sci, Brisbane, Qld 4072, Australia.
   Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM taugust@jhmi.edu
RI Tan, Tin Wee/B-8963-2009; Brusic, Vladimir/B-1478-2008; Nascimento,
   Eduardo/J-4590-2014; Marques, Ernesto T. A/L-4967-2013; Khan, Mohammad
   Asif/F-4663-2010; Marques, Ernesto/L-4514-2013; Miotto,
   Olivo/AAE-7124-2019
OI Tan, Tin Wee/0000-0002-4062-2854; Brusic, Vladimir/0000-0003-0523-5266;
   Nascimento, Eduardo/0000-0002-9851-2332; Marques, Ernesto T.
   A/0000-0003-3826-9358; Khan, Mohammad Asif/0000-0001-9202-279X; Marques,
   Ernesto/0000-0003-3826-9358; Miotto, Olivo/0000-0001-8060-6771
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [5 U19
   AI56541, U19 AI056541, U19 AI056541-05] Funding Source: Medline; PHS
   HHSUnited States Public Health Service [HHSN2662-00400085C] Funding
   Source: Medline
CR Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI 10.1093/nar/gkh121
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BERZOFSKY JA, 1991, J CLIN INVEST, V88, P876, DOI 10.1172/JCI115389
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   Brown SA, 2003, J IMMUNOL, V171, P4140, DOI 10.4049/jimmunol.171.8.4140
   Brusic V, 2004, METHODS, V34, P436, DOI 10.1016/j.ymeth.2004.06.006
   Brusic V, 2004, PHARMACOGENOMICS, V5, P597, DOI 10.1517/14622416.5.6.597
   Bui HH, 2005, IMMUNOGENETICS, V57, P304, DOI 10.1007/s00251-005-0798-y
   Donnes P, 2005, PROTEIN SCI, V14, P2132, DOI 10.1110/ps.051352405
   Esser MT, 2003, VACCINE, V21, P419, DOI 10.1016/S0264-410X(02)00407-3
   EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5
   Gagnon SJ, 1996, J VIROL, V70, P141, DOI 10.1128/JVI.70.1.141-147.1996
   Gupta V, 2006, VIROLOGY, V347, P127, DOI 10.1016/j.virol.2005.11.042
   Khan AM, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S4
   Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5
   KURANE I, 1993, J VIROL, V67, P6285, DOI 10.1128/JVI.67.10.6285-6288.1993
   KURANE I, 1995, J GEN VIROL, V76, P2243, DOI 10.1099/0022-1317-76-9-2243
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Miotto O, 2005, LECT NOTES COMPUT SC, V3578, P398
   Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002
   Okamoto Y, 1998, J GEN VIROL, V79, P697, DOI 10.1099/0022-1317-79-4-697
   Ovsyannikova IG, 2004, PHARMACOGENOMICS, V5, P417, DOI 10.1517/14622416.5.4.417
   Peters B, 2005, IMMUNOGENETICS, V57, P326, DOI 10.1007/s00251-005-0803-5
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   Robinson HL, 2005, NAT MED, V11, pS25, DOI 10.1038/nm1212
   Rosloniec EF, 1997, J EXP MED, V185, P1113, DOI 10.1084/jem.185.6.1113
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI21512
   Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9
   Sette A, 2001, BIOLOGICALS, V29, P271, DOI 10.1006/biol.2001.0297
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Shankar P, 1996, IMMUNOL LETT, V52, P23, DOI 10.1016/0165-2478(96)02574-6
   SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x
   SIDNEY J, 1998, CURRENT PROTOCOLS IM
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1
   Srinivasan KN, 2004, BIOINFORMATICS, V20, P297, DOI 10.1093/bioinformatics/bth943
   Srinivasan KN, 2002, TOXICON, V40, P23, DOI 10.1016/S0041-0101(01)00182-9
   Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898
   Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146
   Wilson CC, 2003, J IMMUNOL, V171, P5611, DOI 10.4049/jimmunol.171.10.5611
   Zeng LL, 1996, J VIROL, V70, P3108, DOI 10.1128/JVI.70.5.3108-3117.1996
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW172, DOI 10.1093/nar/gki452
   Zinkernagel RM, 2004, SCAND J IMMUNOL, V60, P9, DOI 10.1111/j.0300-9475.2004.01460.x
NR 46
TC 58
Z9 60
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PD DEC
PY 2006
VL 244
IS 2
BP 141
EP 147
DI 10.1016/j.cellimm.2007.02.005
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 172AO
UT WOS:000246776700015
PM 17434154
OA Green Accepted
DA 2020-12-16
ER

PT J
AU da Silva, ANM
   Abath, FG
   Furtado, PB
   Montenegro, SM
   Marques, ET
AF da Silva, Andrea Nazare M.
   Abath, Frederico G.
   Furtado, Patricia B.
   Montenegro, Silvia M.
   Marques, Ernesto T., Jr.
TI Identification of continuous B-CELL epitopes in the envelope
   glycoprotein of dengue virus type 3
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013;
   montenegro, silvia/AAD-9090-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2006
VL 75
IS 5
SU S
MA 112
BP 33
EP 34
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 109XW
UT WOS:000242343900113
DA 2020-12-16
ER

PT J
AU Arruda, LB
   Sim, D
   Chikhlikar, PR
   Maciel, M
   Akasaki, K
   August, JT
   Marques, ETA
AF Arruda, Luciana B.
   Sim, Del
   Chikhlikar, Priya R.
   Maciel, Milton, Jr.
   Akasaki, Kenji
   August, J. Thomas
   Marques, Ernesto T. A.
TI Dendritic cell-lysosomal-associated membrane protein (LAMP) and
   LAMP-1-HIV-1 Gag chimeras have distinct cellular trafficking pathways
   and prime T and B cell responses to a diverse repertoire of epitopes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CLASS-II COMPARTMENT; COMPLEX CLASS-II; ANTIGEN-PRESENTING CELLS;
   EXOGENOUS ANTIGENS; DNA VACCINE; CROSS-PRESENTATION; IMMUNE-RESPONSE;
   ENDOCYTIC COMPARTMENTS; CATHEPSIN ACTIVITY; PLASMA-MEMBRANE
AB Ag processing is a critical step in defining the repertoire of epitope-specific immune responses. In the present study, HIV-1 p55Gag Ag was synthesized as a DNA plasmid with either lysosomal-associated membrane protein-1 (LAMP/gag) or human dendritic cell-LAMP (DC-LAMP/gag) and used to immunize mice. Analysis of the cellular trafficking of these two chimeras demonstrated that both molecules colocalized with MHC class II molecules but differed in their overall trafficking to endosomal/lysosomal compartments. Following DNA immunization, both chimeras elicited potent Gag-specific T and B cell immune responses in mice but differ markedly in their IL-4 and IgG1/IgG2a responses. The DC-LAMP chimera induced a stronger Th type 1 response. ELISPOT analysis of T cell responses to 122 individual peptides encompassing the entire p55gag sequence (15-aa peptides overlapping by 11 residues) showed that DNA immunization with native gag, LAMP/gag, or DC-LAMP/gag induced responses to identical immunodominant CD4(+) and CD8(+) peptides. However, LAMP/gag and DC-LAMP/gag plasmids also elicited significant responses to 23 additional cryptic epitopes that were not recognized after immunization with native gag DNA. The three plasmids induced T cell responses to a total of 39 distinct peptide sequences, 13 of which were induced by all three DNA constructs. Individually, DC-LAMP/gag elicited the most diverse response, with a specific T cell response against 35 peptides. In addition, immunization with LAMP/gag and DC-LAMP/gag chimeras also promoted Ab secretion to an increased number of epitopes. These data indicate that LAMP-1 and DC-LAMP Ag chimeras follow different trafficking pathways, induce distinct modulatory immune responses, and are able to present cryptic epitopes.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Rio De Janeiro, Brazil.
   Div John Hopkins Singapore, Singapore, Singapore.
   Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Hiroshima, Japan.
   Fdn Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Biophys 307,725 N Wolfe St, Baltimore, MD 21205 USA.
EM emarques@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana B/N-9086-2013;
   Marques, Ernesto/L-4514-2013; Arruda, Luciana/B-5806-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI041908, R21AI044317, R37AI041908, R21AI044317, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI 44317, R37 AI 41908] Funding Source:
   Medline
CR Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082
   Akasaki K, 2004, ARCH BIOCHEM BIOPHYS, V425, P147, DOI 10.1016/j.abb.2004.02.042
   AKASAKI K, 1995, EXP CELL RES, V220, P464, DOI 10.1006/excr.1995.1338
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Barois N, 2002, TRAFFIC, V3, P894, DOI 10.1034/j.1600-0854.2002.31205.x
   Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
   Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004
   Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Chang MHY, 2004, BIOCHEM J, V382, P481, DOI 10.1042/BJ20031752
   CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Chen L, 2004, SCAND J IMMUNOL, V59, P545, DOI 10.1111/j.1365-3083.2004.01426.x
   Chen LY, 2004, EUR J IMMUNOL, V34, P952, DOI 10.1002/eji.200324359
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chouquet C, 2002, AIDS, V16, P2399, DOI 10.1097/00002030-200212060-00004
   Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006
   Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9
   Delvig AA, 2002, J LEUKOCYTE BIOL, V72, P163
   Delvig AA, 1998, J BIOL CHEM, V273, P3291, DOI 10.1074/jbc.273.6.3291
   DeStafanis D, 1997, CELL TISSUE RES, V289, P109
   Eisen HN, 2001, ANNU REV IMMUNOL, V19, P1, DOI 10.1146/annurev.immunol.19.1.1
   Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Harding CV, 2003, CURR OPIN IMMUNOL, V15, P112, DOI 10.1016/S0952-7915(02)00008-0
   Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512
   Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1
   Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 2001, TRAFFIC, V2, P124, DOI 10.1034/j.1600-0854.2001.020207.x
   Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004
   Lautwein A, 2004, J LEUKOCYTE BIOL, V75, P844, DOI 10.1189/jlb.0803367
   Lautwein A, 2002, EUR J IMMUNOL, V32, P3348, DOI 10.1002/1521-4141(200212)32:12<3348::AID-IMMU3348>3.0.CO;2-S
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Lewis PJ, 1999, J VIROL, V73, P10214, DOI 10.1128/JVI.73.12.10214-10223.1999
   LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673
   MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3
   Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mata M, 1998, J IMMUNOL, V161, P2985
   Meikle PJ, 1999, MOL GENET METAB, V66, P179, DOI 10.1006/mgme.1998.2800
   Murk JL, 2002, SEMIN CELL DEV BIOL, V13, P303, DOI 10.1016/S1084952102000605
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Perrin-Cocon LA, 2004, J IMMUNOL, V172, P3564, DOI 10.4049/jimmunol.172.6.3564
   Potter NS, 2001, J IMMUNOL, V167, P2538, DOI 10.4049/jimmunol.167.5.2538
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089
   Rodriguez F, 2001, J VIROL, V75, P7399, DOI 10.1128/JVI.75.16.7399-7409.2001
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Salaun B, 2004, AM J PATHOL, V164, P861, DOI 10.1016/S0002-9440(10)63174-4
   Santra S, 2002, J VIROL, V76, P6376, DOI 10.1128/JVI.76.12.6376-6381.2002
   Schirmbeck R, 2002, MOL IMMUNOL, V39, P249, DOI 10.1016/S0161-5890(02)00105-0
   Su Z, 2002, CANCER RES, V62, P5041
   Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898
   Tobian AAR, 2004, J IMMUNOL, V172, P5277, DOI 10.4049/jimmunol.172.9.5277
   Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744
   Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088
   Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821
   Wu JM, 2000, J NEUROIMMUNOL, V106, P145, DOI 10.1016/S0165-5728(00)00201-0
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
NR 69
TC 39
Z9 39
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2006
VL 177
IS 4
BP 2265
EP 2275
DI 10.4049/jimmunol.177.4.2265
PG 11
WC Immunology
SC Immunology
GA 073LU
UT WOS:000239745300034
PM 16887987
OA Bronze
DA 2020-12-16
ER

PT J
AU Braga-Neto, UM
   Marques, ETA
AF Braga-Neto, Ulisses M.
   Marques, Ernesto T. A., Jr.
TI From functional genomics to functional immunomics: New challenges, old
   problems, big rewards
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Review
ID T-CELL EPITOPES; MHC CLASS-I; ANTIBODY MICROARRAY ANALYSIS; PROTEIN
   ARRAY PLATFORMS; PARALLEL DETECTION; PROTEASOMAL CLEAVAGE;
   MESSENGER-RNA; TAP TRANSPORT; PREDICTION; PEPTIDE
AB The development of DNA microarray technology a decade ago led to the establishment of functional genomics as one of the most active and successful scientific disciplines today. With the ongoing development of immunomic microarray technology-a spatially addressable, large-scale technology for measurement of specific immunological response-the new challenge of functional immunomics is emerging, which bears similarities to but is also significantly different from functional genomics. Immunonic data has been successfully used to identify biological markers involved in autoimmune diseases, allergies, viral infections such as human immunodefficiency virus (HIV), influenza, diabetes, and responses to cancer vaccines. This review intends to provide a coherent vision of this nascent scientific field, and speculate on future research directions. We discuss at some length issues such as epitope prediction, immunomic microarray technology and its applications, and computation and statistical challenges related to functional immunomics. Based on the recent discovery of regulation mechanisms in T cell responses, we envision the use of immunomic microarrays as a tool for advances in systems biology of cellular immune responses, by means of immunomic regulatory network models.
C1 Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, CPqAM, Recife, PE, Brazil.
   Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
RP Braga-Neto, UM (corresponding author), Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, CPqAM, Recife, PE, Brazil.
EM ub@ieee.org
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, R01AI040085, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R21AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   U19AI056541, R01AI040085, R01AI040085, U19AI056541, U19AI056541,
   R01AI040085] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19 AI56541, U19 AI056541, N01 AI040085] Funding Source: Medline
CR Alcocer MJC, 2004, J MOL BIOL, V343, P759, DOI 10.1016/j.jmb.2004.08.065
   Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333
   Angenendt P, 2002, ANAL BIOCHEM, V309, P253, DOI 10.1016/S0003-2697(02)00257-9
   Athanassakis I, 2002, IMMUNOL LETT, V84, P179, DOI 10.1016/S0165-2478(02)00182-7
   Balboni I, 2006, ANNU REV IMMUNOL, V24, P391, DOI 10.1146/annurev.immunol.24.021605.090709
   Bartling B, 2005, LUNG CANCER-J IASLC, V49, P145, DOI 10.1016/j.lungcan.2005.02.006
   Belov L, 2005, J IMMUNOL METHODS, V305, P10, DOI 10.1016/j.jim.2005.07.007
   Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   Borras E, 2002, J IMMUNOL METHODS, V267, P81
   Brusic V, 1998, BIOINFORMATICS, V14, P121, DOI 10.1093/bioinformatics/14.2.121
   Brusic V, 2004, PHARMACOGENOMICS, V5, P597, DOI 10.1517/14622416.5.6.597
   Brusic V, 2002, IMMUNOL CELL BIOL, V80, P280, DOI 10.1046/j.1440-1711.2002.01088.x
   Brusic Vladimir, 2003, J Bioinform Comput Biol, V1, P179, DOI 10.1142/S0219720003000034
   Bryant PA, 2004, LANCET INFECT DIS, V4, P100, DOI 10.1016/S1473-3099(04)00930-2
   Chao DL, 2004, J THEOR BIOL, V228, P227, DOI 10.1016/j.jtbi.2003.12.011
   CHEN DS, 2005, PLOS MED, V2, DOI DOI 10.1371/JOURNAL.PMED.002065
   CHEN J, 2005, IEEE CIRCUITS SYSTEM, V5, P46
   Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504
   Chen ZL, 2004, CLIN CHEM, V50, P988, DOI 10.1373/clinchem.2004.031096
   Chiari M, 2005, PROTEOMICS, V5, P3600, DOI 10.1002/pmic.200401216
   Christensen JK, 2003, NEURAL COMPUT, V15, P2931, DOI 10.1162/089976603322518803
   Copeland S, 2004, J IMMUNOL METHODS, V284, P99, DOI 10.1016/j.jim.2003.10.011
   CZERKINSKY C, 1988, J IMMUNOL METHODS, V115, P31, DOI 10.1016/0022-1759(88)90306-7
   Davies DH, 2005, J VIROL, V79, P11724, DOI 10.1128/JVI.79.18.11724-11733.2005
   De Groot Anne S, 2004, Expert Rev Vaccines, V3, P59
   De Groot AS, 2004, EXPERT OPIN BIOL TH, V4, P767, DOI 10.1517/14712598.4.6.767
   De Jong H, 2002, J COMPUT BIOL, V9, P67, DOI 10.1089/10665270252833208
   de Vegvar HEN, 2004, CLIN IMMUNOL, V111, P196, DOI 10.1016/j.clim.2003.12.010
   de Vegvar HEN, 2003, J VIROL, V77, P11125, DOI 10.1128/JVI.77.20.11125-11138.2003
   Deinhofer K, 2004, METHODS, V32, P249, DOI 10.1016/j.ymeth.2003.08.018
   Delehanty James B, 2004, Methods Mol Biol, V264, P135
   Delehanty JB, 2004, ANAL CHEM, V76, P7323, DOI 10.1021/ac049259g
   Devroye L., 1996, PROBABILISTIC THEORY
   Dougherty ER, 2006, J BIOL SYST, V14, P65, DOI 10.1142/S0218339006001726
   Du HW, 2004, ANAL CHEM, V76, P6166, DOI 10.1021/ac049159a
   DURBIN R, 1999, BIOL SEQUENCE ANAL
   Fahrer AM, 2001, NATURE, V409, P836, DOI 10.1038/35057020
   Feng YF, 2004, CLIN CHEM, V50, P416, DOI 10.1373/clinchem.2003.023994
   Gao WM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-110
   Givan A. L., 2001, FLOW CYTOMETRY 1 PRI
   GUAN P, 2003, J APPL BIOINFORMATIC, V2, P63
   Haab BB, 2005, PROTEOMICS, V5, P3278, DOI 10.1002/pmic.200401276
   Haab BB, 2001, GENOME BIOL, V2
   Huang S, 1999, J MOL MED-JMM, V77, P469, DOI 10.1007/s001099900023
   Hueber W, 2005, ARTHRITIS RHEUM-US, V52, P2645, DOI 10.1002/art.21269
   Janzi M, 2005, MOL CELL PROTEOMICS, V4, P1942, DOI 10.1074/mcp.M500213-MCP200
   Kalyuzhny A.E, 2005, HDB ELISPOT METHODS
   Kauffman S. A., 1993, ORIGINS ORDER SELF O
   KEMENY DM, 1997, IMMUNOCHEMISTRY, V1, P147
   Klysik J, 2001, ACTA BIOTHEOR, V49, P191, DOI 10.1023/A:1011901410166
   Knecht BG, 2004, ANAL CHEM, V76, P646, DOI 10.1021/ac035028i
   Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6
   KOHANE IS, 2002, MICRORRAYS INTEGRATI
   Kusnezow W, 2003, J MOL RECOGNIT, V16, P165, DOI 10.1002/jmr.625
   Kusnezow W, 2002, BIOTECHNIQUES, P14
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Landgrebe D, 2002, IEEE SIGNAL PROC MAG, V19, P17, DOI 10.1109/79.974718
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   Lee Sang-Yull, 2004, Cancer Immun, V4, P13
   Lee SY, 2003, P NATL ACAD SCI USA, V100, P2651, DOI 10.1073/pnas.0437972100
   Letarte Michelle, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-2
   Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675
   Lund O, 2004, IMMUNOGENETICS, V55, P797, DOI 10.1007/s00251-004-0647-4
   MARGALIT H, 1987, J IMMUNOL, V138, P2213
   MEISTER GE, 1995, VACCINE, V13, P581, DOI 10.1016/0264-410X(94)00014-E
   Mezzasoma L, 2002, CLIN CHEM, V48, P121
   Michaud GA, 2003, NAT BIOTECHNOL, V21, P1509, DOI 10.1038/nbt910
   Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485
   Moreau V, 2006, BIOINFORMATICS, V22, P1088, DOI 10.1093/bioinformatics/btl012
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Nielsen M, 2004, BIOINFORMATICS, V20, P1388, DOI 10.1093/bioinformatics/bth100
   Nino-Vasquez JJ, 2004, MOL IMMUNOL, V40, P1063, DOI 10.1016/j.molimm.2003.11.005
   Nyarady Z, 2006, MOL IMMUNOL, V43, P830, DOI 10.1016/j.molimm.2005.06.044
   Oelke M, 2003, NAT MED, V9, P619, DOI 10.1038/nm869
   Oh SW, 2005, FASEB J, V19, P1335, DOI 10.1096/fj.04-2098fje
   Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163
   Olle EW, 2005, MOL CELL PROTEOMICS, V4, P1664, DOI 10.1074/mcp.M500052-MCP200
   Pang S, 2005, J IMMUNOL METHODS, V302, P1, DOI 10.1016/j.jim.2005.04.007
   Pavlickova P, 2003, BIOTECHNIQUES, V34, P124, DOI 10.2144/03341rr03
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Peters B, 2005, IMMUNOGENETICS, V57, P326, DOI 10.1007/s00251-005-0803-5
   Peters B, 2003, BIOINFORMATICS, V19, P1765, DOI 10.1093/bioinformatics/btg247
   Peters B, 2006, PLOS COMPUT BIOL, V2, P574, DOI 10.1371/journal.pcbi.0020065
   Petrovsky Nikolai, 2003, Novartis Found Symp, V254, P23
   Popper K, 1959, LOGIC SCI DISCOVERY
   Quintana FJ, 2004, P NATL ACAD SCI USA, V101, P14615, DOI 10.1073/pnas.0404848101
   Quintana FJ, 2003, J AUTOIMMUN, V21, P65, DOI 10.1016/S0896-8411(03)00064-7
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   Reineke U, 2002, J IMMUNOL METHODS, V267, P37, DOI 10.1016/S0022-1759(02)00139-4
   Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295
   Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2
   Sampson HA, 2005, ALLERGY, V60, P19, DOI 10.1111/j.1398-9995.2005.00853.x
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Schonbach Christian, 2003, Novartis Found Symp, V254, P177
   Schroeder C. M., 2004, Journal of Allergy and Clinical Immunology, V113, pS329, DOI 10.1016/j.jaci.2004.01.689
   SCHWENK JM, 2002, BIOTECHNIQUES, V33, pS54
   Segel L. A., 2000, Complexity, V5, P39, DOI 10.1002/1099-0526(200007/08)5:6<39::AID-CPLX8>3.0.CO;2-4
   Segel LA, 2001, NOVART FDN SYMP, V239, P31
   Sette Alessandro, 2005, Immunity, V22, P155, DOI 10.1016/j.immuni.2005.01.009
   Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033
   Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588
   Slansky JE, 2003, PLOS BIOL, V1, P329, DOI 10.1371/journal.pbio.0000078
   Soen Y, 2003, PLOS BIOL, V1, P429, DOI 10.1371/journal.pbio.0000065
   Srinivasan KN, 2004, BIOINFORMATICS, V20, P297, DOI 10.1093/bioinformatics/bth943
   Stone JD, 2005, P NATL ACAD SCI USA, V102, P3744, DOI 10.1073/pnas.0407019102
   Sung MH, 2004, METHODS, V34, P460, DOI 10.1016/j.ymeth.2004.06.001
   Tenzer S, 2005, CELL MOL LIFE SCI, V62, P1025, DOI 10.1007/s00018-005-4528-2
   Van Regenmortel MHV, 2001, BIOLOGICALS, V29, P209, DOI 10.1006/biol.2001.0308
   VARNUM SM, 2004, J METHODS MOL BIOL, V264, P161
   Vaughan Hilary A, 2004, Cancer Immun, V4, P5
   Walker LSK, 2004, IMMUNOLOGY, V111, P129, DOI 10.1111/j.0019-2805.2003.01788.x
   Wang YJ, 2004, PROTEOMICS, V4, P20, DOI 10.1002/pmic.200300549
   Weng S, 2002, PROTEOMICS, V2, P48, DOI 10.1002/1615-9861(200201)2:1<48::AID-PROT48>3.0.CO;2-I
   Wraith DC, 2004, CURR OPIN IMMUNOL, V16, P695, DOI 10.1016/j.coi.2004.09.015
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW172, DOI 10.1093/nar/gki452
NR 118
TC 44
Z9 45
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD JUL
PY 2006
VL 2
IS 7
BP 651
EP 662
AR e81
DI 10.1371/journal.pcbi.0020081
PG 12
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 070BA
UT WOS:000239494100001
PM 16863395
OA DOAJ Gold, Green Published
DA 2020-12-16
ER

PT J
AU Gupta, V
   Tabiin, TM
   Sun, K
   Chandrasekaran, A
   Anwar, A
   Yang, K
   Chikhlikar, P
   Salmon, J
   Brusic, V
   Marques, ETA
   Kellathur, SN
   August, TJ
AF Gupta, V
   Tabiin, TM
   Sun, K
   Chandrasekaran, A
   Anwar, A
   Yang, K
   Chikhlikar, P
   Salmon, J
   Brusic, V
   Marques, ETA
   Kellathur, SN
   August, TJ
TI SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is
   common to both exogenous recombinant and endogenous DNA-encoded
   immunogens
SO VIROLOGY
LA English
DT Article
DE SARS coronavirus; nucleocapsid protein; N DNA construct; LAMP-N DNA
   construct; recombinant N; rodent; T cells; antigen peptide epitopes;
   ELISpot
ID MHC CLASS-II; MEMBRANE-PROTEIN; DENDRITIC CELLS; CROSS-PRESENTATION;
   RESTRICTED PRESENTATION; IMMUNOLOGICAL MEMORY; ANTIGEN PRESENTATION;
   ENVELOPE PROTEIN; IMMUNE-RESPONSE; VIRUS ENVELOPE
AB Correspondence between the T-cell epitope responses of vaccine immunogens and those of pathogen antigens is critical to vaccine efficacy. In the present study, we analyzed the spectrum of immune responses of mice to three different forms of the SARS coronavirus nucleocapsid (N): (1) exogenous recombinant protein (N-GST) with Freund's adjuvant; (2) DNA encoding unmodified N as an endogenous cytoplasmic protein (pN); and (3) DNA encoding N as a LAMP-I chimera targeted to the lysosomal MHC II compartment (p-LAMP-N). Lysosomal trafficking of the LAMP/N chimera in transfected cells was documented by both confocal and immunoelectron microscopy. The responses of the immunized mice differed markedly. The strongest T-cell IFN-gamma and CTL responses were to the LAMP-N chimera followed by the pN immunogen. In contrast, N-GST elicited strong T cell IL-4 but minimal IFN-gamma responses and a much greater antibody response. Despite these differences, however, the immunodominant T-cell ELISpot responses to each of the three immunogens were elicited by the same N peptides, with the greatest responses being generated by a cluster of five overlapping peptides, N76-114, each of which contained nonameric H2(d) binding domains with high binding scores for both class I and, except for N76-93, class II alleles. These results demonstrate that processing and presentation of N, whether exogenously or endogenously derived, resulted in common immunodominant epitopes, supporting the usefulness of modified antigen delivery and trafficking forms and, in particular, LAMP chimeras as vaccine candidates. Nevertheless, the profiles of T-cell responses were distinctly different. The pronounced Th-2 and humoral response to N protein plus adjuvant are in contrast to the balanced IFN-gamma and IL-4 responses and strong memory CTL responses to the LAMP-N chimera. (C) 2005 Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Singapore, Div Biomed Sci, Singapore 138669, Singapore.
   Inst Infocomm Res, Singapore 119613, Singapore.
   Univ Queensland, Sch Land & Food Sci, Brisbane, Qld 4072, Australia.
   Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21218 USA.
   Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, BR-50670420 Recife, PE, Brazil.
RP August, TJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM taugust@bs.jhmi.edu
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013; Brusic,
   Vladimir/B-1478-2008
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; Brusic, Vladimir/0000-0003-0523-5266
CR Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082
   Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   BENACERRAF B, 1978, J IMMUNOL, V120, P1809
   BERZOFSKY JA, 1991, J CLIN INVEST, V88, P876, DOI 10.1172/JCI115389
   Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849
   Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   Brode S, 2004, IMMUNOLOGY, V112, P345, DOI 10.1111/j.1365-2567.2004.01920.x
   BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290
   Brown SA, 2003, J IMMUNOL, V171, P4140, DOI 10.4049/jimmunol.171.8.4140
   Bryant P, 2004, CURR OPIN IMMUNOL, V16, P96, DOI 10.1016/j.coi.2003.11.011
   Chen JL, 2005, J EXP MED, V201, P1243, DOI 10.1084/jem.20042323
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Chen L, 2004, SCAND J IMMUNOL, V59, P545, DOI 10.1111/j.1365-3083.2004.01426.x
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Crotty S, 2004, SEMIN IMMUNOL, V16, P197, DOI 10.1016/j.smim.2004.02.008
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Del Porto P, 2000, VIROLOGY, V269, P313, DOI 10.1006/viro.2000.0238
   Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0
   ESOUSA CR, 1995, J EXP MED, V182, P841
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911
   Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912
   Huang LR, 2004, J MED VIROL, V73, P338, DOI 10.1002/jmv.20096
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   Imai J, 2005, INT IMMUNOL, V17, P45, DOI 10.1093/intimm/dxh184
   Kelso A, 2002, INT IMMUNOL, V14, P605, DOI 10.1093/intimm/dxf028
   Kelso A, 1997, P NATL ACAD SCI USA, V94, P8070, DOI 10.1073/pnas.94.15.8070
   Kessler BM, 2002, MOL IMMUNOL, V39, P171, DOI 10.1016/S0161-5890(02)00100-1
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095
   Kloetzel PM, 2004, NAT IMMUNOL, V5, P661, DOI 10.1038/ni1090
   Lau SKP, 2004, J CLIN MICROBIOL, V42, P2884, DOI 10.1128/JCM.42.7.2884-2889.2004
   Lautwein A, 2004, J LEUKOCYTE BIOL, V75, P844, DOI 10.1189/jlb.0803367
   Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009
   Lich JD, 2000, J EXP MED, V191, P1513, DOI 10.1084/jem.191.9.1513
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Maecker HT, 2001, J IMMUNOL METHODS, V255, P27, DOI 10.1016/S0022-1759(01)00416-1
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   MARTINS LP, 1995, J VIROL, V69, P2574, DOI 10.1128/JVI.69.4.2574-2582.1995
   Masopust D, 2004, CURR OPIN IMMUNOL, V16, P217, DOI 10.1016/j.coi.2004.02.005
   MORENO J, 1991, J IMMUNOL, V147, P3306
   Murk JLAN, 2004, TRAFFIC, V5, P936, DOI 10.1111/j.1600-0854.2004.00235.x
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Nimmerjahn F, 2003, EUR J IMMUNOL, V33, P1250, DOI 10.1002/eji.200323730
   Norbury CC, 2001, J IMMUNOL, V166, P4355, DOI 10.4049/jimmunol.166.7.4355
   Oehen S, 2000, IMMUNOLOGY, V99, P163, DOI 10.1046/j.1365-2567.2000.00950.x
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904
   Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Reimann J, 1999, IMMUNOL REV, V172, P131, DOI 10.1111/j.1600-065X.1999.tb01362.x
   Ria F, 2004, J IMMUNOL, V172, P3447, DOI 10.4049/jimmunol.172.6.3447
   Rocha B, 2004, CURR OPIN IMMUNOL, V16, P259, DOI 10.1016/j.coi.2004.03.004
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Rush C, 2002, J IMMUNOL, V169, P4951, DOI 10.4049/jimmunol.169.9.4951
   Schirmbeck R, 1998, EUR J IMMUNOL, V28, P4149, DOI 10.1002/(SICI)1521-4141(199812)28:12<4149::AID-IMMU4149>3.0.CO;2-D
   Shankar P, 1996, IMMUNOL LETT, V52, P23, DOI 10.1016/0165-2478(96)02574-6
   Shibaki A, 2002, EXP DERMATOL, V11, P126, DOI 10.1034/j.1600-0625.2002.110204.x
   Shirai M, 1999, J IMMUNOL, V162, P568
   Srinivasan KN, 2004, BIOINFORMATICS, V20, P297, DOI 10.1093/bioinformatics/bth943
   Storni T, 2004, J IMMUNOL, V172, P6129, DOI 10.4049/jimmunol.172.10.6129
   Su Z, 2002, CANCER RES, V62, P5041
   Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105
   Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898
   Tewari MK, 2005, NAT IMMUNOL, V6, P287, DOI 10.1038/ni1171
   Varga SM, 2000, J IMMUNOL, V165, P6487, DOI 10.4049/jimmunol.165.11.6487
   Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x
   Wang JCE, 2003, J IMMUNOL, V171, P6339, DOI 10.4049/jimmunol.171.12.6339
   Welsh RM, 2004, ANNU REV IMMUNOL, V22, P711, DOI 10.1146/annurev.immunol.22.012703.104527
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yewdell JW, 2001, CURR OPIN IMMUNOL, V13, P13, DOI 10.1016/S0952-7915(00)00175-8
   Yip HC, 1999, J IMMUNOL, V162, P3942
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016
   Zhu MS, 2004, IMMUNOL LETT, V92, P237, DOI 10.1016/j.imlet.2004.01.001
NR 83
TC 29
Z9 33
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR 30
PY 2006
VL 347
IS 1
BP 127
EP 139
DI 10.1016/j.virol.2005.11.042
PG 13
WC Virology
SC Virology
GA 029BA
UT WOS:000236531600012
PM 16387339
OA Bronze, Green Published
DA 2020-12-16
ER

PT J
AU Maciel, M
   Kellathur, S
   Marques, E
   August, T
AF Maciel, Milton
   Kellathur, Srinivasan
   Marques, Ernesto
   August, Thomas
TI T-cell epitope discovery for Yellow Fever Vaccine: Comparing elispot and
   prediction by the Pred(Balb/C)
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 01-05, 2006
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 Johns Hopkins Sch Med, Baltimore, MD USA.
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2006
VL 119
SU S
BP S194
EP S195
DI 10.1016/j.clim.2006.04.529
PG 2
WC Immunology
SC Immunology
GA 048CD
UT WOS:000237924300523
DA 2020-12-16
ER

PT J
AU Anwar, A
   Chandrasekaran, A
   Ng, ML
   Marques, E
   August, JT
AF Anwar, A
   Chandrasekaran, A
   Ng, ML
   Marques, E
   August, JT
TI West Nile premembrane-envelope genetic vaccine encoded as a chimera
   containing the transmembrane and cytoplasmic domains of a
   lysosome-associated membrane protein: increased cellular concentration
   of the transgene product, targeting to the MHC II compartment, and
   enhanced neutralizing antibody response
SO VIROLOGY
LA English
DT Article
DE West Nile virus DNA vaccine; LAMP; MIICs; MHC II; H-2M; neutralizing
   antibody; electron microscopy
ID DNA VACCINE; ANTIGEN PRESENTATION; SKELETAL-MUSCLE; VIRUS-VACCINES;
   LIVE; IDENTIFICATION; TRAFFICKING; INDUCTION; MOLECULES; ENDOSOMES
AB A genetic vaccine for West Nile virus (WN) has been synthesized with the WN premembrane-envelope (WN preM-E) gene sequences encoded as a chimera with the transmembrane and carboxyl terminal domains of the lysosome-associated membrane protein (LAMP). The LAMP sequences are used to direct the antigen protein to the major histocompatibility class II (MHC II) vesicular compartment of transfected professional antigen-presenting cells (APCs). Vaccine constructs encoding the native WN preM-E and WN preM-E/LAMP chimera were synthesized in pVAX1 and pITR plasmid backbones. Extracts of human fibroblast 293 and monkey kidney COS-7 cells transfected with the WN preM-E/LAMP chimera constructs contained much greater amounts of E than did the cells transfected with constructs encoding the native WN preM-E. This difference in the concentration of native E and the E/LAMP chimera in transfected cells is attributed to the secretion of native E. The amount of preM protein in cell extracts, in contrast to the E protein, and the levels of DNA and RNA transcripts, did not differ between WN preM-E- and WN preM-E/LAMP-transfected cells. Additionally, confocal and immunoelectron microscopic analyses of transfected B cells showed localization of the WN preM-E/LAMP chimera in vesicular compartments containing endogenous LAMP, MHC II, and H2-M, whereas native viral preM-E lacking the LAMP sequences was distributed within the cellular vesicular network with little LAMP or MHC II association. Mice immunized with a DNA construct expressing the WN preM-E/LAMP antigen induced significant antibody and long-term neutralization titers in contrast to the minimal and short-lived neutralization titer of mice vaccinated with a plasmid expressing the untargeted antigen. These results underscore the utility of LAMP targeting of the WN envelope to the MHC II compartments in the design of a genetic WN vaccine. (C) 2004 Elsevier Inc. All rights reserved.
C1 Johns Hopkins Singapore, Div Biomed Sci, Genet Immunotherapy Lab, Singapore 138669, Singapore.
   Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Natl Univ Singapore, Dept Microbiol, Singapore 119260, Singapore.
RP Anwar, A (corresponding author), Johns Hopkins Singapore, Div Biomed Sci, Genet Immunotherapy Lab, 31 Biopolis Way,02-01,Nanos, Singapore 138669, Singapore.
EM azlinda@hopkins.edu.sg
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI 56541] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER
CR AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0
   Andersson C, 2000, FEMS IMMUNOL MED MIC, V29, P247, DOI 10.1111/j.1574-695X.2000.tb01530.x
   ANSARI MZ, 1993, J CLIN LAB ANAL, V7, P230, DOI 10.1002/jcla.1860070408
   Arroyo J, 2001, TRENDS MOL MED, V7, P350, DOI 10.1016/S1471-4914(01)02048-2
   Babiuk S, 2002, VACCINE, V20, P3399, DOI 10.1016/S0264-410X(02)00269-4
   Barrett ADT, 2001, ANN NY ACAD SCI, V951, P262
   Berkhout B, 1999, J VIROL, V73, P1138, DOI 10.1128/JVI.73.2.1138-1145.1999
   Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800
   Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923
   Busch R, 2000, CURR OPIN IMMUNOL, V12, P99, DOI 10.1016/S0952-7915(99)00057-6
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   Chang GJJ, 2000, J VIROL, V74, P4244, DOI 10.1128/JVI.74.9.4244-4252.2000
   Chang GJJ, 2001, ANN NY ACAD SCI, V951, P272
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chu JJH, 2002, J MED VIROL, V67, P127, DOI 10.1002/jmv.2201
   Crowther JR, 1995, ELISA THEORY PRACTIC
   Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Donnelly J, 2003, INT J PARASITOL, V33, P457, DOI 10.1016/S0020-7519(03)00056-0
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Durieux AC, 2002, BIOCHEM BIOPH RES CO, V296, P443, DOI 10.1016/S0006-291X(02)00901-4
   Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
   Fournillier A, 1999, J VIROL, V73, P7497, DOI 10.1128/JVI.73.9.7497-7504.1999
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   Gould EA, 1985, VIROLOGY PRACTICAL A, P43
   Grode L, 2002, J IMMUNOL, V168, P1869, DOI 10.4049/jimmunol.168.4.1869
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Gundlach BR, 2000, J VIROL, V74, P3537, DOI 10.1128/JVI.74.8.3537-3542.2000
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Hall RA, 2003, P NATL ACAD SCI USA, V100, P10460, DOI 10.1073/pnas.1834270100
   Hiltbold EM, 2002, CURR OPIN IMMUNOL, V14, P30, DOI 10.1016/S0952-7915(01)00295-3
   Hubalek Z, 2000, VIRAL IMMUNOL, V13, P427, DOI 10.1089/vim.2000.13.427
   HUGHES EN, 1982, J BIOL CHEM, V257, P3970
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Lankar D, 2002, J EXP MED, V195, P461, DOI 10.1084/jem.20011543
   Lin KY, 1996, CANCER RES, V56, P21
   Liu HM, 2003, J VIROL, V77, P10994, DOI 10.1128/JVI.77.20.10994-11005.2003
   Liu JH, 2002, ASIAN J SOC PSYCHOL, V5, P3, DOI 10.1111/1467-839X.00091
   Liu MA, 2003, J INTERN MED, V253, P402, DOI 10.1046/j.1365-2796.2003.01140.x
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Ma XY, 2002, VACCINE, V20, P3263, DOI 10.1016/S0264-410X(02)00304-3
   MacKenzie JM, 2001, J VIROL, V75, P10787, DOI 10.1128/JVI.75.22.10787-10799.2001
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   MARTINS LP, 1995, J VIROL, V69, P2574, DOI 10.1128/JVI.69.4.2574-2582.1995
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262
   Nedry Melissa, 2003, Clin Lab Sci, V16, P43
   Neefjes J, 1999, EUR J IMMUNOL, V29, P1421, DOI 10.1002/(SICI)1521-4141(199905)29:05<1421::AID-IMMU1421>3.0.CO;2-C
   NG ML, 1994, ARCH VIROL, V137, P303, DOI 10.1007/BF01309477
   Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7
   Petersen LR, 2003, JAMA-J AM MED ASSOC, V290, P524, DOI 10.1001/jama.290.4.524
   Pletnev AG, 2003, VIROLOGY, V314, P190, DOI 10.1016/S0042-6822(03)00450-1
   Pugachev KV, 2003, INT J PARASITOL, V33, P567, DOI 10.1016/S0020-7519(03)00063-8
   Putnak Robert, 2003, Adv Virus Res, V61, P445, DOI 10.1016/S0065-3527(03)61012-2
   Rappole JH, 2003, J APPL MICROBIOL, V94, p47S
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Riedl P, 2002, J IMMUNOL, V169, P1251, DOI 10.4049/jimmunol.169.3.1251
   Roehrig JT, 2003, ADV VIRUS RES, V59, P141, DOI 10.1016/S0065-3527(03)59005-4
   ROEHRIG JT, 1983, VIROLOGY, V128, P118, DOI 10.1016/0042-6822(83)90323-9
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Sambrook J., 2001, MOL CLONING LAB MANU
   Tanchot C, 2003, NAT IMMUNOL, V4, P431, DOI 10.1038/ni0503-431
   TOO HP, 1995, PEPTIDES, V16, P45, DOI 10.1016/0196-9781(94)00151-U
   Turell MJ, 2003, EMERG INFECT DIS, V9, P1077, DOI 10.3201/eid0909.030025
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   Vidalin O, 2000, VIROLOGY, V276, P259, DOI 10.1006/viro.2000.0566
   Vogt AB, 1999, SEMIN IMMUNOL, V11, P391, DOI 10.1006/smim.1999.0197
   Vogt AB, 1999, TRENDS BIOCHEM SCI, V24, P150, DOI 10.1016/S0968-0004(99)01364-X
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
NR 76
TC 26
Z9 28
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB 5
PY 2005
VL 332
IS 1
BP 66
EP 77
DI 10.1016/j.virol.2004.11.022
PG 12
WC Virology
SC Virology
GA 892ZM
UT WOS:000226688500008
PM 15661141
DA 2020-12-16
ER

PT J
AU Chikhlikar, P
   de Arruda, LB
   Agrawal, S
   Byrne, B
   Guggino, W
   August, JT
   Marques, ETA
AF Chikhlikar, P
   de Arruda, LB
   Agrawal, S
   Byrne, B
   Guggino, W
   August, JT
   Marques, ETA
TI Inverted terminal repeat sequences of adeno-associated virus enhance the
   antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera
SO VIROLOGY
LA English
DT Article
DE LAMP; MHC II; inverted terminal repeat; AAV; rAAV; DNA vaccine; HIV-1
   Gag; CD4; CD8
ID GENETIC IMMUNIZATION; EXPRESSION; GAG; VECTORS; IMMUNITY;
   IMMUNOGENICITY; INTEGRATION; INDUCTION; CELLS
AB The immune responses to an HIV-1 p55Gag vaccine encoded as a DNA chimera with the lysosomal associated membrane protein-1 (LAMP) have been examined for the effect of the addition of the inverted terminal repeat (ITR) sequences of the adeno-associated virus (AAV) to the DNA plasmid construct, and of packaging the LAMP/gag gene as a recombinant AAV vector (rAAV). DNA plasmids encoding Gag and the LAMP/Gag protein chimera were constructed in two vectors, the pcDNA3.1 and a corresponding plasmid containing the ITR sequences (pITR) flanking the expression elements of the plasmid, and the pITR LAMP/gag DNA plasmid was encapsidated in the rAAV vector. Human 293 cells transfected in vitro with LAMP/gag plasmids either in pcDNA3.1 or pITR produced much Gag protein in cell extracts (1.6 and 2.2 ng of Gag/mg of protein, respectively). The immune responses of mice to immunization with these constructs were examined under three protocols: DNA prime/DNA boost, DNA prime/rAAV boost, and a single rAAV immunization. The results demonstrated that under DNA prime/DNA boost protocol, the "naked" DNA vaccines encoding the LAMP/gag chimera, either as pcDNA3.1 or pITR DNA plasmid constructs, elicited strong CD4(+) T cell responses. In contrast, significantly higher levels of CD8(+) and antibody responses were observed with the pITR-DNA constructs. Immunization with the rAAV vector under the DNA prime/rAAV boost protocol resulted in sustained T cell responses and a markedly increased antibody response, predominantly of the IgG(1) isotype resulting from the activation of the Th2 subset of CD4(+) T cells, that was sustained for at least 5 months after immunization. (C) 2004 Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
   Univ Florida, Gainesville, FL 32610 USA.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Biophys 309,725 N Wolfe St, Baltimore, MD 21205 USA.
EM taugust@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana/B-5806-2014; Marques,
   Ernesto/L-4514-2013; Arruda, Luciana B/N-9086-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI044317, R37AI041908, R21AI044317, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37-AI41908, R21-AI44317] Funding Source:
   Medline
CR Chen ZY, 2001, MOL THER, V3, P403, DOI 10.1006/mthe.2001.0278
   Chirmule N, 2000, J VIROL, V74, P2420, DOI 10.1128/JVI.74.5.2420-2425.2000
   Chou CY, 2001, TRANSGENIC RES, V10, P303, DOI 10.1023/A:1016671513425
   Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001
   Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578
   Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998
   Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821
   Fu YC, 1999, METH MOL B, V127, P167, DOI 10.1385/1-59259-678-9:167
   Hsiao CD, 2001, DEV DYNAM, V220, P323, DOI 10.1002/dvdy.1113
   Hu H, 2001, NAT IMMUNOL, V2, P705, DOI 10.1038/90643
   Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y
   Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000
   MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991
   Manning WC, 1997, J VIROL, V71, P7960, DOI 10.1128/JVI.71.10.7960-7962.1997
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4
   Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179
   Nakai H, 2003, HUM GENE THER, V14, P871, DOI 10.1089/104303403765701169
   Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0
   NAKAI H, 2003, MOL THER, V7, P11221
   NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994
   Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999
   REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   Song SH, 2001, P NATL ACAD SCI USA, V98, P4084, DOI 10.1073/pnas.061014598
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
   Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999
   Xiao X, 1997, J VIROL, V71, P941, DOI 10.1128/JVI.71.2.941-948.1997
   Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996
   Xin KQ, 2003, J GENE MED, V5, P438, DOI 10.1002/jgm.356
   Xin KQ, 2001, HUM GENE THER, V12, P1047, DOI 10.1089/104303401750214276
   Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468-9477.1999
   Yue YP, 2003, VIROLOGY, V313, P1, DOI 10.1016/S0042-6822(03)00432-X
   zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000
NR 37
TC 24
Z9 25
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN 1
PY 2004
VL 323
IS 2
BP 220
EP 232
DI 10.1016/j.virol.2004.02.025
PG 13
WC Virology
SC Virology
GA 830RL
UT WOS:000222140500006
PM 15193918
DA 2020-12-16
ER

PT J
AU Akasaki, K
   Nakamura, N
   Tsukui, N
   Yokota, S
   Murata, S
   Katoh, R
   Michihara, A
   Tsuji, H
   Marques, ETA
   August, JT
AF Akasaki, K
   Nakamura, N
   Tsukui, N
   Yokota, S
   Murata, S
   Katoh, R
   Michihara, A
   Tsuji, H
   Marques, ETA
   August, JT
TI Human dendritic cell lysosome-associated membrane protein expressed in
   lung type II pneumocytes
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
ID ALVEOLAR EPITHELIAL-CELLS; DIFFERENTIAL EXPRESSION; RAT LUNG;
   GLYCOPROTEINS; MHC; TISSUES; COMPARTMENT; TRANSPORT; PURIFICATION;
   TRAFFICKING
AB Human dendritic cell LAMP (hDC-LAMP) is a unique member of the lysosome-associated membrane protein (LAMP) family with a tissue distribution initially described as restricted to major histocompatibility class II (MHC II) compartments of activated DC before the translocation of MHC II to the cell surface [Immunity 9 (1998) 325]. In this report, we show that hDC-LAMP is also expressed by lung type II pneumocytes, another cell type with constitutive expression of MHC II. A recombinant hDC-LAMP protein and a monospecific anti-hDC-LAMP polyclonal antibody were prepared. The antibody reacted specifically with hDC-LAMP sequences of hDC-LAMP protein expressed in transfected cells and with a 54 kDa protein of normal human lung tissue with properties corresponding to those of transgene expressed hDC-LAMP. Immunohistochemical analysis of hDC-LAMP in human lung showed its presence in alveolar type II epithelial cells (type II pneumocytes) as well as in cells in the interfollicular area of bronchus-associated lymph nodes, where interdigitating DCs are concentrated, and with lesser staining of alveolar macrophages. The native protein contained approximately 16% carbohydrates, most of which are sialyl N-linked oligosaccharides, with an acidic isoelectric point (pI 4.8). The restricted localization of this protein to lung type II pneumocytes and DCs is in contrast to hLAMP-1, which was present in many cell types of the lung and lymph node. Type II pneumocytes are known to express MHC II and the abundant expression of hDC-LAMP in these cells as well as in DCs suggests its possible relationship to specific MHC II related function(s) of DC and type II pneumocytes. (C) 2004 Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Fukuyama, Hiroshima 7290292, Japan.
   Yamanashi Univ, Fac Med, Dept Pathol, Yamanashi 4093898, Japan.
   Yamanashi Univ, Fac Med, Biol Lab, Yamanashi 4093898, Japan.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
EM taugust@jhmi.edu
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
CR AKASAKI K, 1991, J BIOCHEM-TOKYO, V110, P922, DOI 10.1093/oxfordjournals.jbchem.a123690
   Allavena P, 2001, EUR J IMMUNOL, V31, P3413, DOI 10.1002/1521-4141(200112)31:12<3413::AID-IMMU3413>3.0.CO;2-P
   ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419
   Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   CUNNINGHAM AC, 1994, J CELL SCI, V107, P443
   de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9
   Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121
   Faries MB, 2001, BLOOD, V98, P2489, DOI 10.1182/blood.V98.8.2489
   FUKUDA M, 1991, J BIOL CHEM, V266, P21327
   Fuller CL, 2002, AM J PATHOL, V161, P969, DOI 10.1016/S0002-9440(10)64257-5
   Geissmann F, 2001, BLOOD, V97, P1241, DOI 10.1182/blood.V97.5.1241
   GIBSON KF, 1991, AM J RESP CELL MOL, V4, P504, DOI 10.1165/ajrcmb/4.6.504
   GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227
   HOLNESS CL, 1993, BLOOD, V81, P1607
   HOLT PG, 1993, EUR RESPIR J, V6, P120
   HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185
   ISHII Y, 1991, J HISTOCHEM CYTOCHEM, V39, P461, DOI 10.1177/39.4.2005374
   Katou F, 2003, J PATHOL, V199, P98, DOI 10.1002/path.1255
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lem L, 1999, J IMMUNOL, V162, P523
   LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839
   LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593
   LU Y, 2003, VACCINE, P1
   Maeda K, 2002, J HISTOCHEM CYTOCHEM, V50, P1475, DOI 10.1177/002215540205001107
   MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Nakamura N, 2002, MODERN PATHOL, V15, P1058, DOI 10.1097/01.MP.0000028572.44247.CF
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   Ozaki K, 1998, CANCER RES, V58, P3499
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Salaun B, 2003, EUR J IMMUNOL, V33, P2619, DOI 10.1002/eji.200324175
   Salik E, 1999, AM J RESP CELL MOL, V21, P365, DOI 10.1165/ajrcmb.21.3.3529
   STEVENS A, 1997, HUMAN HISTOLOGY
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Tsunoda T, 1999, AM J PATHOL, V155, P805, DOI 10.1016/S0002-9440(10)65179-6
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479
   Yayoi Y, 2001, ARCH HISTOL CYTOL, V64, P89, DOI 10.1679/aohc.64.89
   Zissel G, 2000, J INVEST MED, V48, P66
NR 44
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD MAY 15
PY 2004
VL 425
IS 2
BP 147
EP 157
DI 10.1016/j.abb.2004.02.042
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 818LU
UT WOS:000221247400003
PM 15111122
DA 2020-12-16
ER

PT J
AU De Arruda, LB
   Chikhlikar, PR
   August, JT
   Marques, ETA
AF De Arruda, LB
   Chikhlikar, PR
   August, JT
   Marques, ETA
TI DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the
   major histocompatibility complex II compartment by lysosomal-associated
   membrane protein, elicits enhanced long-term memory response
SO IMMUNOLOGY
LA English
DT Article
DE vaccines : DNA LAMP/Gag, prime/boost immunizations; immunological
   memory; T-cell memory; MHC II : trafficking
ID MHC CLASS-II; T-CELL RESPONSES; CHIMERIC GENE-PRODUCT; DENDRITIC CELLS;
   EXOGENOUS ANTIGENS; CROSS-PRESENTATION; PROCESSING PATHWAYS; CD8-T-CELL
   MEMORY; TYPE-1 INFECTION; IMMUNE-RESPONSES
AB Antigen presentation by major histocompatibility complex type II (MHC II) molecules and activation of CD4(+) helper T cells are critical for the generation of immunological memory. We previously described a DNA vaccine encoding human immunodeficiency virus-1 p55Gag as a chimera with the lysosome-associated membrane protein (LAMP/gag). The LAMP/gag chimera protein traffics to the MHC II compartment of transfected cells and elicits enhanced immune responses as compared to a DNA vaccine encoding native gag not targeted to the MHC II compartment. We have now investigated the long-term responses of immunized mice and show that the LAMP/gag DNA vaccine promotes long-lasting B cell- and CD4(+) and CD8(+) T-cell memory responses and elicits a potent Gag-specific CD8(+) recall response to challenge with vaccinia virus encoding gag, even II months after immunization. In contrast, the immune responses induced by DNA encoding non-targeted Gag decay rapidly and elicit very low or undetectable levels of Gag-specific CD4(+) and CD8(+) memory cells. A single priming immunization with LAMP/ gag DNA is sufficient to generate T-cell memory. Following this initial priming immunization with LAMP/gag DNA, booster immunizations with native gag DNA or the LAMP/gag chimera are equally efficient in eliciting B- and T-cell secondary responses, results in accordance with observations that secondary expansion of CD8(+) cells in the boost phase does not require additional CD4(+) help. These findings underscore the significance of targeting DNA-encoded vaccine antigens to the MHC II processing compartments for induction of long-term immunological memory.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM emarques@jhmi.edu
RI Arruda, Luciana/B-5806-2014; Marques, Ernesto/L-4514-2013; Arruda,
   Luciana B/N-9086-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI041908, R21AI044317, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R21AI044317, R37AI041908,
   R37AI041908, R37AI041908] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37 AI041908, R37-AI41908, R21 AI44317]
   Funding Source: Medline
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Bradley LM, 2003, TRENDS MOL MED, V9, P186, DOI 10.1016/S1471-4914(03)00053-4
   Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2
   Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   Delamarre L, 2003, J EXP MED, V198, P111, DOI 10.1084/jem.20021542
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47
   Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512
   Heath WR, 1999, CURR OPIN IMMUNOL, V11, P314, DOI 10.1016/S0952-7915(99)80050-8
   Iwasaki A, 1997, J IMMUNOL, V159, P11
   Jaleco S, 2003, J IMMUNOL, V171, P61, DOI 10.4049/jimmunol.171.1.61
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Langlade-Demoyen P, 2003, EUR J IMMUNOL, V33, P720, DOI 10.1002/eji.200323287
   Lin F-H, 1996, DISCRETE CONTINUOUS, V2, P1, DOI DOI 10.3934/DCDS.1996.2.1
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mata M, 1998, J IMMUNOL, V161, P2985
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141
   Oehen S, 2000, IMMUNOLOGY, V99, P163, DOI 10.1046/j.1365-2567.2000.00950.x
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Rowland-Jones S, 1999, J INFECTION, V38, P67, DOI 10.1016/S0163-4453(99)90070-1
   Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Rush C, 2002, J IMMUNOL, V169, P4951, DOI 10.4049/jimmunol.169.9.4951
   Schirmbeck R, 2002, MOL IMMUNOL, V39, P249, DOI 10.1016/S0161-5890(02)00105-0
   Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Su Z, 2002, CANCER RES, V62, P5041
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J
   Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061
   Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045
NR 62
TC 47
Z9 47
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD MAY
PY 2004
VL 112
IS 1
BP 126
EP 135
DI 10.1111/j.1365-2567.2004.01823.x
PG 10
WC Immunology
SC Immunology
GA 813CW
UT WOS:000220886200015
PM 15129672
OA Green Published, Bronze
DA 2020-12-16
ER

PT B
AU Arruda, LB
   Sim, D
   Maciel, M
   Chikhlikar, P
   August, JT
   Marques, ETA
AF Arruda, LB
   Sim, D
   Maciel, M
   Chikhlikar, P
   August, JT
   Marques, ETA
GP MEDIMOND
TI Different HIV-Gag cellular trafficking mediated by LAMP/gag and
   DC-LAMP/gag DNA chimeras influences the repertoire of activated T and B
   cells
SO IMMUNOLOGY 2004: IMMUNODEFICIENCY, INFECTIOUS DISEASES,
   IMMUNOMODULATION, AND VACCINES
LA English
DT Proceedings Paper
CT 12th Annual International Congress of Immunology/4th Annual Conference
   of the Federation-of-Clinical-Immunology-Societies (FOCIS)
CY JUL 18-23, 2004
CL Montreal, CANADA
SP Federat Clin Immunol Soc
ID INFECTION; RESPONSES; VIRUS; ESCAPE; CD4(+); LYMPHOCYTES; VACCINATION;
   ANTIGEN; VIREMIA
AB In this study, we evaluated the processing pathways, and the repertoire of T- and B- cell epitopes elicited after immunization with HIV-1 p55Gag antigen synthesized, as a DNA vaccine chimera, with lysosomal associated membrane protein-1 (LAMP- 1) or dendritic cell-LAMP (DC-LAMP). We observed that while native Gag localized in the cytoplasm, LAMP/Gag and DC-LAMP/Gag chimeras traffic through the endolysosomal compartments and colocalized with MHC II, but they differ in their overall intracellular trafficking. ELISPOT analysis of T cell specific response showed that immunization with each construct induced a different pattern of epitopes eliciting IFN-gamma response. Moreover, immunization with LAMP chimeras induced antibody secretion to a higher number of peptides than immunization with native gag. These data suggest that differential cellular trafficking of Gag protein can change and amplify the repertoire of responding T and B cells, which can be an important strategy for HIV vaccine design.
C1 Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RP Arruda, LB (corresponding author), Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RI Arruda, Luciana B/N-9086-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897
   Caulfield MJ, 2002, J VIROL, V76, P10038, DOI 10.1128/JVI.76.19.10038-10043.2002
   Gloster SE, 2004, AIDS, V18, P749, DOI 10.1097/00002030-200403260-00005
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Rush C, 2002, J IMMUNOL, V169, P4951, DOI 10.4049/jimmunol.169.9.4951
   Schirmbeck R, 2002, MOL IMMUNOL, V39, P249, DOI 10.1016/S0161-5890(02)00105-0
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
NR 13
TC 0
Z9 0
U1 0
U2 0
PU MEDIMOND PUBLISHING CO
PI BOLOGNA
PA VIA RUBBIANI 6/2, 40124 BOLOGNA, ITALY
BN 88-7587-075-6
PY 2004
BP 165
EP 169
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA BBQ60
UT WOS:000227165600030
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Chikhlikar, P
   de Arruda, LB
   Leao, IC
   Lu, Y
   Wong, J
   Chen, JS
   Byrne, B
   August, JT
AF Marques, ETA
   Chikhlikar, P
   de Arruda, LB
   Leao, IC
   Lu, Y
   Wong, J
   Chen, JS
   Byrne, B
   August, JT
TI HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a
   DNA plasmid vaccine chimera is highly expressed, traffics to the major
   histocompatibility class II compartment, and elicits enhanced immune
   responses
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MHC CLASS-II; T-LYMPHOCYTE RESPONSES; VIRUS TYPE-1 GAG; DENDRITIC CELLS;
   ANTIGEN PRESENTATION; ENDOCYTIC COMPARTMENTS; LONGITUDINAL ANALYSIS;
   GENE-PRODUCT; CD4(+); IMMUNIZATION
AB Several genetic vaccines encoding antigen chimeras containing the lysosome-associated membrane protein ( LAMP) translocon, transmembrane, and cytoplasmic domain sequences have elicited strong mouse antigen-specific immune responses. The increased immune response is attributed to trafficking of the antigen chimera to the major histocompatibility class II (MHC II) compartment where LAMP is colocalized with MHC II. In this report, we describe a new form of an HIV-1 p55gag DNA vaccine, with the gag sequence incorporated into the complete LAMP cDNA sequence. Gag encoded with the translocon, transmembrane and cytoplasmic lysosomal membrane targeting sequences of LAMP, without the luminal domain, was poorly expressed, did not traffic to lysosomes or MHC II compartments of transfected cells, and elicited a limited immune response from DNA immunized mice. In contrast, addition of the LAMP luminal domain sequence to the construct resulted in a high level of expression of the LAMP/ Gag protein chimera in transfected cells that was further increased by including the inverted terminal repeat sequences of the adeno-associated virus to the plasmid vector. This LAMP/ Gag chimera with the complete LAMP protein colocalized with endogenous MHC II of transfected cells and elicited strong cellular and humoral immune responses of immunized mice as compared with the response to DNA-encoding native Gag, with a 10-fold increase in CD4(+) responses, a 4- to 5-fold increase in CD8(+) T-cell responses, and antibody titers of > 100,000. These results reveal novel roles of the LAMP luminal domain as a determinant of Gag protein expression, lysosomal trafficking, and possibly of the immune response to Gag.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St,Biophys Rm 309, Baltimore, MD 21205 USA.
RI Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana/B-5806-2014; Marques,
   Ernesto/L-4514-2013; Arruda, Luciana B/N-9086-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R21AI044317, R37AI041908,
   R37AI041908, R21AI044317] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21-AI44317, R37-AI41908] Funding Source:
   Medline
CR Agarraberes FA, 2001, J CELL SCI, V114, P2491
   Akbari O, 1999, J EXP MED, V189, P169, DOI 10.1084/jem.189.1.169
   Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110
   ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419
   Bear J, 1999, MOL CELL BIOL, V19, P6306
   Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998
   Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997
   Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113
   Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122
   de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9
   Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001
   Drake JR, 1999, J IMMUNOL, V162, P1150
   DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5
   DUBEY C, 1995, J IMMUNOL, V155, P45
   Durali D, 1998, J VIROL, V72, P3547, DOI 10.1128/JVI.72.5.3547-3553.1998
   Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121
   Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001
   HUGHES EN, 1981, J BIOL CHEM, V256, P664
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Ji HX, 1999, HUM GENE THER, V10, P2727, DOI 10.1089/10430349950016474
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Lem L, 1999, J IMMUNOL, V162, P523
   LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839
   Lin KY, 1996, CANCER RES, V56, P21
   LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593
   LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991
   MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3
   Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   MORENO J, 1991, J IMMUNOL, V147, P3306
   MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994
   Norris PJ, 2001, J VIROL, V75, P9771, DOI 10.1128/JVI.75.20.9771-9779.2001
   Obermuller S, 2002, J CELL SCI, V115, P185
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Pontesilli O, 1998, J INFECT DIS, V178, P1008, DOI 10.1086/515659
   Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075
   Prasad DVR, 2002, J IMMUNOL, V169, P1801, DOI 10.4049/jimmunol.169.4.1801
   Qiu JT, 2000, J VIROL, V74, P5997, DOI 10.1128/JVI.74.13.5997-6005.2000
   Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519
   REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F
   Robinson JH, 2002, IMMUNOLOGY, V105, P252, DOI 10.1046/j.0019-2805.2001.01358.x
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   Su Z, 2002, CANCER RES, V62, P5041
   Thery C, 2001, CURR OPIN IMMUNOL, V13, P45, DOI 10.1016/S0952-7915(00)00180-1
   Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000
NR 79
TC 63
Z9 63
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 26
PY 2003
VL 278
IS 39
BP 37926
EP 37936
DI 10.1074/jbc.M303336200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 723MY
UT WOS:000185437200115
PM 12824194
OA Bronze
DA 2020-12-16
ER

PT J
AU Lu, Y
   Raviprakash, K
   Leao, IC
   Chikhlikar, PR
   Ewing, D
   Anwar, A
   Chougnet, C
   Murphy, G
   Hayes, CG
   August, TJ
   Marques, ETA
AF Lu, Y
   Raviprakash, K
   Leao, IC
   Chikhlikar, PR
   Ewing, D
   Anwar, A
   Chougnet, C
   Murphy, G
   Hayes, CG
   August, TJ
   Marques, ETA
TI Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment
   elicits long-lasting neutralizing antibodies
SO VACCINE
LA English
DT Article
DE flavivirus; T-helper cells; humoral response
ID CYTOTOXIC T-LYMPHOCYTES; DNA VACCINATION; DENDRITIC CELLS; ANTIGEN
   PRESENTATION; ENVELOPE PROTEIN; RESTRICTED PRESENTATION;
   MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; IMMUNE-RESPONSES;
   PLASMA-MEMBRANE
AB A dengue 2 plasmid DNA vaccine (pD2) expressing the pre-membrane and envelope proteins (preM-E) was modified by replacing the dengue transmembrane and cytoplasmic sequences with those of the mouse lysosome-associated membrane protein (pD2/LAMP). Immunofluorescence and confocal microscopy of human 293, NIH 3T3, and macrophage IC21 cell lines transfected with pD2/LAMP showed that the preM-E/LAMP protein chimera was present in vesicles containing endogenous LAMP and major histocompatability complex class II (MHC II), in contrast to the non-vesicular localization of native preM-E protein lacking the LAMP targeting sequence. Mice immunized with pD2 showed an antigen-specific immunoglobulin response but the neutralizing antibodies titers (plaque reduction neutralization test, PRNT50) elicited by the native protein were minimal. In contrast, vaccination with pD2/LAMP resulted in PRNT50 Of 270, 320 and 160 at approximately 1, 3 and 8 months after two immunizations with 50 mug DNA, and approached 100% neutralization at 1:20 dilution. Additional immunization with pD2/LAMP, after 8 months, increased the neutralizing antibody titers to >640. Comparable neutralizing antibody responses were induced by two vector backbones, pVR1012 and pVax-1, at 5 and 50 mug of DNA. The neutralizing responses to the pD2/LAMP chimera were greatly superior to those elicited by pD2 in all conditions. These results underscore the importance of MHC class II presentation of DNA-encoded dengue-virus envelope protein for production of neutralizing antibodies. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   USN, Med Res Ctr, Virol Program, Infect Dis Directorate, Silver Spring, MD USA.
   Johns Hopkins Singapore Biomed Ctr, Singapore 117610, Singapore.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM emarques@jhmi.edu
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [5 R03 AI44842-03] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R03AI044842, R03AI044842, R03AI044842] Funding Source: NIH RePORTER
CR ADORINI L, 1991, J EXP MED, V174, P945, DOI 10.1084/jem.174.4.945
   Akbari O, 1999, J EXP MED, V189, P169, DOI 10.1084/jem.189.1.169
   ANSARI MZ, 1993, J CLIN LAB ANAL, V7, P230, DOI 10.1002/jcla.1860070408
   BARRETT AD, 1997, J VIROL, V71, P2921
   CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2
   CHAMBERS TJ, 1997, CLIN EXP IMMUNOL, V110, P35
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1
   CHEN JW, 1986, BIOCHEM SOC SYMP, P97
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Corr M, 1999, J IMMUNOL, V163, P4721
   DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535
   Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373
   Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578
   Donnelly JJ, 2000, AM J RESP CRIT CARE, V162, pS190, DOI 10.1164/ajrccm.162.supplement_3.15tac10
   Fu TM, 1997, MOL MED, V3, P362, DOI 10.1007/BF03401683
   GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Gubler D, 1997, DENGUE DENGUE HEMORR
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Harding CV, 1993, CURR OPIN CELL BIOL, V5, P596, DOI 10.1016/0955-0674(93)90128-D
   HARDING CV, 1993, J IMMUNOL, V151, P3988
   HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830
   HUGHES EN, 1981, J BIOL CHEM, V256, P664
   Jacobs M, 2000, T ROY SOC TROP MED H, V94, P7, DOI 10.1016/S0035-9203(00)90416-4
   Jimenez RO, 2000, VACCINE, V19, P648, DOI 10.1016/S0264-410X(00)00247-4
   Kanesa-thasan N, 2001, VACCINE, V19, P3179, DOI 10.1016/S0264-410X(01)00020-2
   KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715
   Klinman DM, 1998, ANTISENSE NUCLEIC A, V8, P181, DOI 10.1089/oli.1.1998.8.181
   Klinman DM, 1998, J IMMUNOL, V160, P2388
   Konishi E, 2000, VACCINE, V18, P1133, DOI 10.1016/S0264-410X(99)00376-X
   Lin KY, 1996, CANCER RES, V56, P21
   LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5
   LOSS GE, 1993, J EXP MED, V178, P73, DOI 10.1084/jem.178.1.73
   Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4
   McBride WJH, 2000, MICROBES INFECT, V2, P1041, DOI 10.1016/S1286-4579(00)01258-2
   Monath TP, 2002, J VIROL, V76, P1932, DOI 10.1128/JVI.76.4.1932-1943.2002
   MORENO J, 1991, J IMMUNOL, V147, P3306
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2000, J GEN VIROL, V81, P1659, DOI 10.1099/0022-1317-81-7-1659
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0
   REINER SL, 1994, J IMMUNOL METHODS, V173, P133, DOI 10.1016/0022-1759(94)90291-7
   REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
   Vidalin O, 1999, DNA CELL BIOL, V18, P611, DOI 10.1089/104454999315024
   WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T
NR 55
TC 49
Z9 50
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 16
PY 2003
VL 21
IS 17-18
BP 2178
EP 2189
DI 10.1016/S0264-410X(03)00009-4
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 682PF
UT WOS:000183100200047
PM 12706709
DA 2020-12-16
ER

PT J
AU Arruda, LB
   Sim, D
   Chikhlikar, PR
   August, T
   Marques, ETA
AF Arruda, LB
   Sim, D
   Chikhlikar, PR
   August, T
   Marques, ETA
TI Modulation of epitope presentation by differential trafficking to
   antigen processing compartments: Application to HIV vaccine development
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT 90th Annual Meeting of the American-Association-for-Immunologists
CY MAY 06-10, 2003
CL DENVER, COLORADO
SP American Assoc Immunologists
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Singapore Biomed Ctr, Dept Pharmacol & Mol Sci, Singapore, Singapore.
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR 14
PY 2003
VL 17
IS 7
SU S
BP C23
EP C23
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 669TR
UT WOS:000182367000110
DA 2020-12-16
ER

PT J
AU Nascimento, E
   Leao, IC
   Pereira, VRA
   Gomes, YM
   Chikhlikar, P
   August, T
   Marques, E
   Lucena-Silva, N
AF Nascimento, E
   Leao, IC
   Pereira, VRA
   Gomes, YM
   Chikhlikar, P
   August, T
   Marques, E
   Lucena-Silva, N
TI Protective immunity of single and multi-antigen DNA vaccines against
   schistosomiasis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT 8th International Symposium on Schistosomiasis
CY DEC 02-05, 2001
CL RECIFE, BRAZIL
DE naked-DNA; DNA-vaccine; schistosomiasis; Schistosoma; multivalent; SM14;
   IrV5; ECL
ID RECOMBINANT FRAGMENT; VACCINATION; JAPONICUM; MANSONI; SURFACE;
   IMMUNOGENICITY; IMMUNIZATION; INDUCTION; INFECTION; PROTEIN
AB We evaluated the usefulness of the combination of three plasmid, encoding tegumental (pECL and pSM14) and muscular (pIRV5) antigens of the S histosorna mansom oil improving the protective iinniuniti,. over theuse of a single antigen as DNA vaccines. Female BALB/c mice were inoculated twice. with 25 mug DNA; plasmid within two weeks interval. The challenge was performed with 80 cercarias of a regional isolate of S. mansoni (SLM) one week after the last immunization. Six weeks after challenge, all mice were perfused for worm load determination. The following groups were analyzed: saline: empty vector; monovalent formulations of pECL: pSM14 and pIRV5 and also double combinations of pECL/pIRV5 and pIRV5/pSM14 and a triple combination of pECL/pIRV5/pSM14. The protection was expressed as a percentage of worm loads in each group compared with the saline group. The results obtained were 41% (p < 0.05); 52% (p < 0.05); 51% (p < 0.05); 48% (1) < 0.05); 55% p < 0.05); 45% (p < 0.05): 65% (p < 0.05) for each group respectively.
C1 Ctr Pesquisas Aggeu Magalhaes Fiocruz, Dept Imunol, BR-50670420 Recife, PE, Brazil.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Lucena-Silva, N (corresponding author), Ctr Pesquisas Aggeu Magalhaes Fiocruz, Dept Imunol, Av Moraes Rego S-N,Campus UFPE,Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM nlucena@cpqam.fiocruz.br
RI Lucena-Silva, Norma/AAH-9437-2019; Marques, Ernesto T. A/L-4967-2013;
   Marques, Ernesto/L-4514-2013; Nascimento, Eduardo/J-4590-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Nascimento, Eduardo/0000-0002-9851-2332;
   Alves Pereira, Valeria Rego/0000-0002-7995-7360
CR Arichi T, 2000, P NATL ACAD SCI USA, V97, P297, DOI 10.1073/pnas.97.1.297
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   Chlichlia K, 2001, VACCINE, V20, P439, DOI 10.1016/S0264-410X(01)00345-0
   Coulson PS, 1997, ADV PARASIT, V39, P271, DOI 10.1016/S0065-308X(08)60048-2
   Degano P, 1999, VACCINE, V18, P623, DOI 10.1016/S0264-410X(99)00278-9
   El-Garem AA, 1998, DIGESTION, V59, P589, DOI 10.1159/000007534
   Grifantini R, 1998, EUR J IMMUNOL, V28, P1225, DOI 10.1002/(SICI)1521-4141(199804)28:04<1225::AID-IMMU1225>3.0.CO;2-6
   Hota-Mitchell S, 1999, VACCINE, V17, P1338, DOI 10.1016/S0264-410X(98)00391-0
   Johnson PA, 2000, J GEN VIROL, V81, P1737, DOI 10.1099/0022-1317-81-7-1737
   Kalinna BH, 1997, IMMUNOL CELL BIOL, V75, P370, DOI 10.1038/icb.1997.58
   Lodmell DL, 1998, VACCINE, V16, P115, DOI 10.1016/S0264-410X(97)88325-9
   Mohamed MM, 1998, MOL BIOCHEM PARASIT, V96, P15, DOI 10.1016/S0166-6851(98)00088-7
   Morello CS, 2000, J VIROL, V74, P3696, DOI 10.1128/JVI.74.8.3696-3708.2000
   Morris S, 2000, VACCINE, V18, P2155, DOI 10.1016/S0264-410X(99)00540-X
   Raviprakash K, 2000, J GEN VIROL, V81, P1659, DOI 10.1099/0022-1317-81-7-1659
   SAUMA SY, 1991, MOL BIOCHEM PARASIT, V46, P73, DOI 10.1016/0166-6851(91)90200-P
   Schlereth B, 2000, J GEN VIROL, V81, P1321, DOI 10.1099/0022-1317-81-5-1321
   Scott JC, 2000, PARASITOL INT, V49, P289, DOI 10.1016/S1383-5769(00)00058-1
   Sin JI, 2000, CELL IMMUNOL, V203, P19, DOI 10.1006/cimm.2000.1667
   SOISSON LA, 1993, J IMMUNOL, V151, P4782
   SOISSON LA, 1993, EXP PARASITOL, V77, P492, DOI 10.1006/expr.1993.1111
   SOISSON LMA, 1992, J IMMUNOL, V149, P3612
   Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269
   Waine GJ, 1999, PARASITE IMMUNOL, V21, P53, DOI 10.1046/j.1365-3024.1999.00183.x
   Waine GJ, 1997, VACCINE, V15, P846, DOI 10.1016/S0264-410X(96)00258-7
   Waine GJ, 1999, PARASITE IMMUNOL, V21, P377, DOI 10.1046/j.1365-3024.1999.00221.x
   Weissert R, 2000, P NATL ACAD SCI USA, V97, P1689, DOI 10.1073/pnas.030390097
   Wilson RA, 1998, PARASITOL TODAY, V14, P97, DOI 10.1016/S0169-4758(97)01198-8
   Xiang R, 2000, P NATL ACAD SCI USA, V97, P5492, DOI 10.1073/pnas.090097697
   Ximenes Ricardo Arraes de Alencar, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P209
   XU D, 1995, IMMUNOLOGY, V85, P1
   Zhang YB, 2000, VACCINE, V18, P2102, DOI 10.1016/S0264-410X(99)00564-2
NR 32
TC 17
Z9 19
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2002
VL 97
SU 1
BP 105
EP 109
DI 10.1590/S0074-02762002000900021
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 607VH
UT WOS:000178811100021
PM 12426603
OA DOAJ Gold
DA 2020-12-16
ER

PT J
AU Raviprakash, K
   Marques, E
   Ewing, D
   Lu, Y
   Phillips, I
   Porter, KR
   Kochel, TJ
   August, TJ
   Hayes, CG
   Murphy, GS
AF Raviprakash, K
   Marques, E
   Ewing, D
   Lu, Y
   Phillips, I
   Porter, KR
   Kochel, TJ
   August, TJ
   Hayes, CG
   Murphy, GS
TI Synergistic neutralizing antibody response to a dengue virus type 2 DNA
   vaccine by incorporation of lysosome-associated membrane protein
   sequences and use of plasmid expressing GM-CSF
SO VIROLOGY
LA English
DT Article
DE dengue; DNA vaccine; LAMP; GM-CSF; neutralizing antibody; lysosome
   targeting
ID CLASS-II COMPARTMENTS; ENCEPHALITIS-VIRUS; DENDRITIC CELLS; ENVELOPE
   PROTEIN; JAPANESE ENCEPHALITIS; PROTECTIVE IMMUNITY; MICE; ANTIGEN;
   IMMUNIZATION; GENE
AB We have previously shown that a dengue virus type 1 DNA vaccine expressing premembrane (prM) and envelope (E) genes was immunogenic in mice and monkeys and that rhesus monkeys vaccinated with this construct were completely to partially protected from virus challenge. In order to improve the immunogenicity of dengue DNA vaccines, we have evaluated the effect of lysosome targeting of antigens and communization with a plasmid expressing GM-CSF on antibody responses. A dengue virus type 2 candidate vaccine containing prM and E genes was constructed in which the transmembrane and cytoplasmic regions of E were replaced by those of the lysosome-associated membrane protein (LAMP). The modified vaccine construct expressed antigen that was colocalized with endogenous LAMP in lysosomal vesicles of transfected cells, whereas the antigen expressed from the unmodified construct was not. It was hypothesized that targeting of antigen to the lysosomal compartment will increase antigen presentation by MHC class II, leading to stronger CD4-mediated immune responses. Mice immunized with the modified construct responded with significantly higher levels of virus neutralizing antibodies compared to those immunized with the unmodified construct. Communization of mice with a plasmid expressing murine GM-CSF enhanced the antibody response obtained with either the unmodified or the modified construct alone. The highest antibody responses were noted when the modified construct was coinjected with plasmid expressing the GM-CSF gene. These results could form the basis for an effective tetravalent dengue virus DNA vaccine. (C) 2001 Academic Press.
C1 USN, Med Res Ctr, Virol Program, Infect Dis Directorate, Silver Spring, MD 20910 USA.
   Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA.
   Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
RP Raviprakash, K (corresponding author), USN, Med Res Ctr, Virol Program, Infect Dis Directorate, 503 Robert Grant Ave,Room 3N71, Silver Spring, MD 20910 USA.
RI Porter, Kevin/A-8027-2011; Marques, Ernesto T. A/L-4967-2013; Marques,
   Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
CR ANSARI MZ, 1993, J CLIN LAB ANAL, V7, P230, DOI 10.1002/jcla.1860070408
   Barrett ADT, 1997, BIOLOGICALS, V25, P27, DOI 10.1006/biol.1997.0057
   Barrett ADT, 1997, BIOLOGICALS, V25, P17, DOI 10.1006/biol.1997.0056
   Colombage G, 1998, VIROLOGY, V250, P151, DOI 10.1006/viro.1998.9357
   DEUBEL V, 1988, J GEN VIROL, V69, P1921, DOI 10.1099/0022-1317-69-8-1921
   Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000
   ECKELS KH, 1994, AM J TROP MED HYG, V50, P472, DOI 10.4269/ajtmh.1994.50.472
   EDELMAN R, 1994, J INFECT DIS, V170, P1448, DOI 10.1093/infdis/170.6.1448
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383
   Haddad D, 2000, J IMMUNOL, V165, P3772, DOI 10.4049/jimmunol.165.7.3772
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HARDING CV, 1993, J IMMUNOL, V151, P3988
   Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205
   HORN NA, 1995, HUM GENE THER, V6, P566
   IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7
   Kim JJ, 1998, EUR J IMMUNOL, V28, P1089, DOI 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L
   KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Kochel T, 1997, VACCINE, V15, P547, DOI 10.1016/S0264-410X(97)00215-6
   Kochel TJ, 2000, VACCINE, V18, P3166, DOI 10.1016/S0264-410X(00)00105-5
   Konishi E, 1998, J VIROL, V72, P4925, DOI 10.1128/JVI.72.6.4925-4930.1998
   Konishi E, 2000, VACCINE, V18, P1133, DOI 10.1016/S0264-410X(99)00376-X
   Lin KY, 1996, CANCER RES, V56, P21
   Maniatis T., 1984, MOL CLONING LAB MANU
   MCKEE KT, 1987, AM J TROP MED HYG, V36, P435, DOI 10.4269/ajtmh.1987.36.435
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Narita M, 1998, CLIN DIAGN LAB IMMUN, V5, P799, DOI 10.1128/CDLI.5.6.799-803.1998
   PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325
   Phillpotts RJ, 1996, ARCH VIROL, V141, P743, DOI 10.1007/BF01718332
   Porter KR, 1998, ARCH VIROL, V143, P997, DOI 10.1007/s007050050348
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2000, J GEN VIROL, V81, P1659, DOI 10.1099/0022-1317-81-7-1659
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Schlesinger R W, 1977, Virol Monogr, P1
   Schmaljohn C, 1997, J VIROL, V71, P9563, DOI 10.1128/JVI.71.12.9563-9569.1997
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8
   Xiang ZQ, 1997, SPRINGER SEMIN IMMUN, V19, P257, DOI 10.1007/BF00870273
NR 42
TC 64
Z9 66
U1 0
U2 1
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD NOV 10
PY 2001
VL 290
IS 1
BP 74
EP 82
DI 10.1006/viro.2001.1136
PG 9
WC Virology
SC Virology
GA 497NY
UT WOS:000172463400008
PM 11883007
DA 2020-12-16
ER

PT J
AU Lu, Y
   Chikhlikar, PR
   Leao, IC
   August, JT
   Marques, ETA
AF Lu, Y
   Chikhlikar, PR
   Leao, IC
   August, JT
   Marques, ETA
TI HIV-1 Gag DNA vaccine chimera with adjuvant properties of a dendritic
   cell C-type multi-lectin receptor (DC-MLR) signaling domain and
   lysosomal-associated membrane protein (LAMP) in an AAV-ITR plasmid
   vector
SO GLYCOBIOLOGY
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0959-6658
J9 GLYCOBIOLOGY
JI Glycobiology
PD OCT
PY 2001
VL 11
IS 10
MA 73
BP 887
EP 887
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 480JG
UT WOS:000171457800080
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Ichikawa, Y
   Strand, M
   August, JT
   Hart, GW
   Schnaar, RL
AF Marques, ETA
   Ichikawa, Y
   Strand, M
   August, JT
   Hart, GW
   Schnaar, RL
TI Fucosyltransferases in Schistosoma mansoni development
SO GLYCOBIOLOGY
LA English
DT Article
DE FACE; fucose; glycosyltransferase; iminosugar; Schistosome; trematode
ID POLYACRYLAMIDE-GEL ELECTROPHORESIS; CARBOHYDRATE EPITOPES;
   FUCOSYL-TRANSFERASE; GRANULOMA-FORMATION; L-SELECTIN; IDENTIFICATION;
   EGGS; ANTIGENS; ALPHA-3-FUCOSYL-TRANSFERASE; GLYCOPROTEINS
AB Glycoconjugate-bound fucose, abundant in the parasite Schistosoma mansoni, has been found in the form of Fuc alpha1,3GlcNAc, Fuc alpha1,2Fuc, Fuc alpha1,6GlcNAc, and perhaps Fuc alpha1,4GlcNAc linkages. Here we quantify fucosyltransferase activities in three developmental stages of S. mansoni. Assays were performed using fluorophore-assisted carbohydrate electrophoresis with detection of radioactive fucose incorporation from GDP-[C-14]-fucose into structurally defined accepters. The total fucosyltransferase-specific activity in egg extracts was 50-fold higher than that in the other life stages tested (cercaria and adult worms). A fucosyltransferase was detected that transferred fucose to type-2 oligosaccharides (Gal beta1,4GlcNAc-R), both sialylated (with the sialic acid attached to the terminal Gal by alpha2,3 or 2,6 linkage) and nonsialylated. Another fucosyltransferase was identified that transferred fucose to lactose-based and type-2 fucosylated oligosaccharides, such as LNFIII (Gal beta1,4(Fuc alpha1,3)GlcNAc beta1,3Gal beta1,4Glc). A low level of fucosyltransferase that transfers fucose to no-sialylated type-1 oligosaccharides (Gal beta1,3GlcNAc-R) was also detected. These studies revealed multifucosylated products of the reactions. In addition, the effects of fucose-type iminosugars inhibitors were tested on schistosome fucosyltransferases. A new fucose-type 1-N-iminosugar was four- to sixfold more potent as an inhibitor of schistosome fucosyltransferases in vitro than was deoxyfuconojirimycin. In vivo, this novel 1-iminosugar blocked the expression of a fucosylated epitope (mAb 128C3/3 antigen) that is associated with the pathogenesis of schistosomiasis.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.
RI Marques, Ernesto/L-4514-2013; Schnaar, Ronald/S-8967-2016
OI Marques, Ernesto/0000-0003-3826-9358; Schnaar,
   Ronald/0000-0002-7701-5484; Hart, Gerald/0000-0001-7812-4351
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37 AI19217] Funding Source: Medline; NIGMS
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM 52324] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI019217, R37AI019217, R37AI019217, R37AI019217, R37AI019217,
   R37AI019217, R37AI019217, R37AI019217, R37AI019217, R37AI019217,
   R37AI019217] Funding Source: NIH RePORTER
CR ARONSTEIN WS, 1985, AM J TROP MED HYG, V34, P879, DOI 10.4269/ajtmh.1985.34.879
   Cummings RD, 1999, BBA-MOL BASIS DIS, V1455, P363, DOI 10.1016/S0925-4439(99)00063-0
   Cummings RD, 1996, FASEB J, V10, P838
   DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001
   DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447
   ElRidi R, 1996, INFECT IMMUN, V64, P4700, DOI 10.1128/IAI.64.11.4700-4705.1996
   HAWN TR, 1994, J BIOL CHEM, V269, P20083
   Hokke CH, 1998, GLYCOBIOLOGY, V8, P393, DOI 10.1093/glycob/8.4.393
   Ichikawa Y, 1998, J AM CHEM SOC, V120, P3007, DOI 10.1021/ja973443k
   JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705
   Jackson P, 1996, MOL BIOTECHNOL, V5, P101, DOI 10.1007/BF02789060
   Khoo KH, 1997, GLYCOBIOLOGY, V7, P653, DOI 10.1093/glycob/7.5.653
   KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995
   Lejoly-Boisseau H, 1999, EXP PARASITOL, V91, P20, DOI 10.1006/expr.1999.4348
   LeMarer N, 1997, GLYCOBIOLOGY, V7, P357
   LEVERY SB, 1992, J BIOL CHEM, V267, P5542
   LEWIS FA, 1977, J PARASITOL, V63, P413, DOI 10.2307/3279989
   LEWIS FA, 1977, AM J TROP MED HYG, V26, P723, DOI 10.4269/ajtmh.1977.26.723
   Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3
   MANSOUR MH, 1995, MOL BIOCHEM PARASIT, V69, P173, DOI 10.1016/0166-6851(94)00188-S
   Mansour MH, 1996, J PARASITOL, V82, P586, DOI 10.2307/3283782
   Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4
   NORDEN AP, 1985, AM J TROP MED HYG, V34, P495, DOI 10.4269/ajtmh.1985.34.495
   Okano M, 1999, J IMMUNOL, V163, P6712
   PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205
   Qiao L, 1996, J AM CHEM SOC, V118, P7653, DOI 10.1021/ja960274f
   Trottein F, 2000, MOL BIOCHEM PARASIT, V107, P279, DOI 10.1016/S0166-6851(00)00213-9
   Velupillai P, 2000, HUM IMMUNOL, V61, P225, DOI 10.1016/S0198-8859(99)00136-6
   WEISS JB, 1986, J IMMUNOL, V136, P4275
   WEISS JB, 1985, J IMMUNOL, V135, P1421
   WEISS JB, 1987, EXP PARASITOL, V64, P228, DOI 10.1016/0014-4894(87)90147-0
NR 31
TC 23
Z9 24
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0959-6658
J9 GLYCOBIOLOGY
JI Glycobiology
PD MAR
PY 2001
VL 11
IS 3
BP 249
EP 259
DI 10.1093/glycob/11.3.249
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 429DR
UT WOS:000168501200010
PM 11320063
OA Bronze
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Weiss, JB
   Strand, M
   Ichikawa, Y
   Hart, GW
   Schnaar, RL
AF Marques, ETA
   Weiss, JB
   Strand, M
   Ichikawa, Y
   Hart, GW
   Schnaar, RL
TI Molecular characterization of a fucosyltransferase type VII encoded by
   Schistosoma mansoni.
SO GLYCOBIOLOGY
LA English
DT Meeting Abstract
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21218 USA.
RI Marques, Ernesto/L-4514-2013; Schnaar, Ronald L/S-8967-2016; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Schnaar, Ronald
   L/0000-0002-7701-5484; Marques, Ernesto T. A/0000-0003-3826-9358; Hart,
   Gerald/0000-0001-7812-4351
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0959-6658
J9 GLYCOBIOLOGY
JI Glycobiology
PD NOV
PY 1998
VL 8
IS 11
MA 17
BP 1109
EP 1109
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 130CC
UT WOS:000076505300024
DA 2020-12-16
ER

PT J
AU Marques, ETA
   Weiss, JB
   Strand, M
AF Marques, ETA
   Weiss, JB
   Strand, M
TI Molecular characterization of a fucosyltransferase encoded by
   Schistosoma mansoni
SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY
LA English
DT Article
DE Schistosoma mansoni; glycobiology; fucosyltransferase; sialyl-Lewis(x);
   fucose
ID SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE;
   GRANULOMA-FORMATION; L-SELECTIN; CARBOHYDRATE DETERMINANTS;
   FUCOSYL-TRANSFERASE; REPEATING UNIT; MYELOID CELLS; NUCLEIC-ACIDS;
   FUC-TVII
AB The glycans of schistosomes include many complex carbohydrates that contain fucose. Although the biological functions of these complex carbohydrates are not yet clearly understood, some of these structures are thought to play essential roles in the life cycle of the parasite. Here we present the molecular cloning and characterization of a fucosyltransferase of Schistosoma mansoni with a DNA sequence similarity of 84.6 and 63.7% to mouse and human fucosyltransferase type VII. Southern blot analysis of genomic DNA indicated that this S. mansoni fucosyltransferase is the product of a single gene. The schistosome cDNA sequence that we obtained contains an open reading frame encoding a protein of 351 amino acids with a predicted molecular size of 40.5 kDa. From the amino acid sequence, we predicted two potential N-linked and one O-linked glycosylation site. Western blot studies of extracts from stably transfected CHO cells showed a band corresponding to the schistosome fucosyltransferase at 50 kDa, suggesting that the enzyme is indeed glycosylated. We further demonstrated the expression and enzymatic activity of the fucosyltransferase in the transfected cells by immunofluorescence studies and flow microfluorimetric analysis, which indicated that the enzyme is capable of synthesizing the SLe(X) blood group determinant but not the Le(X) determinant in CHO cells. The identification of a fucosyltransferase type VII in schistosomes further underscores the importance of fucose-containing glycans in schistosome glycobiology. (C) 1998 Published by Elsevier Science B.V. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Ctr Monoclonal Studies, Baltimore, MD 21205 USA.
   Roche Mol Syst Inc, Alameda, CA 94501 USA.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Ctr Monoclonal Studies, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM emarques@welchlink.welch.jhu.edu
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
CR AN SF, 1992, MOL CELL PROBE, V6, P193, DOI 10.1016/0890-8508(92)90016-Q
   Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317
   Cummings RD, 1996, FASEB J, V10, P838
   DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001
   ElRidi R, 1996, INFECT IMMUN, V64, P4700, DOI 10.1128/IAI.64.11.4700-4705.1996
   GOELZ S, 1994, J BIOL CHEM, V269, P1033
   GRZYCH JM, 1987, J EXP MED, V165, P865, DOI 10.1084/jem.165.3.865
   GUO MML, 1993, J IMMUNOL, V151, P2225
   HARN DA, 1984, J EXP MED, V159, P1371, DOI 10.1084/jem.159.5.1371
   HAWN TR, 1993, J BIOL CHEM, V268, P7692
   HAWN TR, 1994, J BIOL CHEM, V269, P20083
   HOLTKE HJ, 1992, BIOTECHNIQUES, V12, P104
   HOLTKE HJ, 1990, BIOL CHEM H-S, V371, P929
   KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114
   KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159
   KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995
   KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2
   KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288
   LeMarer N, 1997, GLYCOBIOLOGY, V7, P357
   LEVERY SB, 1992, J BIOL CHEM, V267, P5542
   Lowe J B, 1991, Semin Cell Biol, V2, P289
   LOWE JB, 1991, J BIOL CHEM, V266, P17467
   Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3
   MASTELLER EL, 1995, DEVELOPMENT, V121, P1657
   MASTELLER EL, 1995, J IMMUNOL, V155, P5550
   MCDIARMID SS, 1984, MOL BIOCHEM PARASIT, V10, P33, DOI 10.1016/0166-6851(84)90016-1
   NATSUKA S, 1994, J BIOL CHEM, V269, P16789
   NATSUKA S, 1994, J BIOL CHEM, V269, P20806
   NORDEN AP, 1985, AM J TROP MED HYG, V34, P495, DOI 10.4269/ajtmh.1985.34.495
   Nyame AK, 1996, EXP PARASITOL, V82, P191, DOI 10.1006/expr.1996.0024
   NYAME K, 1988, J PARASITOL, V74, P562, DOI 10.2307/3282171
   OMERALI P, 1988, J IMMUNOL, V140, P258
   Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764
   Richter D, 1996, INFECT IMMUN, V64, P1826, DOI 10.1128/IAI.64.5.1826-1831.1996
   ROBERTSON NP, 1985, COMP BIOCHEM PHYS B, V82, P299, DOI 10.1016/0305-0491(85)90245-7
   Sambrook J, 1989, MOL CLONING LAB MANU
   SASAKI K, 1994, J BIOL CHEM, V269, P14730
   SIMPSON AJG, 1980, PARASITOLOGY, V81, P1, DOI 10.1017/S0031182000054986
   SIMPSON AJG, 1983, MOL BIOCHEM PARASIT, V8, P191, DOI 10.1016/0166-6851(83)90009-9
   Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250
   SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196
   Trottein F, 1997, J IMMUNOL, V159, P804
   VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467, DOI 10.1111/j.1432-1033.1994.00467.x
   WATKINS WM, 1995, ADV EXP MED BIOL, V376, P83
   WEISS JB, 1986, J IMMUNOL, V136, P4275
   WEISS JB, 1985, J IMMUNOL, V135, P1421
   WEISS JB, 1987, EXP PARASITOL, V64, P228, DOI 10.1016/0014-4894(87)90147-0
   WESTON BW, 1992, J BIOL CHEM, V267, P4152
   WESTON BW, 1992, J BIOL CHEM, V267, P24575
   WYNN TA, 1993, J IMMUNOL, V151, P1430
   WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551
NR 51
TC 18
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-6851
EI 1872-9428
J9 MOL BIOCHEM PARASIT
JI Mol. Biochem. Parasitol.
PD JUN 1
PY 1998
VL 93
IS 2
BP 237
EP 250
DI 10.1016/S0166-6851(98)00033-4
PG 14
WC Biochemistry & Molecular Biology; Parasitology
SC Biochemistry & Molecular Biology; Parasitology
GA ZX664
UT WOS:000074541600007
PM 9662708
DA 2020-12-16
ER

PT J
AU Nadruz, W
   Marques, ETA
   Azevedo, WM
   Lima, JL
   Carvalho, LB
AF Nadruz, W
   Marques, ETA
   Azevedo, WM
   Lima, JL
   Carvalho, LB
TI Immobilization of xanthine oxidase on a polyaniline silicone support
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE immobilization; xanthine oxidase; polyaniline
ID HYPOXANTHINE; GLUCOSE
AB A polyaniline silicone support to immobilize xanthine oxidase is proposed as a reactor coil to monitor the action of xanthine oxidase on hypoxanthine, xanthine and 6-mercaptopurine. A purified xanthine oxidase immobilized on this support lost 80% of the initial activity after 12 min of use. Co-immobilization of superoxide dismutase and catalase increased the stability of immobilized xanthine oxidase so that the derivative maintained 79% of its initial activity after 4.6 h of continuous use in which 1.5 mu mol purine bases were converted by the immobilized enzyme system. There is no evidence of either polyaniline or protein leaching from the coil during 3 h of continuous use. When solutions (10 ml) of hypoxanthine, xanthine and 6-mercaptopurine were circulated individually through the xanthine oxidase-superoxide dismutase-catalase-polyaniline coil (1 mm internal diameter and 3 m in length, 3 ml internal volume) activities of 8.12, 11.17 and 1.09 nmol min(-1) coil(-1), respectively, were obtained. The advantages of the reactor configuration and the redox properties of the polymer, particularly with respect to immobilized oxidoreductases, make this methodology attractive for similar enzyme systems. This immobilized enzyme system using polyaniline-silicone as support converted 6-mercaptopurine to 6-thiouric acid with equal efficiency as resins based on polyacrylamide and polyamide 11.
C1 UNIV FED PERNAMBUCO,LAB IMUNOPATOL KEIZO ASAMI,BR-50670 RECIFE,PE,BRAZIL.
   UNIV FED PERNAMBUCO,DEPT BIOQUIM,BR-50670 RECIFE,PE,BRAZIL.
   UNIV FED PERNAMBUCO,DEPT QUIM FUNDAMENTAL,BR-50670420 RECIFE,PE,BRAZIL.
RI Filho, Jose Luiz Lima/M-8076-2019; Marques, Ernesto T. A/L-4967-2013;
   Junior, Wilson Nadruz/I-3643-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Junior, Wilson
   Nadruz/0000-0002-0003-5102; Marques, Ernesto/0000-0003-3826-9358; mendes
   de azevedo, Walter/0000-0001-6110-5728
CR BARBOSA RMN, 1995, BRAZ J MED BIOL RES, V28, P291
   BERGMANN F, 1960, J AM CHEM SOC, V82, P3957, DOI 10.1021/ja01500a041
   CARVALHO LB, 1988, APPL BIOCHEM BIOTECH, V19, P21, DOI 10.1007/BF02921462
   CARVALHO LB, 1981, ARQUIVOS BIOL TECNOL, V24, P203
   JORGENSEN S, 1974, METHOD ENZYMAT AN, V2, P1941
   KITO M, 1990, J CHROMATOGR-BIOMED, V528, P91, DOI 10.1016/S0378-4347(00)82365-8
   KULYS JJ, 1983, ANAL CHIM ACTA, V148, P13, DOI 10.1016/S0003-2670(00)85147-8
   LEITE V, 1994, BIOTECHNOL TECH, V8, P133, DOI 10.1007/BF00152854
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   PARENTE AH, 1992, APPL BIOCHEM BIOTECH, V37, P267, DOI 10.1007/BF02788878
   RUSSEL AD, 1976, PROGR MED CHEM, V13, P121
   TRAMPER J, 1987, METHOD ENZYMOL, V136, P254, DOI 10.1016/S0076-6879(87)36026-4
   TRAMPER J, 1978, BIOTECHNOL BIOENG, V20, P1507, DOI 10.1002/bit.260201002
   WATANABE E, 1984, APPL MICROBIOL BIOT, V19, P18
NR 14
TC 14
Z9 14
U1 1
U2 3
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAR
PY 1996
VL 29
IS 3
BP 347
EP 350
PG 4
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA UB239
UT WOS:A1996UB23900007
PM 8736128
DA 2020-12-16
ER

PT J
AU MARQUES, IDHC
   MARQUES, ETA
   SILVA, AC
   LEDINGHAM, WM
   MELO, EHM
   DASILVA, VL
   LIMA, JL
AF MARQUES, IDHC
   MARQUES, ETA
   SILVA, AC
   LEDINGHAM, WM
   MELO, EHM
   DASILVA, VL
   LIMA, JL
TI ASCORBIC-ACID DETERMINATION IN BIOLOGICAL-FLUIDS USING ASCORBATE OXIDASE
   IMMOBILIZED ON ALKYLAMINE GLASS-BEADS IN A FLOW-INJECTION POTENTIOMETRIC
   SYSTEM
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE FLOW INJECTION ANALYSIS (FIA); ASCORBIC ACID; OXYGEN ELECTRODE; GLASS
   BEADS; CUCURBITA MAXIMA
ID CUCUMBER JUICE; SOFT DRINKS; FRUIT
AB A flow injection method was developed aimed at the determination of ascorbic acid in biological fluids, particularly fruit juices. The enzyme ascorbic oxidoreductase (EC 1.10.3.3), extracted from Cucurbita maxima, was immobilized onto alkylamine glass beads using glutaraldehyde as a bifunctional agent. The ascorbic acid concentration was related to oxygen saturation. Fall in oxygen concentration, as a result of ascorbic acid oxidation, was detected by a low cost, homemade oxygen electrode. The calibration graph was linear over the range 0.05 to 3.00 mM (RSD 1%), the maximum number of samples that could be analysed was 90/h. The immobilized enzyme retained its initial activity for 2 mo with more than 600 assays.
C1 UNIV FED PERNAMBUCO,LIKA,DEPT BIOQUIM,BR-50730 RECIFE,PE,BRAZIL.
   UNIV FED PERNAMBUCO,LIKA,DEPT ENGN QUIM,BR-50730 RECIFE,PE,BRAZIL.
RI Filho, Jose Luiz Lima/M-8076-2019; Silva, Valdinete/C-7739-2013;
   Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358
CR CARVALHO LB, 1981, PHYTOCHEMISTRY, V20, P2423, DOI 10.1016/S0031-9422(00)82680-1
   FUNG YS, 1992, ANAL CHIM ACTA, V261, P375, DOI 10.1016/0003-2670(92)80216-T
   GREENWAY GM, 1990, ANALYST, V115, P1297, DOI 10.1039/an9901501297
   KORELL U, 1992, ANAL CHEM, V64, P147, DOI 10.1021/ac00026a010
   LAZARO F, 1987, ANALUSIS, V15, P183
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARQUES ETA, 1992, APPL BIOCHEM BIOTECH, V32, P73, DOI 10.1007/BF02922149
   MARQUES ETH, 1991, BIOCHEM EDUC, V19, P77, DOI 10.1016/0307-4412(91)90010-6
   MASON WD, 1980, ANAL LETT PT B, V13, P817, DOI 10.1080/00032718008078003
   MCCORNICK DB, 1979, METHODS ENZYMOLOGY D, V62, P3
   SCHAFFAR BPH, 1989, GBF MONOG SERIES, V13, P229
   TIETZ NW, 1986, CLIN CHEM, P959
   UCHIYAMA S, 1988, ANAL CHIM ACTA, V208, P291, DOI 10.1016/S0003-2670(00)80758-8
   UCHIYAMA S, 1991, ANAL CHIM ACTA, V255, P53, DOI 10.1016/0003-2670(91)85086-8
   VERMA KK, 1991, ANALYST, V116, P641, DOI 10.1039/an9911600641
   Weetall H H, 1976, Methods Enzymol, V44, P134
NR 16
TC 10
Z9 10
U1 0
U2 5
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512
SN 0273-2289
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD JAN
PY 1994
VL 44
IS 1
BP 81
EP 89
DI 10.1007/BF02921853
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA MU641
UT WOS:A1994MU64100008
DA 2020-12-16
ER

PT J
AU TAMBINI, G
   ANDRUS, JK
   MARQUES, E
   BOSHELL, J
   PALLANSCH, M
   DEQUADROS, CA
   KEW, O
AF TAMBINI, G
   ANDRUS, JK
   MARQUES, E
   BOSHELL, J
   PALLANSCH, M
   DEQUADROS, CA
   KEW, O
TI DIRECT-DETECTION OF WILD POLIOVIRUS CIRCULATION BY STOOL SURVEYS OF
   HEALTHY-CHILDREN AND ANALYSIS OF COMMUNITY WASTE-WATER
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Note
ID POLIOMYELITIS; ERADICATION; WATERS
AB Cartagena, Colombia, was one of the last cities in the Americas known to have endemic poliomyelitis. After 3 cases were identified in 1991, two approaches for detecting continued silent transmission of wild polioviruses within a high-risk community were used: stool surveys of healthy children and virologic analysis of community sewage. Wild type 1 polioviruses were isolated from 8% of the children studied and from 21% of sewage samples. The proportions of wild polioviruses, vaccine-related polioviruses, and nonpolio enteric viruses were similar for both approaches. Wild poliovirus sequences were also amplified directly from processed sewage samples by the polymerase chain reaction using primer pairs specific for the indigenous type 1 genotype. The last reported cases associated with wild polioviruses in the Americas occurred in Colombia (8 April 1991) and Peru (23 August 199 1). Direct sampling for wild polioviruses in high-risk communities can provide further evidence that eradication of the indigenous wild polioviruses has been achieved in the Americas.
C1 PAN AMER HLTH ORG,EXPANDED PROGRAM IMMUNIZAT,WASHINGTON,DC.
   PAN AMER HLTH ORG,EXPANDED PROGRAM IMMUNIZAT,BOGOTA,COLOMBIA.
   INST NACL SALUD,MINIST SALUD,BOGOTA,COLOMBIA.
   CTR DIS CONTROL & PREVENT,DIV IMMUNIZAT,ATLANTA,GA.
   CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA.
   CO TECNOL SANEAMENTO AMBIENTAL,SAO PAULO,BRAZIL.
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR ANDRUS J K, 1992, Morbidity and Mortality Weekly Report, V41, P21
   DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239
   GELFAND HM, 1960, AM J PUBLIC HEALTH N, V50, P767, DOI 10.2105/AJPH.50.6_Pt_1.767
   HORSTMANN DM, 1973, AM J EPIDEMIOL, V97, P173, DOI 10.1093/oxfordjournals.aje.a121498
   HURST CJ, 1989, CAN J MICROBIOL, V35, P474, DOI 10.1139/m89-073
   Melnick J., 1979, DIAGNOSTIC PROCEDURE, P471
   MISBAH SA, 1991, POSTGRAD MED J, V67, P301, DOI 10.1136/pgmj.67.785.301
   NATHANSON N, 1979, AM J EPIDEMIOL, V110, P672, DOI 10.1093/oxfordjournals.aje.a112848
   OGRA PL, 1971, PROG MED VIROL, V13, P156
   POYRY T, 1988, APPL ENVIRON MICROB, V54, P371
   RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8
   SABIN AB, 1984, REV INFECT DIS, V6, P391
   Sobsey M., 1987, METHODS RECOVERING V, P77
   WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504
   YANG CF, 1992, VIRUS RES, V24, P277, DOI 10.1016/0168-1702(92)90124-R
NR 15
TC 51
Z9 52
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC
PY 1993
VL 168
IS 6
BP 1510
EP 1514
DI 10.1093/infdis/168.6.1510
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MJ709
UT WOS:A1993MJ70900026
PM 8245537
DA 2020-12-16
ER

PT J
AU PARENTE, AH
   MARQUES, ETA
   AZEVEDO, WM
   DINIZ, FB
   MELO, EHM
   FILHO, JLL
AF PARENTE, AH
   MARQUES, ETA
   AZEVEDO, WM
   DINIZ, FB
   MELO, EHM
   FILHO, JLL
TI GLUCOSE BIOSENSOR USING GLUCOSE-OXIDASE IMMOBILIZED IN POLYANILINE
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE GLUCOSE OXIDASE; POLYANILINE; BIOSENSOR; OXYGEN ELECTRODE
AB A biosensor for glucose utilizing kinetics of glucose oxidase (EC 1.1.3.4.) was developed. The enzyme was immobilized on polyaniline by covalent bonding, using glutaraldehyde as a bifunctional agent. The system showed a linear response up to 2.2 mM of glucose with a response time of 2.5-4.0 min. In addition, the immobilized enzyme had a higher activity between pH 6.5 and 7.5. The system retained 50% of its activity after 30 d of daily use. The optical absorption spectra of the polyaniline/glucose oxidase electrode after glucose had been added to the buffer solution showed that the absorption band around 800 nm had changed considerably when glucose was allowed to react with the electrode. This optical variation makes polyaniline a very promising polymer for use as a support in optical sensor for clinical application.
C1 UNIV FED PERNAMBUCO,DEPT QUIM FUNDAMENTAL,BR-50730 RECIFE,PE,BRAZIL.
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; mendes de azevedo, Walter/0000-0001-6110-5728
CR AUBREELECAT A, 1989, ANAL BIOCHEM, V178, P427, DOI 10.1016/0003-2697(89)90665-9
   BOURDILLON C, 1988, BIOTECHNOL BIOENG, V31, P553, DOI 10.1002/bit.260310607
   CLARK LC, 1962, ANN NY ACAD SCI, V102, P29, DOI 10.1111/j.1749-6632.1962.tb13623.x
   EPSTEIN AJ, 1987, SYNTHETIC MET, V18, P303, DOI 10.1016/0379-6779(87)90896-4
   GENIES EM, 1987, J ELECTROANAL CHEM, V67, P220
   HARRISON DJ, 1988, ANAL CHEM, V60, P2002, DOI 10.1021/ac00170a003
   IKEDA T, 1984, AGR BIOL CHEM TOKYO, V48, P1969, DOI 10.1080/00021369.1984.10866431
   KADDISH AH, 1964, AM J MED ELECTRON, V3, P82
   KLEPPE K, 1966, BIOCHEMISTRY-US, V5, P139, DOI 10.1021/bi00865a018
   MARQUES ETH, 1991, BIOCHEM EDUC, V19, P77, DOI 10.1016/0307-4412(91)90010-6
   RANGE MA, 1985, ANAL CHIM ACTA, V175, P89
   Russell A D, 1976, Prog Med Chem, V13, P271, DOI 10.1016/S0079-6468(08)70140-1
   TRETTNAK W, 1989, ANAL CHIM ACTA, V221, P195, DOI 10.1016/S0003-2670(00)81956-X
   TURNER APF, 1985, BIOSENSORS, V1, P1
NR 14
TC 52
Z9 52
U1 1
U2 14
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512
SN 0273-2289
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD DEC
PY 1992
VL 37
IS 3
BP 267
EP 273
DI 10.1007/BF02788878
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA KY486
UT WOS:A1992KY48600005
PM 1303064
DA 2020-12-16
ER

PT J
AU MARQUES, ET
AF MARQUES, ET
TI CORRECTION
SO ANALYTICA CHIMICA ACTA
LA English
DT Correction, Addition
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR MARQUES EP, 1991, ANAL CHIM ACTA, V254, P245, DOI 10.1016/0003-2670(91)90032-Z
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD MAR 20
PY 1992
VL 258
IS 2
BP 356
EP 356
PG 1
WC Chemistry, Analytical
SC Chemistry
GA HK842
UT WOS:A1992HK84200020
DA 2020-12-16
ER

PT J
AU MARQUES, ETA
   LIMA, JL
AF MARQUES, ETA
   LIMA, JL
TI ASCORBIC-ACID BIOSENSOR USING ASCORBATE OXIDASE IMMOBILIZED ON
   ALKYLAMINE GLASS-BEADS
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE ASCORBIC ACID; BIOSENSOR; OXYGEN ELECTRODE; CUCURBITA-MAXIMA
AB A biosensor for ascorbic acid based on enzyme kinetics of ascorbate oxidase (E.C.1.10.3.3.) was developed. The enzyme was extracted from Cucurbita maxima, or jerimun and immobilized by covalent bounding, using glutaradehyde as a bifunctional agent, on alkylamine glass beads, with and without enzyme active site protection. A low-cost, home-made oxygen electrode was applied as a transducer. The system has sensitivity from 62.5 up to 500-mu-M of ascorbic acid with satisfactory operation for more than 2 mo.
C1 UNIV FED PERNAMBUCO,DEPT BIOQUIM,LAB IMUNOPATOL KEIZO ASAMI,LIKA CIDADE UNIV,BR-50730 RECIFE,PE,BRAZIL.
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013; Filho,
   Jose Luiz Lima/M-8076-2019
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
CR CARVALHO LB, 1989, PROCESS BIOCHEM, P52
   HALVATZIS SA, 1989, ANAL CHIM ACTA, P485
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARQUES ETA, 1991, IN PRESS BIOCH ED
   MASON MD, 1980, ANAL LETT, V13, P817
   MASON WD, 1980, ANAL LETT PT B, V13, P817, DOI 10.1080/00032718008078003
   SCHAFFAR BPH, 1988, GBF MONOGRAPH, P229
   Trevan M.D., 1980, IMMOBILIZED ENZYMES
   Weetall H H, 1976, Methods Enzymol, V44, P134
NR 9
TC 12
Z9 12
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512
SN 0273-2289
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD JAN-MAR
PY 1992
VL 32
BP 73
EP 78
DI 10.1007/BF02922149
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA HX887
UT WOS:A1992HX88700007
PM 1416950
DA 2020-12-16
ER

PT J
AU MARQUES, ETH
   NETTO, FACS
   FILHO, JLL
AF MARQUES, ETH
   NETTO, FACS
   FILHO, JLL
TI A LOW-COST OXYGEN METER
SO BIOCHEMICAL EDUCATION
LA English
DT Article
RP MARQUES, ETH (corresponding author), CIDADE UNIV RECIFE,DEPT BIOQUIM,RECIFE 50730,PE,BRAZIL.
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
NR 0
TC 6
Z9 6
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0307-4412
J9 BIOCHEM EDUC
JI Biochem. Educ.
PD APR
PY 1991
VL 19
IS 2
BP 77
EP 78
DI 10.1016/0307-4412(91)90010-6
PG 2
WC Biochemistry & Molecular Biology; Education, Scientific Disciplines
SC Biochemistry & Molecular Biology; Education & Educational Research
GA FT227
UT WOS:A1991FT22700009
DA 2020-12-16
ER

EF